

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number  
**WO 01/40493 A2**

(51) International Patent Classification<sup>7</sup>: **C12N 15/85**,  
C07K 14/47, 16/18, C12Q 1/68, G06F 17/30, 17/50,  
A01K 67/027

(FR). **ESSIOUX, Laurent** [FR/FR]; 107, rue de Reuilly,  
F-75012 Paris (FR).

(21) International Application Number: **PCT/TB00/01507**

(74) Common Representative: **GENSET**; Intellectual Prop-  
erty Department, 24, rue Royale, F-75008 Paris (FR).

(22) International Filing Date: 4 October 2000 (04.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/168,088 30 November 1999 (30.11.1999) **US**

(71) Applicant (for all designated States except US): **GENSET**  
[FR/FR]; Intellectual Property Department, 24, rue Royale,  
F-75008 Paris (FR).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COHEN, Dantel** [FR/FR]; 1, boulevard Richard Wallace, F-92200 Neuilly-sur-Seine (FR). **BLUMENFELD, Marta** [FR/FR]; 5, rue Tagore, F-75013 Paris (FR). **CHU-MAKOV, Ilya** [FR/FR]; 196, rue des Chevrefoilles, F-77000 Vaux-le-Penil (FR). **BOUGUELERET, Lydie** [FR/FR]; 108, avenue Victor Hugo, F-92170 Vanves

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/40493 A2

(54) Title: **SCHIZOPHRENIA ASSOCIATED GENE, PROTEINS AND BIALLELIC MARKERS**

(57) Abstract: The invention concerns the human g35030 gene, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the g35030 gene and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

## SCHIZOPHRENIA ASSOCIATED GENE, PROTEINS AND BIALLELIC MARKERS

5

### FIELD OF THE INVENTION

The invention concerns the human g35030 gene, and g35030 polynucleotides, polypeptides, as well as biallelic markers localized in the g35030 gene and in the human chromosome 13q31-q33 region. The invention also concerns the association established  
10 between schizophrenia and bipolar disorder and the biallelic markers and the g35030 gene and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

15

### BACKGROUND OF THE INVENTION

Advances in the technological armamentarium available to basic and clinical investigators have enabled increasingly sophisticated studies of brain and nervous system function in health and disease. Numerous hypotheses both neurobiological and  
20 pharmacological have been advanced with respect to the neurochemical and genetic mechanisms involved in central nervous system (CNS) disorders, including psychiatric disorders and neurodegenerative diseases. However, CNS disorders have complex and poorly understood etiologies, as well as symptoms that are overlapping, poorly characterized, and difficult to measure. As a result future treatment regimes and drug development efforts will be  
25 required to be more sophisticated and focused on multigenic causes, and will need new assays to segment disease populations, and provide more accurate diagnostic and prognostic information on patients suffering from CNS disorders.

#### **Genetic Analysis of Complex Traits**

30 Until recently, the identification of genes linked with detectable traits has relied mainly on a statistical approach called linkage analysis. Linkage analysis is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. Linkage analysis involves the study of families with multiple affected individuals and is useful in the detection of inherited-traits, which are caused by a  
35 single gene, or possibly a very small number of genes. But, linkage studies have proven



difficult when applied to complex genetic traits. Most traits of medical relevance do not follow simple Mendelian monogenic inheritance. However, complex diseases often aggregate in families, which suggests that there is a genetic component to be found. Such complex traits are often due to the combined action of multiple genes as well as environmental factors. Such  
5 complex trait, include susceptibilities to heart disease, hypertension, diabetes, cancer and inflammatory diseases. Drug efficacy, response and tolerance/toxicity can also be considered as multifactoral traits involving a genetic component in the same way as complex diseases. Linkage analysis cannot be applied to the study of such traits for which no large informative families are available. Moreover, because of their low penetrance, such complex traits do not  
10 segregate in a clear-cut Mendelian manner as they are passed from one generation to the next. Attempts to map such diseases have been plagued by inconclusive results, demonstrating the need for more sophisticated genetic tools.

Knowledge of genetic variation in the neuronal and endocrine systems is important for understanding why some people are more susceptible to disease or respond differently to  
15 treatments. Ways to identify genetic polymorphism and to analyze how they impact and predict disease susceptibility and response to treatment are needed.

Although the genes involved in the neuronal and endocrine systems represent major drug targets and are of high relevance to pharmaceutical research, we still have scant knowledge concerning the extent and nature of, sequence variation in these genes and their regulatory  
20 elements. In the case where polymorphisms have been identified the relevance of the variation is rarely understood. While polymorphisms hold promise for use as genetic markers in determining which genes contribute to multigenic or quantitative traits, suitable markers and suitable methods for exploiting those markers have not been found and brought to bare on the genes related to disorders of the brain and nervous system.

25 The basis for accomplishment of these goals is to use genetic association analysis to detect markers that predict susceptibility for these traits. Recently, advances in the fields of genetics and molecular biology have allowed identification of forms, or alleles, of human genes that lead to diseases. Most of the genetic variations responsible for human diseases identified so far, belong to the class of single gene disorders. As this name implies, the development of  
30 single gene disorders is determined, or largely influenced, by the alleles of a single gene. The alleles that cause these disorders are, in general, highly deleterious (and highly penetrant) to individuals who carry them. Therefore, these alleles and their associated diseases, with some exceptions, tend to be very rare in the human population. In contrast, most common diseases and non-disease traits, such as a physiological response to a pharmaceutical agent, can be  
35 viewed as the result of many complex factors. These can include environmental exposures

(toxins, allergens, infectious agents, climate, and trauma) as well as multiple genetic factors.

Association studies seek to analyze the distributions of chromosomes that have occurred in populations of unrelated (at least not directly related) individuals. An assumption in this type of study is that genetic alleles that result in susceptibility for a common trait arose by ancient mutational events on chromosomes that have been passed down through many generations in the population. These alleles can become common throughout the population in part because the trait they influence, if deleterious, is only expressed in a fraction of those individuals who carry them. Identification of these "ancestral" chromosomes is made difficult by the fact that genetic markers are likely to have become separated from the trait susceptibility allele through the process of recombination, except in regions of DNA which immediately surround the allele. The identities of genetic markers contained within the fragments of DNA surrounding a susceptibility allele will be the same as those from the ancestral chromosome on which the allele arose. Therefore, individuals from the population who express a complex trait might be expected to carry the same set of genetic markers in the vicinity of a susceptibility allele more often than those who do not express the trait; that is these markers will show an association with the trait.

### Schizophrenia

Schizophrenia is one of the most severe and debilitating of the major psychiatric diseases. It usually starts in late adolescence or early adult life and often becomes chronic and disabling. Men and women are at equal risk of developing this illness; however, most males become ill between 16 and 25 years old, while females develop symptoms between 25 and 30. People with schizophrenia often experience both "positive" symptoms (e.g., delusions, hallucinations, disorganized thinking, and agitation) and "negative" symptoms (e.g., lack of drive or initiative, social withdrawal, apathy, and emotional unresponsiveness).

Schizophrenia affects 1% of the world population. There are an estimated 45 million people with schizophrenia in the world, with more than 33 million of them in the developing countries. This disease places a heavy burden on the patient's family and relatives, both in terms of the direct and indirect costs involved and the social stigma associated with the illness, sometimes over generations. Such stigma often leads to isolation and neglect.

Moreover, schizophrenia accounts for one fourth of all mental health costs and takes up one in three psychiatric hospital beds. Most schizophrenia patients are never able to work. The cost of schizophrenia to society is enormous. In the United States, for example, the direct cost of treatment of schizophrenia has been estimated to be close to 0.5% of the gross national product. Standardized mortality ratios (SMRs) for schizophrenic patients are estimated to be two to four times higher than the general population, and their life expectancy overall is 20 %

shorter than for the general population. The most common cause of death among schizophrenic patients is suicide (in 10 % of patients) which represents a 20 times higher risk than for the general population. Deaths from heart disease and from diseases of the respiratory and digestive system are also increased among schizophrenic patients.

5                   **Bipolar Disorder**

Bipolar disorders are relatively common disorders with severe and potentially disabling effects. In addition to the severe effects on patients' social development, suicide completion rates among bipolar patients are reported to be about 15%.

10                   Bipolar disorders are characterized by phases of excitement and often including depression; the excitement phases, referred to as mania or hypomania, and depression can alternate or occur in various admixtures, and can occur to different degrees of severity and over varying time periods. Because bipolar disorders can exist in different forms and display different symptoms, the classification of bipolar disorder has been the subject of extensive studies resulting in the definition of bipolar disorder subtypes and widening of the overall concept to include patients previously thought to be suffering from different disorders. Bipolar disorders often share certain clinical signs, symptoms, treatments and neurobiological features with psychotic illnesses in general and therefore present a challenge to the psychiatrist to make an accurate diagnosis. Furthermore, because the course of bipolar disorders and various mood and psychotic disorders can differ greatly, it is critical to characterize the illness as early as possible in order to offer means to manage the illness over a long term.

20                   Bipolar disorders appear in about 1.3% of the population and have been reported to constitute about half of the mood disorders seen in a psychiatric clinic. Bipolar disorders have been found to vary with gender depending of the type of disorder; for example, bipolar disorder I is found equally among men and women, while bipolar disorder II is reportedly more common in women. The age of onset of bipolar disorders is typically in the teenage years and diagnosis is typically made in the patient's early twenties. Bipolar disorders also occur among the elderly, generally as a result of a medical or neurological disorder.

25                   The costs of bipolar disorders to society are enormous. The mania associated with the disease impairs performance and causes psychosis, and often results in hospitalization. This disease places a heavy burden on the patient's family and relatives, both in terms of the direct and indirect costs involved and the social stigma associated with the illness, sometimes over generations. Such stigma often leads to isolation and neglect. Furthermore, the earlier the onset, the more severe are the effects of interrupted education and social development.

30                   The DSM-IV classification of bipolar disorder distinguishes among four types of disorders based on the degree and duration of mania or hypomania as well as two types of

disorders which are evident typically with medical conditions or their treatments, or to substance abuse. Mania is recognized by elevated, expansive or irritable mood as well as by distractability, impulsive behavior, increased activity, grandiosity, elation, racing thoughts, and pressured speech. Of the four types of bipolar disorder characterized by the particular degree and duration of mania, DSM-IV includes:

- bipolar disorder I, including patients displaying mania for at least one week;
- bipolar disorder II, including patients displaying hypomania for at least 4 days, characterized by milder symptoms of excitement than mania, who have not previously displayed mania, and have previously suffered from episodes of major depression;
- bipolar disorder not otherwise specified (NOS), including patients otherwise displaying features of bipolar disorder II but not meeting the 4 day duration for the excitement phase, or who display hypomania without an episode of major depression; and
- cyclothymia, including patients who show numerous manic and depressive symptoms that do not meet the criteria for hypomania or major depression, but which are displayed for over two years without a symptom-free interval of more than two months.

The remaining two types of bipolar disorder as classified in DSM-VI are disorders evident or caused by various medical disorder and their treatments, and disorders involving or related to substance abuse. Medical disorders which can cause bipolar disorders typically include endocrine disorders and cerebrovascular injuries, and medical treatments causing bipolar disorder are known to include glucocorticoids and the abuse of stimulants. The disorder associated with the use or abuse of a substance is referred to as "substance induced mood disorder with manic or mixed features".

Diagnosis of bipolar disorder can be very challenging. One particularly troublesome difficulty is that some patients exhibit mixed states, simultaneously manic and dysphoric or depressive, but do not fall into the DSM-IV classification because not all required criteria for mania and major depression are met daily for at least one week. Other difficulties include classification of patients in the DSM-IV groups based on duration of phase since patients often cycle between excited and depressive episodes at different rates. In particular, it is reported that the use of antidepressants may alter the course of the disease for the worse by causing "rapid-cycling". Also making diagnosis more difficult is the fact that bipolar patients, particularly at what is known as Stage III mania, share symptoms of disorganized thinking and behavior with bipolar disorder patients. Furthermore, psychiatrists must distinguish between agitated depression and mixed mania; it is common that patients with major depression (14 days or more) exhibit agitation, resulting in bipolar-like features. A yet further complicating factor is that bipolar patients have an exceptionally high rate of substance, particularly alcohol abuse.

While the prevalence of mania in alcoholic patients is low, it is well known that substance abusers can show excited symptoms. Difficulties therefore result for the diagnosis of bipolar patients with substance abuse.

### **Treatment**

5           As there are currently no cures for bipolar disorder or schizophrenia, the objective of treatment is to reduce the severity of the symptoms, if possible to the point of remission. Due to the similarities in symptoms, schizophrenia and bipolar disorder are often treated with some of the same medicaments. Both diseases are often treated with antipsychotics and neuroleptics.

10           For schizophrenia, for example, antipsychotic medications are the most common and most valuable treatments. There are four main classes of antipsychotic drugs which are commonly prescribed for schizophrenia. The first, neuroleptics, exemplified by chlorpromazine (Thorazine), has revolutionized the treatment of schizophrenic patients by reducing positive (psychotic) symptoms and preventing their recurrence. Patients receiving chlorpromazine have been able to leave mental hospitals and live in community programs or their own homes. But  
15           these drugs are far from ideal. Some 20% to 30% of patients do not respond to them at all, and others eventually relapse. These drugs were named neuroleptics because they produce serious neurological side effects, including rigidity and tremors in the arms and legs, muscle spasms, abnormal body movements, and akathisia (restless pacing and fidgeting). These side effects are so troublesome that many patients simply refuse to take the drugs. Besides, neuroleptics do not  
20           improve the so-called negative symptoms of schizophrenia and the side effects may even exacerbate these symptoms. Thus, despite the clear beneficial effects of neuroleptics, even some patients who have a good short-term response will ultimately deteriorate in overall functioning.

25           The well known deficiencies in the standard neuroleptics have stimulated a search for new treatments and have led to a new class of drugs termed atypical neuroleptics. The first atypical neuroleptic, Clozapine, is effective for about one third of patients who do not respond to standard neuroleptics. It seems to reduce negative as well as positive symptoms, or at least exacerbates negative symptoms less than standard neuroleptics do. Moreover, it has beneficial effects on overall functioning and may reduce the chance of suicide in schizophrenic patients. It  
30           does not produce the troubling neurological symptoms of the standard neuroleptics, or raise blood levels of the hormone prolactin, excess of which may cause menstrual irregularities and infertility in women, impotence or breast enlargement in men. Many patients who cannot tolerate standard neuroleptics have been able to take clozapine. However, clozapine has serious limitations. It was originally withdrawn from the market because it can cause agranulocytosis, a  
35           potentially lethal inability to produce white blood cells. Agranulocytosis remains a threat that

requires careful monitoring and periodic blood tests. Clozapine can also cause seizures and other disturbing side effects (e.g., drowsiness, lowered blood pressure, drooling, bed-wetting, and weight gain). Thus it is usually taken only by patients who do not respond to other drugs.

5 Researchers have developed a third class of antipsychotic drugs that have the virtues of clozapine without its defects. One of these drugs is risperidone (Risperdal). Early studies suggest that it is as effective as standard neuroleptic drugs for positive symptoms and may be somewhat more effective for negative symptoms. It produces more neurological side effects than clozapine but fewer than standard neuroleptics. However, it raises prolactin levels. Risperidone is now prescribed for a broad range of psychotic patients, and many clinicians seem  
10 to use it before clozapine for patients who do not respond to standard drugs, because they regard it as safer. Another new drug is Olanzapine (Zyprexa) which is at least as effective as standard drugs for positive symptoms and more effective for negative symptoms. It has few neurological side effects at ordinary clinical doses, and it does not significantly raise prolactin levels. Although it does not produce most of clozapine's most troubling side effects, including  
15 agranulocytosis, some patients taking olanzapine may become sedated or dizzy, develop dry mouth, or gain weight. In rare cases, liver function tests become transiently abnormal.

Outcome studies in schizophrenia are usually based on hospital treatment studies and may not be representative of the population of schizophrenia patients. At the extremes of outcome, 20 % of patients seem to recover completely after one episode of psychosis, whereas  
20 14-19% of patients develop a chronic unremitting psychosis and never fully recover. In general, clinical outcome at five years seems to follow the rule of thirds: with about 35 % of patients in the poor outcome category; 36 % in the good outcome category, and the remainder with intermediate outcome. Prognosis in schizophrenia does not seem to worsen after five years.

Whatever the reasons, there is increasing evidence that leaving schizophrenia untreated  
25 for long periods early in course of the illness may negatively affect the outcome. However, the use of drugs is often delayed for patients experiencing a first episode of the illness. The patients may not realize that they are ill, or they may be afraid to seek help; family members sometimes hope the problem will simply disappear or cannot persuade the patient to seek treatment; clinicians may hesitate to prescribe antipsychotic medications when the diagnosis is uncertain  
30 because of potential side effects. Indeed, at the first manifestation of the disease, schizophrenia is difficult to distinguish from bipolar manic-depressive disorders, severe depression, drug-related disorders, and stress-related disorders. Since the optimum treatments differ among these diseases, the long term prognosis of the disorder also differs the beginning of the treatment.

For both schizophrenia and bipolar disorder, all the known molecules used for the  
35 treatment of schizophrenia have side effects and act only against the symptoms of the disease.

There is a strong need for new molecules without associated side effects and directed against targets which are involved in the causal mechanisms of schizophrenia and bipolar disorder. Therefore, tools facilitating the discovery and characterization of these targets are necessary and useful.

5 The aggregation of schizophrenia and bipolar disorder in families, the evidence from  
twin and adoption studies, and the lack of variation in incidence worldwide, indicate that  
schizophrenia and bipolar disorder are primarily genetic conditions, although environmental  
risk factors are also involved at some level as necessary, sufficient, or interactive causes. For  
example, schizophrenia occurs in 1% of the general population. But, if there is one grandparent  
10 with schizophrenia, the risk of getting the illness increases to about 3%; one parent with  
Schizophrenia, to about 10%. When both parents have schizophrenia, the risk rises to  
approximately 40%.

Consequently, there is a strong need to identify genes involved in schizophrenia and bipolar disorder. The knowledge of these genes will allow researchers to understand the etiology of schizophrenia and bipolar disorder and could lead to drugs and medications which are directed against the cause of the diseases, not just against their symptoms.

There is also a great need for new methods for detecting a susceptibility to schizophrenia and bipolar disorder, as well as for preventing or following up the development of the disease. Diagnostic tools could also prove extremely useful. Indeed, early identification of subjects at risk of developing schizophrenia would enable early and/or prophylactic treatment to be administered. Moreover, accurate assessments of the eventual efficacy of a medicament as well as the patient's eventual tolerance to it may enable clinicians to enhance the benefit/risk ratio of schizophrenia and bipolar disorder treatment regimes.

25 SUMMARY OF THE INVENTION

The present invention stems from the identification of novel polymorphisms including biallelic markers located on the human chromosome 13q31-q33 locus, the identification and characterization of novel schizophrenia-related genes located on the human chromosome 13q31-q33 locus, and from the identification of genetic associations between alleles of biallelic markers located on the human chromosome 13q31-q33 locus and disease, as confirmed and characterized in a panel of human subjects. The invention furthermore provides a fine structure map of the region which includes the schizophrenia-associated gene sequences.

The present invention pertains to nucleic acid molecules comprising the genomic sequences of novel human genes encoding g35030 proteins, proteins encoded thereby, as well as antibodies thereto. The g35030 genomic sequences may also comprise regulatory sequence

located upstream (5'-end) and downstream (3'-end) of the transcribed portion of said gene, these regulatory sequences being also part of the invention. The invention also deals with the cDNA sequences encoding g35030 proteins.

5 Oligonucleotide probes or primers hybridizing specifically with a g35030 genomic or cDNA sequence are also part of the present invention, as well as DNA amplification and detection methods using said primers and probes.

A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences described above, and in particular of recombinant vectors comprising a g35030 regulatory sequence or a sequence encoding a g35030 protein, as well as of cell hosts  
10 and transgenic non human animals comprising said nucleic acid sequences or recombinant vectors.

The invention also concerns to biallelic markers of the g35030 gene and the use thereof. Included are probes and primers for use in genotyping biallelic markers of the invention.

An embodiment of the invention encompasses any polynucleotide of the invention  
15 attached to a solid support polynucleotide may comprise a sequence disclosed in the present specification; optionally, said polynucleotide may comprise, consist of, or consist essentially of any polynucleotide described in the present specification; optionally, said determining may be performed in a hybridization assay, sequencing assay, microsequencing assay, or an enzyme-based mismatch detection assay; optionally, said polynucleotide may be attached to a solid  
20 support, array, or addressable array; optionally, said polynucleotide may be labeled.

Finally, the invention is directed to drug screening assays and methods for the screening of substances for the treatment of schizophrenia, bipolar disorder or a related CNS disorder. One object of the invention deals with animal models of schizophrenia, including mouse, primate, non-human primate bipolar disorder or related CNS disorder. The invention is also  
25 directed to methods for the screening of substances or molecules that modulate the expression of g35030, as well as with methods for the screening of substances or molecules that interact with a g35030 polypeptide, or that modulate the activity of a g35030 polypeptide.

As noted above, certain aspects of the present invention stem from the identification of genetic associations between schizophrenia and bipolar disorder and alleles of biallelic markers  
30 located on the human chromosome 13q31-q33 region, and more particularly on a subregion thereof referred to herein as Region D. The invention provides appropriate tools for establishing further genetic associations between alleles of biallelic markers on the 13q31-13q33 locus and either side effects or benefit resulting from the administration of agents acting on schizophrenia or bipolar disorder, or schizophrenia or bipolar disorder symptoms, including  
35 agents like chlorpromazine, clozapine, risperidone, olanzapine, sertindole, quetiapine and



ziprasidone.

The invention provides appropriate tools for establishing further genetic associations between alleles of biallelic markers on the 13q31-q33 locus and a trait. Methods and products are provided for the molecular detection of a genetic susceptibility in humans to schizophrenia and bipolar disorder. They can be used for diagnosis, staging, prognosis and monitoring of this disease, which processes can be further included within treatment approaches. The invention also provides for the efficient design and evaluation of suitable therapeutic solutions including individualized strategies for optimizing drug usage, and screening of potential new medicament candidates.

Additional embodiments are set forth in the Detailed Description of the Invention and in the Examples.

#### **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 is a diagram showing the exon structure of the g35030 gene.

Figure 2 is a table demonstrating the statistical significance of allelic frequencies of selected chromosome 13q31-q33 biallelic markers of the invention in sporadic and familial French Canadian schizophrenia cases and controls.

Figure 3 is a table demonstrating the results of a haplotype association analysis between total French Canadian schizophrenia cases and haplotypes which consist of chromosome 13q31-q33 biallelic markers of the invention.

Figure 4 is a table showing the involvement of selected biallelic markers of the invention in statistically significant haplotypes.

Figure 5 is a table demonstrating the results of a haplotype association analysis between French Canadian schizophrenia cases and haplotypes which consist of chromosome 13q31-q33 biallelic markers of the invention.

Figure 6 is a table demonstrating the results of a haplotype association analysis between French Canadian schizophrenia cases and haplotypes which consist of chromosome 13q31-q33 biallelic markers of the invention.

Figures 7A and 7B show the results of a haplotype association analysis (Omnibus LR test value distribution) between schizophrenia cases and haplotypes comprising Region D biallelic markers of the invention.

Figures 8A and 8B show the results of a haplotype association analysis (HaplotMaxM test value distribution) between schizophrenia cases and haplotypes comprising Region D biallelic markers of the invention.

Figures 9A and 9B show the results of a haplotype association analysis (Omnibus LR

test value distribution) between bipolar disorder cases and haplotypes comprising Region D biallelic markers of the invention.

Figures 10A and 10B show the results of a haplotype association analysis (HaploMaxM test value distribution) between bipolar disorder cases and haplotypes comprising Region D biallelic markers of the invention.

Figures 11A and 11B show the results of a haplotype association analysis (HaploMaxS test value distribution) between bipolar disorder cases and haplotypes comprising Region D biallelic markers of the invention.

Figure 12 is a block diagram of an exemplary computer system.

Figure 13 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.

Figure 14 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous.

Figure 15 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence.

#### **BRIEF DESCRIPTION OF THE SEQUENCES PROVIDED IN THE SEQUENCE LISTING**

SEQ ID No. 1 contains the approximately 319kb of genomic nucleotide sequence comprising g35030 nucleic acid sequences and the biallelic markers A1 to A71 located on the human chromosome 13q31-q33 locus.

SEQ ID Nos. 2 to 17 contain cDNA sequences of the g35030 gene.

SEQ ID Nos. 18 to 23 contain amino acid sequences of g35030 polypeptides, encoded by cDNAs of the invention.

SEQ ID Nos. 24 to 78 respectively contain the nucleotide sequence of the amplicons which comprise the biallelic markers A72 to A127 located on the human chromosome 13q31-q33 locus.

SEQ ID No. 79 to 132 contain genomic nucleotide sequences comprising exons of the g35030 gene from several different primates.

SEQ ID No 133 contains a primer containing the additional PU 5' sequence described further in Example 2.

SEQ ID No 134 contains a primer containing the additional RP 5' sequence described further in Example 2.

In accordance with the regulations relating to Sequence Listings, the following codes have been used in the Sequence Listing to indicate the locations of biallelic markers within the sequences and to identify each of the alleles present at the polymorphic base. The code "r" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is an adenine. The code "y" in the sequences indicates that one allele of the polymorphic base is a thymine, while the other allele is a cytosine. The code "m" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an cytosine. The code "k" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a thymine. The code "s" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a cytosine. The code "w" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an thymine.

#### **DETAILED DESCRIPTION OF THE INVENTION**

The identification of genes involved in a particular trait such as a specific central nervous system disorder, like schizophrenia, can be carried out through two main strategies currently used for genetic mapping: linkage analysis and association studies. Linkage analysis requires the study of families with multiple affected individuals and is now useful in the detection of mono- or oligogenic inherited traits. Conversely, association studies examine the frequency of marker alleles in unrelated trait (T+) individuals compared with trait negative (T-) controls, and are generally employed in the detection of polygenic inheritance.

##### **Candidate region on the chromosome 13 (linkage analysis)**

Genetic link or "linkage" is based on an analysis of which of two neighboring sequences on a chromosome contains the least recombinations by crossing-over during meiosis. To do this, chromosomal markers, like microsatellite markers, have been localized with precision on the genome. Genetic link analysis calculates the probabilities of recombinations on the target gene with the chromosomal markers used, according to the genealogical tree, the transmission of the disease, and the transmission of the markers. Thus, if a particular allele of a given marker is transmitted with the disease more often than chance would have it (recombination level between 0 and 0.5), it is possible to deduce that the target gene in question is found in the neighborhood of the marker.

Using this technique, it has been possible to localize several genes demonstrating a genetic predisposition of familial cancers. In order to be able to be included in a genetic link study, the families affected by a hereditary form of the disease must satisfy the "informativeness" criteria: several affected subjects (and whose constitutional DNA is available) per generation, and at best having a large number of siblings.

By linkage analysis, observations have been made, according to which a candidate region for schizophrenia is present on chromosome 13q32 locus (Blouin et al., 1998). Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance, but this method suffers from a variety of drawbacks. First, linkage analysis is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, the resolution attainable using linkage analysis is limited, and complementary studies are required to refine the analysis of the typical 20 Mb regions initially identified through this method. In addition, linkage analysis have proven difficult when applied to complex genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. In such cases, too great an effort and cost are needed to recruit the adequate number of affected families required for applying linkage analysis to these situations. Finally, linkage analysis cannot be applied to the study of traits for which no large informative families are available.

In the present invention alternative means for conducting association studies rather than linkage analysis between markers located on the chromosome 13q31-q33 locus and a trait, preferably schizophrenia or bipolar disorder, are disclosed.

In the present application, additional biallelic markers located on the human chromosome 13q31-q33 locus associated with schizophrenia are disclosed. The identification of these biallelic markers in association with schizophrenia has allowed for the further definition of the chromosomal region suspected of containing a genetic determinant involved in a predisposition to develop schizophrenia and has resulted in the identification of novel gene sequences disclosed herein which are associated with a predisposition to develop schizophrenia. The present invention thus provides an extensive fine structure map of the 13q31-q33 locus, including novel biallelic markers located on the human 13q31-q33 locus, approximately 319kb of genomic nucleotide sequence of a subregion of the human 13q31-q33 locus, and polymorphisms including biallelic markers and nucleotide deletions in said 319kb genomic sequence. The biallelic markers of the human chromosome 13q31-q33 locus and the nucleotide sequences, polymorphisms and gene sequences located in Region D subregion of the human chromosome 13q31-q33 locus are useful as genetic and physical markers for further mapping studies. These identified polymorphisms are used in the design of assays for the reliable detection of genetic susceptibility to schizophrenia and bipolar disorder. They can also be used in the design of drug screening protocols to provide an accurate and efficient evaluation of the therapeutic and side-effect potential of new or already existing medicament or treatment regime.

Using the biallelic markers, the inventors have identified the g35030 candidate schizophrenia gene, further described herein. The sequences comprising the the schizophrenia-

associated genes are useful, for example, for the isolation of other genes in putative gene families, the identification of homologs from other species, for the development of medicaments for treatment of disease, and as probes and primers for diagnostic or screening assays as described herein.

5

### Definitions

As used interchangeably herein, the term "oligonucleotides", and "polynucleotides" include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form. The term "nucleotide" as used herein as an adjective to describe molecules comprising RNA, DNA, or RNA/DNA hybrid sequences of any length in single-stranded or duplex form. The term "nucleotide" is also used herein as a noun to refer to individual nucleotides or varieties of nucleotides, meaning a molecule, or individual unit in a larger nucleic acid molecule, comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or polynucleotide. Although the term "nucleotide" is also used herein to encompass "modified nucleotides" which comprise at least one modifications (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar, for examples of analogous linking groups, purine, pyrimidines, and sugars see for example PCT publication No. WO 95/04064. However, the polynucleotides of the invention are preferably comprised of greater than 50% conventional deoxyribose nucleotides, and most preferably greater than 90% conventional deoxyribose nucleotides. The polynucleotide sequences of the invention may be prepared by any known method, including synthetic, recombinant, *ex vivo* generation, or a combination thereof, as well as utilizing any purification methods known in the art.

As used herein, the term "purified" does not require absolute purity; rather, it is intended as a relative definition. Purification of starting material or natural material is at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. As an example, purification from 0.1 % concentration to 10 % concentration is two orders of magnitude.

To illustrate, individual cDNA clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual

35

cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an approximately  $10^4$ - $10^6$  fold purification of the native message.

5 The term "purified" is further used herein to describe a polypeptide or polynucleotide of the invention which has been separated from other compounds including, but not limited to, polypeptides or polynucleotides, carbohydrates, lipids, etc. The term "purified" may be used to specify the separation of monomeric polypeptides of the invention from oligomeric forms such as homo- or hetero- dimers, trimers, etc. The term "purified" may also be used to specify the separation of covalently closed polynucleotides from linear polynucleotides. A polynucleotide 10 is substantially pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polynucleotide sequence and conformation (linear versus covalently close). A substantially pure polypeptide or polynucleotide typically comprises about 50%, preferably 60 to 90% weight/weight of a polypeptide or polynucleotide sample, respectively, more usually about 95%, and preferably is over about 99% pure. Polypeptide and polynucleotide purity, or 15 homogeneity, is indicated by a number of means well known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art. As an alternative embodiment, purification of the polypeptides and polynucleotides of the present invention may be expressed as "at least" a percent purity relative to heterologous polypeptides and polynucleotides (DNA, RNA or both). As a preferred embodiment, 20 the polypeptides and polynucleotides of the present invention are at least; 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 96%, 98%, 99%, or 100% pure relative to heterologous polypeptides and polynucleotides, respectively. As a further preferred embodiment the polypeptides and polynucleotides have a purity ranging from any number, to the thousandth position, between 90% and 100% (e.g., a polypeptide or polynucleotide at least 99.995% pure) 25 relative to either heterologous polypeptides or polynucleotides, respectively, or as a weight/weight ratio relative to all compounds and molecules other than those existing in the carrier. Each number representing a percent purity, to the thousandth position, may be claimed as individual species of purity.

30 The term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such 35 polynucleotide or polypeptide could be part of a composition, and still be isolated in that the

vector or composition is not part of its natural environment.

The term "primer" denotes a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and used to hybridize to the target nucleotide sequence. A primer serves as an initiation point for nucleotide polymerization catalyzed by either DNA polymerase, RNA polymerase or reverse transcriptase.

The term "probe" denotes a defined nucleic acid segment (or nucleotide analog segment, e.g., polynucleotide as defined herein) which can be used to identify a specific polynucleotide sequence present in samples, said nucleic acid segment comprising a nucleotide sequence complementary of the specific polynucleotide sequence to be identified.

The terms "trait" and "phenotype" are used interchangeably herein and refer to any clinically distinguishable, detectable or otherwise measurable property of an organism such as symptoms of, or susceptibility to a disease for example. Typically the terms "trait" or "phenotype" are used herein to refer to symptoms of, or susceptibility to schizophrenia or bipolar disorder; or to refer to an individual's response to an agent acting on schizophrenia or bipolar disorder; or to refer to symptoms of, or susceptibility to side effects to an agent acting on schizophrenia or bipolar disorder.

The term "allele" is used herein to refer to variants of a nucleotide sequence. A biallelic polymorphism has two forms. Typically the first identified allele is designated as the original allele whereas other alleles are designated as alternative alleles. Diploid organisms may be homozygous or heterozygous for an allelic form.

The term "heterozygosity rate" is used herein to refer to the incidence of individuals in a population, which are heterozygous at a particular allele. In a biallelic system the heterozygosity rate is on average equal to  $2P_a(1-P_a)$ , where  $P_a$  is the frequency of the least common allele. In order to be useful in genetic studies a genetic marker should have an adequate level of heterozygosity to allow a reasonable probability that a randomly selected person will be heterozygous.

The term "genotype" as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention a genotype preferably refers to the description of the biallelic marker alleles present in an individual or a sample. The term "genotyping" a sample or an individual for a biallelic marker involves determining the specific allele or the specific nucleotide(s) carried by an individual at a biallelic marker.

The term "mutation" as used herein refers to a difference in DNA sequence between or among different genomes or individuals which has a frequency below 1%.

The term "haplotype" refers to a combination of alleles present in an individual or a sample on a single chromosome. In the context of the present invention a haplotype preferably

refers to a combination of biallelic marker alleles found in a given individual and which may be associated with a phenotype.

The term "polymorphism" as used herein refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals.

5 "Polymorphic" refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A "polymorphic site" is the locus at which the variation occurs. A polymorphism may comprise a substitution, deletion or insertion of one or more nucleotides. A single nucleotide polymorphism is a single base pair change. Typically a single nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the  
10 polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide, also give rise to single nucleotide polymorphisms. In the context of the present invention "single nucleotide polymorphism" preferably refers to a single nucleotide substitution. Typically, between different genomes or between different individuals, the polymorphic site may be occupied by two different nucleotides.

15 The terms "biallelic polymorphism" and "biallelic marker" are used interchangeably herein to refer to a polymorphism having two alleles at a fairly high frequency in the population, preferably a single nucleotide polymorphism. A "biallelic marker allele" refers to the nucleotide variants present at a biallelic marker site. Typically the frequency of the less common allele of the biallelic markers of the present invention has been validated to be greater  
20 than 1%, preferably the frequency is greater than 10%, more preferably the frequency is at least 20% (i.e. heterozygosity rate of at least 0.32), even more preferably the frequency is at least 30% (i.e. heterozygosity rate of at least 0.42). A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a "high quality biallelic marker." All of the genotyping, haplotyping, association, and interaction study methods of the invention may  
25 optionally be performed solely with high quality biallelic markers.

The location of nucleotides in a polynucleotide with respect to the center of the polynucleotide are described herein in the following manner. When a polynucleotide has an odd number of nucleotides, the nucleotide at an equal distance from the 3' and 5' ends of the polynucleotide is considered to be "at the center" of the polynucleotide, and any nucleotide  
30 immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be "within 1 nucleotide of the center." With an odd number of nucleotides in a polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within 2 nucleotides of the center, and so on. When a polynucleotide has an even number of nucleotides, there would be a bond and not a nucleotide at the center of the  
35 polynucleotide. Thus, either of the two central nucleotides would be considered to be "within 1



nucleotide of the center" and any of the four nucleotides in the middle of the polynucleotide would be considered to be "within 2 nucleotides of the center", and so on. For polymorphisms which involve the substitution, insertion or deletion of 1 or more nucleotides, the polymorphism, allele or biallelic marker is "at the center" of a polynucleotide if the difference between the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 3' end of the polynucleotide, and the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 5' end of the polynucleotide is zero or one nucleotide. If this difference is 0 to 3, then the polymorphism is considered to be "within 1 nucleotide of the center." If the difference is 0 to 5, the polymorphism is considered to be "within 2 nucleotides of the center." If the difference is 0 to 7, the polymorphism is considered to be "within 3 nucleotides of the center," and so on. For polymorphisms which involve the substitution, insertion or deletion of 1 or more nucleotides, the polymorphism, allele or biallelic marker is "at the center" of a polynucleotide if the difference between the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 3' end of the polynucleotide, and the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 5' end of the polynucleotide is zero or one nucleotide. If this difference is 0 to 3, then the polymorphism is considered to be "within 1 nucleotide of the center." If the difference is 0 to 5, the polymorphism is considered to be "within 2 nucleotides of the center." If the difference is 0 to 7, the polymorphism is considered to be "within 3 nucleotides of the center," and so on.

The term "upstream" is used herein to refer to a location which, is toward the 5' end of the polynucleotide from a specific reference point.

The terms "base paired" and "Watson & Crick base paired" are used interchangeably herein to refer to nucleotides which can be hydrogen bonded to one another by virtue of their sequence identities in a manner like that found in double-helical DNA with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds (See Stryer, L., *Biochemistry*, 4th edition, 1995).

The terms "complementary" or "complement thereof" are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region. This term is applied to pairs of polynucleotides based solely upon their sequences and not any particular set of conditions under which the two polynucleotides would actually bind.

The terms "g35030 gene", when used herein, encompasses genomic, mRNA and cDNA sequences encoding a g35030 protein, including the untranslated regulatory regions of the genomic DNA.

As used herein the term "13q31-q33-related biallelic marker" relates to a biallelic marker residing in the human chromosome 13q31-q33 region. The term 13q31-q33-related biallelic marker encompasses all of the biallelic markers disclosed in Table 5 and any biallelic markers in linkage disequilibrium therewith, and any biallelic markers in linkage disequilibrium therewith. The preferred chromosome 13q31-q33-related biallelic marker alleles of the present invention include each one the alleles described in Table 5 individually or in groups consisting of all the possible combinations of the alleles listed.

As used herein the term "g35030-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the g35030 gene or a g35030 nucleotide sequence. The term g35030-related biallelic marker encompasses the biallelic markers A13 to A65 disclosed in Table 5 and any biallelic markers in linkage disequilibrium therewith.

The term "polypeptide" refers to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude post-expression modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term polypeptide. Also included within the definition are polypeptides which contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

As used herein, the term "non-human animal" refers to any non-human vertebrate, birds and more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term "animal" is used to refer to any vertebrate, preferable a mammal. Both the terms "animal" and "mammal" expressly embrace human subjects unless preceded with the term "non-human".

As used herein, the term "antibody" refers to a polypeptide or group of polypeptides which are comprised of at least one binding domain, where an antibody binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen, which allows an immunological reaction with the antigen. Antibodies include recombinant proteins comprising the binding domains, as well as fragments, including Fab, Fab', F(ab)<sub>2</sub>, and F(ab')<sub>2</sub> fragments.

As used herein, an "antigenic determinant" is the portion of an antigen molecule, in this case a g35030 polypeptide, that determines the specificity of the antigen-antibody reaction. An

"epitope" refers to an antigenic determinant of a polypeptide. An epitope can comprise as few as 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope comprises at least 6 such amino acids, and more usually at least 8-10 such amino acids.

Methods for determining the amino acids which make up an epitope include x-ray  
5 crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping e.g. the  
Pepscan method described by Geysen et al. 1984; PCT Publication No. WO 84/03564; and  
PCT Publication No. WO 84/03506.

#### 10 Variants and Fragments

The invention also relates to variants and fragments of the polynucleotides described  
herein, particularly of a nucleotide sequence of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to  
132, and particularly of a nucleotide sequence of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to  
132 containing one or more biallelic markers and/or other polymorphisms according to the  
invention.

15 Variants of polynucleotides, as the term is used herein, are polynucleotides that differ  
from a reference polynucleotide. A variant of a polynucleotide may be a naturally occurring  
variant such as a naturally occurring allelic variant, or it may be a variant that is not known to  
occur naturally. Such non-naturally occurring variants of the polynucleotide may be made by  
mutagenesis techniques, including those applied to polynucleotides, cells or organisms.

20 Generally, differences are limited so that the nucleotide sequences of the reference and the  
variant are closely similar overall and, in many regions, identical.

Variants of polynucleotides according to the invention include, without being limited  
to, nucleotide sequences which are at least 95% identical to a polynucleotide selected from the  
group consisting of the nucleotide sequences SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132  
25 or to any polynucleotide fragment of at least 8 consecutive nucleotides of a polynucleotide  
selected from the group consisting of the nucleotide SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79  
to 132, and preferably at least 99% identical, more particularly at least 99.5% identical, and  
most preferably at least 99.8% identical to a polynucleotide selected from the group consisting  
of the nucleotide SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or to any polynucleotide  
30 fragment of at least 30, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000, to the extent that the  
length is consistent with the particular sequence ID, consecutive nucleotides of a polynucleotide  
selected from the group consisting of the nucleotide sequences of SEQ ID Nos. 1 to 17, 24, 25,  
28, 74 and 79 to 132.

35 Nucleotide changes present in a variant polynucleotide may be silent, which means that  
they do not alter the amino acids encoded by the polynucleotide. However, nucleotide changes

may also result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions.

A polynucleotide fragment is a polynucleotide having a sequence that is entirely the same as part but not all of a given nucleotide sequence, preferably the nucleotide sequence of a g35030 polynucleotide, and variants thereof, or of a polynucleotide of any of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132, or a polynucleotide comprising one of the biallelic markers A1 to A127, or the complements thereof. Such fragments may be "free-standing", i.e. not part of or fused to other polynucleotides, or they may be comprised within a single larger polynucleotide of which they form a part or region. Indeed, several of these fragments may be present within a single larger polynucleotide. Optionally, such fragments may comprise, consist of, or consist essentially of a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 30, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length of any of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132.

#### **Identity Between Nucleic Acids Or Polypeptides**

The terms "percentage of sequence identity" and "percentage homology" are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Homology is evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-2448; Altschul et al., 1990, J. Mol. Biol. 215(3):403-410; Thompson et al., 1994, Nucleic Acids Res. 22(2):4673-4680; Higgins et al., 1996, Methods Enzymol. 266:383-402; Altschul et al., 1990, J. Mol. Biol. 215(3):403-410; Altschul et al., 1993, Nature Genetics 3:266-272). In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment

Search Tool ("BLAST") which is well known in the art (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268; Altschul et al., 1990, J. Mol. Biol. 215:403-410; Altschul et al., 1993, Nature Genetics 3:266-272; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402). In particular, five specific BLAST programs are used to perform the following

5 task:

(1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;

(2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;

10 (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;

(4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and

15 (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by  
20 means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992, Science 256:1443-1445; Henikoff and Henikoff, 1993, Proteins 17:49-61). Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical  
25 Research Foundation). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA  
30 87:2267-2268).

The BLAST programs may be used with the default parameters or with modified parameters provided by the user.

#### **Stringent Hybridization Conditions**

By way of example and not limitation, procedures using conditions of high stringency

are as follows: prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture  
5 containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Subsequently, filter washes can be done at 37°C for 1 h in a solution containing 2 x SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1 X SSC at 50°C for 45 min. Following the wash steps, the hybridized probes are detectable by autoradiography. Other conditions of high stringency which may be used are well known in the art and as cited in  
10 Sambrook et al., 1989; and Ausubel et al., 1989. These hybridization conditions are suitable for a nucleic acid molecule of about 20 nucleotides in length. There is no need to say that the hybridization conditions described above are to be adapted according to the length of the desired nucleic acid, following techniques well known to the one skilled in the art. The suitable hybridization conditions may for example be adapted according to the teachings disclosed in the  
15 book of Hames and Higgins (1985) or in Sambrook et al.(1989).

#### **Genomic Sequences of g35030 polynucleotides**

The present invention concerns genomic DNA sequences of the g35030 gene. As referred to herein, genomic sequences of g35030 are indicated by nucleotide position in the 5' to  
20 3' orientation on SEQ ID No 1.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising, consisting essentially of, or consisting of a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of nucleotide positions 201123 to 247802 of SEQ ID No 1, or the complements  
25 thereof. Also encompassed are purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with nucleotide positions 201123 to 247802 of SEQ ID No 1, or a complementary sequence thereto or a fragment thereof. Also encompassed are purified, isolated, or recombinant nucleic acids that hybridize with said span under stringent hybridization conditions as defined above. Nucleic  
30 acids of the invention encompass g35030 nucleic acids from any source, including primate, non-human primate, mammalian and human.

The human g35030 gene comprises exons selected from at least 14 different exons or exon forms, referred to herein as exons S, S2, T, U, V, V1, V2, V3, V4, W, W2, X, Y, Z. As indicated in Table 1, exons V and V2 are considered alternative exons, containing overlapping  
35 sequence. Likewise, exon W2 contains overlapping sequence with exons W and X.

The nucleotide positions of g35030 exons in SEQ ID No. 1 are detailed below in Table 1. The exon structure of the g35030 gene is further shown in Figure 1.

Table 1

Exon	Position in SEQID1		Intron Position in SEQID1	
S	201123	201234	201235	201122
S2	201123	201560	201561	214675
T	214676	214793	214794	215701
U	215702	215746	215747	216835
V	216836	216994	216995	217670
V2	216836	217077	217078	217670
V1	217671	217764	217765	227654
V4	227655	227736	227737	238714
V3	238715	238919	238920	240439
W	240440	240673	240674	244352 or 241071
W2	240440	241153	241154	244352
X	241072	241291	241292	244352
Y	244353	244561	244562	246272
Z	246273	247802		

5 Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the exons of the g35030 gene, or a sequence complementary thereto. Preferred are purified, isolated, or recombinant polynucleotides comprising at least one exon having the nucleotide position ranges listed in Table 1 selected from the group consisting of the exons S, S2, T, U, V, V1, V2, V3, V4, W, 10 W2, X, Y, Z of the g35030 gene, or a complementary sequence thereto or a fragment or a variant thereof. Also encompassed by the invention are purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the g35030 gene selected from the group consisting of exons S, S2, T, U, V, V1, V2, V3, V4, W, W2, X, Y, Z, wherein the polynucleotides are arranged within the nucleic acid in the same relative order as in SEQ ID No. 1. 15

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ 20 ID No 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836

to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802, or the complements thereof.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with a g35030 nucleotide sequence of nucleotide positions 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802 of SEQ ID No 1, or a complementary sequence thereto or a variant thereof, under stringent hybridization conditions as defined above.

The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence of g35030 having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a sequence selected from the group consisting of nucleotide positions 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802 of SEQ ID No. 1 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards the nucleotide positions 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802 of SEQ ID No. 1 may generally be distributed throughout the nucleic acid.

The present invention further embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the introns of the g35030 gene, or a sequence complementary thereto. The present invention thus encompasses the g35030 gene as well as g35030 genomic sequences consisting of, consisting essentially of, or comprising the sequence of nucleotide positions 201235 to 201122, 201561 to 214675, 214794 to 215701, 215747 to 216835, 216995 to 217670, 217078 to 217670, 217765 to 227654, 227737 to 238714, 238920 to 240439, 240674 to 244352, 240674 to 241071, 241154 to 244352, 241292 to 244352 and 244562 to 246272 of SEQ ID No 1, a sequence complementary thereto, as well as fragments and variants thereof.

These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of a gene comprising a g35030 nucleic acid sequence in a test sample, or alternatively in order to amplify a target nucleotide sequence within a g35030 nucleic acid sequence or adjoining region.



Additional preferred nucleic acids of the invention include isolated, purified, or recombinant g35030 polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides of nucleotide positions 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803 and 199122 to 249803 of SEQ ID No 1, or the complements thereof, wherein said contiguous span comprises at least one biallelic marker. Optionally, said contiguous span comprises a g35030-related biallelic marker. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section. Either the original or the alternative allele may be present at said biallelic marker.

As noted above, g35030 gene sequence are indicated by position on SEQ ID No1. Accordingly, in certain embodiments, a g35030 nucleotide sequence may also comprise isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of nucleotide positions 31 to 319608 of SEQ ID No. 1, or the complements thereof. Optionally, said contiguous span comprises a biallelic marker selected from the group consisting of A13 to A18, A20 to A47, A50 to A53, A56, A58, and A60 to A64. Optionally allele 2 is present at the biallelic marker. It should be noted that nucleic acid fragments of any size and sequence may be comprised by the polynucleotides described in this section.

Further nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400 or 500 nucleotides, to the extent that the length of said span is consistent with the length of the SEQ ID, of SEQ ID Nos. 24, 25, 28 and 74. The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity to said span, as well as a purified, isolated, or recombinant nucleic acid that hybridizes with a said span under the stringent hybridization conditions as defined above. Optionally, said contiguous span comprises a biallelic marker selected from the group consisting of A73 to A74, A77 and A124. Optionally allele 2 is present at the biallelic marker. It should be noted that nucleic acid fragments of any size and sequence may be comprised by the polynucleotides described in this section.

Yet further nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60,

70, 80, 90, 100, 150, 200, 500 or 1000 nucleotides, to the extent that said span is consistent with the nucleotide position range, of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 201188 to 201234, 216836 to 216915 and 246273 to 247781, or the complements thereof, as well as  
5 polynucleotides having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with said span, and polynucleotides capable of hybridizing with said span. In other embodiments, said contiguous span may specifically exclude one or more of the following nucleotide positions of SEQ ID No. 1: 201188 to 201234, 216836 to 216915, 214676 to 214793 and 215702 to 215746.

10 The present invention also comprises a purified or isolated nucleic acid encoding a g35030 protein having the amino acid sequence of any one of SEQ ID Nos 18 to 23 or a peptide fragment or variant thereof.

It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

15 While this section is entitled "Genomic Sequences of g35030," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences g35030 on either side or between two or more such genomic sequences.

#### ***g35030 cDNA Sequences***

20 The expression of the g35030 gene has been shown to lead to the production of several mRNA species. Several cDNA sequences corresponding to these mRNA are set forth in SEQ ID Nos 2 to 17.

The invention encompasses a purified, isolated, or recombinant nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 17,  
25 complementary sequences thereto, splice variants thereof, as well as allelic variants, and fragments thereof. Moreover, preferred polynucleotides of the invention include purified, isolated, or recombinant g35030 cDNAs consisting of, consisting essentially of, or comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 17. Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant  
30 polynucleotides comprising a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 75, 80, 100, 200, 500 or 1000 nucleotides, to the extent that the length of said contiguous span is consistent with the length of the SEQ ID, of a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 17, or the complements thereof.

It should be noted that nucleic acid fragments of any size and sequence may also be

comprised by the polynucleotides described in this section.

The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 70, 80, 85, 90 or 95% nucleotide identity with a polynucleotide selected from the group consisting of SEQ ID Nos 2 to 17, advantageously 99% nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide selected from the group consisting of SEQ ID Nos 2 to 17, or a sequence complementary thereto or a biologically active fragment thereof.

Another object of the invention relates to purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of SEQ ID Nos 2 to 17, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

The g35030 cDNA forms of SEQ ID Nos 2 to 17 are further described in Table 2 below. Shown on the Table 2 are the positions of the 5' UTR, the open reading frame (ORF), the 3' UTR and the polyA signal on the respective SEQ ID No. Also shown are the g35030 exons comprising the cDNA form of a particular SEQ ID No.

Table 2

cDNA	SEQ ID No of cDNA	Position range of 5' UTR in SEQ ID		Position range of ORF in SEQ ID		Position range of 3' UTR in SEQ ID		Position range of polyA signal in SEQ ID	
VV1WYZ	2	1	95	96	167	168	2226	2200	2205
VV1V3WYZ	3	1	95	96	167	168	2431	2405	2410
V2WYZ	4	1	95	96	311	312	2215	2189	2194
VWYZ	5	1	95	96	212	213	2132	2106	2111
V2YZ	6	1	95	96	260	261	1981	1955	1960
VV1YZ	7	1	95	96	167	168	1992	1966	1971
VYZ	8	1	95	96	182	183	1898	1872	1877
VV1Z	9	1	95	96	167	168	1783	1757	1762
V2V1WYZ	10	1	95	96	311	312	2309	2283	2288
V2V1YZ	11	1	95	96	311	312	2075	2049	2054
VWZ	12	1	95	96	212	213	1923	1897	1902
VV1V4WYZ	13	1	95	96	167	168	2308	2282	2287
VV1W2YZ	14	1	95	96	167	168	2706	2680	2685
VW2YZ	15	1	95	96	212	213	2612	2586	2591

STUV	16	1	370	371	436	437	434	-	-
S2TUV	17	1	696	697	762	763	760	-	-

The present invention thus further encompasses variant g35030 polynucleotides having at least one nucleotide substitution, insertion or deletion as described further herein. In preferred embodiments described in Table 3, the invention comprises g35030 polynucleotides comprising a variation as described herein by biallelic markers 8-126-286 (also referred to as 8-130-143) and 8-155-258. The invention thus encompasses purified, isolated, or recombinant polynucleotides and polypeptides encoded thereby, wherein the polynucleotides comprise a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 100, 150, or 200 nucleotides of SEQ ID No 2 to 17 or the complement thereof, wherein said contiguous span further comprises nucleotide position 132 of any of SEQ ID Nos 2 to 15 and 17, or nucleotide position 407 of SEQ ID No 16. Optionally, an A is present at said nucleotide position; optionally a G is present at said nucleotide position. In a further embodiment, said contiguous span comprises nucleotide position 328 or SEQ ID 3, or the complement thereof, and optionally a C is present at said position, or optionally a T is present at said position.

Table 3

SEQ ID No	cDNA form	Polymorphism reference	Alleles		Position in SEQ ID No 1	Position in SEQ ID No of cDNA	Position in amino acid seq
2	V1WYZ	8-126-286/ 8-130-143	A	G	216967	132	13
3	VV1V3WYZ					132	13
4	V2WYZ					132	13
5	VWYZ					132	13
6	V2YZ					132	13
7	VV1YZ					132	13
8	VYZ					132	13
9	VV1Z					132	13
10	V2V1WYZ					132	13
11	V2V1YZ					132	13
12	VWZ					132	13
13	VV1V4WYZ					132	13
14	VV1W2YZ					132	13
15	VW2YZ					132	13
16	STUV					407	13
17	S2TUV					733	13
3	VV1V3WYZ	8-155-258	C	T	238789	VV1V3WYZ:328	-

While this section is entitled "g35030 cDNA Sequences," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of g35030 on either side or between

two or more such genomic sequences.

#### G35030 Coding Regions

The *g35030* open reading frame is contained in the corresponding mRNA of a cDNA sequence selected from the group consisting of SEQ ID Nos 2 to 17. The effective *g35030* coding sequence (CDS) may include several forms as indicated above, in some embodiments encompassing isolated, purified, and recombinant polynucleotides which encode a polypeptide comprising a contiguous span of at least 4 amino acids, preferably 6, more preferably at least 8 or 10 amino acids, yet more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 18 to 23. The effective *g35030* coding sequence (CDS) may comprise the region between the first nucleotide of the ATG codon and the end nucleotide of the stop codon of SEQ ID Nos 2 to 17 as indicated in Table 2 above.

The above disclosed polynucleotide that contains the coding sequence of the *g35030* gene may be expressed in a desired host cell or a desired host organism when this polynucleotide is placed under the control of suitable expression signals. The expression signals may be either the expression signals contained in the regulatory regions in the *g35030* gene of the invention or in contrast the signals may be exogenous regulatory nucleic sequences. Such a polynucleotide, when placed under the suitable expression signals, may also be inserted in a vector for its expression and/or amplification.

#### Regulatory Sequences Of *g35030*

As mentioned, the genomic sequence of the *g35030* gene contains regulatory sequences both in the non-coding 5'-flanking region and in the non-coding 3'-flanking region that border the *g35030* coding region containing the exons of the gene.

Polynucleotides derived from the 5' and 3' regulatory regions are useful in order to detect the presence of at least a copy of a *g35030* nucleotide sequence of SEQ ID No 1 or a fragment thereof in a test sample.

The promoter activity of the 5' regulatory regions contained in *g35030* can be assessed as described below.

In order to identify the relevant biologically active polynucleotide fragments or variants of a *g35030* regulatory region, one of skill in the art will refer to Sambrook et al.(1989), which describes the use of a recombinant vector carrying a marker gene (i.e. beta galactosidase, chloramphenicol acetyl transferase, etc.) the expression of which will be detected when placed under the control of a biologically active polynucleotide fragment or variant of the *g35030* sequence of SEQ ID No 1. Genomic sequences located upstream of the first exon of the *g35030* gene are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-

Enhancer, p $\beta$ gal-Basic, p $\beta$ gal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech, or pGL2-basic or pGL3-basic promoterless luciferase reporter gene vector from Promega. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, luciferase,  $\beta$  galactosidase, or green fluorescent protein. The sequences upstream of the g35030 coding region are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for increasing transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Promoter sequence within the upstream genomic DNA may be further defined by constructing nested 5' and/or 3' deletions in the upstream DNA using conventional techniques such as Exonuclease III or appropriate restriction endonuclease digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity, such as described, for example, by Coles et al.(1998). In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into cloning sites in promoter reporter vectors. This type of assay is well-known to those skilled in the art and is described in WO 97/17359, US Patent No. 5,374,544; EP 582 796; US Patent No. 5,698,389; US 5,643,746; US Patent No. 5,502,176; and US Patent 5,266,488.

The strength and the specificity of the promoter of the g35030 gene can be assessed through the expression levels of a detectable polynucleotide operably linked to the g35030 promoter in different types of cells and tissues. The detectable polynucleotide may be either a polynucleotide that specifically hybridizes with a predefined oligonucleotide probe, or a polynucleotide encoding a detectable protein, including a g35030 polypeptide or a fragment or a variant thereof. This type of assay is well-known to those skilled in the art and is described in US Patent No. 5,502,176; and US Patent No. 5,266,488. Some of the methods are discussed in more detail below.

Polynucleotides carrying the regulatory elements located at the 5' end and at the 3' end of the g35030 coding region may be advantageously used to control the transcriptional and translational activity of an heterologous polynucleotide of interest.

Thus, the present invention also concerns a purified or isolated nucleic acid comprising  
5 a polynucleotide which is selected from the group consisting of the 5' and 3' regulatory regions of g35030, or a sequence complementary thereto or a biologically active fragment or variant thereof. In one aspect, "5' regulatory region" may comprise the nucleotide sequence located between positions 199122 to 201122 of SEQ ID No 1. In one aspect, "3' regulatory region" may comprise the nucleotide sequence located between positions 247803 to 249803 of SEQ ID  
10 No 1.

The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 95% nucleotide identity with a polynucleotide selected from the group consisting of the 5' and 3' regulatory regions, advantageously 99 % nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a  
15 polynucleotide selected from the group consisting of the 5' and 3' regulatory regions, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

Another object of the invention consists of purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of the nucleotide  
20 sequences of the 5'- and 3' regulatory regions of g35030, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

Preferred fragments of the 5' regulatory region have a length of about 1500 or 1000 nucleotides, preferably of about 500 nucleotides, more preferably about 400 nucleotides, even more preferably 300 nucleotides and most preferably about 200 nucleotides.

25 Preferred fragments of the 3' regulatory region are at least 50, 100, 150, 200, 300 or 400 bases in length.

"Biologically active" g35030 regulatory polynucleotide derivatives of SEQ ID No 1 are polynucleotides comprising or alternatively consisting in a fragment of said polynucleotide which is functional as a regulatory region for expressing a recombinant polypeptide or a  
30 recombinant polynucleotide in a recombinant cell host. It could act either as an enhancer or as a repressor.

For the purpose of the invention, a nucleic acid or polynucleotide is "functional" as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide if said regulatory polynucleotide contains nucleotide sequences which contain transcriptional and  
35 translational regulatory information, and such sequences are "operably linked" to nucleotide

sequences which encode the desired polypeptide or the desired polynucleotide.

The regulatory polynucleotides of the invention may be prepared from the nucleotide sequence of SEQ ID No 1 by cleavage using suitable restriction enzymes, as described for example in Sambrook et al.(1989). The regulatory polynucleotides may also be prepared by digestion of SEQ ID No 1 by an exonuclease enzyme, such as Bal31 (Wabiko et al., 1986). These regulatory polynucleotides can also be prepared by nucleic acid chemical synthesis, as described elsewhere in the specification.

The g35030 regulatory polynucleotides according to the invention may be part of a recombinant expression vector that may be used to express a coding sequence in a desired host cell or host organism. The recombinant expression vectors according to the invention are described elsewhere in the specification.

A preferred 5'-regulatory polynucleotide of the invention includes the 5'-untranslated region (5'-UTR) of the g35030 cDNA, or a biologically active fragment or variant thereof.

A preferred 3'-regulatory polynucleotide of the invention includes the 3'-untranslated region (3'-UTR) of the g35030 cDNA, or a biologically active fragment or variant thereof.

A further object of the invention consists of a purified or isolated nucleic acid comprising:

a) a nucleic acid comprising a regulatory nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence comprising a polynucleotide of the g35030 5' regulatory region or a complementary sequence thereto;

(ii) a nucleotide sequence comprising a polynucleotide having at least 95% of nucleotide identity with the nucleotide sequence of the g35030 5' regulatory region or a complementary sequence thereto;

(iii) a nucleotide sequence comprising a polynucleotide that hybridizes under stringent hybridization conditions with the nucleotide sequence of the g35030 5' regulatory region or a complementary sequence thereto; and

(iv) a biologically active fragment or variant of the polynucleotides in (i), (ii) and (iii);

b) a polynucleotide encoding a desired polypeptide or a nucleic acid of interest, operably linked to the nucleic acid defined in (a) above; and

c) optionally, a nucleic acid comprising a 3'- regulatory polynucleotide, preferably a 3'- regulatory polynucleotide of the g35030 gene.

In a specific embodiment of the nucleic acid defined above, said nucleic acid includes the 5'-untranslated region (5'-UTR) of the g35030 cDNA, or a biologically active fragment or variant thereof.



In a second specific embodiment of the nucleic acid defined above, said nucleic acid includes the 3'-untranslated region (3'-UTR) of the g35030 cDNA, or a biologically active fragment or variant thereof.

5 The regulatory polynucleotide of the 5' regulatory region, or its biologically active fragments or variants, is operably linked at the 5'-end of the polynucleotide encoding the desired polypeptide or polynucleotide.

The regulatory polynucleotide of the 3' regulatory region, or its biologically active fragments or variants, is advantageously operably linked at the 3'-end of the polynucleotide encoding the desired polypeptide or polynucleotide.

10 The desired polypeptide encoded by the above-described nucleic acid may be of various nature or origin, encompassing proteins of prokaryotic or eukaryotic origin. Among the polypeptides expressed under the control of a g35030 regulatory region include bacterial, fungal or viral antigens. Also encompassed are eukaryotic proteins such as intracellular proteins, like "house keeping" proteins, membrane-bound proteins, like receptors, and secreted proteins like  
15 endogenous mediators such as cytokines. The desired polypeptide may be the g35030 protein, especially the protein of the amino acid sequences of SEQ ID Nos 18 to 23, or a fragment or a variant thereof.

The desired nucleic acids encoded by the above-described polynucleotide, usually an RNA molecule, may be complementary to a desired coding polynucleotide, for example to the  
20 g35030 coding sequence, and thus useful as an antisense polynucleotide.

Such a polynucleotide may be included in a recombinant expression vector in order to express the desired polypeptide or the desired nucleic acid in host cell or in a host organism. Suitable recombinant vectors that contain a polynucleotide such as described herein are disclosed elsewhere in the specification.

25

#### **Polynucleotide Constructs**

The terms "polynucleotide construct" and "recombinant polynucleotide" are used interchangeably herein to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are  
30 not found as contiguous nucleotide sequences in their initial natural environment. It should be noted that the present invention embodies recombinant vectors comprising any one of the polynucleotides described in the present invention.

**DNA Constructs that Enables Directing Temporal and Spatial Expression of  
35 g35030 Nucleic Acid Sequences in Recombinant Cell Hosts and in Transgenic Animals**

In order to study the physiological and phenotypic consequences of a lack of synthesis of a protein encoded by a nucleotide sequence comprising a g35030 polynucleotide, both at the cell level and at the multi cellular organism level, the invention also encompasses DNA constructs and recombinant vectors enabling a conditional expression of a specific allele of a nucleotide sequence comprising a g35030 polynucleotide and also of a copy of a sequence comprising a nucleotide sequence of a g35030 polynucleotide, or a fragment thereof, harboring substitutions, deletions, or additions of one or more bases. These base substitutions, deletions or additions may be located either in an exon, an intron or a regulatory sequence, in particular a 5' regulatory sequence of a g35030 polynucleotide. In a preferred embodiment, the nucleotide sequence comprising a g35030 polynucleotide further comprises a biallelic marker of the present invention.

A first preferred DNA construct is based on the tetracycline resistance operon *tet* from *E. coli* transposon Tn110 for controlling the expression of a g35030 polynucleotide, such as described by Gossen et al. (1992, 1995) and Furth et al. (1994). Such a DNA construct contains seven *tet* operator sequences from Tn10 (*tetO*) that are fused to either a minimal promoter or a 5'-regulatory sequence of the g35030 polynucleotide, said minimal promoter or said g35030 polynucleotide regulatory sequence being operably linked to a polynucleotide of interest that codes either for a sense or an antisense oligonucleotide or for a polypeptide, including a g35030 polynucleotide-encoded polypeptide or a peptide fragment thereof. This DNA construct is functional as a conditional expression system for the nucleotide sequence of interest when the same cell also comprises a nucleotide sequence coding for either the wild type (*tTA*) or the mutant (*rTA*) repressor fused to the activating domain of viral protein VP16 of herpes simplex virus, placed under the control of a promoter, such as the HCMVIE1 enhancer/promoter or the MMTV-LTR. Indeed, a preferred DNA construct of the invention comprises both the polynucleotide containing the *tet* operator sequences and the polynucleotide containing a sequence coding for the *tTA* or the *rTA* repressor.

In a specific embodiment, the conditional expression DNA construct contains the sequence encoding the mutant tetracycline repressor *rTA*, the expression of the polynucleotide of interest is silent in the absence of tetracycline and induced in its presence.

#### **DNA Constructs Allowing Homologous Recombination: Replacement Vectors**

A second preferred DNA construct will comprise, from 5'-end to 3'-end: (a) a first nucleotide sequence comprising a g35030 polynucleotide; (b) a nucleotide sequence comprising a positive selection marker, such as the marker for neomycine resistance (*neo*); and (c) a second nucleotide sequence comprising a respective g35030 polynucleotide, and is located on the genome downstream of the first g35030 polynucleotide sequence (a).

In a preferred embodiment, this DNA construct also comprises a negative selection marker located upstream the nucleotide sequence (a) or downstream the nucleotide sequence (c). Preferably, the negative selection marker comprises the thymidine kinase (*tk*) gene (Thomas et al., 1986), the hygromycin beta gene (Te Riele et al., 1990), the *hprt* gene (Van der Lugt et al., 1991; Reid et al., 1990) or the Diphtheria toxin A fragment (*Dt-A*) gene (Nada et al., 1993; Yagi et al. 1990). Preferably, the positive selection marker is located within and exon of a g35030 polynucleotide so as to interrupt the sequence encoding the g35030 protein. These replacement vectors are described, for example, by Thomas et al. (1986; 1987), Mansour et al. (1988) and Koller et al. (1992).

The first and second nucleotide sequences (a) and (c) may be indifferently located within a g35030 polynucleotide regulatory sequence, an intronic sequence, an exon sequence or a sequence containing both regulatory and/or intronic and/or exon sequences. The size of the nucleotide sequence of (a) and (c) ranges from 1 to 50 kb, preferably from 1 to 10 kb, more preferably from 2 to 6 kb and most preferably from 2 to 4 kb.

#### **DNA Constructs Allowing Homologous Recombination: Cre-LoxP System.**

These new DNA constructs make use of the site specific recombination system of the P1 phage. The P1 phage possesses a recombinase called Cre which interacts specifically with a 34 base pairs *loxP* site. The *loxP* site is composed of two palindromic sequences of 13 bp separated by a 8 bp conserved sequence (Hoess et al., 1986). The recombination by the Cre enzyme between two *loxP* sites having an identical orientation leads to the deletion of the DNA fragment.

The Cre-*loxP* system used in combination with a homologous recombination technique has been first described by Gu et al. (1993, 1994). Briefly, a nucleotide sequence of interest to be inserted in a targeted location of the genome harbors at least two *loxP* sites in the same orientation and located at the respective ends of a nucleotide sequence to be excised from the recombinant genome. The excision event requires the presence of the recombinase (Cre) enzyme within the nucleus of the recombinant cell host. The recombinase enzyme may be brought at the desired time either by (a) incubating the recombinant cell hosts in a culture medium containing this enzyme, by injecting the Cre enzyme directly into the desired cell, such as described by Araki et al. (1995), or by lipofection of the enzyme into the cells, such as described by Baubonis et al. (1993); (b) transfecting the cell host with a vector comprising the Cre coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter being optionally inducible, said vector being introduced in the recombinant cell

host, such as described by Gu et al.(1993) and Sauer et al.(1988); (c) introducing in the genome of the cell host a polynucleotide comprising the *Cre* coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter is optionally inducible, and said polynucleotide being inserted in the genome of the cell host either by a random insertion event or an homologous recombination event, such as described by Gu et al.(1994).

In a specific embodiment, the vector containing the sequence to be inserted in a g35030 gene sequence by homologous recombination is constructed in such a way that selectable markers are flanked by *loxP* sites of the same orientation, it is possible, by treatment by the *Cre* enzyme, to eliminate the selectable markers while leaving the g35030 polynucleotide sequences of interest that have been inserted by an homologous recombination event. Again, two selectable markers are needed: a positive selection marker to select for the recombination event and a negative selection marker to select for the homologous recombination event. Vectors and methods using the *Cre-loxP* system are described by Zou et al.(1994).

Thus, in one aspect, a further preferred DNA construct of the invention comprises, from 5'-end to 3'-end: (a) a first nucleotide sequence that is comprised by a g35030 polynucleotide; (b) a nucleotide sequence comprising a polynucleotide encoding a positive selection marker, said nucleotide sequence comprising additionally two sequences defining a site recognized by a recombinase, such as a *loxP* site, the two sites being placed in the same orientation; and (c) a second nucleotide sequence comprising a g35030 polynucleotide, and is located on the genome downstream of the first g35030 polynucleotide sequence (a).

The sequences defining a site recognized by a recombinase, such as a *loxP* site, are preferably located within the nucleotide sequence (b) at suitable locations bordering the nucleotide sequence for which the conditional excision is sought. In one specific embodiment, two *loxP* sites are located at each side of the positive selection marker sequence, in order to allow its excision at a desired time after the occurrence of the homologous recombination event.

In a preferred embodiment of a method using the third DNA construct described above, the excision of the polynucleotide fragment bordered by the two sites recognized by a recombinase, preferably two *loxP* sites, is performed at a desired time, due to the presence within the genome of the recombinant host cell of a sequence encoding the *Cre* enzyme operably linked to a promoter sequence, preferably an inducible promoter, more preferably a tissue-specific promoter sequence and most preferably a promoter sequence which is both inducible and tissue-specific, such as described by Gu et al.(1994).

The presence of the *Cre* enzyme within the genome of the recombinant cell host may result from the breeding of two transgenic animals, the first transgenic animal bearing the g35030 polynucleotide -derived sequence of interest containing the *loxP* sites as described

above and the second transgenic animal bearing the *Cre* coding sequence operably linked to a suitable promoter sequence, such as described by Gu et al.(1994).

5 Spatio-temporal control of the *Cre* enzyme expression may also be achieved with an adenovirus based vector that contains the *Cre* gene thus allowing infection of cells, or *in vivo* infection of organs, for delivery of the *Cre* enzyme, such as described by Anton and Graham (1995) and Kanegae et al.(1995).

10 The DNA constructs described above may be used to introduce a desired nucleotide sequence of the invention, preferably a g35030 polynucleotide, and most preferably an altered copy of a g35030 polynucleotide sequence, within a predetermined location of the targeted genome, leading either to the generation of an altered copy of a targeted gene (knock-out homologous recombination) or to the replacement of a copy of the targeted gene by another copy sufficiently homologous to allow an homologous recombination event to occur (knock-in homologous recombination). In a specific embodiment, the DNA constructs described above may be used to introduce a g35030 polynucleotide.

15 **Nuclear Antisense DNA Constructs**

Other compositions containing a vector of the invention comprise an oligonucleotide fragment of the g35030 polynucleotide sequences of SEQ ID No.1 respectively, as an antisense tool that inhibits the expression of the corresponding gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995) or those described in PCT Application No WO 95/24223.

20 Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to the 5' end of a g35030 polynucleotide mRNA. In one embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targeted gene are used.

25 Preferably, the antisense polynucleotides of the invention have a 3' polyadenylation signal that has been replaced with a self-cleaving ribozyme sequence, such that RNA polymerase II transcripts are produced without poly(A) at their 3' ends, these antisense polynucleotides being incapable of export from the nucleus, such as described by Liu et al.(1994). In a preferred embodiment, these g35030 antisense polynucleotides also comprise, 30 within the ribozyme cassette, a histone stem-loop structure to stabilize cleaved transcripts against 3'-5' exonucleolytic degradation, such as the structure described by Eckner et al.(1991).

**Constructs for Activation of g35030 gene**

35 The present invention also encompasses primary, secondary, and immortalized homologously recombinant host cells of vertebrate origin, preferably mammalian origin and particularly human origin, that have been engineered to: a) insert exogenous (heterologous)

polynucleotides into the endogenous chromosomal DNA of a targeted gene, b) delete endogenous chromosomal DNA, and/or c) replace endogenous chromosomal DNA with exogenous polynucleotides. Insertions, deletions, and/or replacements of polynucleotide sequences may be to the coding sequences of the targeted gene and/or to regulatory regions, such as promoter and enhancer sequences, operably associated with the targeted gene.

The present invention further relates to a method of making a homologously recombinant host cell in vitro or in vivo, wherein the expression of a targeted gene not normally expressed in the cell is altered. Preferably the alteration causes expression of the targeted gene under normal growth conditions or under conditions suitable for producing the polypeptide encoded by the targeted gene. The method comprises the steps of: (a) transfecting the cell in vitro or in vivo with a polynucleotide construct, the a polynucleotide construct comprising: (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a transfected cell; and (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination.

The present invention further relates to a method of altering the expression of a targeted gene in a cell in vitro or in vivo wherein the gene is not normally expressed in the cell, comprising the steps of: (a) transfecting the cell in vitro or in vivo with a polynucleotide construct, the a polynucleotide construct comprising: (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a transfected cell; and (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination, thereby producing a homologously recombinant cell; and (c) maintaining the homologously recombinant cell in vitro or in vivo under conditions appropriate for expression of the gene.

The present invention further relates to a method of making a polypeptide of the present invention by altering the expression of a targeted endogenous gene in a cell in vitro or in vivo wherein the gene is not normally expressed in the cell, comprising the steps of: a) transfecting the cell in vitro with a a polynucleotide construct, the a polynucleotide construct comprising: (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a transfected cell; (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination, thereby producing a homologously recombinant cell; and c) maintaining the homologously recombinant cell in vitro or in vivo under conditions appropriate for expression of the gene thereby making the polypeptide.

The present invention further relates to a a polynucleotide construct which alters the expression of a targeted gene in a cell type in which the gene is not normally expressed. This

occurs when the a polynucleotide construct is inserted into the chromosomal DNA of the target cell, wherein the a polynucleotide construct comprises: a) a targeting sequence; b) a regulatory sequence and/or coding sequence; and c) an unpaired splice-donor site, if necessary. Further included are a polynucleotide constructs, as described above, wherein the construct further  
5 comprises A a polynucleotide which encodes a polypeptide and is in-frame with the targeted endogenous gene after homologous recombination with chromosomal DNA.

The compositions may be produced, and methods performed, by techniques known in the art, such as those described in U.S. Patent Nos: 6,054,288; 6,048,729; 6,048,724; 6,048,524; 5,994,127; 5,968,502; 5,965,125; 5,869,239; 5,817,789; 5,783,385; 5,733,761; 5,641,670;  
10 5,580,734 ; International Publication Nos: WO96/29411, WO 94/12650; and scientific articles including 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989) (the disclosures of each of which are incorporated by reference in their entirety).

#### **Oligonucleotide Probes And Primers**

15 The polynucleotides of the invention are useful in order to detect the presence of at least a copy of a g35030 nucleotide sequence of SEQ ID Nos 1 to 17 or of the respective g35030 polynucleotide or gene, or a fragment, complement, or variant thereof in a test sample.

Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35,  
20 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides, to the extent that said span is consistent with the length of the nucleotide position range, of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 4, 5, 7 or 10 of the following nucleotide positions of SEQ ID No 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to  
25 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803 and 199122 to 249803, or a complementary sequence thereto or a fragment thereof.

Probes and primers of the invention also include isolated, purified, or recombinant polynucleotides having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a contiguous  
30 span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of nucleotide positions 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803  
35 and 199122 to 249803 of SEQ ID No. 1. Preferred probes and primers of the invention also

include isolated, purified, or recombinant polynucleotides comprising a g35030 nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with at least one sequence selected from the group consisting of the following nucleotide positions of SEQ ID No. 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803 and 199122 to 249803; or a complementary sequence thereto or a fragment thereof.

The invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of nucleotide positions 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803 and 199122 to 249803 of SEQ ID No. 1, or a variant thereof or a sequence complementary thereto.

Probes and primers of the invention further include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides, to the extent that said span is consistent with the length of the nucleotide position range, of SEQ ID No 2 to 17 or 79 to 132. Also included are isolated, purified, or recombinant polynucleotides having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 2 to 17 or 79 to 132, or a complementary sequence thereto, as well as isolated, purified, or recombinant polynucleotides comprising a g35030 nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with at least one sequence selected from the group consisting of the following nucleotide positions of SEQ ID No. 2 to 17 or 79 to 132; or a complementary sequence thereto or a fragment thereof. The invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of nucleotide SEQ ID No. 2 to 17 or 79 to 132, or a variant thereof or a sequence complementary thereto.

The formation of stable hybrids depends on the melting temperature ( $T_m$ ) of the DNA. The  $T_m$  depends on the length of the primer or probe, the ionic strength of the solution and the G+C content. The higher the G+C content of the primer or probe, the higher is the melting



temperature because G:C pairs are held by three H bonds whereas A:T pairs have only two. The GC content in the probes of the invention usually ranges between 10 and 75 %, preferably between 35 and 60 %, and more preferably between 40 and 55 %.

5 A probe or a primer according to the invention may be between 8 and 2000 nucleotides in length, or is specified to be at least 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 , 1000 nucleotides in length. More particularly, the length of these probes can range from 8, 10, 15, 20, or 30 to 100 nucleotides, preferably from 10 to 50, more preferably from 15 to 30 nucleotides. Shorter probes tend to lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the  
10 template. Longer probes are expensive to produce and can sometimes self-hybridize to form hairpin structures. The appropriate length for primers and probes under a particular set of assay conditions may be empirically determined by one of skill in the art.

The primers and probes can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a  
15 method such as the phosphodiester method of Narang et al.(1979), the phosphodiester method of Brown et al.(1979), the diethylphosphoramidite method of Beaucage et al.(1981) and the solid support method described in EP 0 707 592.

Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent  
20 Application WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444; 5,034,506 and 5,142,047. The probe may have to be rendered "non-extendable" in that additional dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation.  
25 For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group. Alternatively, the 3' hydroxyl group simply can be cleaved, replaced or modified; U.S. Patent Application Serial No. 07/049,061 filed April 19, 1993, describes modifications which can be used to render a probe non-extendable.

30 Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating a label detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive substances ( $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ ,  $^{125}\text{I}$ ), fluorescent dyes (5-bromodesoxyuridin, fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at their 3'  
35 and 5' ends. Examples of non-radioactive labeling of nucleic acid fragments are described in

the French patent No. FR-7810975 or by Urdea et al (1988) or Sanchez-Pescador et al (1988). In addition, the probes according to the present invention may have structural characteristics such that they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European patent No. EP 0 225 807 (Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in a sequence comprising a polynucleotide of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132, or a g35030 polynucleotide or gene or mRNA using other techniques.

Any of the polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which

is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, durocytes and other configurations known to those of ordinary skill in the art. The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

Consequently, the invention also comprises a method for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132, a fragment or a variant thereof or a complementary sequence thereto in a sample, said method comprising the following steps of:

a) bringing into contact a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132, a fragment or a variant thereof or a complementary sequence thereto and the sample to be assayed; and

b) detecting the hybrid complex formed between the probe and a nucleic acid in the sample.

The invention further concerns a kit for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132, a fragment or a variant thereof or a complementary sequence thereto in a sample, said kit comprising:

a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the

nucleotide sequences of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132, a fragment or a variant thereof or a complementary sequence thereto; and

b) optionally, the reagents necessary for performing the hybridization reaction.

In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate. In a third preferred embodiment, the nucleic acid probe or the plurality of nucleic acid probes comprise either a sequence which is selected from the group consisting of the nucleotide sequences of P1 to P127 and the complementary sequence thereto, B1 to B114, C1 to C114, D1 to D127, E1 to E127, or a nucleotide sequence comprising a biallelic marker selected from the group consisting of A1 to A127, or the complements thereto.

#### Oligonucleotide Arrays

A substrate comprising a plurality of oligonucleotide primers or probes of the invention may be used either for detecting or amplifying targeted sequences in a nucleotide sequence of SEQ ID No. 1, more particularly in a g35030 polynucleotide, or in genes comprising a g35030 polynucleotide and may also be used for detecting mutations in the coding or in the non-coding sequences of a g35030 nucleic acid sequence, or genes comprising a g35030 nucleic acid sequence.

Any polynucleotide provided herein may be attached in overlapping areas or at random locations on the solid support. Alternatively the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as Genechips™, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., 1991, incorporated herein by reference). The immobilization of arrays of oligonucleotides

on solid supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPS™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPS™ technologies are provided in US Patents 5,143,854; and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

In another embodiment of the oligonucleotide arrays of the invention, an oligonucleotide probe matrix may advantageously be used to detect mutations occurring in a g35030 polynucleotide, including in genes comprising a g35030 polynucleotide and preferably in a g35030 polynucleotide regulatory region. For this particular purpose, probes are specifically designed to have a nucleotide sequence allowing their hybridization to the genes that carry known mutations (either by deletion, insertion or substitution of one or several nucleotides). By known mutations in a g35030 polynucleotide, it is meant, mutations in a g35030 polynucleotide that have been identified according to the technique used by Huang et al.(1996) or Samsoni et al.(1996), for example, may be used to identify such mutations.

Another technique that is used to detect mutations in a g35030 polynucleotide is the use of a high-density DNA array. Each oligonucleotide probe constituting a unit element of the high density DNA array is designed to match a specific subsequence of a g35030 polynucleotide. Thus, an array consisting of oligonucleotides complementary to subsequences of the target gene sequence is used to determine the identity of the target sequence with the wild-type gene sequence, measure its amount, and detect differences between the target sequence and the reference wild-type nucleic acid sequence of a g35030 polynucleotide. In one such design, termed 4L tiled array, is implemented a set of four probes (A, C, G, T), preferably 15-nucleotide oligomers. In each set of four probes, the perfect complement will hybridize more strongly than mismatched probes. Consequently, a nucleic acid target of length L is scanned for mutations with a tiled array containing 4L probes, the whole probe set containing all the possible mutations in the known wild reference sequence. The hybridization signals of the 15-mer probe set tiled array are perturbed by a single base change in the target sequence. As a consequence, there is a characteristic loss of signal or a "footprint" for the probes flanking a mutation position. This technique was described by Chee et al. in 1996.

Consequently, the invention concerns an array of nucleic acid molecules comprising at least one polynucleotide described above as probes and primers. Preferably, the invention concerns an array of nucleic acid comprising at least two polynucleotides described above as probes and primers.

5                   **G35030 Proteins and Polypeptide Fragments:**

The terms "g35030 polypeptides", are used herein to embrace all of the proteins and polypeptides encoded by the respective g35030 polypeptides of the present invention. Forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies proteins from  
10 humans, mammals, primates, non-human primates, and includes isolated or purified g35030 proteins consisting, consisting essentially, or comprising the sequence of SEQ ID Nos 18 to 23.

It should be noted that the g35030 proteins of the invention also comprise naturally-occurring variants of the amino acid sequence of the respective human g35030 proteins.

The present invention embodies isolated, purified, and recombinant polypeptides  
15 comprising a contiguous span of at least 4 amino acids, preferably at least 6, more preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 95 or 100 amino acids, to the extent that said span is consistent with the length of a particular SEQ ID, of SEQ ID Nos 18 to 23. In other preferred embodiments the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition,  
20 swap or truncation of the amino acids in a g35030 protein sequence. In one aspect, the contiguous stretch of amino acids comprises deletion, addition, swap or truncation at amino acid position 13 of SEQ ID Nos 18 to 23, corresponding to polymorphism described herein by biallelic markers 8-126-286 (also referred to as 8-130-143) and 8-155-258.

The invention further embodies g35030 polypeptides, including isolated and  
25 recombinant polypeptides, encoded respectively by g35030 polynucleotides consisting, consisting essentially, or comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or 500 nucleotides of SEQ ID Nos 2 to 17.

The invention further embodies g35030 polypeptides, including isolated and  
30 recombinant polypeptides, encoded respectively by g35030 polynucleotides consisting, consisting essentially, or comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or 500 nucleotides, to the extent that the length of said span is consistent with the nucleotide position range, of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 4, 5, 7 or 10 of the following nucleotide positions of SEQ ID No 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to

216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802, or the complements thereof.

g35030 proteins are preferably isolated from human or mammalian tissue samples or  
5 expressed from human or mammalian genes. The g35030 polypeptides of the invention can be made using routine expression methods known in the art. The polynucleotide encoding the desired polypeptide, is ligated into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems is used in forming recombinant polypeptides, and a summary of some of the more common systems. The polypeptide is then isolated from lysed  
10 cells or from the culture medium and purified to the extent needed for its intended use. Purification is by any technique known in the art, for example, differential extraction, salt fractionation, chromatography, centrifugation, and the like. See, for example, Methods in Enzymology for a variety of methods for purifying proteins.

In addition, shorter protein fragments can be produced by chemical synthesis.  
15 Alternatively the proteins of the invention is extracted from cells or tissues of humans or non-human animals. Methods for purifying proteins are known in the art, and include the use of detergents or chaotropic agents to disrupt particles followed by differential extraction and separation of the polypeptides by ion exchange chromatography, affinity chromatography, sedimentation according to density, and gel electrophoresis.

20 Any g35030 cDNA or fragment thereof, including the respective cDNA sequences of SEQ ID Nos 2 to 17, is used to express g35030 proteins and polypeptides. The nucleic acid encoding the g35030 protein or polypeptide to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The g35030 insert in the expression vector may comprise the full coding sequence for the respective g35030 protein or a portion thereof. For  
25 example, the g35030 derived insert may encode a polypeptide comprising at least 10 consecutive amino acids of the respective g35030 protein of SEQ ID Nos 18 to 23.

The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla,  
30 California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence is optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Patent No. 5,082,767.

35 In one embodiment, the entire coding sequence of the g35030 cDNA through the poly A signal of the cDNA are operably linked to a promoter in the expression vector. Alternatively, if the

nucleic acid encoding a portion of the g35030 protein lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the insert from the g35030 cDNA lacks a poly A signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglI and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The nucleic acid encoding the g35030 protein or a portion thereof is obtained by PCR from a bacterial vector containing the a nucleotide sequence of an exon of a g35030 gene as described herein and in SEQ ID No 1, or from a g35030 cDNA comprising a nucleic acid of SEQ ID No 2 to 17 using oligonucleotide primers complementary to the g35030 nucleic acid or portion thereof and containing restriction endonuclease sequences for Pst I incorporated into the 5' primer and BglII at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the sequence encoding the g35030 protein or a portion thereof is positioned properly with respect to the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1, now containing a poly A signal and digested with BglII.

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri).

Alternatively, the nucleic acids encoding the g35030 protein or a portion thereof is cloned into pED6dpc2 (Genetics Institute, Cambridge, MA). The resulting pED6dpc2 constructs is transfected into a suitable host cell, such as COS 1 cells. Methotrexate resistant cells are selected and expanded.

The above procedures may also be used to express a mutant g35030 protein responsible for a detectable phenotype or a portion thereof.

The expressed proteins are purified using conventional purification techniques such as ammonium sulfate precipitation or chromatographic separation based on size or charge. The protein encoded by the nucleic acid insert may also be purified using standard immunochromatography techniques. In such procedures, a solution containing the expressed g35030 protein or portion thereof, such as a cell extract, is applied to a column having antibodies against the g35030 protein or portion thereof is attached to the chromatography matrix. The expressed protein is allowed to bind the immunochromatography column. Thereafter, the column



is washed to remove non-specifically bound proteins. The specifically bound expressed protein is then released from the column and recovered using standard techniques.

5 To confirm expression of the g35030 protein or a portion thereof, the proteins expressed from host cells containing an expression vector containing an insert encoding the g35030 protein or a portion thereof can be compared to the proteins expressed in host cells containing the expression vector without an insert. The presence of a band in samples from cells containing the expression  
10 vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the g35030 protein or a portion thereof is being expressed. Generally, the band will have the mobility expected for the g35030 protein or portion thereof. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

Antibodies capable of specifically recognizing the expressed g35030 protein or a portion thereof are described below.

15 If antibody production is not possible, the nucleic acids encoding the g35030 protein or a portion thereof is incorporated into expression vectors designed for use in purification schemes employing chimeric polypeptides. In such strategies the nucleic acid encoding the g35030 protein or a portion thereof is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera is  $\beta$ -globin or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to  $\beta$ -globin or nickel attached thereto is then used to purify  
20 the chimeric protein. Protease cleavage sites is engineered between the  $\beta$ -globin gene or the nickel binding polypeptide and the g35030 protein or portion thereof. Thus, the two polypeptides of the chimera is separated from one another by protease digestion.

One useful expression vector for generating  $\beta$ -globin chimeric proteins is pSG5 (Stratagene), which encodes rabbit  $\beta$ -globin. Intron II of the rabbit  $\beta$ -globin gene facilitates  
25 splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al., (1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems  
30 such as the In vitro Express<sup>TM</sup> Translation Kit (Stratagene).

#### **Antibodies That Bind g35030 Polypeptides of the Invention**

Any g35030 polypeptide or whole protein may be used to generate antibodies capable of specifically binding to an expressed g35030 protein or fragments thereof.

For an antibody composition to specifically bind to a g35030 protein, it must

demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for full length g35030 protein than for any full length protein in an ELISA, RIA, or other antibody-based binding assay. For an antibody composition to specifically bind to a variant g35030 protein, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding  
5 affinity for the respective full length variant g35030 protein than for the respective reference g35030 full length protein in an ELISA, RIA, or other antibody-based binding assay.

One antibody composition of the invention is capable of specifically binding or specifically binds to the respective g35030 proteins of SEQ ID Nos 18 to 23. Other antibody compositions of the invention are capable of specifically binding or specifically bind to a  
10 g35030 protein variant.

In one embodiment, the invention concerns antibody compositions, either polyclonal or monoclonal, capable of selectively binding, or selectively bind to an epitope-containing a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a g35030  
15 polypeptide.

The invention also concerns a purified or isolated antibody capable of specifically binding to a mutated g35030 protein or to a fragment or variant thereof comprising an epitope of the mutated g35030 protein. In another preferred embodiment, the present invention concerns an antibody capable of binding to a polypeptide comprising at least 10 consecutive  
20 amino acids of a g35030 protein and including at least one of the amino acids which can be encoded by the trait causing mutations.

An epitope can comprise as few as 3 amino acids in a spatial conformation, which is unique to the epitope. Generally an epitope consists of at least 6 such amino acids, and more often at least 8-10 such amino acids. In preferred embodiment, antigenic epitopes comprise a  
25 number of amino acids that is any integer between 3 and 50. Fragments which function as epitopes may be produced by any conventional means. Epitopes can be determined by a Jameson-Wolf antigenic analysis, for example, performed using the computer program PROTEAN, using default parameters (Version 4.0 Windows, DNASTAR, Inc., 1228 South Park Street Madison, WI.

Predicted antigenic epitopes are shown below. It is pointed out that the immunogenic epitope list describe only amino acid residues comprising epitopes predicted to have the highest degree of immunogenicity by a particular algorithm. Polypeptides of the present invention that are not specifically described as immunogenic are not considered non-antigenic. This is  
30 because they may still be antigenic *in vivo* but merely not recognized as such by the particular algorithm used. Alternatively, the polypeptides are probably antigenic *in vitro* using methods  
35

such a phage display. Thus, listed below are the amino acid residues comprising only preferred epitopes, not a complete list. In fact, all fragments of the polypeptides of the present invention, at least 6 amino acids residues in length, are included in the present invention as being useful as antigenic epitope. Moreover, listed below are only the critical residues of the epitopes  
5 determined by the Jameson-Wolf analysis. Thus, additional flanking residues on either the N-terminal, C-terminal, or both N- and C-terminal ends may be added to the sequences listed to generate an epitope-bearing portion at least 6 residues in length. Amino acid residues comprising other immunogenic epitopes may be determined by algorithms similar to the Jameson-Wolf analysis or by *in vivo* testing for an antigenic response using the methods  
10 described herein or those known in the art.

The epitope-bearing fragments of the present invention preferably comprises 6 to 50 amino acids (i.e. any integer between 6 and 50, inclusive) of a polypeptide of the present invention. Also, included in the present invention are antigenic fragments between the integers of 6 and the full length g35030 sequence.

15 Preferred g35030 immunogenic epitopes:

SEQ ID No. 18: Val-9 to Arg-11; Gly-21 to Lys-22

SEQ ID No. 19: Val-9 to Arg-11; Pro-45 to Pro-52

SEQ ID No. 20: Val-9 to Arg-11

SEQ ID No. 21: Val-9 to Arg-11; Ser-40 to Ser-42

20 SEQ ID No. 22: Val-9 to Arg-11

SEQ ID No. 23: Val-9 to Arg-11; Pro-45 to Glu-49; Ser-57 to Val-60

Non-human animals or mammals, whether wild-type or transgenic, which express a different species of g35030 than the one to which antibody binding is desired, and animals  
25 which do not express g35030 (i.e. a g35030 knock out animal as described herein) are particularly useful for preparing antibodies. g35030 knock out animals will recognize all or most of the exposed regions of a g35030 protein as foreign antigens, and therefore produce antibodies with a wider array of g35030 epitopes. Moreover, smaller polypeptides with only 10 to 30 amino acids may be useful in obtaining specific binding to any one of the g35030 proteins.  
30 In addition, the humoral immune system of animals which produce a species of g35030 that resembles the antigenic sequence will preferentially recognize the differences between the animal's native g35030 species and the antigen sequence, and produce antibodies to these unique sites in the antigen sequence. Such a technique will be particularly useful in obtaining antibodies that specifically bind to any one of the g35030 proteins.

35 Antibody preparations prepared according to either protocol are useful in quantitative

immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

5           The antibodies of the invention may be labeled by any one of the radioactive, fluorescent or enzymatic labels known in the art.

Consequently, the invention is also directed to a method for detecting specifically the presence of a g35030 polypeptide according to the invention in a biological sample, said method comprising the following steps:

10           a) bringing into contact the biological sample with a polyclonal or monoclonal antibody that specifically binds a g35030 polypeptide comprising an amino acid sequence of SEQ ID Nos. 18 to 23, or to a peptide fragment or variant thereof; and

b) detecting the antigen-antibody complex formed.

15           The invention also concerns a diagnostic kit for detecting *in vitro* the presence of a g35030 polypeptide according to the present invention in a biological sample, wherein said kit comprises:

a) a polyclonal or monoclonal antibody that specifically binds a g35030 polypeptide comprising an amino acid sequence of SEQ ID Nos 18 to 23, or to a peptide fragment or variant thereof, optionally labeled;

20           b) a reagent allowing the detection of the antigen-antibody complexes formed, said reagent carrying optionally a label, or being able to be recognized itself by a labeled reagent, more particularly in the case when the above-mentioned monoclonal or polyclonal antibody is not labeled by itself.

25           The present invention thus relates to antibodies and T-cell antigen receptors (TCR), which specifically bind the polypeptides, and more specifically, the epitopes of the polypeptides of the present invention, including but not limited to IgG (including IgG1, IgG2, IgG3, and IgG4), IgA (including IgA1 and IgA2), IgD, IgE, or IgM, and IgY. In a preferred embodiment the antibodies are human antigen binding antibody fragments of the present invention include, but are not limited to, Fab, Fab' F(ab)2 and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a V<sub>L</sub> or V<sub>H</sub> domain. The antibodies may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine, rabbit, goat, guinea pig, camel, horse, or chicken.

30           Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entire or partial of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are any combinations of

35

variable region(s) and hinge region, CH1, CH2, and CH3 domains. The present invention further includes chimeric, humanized, and human monoclonal and polyclonal antibodies, which specifically bind the polypeptides of the present invention. The present invention further includes antibodies that are anti-idiotypic to the antibodies of the present invention.

5           The antibodies of the present invention may be monospecific, bispecific, trispecific or have greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for heterologous compositions, such as a heterologous polypeptide or solid support material. See, e.g., WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, 10   A. et al. (1991) J. Immunol. 147:60-69; US Patents 5,573,920, 4,474,893, 5,601,819, 4,714,681, 4,925,648; Kostelny, S.A. et al. (1992) J. Immunol. 148:1547-1553.

          Antibodies of the present invention may be described or specified in terms of the epitope(s) or epitope-bearing portion(s) of a polypeptide of the present invention, which are recognized or specifically bound by the antibody. In the case of proteins of the present 15   invention secreted proteins, the antibodies may specifically bind a full-length protein encoded by a nucleic acid of the present invention, a mature protein (i.e., the protein generated by cleavage of the signal peptide) encoded by a nucleic acid of the present invention, a signal peptide encoded by a nucleic acid of the present invention, or any other polypeptide of the present invention. Therefore, the epitope(s) or epitope bearing polypeptide portion(s) may be 20   specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or otherwise described herein (including the sequence listing). Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded as individual species. Therefore, the present invention includes antibodies that specifically bind specified polypeptides of the present invention, and allows for the exclusion of 25   the same.

          Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not specifically bind any other analog, ortholog, or homolog of the polypeptides of the present invention are included. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, 30   less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. Further included in the present invention are antibodies, which only bind polypeptides encoded by polynucleotides, which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described 35   herein). Antibodies of the present invention may also be described or specified in terms of their

binding affinity. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

5           Antibodies of the present invention have uses that include, but are not limited to, methods known in the art to purify, detect, and target the polypeptides of the present invention including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al.,  
10   ANTIBODIES: A LABORATORY MANUAL, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference in the entirety).

          The antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalent and non-  
15   covalent conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, or toxins. See, e.g., WO 92/08495; WO 91/14438; WO 89/12624; US Patent 5,314,995; and EP 0 396 387.

          The antibodies of the present invention may be prepared by any suitable method known  
20   in the art. For example, a polypeptide of the present invention or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. The term "monoclonal antibody" is not limited to antibodies produced through hybridoma technology. The term "antibody" refers to a polypeptide or group of polypeptides which are comprised of at least one binding domain, where a binding domain is formed from  
25   the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen., which allows an immunological reaction with the antigen. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including eukaryotic, prokaryotic, or phage clone, and not the method by which it is  
30   produced. Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technology.

          Hybridoma techniques include those known in the art (See, e.g., Harlow et al. (1998); Hammerling, et al. (1981) (said references incorporated by reference in their entireties). Fab and  $F(ab')_2$  fragments may be produced, for example, from hybridoma-produced antibodies by  
35   proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to

produce F(ab')<sub>2</sub> fragments).

Alternatively, antibodies of the present invention can be produced through the application of recombinant DNA technology or through synthetic chemistry using methods known in the art. For example, the antibodies of the present invention can be prepared using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of a phage particle, which carries polynucleotide sequences encoding them. Phage with a desired binding property are selected from a repertoire or combinatorial antibody library (e.g. human or murine) by selecting directly with antigen, typically antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman U. et al. (1995); Ames, R.S. et al. (1995); Kettleborough, C.A. et al. (1994); Persic, L. et al. (1997); Burton, D.R. et al. (1994); PCT/GB91/01134; WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and US Patents 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727 and 5,733,743 (said references incorporated by reference in their entireties).

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host including mammalian cells, insect cells, plant cells, yeast, and bacteria. For example, techniques to recombinantly produce Fab, Fab' F(ab')<sub>2</sub> and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in WO 92/22324; Mullinax, R.L. et al. (1992); and Sawai, H. et al. (1995); and Better, M. et al. (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al. (1991); Shu, L. et al. (1993); and Skerra, A. et al. (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison (1985); Oi et al., (1986); Gillies, S.D. et al. (1989); and US Patent 5,807,715. Antibodies can be humanized using a variety of techniques including CDR-grafting (EP 0 239 400; WO 91/09967; US Patent 5,530,101; and 5,585,089), veneering or resurfacing (EP 0 592 106; EP 0 519 596; Padlan E.A., (1991); Studnicka G.M. et al. (1994); Roguska M.A. et al.

(1994), and chain shuffling (US Patent 5,565,332). Human antibodies can be made by a variety of methods known in the art including phage display methods described above. See also, US Patents 4,444,887, 4,716,111, 5,545,806, and 5,814,318; WO 98/46645; WO 98/50433; WO 98/24893; WO 96/34096; WO 96/33735; and WO 91/10741 (said references incorporated by reference in their entireties).

Further included in the present invention are antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide of the present invention. The antibodies may be specific for antigens other than polypeptides of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al. supra and WO 93/21232; EP 0 439 095; Naramura, M. et al. (1994); US Patent 5,474,981; Gillies, S.O. et al. (1992); Fell, H.P. et al. (1991) (said references incorporated by reference in their entireties).

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides of the present invention may be fused or conjugated to the above antibody portions to increase the in vivo half-life of the polypeptides or for use in immunoassays using methods known in the art. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See e.g., US Patents 5,336,603, 5,622,929, 5,359,046, 5,349,053, 5,447,851, 5,112,946; EP 0 307 434, EP 0 367 166; WO 96/04388, WO 91/06570; Ashkenazi, A. et al. (1991); Zheng, X.X. et al. (1995); and Vil, H. et al. (1992) (said references incorporated by reference in their entireties).

The invention further relates to antibodies that act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies that disrupt the receptor/ligand interactions with the polypeptides of the invention either



partially or fully. Included are both receptor-specific antibodies and ligand-specific antibodies. Included are receptor-specific antibodies, which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. Also include are receptor-specific antibodies which both prevent ligand binding and receptor activation. Likewise, included are neutralizing antibodies that bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies that bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included are antibodies that activate the receptor. These antibodies may act as agonists for either all or less than all of the biological activities affected by ligand-mediated receptor activation. The antibodies may be specified as agonists or antagonists for biological activities comprising specific activities disclosed herein. The above antibody agonists can be made using methods known in the art. See e.g., WO 96/40281; US Patent 5,811,097; Deng, B. et al. (1998); Chen, Z. et al. (1998); Harrop, J.A. et al. (1998); Zhu, Z. et al. (1998); Yoon, D.Y. et al. (1998); Prat, M. et al. (1998); Pitard, V. et al. (1997); Liautard, J. et al. (1997); Carlson, N.G. et al. (1997); Taryman, R.E. et al. (1995); Muller, Y.A. et al. (1998); Bartunek, P. et al. (1996) (said references incorporated by reference in their entireties).

As discussed above, antibodies of the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. See, e.g. Greenspan and Bona, (1989); Nissinoff, (1991). For example, antibodies which bind to and competitively inhibit polypeptide multimerization or binding of a polypeptide of the invention to ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization or binding domain and, as a consequence, bind to and neutralize polypeptide or its ligand. Such neutralization anti-idiotypic antibodies can be used to bind a polypeptide of the invention or to bind its ligands/receptors, and thereby block its biological activity.

#### **Biallelic markers of the inventions**

##### **Advantages of the biallelic markers of the present invention**

The biallelic marker of the inventions of the present invention offer a number of important advantages over other genetic markers such as RFLP (Restriction fragment length polymorphism) and VNTR (Variable Number of Tandem Repeats) markers.

The first generation of markers, were RFLPs, which are variations that modify the length of a restriction fragment. But methods used to identify and to type RFLPs are relatively wasteful of materials, effort, and time. The second generation of genetic markers were VNTRs,

which can be categorized as either minisatellites or microsatellites. Minisatellites are tandemly repeated DNA sequences present in units of 5-50 repeats which are distributed along regions of the human chromosomes ranging from 0.1 to 20 kilobases in length. Since they present many possible alleles, their informative content is very high. Minisatellites are scored by performing Southern blots to identify the number of tandem repeats present in a nucleic acid sample from the individual being tested. However, there are only  $10^4$  potential VNTRs that can be typed by Southern blotting. Moreover, both RFLP and VNTR markers are costly and time-consuming to develop and assay in large numbers.

Single nucleotide polymorphism or biallelic markers can be used in the same manner as RFLPs and VNTRs but offer several advantages. Single nucleotide polymorphisms are densely spaced in the human genome and represent the most frequent type of variation. An estimated number of more than  $10^7$  sites are scattered along the  $3 \times 10^9$  base pairs of the human genome. Therefore, single nucleotide polymorphism occur at a greater frequency and with greater uniformity than RFLP or VNTR markers which means that there is a greater probability that such a marker will be found in close proximity to a genetic locus of interest. Single nucleotide polymorphisms are less variable than VNTR markers but are mutationally more stable.

Also, the different forms of a characterized single nucleotide polymorphism, such as the biallelic markers of the present invention, are often easier to distinguish and can therefore be typed easily on a routine basis. Biallelic markers have single nucleotide based alleles and they have only two common alleles, which allows highly parallel detection and automated scoring. The biallelic markers of the present invention offer the possibility of rapid, high-throughput genotyping of a large number of individuals.

Biallelic markers are densely spaced in the genome, sufficiently informative and can be assayed in large numbers. The combined effects of these advantages make biallelic markers extremely valuable in genetic studies. Biallelic markers can be used in linkage studies in families, in allele sharing methods, in linkage disequilibrium studies in populations, in association studies of case-control populations. An important aspect of the present invention is that biallelic markers allow association studies to be performed to identify genes involved in complex traits. Association studies examine the frequency of marker alleles in unrelated case- and control-populations and are generally employed in the detection of polygenic or sporadic traits. Association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families (linkage studies). Biallelic markers in different genes can be screened in parallel for direct association with disease or response to a treatment. This multiple gene approach is a powerful tool for a variety of human genetic studies as it provides the necessary statistical power to examine the synergistic effect of

multiple genetic factors on a particular phenotype, drug response, sporadic trait, or disease state with a complex genetic etiology.

### Biallelic Markers And Polynucleotides Comprising Them

#### 5      **Polynucleotides of the present invention**

In one aspect, the invention concerns biallelic markers associated with schizophrenia. The invention comprises chromosome 13q31-q33-related biallelic markers and g35030-related biallelic markers. The markers are generally referred to herein as A1, A2, A3 and so on. The biallelic markers of the invention comprise the biallelic markers designated A1 to A127 in  
10      Table 5. Also included are biallelic markers in linkage disequilibrium with the biallelic markers of the invention.

The polynucleotide of the invention may consist of, consist essentially of, or comprise a contiguous span of nucleotides of a sequence from any of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 as well as sequences which are complementary thereto ("complements thereof").  
15      The "contiguous span" may be at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length, to the extent that a contiguous span of these lengths is consistent with the lengths of the particular Sequence ID.

The present invention encompasses polynucleotides for use as primers and probes in the methods of the invention. These polynucleotides may consist of, consist essentially of, or  
20      comprise a contiguous span of nucleotides of a sequence from any of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 as well as sequences which are complementary thereto ("complements thereof"). The "contiguous span" may be at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length, to the extent that a contiguous span of these lengths is consistent with the lengths of the particular Sequence ID. It should be noted that the  
25      polynucleotides of the present invention are not limited to having the exact flanking sequences surrounding the polymorphic bases which, are enumerated in the Sequence Listing. Rather, it will be appreciated that the flanking sequences surrounding the biallelic markers and other polymorphisms of the invention, or any of the primers or probes of the invention which, are more distant from the markers, may be lengthened or shortened to any extent compatible with  
30      their intended use and the present invention specifically contemplates such sequences. It will be appreciated that the polynucleotides of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 may be of any length compatible with their intended use. Also the flanking regions outside of the contiguous span need not be homologous to native flanking sequences which actually occur in human subjects. The addition of any nucleotide sequence, which is compatible with the  
35      nucleotides intended use is specifically contemplated. The contiguous span may optionally

include the biallelic markers of the invention in said sequence. Biallelic markers generally comprise a polymorphism at one single base position. Each biallelic marker therefore corresponds to two forms of a polynucleotide sequence which, when compared with one another, present a nucleotide modification at one position. Usually, the nucleotide modification involves the substitution of one nucleotide for another. Optionally allele 1 or allele 2 of the biallelic markers disclosed in Table 5 may be specified as being present at the biallelic marker of the invention. Preferred polynucleotides may consist of, consist essentially of, or comprise a contiguous span of nucleotides of a sequence from SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 as well as sequences which are complementary thereto. The "contiguous span" may be at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length, to the extent that a contiguous span of these lengths is consistent with the lengths of the particular Sequence ID.

A preferred probe or primer comprises a nucleic acid comprising a polynucleotide selected from the group of the nucleotide sequences of P1 to P127 and the complementary sequence thereto, B1 to B114, C1 to C114, D1 to D127, E1 to E127.

The invention also relates to polynucleotides that hybridize, under conditions of high or intermediate stringency, to a polynucleotide of any of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 as well as sequences, which are complementary thereto. Preferably such polynucleotides are at least 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length, to the extent that a polynucleotide of these lengths is consistent with the lengths of the particular Sequence ID. Preferred polynucleotides comprise a polymorphism of the invention. Optionally either allele 1 or allele 2 of the polymorphism disclosed in Table 5 may be specified as being present at the polymorphism of the invention. Particularly preferred polynucleotides comprise a biallelic marker of the invention. Conditions of high stringency are further described herein.

The primers of the present invention may be designed from the disclosed sequences for any method known in the art. A preferred set of primers is fashioned such that the 3' end of the contiguous span of identity with the sequences of any of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 is present at the 3' end of the primer. Such a configuration allows the 3' end of the primer to hybridize to a selected nucleic acid sequence and dramatically increases the efficiency of the primer for amplification or sequencing reactions. In a preferred set of primers the contiguous span is found in one of the sequences described in Table 4. Allele specific primers may be designed such that a biallelic marker or other polymorphism of the invention is at the 3' end of the contiguous span and the contiguous span is present at the 3' end of the primer. Such allele specific primers tend to selectively prime an amplification or sequencing

reaction so long as they are used with a nucleic acid sample that contains one of the two alleles present at said marker. The 3' end of primer of the invention may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a biallelic marker of the invention in said sequence or at any other location which is appropriate for their intended use in sequencing, amplification or the location of novel sequences or markers.

5 Primers with their 3' ends located 1 nucleotide upstream of an biallelic marker of the invention have a special utility as microsequencing assays. Preferred microsequencing primers are described in Table 6.

The probes of the present invention may be designed from the disclosed sequences for any method known in the art, particularly methods which allow for testing if a particular sequence or marker disclosed herein is present. A preferred set of probes may be designed for use in the hybridization assays of the invention in any manner known in the art such that they selectively bind to one allele of a biallelic marker or other polymorphism, but not the other under any particular set of assay conditions. Preferred hybridization probes may consists of,

10 consist essentially of, or comprise a contiguous span which ranges in length from 8, 10, 12, 15, 18 or 20 to 25, 35, 40, 50, 60, 70, or 80 nucleotides, or be specified as being 12, 15, 18, 20, 25, 35, 40, or 50 nucleotides in length and including an biallelic marker or other polymorphism of the invention in said sequence. In a preferred embodiment, either of allele 1 or 2 disclosed in Table 5 may be specified as being present at the biallelic marker site. In another preferred

20 embodiment, said biallelic marker may be within 6, 5, 4, 3, 2, or 1 nucleotides of the center of the hybridization probe or at the center of said probe.

In one embodiment the invention encompasses isolated, purified, and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of any one of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132 and the

25 complement thereof, wherein said span includes a biallelic marker of the invention, a chromosome 13q31-q33-related biallelic marker or g35030-related biallelic marker in said sequence; optionally, wherein said polymorphism or biallelic marker selected from the group consisting of A1 to A127, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said biallelic marker is selected from the

30 group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 ; optionally, wherein said biallelic marker is selected from the group consisting of A13 to A65, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide;

35 optionally, wherein said polynucleotide consists of said contiguous span and said contiguous

span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide; optionally, wherein the 3' end of said contiguous span is present at the 3' end of said polynucleotide; and optionally, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide. In a preferred embodiment, said probes comprise, consists of, or consists essentially of a sequence selected from the following sequences: P1 to P127 and the complementary sequences thereto.

In another embodiment the invention encompasses isolated, purified and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of any one of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132, or the complement thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located within 20 nucleotides upstream of a polymorphism of the invention, chromosome 13q31-q33-related biallelic marker, or g35030-related biallelic marker in said sequence; optionally, wherein said polymorphism or biallelic marker is selected from the group consisting of A1 to A127, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said biallelic marker is selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said biallelic marker is selected from the group consisting of A13 to A65; optionally, wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of said polymorphism or biallelic marker; and optionally, wherein said polynucleotide comprises, consists of, or consists essentially of a sequence selected from the following sequences: D1 to D127 and E1 to E127.

In a further embodiment, the invention encompasses isolated, purified, or recombinant polynucleotides comprising, consisting of, or consisting essentially of a sequence selected from the following sequences: B1 to B114 and C1 to C114.

In an additional embodiment, the invention encompasses polynucleotides for use in hybridization assays, sequencing assays, and enzyme-based mismatch detection assays for determining the identity of the nucleotide at a polymorphism or biallelic marker in any of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the complement thereof, as well as polynucleotides for use in amplifying segments of nucleotides comprising a polymorphism or biallelic marker of the invention in any of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132 or the complement thereof; optionally, wherein said polymorphism or biallelic marker is selected from the group consisting of A1 to A127, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said biallelic marker

is selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said biallelic marker is selected from the group consisting of A13 to A65, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith.

These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods, which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., Science, 251:767-777, 1991). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPS™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPS™ technologies are provided in US Patents 5,143,854 and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis technique. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

Oligonucleotide arrays may comprise at least one of the sequences selected from the group consisting of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132; and the sequences complementary thereto or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 consecutive nucleotides, to the extent that fragments of these lengths is consistent with the lengths of the particular Sequence ID, for determining whether a sample contains one or more alleles of the biallelic markers of the present invention. Oligonucleotide arrays may also comprise at least one of the sequences selected from the group consisting of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132; and the sequences complementary thereto or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 consecutive nucleotides, to the extent that fragments of these lengths is consistent with the lengths of the particular Sequence ID, for amplifying one or more alleles of the biallelic markers of Table 5. In other embodiments, arrays may also comprise at least one of the sequences selected from the group consisting of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132; and the sequences complementary thereto or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 consecutive nucleotides, to the extent that fragments of these lengths is consistent with the lengths of the

particular Sequence ID, for conducting microsequencing analyses to determine whether a sample contains one or more alleles of the biallelic markers of the invention. In still further embodiments, the oligonucleotide array may comprise at least one of the sequences selecting from the group consisting of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132; and the sequences complementary thereto or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500, 1000 or 2000 nucleotides in length, to the extent that fragments of these lengths is consistent with the lengths of the particular Sequence ID, for determining whether a sample contains one or more alleles of the polymorphisms and biallelic markers of the present invention.

A further object of the invention relates to an array of nucleic acid sequences comprising either at least one of the sequences selected from the group consisting of P1 to P127, B1 to B114, C1 to C114, D1 to D127 E1 to E127 or the sequences complementary thereto or a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 30, or 40 consecutive nucleotides thereof, or at least one sequence comprising at least 1, 2, 3, 4, 5, 10, 20 biallelic markers selected from the group consisting of A1 to A127 or the complements thereof. The invention also pertains to an array of nucleic acid sequences comprising either at least 1, 2, 3, 4, 5, 10, 20 of the sequences selected from the group consisting of P1 to P127, B1 to B114, C1 to C114, D1 to D127, E1 to E127 or the sequences complementary thereto or a fragment thereof of at least 8 consecutive nucleotides thereof, or at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A127 or the complements thereto. In preferred embodiments, said biallelic markers are selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123. In preferred embodiments, said probes, amplification primers and microsequencing primers correspond in Table 6 to said biallelic markers.

The present invention also encompasses diagnostic kits comprising one or more polynucleotides of the invention, optionally with a portion or all of the necessary reagents and instructions for genotyping a test subject by determining the identity of a nucleotide at an biallelic marker of the invention. The polynucleotides of a kit may optionally be attached to a solid support, or be part of an array or addressable array of polynucleotides. The kit may provide for the determination of the identity of the nucleotide at a marker position by any method known in the art including, but not limited to, a sequencing assay method, a microsequencing assay method, a hybridization assay method, or enzyme-based mismatch detection assay. Optionally such a kit may include instructions for scoring the results of the determination with respect to the test subjects' predisposition to schizophrenia, or likely response to an agent acting on schizophrenia, or chances of suffering from side effects to an



agent acting on schizophrenia.

Optionally, in any embodiments described herein, a biallelic marker of the invention may comprise:

- 5 (a) a biallelic marker selected from the group consisting of g35030-related markers A13 to A65; (b) a biallelic marker selected from the group consisting of chromosome 13q31-q33-related-biallelic markers A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123; or (c) a biallelic marker selected from the group consisting of chromosome 13q31-q33-related-biallelic markers A13 to A18, A20 to A47, A49 to A52, A55, A57, A59 to A63. Furthermore, any of the embodiments of the invention may specifically exclude one or  
10 more of the biallelic markers selected from biallelic markers A1 to A127.

#### **Methods For *De Novo* Identification Of Biallelic Markers**

Any of a variety of methods can be used to screen a genomic fragment for single nucleotide polymorphisms such as differential hybridization with oligonucleotide probes,  
15 detection of changes in the mobility measured by gel electrophoresis or direct sequencing of the amplified nucleic acid. A preferred method for identifying biallelic markers involves comparative sequencing of genomic DNA fragments from an appropriate number of unrelated individuals.

In a first embodiment, DNA samples from unrelated individuals are pooled together,  
20 following which the genomic DNA of interest is amplified and sequenced. The nucleotide sequences thus obtained are then analyzed to identify significant polymorphisms. One of the major advantages of this method resides in the fact that the pooling of the DNA samples substantially reduces the number of DNA amplification reactions and sequencing reactions, which must be carried out. Moreover, this method is sufficiently sensitive so that a biallelic  
25 marker obtained thereby usually demonstrates a sufficient frequency of its less common allele to be useful in conducting association studies. Usually, the frequency of the least common allele of a biallelic marker identified by this method is at least 10%.

In a second embodiment, the DNA samples are not pooled and are therefore amplified and sequenced individually. This method is usually preferred when biallelic markers need to be  
30 identified in order to perform association studies within candidate genes. Preferably, highly relevant gene regions such as promoter regions or exon regions may be screened for biallelic markers. A biallelic marker obtained using this method may show a lower degree of informativeness for conducting association studies, e.g. if the frequency of its less frequent allele may be less than about 10%. Such a biallelic marker will however be sufficiently  
35 informative to conduct association studies and it will further be appreciated that including less

informative biallelic markers in the genetic analysis studies of the present invention, may allow in some cases the direct identification of causal mutations, which may, depending on their penetrance, be rare mutations.

5 The following is a description of the various parameters of a preferred method used by the inventors for the identification of the biallelic markers of the present invention.

#### Genomic DNA samples

The genomic DNA samples from which the biallelic markers of the present invention are generated are preferably obtained from unrelated individuals corresponding to a heterogeneous population of known ethnic background. The number of individuals from whom DNA samples are obtained can vary substantially, preferably from about 10 to about 1000, more preferably from about 50 to about 200 individuals. Usually, DNA samples are collected from at least about 100 individuals in order to have sufficient polymorphic diversity in a given population to identify as many markers as possible and to generate statistically significant results.

15 As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples, which can be tested by the methods of the present invention described herein, and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the present invention is from peripheral venous blood of each donor. Techniques to prepare genomic DNA from biological samples are well known to the skilled technician.

20

25 Details of a preferred embodiment are provided in Example 1. The person skilled in the art can choose to amplify pooled or unpooled DNA samples.

#### DNA Amplification

The identification of biallelic markers in a sample of genomic DNA may be facilitated through the use of DNA amplification methods. DNA samples can be pooled or unpooled for the amplification step. DNA amplification techniques are well known to those skilled in the art. Various methods to amplify DNA fragments carrying biallelic markers are further described hereinafter herein. The PCR technology is the preferred amplification technique used to identify new biallelic markers.

30

35 In a first embodiment, biallelic markers are identified using genomic sequence information generated by the inventors. Genomic DNA fragments, such as the inserts of the

BAC clones described above, are sequenced and used to design primers for the amplification of 500 bp fragments. These 500 bp fragments are amplified from genomic DNA and are scanned for biallelic markers. Primers may be designed using the OSP software (Hillier L. and Green P., 1991). All primers may contain, upstream of the specific target bases, a common oligonucleotide tail that serves as a sequencing primer. Those skilled in the art are familiar with primer extensions, which can be used for these purposes.

In another embodiment of the invention, genomic sequences of candidate genes are available in public databases allowing direct screening for biallelic markers. Preferred primers, useful for the amplification of genomic sequences encoding the candidate genes, focus on promoters, exons and splice sites of the genes. A biallelic marker present in these functional regions of the gene have a higher probability to be a causal mutation.

#### **Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms**

The amplification products generated as described above, are then sequenced using any method known and available to the skilled technician. Methods for sequencing DNA using either the dideoxy-mediated method (Sanger method) or the Maxam-Gilbert method are widely known to those of ordinary skill in the art. Such methods are for example disclosed in Maniatis et al. (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Second Edition, 1989). Alternative approaches include hybridization to high-density DNA probe arrays as described in Chee et al. (Science 274, 610, 1996).

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. The products of the sequencing reactions are run on sequencing gels and the sequences are determined using gel image analysis. The polymorphism search is based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position. Because each dideoxy terminator is labeled with a different fluorescent molecule, the two peaks corresponding to a biallelic site present distinct colors corresponding to two different nucleotides at the same position on the sequence. However, the presence of two peaks can be an artifact due to background noise. To exclude such an artifact, the two DNA strands are sequenced and a comparison between the peaks is carried out. In order to be registered as a polymorphic sequence, the polymorphism has to be detected on both strands.

The above procedure permits those amplification products, which contain biallelic markers to be identified. The detection limit for the frequency of biallelic polymorphisms detected by sequencing pools of 100 individuals is approximately 0.1 for the minor allele, as verified by sequencing pools of known allelic frequencies. However, more than 90% of the

biallelic polymorphisms detected by the pooling method have a frequency for the minor allele higher than 0.25. Therefore, the biallelic markers selected by this method have a frequency of at least 0.1 for the minor allele and less than 0.9 for the major allele. Preferably at least 0.2 for the minor allele and less than 0.8 for the major allele, more preferably at least 0.3 for the minor allele and less than 0.7 for the major allele, thus a heterozygosity rate higher than 0.18, preferably higher than 0.32, more preferably higher than 0.42.

In another embodiment, biallelic markers are detected by sequencing individual DNA samples, the frequency of the minor allele of such a biallelic marker may be less than 0.1.

#### 10                    **Validation of the biallelic markers of the present invention**

The polymorphisms are evaluated for their usefulness as genetic markers by validating that both alleles are present in a population. Validation of the biallelic markers is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. Microsequencing is a preferred method of genotyping alleles. The validation by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group can be as small as one individual if that individual is heterozygous for the allele in question. Preferably the group contains at least three individuals, more preferably the group contains five or six individuals, so that a single validation test will be more likely to result in the validation of more of the biallelic markers that are being tested. It should be noted, however, that when the validation test is performed on a small group it may result in a false negative result if as a result of sampling error none of the individuals tested carries one of the two alleles. Thus, the validation process is less useful in demonstrating that a particular initial result is an artifact, than it is at demonstrating that there is a *bona fide* biallelic marker at a particular position in a sequence. All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with validated biallelic markers.

#### 25                    **Evaluation of the frequency of the biallelic markers of the present invention**

30                    The validated biallelic markers are further evaluated for their usefulness as genetic markers by determining the frequency of the least common allele at the biallelic marker site. The determination of the least common allele is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. This determination of frequency by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than

one individual. The group must be large enough to be representative of the population as a whole. Preferably the group contains at least 20 individuals, more preferably the group contains at least 50 individuals, most preferably the group contains at least 100 individuals. Of course the larger the group the greater the accuracy of the frequency determination because of reduced sampling error. A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a "high quality biallelic marker." All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with high quality biallelic markers.

Another embodiment of the invention comprises methods of estimating the frequency of an allele in a population comprising genotyping individuals from said population for a 13q31-q33-related biallelic marker and determining the proportional representation of said biallelic marker in said population. In addition, the methods of estimating the frequency of an allele in a population encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: Optionally, said 13q31-q33-related biallelic marker may be in a sequence selected individually or in any combination from the group consisting of SEQ Nos 1 to 17, 24, 25, 28, 74 and 79 to 132; and the complements thereof; optionally, said 13q31-q33-related biallelic marker may be selected from the biallelic markers described in Table 5; optionally, determining the frequency of a biallelic marker allele in a population may be accomplished by determining the identity of the nucleotides for both copies of said biallelic marker present in the genome of each individual in said population and calculating the proportional representation of said nucleotide at said 13q31-q33-related biallelic marker for the population; optionally, determining the frequency of a biallelic marker allele in a population may be accomplished by performing a genotyping method on a pooled biological sample derived from a representative number of individuals, or each individual, in said population, and calculating the proportional amount of said nucleotide compared with the total.

#### **Methods Of Genotyping An Individual For Biallelic Markers**

Methods are provided to genotype a biological sample for one or more biallelic markers of the present invention, all of which may be performed *in vitro*. Such methods of genotyping comprise determining the identity of a nucleotide at an biallelic marker of the invention by any method known in the art. These methods find use in genotyping case-control populations in association studies as well as individuals in the context of detection of alleles of biallelic markers which, are known to be associated with a given trait, in which case both copies of the biallelic marker present in individual's genome are determined so that an individual may be classified as homozygous or heterozygous for a particular allele.

These genotyping methods can be performed nucleic acid samples derived from a single individual or pooled DNA samples.

Genotyping can be performed using similar methods as those described above for the identification of the biallelic markers, or using other genotyping methods such as those further described below. In preferred embodiments, the comparison of sequences of amplified genomic fragments from different individuals is used to identify new biallelic markers whereas microsequencing is used for genotyping known biallelic markers in diagnostic and association study applications.

Another embodiment of the invention encompasses methods of genotyping a biological sample comprising determining the identity of a nucleotide at a 13q31-q33-related biallelic marker. Thus, the invention encompasses a method of genotyping an individual comprising: (a) obtaining a biological sample comprising a nucleic acid from said individual; (b) determining the identity of a polymorphic base at a biallelic marker from said nucleic acid; wherein said polymorphic base is selected from the group consisting of the first or second respective allele at the nucleotide position of the polymorphic base of SEQ ID No 1, 24, 25, 28, or 74 as indicated in table 5; wherein the identity of the polymorphic base determines the genotype of the individual at said position.

In addition, the genotyping methods of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: Optionally, said 13q31-q33-related biallelic marker may be in a sequence selected individually or in any combination from the group consisting of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132, and the complements thereof; optionally, said 13q31-q33-related biallelic marker may be selected individually or in any combination from the biallelic markers described in Table 5; optionally, said method further comprises determining the identity of a second nucleotide at said biallelic marker, wherein said first nucleotide and second nucleotide are not base paired (by Watson & Crick base pairing) to one another; optionally, said biological sample is derived from a single individual or subject; optionally, said method is performed *in vitro*; optionally, said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome; optionally, said biological sample is derived from multiple subjects or individuals; optionally, said method further comprises amplifying a portion of said sequence comprising the biallelic marker prior to said determining step; optionally, wherein said amplifying is performed by PCR, LCR, or replication of a recombinant vector comprising an origin of replication and said portion in a host cell; optionally, wherein said determining is performed by a hybridization assay, sequencing assay, microsequencing assay, or an enzyme-based mismatch detection assay.

### Source of DNA for genotyping

Any source of nucleic acids, in purified or non-purified form, can be utilized as the starting nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired. DNA or RNA may be extracted from cells, tissues, body fluids and the like as described herein. While nucleic acids for use in the genotyping methods of the invention can be derived from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

### Amplification Of DNA Fragments Comprising Biallelic Markers

Methods and polynucleotides are provided to amplify a segment of nucleotides comprising one or more biallelic marker of the present invention. It will be appreciated that amplification of DNA fragments comprising biallelic markers may be used in various methods and for various purposes and is not restricted to genotyping. Nevertheless, many genotyping methods, although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest. Such methods specifically increase the concentration or total number of sequences that span the biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely on amplification of DNA segments carrying a biallelic marker of the present invention.

Amplification of DNA may be achieved by any method known in the art. The established PCR (polymerase chain reaction) method or by developments thereof or alternatives. Amplification methods which can be utilized herein include but are not limited to Ligase Chain Reaction (LCR) as described in EP A 320 308 and EP A 439 182, Gap LCR (Wolcott, M.J.), the so-called "NASBA" or "3SR" technique described in Guatelli J.C. et al. (1990) and in Compton J. (1991), Q-beta amplification as described in EP A 4544 610, strand displacement amplification as described in Walker et al. (1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461.

LCR and Gap LCR are exponential amplification techniques, both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-3'hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded,

the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either  
5 the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent but are separated by 2 to 3 bases.

For amplification of mRNAs, it is within the scope of the present invention to reverse  
10 transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Patent No. 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall R.L. et al. (1994). AGLCR is a modification of GLCR that allows the amplification of RNA.

Some of these amplification methods are particularly suited for the detection of single  
15 nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as it is further described herein.

The PCR technology is the preferred amplification technique used in the present invention. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see Molecular Cloning to Genetic Engineering White, B.A. Ed. (1997) and the  
20 publication entitled "PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically  
25 hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites. PCR has further been described in several patents including US Patents 4,683,195, 4,683,202 and 4,965,188.

30 Primers can be prepared by any suitable method. As for example, direct chemical synthesis by a method such as the phosphodiester method of Narang S.A. et al. (1979), the phosphodiester method of Brown E.L. et al. (1979), the diethylphosphoramidite method of Beaucage et al. (1981) and the solid support method described in EP 0 707 592.

In some embodiments the present invention provides primers for amplifying a DNA  
35 fragment containing one or more biallelic markers of the present invention. It will be



appreciated that the primers listed are merely exemplary and that any other set of primers which produce amplification products containing one or more biallelic markers of the present invention.

The spacing of the primers determines the length of the segment to be amplified. In the context of the present invention amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical, fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers may be any sequence which allow the specific amplification of any DNA fragment carrying the markers.

Amplification primers may be labeled or immobilized on a solid support as described in the section titled "Oligonucleotide Probes and Primers".

#### **Methods of Genotyping DNA samples for Biallelic Markers**

Any method known in the art can be used to identify the nucleotide present at a biallelic marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove simple for one of ordinary skill in the art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the DNA region carrying the biallelic marker of interest. While the amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al. (1989), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield, V.C. et al. (1991), White et al. (1992), Grompe, M. et al. (1989) and Grompe, M. (1993). Another method for determining the identity of the nucleotide present at a particular polymorphic site employs a specialized exonuclease-resistant nucleotide derivative as described in US patent 4,656,127.

Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, enzyme-based mismatch detection assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the microsequencing technique. The term "sequencing assay" is used herein to refer to polymerase extension of duplex primer/template complexes and includes both traditional sequencing and microsequencing.

#### **1) Sequencing assays**

The nucleotide present at a polymorphic site can be determined by sequencing methods.

In a preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as described above. DNA sequencing methods are described in herein. Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Sequence analysis allows the identification of the base present at the biallelic marker site.

## 2) Microsequencing assays

In microsequencing methods, a nucleotide at the polymorphic site that is unique to one of the alleles in a target DNA is detected by a single nucleotide primer extension reaction. This method involves appropriate microsequencing primers which, hybridize just upstream of a polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3' end of the primer with one single ddNTP (chain terminator) complementary to the selected nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing machines to determine the identity of the incorporated nucleotide as described in EP 412 883. Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously. An example of a typical microsequencing procedure that can be used in the context of the present invention is provided in example 4.

Different approaches can be used to detect the nucleotide added to the microsequencing primer. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al. (1997). In this method amplified genomic DNA fragments containing polymorphic sites are incubated with a 5'-fluorescein-labeled primer in the presence of allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time. Alternatively, the extended primer may be analyzed by MALDI-TOF Mass Spectrometry. The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff L.A. and Smirnov I.P., 1997).

Microsequencing may be achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase microsequencing techniques. The basic microsequencing protocol is the same as described

previously, except that the method is conducted as a heterogenous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase extension. The 5' ends and internal nucleotides of synthetic oligonucleotides can be modified in a number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator reagent. This eliminates the need of physical or size separation. More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if more than one affinity group is used. This permits the analysis of several nucleic acid species or more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner oligonucleotides or templates may be attached to a solid support in a high-density format. In such solid phase microsequencing reactions, incorporated ddNTPs can be radiolabeled (Syvänen, 1994) or linked to fluorescein (Livak and Hainer, 1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be based on the binding of anti fluorescein antibody conjugated with alkaline phosphatase, followed by incubation with a chromogenic substrate (such as *p*-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Harju et al., 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated streptavidin with *o*-phenylenediamine as a substrate (WO 92/15712). As yet another alternative solid-phase microsequencing procedure, Nyren et al. (1993) described a method relying on the detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA).

Pastinen et al. (1997), describe a method for multiplex detection of single nucleotide polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide array format. High-density arrays of DNA probes attached to a solid support (DNA chips) are further described in herein.

In one aspect the present invention provides polynucleotides and methods to genotype one or more biallelic markers of the present invention by performing a microsequencing assay. Preferred microsequencing primers include those being featured Table 6. It will be appreciated that the microsequencing primers listed in Table 6 are merely exemplary and that, any primer

having a 3' end immediately adjacent to a polymorphic nucleotide may be used. Similarly, it will be appreciated that microsequencing analysis may be performed for any biallelic marker or any combination of biallelic markers of the present invention. One aspect of the present invention is a solid support which includes one or more microsequencing primers listed in Table 6, or fragments comprising at least 8, at least 12, at least 15, or at least 20 consecutive nucleotides thereof and having a 3' terminus immediately upstream of the corresponding biallelic marker, for determining the identity of a nucleotide at biallelic marker site.

### 3) Mismatch detection assays based on polymerases and ligases

In one aspect the present invention provides polynucleotides and methods to determine the allele of one or more biallelic markers of the present invention in a biological sample, by mismatch detection assays based on polymerases and/or ligases. These assays are based on the specificity of polymerases and ligases. Polymerization reactions places particularly stringent requirements on correct base pairing of the 3' end of the amplification primer and the joining of two oligonucleotides hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site, especially at the 3' end. The terms "enzyme based mismatch detection assay" are used herein to refer to any method of determining the allele of a biallelic marker based on the specificity of ligases and polymerases. Preferred methods are described below. Methods, primers and various parameters to amplify DNA fragments comprising biallelic markers of the present invention are further described herein.

#### Allele specific amplification

Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy, whereby one of the alleles is amplified without amplification of the other allele. This is accomplished by placing a polymorphic base at the 3' end of one of the amplification primers. Because the extension forms from the 3' end of the primer, a mismatch at or near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary allele. Designing the appropriate allele-specific primer and the corresponding assay conditions are well with the ordinary skill in the art.

#### Ligation/amplification based methods

The "Oligonucleotide Ligation Assay" (OLA) uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target molecules. One of the oligonucleotides is biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable of detecting biallelic markers and may be advantageously combined

with PCR as described by Nickerson D.A. et al. (1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Other methods which are particularly suited for the detection of biallelic markers include LCR (ligase chain reaction), Gap LCR (GLCR) which are described herein. As mentioned above LCR uses two pairs of probes to exponentially amplify a specific target. The sequences of each pair of oligonucleotides, is selected to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-dependant ligase. In accordance with the present invention, LCR can be performed with oligonucleotides having the proximal and distal sequences of the same strand of a biallelic marker site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site. In such an embodiment, the reaction conditions are selected such that the oligonucleotides can be ligated together only if the target molecule either contains or lacks the specific nucleotide(s) that is complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the oligonucleotides will not include the biallelic marker, such that when they hybridize to the target molecule, a "gap" is created as described in WO 90/01069. This gap is then "filled" with complementary dNTPs (as mediated by DNA polymerase), or by an additional pair of oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of serving as a target during the next cycle and exponential allele-specific amplification of the desired sequence is obtained.

Ligase/Polymerase-mediated Genetic Bit Analysis<sup>TM</sup> is another method for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.

#### 4) Hybridization assay methods

A preferred method of determining the identity of the nucleotide present at a biallelic marker site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in such reactions, preferably include the probes defined herein. Any hybridization assay may be used including Southern hybridization, Northern hybridization, dot blot hybridization and solid-phase hybridization (see Sambrook et al., Molecular Cloning - A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., 1989).

Hybridization refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions

of mismatch. Specific probes can be designed that hybridize to one form of a biallelic marker and not to the other and therefore are able to discriminate between different allelic forms. Allele-specific probes are often used in pairs, one member of a pair showing perfect match to a target sequence containing the original allele and the other showing a perfect match to the target sequence containing the alternative allele. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Stringent, sequence specific hybridization conditions, under which a probe will hybridize only to the exactly complementary target sequence are well known in the art (Sambrook et al., Molecular Cloning – A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., 1989). Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1X SSC at 50°C for 45 min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS, or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68°C for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. By way of example and not limitation, procedures using conditions of intermediate stringency are as follows: Filters containing DNA are prehybridized, and then hybridized at a temperature of 60°C in the presence of a 5 x SSC buffer and labeled probe. Subsequently, filters washes are performed in a solution containing 2x SSC at 50°C and the hybridized probes are detectable by autoradiography. Other conditions of high and intermediate stringency which may be used are well known in the art and as cited in Sambrook et al. (Molecular Cloning - A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., 1989) and Ausubel et al. (Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., 1989).

Although such hybridizations can be performed in solution, it is preferred to employ a

solid-phase hybridization assay. The target DNA comprising a biallelic marker of the present invention may be amplified prior to the hybridization reaction. The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a number of methods. Various detection assay formats are well known which utilize detectable labels bound to either the target or the probe to enable detection of the hybrid duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps may be employed to wash away excess target DNA or probe. Standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the primers and probes.

Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., 1998). The TaqMan assay takes advantage of the 5' nuclease activity of Taq DNA polymerase to digest a DNA probe annealed specifically to the accumulating amplification product. TaqMan probes are labeled with a donor-acceptor dye pair that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al, 1995). In an alternative homogeneous hybridization-based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally quenched fluorophore (Tyagi et al., 1998).

By assaying the hybridization to an allele specific probe, one can detect the presence or absence of a biallelic marker allele in a given sample.

High-Throughput parallel hybridizations in array format are specifically encompassed within "hybridization assays" and are described below.

#### **Hybridization to addressable arrays of oligonucleotides**

Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target sequence variants. Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (the chip) at selected positions. Each DNA chip can contain thousands to millions of individual

synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

The chip technology has already been applied with success in numerous cases. For example, the screening of mutations has been undertaken in the BRCA1 gene, in *S. cerevisiae* mutant strains, and in the protease gene of HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996; Kozal et al., 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (HyChip and HyGnostics), and Protogene Laboratories.

In general, these methods employ arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP785280, describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be "tilled" for a large number of specific polymorphisms. By "tiling" is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of monomers, i.e. nucleotides. Tiling strategies are further described in PCT application No. WO 95/11995. In a particular aspect, arrays are tiled for a number of specific, identified biallelic marker sequences. In particular the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of biallelic markers. For example, a detection block may be tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To ensure probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection block. These monosubstituted probes have bases at and up to a certain number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization from artefactual cross-hybridization. Upon completion of hybridization with the target sequence and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning may be carried out as described in PCT application No. WO 92/10092 and WO 95/11995 and US patent No. 5,424,186.

Thus, in some embodiments, the chips may comprise an array of nucleic acid sequences



of fragments of about 15 nucleotides in length. In further embodiments, the chip may comprise an array including at least one of the sequences selected from the group consisting of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 and the sequences complementary thereto, or a fragment thereof at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides. In some embodiments, the chip may comprise an array of at least 2, 3, 4, 5, 6, 7, 8 or more of these polynucleotides of the invention. Solid supports and polynucleotides of the present invention attached to solid supports are further described in the section titled "Oligonucleotide probes and Primers".

#### 5) Integrated Systems

Another technique, which may be used to analyze polymorphisms, includes multicomponent integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions in a single functional device. An example of such technique is disclosed in US patent 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in chips.

Integrated systems can be envisaged mainly when microfluidic systems are used. These systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples are controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip. For genotyping biallelic markers, the microfluidic system may integrate nucleic acid amplification, microsequencing, capillary electrophoresis and a detection method such as laser-induced fluorescence detection.

#### Methods Of Genetic Analysis Using The Biallelic Markers Of The Present Invention

Different methods are available for the genetic analysis of complex traits (see Lander and Schork, 1994). The search for disease-susceptibility genes is conducted using two main methods: the linkage approach in which evidence is sought for cosegregation between a locus and a putative trait locus using family studies, and the association approach in which evidence is sought for a statistically significant association between an allele and a trait or a trait causing allele (Khoury J. et al, 1993). In general, the biallelic markers of the present invention find use in any method known in the art to demonstrate a statistically significant correlation between a genotype and a phenotype. The biallelic markers may be used in parametric and non-parametric linkage analysis methods. Preferably, the biallelic markers of the present invention are used to identify genes associated with detectable traits using association studies, an approach which does not require the use of affected families and which permits the identification of genes

associated with complex and sporadic traits.

The genetic analysis using the biallelic markers of the present invention may be conducted on any scale. The whole set of biallelic markers of the present invention or any subset of biallelic markers of the present invention may be used. In some embodiments a subset of biallelic markers corresponding to one or several candidate genes of the present invention may be used. Alternatively, a subset of biallelic markers of the present invention localised on a specific chromosome segment may be used. Further, any set of genetic markers including a biallelic marker of the present invention may be used. As mentioned above, it should be noted that the biallelic markers of the present invention may be included in any complete or partial genetic map of the human genome. These different uses are specifically contemplated in the present invention and claims.

#### **Linkage analysis**

Linkage analysis is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. Thus, the aim of linkage analysis is to detect marker loci that show cosegregation with a trait of interest in pedigrees.

#### **Parametric methods**

When data are available from successive generations there is the opportunity to study the degree of linkage between pairs of loci. Estimates of the recombination fraction enable loci to be ordered and placed onto a genetic map. With loci that are genetic markers, a genetic map can be established, and then the strength of linkage between markers and traits can be calculated and used to indicate the relative positions of markers and genes affecting those traits (Weir, B.S., 1996). The classical method for linkage analysis is the logarithm of odds (lod) score method (see Morton N.E., 1955; Ott J, 1991). Calculation of lod scores requires specification of the mode of inheritance for the disease (parametric method). Generally, the length of the candidate region identified using linkage analysis is between 2 and 20Mb. Once a candidate region is identified as described above, analysis of recombinant individuals using additional markers allows further delineation of the candidate region. Linkage analysis studies have generally relied on the use of a maximum of 5,000 microsatellite markers, thus limiting the maximum theoretical attainable resolution of linkage analysis to about 600 kb on average.

Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance (i.e., the ratio between the number of trait positive carriers of allele  $a$  and the total number of  $a$  carriers in the population). However, parametric linkage analysis suffers from a variety of drawbacks. First, it

is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, as already mentioned, the resolution attainable using linkage analysis is limited, and complementary studies are required to refine the analysis of the typical 2Mb to 20Mb regions initially identified through linkage analysis. In addition, parametric linkage analysis approaches have proven difficult when applied to complex genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. It is very difficult to model these factors adequately in a lod score analysis. In such cases, too large an effort and cost are needed to recruit the adequate number of affected families required for applying linkage analysis to these situations, as recently discussed by Risch, N. and Merikangas, K. (1996).

#### 10           **Non-parametric methods**

The advantage of the so-called non-parametric methods for linkage analysis is that they do not require specification of the mode of inheritance for the disease, they tend to be more useful for the analysis of complex traits. In non-parametric methods, one tries to prove that the inheritance pattern of a chromosomal region is not consistent with random Mendelian segregation by showing that affected relatives inherit identical copies of the region more often than expected by chance. Affected relatives should show excess "allele sharing" even in the presence of incomplete penetrance and polygenic inheritance. In non-parametric linkage analysis the degree of agreement at a marker locus in two individuals can be measured either by the number of alleles identical by state (IBS) or by the number of alleles identical by descent (IBD). Affected sib pair analysis is a well-known special case and is the simplest form of these methods.

The biallelic markers of the present invention may be used in both parametric and non-parametric linkage analysis. Preferably biallelic markers may be used in non-parametric methods which allow the mapping of genes involved in complex traits. The biallelic markers of the present invention may be used in both IBD- and IBS- methods to map genes affecting a complex trait. In such studies, taking advantage of the high density of biallelic markers, several adjacent biallelic marker loci may be pooled to achieve the efficiency attained by multi-allelic markers (Zhao et al., 1998).

However, both parametric and non-parametric linkage analysis methods analyse affected relatives, they tend to be of limited value in the genetic analysis of drug responses or in the analysis of side effects to treatments. This type of analysis is impractical in such cases due to the lack of availability of familial cases. In fact, the likelihood of having more than one individual in a family being exposed to the same drug at the same time is extremely low.

#### **Population Association Studies**

35           The present invention comprises methods for identifying one or several genes among a

set of candidate genes that are associated with a detectable trait using the biallelic markers of the present invention. In one embodiment the present invention comprises methods to detect an association between a biallelic marker allele or a biallelic marker haplotype and a trait. Further, the invention comprises methods to identify a trait causing allele in linkage disequilibrium with any biallelic marker allele of the present invention.

As described above, alternative approaches can be employed to perform association studies: genome-wide association studies, candidate region association studies and candidate gene association studies. The candidate region analysis clearly provides a short-cut approach to the identification of genes and gene polymorphisms related to a particular trait when some information concerning the biology of the trait is available. Further, the biallelic markers of the present invention may be incorporated in any map of genetic markers of the human genome in order to perform genome-wide association studies. Methods to generate a high-density map of biallelic markers has been described in US Provisional Patent application serial number 60/082,614. The biallelic markers of the present invention may further be incorporated in any map of a specific candidate region of the genome (a specific chromosome or a specific chromosomal segment for example).

As mentioned above, association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families. Association studies are extremely valuable as they permit the analysis of sporadic or multifactor traits. Moreover, association studies represent a powerful method for fine-scale mapping enabling much finer mapping of trait causing alleles than linkage studies. Studies based on pedigrees often only narrow the location of the trait causing allele. Association studies using the biallelic markers of the present invention can therefore be used to refine the location of a trait causing allele in a candidate region identified by Linkage Analysis methods. Biallelic markers of the present invention can be used to identify the involved gene; such uses are specifically contemplated in the present invention and claims.

**1) Determining the frequency of a biallelic marker allele or of a biallelic marker haplotype in a population**

Another embodiment of the present invention encompasses methods of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising the steps of: a) genotyping each individual in said population for at least one 13q31-q33-related biallelic marker, b) genotyping each individual in said population for a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome; and c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of

said frequency. In addition, the methods of estimating the frequency of a haplotype of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: optionally said haplotype determination method is selected from the group consisting of asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark method, or an expectation maximization algorithm; optionally, said second biallelic marker is a 13q31-q33-related biallelic marker in a sequence selected from the group consisting of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132, and the complements thereof; optionally, said 13q31-q33-related biallelic marker may be selected individually or in any combination from the biallelic markers described in Tables 6b and 6c; optionally, the identity of the nucleotides at the biallelic markers in everyone of the sequences of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132 is determined in steps a) and b).

**Association studies explore the relationships among frequencies for sets of alleles between loci.**

**Determining the frequency of an allele in a population**

Allelic frequencies of the biallelic markers in a population can be determined using one of the methods described above under the heading "Methods for genotyping an individual for biallelic markers", or any genotyping procedure suitable for this intended purpose. Genotyping pooled samples or individual samples can determine the frequency of a biallelic marker allele in a population. One way to reduce the number of genotypings required is to use pooled samples. A major obstacle in using pooled samples is in terms of accuracy and reproducibility for determining accurate DNA concentrations in setting up the pools. Genotyping individual samples provides higher sensitivity, reproducibility and accuracy and; is the preferred method used in the present invention. Preferably, each individual is genotyped separately and simple gene counting is applied to determine the frequency of an allele of a biallelic marker or of a genotype in a given population.

**Determining the frequency of a haplotype in a population**

The gametic phase of haplotypes is unknown when diploid individuals are heterozygous at more than one locus. Using genealogical information in families gametic phase can sometimes be inferred (Perlin et al., 1994). When no genealogical information is available different strategies may be used. One possibility is that the multiple-site heterozygous diploids can be eliminated from the analysis, keeping only the homozygotes and the single-site heterozygote individuals, but this approach might lead to a possible bias in the sample composition and the underestimation of low-frequency haplotypes. Another possibility is that single chromosomes can be studied independently, for example, by asymmetric PCR amplification (see Newton et al., 1989; Wu et al., 1989) or by isolation of single chromosome

by limit dilution followed by PCR amplification (see Ruano et al., 1990). Further, a sample may be haplotyped for sufficiently close biallelic markers by double PCR amplification of specific alleles (Sarkar, G. and Sommer S.S., 1991). These approaches are not entirely satisfying either because of their technical complexity, the additional cost they entail, their lack of generalisation at a large scale, or the possible biases they introduce. To overcome these difficulties, an algorithm to infer the phase of PCR-amplified DNA genotypes introduced by Clark A.G. (1990) may be used. Briefly, the principle is to start filling a preliminary list of haplotypes present in the sample by examining unambiguous individuals, that is, the complete homozygotes and the single-site heterozygotes. Then other individuals in the same sample are screened for the possible occurrence of previously recognised haplotypes. For each positive identification, the complementary haplotype is added to the list of recognised haplotypes, until the phase information for all individuals is either resolved or identified as unresolved. This method assigns a single haplotype to each multiheterozygous individual, whereas several haplotypes are possible when there are more than one heterozygous site. Alternatively, one can use methods estimating haplotype frequencies in a population without assigning haplotypes to each individual. Preferably, a method based on an expectation-maximization (EM) algorithm (Dempster et al., J. R. 1977) leading to maximum-likelihood estimates of haplotype frequencies under the assumption of Hardy-Weinberg proportions (random mating) is used (see Excoffier L. and Slatkin M., 1995). The EM algorithm is a generalised iterative maximum-likelihood approach to estimation that is useful when data are ambiguous and/or incomplete. The EM algorithm is used to resolve heterozygotes into haplotypes. Haplotype estimations are further described below under the heading "Statistical methods". Any other method known in the art to determine or to estimate the frequency of a haplotype in a population may also be used.

## 2) Linkage Disequilibrium analysis

Linkage disequilibrium is the non-random association of alleles at two or more loci and represents a powerful tool for mapping genes involved in disease traits (see Ajioka R.S. et al., 1997). Biallelic markers, because they are densely spaced in the human genome and can be genotyped in more numerous numbers than other types of genetic markers (such as RFLP or VNTR markers), are particularly useful in genetic analysis based on linkage disequilibrium. The biallelic markers of the present invention may be used in any linkage disequilibrium analysis method known in the art.

Briefly, when a disease mutation is first introduced into a population (by a new mutation or the immigration of a mutation carrier), it necessarily resides on a single chromosome and thus on a single "background" or "ancestral" haplotype of linked markers. Consequently, there is complete disequilibrium between these markers and the disease

mutation: one finds the disease mutation only in the presence of a specific set of marker alleles. Through subsequent generations recombinations occur between the disease mutation and these marker polymorphisms, and the disequilibrium gradually dissipates. The pace of this dissipation is a function of the recombination frequency, so the markers closest to the disease gene will manifest higher levels of disequilibrium than those that are further away. When not broken up by recombination, "ancestral" haplotypes and linkage disequilibrium between marker alleles at different loci can be tracked not only through pedigrees but also through populations. Linkage disequilibrium is usually seen as an association between one specific allele at one locus and another specific allele at a second locus.

The pattern or curve of disequilibrium between disease and marker loci is expected to exhibit a maximum that occurs at the disease locus. Consequently, the amount of linkage disequilibrium between a disease allele and closely linked genetic markers may yield valuable information regarding the location of the disease gene. For fine-scale mapping of a disease locus, it is useful to have some knowledge of the patterns of linkage disequilibrium that exist between markers in the studied region. As mentioned above the mapping resolution achieved through the analysis of linkage disequilibrium is much higher than that of linkage studies. The high density of biallelic markers combined with linkage disequilibrium analysis provides powerful tools for fine-scale mapping. Different methods to calculate linkage disequilibrium are described below under the heading "Statistical Methods".

### **3) Population-based case-control studies of trait-marker associations**

As mentioned above, the occurrence of pairs of specific alleles at different loci on the same chromosome is not random and the deviation from random is called linkage disequilibrium. Association studies focus on population frequencies and rely on the phenomenon of linkage disequilibrium. If a specific allele in a given gene is directly involved in causing a particular trait, its frequency will be statistically increased in an affected (trait positive) population, when compared to the frequency in a trait negative population or in a random control population. As a consequence of the existence of linkage disequilibrium, the frequency of all other alleles present in the haplotype carrying the trait-causing allele will also be increased in trait positive individuals compared to trait negative individuals or random controls. Therefore, association between the trait and any allele (specifically a biallelic marker allele) in linkage disequilibrium with the trait-causing allele will suffice to suggest the presence of a trait-related gene in that particular region. Case-control populations can be genotyped for biallelic markers to identify associations that narrowly locate a trait causing allele. As any marker in linkage disequilibrium with one given marker associated with a trait will be associated with the trait. Linkage disequilibrium allows the relative frequencies in case-control

populations of a limited number of genetic polymorphisms (specifically biallelic markers) to be analysed as an alternative to screening all possible functional polymorphisms in order to find trait-causing alleles. Association studies compare the frequency of marker alleles in unrelated case-control populations, and represent powerful tools for the dissection of complex traits.

5           **Case-control populations (inclusion criteria)**

Population-based association studies do not concern familial inheritance but compare the prevalence of a particular genetic marker, or a set of markers, in case-control populations. They are case-control studies based on comparison of unrelated case (affected or trait positive) individuals and unrelated control (unaffected or trait negative or random) individuals.

10       Preferably the control group is composed of unaffected or trait negative individuals. Further, the control group is ethnically matched to the case population. Moreover, the control group is preferably matched to the case-population for the main known confusion factor for the trait under study (for example age-matched for an age-dependent trait). Ideally, individuals in the two samples are paired in such a way that they are expected to differ only in their disease status.  
15       In the following "trait positive population", "case population" and "affected population" are used interchangeably.

          An important step in the dissection of complex traits using association studies is the choice of case-control populations (see Lander and Schork, 1994). A major step in the choice of case-control populations is the clinical definition of a given trait or phenotype. Any genetic  
20       trait may be analysed by the association method proposed here by carefully selecting the individuals to be included in the trait positive and trait negative phenotypic groups. Four criteria are often useful: clinical phenotype, age at onset, family history and severity. The selection procedure for continuous or quantitative traits (such as blood pressure for example) involves selecting individuals at opposite ends of the phenotype distribution of the trait under  
25       study, so as to include in these trait positive and trait negative populations individuals with non-overlapping phenotypes. Preferably, case-control populations comprise phenotypically homogeneous populations. Trait positive and trait negative populations comprise phenotypically uniform populations of individuals representing each between 1 and 98%, preferably between 1 and 80%, more preferably between 1 and 50%, and more preferably  
30       between 1 and 30%, most preferably between 1 and 20% of the total population under study, and selected among individuals exhibiting non-overlapping phenotypes. The clearer the difference between the two trait phenotypes, the greater the probability of detecting an association with biallelic markers. The selection of those drastically different but relatively uniform phenotypes enables efficient comparisons in association studies and the possible  
35       detection of marked differences at the genetic level, provided that the sample sizes of the



populations under study are significant enough.

In preferred embodiments, a first group of between 50 and 300 trait positive individuals, preferably about 100 individuals, are recruited according to their phenotypes. A similar number of trait negative individuals are included in such studies.

5 In the present invention, typical examples of inclusion criteria include affection by schizophrenia.

#### Association analysis

The general strategy to perform association studies using biallelic markers derived from a region carrying a candidate gene is to scan two groups of individuals (case-control  
10 populations) in order to measure and statistically compare the allele frequencies of the biallelic markers of the present invention in both groups.

If a statistically significant association with a trait is identified for at least one or more of the analysed biallelic markers, one can assume that: either the associated allele is directly responsible for causing the trait (the associated allele is the trait causing allele), or more likely  
15 the associated allele is in linkage disequilibrium with the trait causing allele. The specific characteristics of the associated allele with respect to the gene function usually gives further insight into the relationship between the associated allele and the trait (causal or in linkage disequilibrium). If the evidence indicates that the associated allele within the gene is most probably not the trait causing allele but is in linkage disequilibrium with the real trait causing  
20 allele, then the trait causing allele can be found by sequencing the vicinity of the associated marker.

Another embodiment of the present invention encompasses methods of detecting an association between a haplotype and a phenotype, comprising the steps of: a) estimating the frequency of at least one haplotype in a trait positive population according to a method of  
25 estimating the frequency of a haplotype of the invention; b) estimating the frequency of said haplotype in a control population according to the method of estimating the frequency of a haplotype of the invention; and c) determining whether a statistically significant association exists between said haplotype and said phenotype. In addition, the methods of detecting an association between a haplotype and a phenotype of the invention encompass methods with any  
30 further limitation described in this disclosure, or those following, specified alone or in any combination: Optionally, said 13q31-q33-related biallelic marker may be in a sequence selected individually or in any combination from the group consisting of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132, and the complements thereof; optionally, said 13q31-q33-related biallelic marker may be selected individually or in any combination from the biallelic markers  
35 described in Tables 6b and 6c; optionally, said control population may be a trait negative

population, or a random population; optionally, said phenotype is a disease involving schizophrenia, a response to an agent acting on schizophrenia, or a side effects to an agent acting on schizophrenia.

#### **Haplotype analysis**

5 As described above, when a chromosome carrying a disease allele first appears in a population as a result of either mutation or migration, the mutant allele necessarily resides on a chromosome having a set of linked markers: the ancestral haplotype. This haplotype can be tracked through populations and its statistical association with a given trait can be analysed. Complementing single point (allelic) association studies with multi-point association studies  
10 also called haplotype studies increases the statistical power of association studies. Thus, a haplotype association study allows one to define the frequency and the type of the ancestral carrier haplotype. A haplotype analysis is important in that it increases the statistical power of an analysis involving individual markers.

In a first stage of a haplotype frequency analysis, the frequency of the possible  
15 haplotypes based on various combinations of the identified biallelic markers of the invention is determined. The haplotype frequency is then compared for distinct populations of trait positive and control individuals. The number of trait positive individuals, which should be, subjected to this analysis to obtain statistically significant results usually ranges between 30 and 300, with a preferred number of individuals ranging between 50 and 150. The same considerations apply to  
20 the number of unaffected individuals (or random control) used in the study. The results of this first analysis provide haplotype frequencies in case-control populations, for each evaluated haplotype frequency a p-value and an odd ratio are calculated. If a statistically significant association is found the relative risk for an individual carrying the given haplotype of being affected with the trait under study can be approximated.

#### **Interaction Analysis**

25 The biallelic markers of the present invention may also be used to identify patterns of biallelic markers associated with detectable traits resulting from polygenic interactions. The analysis of genetic interaction between alleles at unlinked loci requires individual genotyping using the techniques described herein. The analysis of allelic interaction among a selected set  
30 of biallelic markers with appropriate level of statistical significance can be considered as a haplotype analysis. Interaction analysis comprises stratifying the case-control populations with respect to a given haplotype for the first loci and performing a haplotype analysis with the second loci with each subpopulation.

Statistical methods used in association studies are further described herein.

#### **4) Testing for linkage in the presence of association**

The biallelic markers of the present invention may further be used in TDT (transmission/disequilibrium test). TDT tests for both linkage and association and is not affected by population stratification. TDT requires data for affected individuals and their parents or data from unaffected sibs instead of from parents (see Spielmann S. et al., 1993; Schaid D.J. et al., 1996, Spielmann S. and Ewens W.J., 1998). Such combined tests generally reduce the false – positive errors produced by separate analyses.

#### Statistical methods

In general, any method known in the art to test whether a trait and a genotype show a statistically significant correlation may be used.

##### **1) Methods in linkage analysis**

Statistical methods and computer programs useful for linkage analysis are well-known to those skilled in the art (see Terwilliger J.D. and Ott J., 1994; Ott J., 1991).

##### **2) Methods to estimate haplotype frequencies in a population**

As described above, when genotypes are scored, it is often not possible to distinguish heterozygotes so that haplotype frequencies cannot be easily inferred. When the gametic phase is not known, haplotype frequencies can be estimated from the multilocus genotypic data. Any method known to person skilled in the art can be used to estimate haplotype frequencies (see Lange K., 1997; Weir, B.S., 1996) Preferably, maximum-likelihood haplotype frequencies are computed using an Expectation- Maximization (EM) algorithm (see Dempster et al., 1977; Excoffier L. and Slatkin M., 1995). This procedure is an iterative process aiming at obtaining maximum-likelihood estimates of haplotype frequencies from multi-locus genotype data when the gametic phase is unknown. Haplotype estimations are usually performed by applying the EM algorithm using for example the EM-HAPLO program (Hawley M.E. et al., 1994) or the Arlequin program (Schneider et al., 1997). The EM algorithm is a generalised iterative maximum likelihood approach to estimation and is briefly described below.

In the following part of this text, phenotypes will refer to multi-locus genotypes with unknown phase. Genotypes will refer to known-phase multi-locus genotypes. Suppose a sample of N unrelated individuals typed for K markers. The data observed are the unknown-phase K-locus phenotypes that can be categorised in F different phenotypes. Suppose that we have H underlying possible haplotypes (in case of K biallelic markers,  $H=2^K$ ).

For phenotype j, suppose that  $c_j$  genotypes are possible. We thus have the following equation

$$P_j = \sum_{i=1}^{c_j} pr(genotype_i) = \sum_{i=1}^{c_j} pr(h_k, h_l) \quad \text{Equation 1}$$

where  $P_j$  is the probability of the phenotype  $j$ ,  $h_k$  and  $h_l$  are the two haplotypes constituent the genotype  $i$ . Under the Hardy-Weinberg equilibrium,  $pr(h_k h_l)$  becomes :

$$pr(h_k, h_l) = pr(h_k)^2 \text{ if } h_k = h_l, pr(h_k, h_l) = 2 pr(h_k) \cdot pr(h_l) \text{ if } h_k \neq h_l. \text{ Equation 2}$$

The successive steps of the E-M algorithm can be described as follows:

- 5 Starting with initial values of the of haplotypes frequencies, noted  $p_1^{(0)}, p_2^{(0)}, \dots, p_H^{(0)}$ , these initial values serve to estimate the genotype frequencies (Expectation step) and then estimate another set of haplotype frequencies (Maximisation step), noted  $p_1^{(1)}, p_2^{(1)}, \dots, p_H^{(1)}$ , these two steps are iterated until changes in the sets of haplotypes frequency are very small.

- 10 A stop criterion can be that the maximum difference between haplotype frequencies between two iterations is less than  $10^{-7}$ . These values can be adjusted according to the desired precision of estimations. In details, at a given iteration  $s$ , the Expectation step comprises calculating the genotypes frequencies by the following equation:

$$\begin{aligned} pr(genotype_i)^{(s)} &= pr(phenotype_j) \cdot pr(genotype_i | phenotype_j)^{(s)} \\ &= \frac{n_j}{N} \cdot \frac{pr(h_k, h_l)^{(s)}}{p_j^{(s)}} \end{aligned} \quad \text{Equation 3}$$

- 15 where genotype  $i$  occurs in phenotype  $j$ , and where  $h_k$  and  $h_l$  constitute genotype  $i$ . Each probability is derived according to eq.1, and eq.2 described above.

Then the Maximisation step simply estimates another set of haplotype frequencies given the genotypes frequencies. This approach is also known as gene-counting method (Smith, 1957).

$$p_i^{(s+1)} = \frac{1}{2} \sum_{j=1}^F \sum_{l=1}^{c_j} \delta_{il} \cdot pr(genotype_i)^{(s)} \quad \text{Equation 4}$$

- 20 Where  $\delta_{il}$  is an indicator variable which count the number of time haplotype  $l$  in genotype  $i$ . It takes the values of 0, 1 or 2.

To ensure that the estimation finally obtained is the maximum-likelihood estimation several values of departures are required. The estimations obtained are compared and if they are different the estimations leading to the best likelihood are kept.

- 25 **3) Methods to calculate linkage disequilibrium between markers**

A number of methods can be used to calculate linkage disequilibrium between any two genetic positions, in practice linkage disequilibrium is measured by applying a statistical association test to haplotype data taken from a population. Linkage disequilibrium between any pair of biallelic markers comprising at least one of the biallelic markers of the present invention

( $M_i, M_j$ ) having alleles ( $a_i/b_i$ ) at marker  $M_i$  and alleles ( $a_j/b_j$ ) at marker  $M_j$  can be calculated for every allele combination ( $a_i, a_j, a_i, b_j, b_i, a_j$  and  $b_i, b_j$ ), according to the Piazza formula :

$\Delta_{aiaj} = \sqrt{\theta 4} - \sqrt{(\theta 4 + \theta 3)(\theta 4 + \theta 2)}$ , where :

$\theta 4 = - -$  = frequency of genotypes not having allele  $a_i$  at  $M_i$  and not having allele  $a_j$  at  $M_j$

5  $\theta 3 = - +$  = frequency of genotypes not having allele  $a_i$  at  $M_i$  and having allele  $a_j$  at  $M_j$

$\theta 2 = + -$  = frequency of genotypes having allele  $a_i$  at  $M_i$  and not having allele  $a_j$  at  $M_j$

Linkage disequilibrium (LD) between pairs of biallelic markers ( $M_i, M_j$ ) can also be calculated for every allele combination ( $a_i, a_j, a_i, b_j, b_i, a_j$  and  $b_i, b_j$ ), according to the maximum-likelihood estimate (MLE) for delta (the composite genotypic disequilibrium coefficient), as described by Weir (Weir B.S., 1996). The MLE for the composite linkage disequilibrium is:

10

$$D_{aiaj} = (2n_1 + n_2 + n_3 + n_4/2)/N - 2(\text{pr}(a_i) \cdot \text{pr}(a_j))$$

where  $n_1 = \Sigma$  phenotype ( $a_i/a_i, a_j/a_j$ ),  $n_2 = \Sigma$  phenotype ( $a_i/a_i, a_j/b_j$ ),  $n_3 = \Sigma$  phenotype ( $a_i/b_i, a_j/a_j$ ),  $n_4 = \Sigma$  phenotype ( $a_i/b_i, a_j/b_j$ ) and  $N$  is the number of individuals in the sample. This formula allows linkage disequilibrium between alleles to be estimated when only genotype, and not

15

haplotype, data are available.

Another means of calculating the linkage disequilibrium between markers is as follows. For a couple of biallelic markers,  $M_i (a_i/b_i)$  and  $M_j (a_j/b_j)$ , fitting the Hardy-Weinberg equilibrium, one can estimate the four possible haplotype frequencies in a given population according to the approach described above.

20

The estimation of gametic disequilibrium between  $a_i$  and  $a_j$  is simply:

$$D_{aiaj} = \text{pr}(\text{haplotype}(a_i, a_j)) - \text{pr}(a_i) \cdot \text{pr}(a_j).$$

Where  $\text{pr}(a_i)$  is the probability of allele  $a_i$  and  $\text{pr}(a_j)$  is the probability of allele  $a_j$  and where  $\text{pr}(\text{haplotype}(a_i, a_j))$  is estimated as in Equation 3 above.

25

For a couple of biallelic marker only one measure of disequilibrium is necessary to describe the association between  $M_i$  and  $M_j$ .

Then a normalised value of the above is calculated as follows:

$$D'_{aiaj} = D_{aiaj} / \max(-\text{pr}(a_i) \cdot \text{pr}(a_j), -\text{pr}(b_i) \cdot \text{pr}(b_j)) \text{ with } D_{aiaj} < 0$$

$$D'_{aiaj} = D_{aiaj} / \max(\text{pr}(b_i) \cdot \text{pr}(a_j), \text{pr}(a_i) \cdot \text{pr}(b_j)) \text{ with } D_{aiaj} > 0$$

30

The skilled person will readily appreciate that other LD calculation methods can be used without undue experimentation.

Linkage disequilibrium among a set of biallelic markers having an adequate heterozygosity rate can be determined by genotyping between 50 and 1000 unrelated individuals, preferably between 75 and 200, more preferably around 100.

#### 4) Testing for association

Methods for determining the statistical significance of a correlation between a phenotype and a genotype, in this case an allele at a biallelic marker or a haplotype made up of such alleles, may be determined by any statistical test known in the art and with any accepted threshold of statistical significance being required. The application of particular methods and thresholds of significance are well within the skill of the ordinary practitioner of the art.

Testing for association is performed by determining the frequency of a biallelic marker allele in case and control populations and comparing these frequencies with a statistical test to determine if there is a statistically significant difference in frequency which would indicate a correlation between the trait and the biallelic marker allele under study. Similarly, a haplotype analysis is performed by estimating the frequencies of all possible haplotypes for a given set of biallelic markers in case and control populations, and comparing these frequencies with a statistical test to determine if there is a statistically significant correlation between the haplotype and the phenotype (trait) under study. Any statistical tool useful to test for a statistically significant association between a genotype and a phenotype may be used. Preferably the statistical test employed is a chi-square test with one degree of freedom. A P-value is calculated (the P-value is the probability that a statistic as large or larger than the observed one would occur by chance).

#### **Statistical significance**

In preferred embodiments, significance for diagnosis purposes, either as a positive basis for further diagnostic tests or as a preliminary starting point for early preventive therapy, the p value related to a biallelic marker association is preferably about  $1 \times 10^{-2}$  or less, more preferably about  $1 \times 10^{-4}$  or less, for a single biallelic marker analysis and about  $1 \times 10^{-3}$  or less, still more preferably  $1 \times 10^{-6}$  or less and most preferably of about  $1 \times 10^{-8}$  or less, for a haplotype analysis involving several markers. These values are believed to be applicable to any association studies involving single or multiple marker combinations.

The skilled person can use the range of values set forth above as a starting point in order to carry out association studies with biallelic markers of the present invention. In doing so, significant associations between the biallelic markers of the present invention and diseases involving schizophrenia can be revealed and used for diagnosis and drug screening purposes.

#### **Phenotypic permutation**

In order to confirm the statistical significance of the first stage haplotype analysis described above, it might be suitable to perform further analyses in which genotyping data from case-control individuals are pooled and randomised with respect to the trait phenotype. Each individual genotyping data is randomly allocated to two groups, which contain the same number of individuals as the case-control populations used to compile the data obtained in the first

stage. A second stage haplotype analysis is preferably run on these artificial groups, preferably for the markers included in the haplotype of the first stage analysis showing the highest relative risk coefficient. This experiment is reiterated preferably at least between 100 and 10000 times. The repeated iterations allow the determination of the percentage of obtained haplotypes with a significant p-value level.

#### Assessment of statistical association

To address the problem of false positives similar analysis may be performed with the same case-control populations in random genomic regions. Results in random regions and the candidate region are compared as described in US Provisional Patent Application entitled "Methods, software and apparatus for identifying genomic regions harbouring a gene associated with a detectable trait".

#### 5) Evaluation of risk factors

The association between a risk factor (in genetic epidemiology the risk factor is the presence or the absence of a certain allele or haplotype at marker loci) and a disease is measured by the odds ratio (OR) and by the relative risk (RR). If  $P(R^+)$  is the probability of developing the disease for individuals with R and  $P(R^-)$  is the probability for individuals without the risk factor, then the relative risk is simply the ratio of the two probabilities, that is:

$$RR = P(R^+)/P(R^-)$$

In case-control studies, direct measures of the relative risk cannot be obtained because of the sampling design. However, the odds ratio allows a good approximation of the relative risk for low-incidence diseases and can be calculated:

$$OR = \left[ \frac{F^+}{1 - F^+} \right] / \left[ \frac{F^-}{1 - F^-} \right]$$

$F^+$  is the frequency of the exposure to the risk factor in cases and  $F^-$  is the frequency of the exposure to the risk factor in controls.  $F^+$  and  $F^-$  are calculated using the allelic or haplotype frequencies of the study and further depend on the underlying genetic model (dominant, recessive, additive...).

One can further estimate the attributable risk (AR) which describes the proportion of individuals in a population exhibiting a trait due to a given risk factor. This measure is important in quantitating the role of a specific factor in disease etiology and in terms of the public health impact of a risk factor. The public health relevance of this measure lies in estimating the proportion of cases of disease in the population that could be prevented if the exposure of interest were absent. AR is determined as follows:

$$AR = P_E (RR-1) / (P_E (RR-1)+1)$$

AR is the risk attributable to a biallelic marker allele or a biallelic marker haplotype.  $P_E$  is the frequency of exposure to an allele or a haplotype within the population at large; and RR is the relative risk which, is approximated with the odds ratio when the trait under study has a relatively low incidence in the general population.

5           AR is the risk attributable to a biallelic marker allele or a biallelic marker haplotype.  $P_E$  is the frequency of exposure to an allele or a haplotype within the population at large; and RR is the relative risk which, is approximated with the odds ratio when the trait under study has a relatively low incidence in the general population.

10           **Association of Biallelic Markers of the Invention with Schizophrenia**

In the context of the present invention, an association between chromosome 13q31-q33-related biallelic markers and schizophrenia and bipolar disorder were established. Several association studies using different populations and screening samples thereof, and with different sets of biallelic markers distributed on the chromosome 13q31-q33 region were carried out.

15           Further details concerning these association studies and the results are provided herein in Examples 5a to 5e.

          This information is extremely valuable. The knowledge of a potential genetic predisposition to schizophrenia, even if this predisposition is not absolute, might contribute in a very significant manner to treatment efficacy of schizophrenia and to the development of new  
20           therapeutic and diagnostic tools.

**Identification Of Biallelic Markers In Linkage Disequilibrium With The Biallelic Markers of the Invention**

          Once a first biallelic marker has been identified in a genomic region of interest, the  
25           practitioner of ordinary skill in the art, using the teachings of the present invention, can easily identify additional biallelic markers in linkage disequilibrium with this first marker. As mentioned before, any marker in linkage disequilibrium with a first marker associated with a trait will be associated with the trait. Therefore, once an association has been demonstrated between a given biallelic marker and a trait, the discovery of additional biallelic markers  
30           associated with this trait is of great interest in order to increase the density of biallelic markers in this particular region. The causal gene or mutation will be found in the vicinity of the marker or set of markers showing the highest correlation with the trait.

          Identification of additional markers in linkage disequilibrium with a given marker involves: (a) amplifying a genomic fragment comprising a first biallelic marker from a plurality  
35           of individuals; (b) identifying of second biallelic markers in the genomic region harboring said



first biallelic marker; (c) conducting a linkage disequilibrium analysis between said first biallelic marker and second biallelic markers; and (d) selecting said second biallelic markers as being in linkage disequilibrium with said first marker. Subcombinations comprising steps (b) and (c) are also contemplated.

5           Methods to identify biallelic markers and to conduct linkage disequilibrium analysis are described herein and can be carried out by the skilled person without undue experimentation. The present invention then also concerns biallelic markers and other polymorphisms which are in linkage disequilibrium with the specific biallelic markers of the invention and which are expected to present similar characteristics in terms of their respective association with a given  
10 trait. In a preferred embodiment, the invention concerns biallelic markers which are in linkage disequilibrium with the specific biallelic markers.

#### **Identification Of Functional Mutations**

Once a positive association is confirmed with a biallelic marker of the present  
15 invention, the associated candidate gene sequence can be scanned for mutations by comparing the sequences of a selected number of trait positive and trait negative individuals. In a preferred embodiment, functional regions such as exons and splice sites, promoters and other regulatory regions of the gene are scanned for mutations. Preferably, trait positive individuals carry the haplotype shown to be associated with the trait and trait negative individuals do not carry the  
20 haplotype or allele associated with the trait. The mutation detection procedure is essentially similar to that used for biallelic site identification.

The method used to detect such mutations generally comprises the following steps: (a) amplification of a region of the candidate DNA sequence comprising a biallelic marker or a group of biallelic markers associated with the trait from DNA samples of trait positive patients  
25 and trait negative controls; (b) sequencing of the amplified region; (c) comparison of DNA sequences from trait-positive patients and trait-negative controls; and (d) determination of mutations specific to trait-positive patients. Subcombinations which comprise steps (b) and (c) are specifically contemplated.

It is preferred that candidate polymorphisms be then verified by screening a larger  
30 population of cases and controls by means of any genotyping procedure such as those described herein, preferably using a microsequencing technique in an individual test format. Polymorphisms are considered as candidate mutations when present in cases and controls at frequencies compatible with the expected association results.

Candidate polymorphisms and mutations of the g35030 nucleic acid sequences  
35 suspected of being involved in a predisposition to schizophrenia can be confirmed by screening

a larger population of affected and unaffected individuals using any of the genotyping procedures described herein. Preferably the microsequencing technique is used. Such polymorphisms are considered as candidate "trait-causing" mutations when they exhibit a statistically significant correlation with the detectable phenotype.

5

**Biallelic Markers Of The Invention In Methods Of Genetic Diagnostics**

The biallelic markers and other polymorphisms of the present invention can also be used to develop diagnostics tests capable of identifying individuals who express a detectable trait as the result of a specific genotype or individuals whose genotype places them at risk of developing a detectable trait at a subsequent time. The trait analyzed using the present diagnostics may be any detectable trait, including predisposition to schizophrenia, age of onset of detectable symptoms, a beneficial response to or side effects related to treatment against schizophrenia. Such a diagnosis can be useful in the monitoring, prognosis and/or prophylactic or curative therapy for schizophrenia.

The diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a genotype associated with an increased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular mutation, including methods which enable the analysis of individual chromosomes for haplotyping, such as family studies, single sperm DNA analysis or somatic hybrids.

The diagnostic techniques concern the detection of specific alleles present within the human chromosome 13q31-q33 region and optionally within a g35030 nucleic acid sequence. More particularly, the invention concerns the detection of a nucleic acid comprising at least one of the nucleotide sequences of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or a fragment thereof or a complementary sequence thereto including the polymorphic base.

These methods involve obtaining a nucleic acid sample from the individual and, determining, whether the nucleic acid sample contains at least one allele or at least one biallelic marker haplotype, indicative of a risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular the human chromosome 13q31-q33- or g35030-related polymorphism or mutation (trait-causing allele).

Preferably, in such diagnostic methods, a nucleic acid sample is obtained from the individual and this sample is genotyped using methods described above in "Methods Of Genotyping DNA Samples For Biallelic markers." The diagnostics may be based on a single biallelic marker or a on group of biallelic markers.

In each of these methods, a nucleic acid sample is obtained from the test subject and the

biallelic marker pattern of one or more of the biallelic markers of the invention is determined.

In one embodiment, a PCR amplification is conducted on the nucleic acid sample to amplify regions in which polymorphisms associated with a detectable phenotype have been identified. The amplification products are sequenced to determine whether the individual  
5 possesses one or more human chromosome 13q31-q33 region- or g35030-related polymorphisms associated with a detectable phenotype. The primers used to generate amplification products may comprise the primers listed in Table 4. Alternatively, the nucleic acid sample is subjected to microsequencing reactions as described above to determine whether the individual possesses one or more human chromosome 13q31-q33 region-related  
10 polymorphisms associated with a detectable phenotype resulting from a mutation or a polymorphism in the human chromosome 13q31-q33 region or g35030-related biallelic marker. The primers used in the microsequencing reactions may include the primers listed in 6. In another embodiment, the nucleic acid sample is contacted with one or more allele specific oligonucleotide probes which, specifically hybridize to one or more human chromosome 13q31-  
15 q33 region or g35030-related alleles associated with a detectable phenotype. The probes used in the hybridization assay may include the probes listed in Table 5. In another embodiment, the nucleic acid sample is contacted with a second oligonucleotide capable of producing an amplification product when used with the allele specific oligonucleotide in an amplification reaction. The presence of an amplification product in the amplification reaction indicates that  
20 the individual possesses one or more human chromosome 13q31-q33 region or g35030-related alleles associated with a detectable phenotype.

In a preferred embodiment the identity of the nucleotide present at, at least one, biallelic marker selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 and the complements thereof, is determined and the  
25 detectable trait is schizophrenia. Diagnostic kits comprise any of the polynucleotides of the present invention.

These diagnostic methods are extremely valuable as they can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms.

30 Diagnostics, which analyze and predict response to a drug or side effects to a drug, may be used to determine whether an individual should be treated with a particular drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug may be administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a  
35 particular drug, an alternative course of treatment may be prescribed. A negative response may

be defined as either the absence of an efficacious response or the presence of toxic side effects.

Clinical drug trials represent another application for the markers of the present invention. One or more markers indicative of response to an agent acting against schizophrenia or to side effects to an agent acting against schizophrenia may be identified using the methods described above. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

### PREVENTION, DIAGNOSIS AND TREATMENT OF PSYCHIATRIC DISEASE

An aspect of the present invention relates to the preparation of a medicament for the treatment of psychiatric disease, in particular schizophrenia and bipolar disorder. The present invention embodies medicaments acting on g35030.

In preferred embodiments, medicaments of the invention act on g35030, either directly or indirectly, by acting on the g35030 pathways. For example, the medicaments may modulate, and more preferably decrease the level of g35030 activity which occurs in a cell or particular tissue, or increase or decrease the activity of the g35030 protein. In certain embodiments, the invention thus comprises use of a compound capable of increasing or decreasing g35030 expression or g35030 protein activity in the preparation or manufacture of a medicament. Preferably, said compound is used for the treatment of a psychiatric disease, preferably for the treatment of schizophrenia or bipolar disorder. Preferably, said compound acts directly by binding to g35030 of a g35030 receptor.

Such medicaments may also increase or decrease the activity of a compound analogous to g35030, a compound comprising an amino acid sequence having at least 25% homology to a sequence selected from the group consisting of SEQ ID NOs. 18 to 23, a compound comprising an amino acid sequence having at least 50% homology to a sequence selected from the group consisting of SEQ ID NOs. 18 to 23, and a compound comprising an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of SEQ ID NOs. 18 to 23.

Medicaments which increase or decrease the activity of these compounds in an individual may be used to ameliorate or prevent symptoms in individuals suffering from or predisposed to a psychiatric disease, as discussed above in the section entitled "indications".

Alternatively, g35030 activity may be increased or decreased by the expression of the

genes encoding the identified g35030-modulating compounds using gene therapy. Examples of vectors and promoters suitable for use in gene therapy are described above. G35030 activity may also be increased or decreased by preparing an antibody which binds to a g35030 peptide, a g35030 receptor or a protein related thereto, as well as fragments of these proteins. Such antibodies may modulate the interaction between g35030 and a g35030 receptor or a protein related thereto. Antibodies and methods of obtaining them are further described herein.

As described above, the present invention provides cellular assays for identifying compounds for the treatment of psychiatric disease. The assays are based on detection of g35030 expression, measurement of g35030 protein activity, or based on the determination of other suitable schizophrenia, bipolar disorder or related psychiatric disease endpoints. Compounds for the treatment of psychiatric disease include derivative proteins or peptides which are capable of inhibiting the activity of a wild type g35030 protein, which may be identified by determining their ability to bind a wild type g35030 protein. Compounds also include antibodies, and small molecules and drugs which may be obtained using a variety of synthetic approaches familiar to those skilled in the art, including combinatorial chemistry based techniques.

The invention further encompasses said methods for the prevention, treatment, and diagnosis of disease using any of the g35030 nucleic acids or proteins of the invention in analogous methods.

#### **G35030 in Methods of Diagnosis or Detecting Predisposition**

Individuals affected by or predisposed to schizophrenia and bipolar disorder may express abnormal levels of g35030. Individuals having increased or decreased g35030 activity in their plasma, body fluids, or body tissues may be at risk of developing schizophrenia, bipolar disorder or a variety of potentially related psychiatric conditions. In one aspect of the present invention is a method for determining whether an individual is at risk of suffering from or is currently suffering from schizophrenia, bipolar disorder or other psychotic disorders, mood disorders, autism, substance dependence or alcoholism, mental retardation, or other psychiatric diseases including cognitive, anxiety, eating, impulse-control, and personality disorders, as defined with the Diagnosis and Statistical Manual of Mental Disorders fourth edition (DSM-IV) classification, comprising determining whether the individual has an abnormal level of g35030 activity in plasma, body fluids, or body tissues. The level of g35030 or analogous compounds in plasma, body fluids, or body tissues may be determined using a variety approaches. In particular, the level may be determined using ELISA, Western Blots, or protein electrophoresis.

#### **Biallelic Markers Of The Invention In Methods Of Genetic Diagnostics**

The biallelic markers and other polymorphisms of the present invention can also be used to develop diagnostics tests capable of identifying individuals who express a detectable

5 trait as the result of a specific genotype or individuals whose genotype places them at risk of developing a detectable trait at a subsequent time. The trait analyzed using the present diagnostics may be used to diagnose any detectable trait, including predisposition to schizophrenia or bipolar disorder, age of onset of detectable symptoms, a beneficial response to or side effects related to treatment against schizophrenia or bipolar disorder. Such a diagnosis can be useful in the monitoring, prognosis and/or prophylactic or curative therapy for schizophrenia or bipolar disorder.

10 The diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a genotype associated with an increased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular mutation, including methods which enable the analysis of individual chromosomes for haplotyping, such as family studies, single sperm DNA analysis or somatic hybrids.

15 The diagnostic techniques concern the detection of specific alleles present within the human chromosome 13q31-q33 region, and optionally within a g35030 nucleic acid sequence. More particularly, the invention concerns the detection of a nucleic acid comprising at least one of the nucleotide sequences of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or a fragment thereof or a complementary sequence thereto including the polymorphic base.

20 These methods involve obtaining a nucleic acid sample from the individual and, determining, whether the nucleic acid sample contains at least one allele or at least one biallelic marker haplotype, indicative of a risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular the human chromosome 13q31-q33 region-related polymorphism or mutation (trait-causing allele).

25 Preferably, in such diagnostic methods, a nucleic acid sample is obtained from the individual and this sample is genotyped using methods described above in "Methods Of Genotyping DNA Samples For Biallelic markers." The diagnostics may be based on a single biallelic marker or a on group of biallelic markers.

In each of these methods, a nucleic acid sample is obtained from the test subject and the biallelic marker pattern of one or more of a biallelic marker of the invention is determined.

30 In one embodiment, a PCR amplification is conducted on the nucleic acid sample to amplify regions in which polymorphisms associated with a detectable phenotype have been identified. The amplification products are sequenced to determine whether the individual possesses one or more human chromosome 13q31-q33 region, g35030-related polymorphisms associated with a detectable phenotype. The primers used to generate amplification products may comprise the primers listed in Table 4. Alternatively, the nucleic acid sample is subjected

35

to microsequencing reactions as described above to determine whether the individual possesses one or more human chromosome 13q31-q33 region, g35030-related polymorphisms associated with a detectable phenotype resulting from a mutation or a polymorphism in the human chromosome 13q31-q33 region. The primers used in the microsequencing reactions may include the primers listed in Table 6. In another embodiment, the nucleic acid sample is contacted with one or more allele specific oligonucleotide probes which, specifically hybridize to one or more human chromosome 13q31-q33 region, g35030-related alleles associated with a detectable phenotype. The probes used in the hybridization assay may include the probes listed in 6b. In another embodiment, the nucleic acid sample is contacted with a second oligonucleotide capable of producing an amplification product when used with the allele specific oligonucleotide in an amplification reaction. The presence of an amplification product in the amplification reaction indicates that the individual possesses one or more human chromosome 13q31-q33 region, g35030-related alleles associated with a detectable phenotype. In a preferred embodiment, the detectable trait is schizophrenia or bipolar disorder. Diagnostic kits comprise any of the polynucleotides of the present invention.

These diagnostic methods are extremely valuable as they can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms.

Diagnostics, which analyze and predict response to a drug or side effects to a drug, may be used to determine whether an individual should be treated with a particular drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug may be administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects.

Clinical drug trials represent another application for the markers of the present invention. One or more markers indicative of response to an agent acting against schizophrenia or to side effects to an agent acting against schizophrenia may be identified using the methods described above. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

**Prevention And Treatment Of Disease Using Biallelic Markers**

In large part because of the risk of suicide, the detection of susceptibility to schizophrenia, bipolar disorder as well as other psychiatric disease in individuals is very important. Consequently, the invention concerns a method for the treatment of schizophrenia or bipolar disorder, or a related disorder comprising the following steps:

- 5       - selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, preferably g35030-related markers associated with schizophrenia or bipolar disorder;
- following up said individual for the appearance (and optionally the development) of the symptoms related to schizophrenia or bipolar disorder; and
- 10       - administering a treatment acting against schizophrenia or bipolar disorder or against symptoms thereof to said individual at an appropriate stage of the disease.

Another embodiment of the present invention comprises a method for the treatment of schizophrenia or bipolar disorder comprising the following steps:

- 15       - selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers, of the human chromosome 13q31-q33 region, and more preferably g35030-related markers associated with schizophrenia or bipolar disorder;
- administering a preventive treatment of schizophrenia or bipolar disorder to said individual.

In a further embodiment, the present invention concerns a method for the treatment of schizophrenia or bipolar disorder comprising the following steps:

- 20       - selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33, and more preferably g35030-related markers associated with schizophrenia or bipolar disorder;
- administering a preventive treatment of schizophrenia or bipolar disorder to said individual;
- 25       - following up said individual for the appearance and the development of schizophrenia or bipolar disorder symptoms; and optionally
- administering a treatment acting against schizophrenia or bipolar disorder or against symptoms thereof to said individual at the appropriate stage of the disease.

For use in the determination of the course of treatment of an individual suffering from disease, the present invention also concerns a method for the treatment of schizophrenia or bipolar disorder comprising the following steps:

- 30       - selecting an individual suffering from schizophrenia or bipolar disorder whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, and preferably g35030-related markers, associated with the
- 35       gravity of schizophrenia or bipolar disorder or of the symptoms thereof; and



- administering a treatment acting against schizophrenia or bipolar disorder or symptoms thereof to said individual.

The invention also concerns a method for the treatment of schizophrenia or bipolar disorder in a selected population of individuals. The method comprises:

5       - selecting an individual suffering from schizophrenia or bipolar disorder and whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, and more preferably g35030-related markers associated with a positive response to treatment with an effective amount of a medicament acting against schizophrenia or bipolar disorder or symptoms thereof,

10       - and/or whose DNA does not comprise alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, and more preferably g35030-related markers associated with a negative response to treatment with said medicament; and

- administering at suitable intervals an effective amount of said medicament to said selected individual.

15       In the context of the present invention, a "positive response" to a medicament can be defined as comprising a reduction of the symptoms related to the disease. In the context of the present invention, a "negative response" to a medicament can be defined as comprising either a lack of positive response to the medicament which does not lead to a symptom reduction or which leads to a side-effect observed following administration of the medicament.

20       The invention also relates to a method of determining whether a subject is likely to respond positively to treatment with a medicament. The method comprises identifying a first population of individuals who respond positively to said medicament and a second population of individuals who respond negatively to said medicament. One or more biallelic markers is identified in the first population which is associated with a positive response to said medicament  
25       or one or more biallelic markers is identified in the second population which is associated with a negative response to said medicament. The biallelic markers may be identified using the techniques described herein.

A DNA sample is then obtained from the subject to be tested. The DNA sample is analyzed to determine whether it comprises alleles of one or more biallelic markers associated  
30       with a positive response to treatment with the medicament and/or alleles of one or more biallelic markers associated with a negative response to treatment with the medicament.

In some embodiments, the medicament may be administered to the subject in a clinical trial if the DNA sample contains alleles of one or more biallelic markers associated with a positive response to treatment with the medicament and/or if the DNA sample lacks alleles of  
35       one or more biallelic markers associated with a negative response to treatment with the

medicament. In preferred embodiments, the medicament is a drug acting against schizophrenia or bipolar disorder.

Using the method of the present invention, the evaluation of drug efficacy may be conducted in a population of individuals likely to respond favorably to the medicament.

5 Another aspect of the invention is a method of using a medicament comprising obtaining a DNA sample from a subject, determining whether the DNA sample contains alleles of one or more biallelic markers associated with a positive response to the medicament and/or whether the DNA sample contains alleles of one or more biallelic markers associated with a negative response to the medicament, and administering the medicament to the subject if the  
10 DNA sample contains alleles of one or more biallelic markers associated with a positive response to the medicament and/or if the DNA sample lacks alleles of one or more biallelic markers associated with a negative response to the medicament.

The invention also concerns a method for the clinical testing of a medicament, preferably a medicament acting against schizophrenia or or bipolar disorder or symptoms thereof. The method comprises the following steps:  
15

- administering a medicament, preferably a medicament susceptible of acting against schizophrenia or or bipolar disorder or symptoms thereof to a heterogeneous population of individuals,
- identifying a first population of individuals who respond positively to said  
20 medicament and a second population of individuals who respond negatively to said medicament,
- identifying biallelic markers in said first population which are associated with a positive response to said medicament,
- selecting individuals whose DNA comprises biallelic markers associated with a  
25 positive response to said medicament, and
- administering said medicament to said individuals.

In any of the methods for the prevention, diagnosis and treatment of schizophrenia and bipolar disorder, including methods of using a medicament, clinical testing of a medicament, determining whether a subject is likely to respond positively to treatment with a medicament, said biallelic marker may optionally comprise:  
30

- (a) a biallelic marker selected from the group consisting of g35030-related markers A13 to A65; (b) a biallelic marker selected from the group consisting of chromosome 13q31-q33-related-biallelic markers A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 ; or (c) a biallelic marker selected from the group consisting of  
35 chromosome 13q31-q33-related-biallelic markers A13 to A18, A20 to A47, A49 to A52, A55,

A57, A59 to A63. Furthermore, any of the embodiments of the invention may specifically exclude one or more of the biallelic markers selected from biallelic markers A1 to A127.

Such methods are deemed to be extremely useful to increase the benefit/risk ratio resulting from the administration of medicaments which may cause undesirable side effects and/or be inefficacious to a portion of the patient population to which it is normally administered.

Once an individual has been diagnosed as suffering from schizophrenia or bipolar disorder, selection tests are carried out to determine whether the DNA of this individual comprises alleles of a biallelic marker or of a group of biallelic markers associated with a positive response to treatment or with a negative response to treatment which may include either side effects or unresponsiveness.

The selection of the patient to be treated using the method of the present invention can be carried out through the detection methods described above. The individuals which are to be selected are preferably those whose DNA does not comprise alleles of a biallelic marker or of a group of biallelic markers associated with a negative response to treatment. The knowledge of an individual's genetic predisposition to unresponsiveness or side effects to particular medicaments allows the clinician to direct treatment toward appropriate drugs against schizophrenia or bipolar disorder or symptoms thereof.

Once the patient's genetic predispositions have been determined, the clinician can select appropriate treatment for which negative response, particularly side effects, has not been reported or has been reported only marginally for the patient.

The biallelic markers of the invention have demonstrated an association with schizophrenia and bipolar disorders. However, the present invention also comprises any of the prevention, diagnostic, prognosis and treatment methods described herein using the biallelic markers of the invention in methods of preventing, diagnosing, managing and treating related disorders, particularly related CNS disorders. By way of example, related disorders may comprise psychotic disorders, mood disorders, autism, substance dependence and alcoholism, mental retardation, and other psychiatric diseases including cognitive, anxiety, eating, impulse-control, and personality disorders, as defined with the Diagnosis and Statistical Manual of Mental Disorders fourth edition (DSM-IV) classification".

#### **Recombinant Vectors**

The term "vector" is used herein to designate either a circular or a linear DNA or RNA molecule, which is either double-stranded or single-stranded, and which comprise at least one polynucleotide of interest that is sought to be transferred in a cell host or in a unicellular or multicellular host organism.

The present invention encompasses a family of recombinant vectors that comprise a polynucleotide derived from a g35030 nucleic acid sequence. Consequently, the present invention further comprises recombinant vectors comprising: g35030 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 201123 to 201234, 201123 to 5 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803 and 199122 to 249803 of SEQ ID No. 1, SEQ ID Nos 2 to 17 and primate g35030 DNAs of SEQ ID Nos 79 to 132, and the complements thereof;

10 Generally, a recombinant vector of the invention may comprise any of the polynucleotides described herein, as well as any g35030 primer or probe as defined above.

In a first preferred embodiment, a recombinant vector of the invention is used to amplify the inserted polynucleotide derived from a g35030 genomic sequence or cDNA of the invention in a suitable cell host, this polynucleotide being amplified at every time that the 15 recombinant vector replicates.

A second preferred embodiment of the recombinant vectors according to the invention comprises expression vectors comprising either a regulatory polynucleotide or a coding nucleic acid of the invention, or both. Within certain embodiments, expression vectors are employed to express a g35030 polypeptide which can be then purified and, for example be used in ligand 20 screening assays or as an immunogen in order to raise specific antibodies directed against a g35030 protein. In other embodiments, the expression vectors are used for constructing transgenic animals and also for gene therapy. Expression requires that appropriate signals are provided in the vectors, said signals including various regulatory elements, such as enhancers/promoters from both viral and mammalian sources that drive expression of the genes 25 of interest in host cells. Dominant drug selection markers for establishing permanent, stable cell clones expressing the products are generally included in the expression vectors of the invention, as they are elements that link expression of the drug selection markers to expression of the polypeptide.

More particularly, the present invention relates to expression vectors which include 30 nucleic acids encoding a g35030 protein or variants or fragments thereof, under the control of a regulatory sequence of the respective g35030 regulatory polynucleotides, or alternatively under the control of an exogenous regulatory sequence.

The invention also pertains to a recombinant expression vector useful for the expression of a g35030 cDNA sequence.

35 Recombinant vectors comprising a nucleic acid containing a human chromosome

13q31-33-related biallelic marker, or more preferably a g35030-related biallelic marker is also part of the invention. In a preferred embodiment, said biallelic marker is selected from the group consisting of A13 to A65 and the complements thereof.

5 Some of the elements which can be found in the vectors of the present invention are described in further detail in the following sections.

### 1. General features of the expression vectors of the invention

A recombinant vector according to the invention comprises, but is not limited to, a YAC (Yeast Artificial Chromosome), a BAC (Bacterial Artificial Chromosome), a phage, a phagemid, a cosmid, a plasmid or even a linear DNA molecule which may comprise a  
10 chromosomal, non-chromosomal, semi-synthetic and synthetic DNA. Such a recombinant vector can comprise a transcriptional unit comprising an assembly of:

- (1) a genetic element or elements having a regulatory role in gene expression, for example promoters or enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to 300 bp in length that act on the promoter to increase the transcription.
- 15 (2) a structural or coding sequence which is transcribed into mRNA and eventually translated into a polypeptide, said structural or coding sequence being operably linked to the regulatory elements described in (1); and
- (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence  
20 enabling extracellular secretion of translated protein by a host cell. Alternatively, when a recombinant protein is expressed without a leader or transport sequence, it may include a N-terminal residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

Generally, recombinant expression vectors will include origins of replication, selectable  
25 markers permitting transformation of the host cell, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably a leader sequence capable of directing secretion of the translated protein into the periplasmic space or the extracellular medium. In a specific embodiment  
30 wherein the vector is adapted for transfecting and expressing desired sequences in mammalian host cells, preferred vectors will comprise an origin of replication in the desired host, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5'-flanking non-transcribed sequences. DNA sequences derived from the SV40 viral genome, for example  
35 SV40 origin, early promoter, enhancer, splice and polyadenylation sites may be used to provide

the required non-transcribed genetic elements.

The *in vivo* expression of a g35030 polypeptide or fragments or variants thereof may be useful in order to correct a genetic defect related to the expression of the native gene in a host organism or to the production of a biologically inactive g35030 protein.

5           Consequently, the present invention also comprises recombinant expression vectors mainly designed for the *in vivo* production of the g35030 polypeptide by the introduction of the appropriate genetic material in the organism of the patient to be treated. In preferred embodiments, said genetic material comprises at least one nucleotide sequence selected from the group of nucleotide position ranges consisting of: g35030 genomic DNA or cDNAs  
10           comprised in the nucleic acids of any of nucleotide positions 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803 and 199122 to 249803 of SEQ ID No. 1, SEQ ID Nos 2 to 17 and  
15           primate g35030 DNAs of SEQ ID Nos 79 to 132, and the complements thereof;

This genetic material may be introduced *in vitro* in a cell that has been previously extracted from the organism, the modified cell being subsequently reintroduced in the said organism, directly *in vivo* into the appropriate tissue.

## 2. Regulatory Elements

### 20           Promoters

The suitable promoter regions used in the expression vectors according to the present invention are chosen taking into account the cell host in which the heterologous gene has to be expressed. The particular promoter employed to control the expression of a nucleic acid sequence of interest is not believed to be important, so long as it is capable of directing the  
25           expression of the nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell, such as, for example, a human or a viral promoter.

A suitable promoter may be heterologous with respect to the nucleic acid for which it  
30           controls the expression or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted.

Promoter regions can be selected from any desired gene using, for example, CAT  
35           (chloramphenicol transferase) vectors and more preferably pKK232-8 and pCM7 vectors.

Preferred bacterial promoters are the LacI, LacZ, the T3 or T7 bacteriophage RNA polymerase promoters, the gpt, lambda PR, PL and trp promoters (EP 0036776), the polyhedrin promoter, or the p10 protein promoter from baculovirus (Kit Novagen) (Smith et al., 1983; O'Reilly et al., 1992), the lambda PR promoter or also the trc promoter.

5 Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-L. Selection of a convenient vector and promoter is well within the level of ordinary skill in the art.

The choice of a promoter is well within the ability of a person skilled in the field of genetic engineering. For example, one may refer to the book of Sambrook et al.(1989) or also  
10 to the procedures described by Fuller et al.(1996).

#### Other regulatory elements

One will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be  
15 employed such as human growth hormone and SV40 polyadenylation signals. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

The vector containing the appropriate DNA sequence as described above, more preferably a g35030 gene regulatory polynucleotide, a polynucleotide encoding a g35030  
20 polypeptide comprising at least one nucleotide sequence selected from the group of nucleotide sequence ranges consisting of: g35030 genomic DNA or cDNAs comprised in the nucleic acids of any of nucleotide positions 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to  
25 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803 and 199122 to 249803 of SEQ ID No. 1, SEQ ID Nos 2 to 17 and primate g35030 DNAs of SEQ ID Nos 79 to 132, and the complements thereof.

#### **3. Selectable Markers**

Such markers would confer an identifiable change to the cell permitting easy  
30 identification of cells containing the expression construct. The selectable marker genes for selection of transformed host cells are preferably dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for *S. cerevisiae* or tetracycline, rifampicin or ampicillin resistance in *E. coli*, or levan saccharase for mycobacteria, this latter marker being a negative selection marker.

35 **4. Preferred Vectors.**

### Bacterial vectors

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and a bacterial origin of replication derived from commercially available plasmids comprising genetic elements of pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia, Uppsala, Sweden), and GEM1 (Promega Biotec, Madison, WI, USA).

Large numbers of other suitable vectors are known to those of skill in the art, and commercially available, such as the following bacterial vectors: pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); pQE-30 (QIAexpress).

### Bacteriophage vectors

The P1 bacteriophage vector may contain large inserts ranging from about 80 to about 100 kb.

The construction of P1 bacteriophage vectors such as p158 or p158/neo8 are notably described by Sternberg (1992, 1994). Recombinant P1 clones comprising g35030 polynucleotide sequences may be designed for inserting large polynucleotides of more than 40 kb (Linton et al., 1993). To generate P1 DNA for transgenic experiments, a preferred protocol is the protocol described by McCormick et al. (1994). Briefly, *E. coli* (preferably strain NS3529) harboring the P1 plasmid are grown overnight in a suitable broth medium containing 25 µg/ml of kanamycin. The P1 DNA is prepared from the *E. coli* by alkaline lysis using the Qiagen Plasmid Maxi kit (Qiagen, Chatsworth, CA, USA), according to the manufacturer's instructions. The P1 DNA is purified from the bacterial lysate on two Qiagen-tip 500 columns, using the washing and elution buffers contained in the kit. A phenol/chloroform extraction is then performed before precipitating the DNA with 70% ethanol. After solubilizing the DNA in TE (10 mM Tris-HCl, pH 7.4, 1 mM EDTA), the concentration of the DNA is assessed by spectrophotometry.

When the goal is to express a P1 clone comprising a g35030 polynucleotide sequence in a transgenic animal, typically in transgenic mice, it is desirable to remove vector sequences from the P1 DNA fragment, for example by cleaving the P1 DNA at rare-cutting sites within the P1 polylinker (*Sfi*I, *Not*I or *Sal*I). The P1 insert is then purified from vector sequences on a pulsed-field agarose gel, using methods similar to those originally reported for the isolation of DNA from YACs (Schedl et al., 1993a; Peterson et al., 1993, ). At this stage, the resulting purified insert DNA can be concentrated, if necessary, on a Millipore



Ultrafree-MC Filter Unit (Millipore, Bedford, MA, USA - 30,000 molecular weight limit) and then dialyzed against microinjection buffer (10 mM Tris-HCl, pH 7.4; 250  $\mu$ M EDTA) containing 100-mM NaCl, 30  $\mu$ M spermine, 70  $\mu$ M spermidine on a microdialysis membrane (type VS, 0.025  $\mu$ M from Millipore). The intactness of the purified P1 DNA insert is assessed by electrophoresis on 1% agarose (Sea Kem GTG; FMC Bio-products) pulse-field gel and staining with ethidium bromide.

#### Baculovirus vectors

A suitable vector for the expression of a g35030 polypeptide encoded by a polynucleotide of SEQ ID Nos. 1 to 17 or fragments or variants thereof is a baculovirus vector that can be propagated in insect cells and in insect cell lines. A specific suitable host vector system is the pVL1392/1393 baculovirus transfer vector (Pharminogen) that is used to transfect the SF9 cell line (ATCC N<sup>o</sup>CRL 1711) which is derived from *Spodoptera frugiperda*.

Other suitable vectors for the expression of the g35030 polypeptide encoded by the polynucleotides of SEQ ID Nos. 1 to 17, or fragments or variants thereof in a baculovirus expression system include those described by Chai et al.(1993), Vlasak et al.(1983) and Lenhard et al.(1996).

#### Viral vectors

In one specific embodiment, the vector is derived from an adenovirus. Preferred adenovirus vectors according to the invention are those described by Feldman and Steg (1996) or Ohno et al.(1994). Another preferred recombinant adenovirus according to this specific embodiment of the present invention is the human adenovirus type 2 or 5 (Ad 2 or Ad 5) or an adenovirus of animal origin (French patent application N<sup>o</sup> FR-93.05954).

Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery systems of choice for the transfer of exogenous polynucleotides *in vivo*, particularly to mammals, including humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host.

Particularly preferred retroviruses for the preparation or construction of retroviral *in vitro* or *in vitro* gene delivery vehicles of the present invention include retroviruses selected from the group consisting of Mink-Cell Focus Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus and Rous Sarcoma virus. Particularly preferred Murine Leukemia Viruses include the 4070A and the 1504A viruses, Abelson (ATCC No VR-999), Friend (ATCC No VR-245), Gross (ATCC No VR-590), Rauscher (ATCC No VR-998) and Moloney Murine Leukemia Virus (ATCC No VR-190; PCT Application No WO 94/24298). Particularly preferred Rous Sarcoma Viruses include Bryan high titer (ATCC Nos VR-334, VR-657, VR-

726, VR-659 and VR-728). Other preferred retroviral vectors are those described in Roth et al.(1996), PCT Application No WO 93/25234, PCT Application No WO 94/ 06920, Roux et al., 1989, Julian et al., 1992 and Neda et al., 1991.

5 Yet another viral vector system that is contemplated by the invention comprises the adeno-associated virus (AAV). The adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al., 1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (Flotte et al., 1992; Samulski et al., 1989; McLaughlin et al., 1989). One  
10 advantageous feature of AAV derives from its reduced efficacy for transducing primary cells relative to transformed cells.

#### BAC vectors

The bacterial artificial chromosome (BAC) cloning system (Shizuya et al., 1992) has been developed to stably maintain large fragments of genomic DNA (100-300 kb) in *E. coli*. A  
15 preferred BAC vector comprises pBeloBAC11 vector that has been described by Kim et al.(1996). BAC libraries are prepared with this vector using size-selected genomic DNA that has been partially digested using enzymes that permit ligation into either the *Bam* HI or *Hind*III sites in the vector. Flanking these cloning sites are T7 and SP6 RNA polymerase transcription initiation sites that can be used to generate end probes by either RNA transcription or PCR  
20 methods. After the construction of a BAC library in *E. coli*, BAC DNA is purified from the host cell as a supercoiled circle. Converting these circular molecules into a linear form precedes both size determination and introduction of the BACs into recipient cells. The cloning site is flanked by two *Not* I sites, permitting cloned segments to be excised from the vector by *Not* I digestion. Alternatively, the DNA insert contained in the pBeloBAC11 vector may be  
25 linearized by treatment of the BAC vector with the commercially available enzyme lambda terminase that leads to the cleavage at the unique *cos*N site, but this cleavage method results in a full length BAC clone containing both the insert DNA and the BAC sequences.

#### **5. Delivery Of The Recombinant Vectors**

In order to effect expression of the polynucleotides and polynucleotide constructs of the invention, these constructs must be delivered into a cell. This delivery may be accomplished *in*  
30 *vitro*, as in laboratory procedures for transforming cell lines, or *in vivo* or *ex vivo*, as in the treatment of certain diseases states.

One mechanism is viral infection where the expression construct is encapsulated in an infectious viral particle.

35 Several non-viral methods for the transfer of polynucleotides into cultured mammalian

cells are also contemplated by the present invention, and include, without being limited to, calcium phosphate precipitation (Graham et al., 1973; Chen et al., 1987), DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa et al., 1986; Potter et al., 1984), direct microinjection (Harland et al., 1985), DNA-loaded liposomes (Nicolau et al., 1982; Fraley et al., 1979), and receptor-mediate transfection (Wu and Wu, 1987; 1988). Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use.

Once the expression polynucleotide has been delivered into the cell, it may be stably integrated into the genome of the recipient cell. This integration may be in the cognate location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non specific location (gene augmentation). In yet further embodiments, the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle.

One specific embodiment for a method for delivering a protein or peptide to the interior of a cell of a vertebrate *in vivo* comprises the step of introducing a preparation comprising a physiologically acceptable carrier and a naked polynucleotide operatively coding for the polypeptide of interest into the interstitial space of a tissue comprising the cell, whereby the naked polynucleotide is taken up into the interior of the cell and has a physiological effect. This is particularly applicable for transfer *in vitro* but it may be applied to *in vivo* as well.

Compositions for use *in vitro* and *in vivo* comprising a "naked" polynucleotide are described in PCT application N° WO 90/11092 (Vical Inc.) and also in PCT application No. WO 95/11307 (Institut Pasteur, INSERM, Université d'Ottawa) as well as in the articles of Tacson et al.(1996) and of Huygen et al.(1996).

In still another embodiment of the invention, the transfer of a naked polynucleotide of the invention, including a polynucleotide construct of the invention, into cells may be proceeded with a particle bombardment (biolistic), said particles being DNA-coated microprojectiles accelerated to a high velocity allowing them to pierce cell membranes and enter cells without killing them, such as described by Klein et al.(1987).

In a further embodiment, the polynucleotide of the invention may be entrapped in a liposome (Ghosh and Bacchawat, 1991; Wong et al., 1980; Nicolau et al., 1987).

In a specific embodiment, the invention provides a composition for the *in vivo* production of the g35030 protein or polypeptide described herein. It comprises a naked polynucleotide operatively coding for this polypeptide, in solution in a physiologically acceptable carrier, and suitable for introduction into a tissue to cause cells of the tissue to express the said protein or polypeptide.

The amount of vector to be injected to the desired host organism varies according to the site of injection. As an indicative dose, it will be injected between 0,1 and 100 µg of the vector in an animal body, preferably a mammal body, for example a mouse body.

In another embodiment of the vector according to the invention, it may be introduced *in vitro* in a host cell, preferably in a host cell previously harvested from the animal to be treated and more preferably a somatic cell such as a muscle cell. In a subsequent step, the cell that has been transformed with the vector coding for the desired g35030 polypeptide or the desired fragment thereof is reintroduced into the animal body in order to deliver the recombinant protein within the body either locally or systemically.

#### Cell Hosts

Another object of the invention comprises a host cell that have been transformed or transfected with one of the polynucleotides described herein, and more precisely a polynucleotide comprising a g35030 polynucleotide selected from the group consisting of SEQ ID Nos. 1 to 17 and 79 to 132, or a fragment or a variant thereof. Are included host cells that are transformed (prokaryotic cells) or that are transfected (eukaryotic cells) with a recombinant vector such as one of those described above.

Generally, a recombinant host cell of the invention comprises any one of the polynucleotides or the recombinant vectors described therein.

Preferred host cells used as recipients for the expression vectors of the invention are the following:

a) Prokaryotic host cells: *Escherichia coli* strains (I.E.DH5-α strain), *Bacillus subtilis*, *Salmonella typhimurium*, and strains from species like *Pseudomonas*, *Streptomyces* and *Staphylococcus*.

b) Eukaryotic host cells: HeLa cells (ATCC N°CCL2; N°CCL2.1; N°CCL2.2), C<sub>v</sub> 1 cells (ATCC N°CCL70), COS cells (ATCC N°CRL1650; N°CRL1651), Sf-9 cells (ATCC N°CRL1711), C127 cells (ATCC N° CRL-1804), 3T3 (ATCC N° CRL-6361), CHO (ATCC N° CCL-61), human kidney 293. (ATCC N° 45504; N° CRL-1573) and BHK (ECACC N° 84100501; N° 84111301).

c) Other mammalian host cells.

G35030 gene expression in mammalian, and typically human, cells may be rendered defective with the replacement of a g35030 nucleic acid counterpart in the genome of an animal cell by a g35030 polynucleotide according to the invention. These genetic alterations may be generated by homologous recombination events using specific DNA constructs that have been previously described.

One kind of cell hosts that may be used are mammal zygotes, such as murine zygotes.

For example, murine zygotes may undergo microinjection with a purified DNA molecule of interest, for example a purified DNA molecule that has previously been adjusted to a concentration range from 1 ng/ml -for BAC inserts- 3 ng/ $\mu$ l -for P1 bacteriophage inserts- in 10 mM Tris-HCl, pH 7.4, 250  $\mu$ M EDTA containing 100 mM NaCl, 30  $\mu$ M spermine, and 70  $\mu$ M spermidine. When the DNA to be microinjected has a large size, polyamines and high salt concentrations can be used in order to avoid mechanical breakage of this DNA, as described by Schedl et al (1993b).

Any of the polynucleotides of the invention, including the DNA constructs described herein, may be introduced in an embryonic stem (ES) cell line, preferably a mouse ES cell line. ES cell lines are derived from pluripotent, uncommitted cells of the inner cell mass of pre-implantation blastocysts. Preferred ES cell lines are the following: ES-E14TG2a (ATCC n° CRL-1821), ES-D3 (ATCC n° CRL1934 and n° CRL-11632), YS001 (ATCC n° CRL-11776), 36.5 (ATCC n° CRL-11116). To maintain ES cells in an uncommitted state, they are cultured in the presence of growth inhibited feeder cells which provide the appropriate signals to preserve this embryonic phenotype and serve as a matrix for ES cell adherence. Preferred feeder cells are primary embryonic fibroblasts that are established from tissue of day 13- day 14 embryos of virtually any mouse strain, that are maintained in culture, such as described by Abbondanzo et al.(1993) and are inhibited in growth by irradiation, such as described by Robertson (1987), or by the presence of an inhibitory concentration of LIF, such as described by Pease and Williams (1990).

The constructs in the host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

Following transformation of a suitable host and growth of the host to an appropriate cell density, the selected promoter is induced by appropriate means, such as temperature shift or chemical induction, and cells are cultivated for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Microbial cells employed in the expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known by the skill artisan.

#### Transgenic Animals

The terms "transgenic animals" or "host animals" are used herein designate animals that have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from *Mus* (e.g. mice), *Rattus* (e.g. rats) and *Oryctogalus* (e.g.

rabbits) which have their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention. In one embodiment, the invention encompasses non-human host mammals and animals comprising a recombinant vector of the invention or a g35030 gene disrupted by homologous recombination with a knock out vector. The invention  
5 also encompasses non-human primates comprising a recombinant vector of the invention or a g35030 gene disrupted by homologous recombination with a knock out vector.

The transgenic animals of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising a g35030 polynucleotide or a DNA sequence encoding an  
10 antisense polynucleotide such as described in the present specification.

Generally, a transgenic animal according the present invention comprises any one of the polynucleotides, the recombinant vectors and the cell hosts described in the present invention.

In a first preferred embodiment, these transgenic animals may be good experimental models in order to study the diverse pathologies related to cell differentiation, in particular  
15 concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native g35030 protein, or alternatively a mutant g35030 protein.

In a second preferred embodiment, these transgenic animals may express a desired polypeptide of interest under the control of regulatory polynucleotides which lead to good  
20 yields in the synthesis of this protein of interest, and optionally a tissue specific expression of this protein of interest.

The design of the transgenic animals of the invention may be made according to the conventional techniques well known from the one skilled in the art. For more details regarding the production of transgenic animals, and specifically transgenic mice, it may be referred to US  
25 Patents Nos 4,873,191, issued Oct. 10, 1989; 5,464,764 issued Nov 7, 1995; and 5,789,215, issued Aug 4, 1998.

Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that has incorporated exogenous genetic material. The procedure involves obtaining the genetic material, or a portion thereof, which  
30 encodes either a g35030 polynucleotide or antisense polynucleotide such as described in the present specification.

A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is preferably made using electroporation, such as described by Thomas et al.(1987). The cells subjected to electroporation are screened (e.g. by selection via selectable  
35 markers, by PCR or by Southern blot analysis) to find positive cells which have integrated the

exogenous recombinant polynucleotide into their genome, preferably via an homologous recombination event. An illustrative positive-negative selection procedure that may be used according to the invention is described by Mansour et al.(1988).

5 Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from mice, such as described by Bradley (1987). The blastocysts are then inserted into a female host animal and allowed to grow to term.

Alternatively, the positive ES cells are brought into contact with embryos at the 2.5 days old 8-16 cell stage (morulae) such as described by Wood et al.(1993) or by Nagy et al.(1993), the ES cells being internalized to colonize extensively the blastocyst including the  
10 cells which will give rise to the germ line.

The offspring of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

Thus, the present invention also concerns a transgenic animal containing a nucleic acid, a recombinant expression vector or a recombinant host cell according to the invention.

15 **Recombinant Cell Lines Derived From The Transgenic Animals Of The Invention.**

A further object of the invention comprises recombinant host cells obtained from a transgenic animal described herein. In one embodiment the invention encompasses cells derived from non-human host mammals and animals comprising a recombinant vector of the invention or a gene comprising a g35030 nucleic acid sequence disrupted by homologous  
20 recombination with a knock out vector.

Recombinant cell lines may be established *in vitro* from cells obtained from any tissue of a transgenic animal according to the invention, for example by transfection of primary cell cultures with vectors expressing *onc*-genes such as SV40 large T antigen, as described by Chou (1989) and Shay et al.(1991).

25

**Assays For Identification Of Compounds For Treatment Of Schizophrenia And Bipolar Disorder**

The present invention provides assays which may be used to test compounds for their ability to treat CNS disorders, and in particular, to ameliorate symptoms of a CNS disorder  
30 mediated by g35030. In preferred embodiments, compounds tested for their ability to ameliorate symptoms of schizophrenia or bipolar disorder mediated by g35030. Compounds may also be tested for their ability to treat related disorders, including among others psychotic disorders, mood disorders, autism, substance dependence and alcoholism, mental retardation, and other psychiatric diseases including cognitive, anxiety, eating, impulse-control, and personality  
35 disorders, as defined with the Diagnosis and Statistical Manual of Mental Disorders fourth edition

(DSM-IV) classification.

The present invention also provides cell and animal, including primate and mouse, models of schizophrenia, bipolar disorder and related disorders.

5 In one aspect, provided are non-cell based, cell based and animal based assays for the identification of such compounds that affect g35030 activity. g35030 activity may be affected by any mechanism; in certain embodiments, g35030 activity is affected by modulating g35030 gene expression or the activity of the g35030 gene product.

10 The present methods allow the identification of compounds that affect g35030 activity directly or indirectly. Thus, the non-cell based, cell based and animal assays of the present invention may also be used to identify compounds that act on an element of a g35030 pathway other than g35030 itself. These compounds can then be used as a therapeutic treatment to modulate g35030 and other gene products involved in schizophrenia, bipolar disorder and related disorders.

*Cell and non-cell based assays*

15 In one aspect, cell based assays using recombinant or non-recombinant cells may be used to identify compounds which modulate g35030 activity.

20 In one aspect, a cell based assay of the invention encompasses a method for identifying a test compound for the treatment of schizophrenia or bipolar disorder comprising (a) exposing a cell to a test compound at a concentration and time sufficient to ameliorate an endpoint related to schizophrenia or bipolar disorder, and (b) determining the level of g35030 activity in a cell. g35030 activity can be measured, for example, by assaying a cell for mRNA transcript level, g35030 peptide expression, localization or protein activity. Preferably the test compound is a compound capable of or suspected to be capable of ameliorating a symptom of schizophrenia, bipolar disorder or a related disorder. Test compounds capable of modulating g35030 activity  
25 may be selected for use in developing medicaments. Such cell based assays are further described herein in the section titled "Method For Screening Ligands That Modulate The Expression Of The g35030 Gene."

30 In another aspect, a cell based assay of the invention encompasses a method for identifying a compound for the treatment of schizophrenia or bipolar disorder comprising (a) exposing a cell to a level of g35030 activity sufficient to cause a schizophrenia-related or bipolar disorder-related endpoint, and (b) exposing said cell to a test compound. A test compound can then be selected according to its ability to ameliorate said schizophrenia-related or bipolar disorder-related endpoints. g35030 activity may be provided by any suitable method, including but not limited to providing a vector containing a g35030 nucleotide sequence,  
35 treating said cell with a compound capable of increasing g35030 expression, and treating said



cell with a g35030 peptide. Preferably said cell is treated with a g35030 peptide comprising a contiguous span of at least 4 amino acids of SEQ ID Nos. 18 to 23. Preferably the test compound is a compound capable of or suspected to be capable of ameliorating a symptom of schizophrenia, bipolar disorder or a related disorder; alternatively, the test compound is suspected of exacerbating an endpoint schizophrenia, bipolar disorder or a related disorder. A test compound capable of ameliorating any detectable symptom or endpoint of a schizophrenia, bipolar disorder or a related disorder may be selected for use in developing medicaments.

In another embodiment, the invention provides cell and non-cell based assays to g35030 to determine whether g35030 peptides bind to the cell surface, and to identify compounds for the treatment of schizophrenia, bipolar disorder and related disorders that interact with a g35030 receptor. In one such embodiment, a g35030 polynucleotide, or fragments thereof, is cloned into expression vectors such as those described herein. The proteins are purified by size, charge, immunochromatography or other techniques familiar to those skilled in the art. Following purification, the proteins are labeled using techniques known to those skilled in the art. The labeled proteins are incubated with cells or cell lines derived from a variety of organs or tissues to allow the proteins to bind to any receptor present on the cell surface. Following the incubation, the cells are washed to remove non-specifically bound protein. The labeled proteins are detected by autoradiography. Alternatively, unlabeled proteins may be incubated with the cells and detected with antibodies having a detectable label, such as a fluorescent molecule, attached thereto. Specificity of cell surface binding may be analyzed by conducting a competition analysis in which various amounts of unlabeled protein are incubated along with the labeled protein. The amount of labeled protein bound to the cell surface decreases as the amount of competitive unlabeled protein increases. As a control, various amounts of an unlabeled protein unrelated to the labeled protein is included in some binding reactions. The amount of labeled protein bound to the cell surface does not decrease in binding reactions containing increasing amounts of unrelated unlabeled protein, indicating that the protein encoded by the nucleic acid binds specifically to the cell surface.

In another embodiment, the present invention comprises non-cell based binding assays, wherein a g35030 polypeptide is prepared and purified as in cell based binding assays described above. Following purification, the proteins are labeled and incubated with a cell membrane extract or isolate derived from any desired cells from any organs, tissue or combination of organs or tissues of interest to allow the g35030 polypeptide to bind to any receptor present on a membrane. Following the incubation, the membranes are washed to remove non-specifically bound protein. The labeled proteins may be detected by autoradiography. Specificity of membrane binding of g35030 may be analyzed by conducting a competition analysis in which

various amounts of a test compound are incubated along with the labeled protein. Any desired test compound, including test polypeptides, can be incubated with the cells. The test compounds may be detected with antibodies having a detectable label, such as a fluorescent molecule, attached thereto. The amount of labeled g35030 polypeptide bound to the cell surface decreases as the amount of competitive test compound increases. As a control, various amounts of an unlabeled protein or a compound unrelated to the test compound is included in some binding reactions. Test compounds capable of reducing the amount of g35030 bound to cell membranes may be selected as a candidate therapeutic compound.

Said cell based assays may comprise cells of any suitable origin; particularly preferred cells are human cells, primate cells, non-human primate cells and mouse cells. If non-human primate cells are used, the g35030 may comprise a nucleotide sequence or be encoded by a nucleotide sequence according to the primate nucleic acid sequences of SEQ ID No. 79 to 132, or a sequence complementary thereto or a fragment thereof.

*Animal model based assay*

Non-human animal based assays may also be used to identify compounds which modulate g35030 activity. The invention encompasses animal models and animal based assays, including non-transgenic or transgenic animals, including animals containing a human or altered form of the g35030 gene.

Thus, the present invention comprises treating an animal affected by schizophrenia or bipolar disorder or symptoms thereof with a test compound capable of directly or indirectly modulating g35030 activity.

In one aspect, an animal based assay of the invention encompasses a method for identifying a test compound for the treatment of schizophrenia or bipolar disorder comprising (a) exposing an animal to a test compound at a concentration and time sufficient to ameliorate an endpoint related to schizophrenia or bipolar disorder, and (b) determining the level of g35030 activity at a site in said animal. g35030 activity can be measured in any suitable cell, tissue or site. Preferably the test compound is a compound capable of or suspected to be capable of ameliorating a symptom of schizophrenia, bipolar disorder or a related disorder. Optionally said test compound is capable or suspected to be capable of modulating g35030 activity. Test compounds capable of modulating g35030 activity may be selected for use in developing medicaments.

In another aspect, an animal based assay of the invention encompasses a method for identifying a compound for the treatment of schizophrenia or bipolar disorder comprising (a) exposing an animal to a level of g35030 activity sufficient to cause a schizophrenia-related or bipolar disorder-related symptom or endpoint, and (b) exposing said animal to a test compound.

A test compound can then be selected according to its ability to ameliorate said schizophrenia-related or bipolar disorder-related endpoints. g35030 activity may be provided by any suitable method, including but not limited to providing a vector containing a g35030 nucleotide sequence, treating said animal with a compound capable of increasing g35030 expression and  
5 treating said cell with a g35030 peptide. Preferably, said animal is treated with a g35030 peptide comprising a contiguous span of at least 4 amino acids of SEQ ID Nos. 18 to 23. Preferably the test compound is a compound capable of or suspected to be capable of ameliorating a symptom of schizophrenia, bipolar disorder or a related disorder; alternatively,  
10 the test compound is suspected of exacerbating a symptom of schizophrenia, bipolar disorder or a related disorder. A test compound capable of ameliorating any detectable symptom or endpoint of a schizophrenia, bipolar disorder or a related disorder may be selected for use in developing medicaments.

Any suitable animal may be used. Preferably, said animal is a primate, a non-human primate, a mammal, or a mouse.

15 In one embodiment, a mouse is treated with a g35030 peptide, exposed to a test compound, and symptoms indicative of schizophrenia, bipolar disorder or a related disorder are assessed by observing stereotypy. In other embodiments, said symptoms are assessed by performing at least one test from the group consisting of home cage observation, neurological evaluation, stress-induced hypothermia, forced swim, PTZ seizure, locomotor activity, tail  
20 suspension, elevated plus maze, novel object recognition, prepulse inhibition, thermal pain, Y-maze, and metabolic chamber tests (Psychoscreen™ tests available from Psychogenics Inc.). Other tests are known in Crawley et al, Horm. Behav. 31(3):197-211 (1997); Crawley, Brain Res 835(1):18-26 (1999) for example.

Any suitable test compound may be used with the screening methods of the invention.  
25 Examples of compounds that may be screened by the methods of the present invention include small organic or inorganic molecules, nucleic acids, including polynucleotides from random and directed polynucleotide libraries, peptides, including peptides derived from random and directed peptide libraries, soluble peptides, fusion peptides, and phosphopeptides, antibodies including polyclonal, monoclonal, chimeric, humanized, and anti-idiotypic antibodies, and single chain  
30 antibodies, FAb, F(ab')<sub>2</sub> and FAb expression library fragments, and epitope-binding fragments thereof. In certain aspects, a compound capable of ameliorating or exacerbating a symptom or endpoint of schizophrenia, bipolar disorder or a related disorder may include, by way of example, antipsychotic drugs in general, neuroleptics, atypical neuroleptics, antidepressants, anti-anxiety drugs, noradrenergic agonists and antagonists, dopaminergic agonists and  
35 antagonists, serotonin reuptake inhibitors, benzodiazepines.

### Methods for screening substances interacting with a g35030 polypeptides

For the purpose of the present invention, a ligand means a molecule, such as a protein, a peptide, an antibody or any synthetic chemical compound capable of binding to the g35030 protein or one of its fragments or variants or to modulate the expression of the polynucleotide coding for the g35030 or a fragment or variant thereof.

In the ligand screening method according to the present invention, a biological sample or a defined molecule to be tested as a putative ligand of the g35030 protein is brought into contact with the corresponding purified g35030 protein, for example the corresponding purified recombinant g35030 protein produced by a recombinant cell host as described hereinbefore, in order to form a complex between this protein and the putative ligand molecule to be tested.

As an illustrative example, to study the interaction of the g35030 protein, or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6, or preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 18 to 23, with drugs or small molecules, such as molecules generated through combinatorial chemistry approaches, the microdialysis coupled to HPLC method described by Wang et al. (1997) or the affinity capillary electrophoresis method described by Bush et al. (1997), can be used.

In further methods, peptides, drugs, fatty acids, lipoproteins, or small molecules which interact with the g35030 protein, or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6, or preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 18 to 23, may be identified using assays such as the following. The molecule to be tested for binding is labeled with a detectable label, such as a fluorescent, radioactive, or enzymatic tag and placed in contact with immobilized g35030 protein, or a fragment thereof under conditions which permit specific binding to occur. After removal of non-specifically bound molecules, bound molecules are detected using appropriate means.

Another object of the present invention comprises methods and kits for the screening of candidate substances that interact with a g35030 polypeptide.

The present invention pertains to methods for screening substances of interest that interact with a g35030 protein or one fragment or variant thereof. By their capacity to bind covalently or non-covalently to a g35030 protein or to a fragment or variant thereof, these substances or molecules may be advantageously used both *in vitro* and *in vivo*.

*In vitro*, said interacting molecules may be used as detection means in order to identify the presence of a g35030 protein in a sample, preferably a biological sample.

A method for the screening of a candidate substance comprises the following steps :

a) providing a polypeptide comprising, consisting essentially of, or consisting of a g35030 protein or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 18 to 23;

- 5           b) obtaining a candidate substance;  
          c) bringing into contact said polypeptide with said candidate substance; and  
          d) detecting the complexes formed between said polypeptide and said candidate substance.

10           The invention further concerns a kit for the screening of a candidate substance interacting with the g35030 polypeptide, wherein said kit comprises:

- a) a g35030 protein having an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID Nos. 18 to 23 or a peptide fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 18 to 23; and

- 15           b) optionally means useful to detect the complex formed between the g35030 protein or a peptide fragment or a variant thereof and the candidate substance.

          In a preferred embodiment of the kit described above, the detection means comprise monoclonal or polyclonal antibodies directed against the g35030 protein or a peptide fragment or a variant thereof.

20           Various candidate substances or molecules can be assayed for interaction with a g35030 polypeptide. These substances or molecules include, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides. When the candidate substance or molecule comprise a polypeptide, this polypeptide may be the resulting expression product of a phage clone belonging to a phage-based random peptide library, or

25           alternatively the polypeptide may be the resulting expression product of a cDNA library cloned in a vector suitable for performing a two-hybrid screening assay.

          The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a g35030 polypeptide or a fragment or a variant thereof, and optionally means useful to detect the complex formed between the g35030 polypeptide or its fragment or variant and the candidate substance. In a preferred embodiment the detection means comprise monoclonal or polyclonal antibodies directed against the

30           corresponding g35030 polypeptide or a fragment or a variant thereof.

#### A. Candidate ligands obtained from random peptide libraries

In a particular embodiment of the screening method, the putative ligand is the expression product of a DNA insert contained in a phage vector (Parmley and Smith, 1988). Specifically, random peptide phages libraries are used. The random DNA inserts encode for peptides of 8 to 20 amino acids in length (Oldenburg K.R. et al., 1992; Valadon P., et al., 1996; Lucas A.H., 1994; Westerink M.A.J., 1995; Felici F. et al., 1991). According to this particular embodiment, the recombinant phages expressing a protein that binds to the immobilized g35030 protein is retained and the complex formed between the g35030 protein and the recombinant phage may be subsequently immunoprecipitated by a polyclonal or a monoclonal antibody directed against the g35030 protein.

Once the ligand library in recombinant phages has been constructed, the phage population is brought into contact with the immobilized g35030 protein. Then the preparation of complexes is washed in order to remove the non-specifically bound recombinant phages. The phages that bind specifically to the g35030 protein are then eluted by a buffer (acid pH) or immunoprecipitated by the monoclonal antibody produced by the hybridoma anti- g35030, and this phage population is subsequently amplified by an over-infection of bacteria (for example E. coli). The selection step may be repeated several times, preferably 2-4 times, in order to select the more specific recombinant phage clones. The last step comprises characterizing the peptide produced by the selected recombinant phage clones either by expression in infected bacteria and isolation, expressing the phage insert in another host-vector system, or sequencing the insert contained in the selected recombinant phages.

#### B. Candidate ligands obtained by competition experiments.

Alternatively, peptides, drugs or small molecules which bind to the g35030 protein, or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 18 to 23, may be identified in competition experiments. In such assays, the g35030 protein, or a fragment thereof, is immobilized to a surface, such as a plastic plate. Increasing amounts of the peptides, drugs or small molecules are placed in contact with the immobilized g35030 protein, or a fragment thereof, in the presence of a detectable labeled known g35030 protein ligand. For example, the g35030 ligand may be detectably labeled with a fluorescent, radioactive, or enzymatic tag. The ability of the test molecule to bind the g35030 protein, or a fragment thereof, is determined by measuring the amount of detectably labeled known ligand bound in the presence of the test molecule. A decrease in the amount of known ligand bound to the g35030 protein, or a fragment thereof,

when the test molecule is present indicated that the test molecule is able to bind to the g35030 protein, or a fragment thereof.

#### **C. Candidate ligands obtained by affinity chromatography.**

Proteins or other molecules interacting with the g35030 protein, or a fragment  
5 comprising a contiguous span of at 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 18 to 23, can also be found using affinity columns which contain the g35030 protein, or a fragment thereof. The g35030 protein, or a fragment thereof, may be attached to the column using conventional techniques including chemical coupling to a  
10 suitable column matrix such as agarose, Affi Gel®, or other matrices familiar to those of skill in art. In some embodiments of this method, the affinity column contains chimeric proteins in which the g35030 protein, or a fragment thereof, is fused to glutathion S transferase (GST). A mixture of cellular proteins or pool of expressed proteins as described above is applied to the affinity column. Proteins or other molecules interacting with the g35030 protein, or a fragment  
15 thereof, attached to the column can then be isolated and analyzed on 2-D electrophoresis gel as described in Ramunsen et al. (1997). Alternatively, the proteins retained on the affinity column can be purified by electrophoresis based methods and sequenced. The same method can be used to isolate antibodies, to screen phage display products, or to screen phage display human antibodies.

#### **D. Candidate ligands obtained by optical biosensor methods**

Proteins interacting with the g35030 protein, or a fragment comprising a contiguous  
span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ  
ID Nos. 18 to 23, can also be screened by using an Optical Biosensor as described in Edwards  
25 and Leatherbarrow (1997) and also in Szabo et al. (1995). This technique permits the detection of interactions between molecules in real time, without the need of labeled molecules. This technique is based on the surface plasmon resonance (SPR) phenomenon. Briefly, the candidate ligand molecule to be tested is attached to a surface (such as a carboxymethyl dextran matrix). A light beam is directed towards the side of the surface that does not contain the sample to be  
30 tested and is reflected by said surface. The SPR phenomenon causes a decrease in the intensity of the reflected light with a specific association of angle and wavelength. The binding of candidate ligand molecules cause a change in the refraction index on the surface, which change is detected as a change in the SPR signal. For screening of candidate ligand molecules or substances that are able to interact with the g35030 protein, or a fragment thereof, the g35030

protein, or a fragment thereof, is immobilized onto a surface. This surface comprises one side of a cell through which flows the candidate molecule to be assayed. The binding of the candidate molecule on the g35030 protein, or a fragment thereof, is detected as a change of the SPR signal. The candidate molecules tested may be proteins, peptides, carbohydrates, lipids, or small molecules generated by combinatorial chemistry. This technique may also be performed by immobilizing eukaryotic or prokaryotic cells or lipid vesicles exhibiting an endogenous or a recombinantly expressed g35030 protein at their surface.

The main advantage of the method is that it allows the determination of the association rate between the g35030 protein and molecules interacting with the g35030 protein. It is thus possible to select specifically ligand molecules interacting with the g35030 protein, or a fragment thereof, through strong or conversely weak association constants.

#### **E. Candidate ligands obtained through a two-hybrid screening assay.**

The yeast two-hybrid system is designed to study protein-protein interactions *in vivo* (Fields and Song, 1989), and relies upon the fusion of a bait protein to the DNA binding domain of the yeast Gal4 protein. This technique is also described in the US Patent N° US 5,667,973 and the US Patent N° 5,283,173 (Fields et al.).

The general procedure of library screening by the two-hybrid assay may be performed as described by Harper et al. (1993) or as described by Cho et al. (1998) or also Fromont-Racine et al. (1997).

The bait protein or polypeptide comprises, consists essentially of, or consists of a g35030 polypeptide or a fragment comprising a contiguous span of at least 4 amino acids, preferably at least 6 amino acids, more preferably at least 8 to 10 amino acids, and more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos. 18 to 23.

More precisely, the nucleotide sequence encoding the g35030 polypeptide or a fragment or variant thereof is fused to a polynucleotide encoding the DNA binding domain of the GAL4 protein, the fused nucleotide sequence being inserted in a suitable expression vector, for example pAS2 or pM3.

Then, a human cDNA library is constructed in a specially designed vector, such that the human cDNA insert is fused to a nucleotide sequence in the vector that encodes the transcriptional domain of the GAL4 protein. Preferably, the vector used is the pACT vector. The polypeptides encoded by the nucleotide inserts of the human cDNA library are termed "prey" polypeptides.

A third vector contains a detectable marker gene, such as beta galactosidase gene or CAT gene that is placed under the control of a regulation sequence that is responsive to the



binding of a complete Gal4 protein containing both the transcriptional activation domain and the DNA binding domain. For example, the vector pG5EC may be used.

Two different yeast strains are also used. As an illustrative but non limiting example the two different yeast strains may be the followings :

- 5       - Y190, the phenotype of which is (*MATa, Leu2-3, 112 ura3-12, trp1-901, his3-D200, ade2-101, gal4Dgal180D URA3 GAL-LacZ, LYS GAL-HIS3, cyh*);
- Y187, the phenotype of which is (*MATa gal4 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3, -112 URA3 GAL-lacZmer*), which is the opposite mating type of Y190.

10       Briefly, 20 µg of pAS2/ g35030 and 20 µg of pACT-cDNA library are co-transformed into yeast strain Y190. The transformants are selected for growth on minimal media lacking histidine, leucine and tryptophan, but containing the histidine synthesis inhibitor 3-AT (50 mM). Positive colonies are screened for beta galactosidase by filter lift assay. The double positive colonies (*His<sup>+</sup>, beta-gal<sup>+</sup>*) are then grown on plates lacking histidine, leucine, but containing tryptophan and cycloheximide (10 mg/ml) to select for loss of pAS2/ g35030

15       plasmids by retention of pACT-cDNA library plasmids. The resulting Y190 strains are mated with Y187 strains expressing g35030 or non-related control proteins; such as cyclophilin B, lamin, or SNF1, as *Gal4* fusions as described by Harper et al. (1993) and by Bram et al. (Bram RJ et al., 1993), and screened for beta galactosidase by filter lift assay. Yeast clones that are *beta gal-* after mating with the control *Gal4* fusions are considered false positives.

20       In another embodiment of the two-hybrid method according to the invention, interaction between the g35030 or a fragment or variant thereof with cellular proteins may be assessed using the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech). As described in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech), nucleic acids encoding the g35030 protein or a portion thereof, are inserted into an

25       expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. A desired cDNA, preferably human cDNA, is inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which selects for expression of selectable markers on each of the expression

30       vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain interaction between g35030 and the protein or peptide encoded by the initially selected cDNA insert.

**Method For Screening Substances Interacting With The Regulatory Sequences Of A g35030 Gene.**

The present invention also concerns a method for screening substances or molecules that are able to interact with the regulatory sequences of the g35030 gene, such as for example promoter or enhancer sequences.

Nucleic acids encoding proteins which are able to interact with the regulatory sequences of the g35030 gene, more particularly a nucleotide sequence selected from the group consisting of the polynucleotides of the 5' and 3' regulatory region or a fragment or variant thereof, and preferably a variant comprising one of the biallelic markers of the invention, may be identified by using a one-hybrid system, such as that described in the booklet enclosed in the Matchmaker One-Hybrid System kit from Clontech (Catalog Ref. n° K1603-1). Briefly, the target nucleotide sequence is cloned upstream of a selectable reporter sequence and the resulting DNA construct is integrated in the yeast genome (*Saccharomyces cerevisiae*). The yeast cells containing the reporter sequence in their genome are then transformed with a library comprising fusion molecules between cDNAs encoding candidate proteins for binding onto the regulatory sequences of the g35030 gene and sequences encoding the activator domain of a yeast transcription factor such as GAL4. The recombinant yeast cells are plated in a culture broth for selecting cells expressing the reporter sequence. The recombinant yeast cells thus selected contain a fusion protein that is able to bind onto the target regulatory sequence of the g35030 gene. Then, the cDNAs encoding the fusion proteins are sequenced and may be cloned into expression or transcription vectors *in vitro*. The binding of the encoded polypeptides to the target regulatory sequences of the g35030 gene may be confirmed by techniques familiar to the one skilled in the art, such as gel retardation assays or DNase protection assays.

Gel retardation assays may also be performed independently in order to screen candidate molecules that are able to interact with the regulatory sequences of the g35030 gene, such as described by Fried and Crothers (1981), Garner and Revzin (1981) and Dent and Latchman (1993). These techniques are based on the principle according to which a DNA fragment which is bound to a protein migrates slower than the same unbound DNA fragment. Briefly, the target nucleotide sequence is labeled. Then the labeled target nucleotide sequence is brought into contact with either a total nuclear extract from cells containing transcription factors, or with different candidate molecules to be tested. The interaction between the target regulatory sequence of the g35030 gene and the candidate molecule or the transcription factor is detected after gel or capillary electrophoresis through a retardation in the migration.

**Method For Screening Ligands That Modulate The Expression Of The g35030**

### Gene

Another subject of the present invention is a method for screening molecules that modulate the expression of the g35030 protein. Such a screening method comprises the steps of:

- 5           a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding the g35030 protein or a variant or a fragment thereof, placed under the control of its own promoter;
- b) bringing into contact the cultivated cell with a molecule to be tested;
- c) quantifying the expression of the g35030 protein or a variant or a fragment thereof.

10           In an embodiment, the nucleotide sequence encoding the g35030 protein or a variant or a fragment thereof comprises an allele of at least one g35030 related biallelic marker.

            Using DNA recombination techniques well known by the one skilled in the art, the g35030 protein encoding DNA sequence is inserted into an expression vector, downstream from its promoter sequence. As an illustrative example, the promoter sequence of the g35030 gene is  
15           contained in the nucleic acid of the 5' regulatory region.

            The quantification of the expression of the g35030 protein may be realized either at the mRNA level or at the protein level. In the latter case, polyclonal or monoclonal antibodies may be used to quantify the amounts of the g35030 protein that have been produced, for example in an ELISA or a RIA assay.

20           In a preferred embodiment, the quantification of the g35030 mRNA is realized by a quantitative PCR amplification of the cDNA obtained by a reverse transcription of the total mRNA of the cultivated g35030 -transfected host cell, using a pair of primers specific for g35030.

            The present invention also concerns a method for screening substances or molecules  
25           that are able to increase, or in contrast to decrease, the level of expression of the g35030 gene. Such a method may allow the one skilled in the art to select substances exerting a regulating effect on the expression level of the g35030 gene and which may be useful as active ingredients included in pharmaceutical compositions for treating patients suffering from diseases.

            Thus, is also part of the present invention a method for screening of a candidate  
30           substance or molecule that modulated the expression of the g35030 gene, this method comprises the following steps:

- providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises a nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof located upstream a polynucleotide encoding a detectable protein;
- 35           - obtaining a candidate substance; and

- determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a further embodiment, the nucleic acid comprising the nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof also includes a 5'UTR region of the g35030 cDNA of SEQ ID No 2 to 17, or one of its biologically active fragments or variants thereof.

Among the preferred polynucleotides encoding a detectable protein, there may be cited polynucleotides encoding beta galactosidase, green fluorescent protein (GFP) and chloramphenicol acetyl transferase (CAT).

The invention also pertains to kits useful for performing the herein described screening method. Preferably, such kits comprise a recombinant vector that allows the expression of a nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof located upstream and operably linked to a polynucleotide encoding a detectable protein or the g35030 protein or a fragment or a variant thereof.

In another embodiment of a method for the screening of a candidate substance or molecule that modulates the expression of the g35030 gene, wherein said method comprises the following steps:

a) providing a recombinant host cell containing a nucleic acid, wherein said nucleic acid comprises a 5'UTR sequence of a g35030 cDNA, preferably of a g35030, or one of its biologically active fragments or variants, the 5'UTR sequence or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein;

b) obtaining a candidate substance; and

c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5'UTR sequence of a g35030 cDNA, preferably of a g35030 or one of its biologically active fragments or variants, includes a promoter sequence which is endogenous with respect to the g35030 5'UTR sequence.

In another specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5'UTR sequence of a g35030 cDNA or one of its biologically active fragments or variants, includes a promoter sequence which is exogenous with respect to the g35030 5'UTR sequence defined therein.

In a further preferred embodiment, the nucleic acid comprising the 5'-UTR sequence of a g35030 cDNA or the biologically active fragments thereof includes a g35030-related biallelic marker.

The invention further comprises a kit for the screening of a candidate substance modulating the expression of the g35030 gene, wherein said kit comprises a recombinant vector that comprises a nucleic acid including a 5'UTR sequence of the g35030 cDNA of SEQ ID Nos 2 to 17, or one of their biologically active fragments or variants, the 5'UTR sequence or its  
5 biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein.

For the design of suitable recombinant vectors useful for performing the screening methods described above, it will be referred to the section of the present specification wherein the preferred recombinant vectors of the invention are detailed.

10 Expression levels and patterns of g35030 may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277. Briefly, the g35030 cDNA or the g35030 genomic DNA described above, or fragments thereof, is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the g35030 insert comprises at  
15 least 100 or more consecutive nucleotides of the genomic DNA sequence or the cDNA sequences. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridization is performed under standard stringent conditions (40-50°C for 16 hours in an 80%  
20 formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

25 Quantitative analysis of g35030 gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of a plurality of nucleic acids of sufficient length to permit specific detection of expression of mRNAs capable of hybridizing thereto. For example, the arrays may contain a plurality of nucleic acids derived from genes whose expression levels are to be assessed. The  
30 arrays may include the g35030 genomic DNA, the g35030 cDNA sequences or the sequences complementary thereto or fragments thereof, particularly those comprising at least one of the biallelic markers according to the present invention. Preferably, the fragments are at least 15 nucleotides in length. In other embodiments, the fragments are at least 25 nucleotides in length. In some embodiments, the fragments are at least 50 nucleotides in length. More preferably, the  
35 fragments are at least 100 nucleotides in length. In another preferred embodiment, the

fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

For example, quantitative analysis of g35030 gene expression may be performed with a complementary DNA microarray as described by Schena et al.(1995 and 1996). Full length  
5 g35030 cDNAs or fragments thereof are amplified by PCR and arrayed from a 96-well microtiter plate onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0. 2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged in water for 2 min at 95°C, transferred into 0. 2% SDS for 1 min,  
10 rinsed twice with water, air dried and stored in the dark at 25°C.

Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm<sup>2</sup> microarrays under a 14 x 14 mm glass coverslip for 6-12 hours at 60°C. Arrays are washed for 5 min at 25°C in low stringency wash buffer (1 x SSC/0. 2% SDS), then for 10 min at room temperature in high  
15 stringency wash buffer (0. 1 x SSC/0. 2% SDS). Arrays are scanned in 0. 1 x SSC using a fluorescence laser scanning device fitted with a custom filter set. Accurate differential expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

Quantitative analysis of g35030 gene expression may also be performed with full length  
20 g35030 cDNAs or fragments thereof in complementary DNA arrays as described by Pietu et al.(1996). The full length g35030 cDNA or fragments thereof is PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate  
25 experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

Alternatively, expression analysis using the g35030 genomic DNA, the g35030 cDNA, or fragments thereof can be done through high density nucleotide arrays as described by  
30 Lockhart et al.(1996) and Sosnowsky et al.(1997). Oligonucleotides of 15-50 nucleotides from the sequences of the g35030 genomic DNA, the g35030 cDNA sequences particularly those comprising at least one of biallelic markers according to the present invention, or the sequences complementary thereto, are synthesized directly on the chip (Lockhart et al., supra) or synthesized and then addressed to the chip (Sosnowski et al., supra). Preferably, the oligonucleotides are about 20 nucleotides in length.

35 g35030 cDNA probes labeled with an appropriate compound, such as biotin,

digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., supra and application of different electric fields (Sosnowsky et al., 1997), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of g35030 mRNA.

#### Methods For Inhibiting The Expression Of A g35030 Gene

Other therapeutic compositions according to the present invention comprise advantageously an oligonucleotide fragment of the nucleic sequence of g35030 as an antisense tool or a triple helix tool that inhibits the expression of the corresponding g35030 gene. A preferred fragment of the nucleic sequence of g35030 comprises an allele of at least one of the biallelic markers of the invention.

#### Antisense Approach

Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995).

Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to the 5' end of the g35030 mRNA. In another embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targeted gene are used.

Preferred antisense polynucleotides according to the present invention are complementary to a sequence of the mRNAs of g35030 that contains either the translation initiation codon ATG or a splicing donor or acceptor site.

The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the g35030 mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., (1986) and Izant and Weintraub, (1984).

In some strategies, antisense molecules are obtained by reversing the orientation of the g35030 coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of g35030 antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in a suitable expression vector.

Alternatively, suitable antisense strategies are those described by Rossi et al.(1991), in the International Applications Nos. WO 94/23026, WO 95/04141, WO 92/18522 and in the European Patent Application No. EP 0 572 287 A2

5 An alternative to the antisense technology that is used according to the present invention comprises using ribozymes that will bind to a target sequence via their complementary polynucleotide tail and that will cleave the corresponding RNA by hydrolyzing its target site (namely "hammerhead ribozymes"). Briefly, the simplified cycle of a hammerhead ribozyme comprises (1) sequence specific binding to the target RNA via complementary antisense sequences; (2) site-specific hydrolysis of the cleavable motif of the target strand; and (3) release of cleavage products, which gives rise to another catalytic cycle. 10 Indeed, the use of long-chain antisense polynucleotide (at least 30 bases long) or ribozymes with long antisense arms are advantageous. A preferred delivery system for antisense ribozyme is achieved by covalently linking these antisense ribozymes to lipophilic groups or to use liposomes as a convenient vector. Preferred antisense ribozymes according to the present invention are prepared as described by Sczakiel et al.(1995). 15

#### Triple Helix Approach

The g35030 genomic DNA may also be used to inhibit the expression of the g35030 gene based on intracellular triple helix formation.

20 Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity when it is associated with a particular gene.

Similarly, a portion of the g35030 genomic DNA can be used to study the effect of inhibiting g35030 transcription within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can 25 also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from the g35030 genomic DNA are contemplated within the scope of this invention.

To carry out gene therapy strategies using the triple helix approach, the sequences of the g35030 genomic DNA are first scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting g35030 expression. Following identification of candidate homopyrimidine or homopurine stretches, 30 their efficiency in inhibiting g35030 expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which express the g35030 gene.



The oligonucleotides can be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

5 Treated cells are monitored for altered cell function or reduced g35030 expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to monitor the transcription levels of the g35030 gene in cells which have been treated with the oligonucleotide.

10 The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced in vivo using the techniques described above in the antisense approach at a dosage calculated based on the in vitro results, as described in antisense approach.

In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of  
15 oligonucleotides suitable for triple helix formation see Griffin et al.(1989).

### **Pharmaceutical Compositions And Formulations**

#### **G35030-modulating Compounds**

20 Using the methods disclosed herein, compounds that selectively modulate g35030 activity *in vitro* and *in vivo* may be identified. The compounds identified by the process of the invention include, for example, antibodies having binding specificity for the g35030 peptide. It is also expected that homologues of g35030 may be useful for modulating g35030-mediated activity and the related physiological condition associated with schizophrenia or bipolar disorder. Generally, it is further expected that assay methods of the present invention based on the role of g35030 in  
25 central nervous system disorder may be used to identify compounds capable of intervening in the assay cascade of the invention.

#### **Indications**

30 While g35030 has demonstrated an association with schizophrenia and bipolar disorder, indications involving g35030 may include various central nervous system disorders. Nervous system disorders are expected to have complex genetic bases and often share certain symptoms. In particular, as described herein, indications may include schizophrenia and other psychotic disorders, mood disorders, autism, substance dependence and alcoholism, mental retardation, and other psychiatric diseases including cognitive, anxiety, eating, impulse-control, and personality disorders, as defined with the Diagnosis and Statistical Manual of Mental Disorders fourth edition  
35 (DSM-IV) classification.

#### Pharmaceutical Formulations and Routes of Administration

The compounds identified using the methods of the present invention can be administered to a mammal, including a human patient, alone or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at therapeutically effective doses to treat or ameliorate schizophrenia or bipolar disorder related disorders. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms as determined by the methods described herein. Preferably, a therapeutically effective dosage is suitable for continued periodic use or administration. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

#### Routes of Administration

Suitable routes of administration include oral, rectal, transmucosal, or intestinal administration, parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal or intraocular injections. A particularly useful method of administering compounds for treating central nervous system disease involves surgical implantation of a device for delivering the compound over an extended period of time. Sustained release formulations of the invented medicaments particularly are contemplated.

#### Composition/Formulation

Pharmaceutical compositions and medicaments for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries. Proper formulation is dependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer such as a phosphate or bicarbonate buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable

for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable gaseous propellant, *e.g.*, carbon dioxide. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin, for use in an inhaler or insufflator, may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Aqueous suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder or lyophilized form for constitution with a suitable vehicle, such as sterile pyrogen-free water, before use.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.

Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

5                    Effective Dosage

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve their intended purpose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being  
10                    treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays, and a dose can be formulated in animal models. Such information can be used to more accurately determine useful doses in humans.

15                    A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50, (the dose lethal to 50% of the test population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and  
20                    therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD50 and ED50. Compounds which exhibit high therapeutic indices are preferred.

The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50, with little or no toxicity. The  
25                    dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g., Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1).

30                    Computer-Related Embodiments

As used herein the term "nucleic acid codes of the invention" encompass the nucleotide sequences comprising, consisting essentially of, or consisting of any one of the following:

a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof,  
35                    wherein said contiguous span comprises at least one of the following nucleotide positions of

SEQ ID No 1: 201123 to 247802 and 199122 to 249803;

b) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 2 to 17 or the complements thereof;

5 c) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 24, 25, 28 and 74, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID;

10 d) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 79 to 132, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID;

e) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 199122 to 201122 and 247803 to 249803;

15 f) a contiguous span according to a), b), c), d) or e), wherein said span includes a biallelic marker;

20 g) a contiguous span according to a), b), c), d) or e), wherein said span includes a biallelic marker selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 ; and

h) a contiguous span according to f), wherein said span includes a biallelic marker with the alternative allele present at said biallelic marker;

25 The "nucleic acid codes of the invention" further encompass nucleotide sequences homologous to a contiguous span of at least 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides, to the extent that such a length is consistent with the particular sequence of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132, and the complements thereof.

30 The "nucleic acid codes of the invention" also encompass nucleotide sequences homologous to a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No. 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673,

35

240440 to 241153, 241072 to 241291, 244353 to 244561, 246273 to 247802, 201123 to 247802, 199122 to 201122, 247803 to 249803 and 199122 to 249803.

Homologous sequences refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, or 75% homology to these contiguous spans. Homology may be  
5 determined using any method described herein, including BLAST2N with the default parameters or with any modified parameters. Homologous sequences also may include RNA sequences in which uridines replace the thymines in the nucleic acid codes of the invention. It will be appreciated that the nucleic acid codes of the invention can be represented in the traditional single character format (See the inside back cover of Stryer, Lubert. *Biochemistry*,  
10 3<sup>rd</sup> edition. W. H Freeman & Co., New York.) or in any other format or code which records the identity of the nucleotides in a sequence.

As used herein the term "polypeptide codes of SEQ ID Nos. 18 to 23" encompasses the polypeptide sequence of SEQ ID Nos 18 to 23, polypeptide sequences homologous to the polypeptides of SEQ ID Nos. 18 to 23, or fragments of any of the preceding sequences.  
15 Homologous polypeptide sequences refer to a polypeptide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75% homology to one of the polypeptide sequences of SEQ ID Nos. 18 to 23. Homology may be determined using any of the computer programs and parameters described herein, including FASTA with the default parameters or with any modified parameters. The homologous sequences may be obtained using any of the procedures described herein or may  
20 result from the correction of a sequencing error as described above. The polypeptide fragments comprise at least 4, 6, 8, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of the polypeptides of SEQ ID Nos. 18 to 23. Preferably, the fragments are novel fragments. It will be appreciated that the polypeptide codes of the SEQ ID Nos. 18 to 23 can be represented in the traditional single character format or three letter format (See the inside back cover of Starrier,  
25 Lubert. *Biochemistry*, 3<sup>rd</sup> edition. W. H Freeman & Co., New York.) or in any other format which relates the identity of the polypeptides in a sequence.

It will be appreciated by those skilled in the art that the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 and polypeptide codes of SEQ ID Nos. 18 to 23 can be stored, recorded, and manipulated on any medium which can be read and accessed by a  
30 computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate embodiment comprising one or more of nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132, or one or more of the polypeptide codes of SEQ ID Nos. 18 to 23. Another aspect of the  
35 present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20,

25, 30, or 50 nucleic acid codes of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 polypeptide codes of SEQ ID Nos 18 to 23.

5 Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art.

10 Embodiments of the present invention include systems, particularly computer systems which store and manipulate the sequence information described herein. One example of a computer system 100 is illustrated in block diagram form in Figure 12. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to analyze the nucleotide sequences of the nucleic acid codes of SEQ ID Nos 1 to 17, 24, 25, 28, 74 and 79 to 132, or the amino acid sequences of the polypeptide codes of SEQ  
15 ID Nos. 18 to 23. In one embodiment, the computer system 100 is a Sun Enterprise 1000 server (Sun Microsystems, Palo Alto, CA). The computer system 100 preferably includes a processor for processing, accessing and manipulating the sequence data. The processor 105 can be any well-known type of central processing unit, such as the Pentium III from Intel Corporation, or similar processor from Sun, Motorola, Compaq or International Business Machines.

20 Preferably, the computer system 100 is a general purpose system that comprises the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable.

25 In one particular embodiment, the computer system 100 includes a processor 105 connected to a bus which is connected to a main memory 115 (preferably implemented as RAM) and one or more internal data storage devices 110, such as a hard drive and/or other computer readable media having data recorded thereon. In some embodiments, the computer system 100 further includes one or more data retrieving device 118 for reading the data stored on the internal  
30 data storage devices 110.

The data retrieving device 118 may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, etc. In some embodiments, the internal data storage device 110 is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system 100 may  
35 advantageously include or be programmed by appropriate software for reading the control logic

and/or the data from the data storage component once inserted in the data retrieving device.

The computer system 100 includes a display 120 which is used to display output to a computer user. It should also be noted that the computer system 100 can be linked to other computer systems 125a-c in a network or wide area network to provide centralized access to the computer system 100.

Software for accessing and processing the nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132, or the amino acid sequences of the polypeptide codes of SEQ ID Nos. 18 to 23 (such as search tools, compare tools, and modeling tools etc.) may reside in main memory 115 during execution.

In some embodiments, the computer system 100 may further comprise a sequence comparer for comparing the above-described nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or polypeptide codes of SEQ ID Nos. 18 to 23 stored on a computer readable medium to reference nucleotide or polypeptide sequences stored on a computer readable medium. A "sequence comparer" refers to one or more programs which are implemented on the computer system 100 to compare a nucleotide or polypeptide sequence with other nucleotide or polypeptide sequences and/or compounds including but not limited to peptides, peptidomimetics, and chemicals stored within the data storage means. For example, the sequence comparer may compare the nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132, or the amino acid sequences of the polypeptide codes of SEQ ID Nos. 18 to 23 stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies, motifs implicated in biological function, or structural motifs. The various sequence comparer programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.

Figure 13 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database. The database of sequences can be a private database stored within the computer system 100, or a public database such as GENBANK, PIR OR SWISSPROT that is available through the Internet.

The process 200 begins at a start state 201 and then moves to a state 202 wherein the new sequence to be compared is stored to a memory in a computer system 100. As discussed above, the memory could be any type of memory, including RAM or an internal storage device.

The process 200 then moves to a state 204 wherein a database of sequences is opened for analysis and comparison. The process 200 then moves to a state 206 wherein the first sequence stored in the database is read into a memory on the computer. A comparison is then performed at a state 210 to determine if the first sequence is the same as the second sequence. It is important to



note that this step is not limited to performing an exact comparison between the new sequence and the first sequence in the database. Well-known methods are known to those of skill in the art for comparing two nucleotide or protein sequences, even if they are not identical. For example, gaps can be introduced into one sequence in order to raise the homology level between the two tested sequences. The parameters that control whether gaps or other features are introduced into a sequence during comparison are normally entered by the user of the computer system.

Once a comparison of the two sequences has been performed at the state 210, a determination is made at a decision state 210 whether the two sequences are the same. Of course, the term "same" is not limited to sequences that are absolutely identical. Sequences that are within the homology parameters entered by the user will be marked as "same" in the process 200.

If a determination is made that the two sequences are the same, the process 200 moves to a state 214 wherein the name of the sequence from the database is displayed to the user. This state notifies the user that the sequence with the displayed name fulfills the homology constraints that were entered. Once the name of the stored sequence is displayed to the user, the process 200 moves to a decision state 218 wherein a determination is made whether more sequences exist in the database. If no more sequences exist in the database, then the process 200 terminates at an end state 220. However, if more sequences do exist in the database, then the process 200 moves to a state 224 wherein a pointer is moved to the next sequence in the database so that it can be compared to the new sequence. In this manner, the new sequence is aligned and compared with every sequence in the database.

It should be noted that if a determination had been made at the decision state 212 that the sequences were not homologous, then the process 200 would move immediately to the decision state 218 in order to determine if any other sequences were available in the database for comparison.

Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid code of SEQ ID NOs. 1 to 17, 24, 25, 28, 74 and 79 to 132 or a polypeptide code of SEQ ID Nos 18 to 23, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to the nucleic acid code of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or polypeptide code of SEQ ID Nos. 18 to 23 and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the above described nucleic acid code of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 and polypeptide codes of SEQ ID Nos. 18 to 23, or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the

sequences of at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or polypeptide codes of SEQ ID Nos. 18 to 23.

Another aspect of the present invention is a method for determining the level of homology between a nucleic acid code of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 and a reference nucleotide sequence, comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code and the reference nucleotide sequence with the computer program. The computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, including BLAST2N with the default parameters or with any modified parameters. The method may be implemented using the computer systems described above. The method may also be performed by reading 2, 5, 10, 15, 20, 25, 30, or 50 of the above described nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 through use of the computer program and determining homology between the nucleic acid codes and reference nucleotide sequences.

Figure 14 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous. The process 250 begins at a start state 252 and then moves to a state 254 wherein a first sequence to be compared is stored to a memory. The second sequence to be compared is then stored to a memory at a state 256. The process 250 then moves to a state 260 wherein the first character in the first sequence is read and then to a state 262 wherein the first character of the second sequence is read. It should be understood that if the sequence is a nucleotide sequence, then the character would normally be either A, T, C, G or U. If the sequence is a protein sequence, then it should be in the single letter amino acid code so that the first and sequence sequences can be easily compared.

A determination is then made at a decision state 264 whether the two characters are the same. If they are the same, then the process 250 moves to a state 268 wherein the next characters in the first and second sequences are read. A determination is then made whether the next characters are the same. If they are, then the process 250 continues this loop until two characters are not the same. If a determination is made that the next two characters are not the same, the process 250 moves to a decision state 274 to determine whether there are any more characters either sequence to read.

If there aren't any more characters to read, then the process 250 moves to a state 276 wherein the level of homology between the first and second sequences is displayed to the user. The level of homology is determined by calculating the proportion of characters between the sequences that were the same out of the total number of sequences in the first sequence. Thus, if every character in a first 100 nucleotide sequence aligned with a every character in a second

sequence, the homology level would be 100%.

Alternatively, the computer program may be a computer program which compares the nucleotide sequences of the nucleic acid codes of the present invention, to reference nucleotide sequences in order to determine whether the nucleic acid code of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 differs from a reference nucleic acid sequence at one or more positions.

Optionally such a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the nucleic acid code of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132. In one embodiment, the computer program may be a program which determines whether the nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 contain a biallelic marker or single nucleotide polymorphism (SNP) with respect to a reference nucleotide sequence. This single nucleotide polymorphism may comprise a single base substitution, insertion, or deletion, while this biallelic marker may comprise about one to ten consecutive bases substituted, inserted or deleted.

Another aspect of the present invention is a method for determining the level of homology between a polypeptide code of SEQ ID Nos. 18 to 23 and a reference polypeptide sequence, comprising the steps of reading the polypeptide code of SEQ ID Nos. 18 to 23 and the reference polypeptide sequence through use of a computer program which determines homology levels and determining homology between the polypeptide code and the reference polypeptide sequence using the computer program.

Accordingly, another aspect of the present invention is a method for determining whether a nucleic acid code of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program which identifies single nucleotide polymorphisms. The method may be implemented by the computer systems described above and the method illustrated in Figure 14. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.

In other embodiments the computer based system may further comprise an identifier for identifying features within the nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the amino acid sequences of the polypeptide codes of SEQ ID

Nos. 18 to 23.

An "identifier" refers to one or more programs which identifies certain features within the above-described nucleotide sequences of the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the amino acid sequences of the polypeptide codes of SEQ ID Nos. 18 to 23. In one embodiment, the identifier may comprise a program which identifies an open reading frame in the cDNAs codes of SEQ ID Nos 2 to 17 and 36 to 40.

Figure 15 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence. The process 300 begins at a start state 302 and then moves to a state 304 wherein a first sequence that is to be checked for features is stored to a memory 115 in the computer system 100. The process 300 then moves to a state 306 wherein a database of sequence features is opened. Such a database would include a list of each feature's attributes along with the name of the feature. For example, a feature name could be "Initiation Codon" and the attribute would be "ATG". Another example would be the feature name "TAATAA Box" and the feature attribute would be "TAATAA". An example of such a database is produced by the University of Wisconsin Genetics Computer Group ([www.gcg.com](http://www.gcg.com)).

Once the database of features is opened at the state 306, the process 300 moves to a state 308 wherein the first feature is read from the database. A comparison of the attribute of the first feature with the first sequence is then made at a state 310. A determination is then made at a decision state 316 whether the attribute of the feature was found in the first sequence. If the attribute was found, then the process 300 moves to a state 318 wherein the name of the found feature is displayed to the user.

The process 300 then moves to a decision state 320 wherein a determination is made whether more features exist in the database. If no more features do exist, then the process 300 terminates at an end state 324. However, if more features do exist in the database, then the process 300 reads the next sequence feature at a state 326 and loops back to the state 310 wherein the attribute of the next feature is compared against the first sequence.

It should be noted, that if the feature attribute is not found in the first sequence at the decision state 316, the process 300 moves directly to the decision state 320 in order to determine if any more features exist in the database.

In another embodiment, the identifier may comprise a molecular modeling program which determines the 3-dimensional structure of the polypeptides codes of SEQ ID Nos. 18 to 23. In some embodiments, the molecular modeling program identifies target sequences that are most compatible with profiles representing the structural environments of the residues in known three-dimensional protein structures. (See, e.g., Eisenberg et al., U.S. Patent No. 5,436,850

issued July 25, 1995). In another technique, the known three-dimensional structures of proteins in a given family are superimposed to define the structurally conserved regions in that family. This protein modeling technique also uses the known three-dimensional structure of a homologous protein to approximate the structure of the polypeptide codes of SEQ ID Nos. 4 to 8. (See e.g., Srinivasan, et al., U.S. Patent No. 5,557,535 issued September 17, 1996). Conventional homology modeling techniques have been used routinely to build models of proteases and antibodies. (Sowdhamini et al., Protein Engineering 10:207, 215 (1997)). Comparative approaches can also be used to develop three-dimensional protein models when the protein of interest has poor sequence identity to template proteins. In some cases, proteins fold into similar three-dimensional structures despite having very weak sequence identities. For example, the three-dimensional structures of a number of helical cytokines fold in similar three-dimensional topology in spite of weak sequence homology.

The recent development of threading methods now enables the identification of likely folding patterns in a number of situations where the structural relatedness between target and template(s) is not detectable at the sequence level. Hybrid methods, in which fold recognition is performed using Multiple Sequence Threading (MST), structural equivalencies are deduced from the threading output using a distance geometry program DRAGON to construct a low resolution model, and a full-atom representation is constructed using a molecular modeling package such as QUANTA.

According to this 3-step approach, candidate templates are first identified by using the novel fold recognition algorithm MST, which is capable of performing simultaneous threading of multiple aligned sequences onto one or more 3-D structures. In a second step, the structural equivalencies obtained from the MST output are converted into interresidue distance restraints and fed into the distance geometry program DRAGON, together with auxiliary information obtained from secondary structure predictions. The program combines the restraints in an unbiased manner and rapidly generates a large number of low resolution model confirmations. In a third step, these low resolution model confirmations are converted into full-atom models and subjected to energy minimization using the molecular modeling package QUANTA. (See e.g., Aszódi et al., Proteins: Structure, Function, and Genetics, Supplement 1:38-42 (1997)).

The results of the molecular modeling analysis may then be used in rational drug design techniques to identify agents which modulate the activity of the polypeptide codes of SEQ ID Nos. 18 to 23.

Accordingly, another aspect of the present invention is a method of identifying a feature within the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the polypeptide codes of SEQ ID Nos. 18 to 23 comprising reading the nucleic acid code(s) or the

polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) or polypeptide code(s) with the computer program. In one embodiment, computer program comprises a computer program which identifies open reading frames. In a further embodiment, the computer program identifies structural motifs in a polypeptide sequence. In another embodiment, the computer program comprises a molecular modeling program. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the polypeptide codes of SEQ ID Nos. 18 to 23 through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.

The nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the polypeptide codes of SEQ ID Nos. 18 to 23 may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the polypeptide codes of SEQ ID Nos. 18 to 23 may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparers, identifiers, or sources of reference nucleotide or polypeptide sequences to be compared to the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the polypeptide codes of SEQ ID Nos. 18 to 23. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid codes of SEQ ID Nos. 1 to 17, 24, 25, 28, 74 and 79 to 132 or the polypeptide codes of SEQ ID Nos. 18 to 23. The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, *J. Mol. Biol.* 215: 403 (1990)), FASTA (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA*, 85: 2444 (1988)), FASTDB (Brutlag et al. *Comp. App. Biosci.* 6:237-245, 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius<sup>2</sup>.DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II, (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMm (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer

(Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwent's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database. Many other  
5 programs and data bases would be apparent to one of skill in the art given the present disclosure.

Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic  
10 stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

Throughout this application, various publications, patents, and published patent applications are cited. The disclosures of the publications, patents, and published patent specifications referenced in this application are all hereby incorporated by reference in their entireties into the present disclosure to more fully describe the state of the art to which this  
15 invention pertains.

### **EXAMPLES**

Several of the methods of the present invention are described in the following examples, which are offered by way of illustration and not by way of limitation. Many other  
20 modifications and variations of the invention as herein set forth can be made without departing from the spirit and scope thereof and therefore only such limitations should be imposed as are indicated by the appended claims.

#### **Example 1**

##### **25 Identification Of Biallelic Markers - DNA Extraction**

Donors were unrelated and healthy. They presented a sufficient diversity for being representative of a heterogeneous population. The DNA from 100 individuals was extracted and tested for the detection of the biallelic markers.

30 ml of peripheral venous blood were taken from each donor in the presence of EDTA.  
30 Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume: 10 mM Tris pH7.6; 5 mM MgCl<sub>2</sub>; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red cells present in the supernatant, after resuspension of the pellet in the lysis solution.

35 The pellet of white cells was lysed overnight at 42°C with 3.7 ml of lysis solution

composed of:

- 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM) / NaCl 0.4 M
- 200  $\mu$ l SDS 10%
- 500  $\mu$ l K-proteinase (2 mg K-proteinase in TE 10-2 / NaCl 0.4 M).

5

For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

10

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm. The pellet was dried at 37°C, and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD = 50  $\mu$ g/ml DNA). To determine the presence of proteins in the DNA solution, the OD 260 / OD 280 ratio was determined. Only DNA preparations having a OD 260 / OD 280 ratio between 1.8 and 2 were used in the subsequent examples described below.

15

The pool was constituted by mixing equivalent quantities of DNA from each individual.

#### Example 2

##### Identification Of Biallelic Markers: Amplification Of Genomic DNA By PCR

20

The amplification of specific genomic sequences of the DNA samples of Example 1 was carried out on the pool of DNA obtained previously. In addition, 50 individual samples were similarly amplified.

PCR assays were performed using the following protocol:

25

Final volume	25 $\mu$ l
DNA	2 ng/ $\mu$ l
MgCl <sub>2</sub>	2 mM
dNTP (each)	200 $\mu$ M
primer (each)	2.9 ng/ $\mu$ l
Ampli Taq Gold DNA polymerase	0.05 unit/ $\mu$ l
30 PCR buffer (10x = 0.1 M TrisHCl pH8.3 0.5M KCl)	1x

30

35

Each pair of first primers was designed using the sequence information of genomic DNA sequences of SEQ ID Nos 1 to 78 disclosed herein and the OSP software (Hillier & Green, 1991). This first pair of primers was about 20 nucleotides in length and had the sequences disclosed in Table 4 in the columns labeled "Position range of amplification primer".



in SEQ ID No.” and “Complementary position range of amplification primer in SEQ ID No.”.

Table 4

Amplicon	SEQ ID No	Primer name	Position range of amplification primer in SEQ ID		Primer name	Complementary position range of amplification primer in SEQ ID	
99-27943	1	B1	7938	7958	C1	8446	8465
99-27935	1	B2	21365	21385	C2	21845	21864
8-128	1	B3	65453	65471	C3	65856	65874
99-31960	1	B4	95034	95053	C4	95543	95563
99-24656	1	B5	107022	107040	C5	107495	107513
99-24634	1	B6	160770	160787	C6	161240	161257
99-24639	1	B7	160279	160298	C7	160785	160802
99-7652	1	B8	168813	168830	C8	169331	169351
99-16100	1	B9	170666	170686	C9	171153	171173
99-5862	1	B10	173065	173085	C10	173495	173514
99-5919	1	B11	189753	189771	C11	190187	190207
99-24658	1	B12	197116	197135	C12	197555	197572
8-303	1	B13	200587	200606	C13	200994	201012
8-300	1	B14	202440	202459	C14	202852	202871
8-299	1	B15	203061	203080	C15	203486	203505
8-296	1	B16	203943	203962	C16	204345	204362
99-24644	1	B17	204741	204758	C17	205222	205240
8-252	1	B18	204373	204392	C18	204777	204794
8-295	1	B19	205034	205052	C19	205435	205453
8-293	1	B20	205768	205786	C20	206175	206193
8-292	1	B21	206316	206333	C21	206725	206742
8-251	1	B22	207186	207205	C22	207616	207634
8-289	1	B23	208186	208205	C23	208588	208606
8-287	1	B24	208786	208805	C24	209189	209208
8-285	1	B25	209520	209539	C25	209931	209949
8-283	1	B26	210219	210237	C26	210620	210638
8-282	1	B27	210801	210820	C27	211205	211223
8-281	1	B28	211182	211199	C28	211596	211613

8-279	1	B29	212290	212309	C29	212698	212716
8-278	1	B30	212662	212679	C30	213091	213109
8-277	1	B31	213783	213803	C31	214062	214082
8-124	1	B32	214564	214581	C32	214965	214983
8-273	1	B33	215310	215328	C33	215711	215729
8-126	1	B34	216687	216704	C34	217082	217101
8-130	1	B35	216683	216702	C35	217091	217109
99-5897	1	B36	219408	219425	C36	219882	219899
99-24649	1	B37	220505	220522	C37	221004	221021
8-247	1	B38	223011	223028	C38	223549	223566
8-246	1	B39	223962	223978	C39	224588	224605
8-245	1	B40	224564	224581	C40	225044	225061
8-119	1	B41	230210	230227	C41	230622	230641
99-15870	1	B42	231278	231298	C42	231729	231747
99-16087	1	B43	235081	235101	C43	235515	235533
8-155	1	B44	238607	238626	C44	239029	239046
99-16038	1	B45	239405	239425	C45	239862	239880
8-136	1	B46	239606	239624	C46	240012	240029
99-15880	1	B47	241700	241717	C47	242151	242171
8-271	1	B48	243484	243502	C48	243909	243926
8-267	1	B49	245105	245123	C49	245518	245535
8-266	1	B50	245372	245389	C50	245775	245793
8-265	1	B51	245754	245772	C51	246155	246173
99-25940	1	B52	247513	247533	C52	248023	248043
99-16032	1	B53	248204	248223	C53	248588	248606
99-16105	1	B54	255697	255715	C54	256133	256152
99-16033	1	B55	259885	259902	C55	260324	260342
99-15875	1	B56	279626	279644	C56	280154	280173
99-16052	1	B57	300153	300170	C57	300660	300680
99-16047	1	B58	311615	311632	C58	312126	312144
99-25993	1	B59	315649	315668	C59	316129	316147

Amplicon	SEQ ID No	Primer name	Position range of amplification primer in SEQ ID		Primer name	Complementary position range of amplification primer in SEQ ID	
8-102	24	B60	1	20	C60	408	427
8-104	25	B61	1	21	C61	295	310
8-94	26	B62	1	18	C62	400	418
8-95	27	B63	1	18	C63	400	419
8-97	28	B64	1	18	C64	331	350
8-98	29	B65	1	19	C65	415	434
99-14021	30	B66	1	18	C66	465	477
99-14364	31	B67	64	82	C67	434	454
99-15056	32	B68	1	18	C68	482	502
99-15229	33	B69	1	20	C69	476	494
99-15232	34	B70	1	18	C70	467	485
99-15253	35	B71	1	19	C71	459	477
99-15256	36	B72	1	18	C72	439	456
99-15258	37	B73	1	19	C73	521	541
99-15261	38	B74	1	19	C74	481	501
99-15280	39	B75	1	18	C75	521	541
99-15355	40	B76	1	18	C76	471	489
99-15663	41	B77	1	18	C77	430	450
99-15664	42	B78	1	19	C78	483	502
99-15665	43	B79	1	20	C79	458	476
99-15668	44	B80	1	18	C80	439	459
99-15672	45	B81	1	18	C81	533	547
99-15682	46	B82	1	19	C82	482	500
99-16081	47	B83	1	18	C83	443	462
99-16082	48	B84	1	18	C84	512	532
99-20933	49	B85	1	19	C85	432	451
99-20977	50	B86	1	18	C86	491	511
99-20978	51	B87	1	19	C87	446	466
99-20981	52	B88	1	18	C88	429	449
99-20983	53	B89	1	19	C89	431	449
99-22310	54	B90	1	19	C90	446	466

99-25922	55	B91	1	21	C91	451	471
99-25950	56	B92	1	19	C92	479	499
99-25961	57	B93	1	20	C93	464	484
99-25965	58	B94	1	21	C94	451	470
99-25966	59	B95	1	21	C95	503	523
99-25967	60	B96	1	20	C96	473	493
99-25969	61	B97	1	21	C97	510	530
99-25972	62	B98	1	21	C98	428	448
99-25974	63	B99	1	21	C99	524	544
99-25977	64	B100	1	21	C100	520	540
99-25979	65	B101	1	19	C101	518	538
99-25985	66	B102	1	21	C102	449	469
99-25989	67	B103	1	19	C103	533	553
99-26146	68	B104	1	19	C104	436	456
99-26150	69	B105	1	19	C105	437	454
99-26153	70	B106	1	19	C106	429	449
99-26156	71	B107	1	18	C107	491	511
99-27345	72	B108	1	18	C108	531	551
99-30329	73	B109	1	18	C109	496	514
99-31798	74	B110	1	20	C110	491	511
99-5873	75	B111	11	28	C111	466	474
99-6012	76	B112	11	29	C112	477	490
99-6080	77	B113	11	28	C113	519	529
99-7308	78	B114	1	18	C114	469	489

Preferably, the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification which was useful for sequencing.

5 Primers from the column labeled "Position range of amplification primer in SEQ ID No." contain the following additional PU 5' sequence: TGTAACGACGGCCAGT (SEQ ID No. 133); primers from the column labeled "Complementary position range of amplification primer in SEQ ID No." contain the following RP 5' sequence: CAGGAAACAGCTATGACC (SEQ ID No. 134).

10 The synthesis of these primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

DNA amplification was performed on a Genius II thermocycler. After heating at 95°C for 10 min, 40 cycles were performed. Each cycle comprised: 30 sec at 95°C, 54°C for 1 min, and 30 sec at 72°C. For final elongation, 10 min at 72°C ended the amplification. The quantities of the amplification products obtained were determined on 96-well microtiter plates, using a fluorometer and Picogreen as intercalant agent (Molecular Probes).

### Example 3

#### Identification of Polymorphisms

##### a) Identification of Biallelic Markers from Amplified Genomic DNA of Example 2

The sequencing of the amplified DNA obtained in Example 2 was carried out on ABI 377 sequencers. The sequences of the amplification products were determined using automated dideoxy terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of the sequencing reactions were run on sequencing gels and the sequences were determined using gel image analysis (ABI Prism DNA Sequencing Analysis software (2.1.2 version)).

The sequence data were further evaluated to detect the presence of biallelic markers within the amplified fragments. The polymorphism search was based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position as described previously.

The localization of the biallelic markers detected in the fragments of amplification are as shown below in Table 5.

**Table 5**  
**Biallelic Markers**

Amplicon	BM	Marker Name	Polymorphism		SEQ ID No.	BM position in SEQID	Position of probes in SEQ ID No.		Probe No.
			Alt1	Alt2					
99-27943	A1	99-27943-150	G	C	1	8316	8304	8328	P1
99-27935	A2	99-27935-193	G	C	1	21672	21660	21684	P2
8-128	A3	8-128-33	C	T	1	65485	65473	65497	P3
99-31960	A4	99-31960-363	A	G	1	95396	95384	95408	P4
99-24656	A5	99-24656-260	A	G	1	107281	107269	107293	P5
99-24634	A6	99-24639-163	A	C	1	160640	160628	160652	P6
99-24639	A7	99-24634-108	A	T	1	160876	160864	160888	P7
99-7652	A8	99-7652-162	A	G	1	168974	168962	168986	P8
99-16100	A9	99-16100-147	A	G	1	170810	170798	170822	P9
99-5862	A10	99-5862-167	A	G	1	173358	173346	173370	P10

99-5919	A11	99-5919-215	A	G	1	189957	189945	189969	P11
99-24658	A12	99-24658-410	A	G	1	197163	197151	197175	P12
8-303	A13	8-303-235	A	G	1	200778	200766	200790	P13
8-300	A14	8-300-221	A	G	1	202651	202639	202663	P14
8-300	A15	8-300-193	A	G	1	202679	202667	202691	P15
8-299	A16	8-299-128	A	T	1	203378	203366	203390	P16
8-296	A17	8-296-213	A	T	1	204138	204126	204150	P17
8-252	A18	8-252-190	C	T	1	204605	204593	204617	P18
99-24644	A19	99-24644-194	A	G	1	204934	204922	204946	P19
8-295	A20	8-295-248	A	C	1	205206	205194	205218	P20
8-295	A21	8-295-125	C	T	1	205329	205317	205341	P21
8-293	A22	8-293-130	A	G	1	206064	206052	206076	P22
8-292	A23	8-292-198	A	G	1	206545	206533	206557	P23
8-251	A24	8-251-322	A	G	1	207313	207301	207325	P24
8-289	A25	8-289-322	A	G	1	208285	208273	208297	P25
8-287	A26	8-287-249	C	T	1	208960	208948	208972	P26
8-287	A27	8-287-86	A	T	1	209123	209111	209135	P27
8-285	A28	8-285-319	A	G	1	209631	209619	209643	P28
8-283	A29	8-283-278	G	C	1	210361	210349	210373	P29
8-283	A30	8-283-176	A	G	1	210463	210451	210475	P30
8-283	A31	8-283-153	G	C	1	210486	210474	210498	P31
8-283	A32	8-283-56	C	T	1	210583	210571	210595	P32
8-282	A33	8-282-345	G	C	1	210879	210867	210891	P33
8-282	A34	8-282-260	G	T	1	210964	210952	210976	P34
8-282	A35	8-282-245	A	C	1	210979	210967	210991	P35
8-282	A36	8-282-174	Variable motif		1	211050			P36
8-282	A37	8-282-92	A	T	1	211132	211120	211144	P37
8-281	A38	8-281-367	A	G	1	211247	211235	211259	P38
8-281	A39	8-281-299	A	G	1	211315	211303	211327	P39
8-281	A40	8-281-248	G	C	1	211366	211354	211378	P40
8-279	A41	8-279-197	A	C	1	212520	212508	212532	P41
8-278	A42	8-278-289	C	T	1	212821	212809	212833	P42
8-277	A43	8-277-250	C	T	1	213833	213821	213845	P43

8-124	A44	8-124-294	A	G	1	214857	214845	214869	P44
8-273	A45	8-273-383	A	G	1	215347	215335	215359	P45
8-130/ 8-126	A46	8-130-143 / 8-126-286	A	G	1	216967	216955	216979	P46
99-5897	A47	99-5897-143	A	C	1	219540	219528	219552	P47
99-24649	A48	99-24649-186	A	G	1	220836	220824	220848	P48
8-247	A49	8-247-337	A	G	1	223230	223218	223242	P49
8-246	A50	8-246-393	A	T	1	224213	224201	224225	P50
8-245	A51	8-245-270	A	G	1	224792	224780	224804	P51
8-119	A52	8-119-247	A	G	1	230395	230383	230407	P52
99-15870	A53	99-15870-400	A	G	1	231677	231665	231689	P53
99-16087	A54	99-16087-219	G	C	1	235315	235303	235327	P54
8-155	A55	8-155-258	C	T	1	238789	238777	238801	P55
99-16038	A56	99-16038-118	C	T	1	239763	239751	239775	P56
8-136	A57	8-136-267	C	T	1	239763	239751	239775	P57
99-15880	A58	99-15880-162	A	G	1	241861	241849	241873	P58
8-271	A59	8-271-227	A	G	1	243700	243688	243712	P59
8-267	A60	8-267-273	Deletion		1	245263			P60
8-266	A61	8-266-131	A	C	1	245663	245651	245675	P61
8-265	A62	8-265-208	A	G	1	245966	245954	245978	P62
8-265	A63	8-265-203	G	C	1	245971	245959	245983	P63
99-25940	A64	99-25940-182	C	T	1	247864	247852	247876	P64
99-16032	A65	99-16032-292	G	T	1	248315	248303	248327	P65
99-16105	A66	99-16105-152	A	G	1	255848	255836	255860	P66
99-16033	A67	99-16033-244	A	G	1	260099	260087	260111	P67
99-15875	A68	99-15875-165	C	T	1	279789	279777	279801	P68
99-16052	A69	99-16052-214	A	G	1	300365	300353	300377	P69
99-16047	A70	99-16047-115	A	G	1	312030	312018	312042	P70
99-25993	A71	99-25993-367	A	G	1	316014	316002	316026	P71
Amplicon	BM	Marker Name	Polymorphism		SEQ ID No.	BM position in SEQID	Position of probes in SEQ ID No.		Probe No.
			All1	All2					
8-102	A72	8-102-231	C	T	24	231	219	243	P72
8-104	A73	8-104-105	A	G	25	105	93	117	P73

8-94	A74	8-94-252	A	G	26	251	239	263	P74
8-95	A75	8-95-43	A	G	27	43	31	55	P75
8-97	A76	8-97-181	A	G	28	181	169	193	P76
8-97	A77	8-97-98	C	T	28	98	86	110	P77
8-98	A78	8-98-68	A	G	29	68	56	80	P78
99-14021	A79	99-14021-108	A	G	30	108	96	120	P79
99-14364	A80	99-14364-415	C	T	31	415	403	427	P80
99-15056	A81	99-15056-99	C	T	32	99	87	111	P81
99-15229	A82	99-15229-412	A	G	33	412	400	424	P82
99-15232	A83	99-15232-291	G	T	34	291	279	303	P83
99-15253	A84	99-15253-382	C	T	35	382	370	394	P84
99-15256	A85	99-15256-392	C	T	36	392	380	404	P85
99-15258	A86	99-15258-337	G	T	37	337	325	349	P86
99-15261	A87	99-15261-202	A	G	38	200	188	212	P87
99-15280	A88	99-15280-432	C	T	39	432	420	444	P88
99-15355	A89	99-15355-150	C	T	40	150	138	162	P89
99-15663	A90	99-15663-298	C	T	41	298	286	310	P90
99-15664	A91	99-15664-185	G	T	42	185	173	197	P91
99-15665	A92	99-15665-398	A	G	43	398	386	410	P92
99-15668	A93	99-15668-139	C	T	44	139	127	151	P93
99-15672	A94	99-15672-166	C	T	45	166	154	178	P94
99-15682	A95	99-15682-318	A	T	46	318	306	330	P95
99-16081	A96	99-16081-217	C	T	47	217	205	229	P96
99-16082	A97	99-16082-218	A	G	48	218	206	230	P97
99-20933	A98	99-20933-81	A	C	49	81	69	93	P98
99-20977	A99	99-20977-72	A	C	50	71	59	83	P99
99-20978	A100	99-20978-89	G	C	51	89	77	101	P100
99-20981	A101	99-20981-300	A	G	52	300	288	312	P101
99-20983	A102	99-20983-48	A	G	53	48	36	60	P102
99-22310	A103	99-22310-148	C	T	54	148	136	160	P103
99-25922	A104	99-25922-147	G	T	55	147	135	159	P104
99-25950	A105	99-25950-121	G	C	56	121	109	133	P105
99-25961	A106	99-25961-376	A	C	57	373	361	385	P106
99-25965	A107	99-25965-399	A	G	58	399	387	411	P107



99-25966	A108	99-25966-241	A	G	59	241	229	253	P108
99-25967	A109	99-25967-57	A	G	60	56	44	68	P109
99-25969	A110	99-25969-200	G	T	61	200	188	212	P110
99-25972	A111	99-25972-317	C	T	62	315	303	327	P111
99-25974	A112	99-25974-143	A	G	63	143	131	155	P112
99-25977	A113	99-25977-311	A	G	64	311	299	323	P113
99-25979	A114	99-25979-93	A	G	65	93	81	105	P114
99-25985	A115	99-25985-194	C	T	66	194	182	206	P115
99-25989	A116	99-25989-398	A	G	67	398	386	410	P116
99-26146	A117	99-26146-264	G	T	68	264	252	276	P117
99-26150	A118	99-26150-276	A	G	69	276	264	288	P118
99-26153	A119	99-26153-44	A	C	70	44	32	56	P119
99-26156	A120	99-26156-290	A	C	71	290	278	302	P120
99-27345	A121	99-27345-189	G	C	72	189	177	201	P121
99-30329	A122	99-30329-380	C	T	73	380	368	392	P122
99-31798	A123	99-31798-344	Variable motif		74	342			P123
99-5873	A124	99-5873-159	C	T	75	159	147	171	P124
99-6012	A125	99-6012-220	G	T	76	220	208	232	P125
99-6080	A126	99-6080-99	C	T	77	99	87	111	P126
99-7308	A127	99-7308-157	C	T	78	156	144	168	P127

BM refers to "biallelic marker". A111 and A112 refer respectively to allele 1 and allele 2 of the biallelic marker.

Certain biallelic markers of the invention are insertions or deletions, as indicated above.

- 5 In particular, the biallelic marker 8-282-174 comprises a variable motif AAAGG or GAAGGAAGGAAGGAAGGAAGA. The biallelic marker 8-267-273 comprises an insertion or deletion of GTGGGC. The biallelic marker 99-31798-344 comprises a variable motif CAT or ACTGTCTCTACCTCA

10

#### Example 4

##### Validation Of The Polymorphisms Through Microsequencing

The biallelic markers identified in Example 3 were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was

carried out for each individual DNA sample described in Example 1.

Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers (Table 3).

The preferred primers used in microsequencing were about 19 nucleotides in length and hybridized just upstream of the considered polymorphic base. According to the invention, the primers used in microsequencing are detailed in Table 6.

**Table 6**

Marker Name	Biallelic Marker	SEQ ID No.	Mis. 1	Position range of microsequencing primer mis. 1 in SEQ ID No.		Mis. 2	Complementary position range of microsequencing primer mis. 2 in SEQ ID No.	
99-27943-150	A1	1	D1	8297	8315	E1	8317	8335
99-27935-193	A2	1	D2	21653	21671	E2	21673	21691
8-128-33	A3	1	D3	65466	65484	E3	65486	65504
99-31960-363	A4	1	D4	95377	95395	E4	95397	95415
99-24656-260	A5	1	D5	107262	107280	E5	107282	107300
99-24639-163	A6	1	D6	160621	160639	E6	160641	160659
99-24634-108	A7	1	D7	160857	160875	E7	160877	160895
99-7652-162	A8	1	D8	168955	168973	E8	168975	168993
99-16100-147	A9	1	D9	170791	170809	E9	170811	170829
99-5862-167	A10	1	D10	173339	173357	E10	173359	173377
99-5919-215	A11	1	D11	189938	189956	E11	189958	189976
99-24658-410	A12	1	D12	197144	197162	E12	197164	197182
8-303-235	A13	1	D13	200759	200777	E13	200779	200797
8-300-221	A14	1	D14	202632	202650	E14	202652	202670
8-300-193	A15	1	D15	202660	202678	E15	202680	202698
8-299-128	A16	1	D16	203359	203377	E16	203379	203397
8-296-213	A17	1	D17	204119	204137	E17	204139	204157
8-252-190	A18	1	D18	204586	204604	E18	204606	204624
99-24644-194	A19	1	D19	204915	204933	E19	204935	204953
8-295-248	A20	1	D20	205187	205205	E20	205207	205225
8-295-125	A21	1	D21	205310	205328	E21	205330	205348
8-293-130	A22	1	D22	206045	206063	E22	206065	206083
8-292-198	A23	1	D23	206526	206544	E23	206546	206564
8-251-322	A24	1	D24	207294	207312	E24	207314	207332

8-289-322	A25	1	D25	208266	208284	E25	208286	208304
8-287-249	A26	1	D26	208941	208959	E26	208961	208979
8-287-86	A27	1	D27	209104	209122	E27	209124	209142
8-285-319	A28	1	D28	209612	209630	E28	209632	209650
8-283-278	A29	1	D29	210342	210360	E29	210362	210380
8-283-176	A30	1	D30	210444	210462	E30	210464	210482
8-283-153	A31	1	D31	210467	210485	E31	210487	210505
8-283-56	A32	1	D32	210564	210582	E32	210584	210602
8-282-345	A33	1	D33	210860	210878	E33	210880	210898
8-282-260	A34	1	D34	210945	210963	E34	210965	210983
8-282-245	A35	1	D35	210960	210978	E35	210980	210998
8-282-174	A36	1	D36			E36		
8-282-92	A37	1	D37	211113	211131	E37	211133	211151
8-281-367	A38	1	D38	211228	211246	E38	211248	211266
8-281-299	A39	1	D39	211296	211314	E39	211316	211334
8-281-248	A40	1	D40	211347	211365	E40	211367	211385
8-279-197	A41	1	D41	212501	212519	E41	212521	212539
8-278-289	A42	1	D42	212802	212820	E42	212822	212840
8-277-250	A43	1	D43	213814	213832	E43	213834	213852
8-124-294	A44	1	D44	214838	214856	E44	214858	214876
8-273-383	A45	1	D45	215328	215346	E45	215348	215366
8-130-143 / 8-126-286	A46	1	D46	216948	216966	E46	216968	216986
99-5897-143	A47	1	D47	219521	219539	E47	219541	219559
99-24649-186	A48	1	D48	220817	220835	E48	220837	220855
8-247-337	A49	1	D49	223211	223229	E49	223231	223249
8-246-393	A50	1	D50	224194	224212	E50	224214	224232
8-245-270	A51	1	D51	224773	224791	E51	224793	224811
8-119-247	A52	1	D52	230376	230394	E52	230396	230414
99-15870-400	A53	1	D53	231658	231676	E53	231678	231696
99-16087-219	A54	1	D54	235296	235314	E54	235316	235334
8-155-258	A55	1	D55	238770	238788	E55	238790	238808
99-16038-118	A56	1	D56	239744	239762	E56	239764	239782
8-136-267	A57	1	D57	239744	239762	E57	239764	239782

99-15880-162	A58	1	D58	241842	241860	E58	241862	241880
8-271-227	A59	1	D59	243681	243699	E59	243701	243719
8-267-273	A60	1	D60			E60		
8-266-131	A61	1	D61	245644	245662	E61	245664	245682
8-265-208	A62	1	D62	245947	245965	E62	245967	245985
8-265-203	A63	1	D63	245952	245970	E63	245972	245990
99-25940-182	A64	1	D64	247845	247863	E64	247865	247883
99-16032-292	A65	1	D65	248296	248314	E65	248316	248334
99-16105-152	A66	1	D66	255829	255847	E66	255849	255867
99-16033-244	A67	1	D67	260080	260098	E67	260100	260118
99-15875-165	A68	1	D68	279770	279788	E68	279790	279808
99-16052-214	A69	1	D69	300346	300364	E69	300366	300384
99-16047-115	A70	1	D70	312011	312029	E70	312031	312049
99-25993-367	A71	1	D71	315995	316013	E71	316015	316033
Marker Name	Biallelic Marker	SEQ ID No.	Mis. 1	Position range of microsequencing primer mis. 1 in SEQ ID No.		Mis. 2	Complementary position range of microsequencing primer mis. 2 in SEQ ID No.	
8-102-231	A72	24	D72	212	230	E72	232	250
8-104-105	A73	25	D73	86	104	E73	106	124
8-94-252	A74	26	D74	232	250	E74	252	270
8-95-43	A75	27	D75	24	42	E75	44	62
8-97-181	A76	28	D76	162	180	E76	182	200
8-97-98	A77	28	D77	79	97	E77	99	117
8-98-68	A78	29	D78	49	67	E78	69	87
99-14021-108	A79	30	D79	89	107	E79	109	127
99-14364-415	A80	31	D80	396	414	E80	416	434
99-15056-99	A81	32	D81	80	98	E81	100	118
99-15229-412	A82	33	D82	393	411	E82	413	431
99-15232-291	A83	34	D83	272	290	E83	292	310
99-15253-382	A84	35	D84	363	381	E84	383	401
99-15256-392	A85	36	D85	373	391	E85	393	411
99-15258-337	A86	37	D86	318	336	E86	338	356
99-15261-202	A87	38	D87	181	199	E87	201	219

99-15280-432	A88	39	D88	413	431	E88	433	451
99-15355-150	A89	40	D89	131	149	E89	151	169
99-15663-298	A90	41	D90	279	297	E90	299	317
99-15664-185	A91	42	D91	166	184	E91	186	204
99-15665-398	A92	43	D92	379	397	E92	399	417
99-15668-139	A93	44	D93	120	138	E93	140	158
99-15672-166	A94	45	D94	147	165	E94	167	185
99-15682-318	A95	46	D95	299	317	E95	319	337
99-16081-217	A96	47	D96	198	216	E96	218	236
99-16082-218	A97	48	D97	199	217	E97	219	237
99-20933-81	A98	49	D98	62	80	E98	82	100
99-20977-72	A99	50	D99	52	70	E99	72	90
99-20978-89	A100	51	D100	70	88	E100	90	108
99-20981-300	A101	52	D101	281	299	E101	301	319
99-20983-48	A102	53	D102	29	47	E102	49	67
99-22310-148	A103	54	D103	129	147	E103	149	167
99-25922-147	A104	55	D104	128	146	E104	148	166
99-25950-121	A105	56	D105	102	120	E105	122	140
99-25961-376	A106	57	D106	354	372	E106	374	392
99-25965-399	A107	58	D107	380	398	E107	400	418
99-25966-241	A108	59	D108	222	240	E108	242	260
99-25967-57	A109	60	D109	37	55	E109	57	75
99-25969-200	A110	61	D110	181	199	E110	201	219
99-25972-317	A111	62	D111	296	314	E111	316	334
99-25974-143	A112	63	D112	124	142	E112	144	162
99-25977-311	A113	64	D113	292	310	E113	312	330
99-25979-93	A114	65	D114	74	92	E114	94	112
99-25985-194	A115	66	D115	175	193	E115	195	213
99-25989-398	A116	67	D116	379	397	E116	399	417
99-26146-264	A117	68	D117	245	263	E117	265	283
99-26150-276	A118	69	D118	257	275	E118	277	295
99-26153-44	A119	70	D119	25	43	E119	45	63
99-26156-290	A120	71	D120	271	289	E120	291	309
99-27345-189	A121	72	D121	170	188	E121	190	208

99-30329-380	A122	73	D122	361	379	E122	381	399
99-31798-344	A123	74	D123			E123		
99-5873-159	A124	75	D124	140	158	E124	160	178
99-6012-220	A125	76	D125	201	219	E125	221	239
99-6080-99	A126	77	D126	80	98	E126	100	118
99-7308-157	A127	78	D127	137	155	E127	157	175

Mis 1 and Mis 2 respectively refer to microsequencing primers which hybridized with the coding strand or with the non-coding strand of the nucleotide sequences of the invention.

The microsequencing reaction was performed as follows :

5 After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20 µl final volume: 10 pmol microsequencing oligonucleotide, 1 U Thermosequenase (Amersham E79000G), 1.25 µl Thermosequenase buffer (260 mM Tris HCl pH 9.5, 65 mM MgCl<sub>2</sub>), and the two appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each

10 biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94°C, 20 PCR cycles of 15 sec at 55°C, 5 sec at 72°C, and 10 sec at 94°C were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators were then removed by ethanol precipitation. Samples were finally resuspended in formamide-EDTA

15 sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

20 The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position. When two significant peaks are detected for the same position, each sample is categorized classification as homozygous or heterozygous type based

25 on the height ratio.

#### Example 5a

#### Association Study Between Schizophrenia And The Biallelic Markers Of The Invention

**Collection Of DNA Samples From Affected And Non-Affected Individuals****A) Affected population**

5 All the samples were collected from a large epidemiological study of schizophrenia undertaken in hospital centers of Quebec from October 1995 to April 1997. The population was composed of French Caucasian individuals. The study design consisted in the ascertainment of cases and two of their first degree relatives (parents or siblings).

As a whole, 956 schizophrenic cases were ascertained according to the following inclusion criteria:

- the diagnosis had been done by a psychiatrist;
- 10 - the diagnosis had been done at least 3 years before recruitment time, in order to exclude individuals suffering from transient manic-depressive psychosis or depressive disorders;
- the patient ancestors had been living in Quebec for at least 6 generations;
- it was possible to get a blood sample from 2 close relatives.

15 Among the 956 schizophrenic ascertained cases, 834 individuals were included in the study for the following reasons:

- for the included individual cases, the diagnosis of schizophrenia was established according to the DSM-IV (Diagnostic and Statistical Manual, Fourth edition, Revised 1994, American Psychiatric Press);
- 20 - samples from individuals suffering from schizoaffective disorder were discarded;
- individuals suffering from catatonic schizophrenia were also excluded from the population of schizophrenic cases;
- were also excluded the individuals having a first degree relative or 2 or more second degree relatives suffering from depression or mood disorder;
- 25 - individuals having had severe head trauma, severe obstretical complications, encephalitis, or meningitis before onset of symptoms were also excluded;
- has also been excluded from the population of schizophrenic cases a patient suffering from epilepsy and treated with anticonvulsants.

The age at onset was not added as an inclusion criteria.

30 **B) Unaffected population**

Control cases were respectively ascertained based on the following cumulative criteria:

- the individual must not be affected by schizophrenia or any other psychiatric disorder;
- the individual must have 35 years old or more;
- the individual must belong to the French-Canadian population;
- 35 - the individual must have one or two first degree relative available for blood sampling.

Controls were matched with cases sex when possible.

**C) Cases and Control Populations Selected for the Association Study**

The unaffected population retained for the study was composed of 241 individuals. The initial sample of the clinical study was composed of 215 cases and 214 controls. The controls were composed of 116 males and 98 females while the cases were composed of 154 males and 64 females. For each control, two first degree relatives (father, mother, sisters and brothers) were available. In order to match the sex of cases and controls, the parents of female controls were substituted for the female controls where possible and where the parents were known to be unaffected by schizophrenia or other psychosis. The parents of 27 female controls were thus substituted for the respective females, resulting in a total control sample size of 241 individuals. The composition of the control sample is detailed below in Table 7.

**Table 7**

Description of control samples

<b>Probands</b>	<b>187</b>
Male	116
Female	71
<b>Parents of probands</b>	<b>54</b>
Fathers	27
Mothers	27
<b>Total</b>	<b>241</b>

The association data that are presented below were obtained on a population size detailed in Table 8 below, wherein the individuals have been randomly selected from the populations detailed above.

**Table 8**

Cases and Control Populations Selected for the Association Study			
sample type		Cases	Controls
sample size		215	241
Gender			
	Male	151	143
	Female	64	98
Familial history of psychosis (FH)*			
	positive (FH+)	82	0
	none (FH-)	133	241



* : close relatives (first or second degree)		
--	--	--

Both case and control populations form two groups, each group consisting of unrelated individuals that do not share a known common ancestor. Additionally, the individuals of the control population were selected among those having no family history of schizophrenia or schizophrenic disorder.

#### Genotyping of affected and control individuals

##### A) Results from the genotyping

The general strategy to perform the association studies was to individually scan the DNA samples from all individuals in each of the populations described above in order to establish the allele frequencies of biallelic markers, and among them the biallelic markers of the invention, in the diploid genome of the tested individuals belonging to each of these populations.

Allelic frequencies of every biallelic marker in each population (cases and controls) were determined by performing microsequencing reactions on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual. Genomic PCR and microsequencing were performed as detailed above in Examples 1 to 4 using the described PCR and microsequencing primers.

##### Single biallelic marker frequency analysis

For each allele of the biallelic markers included in this study, the difference between the allelic frequency in the unaffected population and in the population affected by schizophrenia was calculated and the absolute value of the difference was determined. The more the difference in allelic frequency for a particular biallelic marker or a particular set of biallelic markers, the more probable an association between the genomic region harboring this particular biallelic marker or set of biallelic markers and schizophrenia. Allelic frequencies were also useful to check that the markers used in the haplotype studies meet the Hardy-Weinberg proportions (random mating).

The allelic frequencies of biallelic markers in the chromosome 13q31-q33 region between the affected and the unaffected population, using the sample population described above, is set forth in Table 9.

**Table 9**

Allelic frequencies of markers in different sub-samples

marker	alleles	all sample			
		cases			controls
		all	HF+	HF-	

99-20978/89	C/G	0.51	0.47	0.51	0.55
99-20983/48	A/G	0.30	0.28	0.33	0.29
99-20981/300	A/G	0.54	0.51	0.55	0.56
99-20977/72	A/C	0.40	0.41	0.38	0.35
99-6080/99	C/T	0.58	0.57	0.57	0.55
99-15229/412	A/G	0.54	0.52	0.55	0.53
99-22310/148	C/T	0.46	0.48	0.44	0.47
99-15232/291	C/T	0.46	0.48	0.43	0.47
99-14021/108	A/G	0.46	0.48	0.44	0.47
8-98/68	A/G	0.20	0.18	0.23	0.19
8-97/98	C/T	0.78	0.75	0.81	0.80
99-6012/220	C/T	0.20	0.19	0.23	0.19
8-95/43	A/G	0.18	0.20	0.18	0.21
99-7308/157	C/T	0.39	0.42	0.36	0.39
99-14364/415	C/T	0.38	0.40	0.36	0.39
99-15672/166	C/T	0.51	0.47	0.54	0.54
99-15668/139	C/T	0.58	0.56	0.62	0.65
99-15665/398	A/G	0.72	0.67	0.72	0.76
99-15663/298	C/T	0.72	0.67	0.72	0.76
99-15664/185	C/T	0.69	0.62	0.72	0.72
99-15682/318	A/T	0.35	0.40	0.34	0.32
99-20933/81	A/C	0.43	0.41	0.42	0.40
99-16081/217	C/T	0.43	0.38	0.46	0.39
99-16082/218	A/G	0.33	0.31	0.35	0.32
99-5862/167	C/T	0.47	0.43	0.44	0.51
99-16100/147	A/G	0.48	0.44	0.45	0.50
99-7652/162	A/G	0.49	0.46	0.46	0.52
99-5919/215	A/G	0.66	0.71	0.69	0.60
99-5897/143	A/C	0.58	0.61	0.53	0.59
99-15870/400	A/G	0.32	0.38	0.27	0.33
99-16032/292	A/C	0.61	0.62	0.64	0.58
99-15880/162	A/G	0.62	0.63	0.65	0.58
99-16038/118	A/G	0.38	0.36	0.35	0.42
99-15875/165	C/T	0.58	0.57	0.57	0.63
99-16033/244	C/T	0.55	0.57	0.49	0.54
99-16047/115	C/T	0.73	0.75	0.68	0.73

In the association study described herein, several individual biallelic markers were

shown to be significantly associated with schizophrenia. In particular, several of the chromosome 13q31-q33 region biallelic markers (99-16038/118 (A56), 99-7652/162 (A8), 99-5919/215 (A11), 99-15875/165 (A68), 99-16032/292 (A9)) showed significant association with schizophrenia in both familial and sporadic schizophrenia cases. The significance of the absolute value of the difference of allelic frequency of the individual biallelic markers in the affected and the unaffected population is set forth in 2, with several biallelic marker having allelic frequency differences with p-values approaching or less than 0.05, biallelic marker 99-5919/215 (A11) having a p-value of less than 0.01. Figure 2 also shows the physical order of certain specific biallelic markers. These results show that several biallelic markers individually associated with schizophrenia are physically located in a particular region of significance, the subregion of the chromosome 13q31-q33 region referred to herein as Region D.

#### Haplotype frequency analysis

Analysis of markers Haplotype analysis for association of chromosome 13q31-q33-related biallelic markers and schizophrenia was performed by estimating the frequencies of all possible 2, 3 and 4 marker haplotypes in the affected and control populations described above. Haplotype estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier and Slatkin, 1995), using the EM-HAPLO program (Hawley et al., 1994) as described above. Estimated haplotype frequencies in the affected and control population were compared by means of a chi-square statistical test (one degree of freedom).

#### Haplotype association results in schizophrenia cases

The results of the haplotype analysis using the chromosome 13q31-q33-related biallelic markers biallelic markers is shown in Figure 3. In particular, the figures show the most significant haplotypes using the biallelic markers: 99-16047/115 (A10), 99-16033/244 (A67), 99-16038/118 (A56), 99-15875/165 (A68), 99-16032/292 (A9), 99-5897/143 (A47), 99-15880/162 (A58), 99-16082/218 (A97), 99-5919/215 (A11), 99-7652/162 (A8), 99-16100/147 (A9), 99-5862/167 (A10).

A number of biallelic marker haplotypes were shown to be significantly associated with schizophrenia. A first preferred haplotype (HAP287 of Figure 3) consisting of four biallelic markers (99-16038/118 (A56), 99-16082/218 (A97), (99-7652/162 (A8) and 99-16100/147 (A9)) is highly significantly associated with schizophrenia in both total cases and sporadic cases. Figure 4 shows the characteristics of this haplotype. This haplotype presented a p-value of  $3.1 \times 10^{-7}$  and an odd-ratio of 4.01 for total cases and a p-value of  $3.9 \times 10^{-6}$  and an odd-ratio of 3.88 for sporadic cases. Phenotypic permutation tests confirmed the statistical significance of these results. Estimated haplotype frequencies were 13.8% in total cases, 13.5% in the sporadic cases, and 3.8 % in the controls.

Several other significant haplotypes are listed in Figure 3, including several 2-, 3- and 4-marker haplotypes. Considered to be highly significantly associated with schizophrenia are the most significant 2-marker haplotype (HAP1 consisting of biallelic markers 99-15875/165 (A68) and 99-5919/215 (A11)) and the most significant 3-marker haplotype (HAP67 consisting of biallelic markers 99-16038/118 (A56), 99-16082/218 (A97) and 99-7652/162 (A8)).

Further preferred significant haplotypes considered associated with schizophrenia are haplotypes having p-values above a desired threshold level are also; all the haplotypes listed in Figure 3 present p-values below  $1.0 \times 10^{-2}$  for 2-marker haplotypes,  $1.0 \times 10^{-4}$  for 3-marker haplotypes, and  $1.0 \times 10^{-5}$  for 4-marker haplotypes. All of the biallelic markers presented in Figure 4 except for 1 (99-16047/115 (A70)) are involved in haplotypes having a p-value above these threshold levels. Figure 3 shows several 2-marker haplotypes, HAP1 to HAP8, having p-values ranging from  $1.0 \times 10^{-2}$  to  $1.2 \times 10^{-3}$ , several 3-marker haplotypes, HAP67 to HAP76, having p-values ranging from  $1.3 \times 10^{-5}$  to  $1.0 \times 10^{-4}$  and several 4-marker haplotypes, HAP287 to HAP291, having p-values ranging from  $8.2 \times 10^{-7}$  to  $3.1 \times 10^{-7}$ . Figure 4 shows biallelic markers involved in significant haplotypes having significance thresholds of  $1.0 \times 10^{-2}$ ,  $1.0 \times 10^{-4}$ , and  $1.0 \times 10^{-5}$  for 2-, 3- and 4-marker haplotypes, respectively.

Several 2-, 3- and 4-marker haplotypes, HAP 1, HAP8, HAP70, HAP71, HAP75, HAP76, HAP288, HAP290 and HAP291, often comprised the biallelic marker 99-5919/215 (A11) allele A. Furthermore, several 2-, 3- and 4-marker haplotypes, HAP7, HAP67, HAP69, HAP75, HAP287 AND HAP288, often comprised the biallelic marker 99-16038/118 (A56) allele G.

#### Example 5b

#### Association Study Between Schizophrenia And The Biallelic Markers Of The Invention

#### Collection Of DNA Samples From Affected And Non-Affected Individuals

Biallelic markers of the invention were further analyzed in the French Canadian population described above. For this analysis, the proband case population under study consisted of 139 individuals, the control population consisted of 141 individuals, as described in Table 10 below.

**Table 10**

Cases and Control Populations Selected for the Association Study			
Sample type		Cases	Controls
Sample size		139	141
Gender			
	Male	94	96

	Female	45	45
Familial history of psychosis (FH)*			
	positive (FH+)	76	0
	none (FH-)	63	141
* : close relatives (first or second degree)			

### Genotyping of affected and control individuals

#### A) Results from the genotyping

5 The general strategy for performing the association studies was to individually scan the DNA samples from all individuals in each of the populations described above in order to establish the allele frequencies of biallelic markers, and among them the biallelic markers of the invention, in the diploid genome of the tested individuals belonging to each of these populations.

10 Allelic frequencies of every biallelic marker in each population (cases and controls) were determined by performing microsequencing reactions on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual. Genomic PCR and microsequencing were performed as detailed above in Examples 1 to 3 using the described PCR and microsequencing primers.

#### Single biallelic marker frequency analysis

15 For each allele of the biallelic markers included in this study, the difference between the allelic frequency in the unaffected population and in the population affected by schizophrenia was calculated and the absolute value of the difference was determined. The allelic frequencies of between the affected and the unaffected population in the regions is set forth in Table 11, using the sample population described above and in Table 10. The more the difference in allelic frequency for a particular biallelic marker or a particular set of biallelic markers, the more probable an association between the genomic region harboring this particular biallelic marker or set of biallelic markers and schizophrenia. Allelic frequencies were also useful to check that the markers used in the haplotype studies meet the Hardy-Weinberg proportions (random mating).

Table 11

25 Allelic frequencies of markers in different sub-samples (%)

Marker	polymorphism	Cases			All controls
		All cases	HF+	HF-	
99-20978/89	C/G	50,37	47,26	54,03	55,43
99-20983/48	A/G	30,37	28,67	32,5	26,52

99-20977/72	A/C	41,01	42,11	39,68	34,4
99-20981/300	A/G	52,17	51,33	53,17	60
99-6080/99	C/T	58,82	58	59,84	54,85
99-15229/412	A/G	54,92	52,86	57,26	51,88
99-22310/148	C/T	44,2	46,71	41,13	48,57
99-15232/291	G/T	43,85	46,43	40,83	49,28
99-14021/108	A/G	44,85	47,26	42,06	48,54
8-94/252	A/G	2,22	1,97	2,54	2,52
8-98/68	A/G	19,06	17,76	20,63	19,06
8-97/98	C/T	76,26	74,34	78,57	77,3
99-6012/220	G/T	20	18,49	21,77	18,79
99-7308/157	C/T	40,31	41,89	38,18	39,36
99-14364/415	C/T	39,93	40,79	38,89	40
8-95/43	A/G	20,29	20,39	20,16	22,14
99-15672/166	C/T	49,28	47,37	51,59	56,74
99-15668/139	C/T	58,21	56,16	60,66	66,67
99-15665/398	A/G	70,5	67,76	73,81	76,79
99-15663/298	C/T	70,5	67,76	73,81	76,95
99-15664/185	G/T	66,54	62,33	71,43	72,5
99-15682/318	A/T	35,27	39,58	29,82	32,66
99-20933/81	A/C	43,12	42,76	43,55	42,45
99-26146/264	G/T	39,62	38,67	40,91	38,85
99-25922/147	G/T	44,19	39,58	50	40,94
99-16081/217	C/T	42,28	38,82	46,67	36,74
99-16082/218	A/G	34,73	31,94	38,14	33,81
99-24656/260	A/G	48,87	49,32	48,31	54,04
99-24639/163	G/T	38,52	33,33	45	40,51
99-24634/108	A/T	44,85	42,67	47,54	50
99-7652/162	A/G	45,29	44,08	46,77	50,36
99-16100/147	A/G	44,66	42,75	46,77	48,89
99-5862/167	C/T	43,53	41,45	46,03	49,29
99-5919/215	A/G	69,42	71,05	67,46	60,28
99-24658/410	C/T	64,13	69,08	58,06	61,07
99-24644/194	A/G	39,42	41,22	37,3	40,51
99-5897/143	A/C	57,61	60,67	53,97	61,07
99-24649/186	C/T	67,75	67,33	68,25	62,95
99-15870/400	A/G	33,46	36,67	29,51	30,29
99-16038/118	A/G	34,53	36,18	32,54	43,62

99-15880/162	A/G	65,11	63,16	67,46	56,43
99-25940/182	A/G	59,42	56,67	62,7	52,59
99-16032/292	A/C	64,03	61,84	66,67	55,67
99-16033/244	C/T	54,51	56,76	51,69	56,44
99-15875/165	C/T	56,88	57,89	55,65	66,3
99-16047/115	C/T	71,69	74,67	68,03	75,19
99-25993/367	A/G	44,53	40,79	49,18	40,51
99-25989/398	A/G	32,81	33,33	32,2	27,86
99-25979/93	A/G	68,12	69,08	66,94	69,32
99-25969/200	G/T	36,67	38,67	34,17	38,85
99-25966/241	A/G	66,3	67,11	65,32	63,21
99-25961/376	A/C	39,63	42,57	36,07	37,31
99-25965/399	A/G	50,36	51,97	48,39	49,64
99-25977/311	A/G	72,01	67,76	77,59	73,72
99-25950/121	C/G	31,75	36	26,61	27,54
99-25974/143	A/G	25,55	28,29	22,13	22,7
99-26150/276	A/G	46,54	51,43	40,83	47,76
99-15258/337	G/T	25,55	26,97	23,77	24,1
99-15261/202	A/G	63,06	59,46	67,5	65,15
99-15256/392	C/T	64,96	61,33	69,35	65,3
99-15056/99	C/T	32,72	36,49	28,23	31,11
99-15280/432	C/T	42,28	44	40,16	38,97
99-15355/150	C/T	72,3	70,39	74,6	68,79
99-15253/382	C/T	63,04	62,67	63,49	62,95
99-5873/159	C/T	78,1	79,05	76,98	77,34

### Haplotype frequency analysis

Analysis of markers Haplotype analysis for association of chromosome 13q31-q33-related biallelic markers and schizophrenia was performed by estimating the frequencies of all possible 2, 3 and 4 marker haplotypes in the affected and control populations described above. Haplotype estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier and Slatkin, 1995), using the EM-HAPLO program (Hawley et al., 1994) as described above. Estimated haplotype frequencies in the affected and control population were compared by means of a chi-square statistical test (one degree of freedom).

### Haplotype association results in schizophrenia cases

Haplotype studies yielded significant results indicating an association of the nucleotide sequences of the invention with schizophrenia. Significant results are shown in Figures 5 and 6,

including descriptions of the frequency of the haplotype leading to the maximum chi square test (reference no. (1) in figures), the test of the frequency of a particular haplotype in cases vs in controls (reference no. (2) in figures) and the p- value assuming that the test has a chi-square distribution with 1 degree of freedom (ddl) (reference no. (3) in figures). The results of the haplotype analysis using 28 preferred biallelic markers of the invention, 99-24656-260 (A5), 99-24639-163 (A6), 99-24634-108 (A7), 99-7652-162 (A8), 99-16100-147 (A9), 99-5862-167 (A10), 99-5919-215 (A11), 99-24658-410 (A12), 99-24644-194 (A19), 99-5897-143 (A47), 99-24649-186 (A48), 99-16038-118 (A56), 99-15880-162 (A58), 99-25940-182 (A64), 99-16032-292 (A9), 99-16033-244 (A67), 99-15875-165 (A68), 99-16047-115 (A70), 99-25950-121 (A105), 99-25961-376 (A106), 99-25965-399 (A103), 99-25966-241 (A108), 99-25969-200 (A110), 99-25974-143 (A112), 99-25977-311 (A113), 99-25979-93 (A114), 99-25989-398 (A116), and 99-26150-276 (A118) are shown in Figures 5 and 6. Figures 5 and 6 also show the physical order of the biallelic markers comprising the haplotypes.

Figure 5 shows the results of the haplotype analysis using the following biallelic markers located on the approximately 319kb sequence of SEQ ID No. 1: 99-24656-260 (A5), 99-24639-163 (A6), 99-24634-108 (A7), 99-7652-162 (A8), 99-16100-147 (A9), 99-5862-167 (A10), 99-5919-215 (A11), 99-24658-410 (A12), 99-24644-194 (A19), 99-5897-143 (A47), 99-24649-186 (A48), 99-16038-118 (A56), 99-15880-162 (A58), 99-25940-182 (A64), 99-16032-292 (A65), 99-16033-244 (A67), 99-15875-165 (A68), and 99-16047-115 (A70).

Figure 6 shows the results of the haplotype analysis using the following biallelic markers located on the approximately 319kb of SEQ ID No. 1 as well as additional biallelic markers located on the human chromosome 13q31-q33 locus: 99-16038-118 (A56), 99-15880-162 (A58), 99-25940-182 (A64), 99-16032-292 (A65), 99-16033-244 (A67), 99-15875-165 (A68), 99-16047-115 (A70), 99-25950-121 (A105), 99-25961-376 (A106), 99-25965-399 (A102), 99-25966-241 (A108), 99-25969-200 (A110), 99-25974-143 (A112), 99-25977-311 (A113), 99-25979-93 (A114), 99-25989-398 (A116), and 99-26150-276 (A119).

A number of biallelic marker haplotypes were shown to be significantly associated with schizophrenia.

Several preferred haplotype all showing highly significant association with schizophrenia and including various 2-, 3- and 4- marker haplotypes are haplotypes 817, 818 and 819, 137, 138, 1 and 2 of Figure 6, and haplotypes 970, 154 and 1 of Figure 5. The p-values, odd-ratios and estimated haplotype frequencies are further described in Figures 5 and 6. In particular, the two marker haplotype 1 of Figure 5 consisting of biallelic markers 99-5862-167 (A10) and 99-15875-165 (A68) showed a highly significant p-value of  $7.8 \times 10^{-5}$  and an odd-ratio of 1.61. Haplotype 818 of Figure 6 consisting of four biallelic markers (99-16032-292



(A65), 99-25969-200 (A110), 99-25977-311 (A113), and 99-25989-398 (A116)) presented a p-value of  $3.1 \times 10^{-7}$  and an odd-ratio of 9.08. Another example showing significance is haplotype 817 of Figure 6-consisting of four biallelic markers (99-16033-244 (A67), 99-15875-165 (A68), 99-25950-121 (A105) and 99-25979-93 (A114)), presented a p-value of  $2.4 \times 10^{-7}$  and an odd-ratio of 100. Phenotypic permutation tests confirmed the statistical significance of these results. Estimated haplotype frequencies were 10.5% in cases and 0 % in the controls. Haplotype 970 of Figure 5 consisting of four biallelic markers (99-5919-215 (A11), 99-24658-410 (A12), 99-15875-165 (A68), and 99-16047-115 (A10)) presented a p-value of  $7.8 \times 10^{-7}$  and an odd-ratio of 2.41. Phenotypic permutation tests confirmed the statistical significance of these results. Estimated haplotype frequencies were 25.7% in cases and 12.5 % in the controls.

Several other significant haplotypes are listed in Figures 5 and 6, including several 2-, 3- and 4-marker haplotypes. Considered to be highly significantly associated with schizophrenia are the most significant 2-marker haplotypes (for example haplotype 1 of Figure 5 noted above and the most significant 3-marker haplotypes (for example haplotype 137 of Figure 6 consisting of biallelic markers (99-15875-165 (A68), 99-16047-115 (A70) and 99-25950-121 (A105)).

Further preferred significant haplotypes considered associated with schizophrenia are haplotypes having p-values above a desired threshold level; all the haplotypes listed in Figures 5 and 6 present p-values below  $1.0 \times 10^{-2}$  for 2-marker haplotypes,  $1.0 \times 10^{-4}$  for 3-marker haplotypes, and  $1.0 \times 10^{-5}$  for 4-marker haplotypes. Figures 5 and 6 show several 2-marker haplotypes, haplotypes 1 to 9 and haplotypes 1 to 5 of Figures 5 and 6 respectively, having p-values ranging from  $7.8 \times 10^{-5}$  to  $8.6 \times 10^{-3}$ , several 3-marker haplotypes, haplotypes 154 to 163 and 137 to 141 of Figures 5 and 6 respectively, having p-values ranging from  $3.9 \times 10^{-6}$  to  $1.1 \times 10^{-4}$  and several 4-marker haplotypes, haplotypes 970 to 973 and 817 to 836 of Figures 5 and 6 respectively, having p-values ranging from  $2.4 \times 10^{-7}$  to  $7.3 \times 10^{-6}$ .

Additionally, a particularly large number of the significant 2-, 3- and 4-marker haplotypes often comprised the biallelic markers A65, A12, A67, A70, A107, A110, A116 and most commonly A68 (99-15875-165), allele T.

The statistical significance of the results obtained for the haplotype analysis was evaluated by a phenotypic permutation test reiterated 100 times on a computer. For this computer simulation, data from the affected and control individuals were pooled and randomly allocated to two groups which contained the same number of individuals as the case-control populations used to produce the data summarized in figures 5 and 6. A haplotype analysis was then run on these artificial groups for the markers included in the haplotypes showing strong

association with schizophrenia. This experiment was reiterated 100 times and the results are shown in the columns of Figures 5 and 6 labelled "Haplotype test by permutation procedure". For a given haplotype, these results demonstrate the number of obtained (simulated) haplotypes having a p-value comparable to the one obtained for the given haplotype among 100 iterations. These results, set forth in Figures 5 and 6 validate the statistical significance of the association between the haplotypes and schizophrenia.

#### Example 5c

#### Association Study Between Schizophrenia and the Biallelic Markers of the Invention in French Canadian Samples

##### Collection Of DNA Samples From Affected And Non-Affected Individuals

Biallelic markers of the present invention were further genotyped in French Canadian samples as described above in order to compare the association of the 1st and the 2nd portion of Region D with schizophrenia. The population used in the study was the same as described above with the exception that 2 male FH+ cases were not included.

The biallelic markers analyzed in the study include 34 preferred biallelic markers of the invention located in Region D of the chromosome 13q31-33 region. Included in the analysis were the 14 following biallelic markers from the first of two portions of Region D: 99-26150/276 (A118), 99-26156/290 (A120), 99-26153/44 (A119), 99-25985/194 (A115), 99-25974/143 (A112), 99-25977/311 (A114), 99-25972/317 (A111), 99-25965/399 (A107), 99-25961/376 (A106), 99-25966/241 (A108), 25967/57 (A109), 99-25969/200 (A110), 99-25979/93 (A114) and 99-25989/398 (A116). Included in the analysis were also the 20 following biallelic markers from the second of two portions of Region D: 99-25993/367 (A71), 99-16047/115 (A70), 99-15875/165 (A68), 99-16033/244 (A67), 99-16032/292 (A65), 99-25940/182 (A64), 99-15880/162 (A58), 99-16038/118 (A56), 99-15870/400 (A53), 99-24649/186 (A48), 99-5897/143 (A47), 99-24644/194 (A19), 99-24658/410 (A12), 99-5919/215 (A11), 99-5862/167 (A10), 99-16100/147 (A9), 99-7652/162 (A8), 99-24634/108 (A7), 99-24639/163 (A6) and 99-24656/260 (A5).

##### Single biallelic marker association results in schizophrenia cases

Single biallelic marker studies yielded significant results, indicating an association of the nucleotide sequences of the invention with schizophrenia. Biallelic markers used in the analysis included the set of 34 biallelic markers shown in Table 11 below, 14 biallelic markers of which were located on the first of two portions of Region D, and 20 of which were located on the second portion. The distribution of markers is shown in Table 12 below. As summarized in Table 13, analyses using these biallelic markers demonstrated a significant association with schizophrenia for 5 markers on the second portion of Region D.

Table 11

REGION	CONTIG	SNPS GENOTYPED	POLYMORPHISM	FREQUENCY IN CONTROLS
D	1 <sup>st</sup> portion	99-26150/276	A/G	50
		99-26156/290	A/C	69
		99-26153/44	A/C	61
		99-25985/194	C/T	29
		99-25974/143	A/G	25
		99-25977/311	A/G	73
		99-25972/317	C/T	72
		99-25965/399	A/G	49
		99-25961/376	A/C	40
		99-25966/241	A/G	63
		99-25967/57	A/G	43
		99-25969/200	G/T	40
		99-25979/93	A/G	72
		99-25989/398	A/G	29
	2 <sup>nd</sup> portion	99-25993/367	A/G	44
		99-16047/115	C/T	73
		99-15875/165	C/T	63
		99-16033/244	C/T	54
		99-16032/292	A/C	58
		99-25940/182	A/G	53
		99-15880/162	A/G	58
		99-16038/118	A/G	42
		99-15870/400	A/G	33
		99-24649/186	C/T	65
		99-5897/143	A/C	59
		99-24644/194	A/G	39
		99-24658/410	C/T	58
		99-5919/215	A/G	60
		99-5862/167	C/T	51
		99-16100/147	A/G	50
		99-7652/162	A/G	52
		99-24634/108	A/T	53
		99-24639/163	G/T	44
		99-24656/260	A/G	54

Table 12

Region	No. of Biallelic markers ( $\sigma$ )	Mean frequency ( $\sigma$ )	Mean inter-marker distance ( $\sigma$ )
D 1 <sup>st</sup> half	14 (14)	0.34 (0.07)	7 (6.3)
D 2 <sup>nd</sup> half	20 (8)	0.42 (0.06)	11 (13)
D 1 <sup>st</sup> and 2 <sup>nd</sup> half	34 (22)	0.39 (0.07)	10.3 (11)

Analysis of markers Haplotype analysis for association of chromosome 13q31-q33-related biallelic markers and schizophrenia was performed by estimating the frequencies of all possible 2, 3 and 4 marker haplotypes in the affected and control populations described above. Haplotype estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier and Slatkin, 1995), using the EM-HAPLO program (Hawley et al., 1994) as described above.

#### Haplotype association results in schizophrenia cases

Significant results were also obtained in haplotype studies indicating an association of the nucleotide sequences of the invention with schizophrenia.

The present inventors having previously demonstrated highly significant association of biallelic markers located on the Region D subregion of the human chromosome 13q31-q33 locus with disease. Using the Omnibus LR test which compares the profile of haplotype frequencies, and Haplo-maxM test which is based on haplotype differences for each haplotype in two groups, Figures 7 and 8 describe the results of an analysis of the first and second portions of Region D which demonstrated an association of the second portion of Region D with schizophrenia.

For combinations of 2 and 3 biallelic markers, one likelihood ratio test is obtained based on the haplotype frequency values calculated using the E-M algorithm. A permutation procedure was used, where data from the affected and control individuals was pooled and randomly allocated to two groups which contained the same number of individuals as the case-control populations used to produce the data. A haplotype analysis was then run on these artificial groups for the markers included in the haplotypes showing strong association with schizophrenia. This experiment was reiterated 100 times. For a given haplotype, these results demonstrate the number of obtained (simulated) haplotypes having a p-value comparable to the one obtained for the given haplotype among 100 iterations.

Figure 7 shows a comparison of the LR test value distributions of haplotype frequencies in the two portions of Region D. This association of the second portion of Region D with schizophrenia is shown using both 2-marker and 3-marker combinations. The distribution of LR test values in the different regions was analyzed using a Kruskal-Wallis rank test, a chi-square test with  $r-1$  degrees of freedom, where  $r$  represents the number of value sets compared. As shown, the significance of the association is demonstrated by a chi-square value (one degree of freedom) of 74.405 and a p-value of less than  $1 \times 10^{-10}$  for 2 marker combinations, and a chi-square value (one degree of freedom) of 228.72 and a p-value of  $1 \times 10^{-10}$  for 3- marker combinations.

Another association analysis approach based on haplotype frequency differences, referred to as the Haplo-maxM test, was conducted using region D biallelic markers. For one combination of markers having  $h$  haplotypes,  $h$  differences of haplotype frequencies can be compared via a Pearson chi-square statistic (one degree of freedom). The haplo-max test selects the difference showing the maximum positive test value between cases versus controls (rejecting test values based on rare haplotype frequencies, i.e., with an estimated number of haplotypes inferior to 10); for one combination of markers there is therefore one Max-M test value. The results of the Haplo-maxM test using Region D biallelic markers are shown in Figure 8.

Figure 8 shows the distribution of haplo-maxM test values obtained for both 2-marker and 3-marker combinations in the two portions of Region D, demonstrating an association of the second portion of Region D with schizophrenia. The comparison of the distribution of Haplo-maxM test values on the two regions was analyzed using a Kruskal-Wallis rank test, a chi-square test with  $r-1$  degrees of freedom, where  $r$  represents the number of value sets compared. As shown, the significance of the association is demonstrated by a chi-square value (one degree of freedom) of 34.839 and a p-value of less than  $3.58 \times 10^{-9}$  for 2 marker combinations, and a chi-square value (one degree of freedom) of 13.773 and a p-value of  $2.6 \times 10^{-4}$  for 3- marker combinations.

The results from the haplo-maxM tests further confirms the association shown using the Omnibus LR test results.

Results of association studies discussed above using biallelic markers of the invention are further summarized in Table 13 below, showing a significant association of the biallelic markers with schizophrenia in both single biallelic marker and haplotype analysis.

Table 13

	Single-point Analysis		Multi-point analysis (Haplotype-based analysis)		
	No. of allelic freq differences > 10%	No. Significant allelic tests	Omnibus LR TEST *		
			2-mks	3-mks	4-mks
Region D, 1st portion	0	0	0,03	0,05	0,06
Region D, 2nd portion	0	5	0,30	0,30	0,31

\* percentage of significant tests (5% level of significance)  
Cases (N=213) / Controls (N=241)

#### Example 5d

#### Association Study Between Bipolar Disorder and the Biallelic Markers of the Invention

**Description of study design**

Biallelic markers of the invention were analyzed in bipolar disorder cases. As in examples above, single and multi-point analyses showed a significant association of the markers of the invention, of Region D of the chromosome 13q33 locus, and more particularly of a sub-region of Region D with bipolar disorder.

**A) Description of the Affected population**

All the samples were collected from a study of bipolar disorder undertaken in a hospital located south of Buenos Aires, Argentina, generally representing a population estimated at about 400,000 inhabitants. Patients were evaluated by four doctors in 1994 and 1995. The study design involved in the ascertainment of cases and their first degree relatives (parents or siblings). 514 individuals were available for the study. This group consisted of 158 subjects from 51 different families, and 356 independent subjects.

As a whole, bipolar disorder cases were ascertained according to the diagnosis of bipolar disorder established by the DSM-IV (Diagnostic and Statistical Manual, Fourth edition, Revised 1994, American Psychiatric Press);

Available for consideration for each coded case were also age, sex, nationality of parents and grand parents, ethnic origin, familial composition, marital state, socio-economic level, educational level, professional situation, employment, recreational activities, age of onset of psychiatric symptoms, age of first consultation, occurrences of obstetric or prenatal incidents, suicide attempts, other medical conditions, treatment for or occurrence of a neurological condition, familial occurrence of symptoms, previous or concurrent use of psychotropic drugs, other admissions to a hospital or medical treatments, and diagnostic reason for admission including (a) DSM-IV diagnosis and (b) symptoms first presented on admission to hospital.

Available for study were 226 bipolar disorder ascertained cases of which 203 were independent cases. This group consisted of 51 cases from 51 families, 20 cases in relatives thereof, and 155 independent cases. Upon elimination of 3 cases from the initial independent 155 cases due to discovery of a familial relation, the total number of independent cases was 203.

Cases were classified according to bipolar disorder type. The cases included 115 bipolar disorder type I individuals (including 1 rapid cycling case), 67 bipolar disorder type II individuals (including 1 rapid cycling case), 18 unclassified bipolar disorder cases, and 3 cases which remained unclassified due to lack of or inconsistent information.

The 203 independent cases were examined for a familial history of psychosis. 53 of these cases reported an occurrence of psychosis (characterized as schizophrenia or bipolar disorder) among first degree relatives (father, mother, brothers, sisters or children).

**B) Description of the Unaffected population**

Available for study were 201 controls which had not been affected by any psychiatric difficulties or reported any familial history of psychiatric difficulties. Available for consideration were also age, sex and ethnic origin of the unaffected population.

5

**C) Case and Control Populations Selected for the Association Study**

For the association study, the case population under study consisted of 201 individuals selected from the 226 total cases above; the control population consisted of 198 individuals selected from the 201 controls described above.

10

The association data that are presented in the Example 5d below were obtained on a population size detailed in Table 14 below.

**Table 14**

Cases and Control Populations Selected for the Association Study			
Sample type		Cases	Controls
Sample size		201	198
Gender			
	Male	68	81
	Female	124	117
	Missing	9	
Ethnic origin			
	Caucasian	182	177
	Non caucasian	5	21
	Missing	14	
Familial history of psychosis (FH)*			
	positive (FH+)	54	0
	none (FH-)	147	198
* : close relatives (first degree)			

Both case and control populations form two groups, each group consisting of unrelated individuals that do not share a known common ancestor.

15

**Genotyping of affected and control individuals**

The general strategy was to individually scan the DNA samples from all individuals in each of the populations described above in order to establish the allele frequencies of biallelic markers, and among them the biallelic markers of the invention, in the diploid genome of the tested individuals belonging to each of these populations.

20

Allelic frequencies of every biallelic marker in each population (cases and controls) were determined by performing microsequencing reactions on amplified fragments obtained by

genomic PCR performed on the DNA samples from each individual. Genomic PCR and microsequencing were performed as detailed above in Examples 1 to 4 using the described PCR and microsequencing primers.

#### Association analysis

5 The association analysis included 30 preferred biallelic markers of the invention located in Region D of the chromosome 13q31-33 region. Included in the analysis were the 14 following biallelic markers from the first of two subjective portions of Region D: 99-26150/276 (A118), 99-26156/290 (A120), 99-26153/44 (A119), 99-25985/194 (A115), 99-25974/143 (A112), 99-25977/311 (A113), 99-25972/317 (A111), 99-25965/399 (A107), 99-25961/376 (A106), 99-25966/241 (A108), 25967/57 (A109), 99-25969/200 (A110), 99-25979/93 (A114) and 99-25989/398 (A116). Included in the analysis were also the 16 following biallelic markers from the second of two portions of Region D: 99-25993/367 (A71), 99-16047/115 (A70), 99-15875/165 (A68), 99-16033/244 (A67), 99-16032/292 (A66), 99-25940/182 (A65), 99-15880/162 (A58), 99-16038/118 (A56), 99-15870/400 (A53), 99-24649/186 (A48), 99-5897/143 (A47), 99-24644/194 (A19), 99-5919/215 (A11), 99-5862/167 (A10), 99-16100/147 (A9), and 99-7652/162 (A8).

#### A) Single biallelic marker association results in bipolar disorder cases

For each allele of the biallelic markers included in this study, the difference between the allelic frequency in the unaffected population and in the population affected by bipolar disorder was calculated and the absolute value of the difference was determined. The set of biallelic markers and their allelic frequencies included in this study are set forth in Table 15. The more the difference in allelic frequency for a particular biallelic marker or a particular set of biallelic markers, the more probable an association between the genomic region harboring this particular biallelic marker or set of biallelic markers and bipolar disorder. Allelic frequencies were also useful to check that the markers used in the haplotype studies meet the Hardy-Weinberg proportions (under random mating assumptions)

Table 15

REGION	CONTIG	POSITION ON CONTIG	SNPS GENOTYPED	POLYMORPHISM	FREQUENCY IN CONTROLS
		168,02	99-26150/276	A/G	62,93
		173,29	99-26156/290	A/C	72,42
		177,01	99-26153/44	A/C	52,66
		186,41	99-25985/194	C/T	28,87
		190,15	99-25974/143	A/G	31,79
		216,43	99-25977/311	A/G	63,82

Region D  
first Half



	224,62	99-25972/317	C/T	72,32
	236,64	99-25965/399	A/G	58,24
	244,82	99-25961/376	A/C	44,35
	254,70	99-25966/241	A/G	66,18
	257,85	99-25967/57	A/G	42,44
	261,23	99-25969/200	G/T	35,76
	263,67	99-25979/93	A/G	67,15
	269,39	99-25989/398	A/G	35,88
	299,02	99-25993/367	A/G	47,38
	303,04	99-16047/115	C/T	69,01
	335,02	99-15875/165	C/T	61,3
	354,81	99-16033/244	C/T	50,3
	366,51	99-16032/292	A/C	62,87
	367,14	99-25940/182	A/G	54,39
	372,98	99-15880/162	A/G	62,72
	375,28	99-16038/118	A/G	37,29
	383,41	99-15870/400	A/G	29,65
	394,16	99-24649/186	C/T	66,57
	395,27	99-5897/143	A/C	52,6
	409,93	99-24644/194	A/G	38,29
	424,95	99-5919/215	A/G	60,63
	441,62	99-5862/167	C/T	46,53
	444,00	99-16100/147	A/G	48,84
	445,84	99-7652/162	A/G	49,7
<b>TOTAL</b>		<b>30</b>		

(1) : frequency (%) in caucasian controls (N=177) of the first allele (alphabetic order)

Region D was arbitrarily split in two halves (D 1<sup>st</sup> half and D 2<sup>nd</sup> half) for purpose of the analysis.

5

The present inventors have previously demonstrated significant association of biallelic markers located on the Region D subregion of the human chromosome 13q31-33 region with disease. Using a set of 30 biallelic markers shown in Table 15, D 1<sup>st</sup> half contained 14 markers and D 2<sup>nd</sup> half contained 16 markers.

10

Table 15 also shows the physical order of the biallelic markers on Region D of the human chromosome 13q31-q33 region. The mean intermarker distances of the biallelic markers on the first and the second subjective portions of Region D were as listed below in Table 16.

**Table 16**

Region	Mean Inter-marker distance (std)
D 1 <sup>st</sup> half	7.80(6.33)
D 2 <sup>nd</sup> half	9.79 (8.78)
D 1 <sup>st</sup> and 2 <sup>nd</sup> half	9.58 (8.46)

The analysis using selected Region D biallelic markers of the invention demonstrated a significant association with bipolar disorder for the second portion of Region D. The analysis was conducted using the sample population described above with 182 caucasian cases and 177 caucasian controls selected from the total case and control group.

One biallelic marker in particular, 99-15875/165(A68), located on the second half of Region D, demonstrated a significant association with disease at a significance level of better than 5% (corresponding to an absolute logarithm (p-value) of 1.3).

#### **B) Haplotype association results in bipolar disorder cases**

Haplotype analysis for association of chromosome 13q31-q33-related biallelic markers and bipolar disorder was performed by estimating the frequencies of all possible 2, 3 and 4 marker haplotypes in the affected and control populations described above. Haplotype frequencies estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier and Slatkin, 1995), modified by Nicholas Schork.

Significant results were obtained in haplotype studies indicating an association of the nucleotide sequences of the invention with bipolar disorder. The haplotype analysis as shown in the Figures 9A, 9B, 10A, 10B, 11A and 11B was conducted using the sample population described above, using 182 caucasian cases and 177 caucasian controls selected from the total case and control group.

Using the Omnibus LR test which compares the profile of haplotype frequencies, and Haplo-maxM test which is based on haplotype frequencies differences for each haplotype in two groups, Figures 9A, 9B, 10A, 10B, 11A and 11B show the results of a comparison of the first and second portions of Region D which demonstrated an association of the second portion of Region D with bipolar disorder.

#### **a - Omnibus LR tests values**

For a given combination of 2, 3 or 4 biallelic markers, one likelihood ratio test (LR test) is obtained based on the haplotype frequencies values calculated using the E-M algorithm.

Figures 9A and 9B show a comparison of the LR test value distributions of haplotype frequencies in the two portions of Region D. This association of the second portion of Region

D with bipolar disorder is shown using both 2-marker and 3-marker combinations. A Kruskal Wallis rank test was used to compare LR test values distributions in the two subjective portions of Region D. This test has an asymptotic Chi-square distribution, under the null hypothesis of no difference between the sets compared, with  $(r-1)$  degrees of freedom, where  $r$  represents the number of sets compared. Here, we compare the 2 portions of region D, so  $r=2$ , and the asymptotic Chi-square distribution has 1 degree of freedom. As shown, the significance of the association is demonstrated by a chi-square value (one degree of freedom) of 46.62 and a p-value of  $8.62 \times 10^{-12}$  for 2 marker combinations, and a chi-square value (one degree of freedom) of 124.72 and a p-value of  $5.86 \times 10^{-29}$  for 3- marker combinations.

#### 10      **b - Haplo-max tests values**

Another association analysis approach based on haplotype frequencies differences, referred to as the Haplo-max test, was conducted using region D biallelic markers. The haplo-max test selects the difference showing the maximum positive (maxM) or negative (maxS) test value between cases versus controls (rejecting test values based on rare haplotype frequencies, i.e, with an estimated number of haplotypes carriers inferior to 10) ; for one combination of markers there is therefore one Max-M and one Max-S test values.

Figures 10A and 10B show the distribution of haplo-maxM test values obtained for both 2-marker and 3-marker combinations in the two portions of Region D, demonstrating an association of the second portion of Region D with bipolar disorder. The comparison of the distribution of Haplo-maxM test values in the two regions was analyzed using a Kruskal-Wallis rank test, a chi-square test with 1 degree of freedom. As shown, the significance of the association is demonstrated by a chi-square value of 29.07 and a p-value  $6.98 \times 10^{-8}$  for 2 marker combinations, and a chi-square value of 98.63 and a p-value of  $3.04 \times 10^{-23}$  for 3- marker combinations.

Figures 11A and 11B show the distribution of Haplo-maxS test values again obtained for all 2-marker and 3-marker combinations in the two portions of Region D, demonstrating an association of the second portion of Region D with bipolar disorder. The comparison of the distributions of Haplo-maxS test values in the two portions was analyzed using a Kruskal-Wallis rank test with one degree of freedom. As shown, the significance of the association is demonstrated by a chi-square value of 34.6 and a p-value of  $4.05 \times 10^{-9}$  for 2 marker combinations, and a chi-square value of 98.31 and a p-value of  $3.58 \times 10^{-23}$  for 3- marker combinations.

The results from the haplo-maxM and haplo-maxS tests thus further confirm the

association shown using the Omnibus LR test results.

### Example 5e

#### Identification of Common Haplotypes in Three Schizophrenia Populations

5

Based on the results above indicating an association of biallelic markers located in Region D3 with schizophrenia, further biallelic markers in Region D3 were screened in three different populations of schizophrenia cases and controls. The D3 region is an approximately 150kb genomic region containing the g35030 gene.

10

Several significant haplotypes comprised of markers in or flanking the g35030 gene and common to the three populations were identified. These haplotypes demonstrated significance in Omnibus LR and individual haplotype frequency tests. Furthermore, the estimated frequencies of the haplotypes were highly similar for each of the different populations.

15

The samples used were obtained from a French Canadian population, an Eastern European population, and a United States sample. The French Canadian schizophrenia sample is described above in Example 5a, and Tables 7 and 8. The United States schizophrenia sample is described in Table 17 below. The Eastern European sample, is described in Table 18 below.

Table 17

United States Schizophrenia Cases and Control Populations (United States Caucasians)			
Sample type		Cases	Random US Controls
Sample size		131	188
Ethnic origin			
	European Caucasians (26 female, 66 male)	92	
	Ashkenazi caucasians (7 female, 17 female)	24	
	Other Caucasians (7 female, 8 male)	15	
Familial history of psychosis (FH)			
	positive (FH+)	133	
	none (FH-)	147	198

20

Table 18

Eastern European (Rogaev) Schizophrenia Cases and Control Populations			
Sample type		Cases	Controls
Sample size		183	183
Ethnic origin: European Causasians (97 female, 86 male)			
Familial history of psychosis (FH)			
	positive (FH+)	55	
	none (FH-)	128	

For each of the three populations, multipoint analyses were carried out using biallelic markers from the D3 region. The haplotypic frequency differences between case and controls was examined, reported as MaxM for the maximum positive difference, and MaxS as the maximum negative difference, and the profile of haplotype frequency differences, where the distribution of haplotype frequency differences is described using the Omnibus LR test.

Several significant two-marker haplotypes were found to be in common among the three populations. One haplotype, referred to haplotype 2, is described further in Tables 19 and 20. Other haplotypes are comprised of biallelic markers which are in linkage disequilibrium with one of the biallelic markers of haplotype 2, and thus also provide significant results. Biallelic markers 99-15875-165 (A68) (allele T) and 99-5862-167, involved in haplotype 2, demonstrated a range of estimation of haplotype frequencies of 23.6 to 24.5 in cases, and 15.5 to 17.6 in controls. Again, similar differences in frequency estimates were seen with other haplotypes. Markers 99-15875-165 (A68) (allele T) and 99-5862-167 are located in or flanking the g35030 gene.

Table 19 shows the results of analysis of estimated haplotype frequencies for haplotype 2, comprising biallelic markers 99-15875-165 (A68) (allele T) and 99-5862-167 (A10) (allele T). Presented are the results of a likelihood ratio test (LR test), demonstrating a significant p-value in each of the three populations; the results of the LR test on which a permutation procedure has been carried out (Omnibus), demonstrating a significant p-value of  $5 \times 10^{-3}$  for French Canadian samples,  $8 \times 10^{-2}$  for Eastern European (Rogaev) samples, and  $1 \times 10^{-2}$  for U.S. samples; and the estimated haplotype frequencies in cases and controls, and their positive or negative difference (MaxM). Notably, the haplotype frequencies in the three populations are highly similar at 23.60, 23.90 and 24.50 for cases and 15.5, 17.6 and 15.5 for controls.

Table 19

HAP2: 99-15875/165 (T), 99-5862/167 (T)							
POP	haplotype	Pvalue-hap	Omnibus (1000 perm)	freq cas	freq controls	Difference	
French Canadian	TT LD Normalized:-0.16 )	2,20E-03	5,00E-03	23,60	15,5	8,10	axM
Eastern European		4,60E-02	8,70E-02	23,90	17,6	6,3	axM
U.S.		8,60E-03	1,30E-02	24,50	15,5	9	axM

5

**Example 6****Preparation of Antibody Compositions to the g35030 protein**

Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the g35030 protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

10

**A. Monoclonal Antibody Production by Hybridoma Fusion**

15

Monoclonal antibody to epitopes in the g35030 protein or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., Nature 256:495 (1975) or derivative methods thereof. Also see Harlow, E., and D. Lane. 1988. Antibodies A Laboratory Manual. Cold Spring Harbor Laboratory. pp. 53-242.

20

Briefly, a mouse is repetitively inoculated with a few micrograms of the g35030 protein or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant

fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2.

#### B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogeneous epitopes in the g35030 protein or a portion thereof can be prepared by immunizing suitable non-human animal with the g35030 protein or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable non-human animal is preferably a non-human mammal is selected, usually a mouse, rat, rabbit, goat, or horse. Alternatively, a crude preparation which has been enriched for g35030 concentration can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e.g. aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent which will increase antigenicity, such agents are known in the art and include, for example, methylated bovine serum albumin (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987). An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12  $\mu$ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

The disclosures of all issued patents, published PCT applications, scientific references or other publications cited herein are incorporated herein by reference in their entireties.

Although this invention has been described in terms of certain preferred embodiments, other embodiments which will be apparent to those of ordinary skill in the art of view of the disclosure herein are also within the scope of this invention. Accordingly, the scope of the invention is intended to be defined only by reference to the appended claims.

15



**Sequence listing free text**

The following free text appears in the accompanying Sequence Listing:

	schizophrenia
5	associated
	proteins
	biallelic
	markers
	regulatory
10	region
	gene
	exon
	complement
	polymorphic base
15	or
	allele
	deletion
	of
	basic
20	protease
	cleavage
	site
	probe
	primer
25	downstream
	upstream
	amplification
	sequencing
	oligonucleotide

The disclosures of the following references are incorporated herein by reference in their entireties:

- Abbondanzo S.J. et al. (1993) *Methods in Enzymology*, Academic Press, New York. pp. 803-823.
- 5 Ajioka R.S. et al. (1997) *Am. J. Hum. Genet.* 60:1439-1447.
- Altschul et al., 1990, *J. Mol. Biol.* 215(3):403-410;
- Altschul et al., 1993, *Nature Genetics* 3:266-272
- Altschul et al., 1997, *Nuc. Acids Res.* 25:3389-3402
- Ames, R.S. et al. *J. Immunol. Methods* 184:177-186(1995)
- 10 Anton M. et al., 1995, *J. Virol.*, 69: 4600-4606.
- Araki K et al. (1995) *Proc. Natl. Acad. Sci. US A.* 92(1):160-4.
- Ashkenazi, A. et al. *PNAS* 88:10535-10539(1991)
- Ausubel et al. (1989) *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Interscience, N.Y.
- 15 Bartunek, P. et al. *Cytokine* 8(1):14-20 (1996)
- Baubonis W. (1993) *Nucleic Acids Res.* 21(9):2025-9.
- Beaucage et al., *Tetrahedron Lett* 1981, 22: 1859-1862
- Better, M. et al. *Science* 240:1041-1043(1988)
- Bradley A., (1987) *Production and analysis of chimaeric mice.* In: E.J. Robertson (Ed.),
- 20 *Teratocarcinomas and embryonic stem cells: A practical approach.* IRL Press, Oxford, pp. 113.
- Brinkman U. et al. *J. Immunol. Methods* 182:41-50(1995)
- Brown EL, Belagaje R, Ryan MJ, Khorana HG, *Methods Enzymol* 1979;68:109-151
- Brutlag et al. *Comp. App. Biosci.* 6:237-245, 1990
- Burton, D.R. et al. *Advances in Immunology* 57:191-280(1994)
- 25 Carlson, N.G. et al. *J. Biol. Chem.* 272(17):11295-11301(1997)
- Chai H. et al. (1993) *Biotechnol. Appl. Biochem.* 18:259-273.
- Chee et al. (1996) *Science.* 274:610-614.
- Chen and Kwok *Nucleic Acids Research* 25:347-353 1997
- Chen et al. (1987) *Mol. Cell. Biol.* 7:2745-2752.
- 30 Chen et al., 1987, *Mol. Cell. Biol.*, 7: 2745-2752.
- Chen, Z. et al. *Cancer Res.* 58(16): 3668-3678(1998)
- Chou J.Y. (1989) *Mol. Endocrinol.* 3:1511-1514.
- Clark A.G. (1990) *Mol. Biol. Evol.* 7:111-122.
- Coles et al. *Hum. Mol. Genet.*, 7:791-800, 1998
- 35 Compton J. (1991) *Nature.* 350(6313):91-92.

- Davis et al., Basic Methods in Molecular Biology, ed., Elsevier Press, NY, 1986
- Dempster et al., (1977) J.R. Stat. Soc., 39B:1-38.
- Deng, B. et al. Blood 92(6): 1981-1988(1998)
- Dent D.S. and Latchman D.S. (1993) The DNA mobility shift assay. In: Transcription Factors: A Practical Approach (Latchman DS, ed.) Oxford: IRL Press. pp1-26.
- 5 Eckner R. et al. (1991) EMBO J. 10:3513-3522.
- Excoffier L. and Slatkin M. (1995) Mol. Biol. Evol., 12(5): 921-927.
- Feldman and Steg, 1996, Medecine Sciences, synthese, 12:47-55
- Fell, H.P. et al. J. Immunol. 146:2446-2452(1991)
- 10 Flotte et al. (1992) Am. J. Respir. Cell Mol. Biol. 7:349-356.
- Fodor et al. (1991) Science 251:767-777.
- Fraleigh et al. (1979) Proc. Natl. Acad. Sci. USA. 76:3348-3352.
- Fried M. and Crothers D.M. (1981) Nucleic Acids Res. 9:6505-6525.
- Fuller S. A. et al. (1996) Immunology in Current Protocols in Molecular Biology, Ausubel et al. Eds, John Wiley & Sons, Inc., USA.
- 15 Furth P.A. et al. (1994) Proc. Natl. Acad. Sci. USA. 91:9302-9306.
- Garner M.M. and Revzin A. (1981) Nucleic Acids Res. 9:3047-3060.
- Geysen H. Mario et al. 1984. Proc. Natl. Acad. Sci. U.S.A. 81:3998-4002
- Ghosh and Bacchawat (1991) Targeting of liposomes to hepatocytes, IN: Liver Diseases, Targeted diagnosis and therapy using specific receptors and ligands. Wu et al. Eds., Marcel Dekker, New York, pp. 87-104.
- 20 Gillies, S.D. et al. J. Immunol. Methods 125:191-202(1989)
- Gillies, S.O. et al. PNAS 89:1428-1432(1992)
- Gonnet et al., 1992, Science 256:1443-1445;
- 25 Gopal (1985) Mol. Cell. Biol., 5:1188-1190.
- Gossen M. et al. (1992) Proc. Natl. Acad. Sci. USA. 89:5547-5551.
- Gossen M. et al. (1995) Science. 268:1766-1769.
- Graham et al. (1973) Virology 52:456-457.
- Green et al. (1986) Ann. Rev. Biochem. 55:569-597.
- 30 Greenspan and Bona, FASEB J. 7(5):437-444 (1989)
- Griffin et al. (1989) Science. 245:967-971.
- Grompe, M. (1993) Nature Genetics. 5:111-117.
- Grompe, M. et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:5855-5892.
- Gu H. et al. (1993) Cell 73:1155-1164.
- 35 Guatelli J C et al. Proc. Natl. Acad. Sci. USA. 90:273-286.

- Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS, Nat Genet 1996;14(4):441-447
- Haff L. A. and Smirnov I. P. (1997) GenomeResearch, 7:378-388.
- Hames B.D. and Higgins S.J. (1985) Nucleic Acid Hybridization: A Practical Approach. Hames and Higgins Ed., IRL Press, Oxford.
- 5 Hammerling, et al., in: MONOCLONAL ANTIBODIES AND T-CELL HYBRIDOMAS 563-681 (Elsevier, N.Y., 1981)
- Harju L, Weber T, Alexandrova L, Lukin M, Ranki M, Jalanko A, Clin Chem 1993;39(11 Pt 1):2282-2287
- Harland et al. (1985) J. Cell. Biol. 101:1094-1095.
- 10 Harrop, J.A. et al. J. Immunol. 161(4): 1786-1794 (1998)
- Hawley M.E. et al. (1994) Am. J. Phys. Anthropol. 18:104.
- Henikoff and Henikoff, 1993, Proteins 17:49-61
- Higgins et al., 1996, Methods Enzymol. 266:383-402;
- Hillier L. and Green P. Methods Appl., 1991, 1: 124-8. Gu H. et al. (1994) Science 265:103-106.
- 15 Hoess et al. (1986) Nucleic Acids Res. 14:2287-2300.
- Huang L. et al. (1996) Cancer Res 56(5):1137-1141.
- Huston et al. Methods in Enzymology 203:46-88 (1991)
- Huygen et al. (1996) Nature Medicine. 2(8):893-898.
- 20 Izant J.G. and Weintraub H. (1984) Cell 36(4):1007-1015.
- Julan et al. (1992) J. Gen. Virol. 73:3251-3255.
- Kanegae Y. et al., Nucl. Acids Res. 23:3816-3821.
- Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268;
- Kettleborough, C.A. et al. Eur. J. Immunol. 24:952-958 (1994)
- 25 Khoury J. et al. (1993) Fundamentals of Genetic Epidemiology, Oxford University Press, NY.
- Kim U-J. et al. (1996) Genomics 34:213-218.
- Kleinet al. (1987) Nature. 327:70-73.
- Koller et al. (1992) Annu. Rev. Immunol. 10:705-730.
- Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR, Nat Med 1996;2(7):753-759
- 30 Landegren U. et al. (1998) Genome Research, 8:769-776.
- Lander and Schork, Science, 265, 2037-2048, 1994
- Lenhard T. et al. (1996) Gene. 169:187-190.
- Liautard, J. et al. Cytokine 9(4):233-241 (1997)
- 35 Linton M.F. et al. (1993) J. Clin. Invest. 92:3029-3037.

- Liu Z. et al. (1994) *Proc. Natl. Acad. Sci. USA.* 91:4528-4262.
- Livak et al., *Nature Genetics*, 9:341-342, 1995
- Livak KJ, Hainer JW, *Hum Mutat* 1994;3(4):379-385
- Lockhart et al. (1996) *Nature Biotechnology* 14:1675-1680.
- 5 Mansour S.L. et al. (1988) *Nature.* 336:348-352.
- Marshall R. L. et al. (1994) *PCR Methods and Applications*. 4:80-84.
- McCormick et al. (1994) *Genet. Anal. Tech. Appl.* 11:158-164.
- McLaughlin B.A. et al. (1996) *Am. J. Hum. Genet.* 59:561-569.
- Morton N.E. (1955) *Am. J. Hum. Genet.* 7:277-318.
- 10 Morrison, *Science* 229:1202 (1985)
- Muller, Y.A. et al. *Structure* 6(9):1153-1167(1998)
- Mullinax, R.L. et al. *BioTechniques* 12(6):864-869(1992)
- Muzyczka et al. (1992) *Curr. Topics in Micro. and Immunol.* 158:97-129.
- Padlan E.A., *Molecular Immunology* 28(4/5): 489-498(1991)
- 15 Nada S. et al. (1993) *Cell* 73:1125-1135.
- Nagy A. et al. (1993) *Proc. Natl. Acad. Sci. USA.* 90: 8424-8428.
- Naramura, M. et al. *Immunol. Lett.* 39:91-99(1994)
- Narang SA, Hsiung HM, Brousseau R, *Methods Enzymol* 1979;68:90-98
- Neda et al. (1991) *J. Biol. Chem.* 266:14143-14146.
- 20 Newton et al. (1989) *Nucleic Acids Res.* 17:2503-2516.
- Nickerson D.A. et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:8923-8927.
- Nicolau et al. (1982) *Biochim. Biophys. Acta.* 721:185-190.
- Nissinoff, J. *Immunol.* 147(8): 2429-2438 (1991).
- Nyren P, Pettersson B, Uhlen M, *Anal Biochem* 1993;208(1):171-175
- 25 O'Reilly et al. (1992) *Baculovirus Expression Vectors: A Laboratory Manual.* W. H. Freeman and Co., New York.
- Ohno et al. (1994) *Science.* 265:781-784.
- Oi et al., *BioTechniques* 4:214 (1986)
- Orita et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86: 2776-2770.
- 30 Ott J. (1991) *Analysis of Human Genetic Linkage.* John Hopkins University Press, Baltimore.
- Pastinen et al., *Genome Research* 1997; 7:606-614
- Pearson and Lipman, 1988, *Proc. Natl. Acad. Sci. USA* 85(8):2444-2448;
- Pease S. and William R.S. (1990) *Exp. Cell. Res.* 190:09-211.
- Perlin et al. (1994) *Am. J. Hum. Genet.* 55:777-787.
- 35 Persic, L. et al. *Gene* 187 9-18(1997)

- Peterson et al.(1993) Proc. Natl. Acad. Sci. USA. 90: 7593-7597.
- Pietu et al.(1996) Genome Research.6:492-503.
- Pitard, V. et al. J. Immunol. Methods 205(2):177-190(1997)
- Potter et al. (1984) Proc. Natl.Acad. Sci. U.S.A. 81(22):7161-7165.
- 5 Prat, M. et al. J. Cell. Sci. 111(Pt2): 237-247(1998)
- Rayl et al., (1996) J. Bio.Chem, 271, 2225-2233.
- Reid L.H. et al. (1990) Proc. Natl. Acad.Sci. U.S.A. 87:4299-4303.
- Risch, N. and Merikangas, K. (1996)Science. 273:1516-1517.
- Robertson E. (1987) "Embryo-Derived StemCell Lines." In: E.J. Robertson Ed.
- 10 Teratocarcinomas And Embrionic Stem Cells: A Practical Approach. IRL Press, Oxford, pp. 71.
- Roguska M.A. et al. PNAS 91:969-973), (1994)
- Rossiet al. (1991) Pharmacol. Ther. 50:245-254.
- Roth J.A. et al. (1996)Nature Medicine. 2(9):985-991.
- 15 Roux et al. (1989) Proc. Natl. Acad.Sci. U.S.A. 86:9079-9083.
- Ruano et al. (1990) Proc. Natl. Acad.Sci. U.S.A. 87:6296-6300.
- Sambrook, J., Fritsch, E.F., and T.Maniatis. (1989) Molecular Cloning: A Laboratory Manual. 2ed. ColdSpring Harbor Laboratory, Cold Spring Harbor, New York.
- Samson M, etal. (1996) Nature, 382(6593):722-725.
- 20 Samulski et al. (1989) J.Virol. 63:3822-3828.
- Sanchez-Pescador R. (1988) J. Clin.Microbiol. 26(10):1934-1938.
- Sarkar, G. and Sommer S.S. (1991)Biotechniques.
- Sauer B. et al. (1988) Proc. Natl. Acad. Sci.U.S.A. 85:5166-5170.
- Sawai, H. et al. AJRI 34:26-34(1995)
- 25 Schaid D.J. et al. (1996) Genet. Epidemiol.13:423-450.
- Schedl A. et al. (1993a) Nature. 362:258-261.
- Schedl et al. (1993b) Nucleic Acids Res. 21:4783-4787.
- Schedl etal. (1993b) Nucleic Acids Res. 21:4783-4787.
- Schena et al. (1995)Science. 270:467-470.
- 30 Schena et al. (1996) Proc. Natl. Acad. Sci.U.S.A. 93(20):10614-10619.
- Schneider et al.(1997) Arlequin: ASoftware For Population Genetics Data Analysis. University of Geneva.
- Schwartz and Dayhoff, eds., 1978, Matrices for Detecting DistanceRelationships: Atlas of Protein Sequence and Structure, Washington:National Biomedical Research Foundation
- 35 Sczakiel G. et al. (1995)Trends Microbiol. 3(6):213-217.

- Shay J.W. et al. (1991) *Biochem. Biophys. Acta.* 1072:1-7.
- Sheffield, V.C. et al. (1991) *Proc. Natl. Acad. Sci. U.S.A.* 49:699-706.
- Shizuya et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:8794-8797.
- Shoemaker DD, Lashkari DA, Morris D, Mittmann M, Davis RW, *Nat Genet* 1996;14(4):450-456
- 5 Shu, L. et al. *PNAS* 90:7995-7999(1993)
- Skerra, A. et al. *Science* 240:1038-1040. (1988)
- Smith(1957) *Ann. Hum. Genet.* 21:254-276.
- Smith et al. (1983) *Mol. Cell. Biol.* 3:2156-2165.
- 10 Sosnowski R.G. et al. (1997) *Proc. Natl. Acad. Sci. U.S.A.* 94:1119-1123.
- Spielmann S. and Ewens W. J. (1998) *Am. J. Hum. Genet.* 62:450-458.
- Spielmann S. et al. (1993) *Am. J. Hum. Genet.* 52:506-516.
- Sternberg N.L. (1992) *Trends Genet.* 8:1-16.
- Sternberg N.L. (1994) *Mamm. Genome.* 5:397-404.
- 15 Studnicka G.M. et al. *Protein Engineering* 7(6):805-814(1994)
- Syvanen AC, *Clin Chim Acta* 1994;226(2):225-236
- Tacson et al. (1996) *Nature Medicine.* 2(8):888-892.
- Taryman, R.E. et al. *Neuron* 14(4):755-762(1995)
- Te Riele et al. (1990) *Nature.* 348:649-651.
- 20 Terwilliger J.D. and Ott J. (1994) *Handbook of Human Genetic Linkage.* John Hopkins University Press, London.
- Thomas K.R. et al. (1986) *Cell.* 44:419-428.
- Thomas K.R. et al. (1987) *Cell.* 51:503-512.
- Thompson et al., 1994, *Nucleic Acids Res.* 22(2):4673-4680;
- 25 Tur-Kaspa et al. (1986) *Mol. Cell. Biol.* 6:716-718.
- Tyagi et al. (1998) *Nature Biotechnology.* 16:49-53.
- Urdea M.S. (1988) *Nucleic Acids Research.* 11:4937-4957.
- Urdea M.S. et al. (1991) *Nucleic Acids Symp. Ser.* 24:197-200.
- Van der Lugt et al. (1991) *Gene.* 105:263-267.
- 30 Vil, H. et al. *PNAS* 89:11337-11341(1992)
- Vlasak R. et al. (1983) *Eur. J. Biochem.* 135:123-126.
- Wabiko et al. (1986) *DNA.* 5(4):305-314.
- Walker et al. (1996) *Clin. Chem.* 42:9-13.
- Weir, B.S. (1996) *Genetic data Analysis II: Methods for Discrete population genetic Data,*
- 35 Sinauer Assoc., Inc., Sunderland, MA, U.S.A.

- White, M.B. et al. (1992) *Genomics*. 12:301-306.
- White, M.B. et al. (1997) *Genomics*. 12:301-306.
- Wong et al. (1980) *Gene*. 10:87-94.
- Wood S.A. et al. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:4582-4585.
- 5 Wu and Wu (1987) *J. Biol. Chem.* 262:4429-4432.
- Wu and Wu (1988) *Biochemistry*. 27:887-892.
- Wu et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86:2757.
- Yagi T. et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:9918-9922.
- Yoon, D.Y. et al. *J. Immunol.* 160(7): 3170-3179(1998)
- 10 Zhao et al. (1998) *Am.J. Hum. Genet.* 63:225-240.
- Zheng, X.X. et al. *J. Immunol.* 154:5590-5600(1995)
- Zhu, Z. et al. *Cancer Res.* 58(15): 3209-3214(1998)
- Zou Y. R. et al. (1994) *Curr. Biol.* 4:1099-1103



## CLAIMS

1. An isolated, purified or recombinant polynucleotide comprising a contiguous span of at least 30 nucleotides selected from the group consisting of:
  - 5 (a) SEQ ID Nos. 2 to 17, and the complements thereof;
  - (b) SEQ ID Nos 24, 25, 28, 74 and 79 to 132, and the complements thereof; and
  - (c) at least one of nucleotide positions 199122 to 249803 of SEQ ID No 1.
- 10 2. An isolated, purified or recombinant polynucleotide according to claim 1, wherein said contiguous span of SEQ ID No 1 or the complements thereof comprises at least one of the following nucleotide positions of SEQ ID No 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802;
- 15 3. An isolated, purified or recombinant polynucleotide according to claim 1, wherein said span comprises a biallelic marker selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 .
- 20 4. A recombinant vector comprising a polynucleotide according to any one of claims 1 to 3.
5. A host cell comprising a recombinant vector according to claim 4.
- 25 6. A non-human host animal or mammal comprising a recombinant vector according to claim 5.
7. A mammalian host cell comprising a g35030 gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1 to 3.
- 30 8. A non-human host mammal comprising a g35030 gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1 to 3.
- 35 9. Use of a polynucleotide comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of SEQ ID Nos. 2 to 17, SEQ ID Nos 24, 25, 28, 74 and 79

to 132, at least one of nucleotide positions 199122 to 249803 of SEQ ID No 1, and the complementary sequences thereto, for determining the identity of the nucleotide at a biallelic marker selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 .

5

10. Use of a polynucleotide according to claim 9 in a microsequencing assay, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of a biallelic marker in said sequence.

10

11. Use of a polynucleotide according to claim 10 in a hybridization assay, wherein said span includes a biallelic marker.

12. A polynucleotide according to any one of claims 1 to 3 attached to a solid support.

15

13. An array of polynucleotides comprising at least one polynucleotide according to claim 12.

14. An array according to claim 13, wherein said array is addressable.

20

15. A polynucleotide according to any one of claims 1 to 3 or 12 further comprising a label.

16. A method of genotyping comprising determining the identity of a nucleotide at a biallelic marker selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 or the complement thereof in a biological sample.

25

17. A method according to claim 16, wherein said biological sample is derived from a single subject.

18. A method according to claim 16, wherein said biological sample is derived from multiple subjects.

30

19. A method according to claim 16, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step.

35

20. A method according to claim 19, wherein said amplifying is performed by PCR.

21. A method according to claim 16, wherein said determining is performed by a hybridization assay.
- 5 22. A method according to claim 16, wherein said determining is performed by a sequencing assay.
23. A method according to claim 16, wherein said determining is performed by a microsequencing assay.
- 10 24. A method according to claim 16, wherein said determining is performed by an enzyme-based mismatch detection assay.
25. A method of estimating the frequency of an allele of a biallelic marker in a population comprising:
- 15 a) genotyping individuals from said population for said biallelic marker according to the method of claim 16; and
- b) determining the proportional representation of said biallelic marker in said population.
- 20 26. A method of detecting an association between a genotype and a trait, comprising the steps of:
- a) determining the frequency of at least one biallelic marker in trait positive population according to the method of claim 25;
- b) determining the frequency of at least one biallelic marker in a control population according to
- 25 the method of claim 25; and
- c) determining whether a statistically significant association exists between said genotype and said trait.
27. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:
- 30 a) genotyping at least one biallelic marker according to claim 16 for each individual in said population;
- b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the
- 35 genome of each individual in said population; and

c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

5 28. A method according to claim 27, wherein said haplotype determination method is selected from the group consisting of asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark method, or an expectation maximization algorithm.

29. A method of detecting an association between a haplotype and a trait, comprising the steps of:

10 a) estimating the frequency of at least one haplotype in a trait positive population according to the method of claim 27;

b) estimating the frequency of said haplotype in a control population according to the method of claim 27; and

15 c) determining whether a statistically significant association exists between said haplotype and said trait.

30. A method according to claim 26, wherein said genotyping of step a) is performed on each individual of said population.

20 31. A method according to claim 26, wherein said genotyping is performed on a single pooled biological sample derived from said population.

32. A method of detecting an association between an allele and a phenotype, comprising the steps of:

25 a) determining the frequency of at least one biallelic marker allele in a trait positive population according to the method of claim 25;

b) determining the frequency of said biallelic marker allele in a control population according to the method of claim 25; and

30 c) determining whether a statistically significant association exists between said allele and said phenotype.

33. A method according to claim 26 or 29, wherein said trait is schizophrenia or bipolar disorder.

35 34. A method according to claim 26 or 29, wherein said trait is predisposition to schizophrenia

or bipolar disorder, an early onset of schizophrenia or bipolar disorder, or a beneficial response to or side effects related to treatment against schizophrenia or bipolar disorder.

5 35. A method according to claim 39, wherein said phenotype is a symptom of schizophrenia or bipolar disorder.

36. A method according to claim 26 or 29, wherein said control population is a trait negative population.

10 37. A method according to claim 26 or 29, wherein said case control population is a random population.

38. A method of determining whether an individual is at risk of schizophrenia or bipolar disorder, comprising:

- 15 a) genotyping at least one biallelic marker according to the method of claim 16; and  
b) correlating the result of step a) with a risk of developing schizophrenia or bipolar disorder.

39. A diagnostic kit comprising a polynucleotide according to any one of claims 1 to 3 or 12.

20 40. A purified or isolated g35030 polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 17, and fragments or variants thereof.

25 41. A purified or isolated g35030 polypeptide comprising at least 6 contiguous amino acid residues of any of SEQ ID Nos 18 to 23.

42. A purified or isolated g35030 polypeptide according to claim 41, comprising at least one amino acid substitution, addition or deletion.

30 43. A method for producing a g35030 polypeptide, wherein said method comprises the following steps:  
a) providing a cell host comprising a recombinant vector according to claim 4 containing a nucleic acid encoding a g35030 polypeptide;  
b) recovering the g35030 polypeptide produced by said recombinant cell host.

35

44. The method according to claim 43, wherein the recombinant cell host is a recombinant cell host according to claim 5.
- 5 45. An isolated or purified antibody composition capable of selectively binding to a polypeptide according to claim 40 to 42.
46. A method for specifically detecting the presence of a g35030 polypeptide in a biological sample, said method comprising the following steps :
- 10 a) bringing into contact the biological sample with an antibody directed against a g35030 polypeptide according to any one of claims 40 to 42;
- b) detecting the antigen-antibody complex formed between said antibody and said polypeptide.
47. A diagnostic kit for detecting *in vitro* the presence of a g35030 polypeptide in a biological sample, said kit comprising:
- 15 a) a polyclonal or monoclonal antibody directed against a g35030 polypeptide according to any one of claims 40 to 42 or a fragment thereof, optionally labeled;
- b) a reagent allowing the detection of the antigen-antibody complexes formed between said g35030 polypeptide and an antibody.
- 20 48. A method for the screening of a candidate substance, wherein said method comprises the following steps:
- a) providing a polypeptide according to anyone of claims 40 to 42;
- b) obtaining a candidate substance;
- 25 c) bringing into contact said polypeptide with said candidate substance;
- d) detecting the complexes formed between said polypeptide and said candidate substance.
49. The method of claim 48, wherein at step d), the complexes formed are incubated in the presence of a polyclonal or a monoclonal antibody according to claim 45 .
- 30 50. A kit for screening a candidate substance interacting with a g35030 polypeptide, wherein said kit comprises:
- a) a polypeptide according to anyone of claims 40 to 42;
- b) optionally a monoclonal or a polyclonal antibody according to claim 45.
- 35 51. A method for the screening of a candidate substance, where said method comprises the

following steps:

- a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding a g35030 protein or a variant or a fragment thereof, placed under the control of its own promoter;
- 5 b) bringing into contact the cultivated cell with a molecule to be tested;
- c) quantifying the expression of the g35030 protein or a variant or a fragment thereof.

52 A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:

- 10 a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 201123 to 247802 and 199122 to 249803;
- b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 15 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 17, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID;
- c) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 24, 25, 28, 74 and 79 to 132, or the complements thereof;
- 20 d) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 25 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802;
- e) a contiguous span according to a), b), c) or d), wherein said span includes a biallelic marker selected from the group consisting of A1 to A127;
- f) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, 30 wherein said span includes a polymorphism selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 ; and
- g) a nucleotide sequence complementary to any one of the contiguous spans of a), b), c), d), e), f), and g).

- 35 53. A computer readable medium having stored thereon a sequence consisting of a polypeptide

code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos. 18 to 23.

5 54. A computer system comprising a processor and a data storage device wherein said data storage device comprises a computer readable medium according to any one of claims 52 or 53.

55. A computer system according to claim 54, further comprising a sequence comparer and a data storage device having reference sequences stored thereon.

10 56. A computer system of claim 55 wherein said sequence comparer comprises a computer program which indicates polymorphisms.

57. A computer system of claim 55 further comprising an identifier which identifies features in said sequence.

15

58. A method for comparing a first sequence to a reference sequence, comprising the steps of:

a) reading said first sequence and said reference sequence through use of a computer program which compares sequences; and

b) determining differences between said first sequence and said reference sequence with said  
20 computer program,

wherein said first sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

(i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein  
25 said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 201123 to 247802 and 199122 to 249803;

(ii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 17, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID;

30 (iii) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 24, 25, 28, 74 and 79 to 132, or the complements thereof;

(iv) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous  
35 span comprises at least one of the following nucleotide positions of SEQ ID No 1: 201123 to



201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802;

5 (v) a contiguous span according to (i) to (iv), wherein said span includes a biallelic marker selected from the group consisting of A1 to A127.

(vi) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123;

10 (vii) a nucleotide sequence complementary to any one of the contiguous spans of (i) to (vi); and

(viii) a polypeptide code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos 18 to 23.

15 59. A method according to claim 58, wherein said step of determining differences between the first sequence and the reference sequence comprises identifying at least one polymorphism.

60. A method for identifying a feature in a sequence, comprising the steps of:

20 a) reading said sequence through the use of a computer program which identifies features in sequences; and

b) identifying features in said sequence with said computer program;

wherein said sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

25 (i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 201123 to 247802 and 199122 to 249803;

30 (ii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 17, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID;

(iii) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 24, 25, 28, 74 and 79 to 132, or the complements thereof;

35 (iv) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous

span comprises at least one of the following nucleotide positions of SEQ ID No 1: 201123 to 201234, 201123 to 201560, 214676 to 214793, 215702 to 215746, 216836 to 216994, 216836 to 217077, 217671 to 217764, 227655 to 227736, 238715 to 238919, 240440 to 240673, 240440 to 241153, 241072 to 241291, 244353 to 244561 and 246273 to 247802;

5 (v) a contiguous span according to (i) to (iv), wherein said span includes a biallelic marker selected from the group consisting of A1 to A127;

(vi) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A13 to A18, A20 to A46, A49 to A52, A55, A57, A59 to A63, A72 to A73, A76 and A123 ;

10

(vii) a nucleotide sequence complementary to any one of the contiguous spans of (i) to (vi); and

(viii) a polypeptide code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos 18 to 23.

15

1/15




Figure 1

2/15

# SIGNIFICANCE OF SINGLE BIALLELIC MARKER ASSOCIATION STUDY IN THE 13q31-33 REGION




Figure 2

Detailed haplotype analysis (case/controls: N=215/N=241)

MARKERS	HAPLOTYPE DESCRIPTION									
	Statistics on a haplotype (a)									
	Frequency (i) p-value (1df) (4)									
frequency in controls (Allele)	99-16082/218	99-5862/167	99-16100/147	99-7652/162	99-5919/215	99-5897/143	99-16032/292	99-15880/162	99-16038/118	99-15875/165
cliff (cases-controls)	32.14 (A)	48.75 (T)	49.56 (G)	48.48 (G)	60.17 (A)	40.55 (C)	57.5 (A)	57.56 (A)	57.74 (G)	37.39 (T)
Single association (p-value)	0.66	0.02	0.09	0.09	0.00355	0.34	0.06	0.03	0.03	0.08
haplotype 1					A					T
haplotype 2		T		G						T
haplotype 3	A		G			C				T
haplotype 4										T
haplotype 5										T
haplotype 6								A	G	T
haplotype 7										T
haplotype 8										T
haplotype 67	A			G	A		A		G	
haplotype 68	A			G			A		G	
haplotype 69	A		G						G	
haplotype 70					A	A				T
haplotype 71			A		A		A			
haplotype 72	A		G							
haplotype 73	A		G							
haplotype 74	A		G					A		
haplotype 75	A				A					
haplotype 76	A	C			A				G	
haplotype 287										
haplotype 288	A		G	G	A				G	
haplotype 289	A		G		A				G	
haplotype 290	A	C			A	C	A			T
haplotype 291	A		G		A		A			

\*maxM: Table of haplotypes giving the Maximum positive difference between cases/controls.

1: Frequency of the haplotype leading to the maximum chi square test

2: Test on the frequency of this haplotype in cases vs in controls

3: p-value assuming that the test has a chi-square distribution with 1 degree of freedom

Figure 3

4/15

Figure 4

Markers involved in selected haplotypes

			markers											
# of markers in the haplotype	Threshold of significance	# of haplotypes concerned	99-16082/218	99-5862/167	99-16100/147	99-7652/162	99-5919/215	99-5897/143	99-16032/292	99-15880/162	99-16038/118	99-15875/165	99-16033/244	99-16047/115
2-mks	$\leq 10^{-2}$	7	*	*	*	*	*	*	*	*	*	*		
3-mks	$\leq 10^{-5}$	10	*	*	*	*	*	*	*	*	*	*	*	
4-mks	$\leq 10^{-6}$	5	*	*	*	*	*	*	*		*		*	*

5/15

## SCHIZOPHRENIA STUDY

MARKERS	HAPLOTYPE DESCRIPTION												HAPLOTYPE TEST BY PERMUTATION PROCEDURE					
													av.Chiz	# Heterobs				
sample size (cases/controls)	Statistics on a haplotype <sup>(a)</sup>																	
frequency in controls (Allele)	Frequency <sup>(b)</sup>																	
diff (cases-controls)																		
p-value																		
HIV-test																		
controls	haplotype 1	140 vs 138													0.257	0.125	2.41	7.80E-05
	haplotype 2	140 vs 138													0.3	0.162	2.22	1.10E-04
	haplotype 3	139 vs 138													0.243	0.119	2.38	1.50E-04
	haplotype 4	137 vs 133													0.238	0.121	2.28	3.70E-04
	haplotype 5	132 vs 133													0.246	0.132	2.14	8.20E-04
	haplotype 6	135 vs 132													0.309	0.197	1.82	3.00E-03
	haplotype 8	140 vs 137													0.296	0.196	1.72	6.50E-03
	haplotype 9	140 vs 138													0.294	0.197	1.7	7.70E-03
	haplotype 154	138 vs 138													0.252	0.116	2.57	3.40E-05
	haplotype 155	139 vs 138													0.247	0.113	2.57	4.20E-05
cases	haplotype 156	137 vs 135													0.252	0.117	2.54	4.90E-05
	haplotype 157	139 vs 138													0.265	0.128	2.45	4.90E-05
	haplotype 158	136 vs 133													0.247	0.113	2.58	5.10E-05
	haplotype 159	132 vs 124													0.144	0.04	4	5.70E-05
	haplotype 160	135 vs 129													0.153	0.048	3.57	6.70E-05
	haplotype 161	139 vs 136													0.245	0.118	2.43	1.00E-04
	haplotype 162	136 vs 133													0.244	0.116	2.47	1.00E-04
	haplotype 163	137 vs 137													0.075	0.009	8.8	1.10E-04
	haplotype 970	136 vs 132													0.199	0.056	4.17	7.80E-07
	haplotype 971	139 vs 138													0.076	0	100	2.70E-05
haplotype 972	139 vs 138													0.076	0	100	3.00E-05	
haplotype 973	139 vs 137													0.076	0	100	3.40E-05	

Figure 5

MARKERS	HAPLOTYPE DESCRIPTION										HAPLOTYPE TEST BY PERMUTATION PROCEDURE			
	Statistics on a haplotype <sup>(2)</sup>										av. Ch2	# iter/chs		
	Frequency <sup>(1)</sup>													
	Cases													
P-value	Controls										OR	p-value (adj) <sup>(3)</sup>		
HW-test														
sample size (cases/controls)	141/141	140/135	141/141	139/135	130/131	140/132	137/130	140/140	137/130	140/139	136/137	139/141	131/134	
frequency in controls (Allele)	56.38	56.43	52.59	55.67	43.56	33.7 (T)	9.2	1.6	8.5	6.7	8.8	5.6	52.24	
diff (cases-controls)	9.2	8.8	6.7	8.5	1.6	33.7 (T)	9.2	1.6	8.5	6.7	8.8	5.6	52.24	
	0.0239	0.032	0.114	0.038	0.655	0.0253	0.403	0.221	0.655	0.273	0.371	0.752	0.346	
	-0.019	-0.021	-0.016	-0.029	0.025	-0.012	-0.013	0.009	-0.003	-0.016	-0.008	-0.01	-0.018	
	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	
	0.023	0.024	0.012	0.016	-0.008	0.017	0.02	0.022	-0.011	0.034	0.015	-0.024	0.011	
	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	(NS)	
haplotype 1	140 vs 140	A	A	A	A	A	A	A	A	A	A	A	0.46	
haplotype 2	140 vs 137	A	A	A	A	A	A	A	A	A	A	A	0.3	
haplotype 3	140 vs 138	G	T	T	T	T	T	T	T	T	T	T	0.29	
haplotype 4	137 vs 132	A	T	T	T	T	T	T	T	T	T	T	0.16	
haplotype 5	140 vs 139	A	T	T	T	T	T	T	T	T	T	T	0.46	
haplotype 137	135 vs 131	A	T	T	T	T	T	T	T	T	T	T	0.08	
haplotype 138	133 vs 130	A	T	T	T	T	T	T	T	T	T	T	0.08	
haplotype 139	127 vs 124	A	T	T	T	T	T	T	T	T	T	T	0.13	
haplotype 140	128 vs 119	A	T	T	T	T	T	T	T	T	T	T	0.11	
haplotype 141	135 vs 127	A	T	T	T	T	T	T	T	T	T	T	0.21	
haplotype 817	133 vs 121	A	T	T	T	T	T	T	T	T	T	T	0.11	
haplotype 818	124 vs 119	A	T	T	T	T	T	T	T	T	T	T	0.15	
haplotype 819	126 vs 113	A	T	T	T	T	T	T	T	T	T	T	0.13	
haplotype 820	127 vs 124	A	T	T	T	T	T	T	T	T	T	T	0.1	
haplotype 821	127 vs 124	A	T	T	T	T	T	T	T	T	T	T	0.09	
haplotype 822	130 vs 115	A	T	T	T	T	T	T	T	T	T	T	0.15	
haplotype 823	124 vs 119	A	T	T	T	T	T	T	T	T	T	T	0.15	
haplotype 824	124 vs 118	A	T	T	T	T	T	T	T	T	T	T	0.1	
haplotype 825	126 vs 111	A	T	T	T	T	T	T	T	T	T	T	0.09	
haplotype 826	127 vs 117	A	T	T	T	T	T	T	T	T	T	T	0.09	
haplotype 827	126 vs 122	A	T	T	T	T	T	T	T	T	T	T	0.09	
haplotype 828	124 vs 117	A	T	T	T	T	T	T	T	T	T	T	0.09	
haplotype 829	125 vs 119	A	T	T	T	T	T	T	T	T	T	T	0.09	
haplotype 830	125 vs 120	A	T	T	T	T	T	T	T	T	T	T	0.15	
haplotype 831	126 vs 122	A	T	T	T	T	T	T	T	T	T	T	0.08	
haplotype 832	128 vs 119	A	T	T	T	T	T	T	T	T	T	T	0.09	
haplotype 833	125 vs 117	A	T	T	T	T	T	T	T	T	T	T	0.15	
haplotype 834	125 vs 119	A	T	T	T	T	T	T	T	T	T	T	0.11	
haplotype 835	125 vs 113	A	T	T	T	T	T	T	T	T	T	T	0.09	
haplotype 836	129 vs 113	A	T	T	T	T	T	T	T	T	T	T	0.09	

Figure 6



# SCHIZOPHRENIA STUDY OMNIBUS LR TEST VALUES DISTRIBUTIONS ALL SAMPLE

CASES (N=213) / ALL CONTROLS (N=241)

Combination of 2 markers




Figure 7A

Combination of 3 markers




Figure 7B

# SCHIZOPHRENIA STUDY HAPLO\_MAXM TEST DISTRIBUTIONS ALL SAMPLE

CASES (N=213) / ALL CONTROLS (N=241)




Figure 8A

Figure 8B

# BIPOLAR DISORDERS STUDY OMNIBUS LR TEST VALUES DISTRIBUTIONS FIRST HALF AND SECOND HALF D REGION

CAUCASIAN CASES (N=182) / CAUCASIAN CONTROLS (N=177)




Figure 9A

Figure 9B

# BIPOLAR DISORDERS STUDY HAPLO\_MAXM TEST VALUES DISTRIBUTIONS

CAUCASIAN CASES (N=182) / CAUCASIAN CONTROLS (N=177)

Combination of 2 markers




Figure 10A

10/15

Combination of 3 markers




Figure 10B

# BIPOLAR DISORDERS STUDY HAPLO\_MAXS TEST VALUES DISTRIBUTIONS

CAUCASIAN CASES (N=182) / CAUCASIAN CONTROLS (N=177)

Combination of 2 markers




Figure 11A

Combination of 3 markers




Figure 11B




Figure 12




Figure 13

14/15




Figure 14



15/15




Figure 15

## SEQUENCE LISTING

&lt;110&gt; GENSET

&lt;120&gt; SCHIZOPHRENIA ASSOCIATED GENE, PROTEINS AND BIALLELIC MARKERS

&lt;130&gt; 53.WO2

&lt;150&gt; 60/168,088

&lt;151&gt; 1999-11-30

&lt;160&gt; 134

&lt;170&gt; Patent.pm

&lt;210&gt; 1

&lt;211&gt; 319608

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 199122..201122

&lt;223&gt; 5'regulatory region

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; 201123..201234

&lt;223&gt; exon S

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; 201123..201560

&lt;223&gt; exon S2

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; 214676..214793

&lt;223&gt; exon T

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; 215702..215746

&lt;223&gt; exon U

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; 216836..216994

&lt;223&gt; exon V

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; 216836..217077

&lt;223&gt; exon V2

&lt;220&gt;

&lt;221&gt; exon

<222> 217671..217764  
<223> exon V1

<220>  
<221> exon  
<222> 227655..227736  
<223> exon V4

<220>  
<221> exon  
<222> 238715..238919  
<223> exon V3

<220>  
<221> exon  
<222> 240440..240673  
<223> exon W

<220>  
<221> exon  
<222> 240440..241153  
<223> exon W2

<220>  
<221> exon  
<222> 241072..241291  
<223> exon X

<220>  
<221> exon  
<222> 244353..244561  
<223> exon Y

<220>  
<221> exon  
<222> 246273..247802  
<223> exon Z

<220>  
<221> misc\_feature  
<222> 247803..249803  
<223> 3'regulatory region

<220>  
<221> allele  
<222> 8316  
<223> 99-27943-150 : polymorphic base G or C

<220>  
<221> allele  
<222> 21672  
<223> 99-27935-193 : polymorphic base G or C

<220>  
<221> allele  
<222> 65485  
<223> 8-128-33 : polymorphic base C or T

<220>  
<221> allele  
<222> 95396

<223> 99-31960-363 : polymorphic base A or G

<220>

<221> allele

<222> 107281

<223> 99-24656-260 : polymorphic base A or G

<220>

<221> allele

<222> 160640

<223> 99-24639-163 : polymorphic base A or C

<220>

<221> allele

<222> 160876

<223> 99-24634-108 : polymorphic base A or T

<220>

<221> allele

<222> 168974

<223> 99-7652-162 : polymorphic base A or G

<220>

<221> allele

<222> 170810

<223> 99-16100-147 : polymorphic base A or G

<220>

<221> allele

<222> 173358

<223> 99-5862-167 : polymorphic base A or G

<220>

<221> allele

<222> 189957

<223> 99-5919-215 : polymorphic base A or G

<220>

<221> allele

<222> 197163

<223> 99-24658-410 : polymorphic base A or G

<220>

<221> allele

<222> 200778

<223> 8-303-235 : polymorphic base A or G

<220>

<221> allele

<222> 202651

<223> 8-300-221 : polymorphic base A or G

<220>

<221> allele

<222> 202679

<223> 8-300-193 : polymorphic base A or G

<220>

<221> allele

<222> 203378

<223> 8-299-128 : polymorphic base A or T

<220>  
<221> allele  
<222> 204138  
<223> 8-296-213 : polymorphic base A or T

<220>  
<221> allele  
<222> 204605  
<223> 8-252-190 : polymorphic base C or T

<220>  
<221> allele  
<222> 204934  
<223> 99-24644-194 : polymorphic base A or G

<220>  
<221> allele  
<222> 205206  
<223> 8-295-248 : polymorphic base A or C

<220>  
<221> allele  
<222> 205329  
<223> 8-295-125 : polymorphic base C or T

<220>  
<221> allele  
<222> 206064  
<223> 8-293-130 : polymorphic base A or G

<220>  
<221> allele  
<222> 206545  
<223> 8-292-198 : polymorphic base A or G

<220>  
<221> allele  
<222> 207313  
<223> 8-251-322 : polymorphic base A or G

<220>  
<221> allele  
<222> 208285  
<223> 8-289-322 : polymorphic base A or G

<220>  
<221> allele  
<222> 208960  
<223> 8-287-249 : polymorphic base C or T

<220>  
<221> allele  
<222> 209123  
<223> 8-287-86 : polymorphic base A or T

<220>  
<221> allele  
<222> 209631  
<223> 8-285-319 : polymorphic base A or G

<220>  
<221> allele  
<222> 210361  
<223> 8-283-278 : polymorphic base G or C

<220>  
<221> allele  
<222> 210463  
<223> 8-283-176 : polymorphic base A or G

<220>  
<221> allele  
<222> 210486  
<223> 8-283-153 : polymorphic base G or C

<220>  
<221> allele  
<222> 210583  
<223> 8-283-56 : polymorphic base C or T

<220>  
<221> allele  
<222> 210879  
<223> 8-282-345 : polymorphic base G or C

<220>  
<221> allele  
<222> 210964  
<223> 8-282-260 : polymorphic base G or T

<220>  
<221> allele  
<222> 210979  
<223> 8-282-245 : polymorphic base A or C

<220>  
<221> allele  
<222> 211050  
<223> 8-282-174 : variable motif AAAGG or GAAGGAAGGAAGGAAGGAAGA

<220>  
<221> allele  
<222> 211132  
<223> 8-282-92 : polymorphic base A or T

<220>  
<221> allele  
<222> 211247  
<223> 8-281-367 : polymorphic base A or G

<220>  
<221> allele  
<222> 211315  
<223> 8-281-299 : polymorphic base A or G

<220>  
<221> allele  
<222> 211366  
<223> 8-281-248 : polymorphic base G or C

<220>

<221> allele  
<222> 212520  
<223> 8-279-197 : polymorphic base A or C

<220>  
<221> allele  
<222> 212821  
<223> 8-278-289 : polymorphic base C or T

<220>  
<221> allele  
<222> 213833  
<223> 8-277-250 : polymorphic base C or T

<220>  
<221> allele  
<222> 214857  
<223> 8-124-294 : polymorphic base A or G

<220>  
<221> allele  
<222> 215347  
<223> 8-273-383 : polymorphic base A or G

<220>  
<221> allele  
<222> 216967  
<223> 8-126-286 or 8-130-143 : polymorphic base A or G

<220>  
<221> allele  
<222> 219540  
<223> 99-5897-143 : polymorphic base A or C

<220>  
<221> allele  
<222> 220836  
<223> 99-24649-186 : polymorphic base A or G

<220>  
<221> allele  
<222> 223230  
<223> 8-247-337 : polymorphic base A or G

<220>  
<221> allele  
<222> 224213  
<223> 8-246-393 : polymorphic base A or T

<220>  
<221> allele  
<222> 224792  
<223> 8-245-270 : polymorphic base A or G

<220>  
<221> allele  
<222> 230395  
<223> 8-119-247 : polymorphic base A or G

<220>  
<221> allele

<222> 231677  
<223> 99-15870-400 : polymorphic base A or G

<220>  
<221> allele  
<222> 235315  
<223> 99-16087-219 : polymorphic base G or C

<220>  
<221> allele  
<222> 238789  
<223> 8-155-258 : polymorphic base C or T

<220>  
<221> allele  
<222> 239763  
<223> 8-136-267 or 99-16038-118 : polymorphic base C or T

<220>  
<221> allele  
<222> 241861  
<223> 99-15880-162 : polymorphic base A or G

<220>  
<221> allele  
<222> 243700  
<223> 8-271-227 : polymorphic base A or G

<220>  
<221> allele  
<222> 245264  
<223> 8-267-273 : deletion of GTGGGC

<220>  
<221> allele  
<222> 245663  
<223> 8-266-131 : polymorphic base A or C

<220>  
<221> allele  
<222> 245966  
<223> 8-265-208 : polymorphic base A or G

<220>  
<221> allele  
<222> 245971  
<223> 8-265-203 : polymorphic base G or C

<220>  
<221> allele  
<222> 247864  
<223> 99-25940-182 : polymorphic base C or T

<220>  
<221> allele  
<222> 248315  
<223> 99-16032-292 : polymorphic base G or T

<220>  
<221> allele  
<222> 255848



<223> 99-16105-152 : polymorphic base A or G

<220>

<221> allele

<222> 260099

<223> 99-16033-244 : polymorphic base A or G

<220>

<221> allele

<222> 279789

<223> 99-15875-165 : polymorphic base C or T

<220>

<221> allele

<222> 300365

<223> 99-16052-214 : polymorphic base A or G

<220>

<221> allele

<222> 312030

<223> 99-16047-115 : polymorphic base A or G

<220>

<221> allele

<222> 316014

<223> 99-25993-367 : polymorphic base A or G

<220>

<221> primer\_bind

<222> 7938..7958

<223> 99-27943.rp

<220>

<221> primer\_bind

<222> 8446..8465

<223> 99-27943.pu complement

<220>

<221> primer\_bind

<222> 21365..21385

<223> 99-27935.rp

<220>

<221> primer\_bind

<222> 21845..21864

<223> 99-27935.pu complement

<220>

<221> primer\_bind

<222> 65453..65471

<223> 8-128.pu

<220>

<221> primer\_bind

<222> 65856..65874

<223> 8-128.rp complement

<220>

<221> primer\_bind

<222> 95034..95053

<223> 99-31960.pu

<220>  
<221> primer\_bind  
<222> 95543..95563  
<223> 99-31960.rp complement

<220>  
<221> primer\_bind  
<222> 107022..107040  
<223> 99-24656.pu

<220>  
<221> primer\_bind  
<222> 107495..107513  
<223> 99-24656.rp complement

<220>  
<221> primer\_bind  
<222> 160279..160298  
<223> 99-24639.rp

<220>  
<221> primer\_bind  
<222> 160770..160787  
<223> 99-24634.pu

<220>  
<221> primer\_bind  
<222> 160785..160802  
<223> 99-24639.pu complement

<220>  
<221> primer\_bind  
<222> 161240..161257  
<223> 99-24634.rp complement

<220>  
<221> primer\_bind  
<222> 168813..168830  
<223> 99-7652.pu

<220>  
<221> primer\_bind  
<222> 169331..169351  
<223> 99-7652.rp complement

<220>  
<221> primer\_bind  
<222> 170666..170686  
<223> 99-16100.pu

<220>  
<221> primer\_bind  
<222> 171153..171173  
<223> 99-16100.rp complement

<220>  
<221> primer\_bind  
<222> 173065..173085  
<223> 99-5862.rp

<220>  
<221> primer\_bind  
<222> 173495..173514  
<223> 99-5862.pu complement

<220>  
<221> primer\_bind  
<222> 189753..189771  
<223> 99-5919.pu

<220>  
<221> primer\_bind  
<222> 190187..190207  
<223> 99-5919.rp complement

<220>  
<221> primer\_bind  
<222> 197116..197135  
<223> 99-24658.rp

<220>  
<221> primer\_bind  
<222> 197555..197572  
<223> 99-24658.pu complement

<220>  
<221> primer\_bind  
<222> 200587..200606  
<223> 8-303.rp

<220>  
<221> primer\_bind  
<222> 200994..201012  
<223> 8-303.pu complement

<220>  
<221> primer\_bind  
<222> 202440..202459  
<223> 8-300.rp

<220>  
<221> primer\_bind  
<222> 202852..202871  
<223> 8-300.pu complement

<220>  
<221> primer\_bind  
<222> 203061..203080  
<223> 8-299.rp

<220>  
<221> primer\_bind  
<222> 203486..203505  
<223> 8-299.pu complement

<220>  
<221> primer\_bind  
<222> 203943..203962  
<223> 8-296.rp

<220>

<221> primer\_bind  
<222> 204345..204362  
<223> 8-296.pu complement

<220>  
<221> primer\_bind  
<222> 204373..204392  
<223> 8-252.rp

<220>  
<221> primer\_bind  
<222> 204741..204758  
<223> 99-24644.pu

<220>  
<221> primer\_bind  
<222> 204777..204794  
<223> 8-252.pu complement

<220>  
<221> primer\_bind  
<222> 205034..205052  
<223> 8-295.rp

<220>  
<221> primer\_bind  
<222> 205222..205240  
<223> 99-24644.rp complement

<220>  
<221> primer\_bind  
<222> 205435..205453  
<223> 8-295.pu complement

<220>  
<221> primer\_bind  
<222> 205768..205786  
<223> 8-293.rp

<220>  
<221> primer\_bind  
<222> 206175..206193  
<223> 8-293.pu complement

<220>  
<221> primer\_bind  
<222> 206316..206333  
<223> 8-292.rp

<220>  
<221> primer\_bind  
<222> 206725..206742  
<223> 8-292.pu complement

<220>  
<221> primer\_bind  
<222> 207186..207205  
<223> 8-251.rp

<220>  
<221> primer\_bind

<222> 207616..207634  
<223> 8-251.pu complement

<220>  
<221> primer\_bind  
<222> 208186..208205  
<223> 8-289.rp

<220>  
<221> primer\_bind  
<222> 208588..208606  
<223> 8-289.pu complement

<220>  
<221> primer\_bind  
<222> 208786..208805  
<223> 8-287.rp

<220>  
<221> primer\_bind  
<222> 209189..209208  
<223> 8-287.pu complement

<220>  
<221> primer\_bind  
<222> 209520..209539  
<223> 8-285.rp

<220>  
<221> primer\_bind  
<222> 209931..209949  
<223> 8-285.pu complement

<220>  
<221> primer\_bind  
<222> 210219..210237  
<223> 8-283.rp

<220>  
<221> primer\_bind  
<222> 210620..210638  
<223> 8-283.pu complement

<220>  
<221> primer\_bind  
<222> 210801..210820  
<223> 8-282.rp

<220>  
<221> primer\_bind  
<222> 211182..211199  
<223> 8-281.rp

<220>  
<221> primer\_bind  
<222> 211205..211223  
<223> 8-282.pu complement

<220>  
<221> primer\_bind  
<222> 211596..211613

<223> 8-281.pu complement

<220>

<221> primer\_bind

<222> 212290..212309

<223> 8-279.rp

<220>

<221> primer\_bind

<222> 212662..212679

<223> 8-278.rp

<220>

<221> primer\_bind

<222> 212698..212716

<223> 8-279.pu complement

<220>

<221> primer\_bind

<222> 213091..213109

<223> 8-278.pu complement

<220>

<221> primer\_bind

<222> 213783..213803

<223> 8-277.rp

<220>

<221> primer\_bind

<222> 214062..214082

<223> 8-277.pu complement

<220>

<221> primer\_bind

<222> 214564..214581

<223> 8-124.pu

<220>

<221> primer\_bind

<222> 214965..214983

<223> 8-124.rp complement

<220>

<221> primer\_bind

<222> 215310..215328

<223> 8-273.rp

<220>

<221> primer\_bind

<222> 215711..215729

<223> 8-273.pu complement

<220>

<221> primer\_bind

<222> 216683..216702

<223> 8-130.rp

<220>

<221> primer\_bind

<222> 216687..216704

<223> 8-126.pu

<220>  
<221> primer\_bind  
<222> 217082..217101  
<223> 8-126.rp complement

<220>  
<221> primer\_bind  
<222> 217091..217109  
<223> 8-130.pu complement

<220>  
<221> primer\_bind  
<222> 219408..219425  
<223> 99-5897.pu

<220>  
<221> primer\_bind  
<222> 219882..219899  
<223> 99-5897.rp complement

<220>  
<221> primer\_bind  
<222> 220505..220522  
<223> 99-24649.rp

<220>  
<221> primer\_bind  
<222> 221004..221021  
<223> 99-24649.pu complement

<220>  
<221> primer\_bind  
<222> 223011..223028  
<223> 8-247.rp

<220>  
<221> primer\_bind  
<222> 223549..223566  
<223> 8-247.pu complement

<220>  
<221> primer\_bind  
<222> 223962..223978  
<223> 8-246.rp

<220>  
<221> primer\_bind  
<222> 224564..224581  
<223> 8-245.rp

<220>  
<221> primer\_bind  
<222> 224588..224605  
<223> 8-246.pu complement

<220>  
<221> primer\_bind  
<222> 225044..225061  
<223> 8-245.pu complement

<220>  
<221> primer\_bind  
<222> 230210..230227  
<223> 8-119.rp

<220>  
<221> primer\_bind  
<222> 230622..230641  
<223> 8-119.pu complement

<220>  
<221> primer\_bind  
<222> 231278..231298  
<223> 99-15870.pu

<220>  
<221> primer\_bind  
<222> 231729..231747  
<223> 99-15870.rp complement

<220>  
<221> primer\_bind  
<222> 235081..235101  
<223> 99-16087.rp

<220>  
<221> primer\_bind  
<222> 235515..235533  
<223> 99-16087.pu complement

<220>  
<221> primer\_bind  
<222> 238607..238626  
<223> 8-155.rp

<220>  
<221> primer\_bind  
<222> 239029..239046  
<223> 8-155.pu complement

<220>  
<221> primer\_bind  
<222> 239405..239425  
<223> 99-16038.rp

<220>  
<221> primer\_bind  
<222> 239606..239624  
<223> 8-136.rp

<220>  
<221> primer\_bind  
<222> 239862..239880  
<223> 99-16038.pu complement

<220>  
<221> primer\_bind  
<222> 240012..240029  
<223> 8-136.pu complement

<220>



<221> primer\_bind  
<222> 241700..241717  
<223> 99-15880.pu

<220>  
<221> primer\_bind  
<222> 242151..242171  
<223> 99-15880.rp complement

<220>  
<221> primer\_bind  
<222> 243484..243502  
<223> 8-271.rp

<220>  
<221> primer\_bind  
<222> 243909..243926  
<223> 8-271.pu complement

<220>  
<221> primer\_bind  
<222> 245105..245123  
<223> 8-267.rp

<220>  
<221> primer\_bind  
<222> 245372..245389  
<223> 8-266.rp

<220>  
<221> primer\_bind  
<222> 245518..245535  
<223> 8-267.pu complement

<220>  
<221> primer\_bind  
<222> 245754..245772  
<223> 8-265.rp

<220>  
<221> primer\_bind  
<222> 245775..245793  
<223> 8-266.pu complement

<220>  
<221> primer\_bind  
<222> 246155..246173  
<223> 8-265.pu complement

<220>  
<221> primer\_bind  
<222> 247513..247533  
<223> 99-25940.rp

<220>  
<221> primer\_bind  
<222> 248023..248043  
<223> 99-25940.pu complement

<220>  
<221> primer\_bind

<222> 248204..248223

<223> 99-16032.rp

<220>

<221> primer\_bind

<222> 248588..248606

<223> 99-16032.pu complement

<220>

<221> primer\_bind

<222> 255697..255715

<223> 99-16105.pu

<220>

<221> primer\_bind

<222> 256133..256152

<223> 99-16105.rp complement

<220>

<221> primer\_bind

<222> 259885..259902

<223> 99-16033.rp

<220>

<221> primer\_bind

<222> 260324..260342

<223> 99-16033.pu complement

<220>

<221> primer\_bind

<222> 279626..279644

<223> 99-15875.pu

<220>

<221> primer\_bind

<222> 280154..280173

<223> 99-15875.rp complement

<220>

<221> primer\_bind

<222> 300153..300170

<223> 99-16052.pu

<220>

<221> primer\_bind

<222> 300660..300680

<223> 99-16052.rp complement

<220>

<221> primer\_bind

<222> 311615..311632

<223> 99-16047.rp

<220>

<221> primer\_bind

<222> 312126..312144

<223> 99-16047.pu complement

<220>

<221> primer\_bind

<222> 315649..315668

<223> 99-25993.pu

<220>  
<221> primer\_bind  
<222> 316129..316147  
<223> 99-25993.rp complement

<220>  
<221> primer\_bind  
<222> 8297..8315  
<223> 99-27943-150.mis

<220>  
<221> primer\_bind  
<222> 8317..8335  
<223> 99-27943-150.mis complement

<220>  
<221> primer\_bind  
<222> 21653..21671  
<223> 99-27935-193.mis

<220>  
<221> primer\_bind  
<222> 21673..21691  
<223> 99-27935-193.mis complement

<220>  
<221> primer\_bind  
<222> 65466..65484  
<223> 8-128-33.mis

<220>  
<221> primer\_bind  
<222> 65486..65504  
<223> 8-128-33.mis complement

<220>  
<221> primer\_bind  
<222> 95377..95395  
<223> 99-31960-363.mis

<220>  
<221> primer\_bind  
<222> 95397..95415  
<223> 99-31960-363.mis complement

<220>  
<221> primer\_bind  
<222> 107262..107280  
<223> 99-24656-260.mis

<220>  
<221> primer\_bind  
<222> 107282..107300  
<223> 99-24656-260.mis complement

<220>  
<221> primer\_bind  
<222> 160621..160639  
<223> 99-24639-163.mis

<220>  
<221> primer\_bind  
<222> 160641..160659  
<223> 99-24639-163.mis complement

<220>  
<221> primer\_bind  
<222> 160857..160875  
<223> 99-24634-108.mis

<220>  
<221> primer\_bind  
<222> 160877..160895  
<223> 99-24634-108.mis complement

<220>  
<221> primer\_bind  
<222> 168955..168973  
<223> 99-7652-162.mis

<220>  
<221> primer\_bind  
<222> 168975..168993  
<223> 99-7652-162.mis complement

<220>  
<221> primer\_bind  
<222> 170791..170809  
<223> 99-16100-147.mis

<220>  
<221> primer\_bind  
<222> 170811..170829  
<223> 99-16100-147.mis complement

<220>  
<221> primer\_bind  
<222> 173339..173357  
<223> 99-5862-167.mis

<220>  
<221> primer\_bind  
<222> 173359..173377  
<223> 99-5862-167.mis complement

<220>  
<221> primer\_bind  
<222> 189938..189956  
<223> 99-5919-215.mis

<220>  
<221> primer\_bind  
<222> 189958..189976  
<223> 99-5919-215.mis complement

<220>  
<221> primer\_bind  
<222> 197144..197162  
<223> 99-24658-410.mis

<220>  
<221> primer\_bind  
<222> 197164..197182  
<223> 99-24658-410.mis complement

<220>  
<221> primer\_bind  
<222> 200759..200777  
<223> 8-303-235.mis

<220>  
<221> primer\_bind  
<222> 200779..200797  
<223> 8-303-235.mis complement

<220>  
<221> primer\_bind  
<222> 202632..202650  
<223> 8-300-221.mis

<220>  
<221> primer\_bind  
<222> 202652..202670  
<223> 8-300-221.mis complement

<220>  
<221> primer\_bind  
<222> 202660..202678  
<223> 8-300-193.mis

<220>  
<221> primer\_bind  
<222> 202680..202698  
<223> 8-300-193.mis complement

<220>  
<221> primer\_bind  
<222> 203359..203377  
<223> 8-299-128.mis

<220>  
<221> primer\_bind  
<222> 203379..203397  
<223> 8-299-128.mis complement

<220>  
<221> primer\_bind  
<222> 204119..204137  
<223> 8-296-213.mis

<220>  
<221> primer\_bind  
<222> 204139..204157  
<223> 8-296-213.mis complement

<220>  
<221> primer\_bind  
<222> 204586..204604  
<223> 8-252-190.mis

<220>

<221> primer\_bind  
<222> 204606..204624  
<223> 8-252-190.mis complement

<220>  
<221> primer\_bind  
<222> 204915..204933 -  
<223> 99-24644-194.mis

<220>  
<221> primer\_bind  
<222> 204935..204953  
<223> 99-24644-194.mis complement

<220>  
<221> primer\_bind  
<222> 205187..205205  
<223> 8-295-248.mis

<220>  
<221> primer\_bind  
<222> 205207..205225  
<223> 8-295-248.mis complement

<220>  
<221> primer\_bind  
<222> 205310..205328  
<223> 8-295-125.mis

<220>  
<221> primer\_bind  
<222> 205330..205348  
<223> 8-295-125.mis complement

<220>  
<221> primer\_bind  
<222> 206045..206063  
<223> 8-293-130.mis

<220>  
<221> primer\_bind  
<222> 206065..206083  
<223> 8-293-130.mis complement

<220>  
<221> primer\_bind  
<222> 206526..206544  
<223> 8-292-198.mis

<220>  
<221> primer\_bind  
<222> 206546..206564  
<223> 8-292-198.mis complement

<220>  
<221> primer\_bind  
<222> 207294..207312  
<223> 8-251-322.mis

<220>  
<221> primer\_bind

<222> 207314..207332  
<223> 8-251-322.mis complement

<220>  
<221> primer\_bind  
<222> 208266..208284  
<223> 8-289-322.mis

<220>  
<221> primer\_bind  
<222> 208286..208304  
<223> 8-289-322.mis complement

<220>  
<221> primer\_bind  
<222> 208941..208959  
<223> 8-287-249.mis

<220>  
<221> primer\_bind  
<222> 208961..208979  
<223> 8-287-249.mis complement

<220>  
<221> primer\_bind  
<222> 209104..209122  
<223> 8-287-86.mis

<220>  
<221> primer\_bind  
<222> 209124..209142  
<223> 8-287-86.mis complement

<220>  
<221> primer\_bind  
<222> 209612..209630  
<223> 8-285-319.mis

<220>  
<221> primer\_bind  
<222> 209632..209650  
<223> 8-285-319.mis complement

<220>  
<221> primer\_bind  
<222> 210342..210360  
<223> 8-283-278.mis

<220>  
<221> primer\_bind  
<222> 210362..210380  
<223> 8-283-278.mis complement

<220>  
<221> primer\_bind  
<222> 210444..210462  
<223> 8-283-176.mis

<220>  
<221> primer\_bind  
<222> 210464..210482

<223> 8-283-176.mis complement

<220>

<221> primer\_bind

<222> 210467..210485

<223> 8-283-153.mis

<220>

<221> primer\_bind

<222> 210487..210505

<223> 8-283-153.mis complement

<220>

<221> primer\_bind

<222> 210564..210582

<223> 8-283-56.mis

<220>

<221> primer\_bind

<222> 210584..210602

<223> 8-283-56.mis complement

<220>

<221> primer\_bind

<222> 210860..210878

<223> 8-282-345.mis

<220>

<221> primer\_bind

<222> 210880..210898

<223> 8-282-345.mis complement

<220>

<221> primer\_bind

<222> 210945..210963

<223> 8-282-260.mis

<220>

<221> primer\_bind

<222> 210960..210978

<223> 8-282-245.mis

<220>

<221> primer\_bind

<222> 210965..210983

<223> 8-282-260.mis complement

<220>

<221> primer\_bind

<222> 210980..210998

<223> 8-282-245.mis complement

<220>

<221> primer\_bind

<222> 211113..211131

<223> 8-282-92.mis

<220>

<221> primer\_bind

<222> 211133..211151

<223> 8-282-92.mis complement



<220>  
<221> primer\_bind  
<222> 211228..211246  
<223> 8-281-367.mis

<220>  
<221> primer\_bind  
<222> 211248..211266  
<223> 8-281-367.mis complement

<220>  
<221> primer\_bind  
<222> 211296..211314  
<223> 8-281-299.mis

<220>  
<221> primer\_bind  
<222> 211316..211334  
<223> 8-281-299.mis complement

<220>  
<221> primer\_bind  
<222> 211347..211365  
<223> 8-281-248.mis

<220>  
<221> primer\_bind  
<222> 211367..211385  
<223> 8-281-248.mis complement

<220>  
<221> primer\_bind  
<222> 212501..212519  
<223> 8-279-197.mis

<220>  
<221> primer\_bind  
<222> 212521..212539  
<223> 8-279-197.mis complement

<220>  
<221> primer\_bind  
<222> 212802..212820  
<223> 8-278-289.mis

<220>  
<221> primer\_bind  
<222> 212822..212840  
<223> 8-278-289.mis complement

<220>  
<221> primer\_bind  
<222> 213814..213832  
<223> 8-277-250.mis

<220>  
<221> primer\_bind  
<222> 213834..213852  
<223> 8-277-250.mis complement

<220>  
<221> primer\_bind  
<222> 214838..214856  
<223> 8-124-294.mis

<220>  
<221> primer\_bind  
<222> 214858..214876  
<223> 8-124-294.mis complement

<220>  
<221> primer\_bind  
<222> 215328..215346  
<223> 8-273-383.mis

<220>  
<221> primer\_bind  
<222> 215348..215366  
<223> 8-273-383.mis complement

<220>  
<221> primer\_bind  
<222> 216948..216966  
<223> 8-126-286.mis

<220>  
<221> primer\_bind  
<222> 216948..216966  
<223> 8-130-143.mis

<220>  
<221> primer\_bind  
<222> 216968..216986  
<223> 8-126-286.mis complement

<220>  
<221> primer\_bind  
<222> 216968..216986  
<223> 8-130-143.mis complement

<220>  
<221> primer\_bind  
<222> 219521..219539  
<223> 99-5897-143.mis

<220>  
<221> primer\_bind  
<222> 219541..219559  
<223> 99-5897-143.mis complement

<220>  
<221> primer\_bind  
<222> 220817..220835  
<223> 99-24649-186.mis

<220>  
<221> primer\_bind  
<222> 220837..220855  
<223> 99-24649-186.mis complement

<220>

<221> primer\_bind  
<222> 223211..223229  
<223> 8-247-337.mis

<220>  
<221> primer\_bind  
<222> 223231..223249  
<223> 8-247-337.mis complement

<220>  
<221> primer\_bind  
<222> 224194..224212  
<223> 8-246-393.mis

<220>  
<221> primer\_bind  
<222> 224214..224232  
<223> 8-246-393.mis complement

<220>  
<221> primer\_bind  
<222> 224773..224791  
<223> 8-245-270.mis

<220>  
<221> primer\_bind  
<222> 224793..224811  
<223> 8-245-270.mis complement

<220>  
<221> primer\_bind  
<222> 230376..230394  
<223> 8-119-247.mis

<220>  
<221> primer\_bind  
<222> 230396..230414  
<223> 8-119-247.mis complement

<220>  
<221> primer\_bind  
<222> 231658..231676  
<223> 99-15870-400.mis

<220>  
<221> primer\_bind  
<222> 231678..231696  
<223> 99-15870-400.mis complement

<220>  
<221> primer\_bind  
<222> 235296..235314  
<223> 99-16087-219.mis

<220>  
<221> primer\_bind  
<222> 235316..235334  
<223> 99-16087-219.mis complement

<220>  
<221> primer\_bind

<222> 238770..238788

<223> 8-155-258.mis

<220>

<221> primer\_bind

<222> 238790..238808

<223> 8-155-258.mis complement

<220>

<221> primer\_bind

<222> 239744..239762

<223> 8-136-267.mis

<220>

<221> primer\_bind

<222> 239744..239762

<223> 99-16038-118.mis

<220>

<221> primer\_bind

<222> 239764..239782

<223> 8-136-267.mis complement

<220>

<221> primer\_bind

<222> 239764..239782

<223> 99-16038-118.mis complement

<220>

<221> primer\_bind

<222> 241842..241860

<223> 99-15880-162.mis

<220>

<221> primer\_bind

<222> 241862..241880

<223> 99-15880-162.mis complement

<220>

<221> primer\_bind

<222> 243681..243699

<223> 8-271-227.mis

<220>

<221> primer\_bind

<222> 243701..243719

<223> 8-271-227.mis complement

<220>

<221> primer\_bind

<222> 245644..245662

<223> 8-266-131.mis

<220>

<221> primer\_bind

<222> 245664..245682

<223> 8-266-131.mis complement

<220>

<221> primer\_bind

<222> 245947..245965

<223> 8-265-208.mis

<220>

<221> primer\_bind

<222> 245952..245970

<223> 8-265-203.mis

<220>

<221> primer\_bind

<222> 245967..245985

<223> 8-265-208.mis complement

<220>

<221> primer\_bind

<222> 245972..245990

<223> 8-265-203.mis complement

<220>

<221> primer\_bind

<222> 247845..247863

<223> 99-25940-182.mis

<220>

<221> primer\_bind

<222> 247865..247883

<223> 99-25940-182.mis complement

<220>

<221> primer\_bind

<222> 248296..248314

<223> 99-16032-292.mis

<220>

<221> primer\_bind

<222> 248316..248334

<223> 99-16032-292.mis complement

<220>

<221> primer\_bind

<222> 255829..255847

<223> 99-16105-152.mis

<220>

<221> primer\_bind

<222> 255849..255867

<223> 99-16105-152.mis complement

<220>

<221> primer\_bind

<222> 260080..260098

<223> 99-16033-244.mis

<220>

<221> primer\_bind

<222> 260100..260118

<223> 99-16033-244.mis complement

<220>

<221> primer\_bind

<222> 279770..279788

<223> 99-15875-165.mis

<220>  
<221> primer\_bind  
<222> 279790..279808  
<223> 99-15875-165.mis complement

<220>  
<221> primer\_bind  
<222> 300346..300364  
<223> 99-16052-214.mis

<220>  
<221> primer\_bind  
<222> 300366..300384  
<223> 99-16052-214.mis complement

<220>  
<221> primer\_bind  
<222> 312011..312029  
<223> 99-16047-115.mis

<220>  
<221> primer\_bind  
<222> 312031..312049  
<223> 99-16047-115.mis complement

<220>  
<221> primer\_bind  
<222> 315995..316013  
<223> 99-25993-367.mis

<220>  
<221> primer\_bind  
<222> 316015..316033  
<223> 99-25993-367.mis complement

<220>  
<221> misc\_binding  
<222> 8304..8328  
<223> 99-27943-150.probe

<220>  
<221> misc\_binding  
<222> 21660..21684  
<223> 99-27935-193.probe

<220>  
<221> misc\_binding  
<222> 65473..65497  
<223> 8-128-33.probe

<220>  
<221> misc\_binding  
<222> 95384..95408  
<223> 99-31960-363.probe

<220>  
<221> misc\_binding  
<222> 107269..107293  
<223> 99-24656-260.probe

<220>  
<221> misc\_binding  
<222> 160628..160652  
<223> 99-24639-163.probe

<220>  
<221> misc\_binding  
<222> 160864..160888  
<223> 99-24634-108.probe

<220>  
<221> misc\_binding  
<222> 168962..168986  
<223> 99-7652-162.probe

<220>  
<221> misc\_binding  
<222> 170798..170822  
<223> 99-16100-147.probe

<220>  
<221> misc\_binding  
<222> 173346..173370  
<223> 99-5862-167.probe

<220>  
<221> misc\_binding  
<222> 189945..189969  
<223> 99-5919-215.probe

<220>  
<221> misc\_binding  
<222> 197151..197175  
<223> 99-24658-410.probe

<220>  
<221> misc\_binding  
<222> 200766..200790  
<223> 8-303-235.probe

<220>  
<221> misc\_binding  
<222> 202639..202663  
<223> 8-300-221.probe

<220>  
<221> misc\_binding  
<222> 202667..202691  
<223> 8-300-193.probe

<220>  
<221> misc\_binding  
<222> 203366..203390  
<223> 8-299-128.probe

<220>  
<221> misc\_binding  
<222> 204126..204150  
<223> 8-296-213.probe

<220>

<221> misc\_binding  
<222> 204593..204617  
<223> 8-252-190.probe

<220>  
<221> misc\_binding  
<222> 204922..204946  
<223> 99-24644-194.probe

<220>  
<221> misc\_binding  
<222> 205194..205218  
<223> 8-295-248.probe

<220>  
<221> misc\_binding  
<222> 205317..205341  
<223> 8-295-125.probe

<220>  
<221> misc\_binding  
<222> 206052..206076  
<223> 8-293-130.probe

<220>  
<221> misc\_binding  
<222> 206533..206557  
<223> 8-292-198.probe

<220>  
<221> misc\_binding  
<222> 207301..207325  
<223> 8-251-322.probe

<220>  
<221> misc\_binding  
<222> 208273..208297  
<223> 8-289-322.probe

<220>  
<221> misc\_binding  
<222> 208948..208972  
<223> 8-287-249.probe

<220>  
<221> misc\_binding  
<222> 209111..209135  
<223> 8-287-86.probe

<220>  
<221> misc\_binding  
<222> 209619..209643  
<223> 8-285-319.probe

<220>  
<221> misc\_binding  
<222> 210349..210373  
<223> 8-283-278.probe

<220>  
<221> misc\_binding



<222> 210451..210475  
<223> 8-283-176.probe

<220>  
<221> misc\_binding  
<222> 210474..210498  
<223> 8-283-153.probe

<220>  
<221> misc\_binding  
<222> 210571..210595  
<223> 8-283-56.probe

<220>  
<221> misc\_binding  
<222> 210867..210891  
<223> 8-282-345.probe

<220>  
<221> misc\_binding  
<222> 210952..210976  
<223> 8-282-260.probe

<220>  
<221> misc\_binding  
<222> 210967..210991  
<223> 8-282-245.probe

<220>  
<221> misc\_binding  
<222> 211120..211144  
<223> 8-282-92.probe

<220>  
<221> misc\_binding  
<222> 211235..211259  
<223> 8-281-367.probe

<220>  
<221> misc\_binding  
<222> 211303..211327  
<223> 8-281-299.probe

<220>  
<221> misc\_binding  
<222> 211354..211378  
<223> 8-281-248.probe

<220>  
<221> misc\_binding  
<222> 212508..212532  
<223> 8-279-197.probe

<220>  
<221> misc\_binding  
<222> 212809..212833  
<223> 8-278-289.probe

<220>  
<221> misc\_binding  
<222> 213821..213845

<223> 8-277-250.probe

<220>

<221> misc\_binding

<222> 214845..214869

<223> 8-124-294.probe

<220>

<221> misc\_binding

<222> 215335..215359

<223> 8-273-383.probe

<220>

<221> misc\_binding

<222> 216955..216979

<223> 8-126-286.probe

<220>

<221> misc\_binding

<222> 216955..216979

<223> 8-130-143.probe

<220>

<221> misc\_binding

<222> 219528..219552

<223> 99-5897-143.probe

<220>

<221> misc\_binding

<222> 220824..220848

<223> 99-24649-186.probe

<220>

<221> misc\_binding

<222> 223218..223242

<223> 8-247-337.probe

<220>

<221> misc\_binding

<222> 224201..224225

<223> 8-246-393.probe

<220>

<221> misc\_binding

<222> 224780..224804

<223> 8-245-270.probe

<220>

<221> misc\_binding

<222> 230383..230407

<223> 8-119-247.probe

<220>

<221> misc\_binding

<222> 231665..231689

<223> 99-15870-400.probe

<220>

<221> misc\_binding

<222> 235303..235327

<223> 99-16087-219.probe

<220>  
<221> misc\_binding  
<222> 238777..238801  
<223> 8-155-258.probe

<220>  
<221> misc\_binding  
<222> 239751..239775  
<223> 8-136-267.probe

<220>  
<221> misc\_binding  
<222> 239751..239775  
<223> 99-16038-118.probe

<220>  
<221> misc\_binding  
<222> 241849..241873  
<223> 99-15880-162.probe

<220>  
<221> misc\_binding  
<222> 243688..243712  
<223> 8-271-227.probe

<220>  
<221> misc\_binding  
<222> 245651..245675  
<223> 8-266-131.probe

<220>  
<221> misc\_binding  
<222> 245954..245978  
<223> 8-265-208.probe

<220>  
<221> misc\_binding  
<222> 245959..245983  
<223> 8-265-203.probe

<220>  
<221> misc\_binding  
<222> 247852..247876  
<223> 99-25940-182.probe

<220>  
<221> misc\_binding  
<222> 248303..248327  
<223> 99-16032-292.probe

<220>  
<221> misc\_binding  
<222> 255836..255860  
<223> 99-16105-152.probe

<220>  
<221> misc\_binding  
<222> 260087..260111  
<223> 99-16033-244.probe

<220>  
 <221> misc\_binding  
 <222> 279777..279801  
 <223> 99-15875-165.probe

<220>  
 <221> misc\_binding  
 <222> 300353..300377  
 <223> 99-16052-214.probe

<220>  
 <221> misc\_binding  
 <222> 312018..312042  
 <223> 99-16047-115.probe

<220>  
 <221> misc\_binding  
 <222> 316002..316026  
 <223> 99-25993-367.probe

<220>  
 <221> misc\_feature  
 <222> 4222,11245,27205..27206,27212..27213,27240,27347,27378,28258  
 108818,128283,137062..137063,164757,172148..172150,180820,184929  
 194460,200104,207061..207062,207949,239085,249787,249806,250156  
 250189,250841,251114,264938,265019,265078,274640,277770,314308  
 318680,318731  
 <223> n=a, g, c or t

<400> 1  
 cgggcggaatt cgagctcggt acccggggat catctttgtc atagattgta gtaaaaataa 60  
 tctgtgaaaa gtgactgatt attgacaggt agccttgggt atgcagctca agtaggcatt 120  
 ataaaataaa aaacatcaca ttccatgtat tttcaaaaaa agcttctggc ttactcaaaa 180  
 ggtaagtgtt ctttaaaciaa cttcaatgga aaaggagttt cttccaaatg cttggagaac 240  
 tccttctcaa gtccggaata aagcaaggtc tacagagaca aagtataaat aaaaccatgg 300  
 tgctgagctg gtaccactat tgggctgcta agcactgcta agcattgcct tcagatgagt 360  
 tacctagcct ttgtaaagct cagattccac agctataaac tgagatgaat aataatacac 420  
 aaaacactaa gctgttgagt agattaaatg aaattattta tgtagagcaa atagaacagt 480  
 actgtacctt ataaaattta aaacaaaaat gtaaattctg atttttaccc aagggtcaac 540  
 tccgcacaat ttgtcaatgg acccttcccc ggccctccag aagctgaata tcgttgtgta 600  
 tcatatccaa attcagtatc accagggcac agagtaagtg ccaactgtga ggccatagct 660  
 atgctgcac tccctgaaa cacattgtgt accttcattc ttggagttga gtctttgcat 720  
 ttcatcctcc agagtggaga tagactgcgt gttggagagg tcagggaaat tatgtctttc 780  
 tatgtctagc cttttatagg tcgattattt gaatgcttga cagcatctgt ccacttatct 840  
 atccctgcaa taataaataa cgggactaaa gtactcgtta tctctagtgg gagagtgcac 900  
 atattttata cgtcaattct ttaaaagggg aaattctttc agagcttcag aaaatatcac 960  
 ggaagagtta aaagaatgtt tgagaagaac atgtctgagt attacctact agcattacaa 1020  
 ttttactgct ttaaagtaat tataattttc attgcaggat ctattaaaaa ggcttttacc 1080  
 tgacggtaat tcttcttgta cttacaggtc attattacaa tgaagggaag aaaggaagac 1140  
 atgaagggga aatgggacta tttaccaagt gtatctgcat agactaaagg agacaagagg 1200  
 aagtactgag caccttgatt cctgcagata attatttaag aaccataaga attctttcct 1260  
 agcttctcat aagcctgctc cttcaaaggg tgagtagttg acatgatttt acatccatt 1320  
 tatatttctt tattagataa ttttatttca aatctagtct tattttttct gaaccttctg 1380  
 ggatatataa cattttatat tatcatttat gtcataaga atgtagattt atattctttt 1440  
 ctattcacat gtttatgtaa ataattgaac acctctaaat gacagatact atcattttat 1500  
 atattgttaa taagtattct catggctggg cctgtgggct caccgccgta atcccagcac 1560  
 tttgggaggc cgaggtggga ggatcacctg aggtcaggag tttgagatca gcctggcgaa 1620  
 cgtggtgaaa tcccatctct actaaaaaca acaaaaatta gctgggcatg gtagcatgcg 1680  
 cctatagtcc cagctactag ggaggccaag gcaggagaat cgatcgctca aaactgggag 1740  
 gcagaggttt cagtggagctg atatcgtgcc actgcactct ggccctgggca acagaatgag 1800  
 accctgcttc aataaataaa taaattaatt aattaattaa taaagtatct taatgacaaa 1860

tatttaaata	tatataaata	tttacattta	catatgggaa	gagagatctg	aaattttaag	1920
caacttttat	ccaaaaacct	atTTTTttca	aagttcctcc	aacatctata	aaagaagtaa	1980
agtcacttat	agatctatct	tacttcaggg	cctatgtttt	cctctacccat	acaacactgc	2040
acattcacag	acacagaaat	cttttacatt	tctaaaataa	ataaaacatc	caaacttcag	2100
tttaaaaaaa	atggatctac	agatccacca	tagactaaac	gaccaaacat	agtcagaggt	2160
gtttacttgt	ttgtttcggg	cttaagggaa	tcttcaaact	accctagagc	ctcgtgtatc	2220
caatgagagc	agtctggaca	ttgaatgaat	gggtgatgtca	ttaaatgagc	tatggagcaa	2280
gatgtaagaa	cacgcttttag	agtaaataac	atattttggct	tctgaggtat	aaaaagggaa	2340
ggaggctttc	tcaggacatt	tgggtacctg	gtccttcata	ctcaggaggt	ttttccatct	2400
tcagtgcattg	gaataaaacta	tgctttaaag	aaatgctgcg	tcagcagaaa	gtgtttcaaa	2460
tataaggaaa	ttgtcatagc	tttgaaatta	tgtcaaatat	catttttaact	aagagagcca	2520
ttgtctttcc	atataatttat	ctagaagaaa	atttactgga	caaaaataaat	atagaacaac	2580
ttcatgtgta	gtcattaatg	gtcggatagg	cagttactat	aaaatatgaa	taatctaaaa	2640
atcatttttag	ccatttggtt	tttaataaatc	tcactttgtga	ttgattttatt	aaaaacaggg	2700
cctccagaag	aaagaaactt	aatacctttc	ctccatcatt	atgaaggcac	tagtactgac	2760
gtaactaaaa	ttagatggca	gcttgaggga	ggaagagatg	atgtagagat	gggtgtgtaat	2820
ctgtgtaaac	agtctctcaa	ctgtctagag	ttagctgtac	gaatctgttg	ttggctccag	2880
ttataagaac	caagatatgt	atgtaaggac	aaacatcctt	aatttgctta	gcaagtcgta	2940
tgtatttgat	agaccaccaa	ttttatttta	ttttatttta	tttttgagat	ggagtcttgc	3000
tctgtcacct	gggctggagt	gcagtgggcg	gatctcggct	cactgcaaac	tccatttagc	3060
aggttcaagt	gattcttctg	cctcagcctc	ccgagtagct	gggattacaa	gtgctcaaaa	3120
ccacccccgg	ttaatgtttt	tttcttttct	tttcttttct	tttcttttct	tttcttttct	3180
tttcttttct	tttcttttct	tttttttagta	gtagacacag	ggtttccacta	tgttggccag	3240
gctggtctca	aactcctgac	ctcgtgatct	gccccactcg	gcctcccaaa	gtgctgggat	3300
tacgggtatta	caagcgtgag	ccactgcacc	agccctgatt	tttaaaaggg	attttagaat	3360
ttcagttgaa	catgtgtttt	tgaagtaact	ccatattgaa	caggggaatc	agagtaagta	3420
aaccactaca	ggaaaatcag	gaaggcagac	tccaatttat	gttttctgtg	tataacctac	3480
tttaataaag	aattaaaaat	cataagagta	gttttatcta	gtggcctaga	acttgattat	3540
gaaaagtaag	acaaaaggaa	tctgacctca	tgccagtgtc	tggaaagcctt	acaggaactg	3600
aaaggaccca	cgtggaacag	ctggcaactg	aaactcatct	tgtcaatttc	aagtgtagtc	3660
cctcttccca	attcaccgga	gaaaacacag	ccagctttgc	atacagtgtc	tgggtgcacc	3720
agagaaaaca	cagtcagctt	tgcatacaat	atctggtgtc	agaatgacca	aacgattggc	3780
ttctatcctt	caggattgtg	aacagagagc	caaggcatac	aaccagtatg	cccactccgt	3840
cagctgcgag	acagaggaga	taaagaatgc	tgaacattat	gggtcactgc	tttgaagtat	3900
tcagaggcca	aaatagttca	aaataattgt	gttaactcatt	aaaagtagaa	gaagtggaa	3960
ccaaaattat	gcctgcctat	atttcagttt	tgaatgtgtg	gagatcagaa	atttataaaa	4020
aagtttatga	gtttccctt	ttaaactttg	agaaaagacc	ataagaaccg	gtgttttagt	4080
aaatcatctt	caagagtaat	ttactcataa	aaagaaaaga	actcatgata	ccgtgtaaac	4140
aaaaggctaa	taaatgctgg	tgtaaataag	attaagggag	gacaaagatg	aaggaaagca	4200
ggacataatca	aaaaacaaat	anaataagaa	attttcagag	cttgaatata	caaacaggca	4260
catcaaaaaga	ggttcaatgg	aaacctaatg	caatgaatgg	gacaattaat	gcttttaaac	4320
atcacttgga	accacagaaa	ataccaacag	aaaaatctgg	tcacgtacaa	gagataagag	4380
tcagggttcc	atggatgttc	ttcttagatg	agaaggacac	ttcactttta	tggcattgtt	4440
cccacaaatc	cataacccaa	gtttcatcat	gagcaagcct	cagccaaaga	aaaattgaga	4500
tgtattttac	aacatacccg	ttcaggccct	ttaaaaatgt	caaagttggc	caggcaccat	4560
ggcttccacc	tgtaatccca	gcactttggg	aggtctgagat	gggtggatca	tttgaggta	4620
ggagtctcag	accagcctgg	acaatatggg	gaaaccccaa	ctgtactaaa	aaaagataac	4680
aaaattagcc	aggtgtgggtg	gtgtgggcct	gtaatcccag	ctacttgaga	ggctgaggca	4740
ggagaatcgc	ttgaaccocag	gagccaggag	gtggagggtg	cagttagcca	agatcatgcc	4800
actgtattcc	aacctgggcg	acagagcaaa	actccatctc	cccccaaaaa	aagcaaagtc	4860
gtgaaaaaca	aagtaagact	aaggaactgt	cagattagag	gggactgagg	aaacatgaaa	4920
attagatgaa	atagggata	cagtttagaa	ttatagaaca	gaaagcagga	catcagttga	4980
acaactaaag	aaatacaaat	aaagtctatt	ttagttaata	ttgttgtaac	aataactaatt	5040
tcttagttgt	aacaaataaa	atatcattat	gtaagatggc	aacttcagga	aaagttgggg	5100
gaaagatata	caggaataact	ttgtattatc	ttagaaacta	ttatgtcaat	attttaatat	5160
aaaattatta	gaaattgtgt	cagaaacact	ggatgttaga	agacaatgga	ggaatgcctc	5220
aaaaaatcta	cagagaactt	cttttcaatc	tatcatcata	gcataaatca	agtatgagct	5280
tcaaattatg	atattttata	atagtgaat	aattctgaaa	atttacctta	taccaatatt	5340
ttcttagaag	attacttttag	gatgtgctat	agtcaaacag	aggaataaac	taagaaaaag	5400
tatgatgtga	gatacagaaa	aatatataga	aacaatttag	aaaaataata	aaaagtagtc	5460
ctatgataat	agcaatataa	gaatgtttag	attggaatag	aagatgaatg	ccctcaagag	5520

tataacctct	gaaagaaaaa	ttaaataaat	aaaaaaatc	tgacaggata	cctgatcaga	5580
tagagatgtg	acaaaccagt	atgttgaaa	gtgatgacag	aaagagagaa	cggaagaga	5640
gaggcaggaa	ggaagggga	aaaaaagaa	gaaatgaaag	gcgattctca	caccagttag	5700
aatggcaatt	attaaaaagt	caggaaacaa	caggtgctag	acaggatgtg	gagaaatagg	5760
aacactttta	cactattggt	gggactgtaa	actagtcca	ccattgtgga	agtcagtgtg	5820
gcgattcctc	agggatctag	aactagaaat	accatttgac	ccagtcaccc	cattactggc	5880
tatatacca	aaggattata	aatcatgctt	ctataaagac	acatgcacac	gtatgtttat	5940
tgcggcacta	ttcacaaatg	caaagacttg	gaaccaaccc	aaatgtccaa	caatgataga	6000
ctgggttaag	aaaatgtggc	acataacac	catggaatac	tatgcagcca	taaaaaatga	6060
tgagttcatg	tcctttgtag	ggacatggat	gaagctggaa	accatcattc	tcagcaact	6120
atagcaagga	cagaaaacca	aacaccacat	gttctcactc	ataggtggga	attgaataat	6180
gggaacacct	ggacacagga	aggggaacat	cacacaccag	ggcctgttgt	gggtggggg	6240
gaggggggag	ggatagcatt	aggagatata	cctaagtcta	aatgacgagt	taatgggtgc	6300
agcacaccag	catggcacat	gtatacatat	gttaactaac	tgtacgttgt	gccatgttac	6360
cctagaactt	aaagtataat	atataatatta	tatatatata	aagaaattcc	aagaaaatca	6420
aaaggctgca	tacaaatgaa	atactatatg	accattatct	ccttcttggc	tttttcaaga	6480
acaacattta	cttagctacc	acactgaaat	tactattcat	taattttaag	taaaactggca	6540
ttgaaaatat	ggttaactctg	gtttttcttt	ttttttttga	gacagggtct	cgctctgtta	6600
ccaaggctgg	agtgcagtg	tgtgatctta	gtcactgca	acctctgoc	cccaggttcc	6660
aacaatcctc	ccacctcagc	ttccccagct	agctgggatt	acagctgtgt	gccaccatga	6720
acagctaatt	ttatatTTTT	agtagagatg	gggttcgccc	tggtggccag	gctggcctcg	6780
aactcctgac	ttcaagtgat	ctgcctgcct	cagcctcccc	aagtgttggg	attacagggtg	6840
tgagccaccg	tgcccagccc	agaaatgtgt	ttagtagttt	gaaggggcaa	gtaccagggtg	6900
ctaagagttc	acaggggagg	gatactggac	ttagaccctt	ggaatcaaga	aaagctttct	6960
atagaaagta	ctgcctaagc	tgaagactga	acactgacca	ggctgaatga	aagatgtagt	7020
gctggagagg	atttcagtca	gaaaaaacat	ttgagaaggt	ccagaagaaa	aataaaacaa	7080
tttatttcaa	ggtactgaaa	taaattgaga	ttagggggag	tgaagagtca	aggtctggag	7140
aggtattgag	ttgtcaagaa	atacagtttg	agaggtaaag	gccatattag	gaagtaatat	7200
atttttaaac	ttttgaagct	tattctaagg	ctaataacaa	agtgtgttag	gcaggaaagt	7260
tgcaattatt	ataaaacttt	cagaaagatt	tattttaatt	aattgggaatt	gagaaagaaa	7320
ggcattattt	tacgtaataa	aaatatttat	ttgttgtgta	aaaaataaat	agtttggcct	7380
agaggagaac	agggccagta	aggaagagga	gaaatgcata	gatataaagg	gtgttaggat	7440
aaagcataag	taagacttaa	tgataattta	aacttaagga	acaaggaaaa	tgaaggagta	7500
atgaataact	gagtcaactt	gtagatagag	gcaccaatca	ctcaactcag	acagagtaga	7560
ctagagggtg	ttttggggaa	gtataaagact	ccacttttag	atctctggaa	tatccaagat	7620
gggaattcaa	ttaggctatg	atttcaagtt	caaacaagag	aaacgggatg	gagatatttt	7680
tagataccat	ctgataatga	ttagtgtatt	aagccatggg	aatggatatt	ttgtcaatgt	7740
tcttttgaga	gctgtatcct	tcogtagtta	tctgatgggt	tttttaaatg	gcgtaaaata	7800
atcagtaatt	tagaagtttc	tataaagaaa	gttcggctac	aaatacttat	cctttctctt	7860
tcattctcaa	accatgcatt	aaccacctat	taattgtgtt	agaaaaacag	taagtaattc	7920
agggttcatg	ctgacagaga	agaccacat	aagcaaacct	cgctataata	caaggagcta	7980
aattccccaa	tataagaatg	cagtgtgtct	tgtgggaata	tgagaaaca	aagataagga	8040
aaacctaggc	agaaatagtt	caattgattg	ttatttcata	ctgagacaaa	tttgccaaagt	8100
ataaactata	tcctattaca	aatttagatg	ctttgggcca	tggttcagct	ccacggcgac	8160
acctacactg	aagttgtatt	taagctatct	gtctggatca	cttgggtcac	aaaaatgttt	8220
ggattacaaa	aaggaaatat	catacacctt	ggaagaactg	gctcattagt	caagatgctg	8280
cttaccagtt	gcctgggttg	gctgctgttg	taaagsaata	tcggttgga	agccggggct	8340
ggaggtcggg	gagaggctgt	cttctatata	ttacatttgc	tatgtctttg	gaggaaagat	8400
gctttcggga	gtgttcctta	aatttaaata	tcttttcctt	ttggactcaa	gggtatgttt	8460
attcgacttc	atcatatcta	atctcctaga	atattattaa	cctgaagtta	ttgtcagtat	8520
ogtatgatat	ttattgaata	acaatatgct	ctgatactgc	atatgaaatg	aaataacaaa	8580
tgaacctccc	ttactttaac	ttactacta	attaattaga	aaagaacctt	cactcaaggg	8640
gtttggaaag	gtccaataag	ggaatttaaca	gatgagaatt	taagagtacc	tgaacccatc	8700
tcgatttgag	atttacgtga	tgctgggtga	ttagtataaa	gaacagaatg	aagtcagctc	8760
aggaggcatc	gtgactctga	aaggaggag	atatttcagt	gaataattga	gaggattcag	8820
acaaagtcac	atgagagaag	cagagacaga	cagagggcag	gagtcagtgg	atatgagaat	8880
gatactagga	agatgaagaa	tggaactgatt	tgtaaaagaa	ttgagaccca	agttatactg	8940
tgtaagagaa	taagttaaaa	ccattaaaaa	atattgggag	atcctgaatt	gctttcaagc	9000
ctagtaattt	gatgtaagaa	atagtgaagaa	atgctcttga	tggtgtgtct	gtttcaggga	9060
aagttttgtg	gagacaatga	aataaataaa	atagcatatt	tagatcaaga	ggctgggttt	9120
ctttttcaca	ggaaacatct	aagaaactgt	taaaagggac	aagggttgag	tgtagaagcg	9180

tgaaataggg	ctatggtaat	aaattgttac	cattccgaag	attatcaa	tatctcccag	9240
ccaaaaaaag	agtttttaaa	caaacatatg	aagatataca	atataataaa	taaactagta	9300
tgtttatctc	agattcaacc	attttaacca	caaagaacaa	aacaacctca	actgagagca	9360
ggcttgattt	atgtaagcaa	agatttggtt	ttgaggcagt	gaatatagga	ggcattggaa	9420
aagtttgga	aaaggctggt	gggctttgtg	agacaaagt	accatgccat	gagaattgtg	9480
aaaataatgt	agatgtggaa	tcctgttaaca	atggcaatta	gtgatgaagt	ggtgacatgg	9540
gaataaaag	aaatgggtca	acgtggatca	tttttagaag	gaaaagcact	gaaactttgg	9600
aatgagatta	tgaaaaaaag	aggatgagaa	attatgtttc	caaggtttat	tgcaaaagct	9660
gtgatgatgg	catacctcag	atagaaatga	attattttaa	aggaaaccag	tttttagaga	9720
aagataatga	atccaatttt	gaacacattg	aattcaaagt	gacaatccgt	catccatgca	9780
gactaccatg	tagacagata	accaaataga	atagaaacac	ccaccatata	taataaaacc	9840
acaggtgcac	tcattgagtg	aaccagtaca	gataaactat	attgtagggg	ctctcacatc	9900
tggaatagg	aagactcaat	gaaggcaata	aggggaagtt	aaaaagaata	agataaaactg	9960
gggaattcaa	gaagatcttc	tttggcttcc	ataagatcct	agactgtttc	taggaagcag	10020
tcacagttca	gccatggccc	agaatggtga	tgaccgaggg	cagggccatg	gtttggtgct	10080
cagagaccat	ttgccctcta	ggagcaactg	atggagagaa	taaattgggg	agagaataaa	10140
tctagggcag	ttgaaggaga	gagtaaattg	taaaccaaga	atgccatagc	taaaagggaa	10200
gcagcaggca	agtttgcaat	tttgaggaga	aattctagga	agggatttct	ccacatttcc	10260
attttaggcc	agaagtcttt	gacatgctag	agagaagat	ggattttttt	tttaatgaat	10320
aaatgagata	ttggcatttt	ttggcatttt	tggaagaa	agatttcatt	ttcaagacca	10380
aaatttaaac	agcaatattt	agcacaaaaa	atgcttgtca	aattcctgct	gaatttgaaa	10440
gcaacagcat	attaagcttt	tttcttcttt	cctgcaatag	ctgatgttca	cgatacagta	10500
ttcccttgcc	ctggtgggag	tatgtcctcg	cttatcctgg	tggaatatg	ttcccttta	10560
tectggtggg	atatactccc	tcttatccta	gtgggacatg	ttccaagact	cccagtggat	10620
gcctggaaac	atgaatggtg	ccaagcccta	cacacactat	gttttcatca	tatacatata	10680
catgtatgat	aaagttaaat	ttataaatta	ggcatagtta	gagataaaca	ataatagcta	10740
ataataaaat	agaataatta	taacaatata	ctgtaataaa	agttgtctga	tgtggtctct	10800
ctttctttca	aaatatctta	ttgtactgta	ctcacccttt	tttgatgatg	tgagaagata	10860
ccatgcctat	gtgatgtgat	gtgatgaagt	aaggtgaatg	agaaaggcat	catgacgcag	10920
ggtggcctac	tattgacctg	ataagcaggt	tgtgtctgca	gcattggagac	tctggaaaag	10980
ggatgattca	tgtcaaggga	agaattgaat	gggacagcac	agattttatc	acattactca	11040
gagcagtgca	caatttaaaa	cttatgaatt	gtttatttat	agaattttcc	atttaattatt	11100
ttgaaaaggc	agtgtgccac	aggtaattga	aaccacagaa	agtgaactg	cagatgaggg	11160
aggactactg	tattcttaga	gcaattgtat	atcattggaa	tattattgat	agtttaattg	11220
aaaaacaaat	tagatcaaca	tgggntggtg	ccattaggaa	agatggtaga	ttttcaattc	11280
aaattcacaa	ctttcaaaga	aaaatattgt	gagtctctgc	tatgagatag	atattgagaa	11340
atggtgtaga	tatatattcg	tctgttttca	tggtgctaac	aaagacacac	ccgagactgg	11400
gcaattttaca	aaagaaagag	gttttaagaga	cgcacagttc	caagtggctg	gggaggccctc	11460
acaatcatga	tggaaggcaa	gaatgagcaa	atcacgtctt	acacggttgg	cagcggggcaa	11520
agagagagaa	cttgtgcagg	gaaactcctg	tttgttaaaa	ccatcagatc	tgatgagaca	11580
tagtcaactac	cataagaaaa	gcacaggaaa	gatccacccc	atgattcagt	tacctcttac	11640
caggttcctt	ccacaacgtg	tggaattgt	gggagttaca	gttcaagatg	agatttgggt	11700
ggggacacag	ccaaaccata	tcaagatatc	agcagaaatg	agcaaaaaat	gagtgatttt	11760
aaaattactc	ggtttattac	tgacattctg	atgtgcattc	cttaagagat	aattacattt	11820
tacacctaat	gccaaaagttc	ttacagttca	aactctagga	gcaagagctg	ccaagaacc	11880
attgccaaaa	agttacaggg	agagcctcag	tgtttgtttg	gactctccag	ctcctacctt	11940
ccctctctc	tttcttctct	cttctctctc	catcattctt	cccagccttc	ccaggttctg	12000
gggactcagc	ttccatgatg	ctgcctcaga	ctttctatcc	atacgttatt	attgcaactg	12060
gtctcagagg	agaagaggga	ggccatcttg	agaaggtaca	gggcacctca	gcagtgtctc	12120
ttgctgtctc	attgtcctg	cttctctgac	cctgccaggg	gcacacctgg	agaaacttag	12180
aaaacccttc	agaaaagagt	aacagagaaa	actcaccaaa	tacaagccat	tcaatgtgcc	12240
atcataggtt	caaccctaat	cttgtttcag	gttacagata	gagaattcca	gtgcttctta	12300
tcagctttac	gaattttatt	catgcttcag	aaagttgcta	aacagtgtaa	atgaatattt	12360
gggagaagaa	taaaaagaact	actccgaaaa	tctgaaaaga	gttaaaataa	attccagtg	12420
actttgatct	ttcctttata	aatacaaagg	atttatggtc	ttttgcatca	gccaggggtg	12480
ccactgggaa	gtcagagttt	atctatctcc	atcttcacat	ttattacaac	cacacacagc	12540
atttatcata	cttgatttca	gacatgatgc	tattattatt	ttccactggc	atggctttta	12600
aaccccaag	cattagagac	agatagatag	atagatagac	agagatattt	atacaataaa	12660
agaattatat	atataaataa	aatttcttta	tataatgaag	aaattoatat	aaaggaatat	12720
attatatact	atataatggtt	gtataaaaatt	atataattata	cattatatat	tatatgtaat	12780
ttacatgttt	ataattttata	attatatttat	atataatttat	ataattttata	aaattatata	12840

taaaaattgt	gtatattata	aaatatgtaa	tataataattt	ataatatatt	ataatttata	12900
tataatacat	aatatataatt	ataattttata	tataatacat	aatatataat	atattataat	12960
ttatatataa	tataataatgt	attatatata	tgatgtattg	tatatataca	tacatatattc	13020
caccaatgtg	attttaaaag	actaccataa	actcactgaa	aagaaaacat	aacagttggt	13080
ttccaagaca	tgaggacatc	agttggaata	acgtttcttc	catagaatta	aatgcattctc	13140
tggtgtcttg	gaaaggcaat	ttcctctcaa	atgggtaaag	tgttgtact	aatactgtat	13200
aaaaatgaat	acaataaaaat	aggcgcaaaag	aatctcacia	cttaaaacat	cccatcttta	13260
ttctatagct	gtaagctcag	agagacaatg	atcccatgat	tttatgggag	tagaaaaaca	13320
ctttattgag	tgttttctat	gtatcagaca	ctgtgtacat	tttgctatgt	tgtcccgatt	13380
ttattaaatg	cagtcctttt	cctgttcagt	gtcaccattc	ggaggttttt	ttcaagacac	13440
tctggtgctc	catgagatct	aatctccatt	aatgtgacat	atatgctgat	attatgtaag	13500
tgtgtgtgca	tacgtacact	gacacacatc	gtttgcattt	gtaatttttt	tttaccagat	13560
tgccatataa	aagattaaaa	tggaagatta	gactccattc	agagtttgac	aatgcctcaa	13620
taataaatca	gttctcatca	tttgaagaac	tatgaggtgg	aacaaaaact	gatttgagat	13680
tcataccgtt	gtatacctac	tcittaaaaa	aaagatgcaa	tttacacatc	tgcaaatctt	13740
aggaaatggc	ttagagaatt	tgcatgattt	gggcacatga	agccatttta	gcacataaat	13800
tccttccttt	catctctaac	gggtgtagaa	aggatacaaa	catatttttt	gcagatgatg	13860
tgaattattg	actggcataa	atagcaactc	acactaaatg	cttcagaaat	gtgtttttta	13920
attgagtga	gatggaataa	aaaaatgcag	gaaaagtcct	gttctatgag	agctgaagat	13980
atggaattag	atacagtatt	tgtgagtgtg	tgtgtatgtg	tgtgccatag	ctaattattat	14040
aatttttggt	tggtcttcct	tgtccattta	atgtttgcag	catttggtga	tggattttta	14100
ctaaatgatg	acaaaataat	gaagcagatt	agtaagaaaa	cctacaaatt	gtttactaga	14160
tcttcactat	ctatattaaa	tagatgaact	aaaaggtaaa	tatggatttt	tacctaactaa	14220
agaaaaactac	tagaattttat	tgcactttta	aaatatcatg	tagtgtgttg	taaaatgaac	14280
ccaatcagat	gttctcttaa	aggactatat	tagggatttg	taaatagttt	tcctaaaagt	14340
ggattttttt	tttttgcacc	acaattcaaa	taatgccaga	attgccagct	ataaaccaaa	14400
tgtgaagtcc	atgagcttga	aaagcccata	gtgttcacgg	ggatcagtc	ctttttttac	14460
actgaaaca	gccccagaaa	gttccagcca	gtaatgaaag	atggtgcaca	atggtcttga	14520
cagaaccgtg	atcaaatctg	gtcattgtga	gtcttctggc	cagcgtcgat	ttctaccac	14580
atgtgttttg	cggcctccat	aagatgttaa	aggaacactg	aatcattggc	aatccataat	14640
actcagattc	ttggcttaga	gagattattt	accccggggt	gcctttctaa	cataaacact	14700
agccttgggt	atagtaacag	ggagtacata	gaatagtcca	actcatatga	atgcaagaaa	14760
ttataatgtg	attaattttt	ttggtcattt	caattttattg	aaggtaattc	agttggctct	14820
gtgaatgtat	ataggaaatt	tagaaatatt	aatatgtttt	tatttttttc	ctctaggtta	14880
actgaagtga	atcaaaactat	tggattataa	ttccatgaag	gtaagaaaga	gctccagatg	14940
gttttcatcc	tatcaccagg	acctgcacag	tatgagtacc	tggtgcataa	caaactttat	15000
taattatctt	ttctctcttt	ctttccccaa	ccatgtgtat	acatacacac	gcacacacac	15060
atatatatgt	acatacacat	atatacatgt	gtatggatgc	ataatcacat	acacacgtgt	15120
atatatacac	atatatacat	gtgtatgtac	atactcacgt	acacatatgt	gtatatattc	15180
acatatatac	atgtgtatgg	gcataatac	atataataa	catgtgtatg	ggcacattcc	15240
tctatatata	cacatacaca	cacgtacata	caataaataa	atggttgaat	ggcaaaatga	15300
ctaaatggat	ttagtacaa	ctaatagat	gccacagatt	tgtcaaagag	ccctggaatt	15360
gagtaaaaat	gaatgaacta	aattccaaga	tcttttacaa	cctatgattt	cattccagca	15420
gaaatttgta	aatatgtgta	ccatagattt	atacaaaacg	ttaatgggtg	cattattttg	15480
aatagctcca	aatgggaaaa	agcccaaatg	tcaatcaaca	gtagaatgga	tggatttttg	15540
tatatccata	gaatggaatt	ctagaccaca	gttaaaatga	gtagattatt	gctacaccca	15600
gcaacatgga	tgaaactcaa	aactccttga	gtggataaag	ccaggctgtt	tacgattaca	15660
ttctctgtaa	gaacttttat	tcaaatttca	aatacaagca	aaactattct	acagtgaagc	15720
aagtcatggg	ttaccttttg	cagtttagtgt	acccagcgtg	gggcaggagg	gaagtttcta	15780
ggtgatgaag	atgttttaat	tcctgatcta	atcctagctt	tactgatggg	tttactttga	15840
aaaattcatc	aagggtgacta	tgcactttct	gtaggtttac	atgaaaattt	caatgacaca	15900
cttgattgta	tgacttttga	tattactttt	cttttctgtg	ccttaatttc	ctcaattgaa	15960
aagtgaggaa	gagaatgctt	acctctaagg	attgacatca	agattagtg	ctgagcacgg	16020
tggttcacac	ctgtaatccc	agcatttttg	gaggcagagg	caggcagatc	acaagatcag	16080
gagtttgaaa	ccagcctggg	caagatgggt	aaaccccgct	tctactaaaa	aaatacaaaa	16140
aaaaaaataa	ttagccaggc	atgggtggcat	cgccctgtat	tcccagctac	ttgggaggct	16200
gagtcatgag	aattgcttga	acccgggagg	cagaggttgc	agtgagctga	gatcacgcca	16260
ctacactcca	gcctgagcaa	cagagcaaga	ctccatctaa	aaaaaacaaa	acaaaacaaa	16320
aacaaacaaa	caaacyaaaa	gattagatta	gcaagtagag	tatgtgtaaa	accacctgga	16380
aaaatgcctg	gagtggtgtg	tcagtattta	attgtagaaa	cagttacott	cataaacac	16440
aggacattgt	gggaacatct	gttaattacc	gaacagctct	tttaggacc	cctgggggtt	16500



gtggatagta	atTTTTatta	ataacacctt	tatatgggct	gaaatcacaa	tgatactgtg	16560
tcaaattaac	cagcagttaa	gagctatgct	tcttcttttt	gccaatTTac	ttgTTTTatt	16620
tgTTTTtaat	tgacaaataa	aattgtgtgt	atttatcttg	cacaacaagg	tgTTTTtaaa	16680
tatgtataca	ttgtggaatg	gctaaattga	gttaattaac	atatgcatta	cctcacacag	16740
ttatttttagg	aactacgttt	ccagaagtct	gtaaggtaga	tggaattgata	TTTTtaacct	16800
gattcattca	ttcttcattt	aacccaggaa	TTTTttgagg	gtcagtttca	gagcatgcgc	16860
tacactaagt	gtcgggatta	ctaacatcaa	ggaacagtta	ctgacacaa	aaatcgatgt	16920
gaagtcctaa	aagagagaac	atagacagac	acataaaaac	atagtataac	acaatatatt	16980
aaaatataca	caacaaaaca	tataagataa	acacagaaat	gtttggagca	atgaattaga	17040
tacttaactg	gtttagaat	gttttgaaga	aatgtatgct	aatatgtctt	ttgttcaaaa	17100
tttattaatt	atataattaa	cttttaatta	tgataaaata	cataatataa	aattttattat	17160
cttaagtaot	tttaagtatt	cagttcagtc	atgttccacta	tattttatatt	gatgtggaac	17220
agatctctaa	aacatttttta	tcttgcaaaa	ctgagactct	acaccctttg	aacaaccttc	17280
cattaatatt	gtttacatgt	taacacattt	catttatatta	taatgtatta	tcgataacat	17340
atttatatata	aatatatatta	taaatatata	tgaaatttgt	atattttgag	tattagtctc	17400
aaacaatgct	acatatatct	aaggcttcta	gtccttatatt	ggacttacag	tggaaatctg	17460
ggaaattggc	cagcatttca	gtgtgaaggga	ggaaggatgc	cgtgttctct	cccactctgtt	17520
tcagaaaacc	agtgtggaga	agatgcataa	taggcttgac	gcatttttta	taatgatgtt	17580
tatatTTTca	ttttcttttt	catagtcaca	atgaaagtga	aagcaaagga	aagagctaatt	17640
gtccacacag	ccactgggta	atagcgaact	gtgaagggtg	tggaagtggac	tcactgggag	17700
acgggagccc	atggaccctt	ccccagctcc	tttgctccca	cagcaatctt	ctcccttctc	17760
tttctttgtc	tcacagtcta	gaagagtgc	atttcaaaaa	ttatagcagc	agaggtgttt	17820
ttacctatag	caaaaagtgt	acatgtaatc	acattatgac	atactacaaa	acaggtaaaa	17880
acagtagtgt	ttagtacttt	tataaattca	aacttagcaa	ttttcttat	ttcaacatta	17940
atatcaatag	gcattaatgc	cagtttttta	atgccagtga	tttttaacct	gctgaaattt	18000
gttttataac	ttactgcggg	gtaaatgaga	tatttagtta	tacttttgaa	agtattgctt	18060
gtgtataaaa	caccttgaaa	taaaagtgtg	aagatgtcct	atgagttgct	gtgaaaagag	18120
tagttgtgaa	agtttcaaaa	tgacagatgc	attttaatgg	cagagtagga	gttcatttat	18180
ccaaaaaaga	gggaaataca	gctcaaagag	taaagcagat	gcagagaaca	gcaaacacag	18240
gtcagagcat	tgtgaatctt	cggctttgat	cttgagtacc	tagctagata	ttactgtcaa	18300
cggctaagat	taaaagttaa	caatatcagg	ggaaatgcat	ttgagaacag	taaaacattt	18360
atTTTgtaca	tatatagctt	gaaatgcata	tgggaaatgt	aggtggagat	ttttagttagg	18420
caatagcata	tgtgagtttg	aaatgtaatg	cggatatata	atctaaaaact	ggttctcaat	18480
tctgactgca	cattaggaaa	tttactgctt	aaaatgacta	aatctcaggc	ccaactgcag	18540
attgattaaa	ttaaaattta	tggggatgtg	cgctgaatt	ttttttttca	ttaaaaaaa	18600
aaaaaaaaga	gtccccaggc	gattataaga	aactgccagc	tttggaact	gctggcctac	18660
aattagtgtc	aacgtcatca	ttgtgtgggc	tggtgttgga	tggaatgaga	caaggatgga	18720
tgagaacatc	tagagagtgc	aggttggtcc	tcttcttgct	ttctatttgc	ccttcagatc	18780
tgccctttca	tgtagtctgg	gcaccagagc	accctgagcc	cagtggactg	caccagtggg	18840
ctcttccatc	ctcagggttt	tggttaagcac	catctagagg	aggcatagag	agaaaatcag	18900
ggaccacagg	aggttttggt	ttccagctt	cctttctgct	gggtcaagg	gggtcaagg	18960
gtaactgcag	gttgagggtc	atcctcagtc	aaaggccaca	gctgcagcag	gtgcacctct	19020
tcacacagct	gcttctagag	tctgcttagc	tgcttcaggt	caaggatgga	tgaggtctcc	19080
caactgttgc	tagctctata	gttctcagcc	atcttcagtt	gattcccccta	aatcctgcct	19140
gccccttctg	agacagtacc	ttcattaaat	attctctcatt	ggttaaaaag	tagtgacctt	19200
gtgctgaata	ttctatgcca	agcctctgcc	tgctgcagta	acataagaag	agttgtggct	19260
gaagatggaa	ccaagagaga	aaatgacctt	taaaagatgt	aacgaggtgc	ccagggaag	19320
ttttggcaat	ggaatctgag	catgtagagt	ttaaatgtaa	gaacggaaaa	atatctgttg	19380
tatttgaaag	gtcacgaaag	gcttcttccc	gagaggaatt	ttagtggtgc	gctaacaaaa	19440
atcagatggc	aggggctggg	gcatcaatgc	aagtgaagaa	atgaagggtg	gttattttgac	19500
aagtttgatg	ataggaggaa	taaagaattt	ggatttatta	aaaataagac	atggagctaa	19560
tcaattgaga	ttgccaaaact	cttttaatga	aaagttagctg	tgctctatct	ccagcagttg	19620
caacagagca	ctaataatat	caccgagact	attgatgtga	gggcaatata	catactcagt	19680
gctgtaaagg	cttagatttt	tgatagctac	tcaaggaaga	acacaaagaa	ttaagtcttg	19740
atTTTtaaaa	tgaacaaaga	tataaagaga	gaaaatacag	aatgtatacg	aataatcaaa	19800
acatatgaaa	cgacagccat	ctctggtaat	caaaaagaag	ctactacaag	caatgatata	19860
tgTTTTgcct	tataacttca	taaagattca	gaaaatgggc	catagccact	attggcaaga	19920
aggcaataaa	agtccatttt	tggtcagaat	gtcaatttat	gtatcttttc	tgaagtctgg	19980
tctttgcact	cttacccttt	taaagaaaac	attaattgtt	tactgaagc	tctgagttca	20040
tatggccatg	ctctcctgcc	caggtgttct	ctcccttaag	ccttctcttg	agcacttatg	20100
tgccactcat	catcatgact	tcagtcttta	aagtttcttt	aataccactg	gactataaaa	20160

taggactgac	gaaaagaccc	attcaacatt	ccattgaagg	attaaatgct	atgttttaag	20220
atataatttt	ataacatata	tctatcatga	aatccattga	ctcttcacaa	ttagatgctc	20280
ttacatagaa	aacatagtta	cttacaaaagt	catgggtgaa	atgaatctct	gctgtaacgc	20340
cattacatat	ccctaaaaca	tattttaagaa	ttatgaagag	gagcattatt	gaaaacaaaa	20400
tgtattgaca	ctaaagagta	actatttttaa	aaaggtaata	tcatgatact	catatgaata	20460
tcaaataaat	gcatgtcaaa	tatttttattt	aactcttttaa	ctaatagaaga	aatgggtatg	20520
atgctacacc	caattcaagg	tagaattcaa	aattcaaaaat	aaacacatat	atacataaat	20580
caggaatttt	gaaatgaatg	tacaaaatga	tgcaaaaactg	gctttttcca	tggagattgg	20640
ggtcgttgtc	caggaatcag	tagttatttc	cagggacaaa	attcatttgc	atttctatgg	20700
gcaagtgtca	tttaaaactgc	aatcagttat	ctacaattta	tggaaatcgta	accactttta	20760
aaaagatgaa	aacagtttaac	ctgaaagttt	ctcctgcact	aaatgagaaa	gaagctcagt	20820
tattttttaa	tttgcttatt	tttgtcttgt	tcttttttaa	tttcacaata	tttgactgac	20880
agtaacttac	ctgatagtga	taaatcaatt	tgtgccacat	ctcatggcat	atcagctttc	20940
tgtgtctttg	tccatctcaa	acaacccac	atgcctacct	caacatgagt	tttatctccc	21000
ttcaaaactgg	attaatggta	tccatgttac	atgactttat	acgtgttctt	cactttacag	21060
caaatagtta	tgaacaatta	atggaacaca	cacacacacc	cagataggaa	tgggaccctc	21120
tgagttttgt	tcacagagtc	tatactcttt	tctatttgtgt	catataatgg	tgacaattca	21180
attaggtggc	ctatgtccac	aatccatggc	ataaacgccg	gtaaatttac	agattctccg	21240
catcctattt	ggcaagtgtc	tcagtgtat	ctgttagcctg	aagagaaaaag	ctaagttttt	21300
cctattttctc	tctcttcttt	ccttcccttt	tcttttgaat	ttcctaaaaac	aaaggaagaa	21360
aaaggagggg	aagaatttgg	caatgtgtca	gttaatttca	tcaatgtaga	caaagttaaa	21420
ttagggaggct	gaattaccaa	gactggctgt	ttccattgat	gaaattaaat	caggtaaatt	21480
gccagtgtct	caaaaatgct	gtctcaggtg	tgactgaagt	tgtgattgat	tggaaagtac	21540
tcacagagaa	aacaagtaca	ggaaaaacag	cactattcca	aaatgcagaa	caaaaccaca	21600
catatttagg	cittacagtt	ttcgtgtctc	ttcatattct	tactttgatg	tatttctgcc	21660
ttttaattta	gsccttttct	aaaaaaaata	gtttgcttta	cagtttacaa	agtaagatat	21720
gctttaagag	gtagaaaaat	gaggcaagtg	aaaatgaatt	aaaaaaaaaa	aaagaatcca	21780
ggagcaaaat	cagtccacaa	agtttgtctg	tgacatcatt	gtccttccaa	acaaggagct	21840
tcgagttcaa	ctccaaacat	tagcagtgca	gacgggaaaa	tgcaagataa	aaaatcagag	21900
tcctgggtg	aaaagcaagc	catttaatat	gaatgaaaga	gtcctgtctat	aaatactaca	21960
gaaaataatt	ttcaaatcta	ctatcctaag	gagaacactg	tgcaagataa	tgaatatcat	22020
ctttagaaac	atcttcttgt	aattatttct	taaaatatcc	ttccagacaa	agcaatgaca	22080
tcattacaaa	ctccaactta	gcaaaacgct	ttttggaaaa	aggaaagtgg	aaggacattg	22140
agtgttgtcc	acatatgtag	ctctctgatg	atttgacttc	atccaagaat	cgtgtggaaa	22200
cagctagaat	gggtgtgaat	ttatatctcc	caaacagttt	ttcataaata	tcatttttatt	22260
tgactaagct	ttcaagtgtg	actcaatgat	agtaaagggg	agaacctaat	tcctgacaat	22320
tgcatgagat	gttggtcttc	agtgttgcca	gttaactgag	aaactatggt	aataatcagc	22380
cgcgttagcc	cttttctgtt	agataatttt	attattcgca	attctctttg	atgggtatta	22440
ggtttagaca	attgaccagc	aaactatttt	tttttgaaaa	tgaccacaaa	catgttaaaa	22500
atggatgaac	cctgagagga	gacaggaaaa	cagcacctaa	aaatagtaga	aggatattat	22560
ttctctgccca	ttatggactt	ataacataat	aaacatttag	ttggttcact	tttttagtat	22620
caacactttt	attaattgct	tcttttttta	caaatttgat	tttattattt	tgatacctac	22680
tgatctctaa	tttcttgaga	aagtctgtct	tactttaata	aaatgacata	cagtgcattt	22740
taaacttaaa	tactgtatat	tcataattta	atctgagatt	attgggacat	aatgatataa	22800
gaattttatat	aaggccatcc	tctgaatcca	tattcaatta	aactaaaaaa	ggatgtccga	22860
tttaggaatc	ccacagaccc	atcagtaatc	aggcaagtac	ttaacagcca	tcctatcatt	22920
ggctctctcta	gtttttattt	attctgttag	tattagcaga	tgatttctat	aatgttgatc	22980
aaatcagatt	tacgatctaa	gttgagttaa	atctcagaga	atcaaaactcc	attgtggaat	23040
ggaagttttt	agtttcttat	atatggcaat	attttgttaag	atattttcat	aactaacaaa	23100
gtattctctat	tataaattaa	gtacatttct	cccttaagct	ttttaaaaaa	aatgatttta	23160
gaaaattcct	gaaataagta	tcaaaatgca	agattgtaaa	atacgttttg	ataaatcaga	23220
aacattctta	ttaaagattt	tctttattga	taagttatac	ttctatgttt	ataaaatatg	23280
ttgtattgtt	aaatgaagcc	aatgaaattg	atcaagggtt	aggtttttaga	atatttctgt	23340
ccagagcttt	gtcctcccaa	attctgtcgt	gttagaattt	tattttttga	ctacaggagg	23400
atagaagcct	aaaactacat	aaatcogttt	taaaattaca	taaaattaca	catgtaaaat	23460
gggtgtgcaca	aataaatact	ctgtcacaca	aacatgcaca	cagagcataa	acacatgtac	23520
acacattaca	tattaatgct	tcttctagga	cagagattaa	taagtagtag	agaaaaaaga	23580
attacagata	caatctcaaa	gcttgctcata	tttctacaag	gtaaatatat	atctcagtg	23640
tagtgctatc	aaaaccatac	catcaggtta	aagaagtggg	taaatattat	cagaatttaa	23700
tgtgaaaaca	ggatttatatt	cctactattg	ctgggtgaca	tagtactcaa	cacatttttt	23760
ttcgtgttat	tcagtgttaa	tgtaaatctg	ttaaatcaaa	ttaaatcaaa	ttaaataaaa	23820

tctgttaaag	aaaattgttc	aaatagcttc	tccctaaagt	tttctttagt	tcaaaagatt	23880
ctgatgctat	atttttaacct	acagctttaca	aacaaatttg	ggtcttttaa	aacttccatt	23940
ccctcaattt	tagtaaaaaa	gaaccctact	tttataactt	acattaaaca	ttggaaataa	24000
tgtataactt	acttattagt	cttaactttg	ggagagaaga	ggtttaagta	cgtattttta	24060
aaaaaacaac	agaaatgagt	actcatgata	aatagtatat	gcacctaaaa	tatactaaaa	24120
ttaatgagta	caaatactca	ttcagctctc	aaagtaactc	tcccaactga	ataaacacgt	24180
ttaaaaatat	tttaattgat	ttattttgtga	gttacacaaa	tccatttagt	taataatttag	24240
ataatatgac	aatgatatat	gagacacaa	ttatttttaag	aataatttata	taataaataa	24300
ataaataaat	aaataaaaaat	aacataacct	aagtataacct	tagaaaaact	atggggaaat	24360
gttaaagata	aggcttggga	actttgccag	cacagtgtgg	gtatcatagt	gtaggtattc	24420
ttattttcaat	taaactagtt	gctttcagtt	taaaaagtag	atgatttttac	atacaagttt	24480
gcactttctag	cttctctttt	caaaatgagt	tcaggccttc	ccatcctgac	accttgaaaa	24540
agctgtggcg	aggcggggcg	cgggtggctca	cgtctgtaat	cccagcactt	tgggaggctg	24600
aggcggggcg	ctcacgaggt	caggagatcg	agatcatcct	ggctaacatg	gtgaaacccc	24660
gtctctacta	aaaatacgaa	aaattagccg	ggcggggtgg	cgggcacctg	tgggtcccagc	24720
tactcggag	gctgaggcag	gagaatggcg	tgaacccggg	aggcggagct	tgcagtgagc	24780
ccagatggcg	ccactgccct	ccagcctggg	gaacagagag	agactccgtc	tcaaaaaaaa	24840
ccaaaaaac	aaaaaaaaa	acaaaagctg	cagcaggcc	gtttctgaag	atggcgggta	24900
ttgggcactc	tttacttctt	tgactctact	cctgcactct	gagactgacc	gtataacatt	24960
tccgattttc	tttgatttgt	gctattgttt	ttcttatagt	taagggaat	gtgaaatatt	25020
attgtacctt	tgtctgtcaa	aatttagaaa	aatgaaaaat	agaccaaagg	tgggagtata	25080
attcattgca	aaaacttgat	atcctaagct	agtgtgtcaa	aagtgtacaa	tttcgagcat	25140
tattatgaaa	taaatttagt	aagatctatc	accaatatat	aagaaatagg	atacaaagtt	25200
ttatgaacta	aaaagaaaat	tctcattgaa	ttgtttttta	atcaaattaa	atgaagctac	25260
atcgaaatat	ttaaaaacat	gttggtcaatg	atgagtctat	aaagcaattt	agtggtgata	25320
acctcccaa	tttgctgata	tgggacctgc	ctgggttttg	gggccttgaa	tctgcaatcc	25380
ctggtggagg	acaacacccc	tgtttctccg	gacctgagag	tttttctttt	aatctaattt	25440
ccttcacatt	ttaatcatta	gcttatcttc	aaactttttt	aagaatgatc	ttaacaaatt	25500
aaaagtaact	tacaatgtat	tgcattttact	atgtttgaat	aaaacattat	tttgccacta	25560
tcccaaggga	ttgttatatt	tttctatttt	agtaagttta	ttgaagacaa	acaggccttg	25620
ggcgcgtgcc	tctgtctctc	ctgccttccc	cactgaatct	ccagcccaca	ttcacaaaca	25680
aagacaaacc	tgtgtaaact	gaagcaccac	aaaactactt	ttatgaaagc	agaatggaag	25740
gtaagtgtca	taatctgttc	ccccttgtag	tgtagcataa	actttatcga	actcactgca	25800
gcaaataacct	ttgtctttca	ccaagaaatg	gaaattgttt	ggtgtaattg	tgccttacct	25860
tcccagagta	tatttctgga	tttgattttac	tgaattcaaa	gttgaatgat	tcaccaacct	25920
tottggtttt	caatgcttaa	agtcccaaat	aacttttctt	aaaaatcagag	ctgccaaagt	25980
taggaatgat	tttaatatca	attcccagaga	ggtgtagaag	tagctactgt	gctatttctc	26040
acactttatc	aaccaaagtc	accttcacaa	gcactcctcag	gatgaagact	tcaataaactc	26100
ttaggctgtc	catttctcta	atgcacattt	gtggttgtca	gaaaattttt	tttatattga	26160
tttgaatcaa	ttgatccatg	ttttgcccac	cagaacaaca	gaaaccaa	gtattctttt	26220
tgtagtactt	ttcattttta	aaaacaatta	ctagaatccc	ctgagtcttc	ttttgtcttg	26280
tggctcctcc	cccaggacag	tgtgtccagg	tggactgccc	ttccaacctt	ctcctctctt	26340
tcagacaact	ttgtccatgt	ccctttgcag	aggccctggg	cagagattcc	cgccgggagg	26400
totgtcaga	ccagtgcacg	ctgaagctaa	tgagtcattt	tatatggact	tgggtgatgat	26460
ctcagtgtca	taaaaaggag	attccattat	ttctctttca	aatacagccc	tagctgtctga	26520
ggcagatctc	tctgattctg	tatttttaaat	tgatttttga	atttaaattg	agagatttca	26580
ggtcttatac	tttttagagcc	aaaagagaa	gttcacatca	actggagatt	aggggttaatg	26640
ttccagatca	acggccaaat	agttacgtgg	gcttgaacaa	ctgtcccagt	tggcctcctg	26700
ggacagctgt	ttgtgttaat	atgggaatag	gaatgtcatc	tcccctgcc	ttacaggact	26760
cttgtgagga	tctactaaag	aatacccata	aaagtctttt	aaaaagggtta	gagaacagaa	26820
gatgtcattg	gtttatacgt	gtatcctgat	tccactcctt	ccatatcatt	gtctctctgt	26880
gaaaaccaga	cttctctaaa	agctcttgta	ttattatttt	ttttttttcc	aaacaccaac	26940
caatactctg	acaccatctg	tgtggacagc	agttcaattg	gattctaact	aaccagagtt	27000
agagaaaacc	ccacgggatg	agggcccaat	gcacaagat	tgcccccata	tcacatgcca	27060
gccacaaaaa	gagtgccagc	cttcctggtc	tccctgccag	cccactacaa	acacagggtt	27120
cccacccttc	ccaccctcc	aaatgtgaca	actttttaga	acaactcata	gaactcagga	27180
gaacactaca	cttactgatt	ttttnnnggt	tnnattatga	aggacagttc	aggaccagtn	27240
caaatggaag	tgggtgcacag	gacgggctgg	gtatggggtg	ggggaatgac	tgggagcgtc	27300
ctcaccctct	ctgggggcac	caccctccca	gcacatccat	gtgtttngcc	agcttgggaag	27360
ctccttgaat	ctcttttngc	tcacgagttt	ttataaccca	atctctaata	ccctcctttc	27420
cctggagggt	aggggggtata	gctgaagatt	tccaacgctt	aatcaccatt	tgggtctttgt	27480

tgtgaccagc	cctatcctga	agctatacag	aggggccgac	cctaggttac	ctcagtgcca	27540
taaacacagg	tgtagtagaa	aggggcttat	tatgaataac	agaaggcact	cccattttctg	27600
ctagtcccga	gggttttggg	agttctgtgc	caagaacagg	ggaaaaagat	gaagtacaat	27660
ttttattaca	ccactgctgt	ccatactggg	taccagcatt	ttctttgggc	tctcctcaaa	27720
tgacaccact	ctccgctgcc	ctgtcacttc	cctgaacagt	tctcttggtg	attttctctc	27780
ctcgtcctac	tttccctttc	atgagcacaa	gaagtagtca	agcgggtgaac	cctttatcgt	27840
tcttgaagca	cctctcactt	tggagacttt	aataccacaa	cctgcttggt	ttccttccat	27900
gcttctgact	cttctgtgtt	tgtctccttg	gagatatatt	agtgaagaaa	gtaaaatggt	27960
gcaactgggt	taaatgataa	tttgatatac	agatatatgc	attctccaag	gcacagaatg	28020
tatttatatt	gctaagaaat	gtgctaaaaa	gtggagacaa	ggcctgaaga	atccctgagc	28080
agacaacact	agtcaggcct	cataagtga	ctcaaccttg	tttgatttgc	aaacataagt	28140
gaatgtcagc	ttgagctatt	tcttgtaaat	gcctgtattc	aaaacagaa	ttaagcttaa	28200
ccagtcagaa	gcagctctact	cacttataat	cctataactg	gggggacttt	ccgaaggnat	28260
agatcaaaata	aggcaactgt	ataactgaaa	ccaaccaa	gctttctctg	atttacttct	28320
gtgtgttct	ataaaagcct	cctctttctg	tttctcagt	aaagctcctg	aaccagttct	28380
actttggagg	tgccaatttc	atgaattgct	tgtctcaata	aactattctt	ttaaaattta	28440
ttgggcctcc	atttactttc	agataacagt	aattatttgc	atgcctatgg	aaggaaacat	28500
tggtattact	gtcttttttt	tttttttttt	tacaatttaa	gttctaactc	tacagaattg	28560
taaaataaca	taagaattaa	ccaaaatgt	gcattcctat	caagtcagat	aatcaccag	28620
aaatcctgct	aaaataattt	ccagaatttc	actgaaagga	cacctagtca	tttcttttgc	28680
ccatttctctg	acagtatctc	cactagtaat	aaaaataata	tgaaagaaa	attcttaatc	28740
tcaaacaggc	caaggatgcc	cataagggtt	gacctgatat	ttacatagtt	gcagaagaat	28800
ttaaactaac	catatgggca	tctttgagtt	tattctgtag	ttcttaatac	atgaattatt	28860
aagcaactac	taagaccaga	gaataaactt	atgactagga	gttttcaaaa	gaaatctttg	28920
attggtcttc	taaaaatccc	tatgattttc	ttttctgtat	tagttcattt	tcacactgct	28980
ataaagaact	acctgagact	gagtaattta	tgaagaatag	agggttaatt	gactcacagt	29040
tctgcaggct	taacaggaag	catgacttag	gggtctcagg	aaacttaca	tcatgccaga	29100
aggctaaggg	gaagcaagca	catcttacca	tggcagagca	ggagacagag	cgagtgaaca	29160
aagggggaag	tgccacacat	tttcaaacca	ccagatctct	tgagaactca	ctcactatca	29220
caagaataac	aaggggagaag	tctgcctcca	tgattcaatc	acctcccacc	aggccccttt	29280
cccgacacat	ggggattaca	gttcgagatg	agatttgggt	ggggacacag	agccaaacca	29340
taacatattc	taagacgagg	aaactgacca	caagaaactt	tctccagcag	atttcacctg	29400
catttccctac	attcaactga	atcctttaaa	ttgactgagg	cacatcctgt	accaaggaga	29460
gacctttggt	actgcctttg	atcctgagac	cttctgagcc	aggtaacttg	gtgcttttcc	29520
tggggaggct	ttgaggcgtt	tactccacac	ataatgtcaa	acgtgtttta	taatagtggg	29580
atagtcagac	ttgattaaat	gagaattatt	ttcaaatatg	atactaagta	aggctcttgag	29640
tgtagaatca	aattgtccaa	ttatatccta	ataaaaagga	agacagattc	ttagtggacc	29700
ttttcaacta	tctatacagc	agtttcataa	aacattagga	aatttagtaa	accttattac	29760
ttctggggag	tcagtgagaa	tcagatacat	ttcttaaatg	tttcatttca	tcaagagcag	29820
agtctatgaa	attaagggtg	agatttgctt	caaatcttaa	gaagaaagca	ctttgatata	29880
tatcttttaa	aactaaaaac	aacattgatg	gtattctaca	atacttgcac	tttctcttca	29940
cttatgtagt	tcattcctgt	tctcaggaac	cctgctttta	agaggaaggt	cttggccagg	30000
ctcagtggtg	cacacctgta	atcccagcac	tttggggagg	cgaggcgggc	agatcacctg	30060
aggtcaggag	ttcaagacca	gcctgaccaa	tatggtgaaa	ccccatctct	actaaaaata	30120
caaaaattag	ccaggcatgg	tggcaggtgc	ctgtagtccc	agctactcgg	gaggctgaga	30180
caggagaatt	gcttgaacct	gggaggcgga	ggttgacgtg	agccaagatc	acaccactgc	30240
actccagcct	gggcaacaga	gtgagactcc	atctcaaat	aagtaagtaa	ataaataaat	30300
aaataaataa	ataaataaat	acagtgtcct	ggaaagcctg	actcggtaga	tggttacctt	30360
ctgagagtgt	gttaagtaat	atcaccttag	caggtgatat	tacataagag	accattcttg	30420
aagtataaaa	agttaaagtt	gctggtacaa	acatttccac	aaggctctaa	gagccctctt	30480
ttactgaaga	caaactgtgg	tgtgaatctt	acatcagtat	ccaacatcag	agtaacgaga	30540
aactacctgt	agatgacaaa	gactgaatgg	ctgtggccaa	tttattataa	taaccagtga	30600
tgtcagaatg	gagaagaggg	gaattctcta	tgggtgttag	taggcaacaa	ttccataaga	30660
ttttggcaat	gtttctcctg	tgtggaat	cagctgtac	agccagagta	ctggcaaatc	30720
ttctggacct	tcccatgaat	tatataattt	ctaaaatatt	tatattaata	atttataata	30780
ataaatgaaa	ttgtgtcctt	gaagttcata	catcaaattc	ctaaccacga	ataggactct	30840
atttgagat	aagggttttg	tggaggtaat	gaagtttgaa	tgagatcgta	agggcagggt	30900
actgtgatca	taagaacccc	aatatgactg	gtgtccttat	aagaagaggg	agagacacaa	30960
ggagcatgct	tacaagaaaa	ggcaatgtga	ggacatagtg	agaaggtggc	catctgcaaa	31020
tcaaggagag	agaccttaca	agaaacctac	cttgccagca	ccgtggtctt	ggatttccag	31080
ccoctagaac	tgtgagaaaa	taggtttatg	ttgttcaagc	caccacagaca	gtgttatttt	31140

attatggcag	ccaaagagac	taatacaata	atattttttct	gtttaaattt	tatctagcaa	31200
tagctgagga	tctttcccaa	tttaataatg	cttgctatgc	agctctcacc	atagtgtcga	31260
ggtaatttaa	gaaatatagt	gcacatcaca	aaacataatt	attttagtagca	tcactctttt	31320
cttaagggtga	aagaataaat	ttttatgaaa	tctcaaaaaga	gatgtagaca	tttgattcat	31380
ttttcttaaat	ttaggataca	atccttagaaa	gccaaaatct	aaataattgt	tggtggagat	31440
ttgggcactt	atttaggata	agatcatgga	tacctaaaaa	acagtgggtg	gttaattcat	31500
caaaatgaca	tcaaaatatt	ttaaagttaa	cttagaagtt	tccacaatta	taaattattct	31560
tagctctttc	caaagctaga	aaatgtttta	tttttagtaa	tcaaagatat	atgaaagtaa	31620
acacagaaaa	attattcaag	tgggatacag	aatctctatc	acctattatc	agaattttga	31680
ttacacaaaa	gattaaaaaa	tgacttttca	cattgttaggc	aagtcacgca	tcattaaacc	31740
aagggaacaa	gcacatcaaa	aacagagtga	aatttgccaa	aatataaaat	atttttagttt	31800
tgtttttagat	taatatgtta	ttacaaaaga	caaaattcaa	tttctaagtt	ttgtttttca	31860
ctatactott	tcatattctg	gaaagatctg	tcacttttct	aaaatacaaa	actaatttctt	31920
ttcctcgaaa	gacaaaaata	tacacacttg	tgtttccctg	actctattat	ccttagtaga	31980
gtctcaatca	cccatttgat	taagcttatt	tcatagaaaa	aactgggtta	atgggggaat	32040
aattaagaac	ggatgtcata	cagtatttac	tgtattacca	aagggtcacag	gaaacacacc	32100
tggtggccgt	gtcatccatc	ctttacatct	gcttgccatg	gcaaaaaata	atatactcat	32160
tgatatagat	gtatcccaag	agatagtctt	ctggacagca	tataaaaaata	acaagcacaa	32220
gtatgtaaac	ttaaattttat	atttagtagt	caaggactca	actggttatac	attcattaga	32280
agttactttg	ttttctaaga	attctccaat	tttaagggtta	tttaacatta	gtcaagggtct	32340
taagttaacct	aagggaagtta	gaaactaagt	taaagctgtc	acactgcaac	acatagttac	32400
tattgacaga	aaaggtttat	cataataata	atttaattta	atgcaattttt	tcatatttta	32460
cacattgtgc	agaaataatg	ttagttttta	tgatcgatag	accactataa	attcagaaat	32520
tgcagtttga	ctcttatcat	catgagaaaa	gcaacccaaa	tagagtgaat	tgtaggtcaa	32580
attatatttta	gtgtggcttt	atcagaaaaa	acatatagac	tttttaataa	atgaaattat	32640
ttatataatt	tgccctaata	tggaattaga	taaacttgga	atttaaaaaat	gcttctgaac	32700
taaaggtttt	ataagaacat	ttttaatgtt	ttccaacttt	attggtttat	aattaacata	32760
aaaaatgtat	atggtgggtt	gatgcaaaac	agcaattact	tttacacaaa	ccaaatattt	32820
aatgtacaac	ttgatgttgt	gacatacata	tacactgtga	cgtgacaatc	acaaacaact	32880
tagtgtatgt	atctattaca	taccatgggt	atctttgtgt	gtttgtgggtg	aaaactctta	32940
atatctatcc	acttagcaaa	ttttaagtat	acaatacact	attaaagatg	atatttttta	33000
tctagtgtat	ttaaagtatt	agtttatttt	tctttttttt	gaatttgga	aaattggatt	33060
tatatgtaca	tttatcttta	aaagccaatt	agaatagtac	ctctttaatt	aaagagatag	33120
gaacatttat	atccataac	tgaggtcaag	acctttcaca	attacagagt	cacaaacgtg	33180
ttagagaact	cacagcctga	tatcttccac	ttcagccacg	agtcaagaat	acacacaaag	33240
atgcaaaaaat	ccaatggctg	agatctcaaa	gagaagttca	gtttcccaat	gtgcataaaa	33300
ttctcaattg	atttgagctc	acaagtaaaa	caaaatagac	aataagaata	ataagccgat	33360
tacgtcatct	tttattcaac	agacagtga	cctacagaga	tcatcgatt	ggcagatcat	33420
aaagccaaat	tctaattgc	ttcctccagt	ggaaaataag	ccatcagcta	tgtcttactc	33480
agcaacaaaa	caaaatatat	agttagtagg	aaacaaaagt	aaagaaacag	agtgaacaag	33540
gttaaatatc	tattgccatt	tgataccctc	tctgggaggc	aggaaaattg	ttcatgggct	33600
taagcaattc	aggaggtcca	tttcttcagc	cccacagttt	acctgactct	aagttgatga	33660
actagacatt	ttggcagata	atctacctct	aaacccatta	acacataaca	ttcccacagg	33720
taaaatcaca	attctcatgg	aaatatcaaa	taaacatatg	tcaaattgta	tttaactcat	33780
cagtttaacg	aaagaaccag	taagatgttg	aaatcagttc	tcagaaattt	gttgggtttt	33840
ttttcaacca	agaactcccc	actgacacca	acctatcaa	aaattgccat	ttgacatttc	33900
atctggatgt	tttaaaggcc	tctcaattca	ctgtgtccaa	aaaggaattc	atgactttct	33960
tttccaaatc	tctttccttc	tcttgggtg	ttcaactact	ctggcaatga	tcccactttg	34020
tgttgaaatta	tttacaccag	aaatctaaga	ctaataaatg	atactttatc	tcactacact	34080
ttcacctgcc	attacatgtt	tattaccaaa	ctctgttgat	tttactttct	aaatatctct	34140
tacctgtatc	tgcttctaac	ttaacaccgt	tcatccatac	catgacacca	ccatcaccat	34200
ttcatctgga	ccatatcact	tagactaaac	cattagccat	atgtttttct	cattgggttc	34260
actacctcaa	gcattctctt	atccctccag	ttttgtccat	atatacagca	gagtgataga	34320
tatgataatg	tattctacta	ttagaaatcc	gtaatgattt	cctattgctc	ttgggataaa	34380
aaacaaaaca	ctatgaagcc	ccattgatct	taggataggg	acttaaaact	tcttattctc	34440
caccattttt	gtgatagaga	ctcaaacact	tgatctctcc	ctcctcttat	aataaagacc	34500
caaaccttat	aacacttcat	ctctcttagg	ataaagacca	aaatctatga	tacctgtctg	34560
ctctcaggat	agagacccaa	gccctctatc	tggagtacaa	ggctctctta	caatgctgct	34620
agttacctta	acttctctct	ttcaaatattg	tcatgaacca	ggattccccct	cactttctgg	34680
ctcagccttc	cttaattttct	tcataggttt	ctcaacttct	catcactgca	tcttagaagt	34740
gtataattta	tttattttatt	tatttttact	ttcaatattt	ttctcttaaa	tctcctactt	34800

tgtgcctg	ttcaaaccta	tgattatcca	agtttatctc	atttttat	tgtcagggcc	34860
ttttccttga	ctgttcaggc	aagaccaagt	tataccctc	tcctgatagc	acttaaaaaa	34920
cattgtaate	ttggccaggt	gtgggtggctc	acgcctgtaa	tcccagcact	ttgggagacc	34980
gaggcaggtg	tatcacgagg	tcaggagttc	cagaccagcc	tggccaatgt	ggtgaaaccc	35040
cgcttttact	aaaactatga	aaatttagcca	ggcacgggtg	ctcatgcctg	taatcctagc	35100
tactcggtg	gctgagacag	aagaattgct	tgaatctggg	aggcagaggt	tgcatgtagt	35160
tgagctgaga	tcacatcatt	gcactccagc	ctgggcgaca	gagcgtgact	ccgtctcaaa	35220
aaaaaaaaaa	aaaaaattgt	aatcttacat	tgaattttgt	ggttcagttt	ttttctctac	35280
cactgcacag	ttaattttcaa	gagggcaggg	ccatgtctaa	ttctacttat	tatattccta	35340
ctgaatatta	tgtagtgtgac	atatattaaa	taattttaat	ttaaataaaa	tgtattttatt	35400
gagtgaatgt	aggacttggc	gtcatataac	atattttctaa	gtctgattct	atcttctact	35460
atactagata	attagtttcca	aatttttatgt	atatacgtta	taatgtgatt	agactcccat	35520
aaaaaagtat	taaataataa	agagagttaa	tgtgtcatat	cacaagaagg	ccagaagtag	35580
gaaaagtgtg	gtagttagc	ctctgaatca	gatgggggta	taaattaact	tcttttactc	35640
accagctgtg	tgagcacagt	tatatattta	cagatcactg	aaacattttt	ttgaaattca	35700
gtctgctcaa	gaaaaaaaaa	aggaatgaga	atattacctt	tcacacaggg	attctttcaa	35760
aattactgaa	ttaatgcatt	caaagaattc	tttcagtact	gttcaagcac	ttcaatatta	35820
ccaatgacag	tttctctgag	tatcttggat	attattcacg	tggacctata	gagtgttagc	35880
catttaaaag	tcctcagctg	cttttgctgt	ctccatgttt	attgcagcat	ttaggactag	35940
gttcaactac	tcataacaga	aaatgttact	gtagtggctt	aaacacaaat	aatttatctt	36000
gtgcaaaaca	ttcaggggtg	agcatttggg	gagaataaca	ccaagaagcc	agacctttt	36060
taacttctctg	cagtgtgttt	agcaccttca	ggcgggaaag	tcaaagaaga	gaggagtgc	36120
attgggagac	tttgatgtac	gtatcaactg	ccagaagcaa	tcatttctaa	cagtgaaaaa	36180
ggaggggaaa	tgaaggtttt	tgctccaca	atctctatag	tagaagcaga	caaggcaata	36240
ggggaaggga	aaaaagttt	gtccatcata	tatcctaggt	gtagggtattt	gaggggtgatg	36300
accataccag	ttaattaggg	ggagatgagt	agatcctcat	ctcttccaag	tataggaagc	36360
taactttgcc	gtaattgtta	ctaatacacc	cttcaaaaatc	accattttga	aaggttttgt	36420
gaaatgagca	tatttttctt	ttaatacaag	gtcagacctt	cagaatgatg	aataaactca	36480
tttgaggcca	agtaccaatt	cagagctgct	gtaaagtagg	cattttcaag	aagaaggaat	36540
acttctcatg	tttgaactgt	gtaagcaagt	ctttattttat	tttttgaatc	ctgaaacagc	36600
aattagaaaa	gagagaggaa	gatatttctt	tttctgaagg	ctgccaagaa	taaatcctat	36660
tctcatttgt	taaaataaaa	agaggttaata	agctaaagta	agaatacact	aacctttatc	36720
ttgaacccag	cgcctctag	aaaaaaacac	tataaaagtg	aagctaagtt	cagtaatttt	36780
tgcagtcatt	gcctttttgt	tagctctagt	tatctttcaa	gtttttattga	taataaaaca	36840
ttaattgcaa	ggacaacttt	tgaatctat	tattgaatac	ctaggacact	catgatgtct	36900
ctccacattc	ttgccaagga	attgctttat	gaattaaacc	acttggggaa	ttaaaccact	36960
atcaattaaa	catcacagttg	tataaggata	gacatatact	actttacatg	caaaaattta	37020
ggccatagca	atttagtaac	taccacgtta	cagggactgg	aacttttcac	tcctccactt	37080
cttctatctc	accactctgt	tatatgaagc	tatgattctc	cattcagaat	ataactacat	37140
tagtttttga	aataggaaaa	tatgaaggac	agactctaga	aatatcagaa	tcacttggac	37200
aacaaagtcc	aaaatatgta	ttatgaaagt	gaattatcat	gttgactca	atatgttgct	37260
gcaaataaat	aaaaattatt	tgctcaatat	agatactcct	tatatgcctc	aataattttat	37320
atacactgac	tgaatattta	tgactatgta	tgagcagaat	aatgagaaaa	aaacttacta	37380
aaaaatctaa	ttattttgtt	ccttttctta	ataaaagtcc	cgtttcacag	ttataacact	37440
ttctggattt	ttatttttat	tctgacttta	taaaataaac	attattttta	gaatagtttt	37500
aaattaacaa	aaaaacacac	agagattaca	gaatgtcca	tatatgttat	acatatatat	37560
atatattata	tatacacaca	cacacatata	tttaaatagc	tatatatat	atatatttta	37620
tatatcccg	ccctccct	agaaatcact	gaattgttta	ctggctctaa	agttttgctc	37680
tcattattaa	atatgtaaca	aatatatatt	atatatttat	atacaatgta	tataaaataa	37740
atatatatac	acatgtaaaa	aaatatatat	atattttgct	tgctccagaa	ttccattcca	37800
tccaggatac	cacagaactt	tcactaatct	tgtctctttg	ggtgcttctt	ggctataaca	37860
gtttcttagg	attttcttat	ttttgatgac	cttcacagtt	ttgaggagtg	ctggtcagat	37920
attttgtaaa	atgttccctt	cttgtaattt	ttctgatttt	ttaccatgat	tagactggac	37980
ttagggcttg	tggggatgga	ctgtcacaga	ggtaaaatac	attctcatca	cagcatatca	38040
agggtttata	catattgacat	gacttaaaac	tattgatgtt	aacactgatc	acctggttga	38100
ggtagtattt	gtcaggattc	tccactgtaa	agtttaatttt	ttccctgttt	ctatatgtga	38160
tttttagctat	atcaataaga	actcatggac	atttctcttg	tactttgggt	tataatccaa	38220
tcttttttat	ttttgctcaa	attgttccag	ctttggtcat	cggacacttt	aagtagctgc	38280
tgtgtgcttt	tgtgttatt	gcagcttgg	ctgttttagca	ctttcttact	ttctaaaatg	38340
tcaagatgct	ccaggcttat	cttgatatatt	accttatgtc	gctccaggat	taaccatttc	38400
tccaaggttt	tgacaaactc	atagtgtcat	gtattcacca	ttacagtatc	atacagaata	38460



atTTTtacagc	ccgagaacag	ccctgtgatt	cacccagtca	acctttccct	cccttagaaa	38520
ttactgattg	cttactggct	ctaaagtttt	gctcttttaca	gaatatcaca	taaatgaact	38580
catgggtatg	tagcttttac	agactgaact	ccttcattta	gtaatatgga	tttaagattc	38640
atccatgtct	ttgtgtatgt	tgatagccca	tttttaaact	actgaataat	atttcacac	38700
atggatatac	catgggttat	ttgttcattc	acctattgaa	aggcatcttg	attgtttcca	38760
atTTgggaca	attataaata	aagttgccac	atgtataaat	atgcatgctg	ctttttgtgt	38820
ggatataaat	gttcaaataa	gttagttaaa	cacctggtag	tctgattgct	ggattatatg	38880
ataatgctac	atTTttccct	gttaagaaac	tgacaaattg	tcttctaag	cagttgtgcc	38940
atTTtgagtt	ctgatcagca	gtggatgaaa	gttcccatta	ctccatttca	ttgtcaacaa	39000
ttatTTtcat	tatgtttgtt	tcttttttgt	gagttttaaa	atggctttgt	atattttata	39060
tataagtaat	ttattagata	tgtgttttgc	aaatatctcc	ttttagtctg	tggattgtct	39120
TTTTattcct	tgaacaattt	atTTttataa	acataagttt	ttatTTttga	taaagtccaa	39180
cacatctatt	tgttttaattg	attgtgctat	ttgtgttatg	tttaaaaaact	catcaccaaa	39240
tccctgggtca	gacagatttt	ctattatgtt	tgttcttaga	aatttcacat	tttgtatttt	39300
acatacattt	gtgatccatt	ttgatttaat	tttgtgtaag	gtataagggtc	tttttctaag	39360
tttattttatt	tattttatttt	tgtatgtgga	tgttcaatta	atccagaatc	atTTgttgaa	39420
aaaactattc	tctttttcct	tcaacctttt	tgacctttt	gtcaaagatt	aaatgatggt	39480
atTTctgtac	aataatcata	tgatgtggct	gtgtcccac	ccaaatctca	tcttgaattg	39540
tagttcccat	gattcccacg	tgttgtggga	gggacctgt	gaaagataat	tgaatcatgg	39600
gtgaggTTTT	ccctatactg	tccctgtgga	gtgaataagt	ctcatgagat	ctgatgggtt	39660
tataaggggc	acctctttca	ctcggttccc	atTTtctcct	ttgctgccgc	catgtgggac	39720
atgcccTTTT	ccttccacca	ggattgtggg	cctccccagc	cacgtggaac	tgtgagttcca	39780
ttgaacatct	TTTTtcttgt	agattgcccc	gtttctatca	ggagcacaaa	ataaaactaat	39840
acogatgata	tctgtcTTTT	ctgttctggt	ccattgatct	aagtgtttat	tgattggcta	39900
atatcatgct	atcttgatta	ctgtagcttt	gcagtaaatc	atgaaggcta	ataggacaag	39960
tcttttgact	ttcttcttat	tcttttttac	tactgtattt	gtttttccag	gtcttgtgcc	40020
atTTgtatga	aatttagaat	cagtttggtt	ccatctacaa	aatagcttgc	cacgattttc	40080
TTTTtgtggt	tacattgaat	ctacagatta	ggttgaagga	aattgacatc	tcaacaatgt	40140
tatgtcttct	aatgcataaa	catgaaatat	tgtccatttt	attgagatct	ttgatttttt	40200
catcaattgt	ttatagtTTT	caacatacaa	atctctgcca	tattttgtta	gattttatatt	40260
tgagtatatc	atTTattgga	tgctattgta	aattataagg	TTTTttttac	atTTtaattc	40320
caaactcttg	tctttcatgt	atgagaaagc	catggacttt	ttatattgcc	ctgatatcct	40380
gtaaccttgc	tgtattcact	tattattcca	cctaagcgga	tctcagctgc	atctgctgga	40440
tgagggtggtg	ctttatccta	taacttctat	tctctgatgc	atccaataaa	attcattgat	40500
tttcactttg	tctgtcTTTT	ccttgtaaga	acaggaaata	tgaagtccaa	gctttcacac	40560
ataggagata	aaactgaaag	tccacacatt	ctgattttta	aaaatcttct	attcttttgt	40620
tttgcatttc	atatgtgttt	tttaaagtgt	tatgcttgag	gtttgaattg	tttatgtaat	40680
gtagaatcca	cagataaaca	caattagcaa	atgtaaagcta	taattcttac	agttttaaag	40740
gtacctttgt	atgtacccca	caaaaaatag	atgtcaacaa	tttgagggtc	actttttatt	40800
taagtaattt	tacacctgct	ttctcttttt	tttaattgaa	cccagttgca	gttctttgaa	40860
caccagggaaa	aacttctctag	caacctctga	tgtattcctg	catctagagt	agaaacacag	40920
cacacagcac	agtagagaat	tgaaaaattt	gagaaaaaga	gtcagttgtt	ggccacattg	40980
actaagactc	aggcacgcac	atacacatac	caaagtgtt	agcaccttag	ttgagctcaa	41040
ataaggaggga	aaaaaaccag	cattacaaga	gtgagacagt	ggcaggttac	tactagccct	41100
gctgttggtg	ttctctttcc	atTTgaccag	aaatggcaaa	ttctgttgaa	aagaatggcc	41160
catTTtccagg	caaagcttta	ggaagcacat	gatttccaca	tagaatctgg	cctttgtcag	41220
acatgggtatg	ggactgtaaa	aatgacttat	tccaagatga	gaacacatgg	ggtagagctt	41280
taaaaacctgc	aagccatgcg	ttgttctctt	attgaagtgt	tgttaaagct	gttccagaca	41340
tttgcctgct	ttgcttccat	ttttggactt	gagagagaag	aggcatcaag	acgtctgcag	41400
gggggacatg	aataagtgtg	tgtgcacatg	cgcacctgtg	tggatatgtc	aaaataataa	41460
agtttaataa	ttgatttcta	taattattaa	atatagcttt	actaattgat	agctataatt	41520
attaaacata	gctataatta	ttaaatatta	attattttat	atgtttagaa	aaaatcctat	41580
acctttgata	atattcatgt	gtgcaaaata	tattcttctg	tcttggtaac	tgctctgttc	41640
ataatcatct	TTTTttggac	aaacaaagaa	aacatataga	caaacaggat	taatataaaa	41700
tttaacaatt	atatagcaat	acagtggcta	actatagcta	ctctaattaa	ttacctgttc	41760
tagagtgatt	ggactatcgc	aggtataaac	cctagcaggg	ataaaatctt	tttattttata	41820
tgctatataa	ataaagtatg	ttctaaaaca	cttgcatgat	ttattccaag	aatactgcac	41880
ggatttctgt	gcacgtgaga	atTTtctctgc	ctgttcttcc	tattaaccac	taaatgttat	41940
gtcatgctgg	ggatgtgagc	cctgaagcag	tgacaggaaa	tatctgcaaa	atggcaaatg	42000
cctcccatta	ctgagagtgc	tgattacaaa	gctacaatta	catgtggatt	attcatgttt	42060
gcagcaaatat	aatgaactgg	tttatagttt	ttcaagaaga	aagcatctgt	agtatagtaa	42120

aaattactct	gaatcttggg	tcaaagaatc	cggtttccaa	tccagccttt	gttaccagta	42180
gctgtgttag	ttaactattg	ctgtgtaaca	aattatccca	agacttagtg	gcttaaaaca	42240
gtaagtattt	gttatctctt	acagatttga	tgggtcaagc	atlttggaat	ggctaaactg	42300
gacggttctg	gcttgggagc	tttcatgagg	ttacagtgat	gatgccagtc	agggcagcag	42360
ccacctgtag	gtatgacagt	ggctgcagca	tcggcatccg	aggtatctta	tttatgtggt	42420
attggcagaa	gatataccact	cctcactggc	agcttgactg	gcctcacttt	ttagcagctg	42480
actttcccca	gaatgggaga	tacaagaaag	agagggtgag	aaggaaacca	taatgccttt	42540
ttgacctggg	cttagacgtc	acaagtcacc	atttatacac	attcagttta	ttggaagtga	42600
gtcactaagg	gtgggtcatc	ttcagagcaa	gaaaactagc	ctcccttgta	tgaagtggag	42660
aatgatataa	aaaaaagggt	gtattttcat	accaccatgg	tggccatatg	agcttcagta	42720
gttaaacctc	gctgaacatc	agtcttctcc	acaaatgaaa	ataacaatat	ctacctcaaa	42780
gaattattgg	ggctgttcag	taagatgatg	catctgacat	atlttgtaaa	atgtaagcta	42840
ttgcatcagt	gtaaagtgtg	ttgaatgtaa	tgtcagtgat	gttttgtcat	agacatcacc	42900
aatgcatggt	gaggaaatct	tgttttagtga	cttccaagtt	aggcagacac	tggtagcttg	42960
cacctctctc	tcaaaaaaga	agcatgcaaa	tctttgactg	ttaaagtata	tagcattcaa	43020
agattttgtt	gtaatcattg	agaataataa	tttaattatt	tatatataat	taattattgt	43080
ttaattatta	attaaattat	tatttaatta	tataataata	tataattatt	taattattat	43140
ataatgaatc	aggtgcagtg	gttcacgcct	gtaatcctaa	tcccagcact	ttgggaggcc	43200
gaggtgggtg	gatctcctga	cgtcaggagt	tcgagaccag	cctggccaac	atggtaaaaa	43260
ccggtttcta	ctaaaaatat	aaaaattagc	caagcatggg	gggtgcagtc	tgtaatccca	43320
gcaactcagg	aggctgagac	aggagaatcg	cttgaacccc	aggaagcgga	ggttgcagtg	43380
agctgacatt	gcaccactac	actccaagtct	gggcaacaaa	gcaagactcc	atctcataaa	43440
taataataat	aattttgtta	tgaaaaatgt	taatttccaa	agaatgatag	agttttaaata	43500
tcagaattat	ttatcttatt	atltttgggtg	gattgcttaa	atatacagac	tttgtttttc	43560
gtgtttttgt	ttgttttccc	atatgacaag	aggtctggaga	ctggcaggca	ggcagcatga	43620
gcttctgcag	cagcgcagtt	ctgtgagcca	tggccctctt	gtttctgggt	aatcaccttc	43680
gtccttggtg	ccttctgcct	gctccccttg	cagcactgat	ccttcattcc	aggcagatgg	43740
aataagatca	aagcacaaaa	aaaaaagttt	gctgaatatg	ccctgtttta	ttttaatttc	43800
ttattttcaa	ataaatttag	acttttggaa	aaactgtaaa	gatagtagaa	agtttttgta	43860
tacttttcat	ccagattcac	ttaaggataa	cgtcttttat	aatcatggta	tatttattga	43920
aatcagaaaa	ccaacattca	ctatgagcca	attgggtatta	gttacgctat	aactaattat	43980
tattaactaa	tagtatcatt	atlttacttat	ccacaataca	atgatgtaat	aacaaaatgt	44040
agtatataat	attaaataca	gcaatgtagg	atagtaatga	tagtactact	gctagtttta	44100
gttaataata	ttactaatt	tacaggcctt	attaaaaat	tttcagtttt	accactaatg	44160
tctttcttct	ggttccacga	ttcacaaatgc	atltttgtgt	catgtcacca	ctgtttgtctg	44220
caatctgtgc	cagtcctcca	ctcttttctt	gtcttttgcg	aacttgaaac	tcatggagaa	44280
cgcttggtct	gttattgtgt	atagaatgcc	cctcagtttg	ggtttagtctg	atgttttcac	44340
atgactaaat	tgagggttatg	cagtttttca	aaactgcggc	agatgtgatg	atactgtgct	44400
tttccactat	atgatagcat	gtgatgtatg	agatgtaaac	acggatcatt	gttttctttt	44460
cctttttttt	tttaagacgg	agtctcgctc	tgtcccagg	ccagagttca	gtggcatgat	44520
ctcggtcac	tttaacctct	acctcccagg	ttcaagcgat	tctcctgcct	cagccttcca	44580
agtagctggg	attacaagca	tgcgccacca	ccccagcta	atlttttgcat	tttttagtagg	44640
acgagatttc	accacgttgg	ccagaatggg	ctggatctct	caacctcgtg	atccaccac	44700
ctcggccttc	caaagtgcgtg	ggatttatagg	catgagccac	catgctcagt	ggatcatttt	44760
ttttttatgt	tttgtttgtt	tgtttgtttt	gattttctatg	ttgtctgtca	gatgtctttt	44820
aagtgatttt	tttttaaat	tataacttgt	aagtgtcttc	tgggaagata	tttttaggct	44880
atggaaatac	tctgtttttc	atcatacact	tgcctactaa	tttttagcatc	aataatggct	44940
tttgcttgca	gtgactactt	atgtagtgtt	taatgtgatg	atlttctgtag	ggatatataa	45000
atgagccaat	gagaaaccac	agacatcaca	tttctagctt	aattctgaaa	ggtaaacgtc	45060
tcattggcaa	atltttaaaaa	gttaagacaa	tttggtttca	tcaggagacc	caaagaaaaa	45120
atgagtagtt	tgaattttctg	gtcataagga	tagtattctt	gatcttctta	atatggaagc	45180
aactaaatat	atlttacaaca	ggaagaacta	gatatacttg	caaaattcaa	agagaaaacc	45240
aaagcaatac	agccaagtct	tatttgcagg	tcgagatctt	ccaaagaaat	ggcagttattg	45300
tgatagtatt	gtacttttaa	aactggaaag	agatgggaaa	ggtacaagtg	gatgttcatc	45360
atggcgtaga	catcaatata	tgtacagtca	atltttactt	cttgttttta	tgagaagaaa	45420
aagctgtgat	tctttattta	ttcaaaatca	ccatcacttt	tttcttttaa	atagtcagac	45480
tactagggcc	tctgatactt	attggaagat	aaagttaagg	agagaaaagg	gggtgtataaa	45540
gtaaaaatat	atggcagctg	tccaacaaag	tcaataatcc	acttttaggga	ccccaaaaata	45600
gattttcttg	agtgtctgtc	tgtgcacaag	tttgtcagca	tttgagagaa	atgactgagc	45660
agccacaaca	aagagtgttt	aaacaaacca	atctggatgt	caaaagggtta	tgtgccgcag	45720
agggctgctg	gtgttaattc	tatatggatt	aacacacag	cogtttctta	aaatagaaaa	45780



acttgaaaga	agtgaagtga	ctcagagacc	tttttttttt	gtaggaagtc	tagatgagac	45840
atttattttt	ttctttgaac	tggtgaagtt	ctctctactc	agtgcgactg	gtgaggttgc	45900
atgaaaagtc	tgtgaatcaa	tcacaggacc	cagttctgcc	ctgagacctc	aaggagagag	45960
gaggctatgc	tggaacccgt	actgtagagg	atccccactc	ctaccctctt	gtggacaatg	46020
cacccctcgg	catggggcaa	gaagtccaag	aacgccataa	gccaaagggaa	cgtacacaca	46080
attagcctgt	gtctccttct	gcacaatgct	ttctgcggct	cttccttgca	gagtgtggag	46140
ctcatttgca	agagcagatc	tcttgcttgg	attcatgttc	ttgtggtcac	accacacccat	46200
ccccagtatg	ggcctctctc	cagcaagggg	atgaggatgt	tggttgatcg	tggggctaatt	46260
gtacatgacc	actgggaacc	tcgaaggtgt	ggcaggctag	gcaggaatag	cagagaattc	46320
actacagggg	tgtgtgtgtg	tgtgtgtgtg	tggttgtgtg	tgtgtgtagg	taaggaaatg	46380
agagcaggag	gctttcacaa	tattccagat	ggaagacagt	gaaatccgcc	aagcctaaat	46440
tcaaatcata	ccaaaaggtg	taaggagtta	agagaagaga	ataggatata	ccttacttgt	46500
ttacaaatt	gtttcctttt	ttatataaag	taattttagg	tggtaaaaata	tacagaaaat	46560
ataaatatat	acaaaacctc	cataaaattt	accattttca	tcatttttca	gtgtgaaatt	46620
cagtggcttt	aagttcattc	atgatgttgt	acaaccatcg	gtactatata	cagaacattt	46680
tcataatttt	aaacgaaaca	tttgttccta	ttaaacgcta	acttcccaat	cccctgtacc	46740
ctcaggcctt	ggtaaccatt	attcttcctt	ctgctttcct	gcatttgcct	attctagatc	46800
ctgaatatag	tggacacatg	cagtgttttc	cctttatgtc	tagcttcttt	cctgtagcac	46860
agtgttatca	agtttcatcc	atgttgttgc	gtgtatcagt	acttcattca	cataatttta	46920
tagataaata	atatttcatt	gcatgtgtgt	accgcataat	gcttatccat	tcattagtgt	46980
ctgggcactt	gacttgcttc	catgttttaa	ctacagtgaa	tatgctgcta	tgaacattgt	47040
tgtacaagtg	tctgcttgag	tcctgttttt	caattttttg	gggtatataa	ttaagagtgg	47100
aattgctgga	tcagacagaa	actgtatgtt	taacattttg	aagaactgac	aagttatcgt	47160
ttccttggtc	ttcccttata	ctatttgca	atgtagcatg	cagatctcca	ctgtagccct	47220
gggtcctgca	aataattatta	gggacaggac	gtgacagcaa	ccttatggat	ctatacatgt	47280
agacagttaa	tcaatccttg	taaatgttag	cttttcactt	tttttcactt	ttgctttcca	47340
tattatataa	atgagaaatc	tgggtttcca	tcagtgttca	aacttggaat	cttttgtgtc	47400
atattaaaaa	aaaaatccaa	atcaagctgt	tttgtggtat	ttcagatctg	actgaaacca	47460
ggaagtaata	gaaatataaa	aagaaaactt	gatcttctga	ggttttcttt	accaaagtta	47520
ctgggataaa	aattaagcct	ttaaaatttt	tgagggtcat	atatcaatgc	cactgatttc	47580
taaaaaatat	tgtattgacta	gcttcttttg	gaaggtaaaa	aaactcagtt	ctcctacaag	47640
actttgtaga	aattcctttgt	cttaaatcat	atagcttaaa	aaatgagcct	tttaaaactg	47700
tgaaggatat	cagaaagaaa	tgtgaagaaa	gaagaaaagc	acaaattaaa	agaacgaaca	47760
agagctacgt	tagcagtgag	acccaattta	aagagtttgg	gtccagccag	agcttttcaa	47820
atcttttgaa	gottatacag	tgttctgata	cctaacaacc	catattcttg	aaaaattaac	47880
cagaaaaacta	gcatgagcta	aatgtcttta	tgtttgaatt	agagaacagg	gaaaggtcct	47940
gctgccttta	ggaaaagcct	ttaatcagaa	tgtctcttca	tcctggcttt	tgacctttcc	48000
taacattcaa	ttgttttttc	acactgctct	tgaagagacc	tgccgctcta	agaaagaagg	48060
atggatatct	ttcccttgct	tagcacggtt	tatgtcaaga	ttttgccctt	gtaaaagcac	48120
ctaaatgtgc	tgtgtgacaga	cagagaggga	tgatcattca	aaagtagtct	ctgcttttgt	48180
taaaccttta	tttcaaaaaca	atggagagca	catcccatca	ctgctacgaa	aagttctaac	48240
ttccaattca	taggtcattt	ttttgaaatt	gtattttctg	attaaaaaca	catattttct	48300
caactagtat	ccatccttat	ttctagaggt	atcaccgtgc	atttcgcacc	ccctaaataa	48360
ccttcttgcc	cgttaaaaaa	tattttgtaa	gtattcgtat	gtaccacacag	tcataatta	48420
ggacatctca	cttctctttg	ttaaaaattc	cttatgttta	cagcttttca	aagggtcttg	48480
cattcactaa	ctaagtatgc	ggaaactttt	gagacagctt	tgcagaacaa	gacacaacaa	48540
ctacatgttg	agtaacttgc	tcacggttac	atgatagtta	tgtgaagatgc	ttggtgatag	48600
gactgggcgc	taacatgttt	ttccaagaa	aaataaacct	ccattgcac	tagtccacac	48660
taggacgatg	ttttgggcat	atgtttttcc	aagcatctgg	tagggacaga	tcagggtctaa	48720
gggatttctg	aaagggttaa	attaaatagg	atttcctctt	aaaattttga	tagagaaatt	48780
tagaaaaaaa	aggaatcaaa	tgotaattca	gaaggatttg	agaacaggaa	aaatattagc	48840
ttatcaggga	acttcttaag	gtcagagttt	cactatcaca	ttctagcttc	ttcagtgctt	48900
cctcattttg	gaaagtgttc	aggactttta	ggtgcagttc	tggacacctc	acatgtctga	48960
acatatccag	tggctcttct	taaagattat	aaggacttag	cagcaaatta	gtctgttttt	49020
cacatggctg	gagatggctg	aggcttaaga	atgctgcaca	gcacctctgag	gtgattatta	49080
gtaactcagaa	ggcctcccca	cctctcttgc	acctgtgatc	ctcatcttgc	ccttttccaa	49140
atatcgagca	gccaccataa	tatgtgtgtg	tgtgattaat	caattattac	taaaggatca	49200
gtaatcctta	acctctgaga	ttctcactgg	atttaagga	ttttaaaaat	aggagaataa	49260
tcaatttaaa	cctttaagct	gttttgcttc	tgatactatt	ccatgtctta	gcattcaatg	49320
tatttttatt	ggtggatcca	tatgacaaag	tgaaaaggag	gagggttttg	gaaaaagaga	49380
tacagaagtt	cacattttag	ctacccgata	actgtaaaaa	caagggtcaat	tctgtattgg	49440

gcttacattt	atcttttcag	tggatctatt	taatagaaat	agaaataaaa	cacatatcaa	49500
taattgcacc	aagatactga	aggtagtttt	tattgaaaa	ttgatcacta	aggaattgac	49560
agaattgaga	agtgaagaaa	tttcaaagat	acacatgcct	gaaagcagaa	atcatatcct	49620
atatgtcaaa	catgaaaatc	aaagtcagct	gcttgaatg	tgggccta	aaatcttgaa	49680
tctctgcaac	tgtagggaat	agttattgtt	ttctaatact	gcacacattt	tagtaaactt	49740
ttctgtcctt	aatgttaaac	ttcatatttc	ctacacatct	tttttaatgt	taattatttt	49800
aatatgcatt	catatattta	ccacttatta	catgggaaga	aacaattctt	aagtctgaga	49860
aggttggtaa	tcattttacat	ttctgacaca	aaactgaagg	catggttgag	aattagaata	49920
attaaaaatg	cactggggga	caacctgaaa	actgtgactc	cattctgata	gaaggagtca	49980
ttgtccttga	acaatttgca	aatatgttcc	cttcttttcc	caaataatgt	cccttctttt	50040
cccataacag	gcttccatgc	tttatgcaac	taatgcgtta	tgaattgcag	ctctgtttct	50100
tacagagaag	tgaatttaca	aaagacatac	ctttcacatc	atgttcacct	ttttcacctc	50160
aatgacaccc	tgctcccttc	tcttaccttc	cctgacacca	cacagttcac	catcagctct	50220
tctcctctot	caacacccta	acttctaacc	tgcaactgaa	gctcacagtt	gtgcttagta	50280
tctgctgac	agttcccttc	acttgacaag	ttttaaaagt	caactttctt	tgtcttacag	50340
tttattgtct	tcagtctttt	atttccctta	ccttttaata	aaaggattca	gtattccatt	50400
tctattaatc	ttttattaaa	gtttattaga	aatagaatgc	tgaatagaaa	atagggaagt	50460
tagctgtagt	taagattgtg	attattcatt	atactgatat	ttttcttata	ttgtttttga	50520
actgatttat	gggtagttag	ctccaaaact	gaaggaaatac	tatgatattt	tcaacactat	50580
taccagcaat	atgtcaggta	tttaagttta	tccatgagca	gagtgcattt	tcaagatcat	50640
gaattttcac	aaacttcaat	gttactactg	tgtttatgct	gaataaatgg	tttctttggc	50700
acctctttca	cacacacaca	cgcacacatc	tatacatggt	aacataggct	aaagcaatta	50760
gagaagttca	ggtatttcaa	tgactgaatc	acaaaaatat	gttattgatc	tcattttgta	50820
atcaatgaat	ggttaataag	aagattaaga	agacaaatta	caaggtcaca	gccatttcag	50880
ctgaagcatg	ttgttatggc	cagaggctca	tgagaggaaa	aggtgtggct	aagaacagaa	50940
gatccgttaa	gctccaagcc	tgttcaatta	tttaagtcac	tgagacaaag	tagatgtgga	51000
gtgtgagacg	ccagtgtaga	gccttcaact	gattttcctt	ggggaggttg	acctgactta	51060
atagtgtggg	aaatcagggtg	aatttttggt	gtgactagat	ttgaccaaga	tggagttttc	51120
catgaaaatg	caaaaccaat	tttgaattt	gaattccata	aagcaaaaaa	ttctttacata	51180
aatgcttata	ttttaccac	tctaccactg	tgggatgcac	gccacgagat	tttgtgagta	51240
gttctaaaaa	gtatgtcttc	ttggacaaca	tccaaagtag	accacatgca	cactgaaaca	51300
agccttacac	aatagctttt	ctatatatgt	atctatatct	acatctatat	ttatatctgt	51360
atctagctaa	aagaaaagct	ccacatactg	atagaattat	ataaaagcaa	atactaactg	51420
ttgggaattt	cgattataat	acacttaatt	gaaaacaaaa	caaaaatatt	ttttaaaagta	51480
ttaagcaagc	atagagagac	atttttgtgc	ttacaaggat	ttctgggaat	acaagcaatt	51540
attttttgtc	agggaccata	tatttaggta	cagatcatta	acaatgcttt	ctttaatatt	51600
tatttagtga	attgtacatg	tttaactctaa	gggcaattaa	aaccacataat	tataatatga	51660
gaaacttttt	ctccacttag	tattttttat	tataaatatg	gctagcattg	aatcattggc	51720
tataaccatg	taattttaat	gcttgggaaa	catctgttag	aaaaactttc	cctatagaag	51780
acatttatca	atgtcctgcc	ttatctctgg	tttattacat	tttatgataa	tttatgataa	51840
ccataaaaact	gaaaccatcc	tcattttacat	ttttcctctt	ctaaatttgg	ggaaattata	51900
ttttaagtgt	ttatcattat	ctcattatat	aatctacaga	aataataaac	agcagcatac	51960
ctgattttta	aatgagactt	ttgaatttct	acaataaata	gaatataacg	aactctgctt	52020
ctttgggtat	atcacgtcaa	atatacatta	atgagcagat	agctttaaca	tgtttatcat	52080
gttataatct	gattgttgtc	tttaactaat	aagataccta	atttaactga	agtatcaagt	52140
gatctcaaaa	cctcagtagc	atctgataaa	ggttgctgtc	tcacctgtgc	cacatggcca	52200
ttgccatttg	actgctgctt	caccacacac	acctgcactc	ccaaactcag	cctggctgga	52260
tatcttttta	caagatacct	gataatgaag	gagagaagga	acatggtgaa	cactatgcag	52320
tctcagaaga	tctgcttgga	agagacatgt	tacttctgct	gtcatttcct	tggccagagc	52380
aagtgaatg	ctgaacctga	tcagtggctt	attgtttgaa	cagtaataca	acctactgtt	52440
ctatcataga	atgatattgg	agtcataat	ttcaattagc	cattatcaat	gtctctcata	52500
attttcttta	cacattttct	cagaatctag	agtaaaattt	aaaaaaggaa	agacagataa	52560
atgctctcat	ctccaaattc	agtgtcctaa	attccactta	ctttaatcag	tataaaaaatc	52620
aggtagctca	gatttttaatg	gactagtcac	ttttgtctct	ttttttttgc	tatcagcgtt	52680
tatatgtatt	atttgggaaga	aaaaagagcc	ccctcaacct	tccagagcgg	acacacacac	52740
gtacacacac	actatggcaa	cattagagag	cttgacctga	aagtgtttta	aaaactatga	52800
cacagttaaa	ctatgatttc	aaagtttttc	caagcaagtt	atatgtcaga	atatgagtag	52860
gggaaaacta	ttgaactgcc	acaattctgc	tgggtggttc	attggcaatt	ccaattatgt	52920
tctgatcata	gtgtcatcag	agcaattagt	tcattcccaa	cttggtttgt	attgccactc	52980
cacagggaaa	atagtaaatc	tgtcctactg	actgcagttc	tctaaaatgt	ccttaaggtt	53040
tagttatttc	aaacttagtg	gaagaaatat	gttggttgta	gtggtcatcc	ttgctagtag	53100

tctttaatca	ttacctgcc	ggaacactt	tttattttacc	agtgcattgag	agtttaggtg	53160
agaattattc	tactaccgaa	agctcaagat	gtattttgtgc	tatagttata	aatatagatt	53220
ttttttttgt	aattctaact	tttcaggtag	ttttctcttt	agctgtttta	tttttagtata	53280
tgtatttttt	ccatttttta	tggaattgta	aggcatattt	ggtggttcta	gtttacaact	53340
ataacatcat	ttccagagtc	atcaattcct	ttgtcaggac	atgacattat	gtttttccat	53400
tttttagact	tcctaaaatg	tcttgataac	caaaacacag	aggggttatca	ttatacagtt	53460
atgtatgata	cggtttcctc	tatataatgt	gtcacataga	gtattttatt	tocagccaaa	53520
gatcattatt	ttttaaagaa	actcaggaac	aagaaataag	gatgcactca	cacaaataga	53580
cagtagtgaa	ttcagaatgc	atagcagagt	gtgcaaagta	aagcaaagtc	atccatgccc	53640
aattacctaa	tttgtaattg	cagctattca	ttgcacttga	ttctttcctt	caactccttc	53700
ctctccttcc	ctccccggag	ctctccttcc	ccagcggttg	tatggcagct	tcgtaataaa	53760
cccagaacac	ttagcaattt	ctgctccgat	ttgctctagc	ttcaaaggtc	tatggctcatg	53820
attacatgca	ataacgatac	attcaatgtg	aaactacaat	ctgtgtaact	ttgtatttct	53880
ctttgaaggt	ttagatacga	ttgactgtgt	caaccataag	cagaataata	attcctgtgc	53940
tcagagacaa	gtcagagaga	gagagagaga	gattgacaaa	caaacaaaac	aacaaacaaa	54000
caaacaaaaa	acagatttta	agaactgagc	cctaattcat	ttttttttct	tttttattgt	54060
ggcaaaaatac	acatgacatt	tactatctta	accattttta	aatgaacagt	ttagtatat	54120
taaatacata	tattacattg	tgtagacatc	accatcctcc	atcttcaggg	ttctttccac	54180
ctttcaaaac	tgaaattcta	cccattaaac	aattcctcat	tccccccctt	ccccagctc	54240
ggctgctggc	aaacagttct	acttattgtc	tgtatgattt	tgatcactgt	aagtacctca	54300
tagaagtgtg	atcatcacga	atttaccctt	ttgtgatggg	cttatttcac	ttagcatcct	54360
aaaggtttgt	ccatgttgta	gtctatgtca	gaactggctt	cccttttaag	gctgaatgat	54420
attccattgt	atatataaat	cacattatat	atgtttatatt	ctaagcattt	tatatatttt	54480
ggccttacat	ttgggtcttt	gattcatatt	cagttaattt	ttatatggag	gttcatataa	54540
ggttcaactt	cattccgttg	catgtggaga	ttcagttttc	tcagcatctg	ttgttaaaaa	54600
tagtgtcttt	ttcccattaa	atgatcttgc	cacccttgct	aaaaataatt	tggccatgta	54660
agtattttat	tctattggcc	aacatgtttg	ttttacgcca	gctgatataa	ccatagttaa	54720
ttattcactt	attagttctg	aattcattta	ttagtttcat	atgggatttt	ttgggtggaat	54780
cataagagtt	gtctacatat	atgattatat	catctatgga	cagagataag	tttacttctt	54840
cccttattcc	aacatatgtt	ctctcttttt	cttgccataat	tgctctagct	aggatttcca	54900
gtactacggt	aaatagaagt	gaggaaaagca	gacacccttg	ctttgttccct	gatctgaact	54960
gaaaaacttt	ttaaaaaatt	gtgatgaggt	agtttccttc	tatcctagta	tactgagtat	55020
tgttttaatt	atgaaaggtt	attgaatttt	ctcaagtgtc	tttactgcat	caataaaaaga	55080
tgattacatg	tcttttttct	tcatttagtgt	ggtgtattcc	attgttaatg	tgggtatattc	55140
cactgtttta	tttttgtgtg	ttgaaccatc	tttgatttcc	aggcataaat	cctactttga	55200
ttttcgtagt	ttgaaccatc	tttgatttcc	aggcataaat	cctactttga	aatggtgtat	55260
aattccttta	atatgttgca	aaattcagtt	tgctagtact	tttttgaaga	ttgttcccat	55320
taatgttcat	acggaatatt	gatcttttagt	tttctatttt	ttgtgatgtc	tttgtctgac	55380
ttgggtatca	aggtagttct	ggcctcatag	aatgtgttag	gaagtgttcc	ctcttctttg	55440
atattttgga	aattattgaa	aattgggggtg	agcccttctt	taaatgtttg	gtagaattca	55500
gcaaaaagc	catcaggcca	aggacttttg	tttgtcagga	tatttttgat	tagtaattca	55560
tctcctgact	cttaaaaatg	ctattacaat	tttctatttg	tttgtgggtt	agattttagta	55620
ggctttgcgt	ttctagaaat	ttgtccactt	catccagggt	attcaatttg	ttggcatatc	55680
attactttcg	taatactctc	tgctgatctt	tgtatttatg	tagacttgga	agtaatgttc	55740
ctatgttccct	tttttttttt	tttatttttg	taacttgagt	ctttcttctt	tctttctagc	55800
taaaggtttt	ctaaatttgt	tactattttg	aagaaccaac	ttttggtttc	atttattttc	55860
cctattattt	tacattctct	attttatctc	agctgtaata	tttattattt	catttttttt	55920
gctagtttctg	ggttcagtat	attcttattt	ttttagttcc	ttaagttgta	aagtttaggtt	55980
gatgattttaa	gatctttctt	gttttttgta	atgtatgcat	ctaaattttc	taacagtgtc	56040
ttcattatgt	cccatatgtt	ttgacatatt	gtttgttcat	tttoggttat	ctccaagtat	56100
ttttctaattt	ctcatgtaat	ttattatttg	atccattggg	aagagtatgt	tgttttaattt	56160
ccacaaattt	gtaaaagttc	tcgtttttct	tctgttactg	atttcttact	ttatccattt	56220
ttgatcagaa	aaatgttttg	tatgatattt	tttacogtaa	gttttttgag	acttaatttg	56280
tgacctataa	tatgttctat	ccaggaaaat	gttccatgtg	tacttaaaat	aatgtgtatg	56340
ccatagaaaac	tgggtagagt	gttccgtatc	tgtccattag	acctagtggg	tgtattgtgc	56400
cattcaagtt	ctctgttgcc	ttacttatat	tctgtctcat	tgttctattc	attattgaga	56460
gtggggtatg	ataactacaa	caattattat	agaactgtat	gtttctgttt	tcaattctgt	56520
cactttttgc	ttcatatatt	ttatgggtctg	ttattagatg	cataaatatt	tataattttt	56580
atatcttctt	gtacatttaa	accttttaat	aatatataat	gtccttcttg	tatgttttaa	56640
aatctacttt	gtctgatatt	agtatagcca	ctcttgcctt	tcttcactta	ctatttggac	56700
aaaaatatatt	ttttcatcct	ttaactttca	gtgtatctgt	gtctttgggt	ctaaagttag	56760

tctattgtag	actgggccta	catcattttt	taaaatccat	tttactaacc	tctgtcttct	56820
gattggagag	cttaattccat	ttacacttaa	aatcattgct	gataagcaag	caattttgct	56880
atttggtttt	tatatgctt	atagctttct	catacctcat	tttctacatt	tctgtgtttt	56940
gtgtttagtt	catctagttg	atttttcagt	taaatattaa	aagtcttttt	ttctgtctatt	57000
ttctttcttc	tatattcttt	gttggtacca	tggtgattat	attcaacatg	ctaaagtatt	57060
aacattctaa	tttgaatttg	tgccaactta	attttaataa	tacactcaaa	tattttttac	57120
agctctgtoc	ccacctcttt	cagctgttca	tgctataaaa	ttatatctta	tacatttcat	57180
gttcgaaaac	ataaactaat	aattctttga	tgcatctatc	tctcaaatta	tgtagaaaac	57240
aaaatgtgga	attgcaaacc	aaaattacaa	taccaacttt	tagcataata	attatcttaa	57300
tggttttagtg	tcttaaatga	agtagaaaac	aaaatgaagt	tatacagcgt	gttacaataa	57360
tactagcttt	taaaattgcc	tatttttaat	tcagatttaa	tttttgata	gcttttagtt	57420
attgtctagg	gtcctttaat	ttcatcccaa	ataactcccc	tgagcatttc	ttgcagggaa	57480
ggcttagagg	taataaacte	ccccagcttt	tgtttaacctg	gaatgcctta	atttctccct	57540
catttttagat	aacagttttg	ctgaatctag	tattgttggt	tgacagtatt	ttacacttag	57600
tattttgtat	gccttctgat	tttcaactga	aaactgagca	tttgaatcta	ataatatgtt	57660
aactctgata	accggattct	ctttctttct	gagggtttgc	tggtttgttc	ttgacttttt	57720
tttattgttg	cagctgtctc	tgtgccaaagt	attagcatga	gggtgaaact	tattctctcc	57780
tcaggttttt	ttctgaactt	gtatcttccc	actgtgtcta	catggtgact	tcctaatttc	57840
acctatata	acagttgctt	gtgaatgtct	ttatcttcaa	tgtcagccgt	ccaaaagagt	57900
aaaaagagaa	aaacaaagg	agaaaaaatg	aggcaccacc	ctctttacat	tccttgggaa	57960
ccacctcagc	caggggagag	gggctgacaa	taattgagga	ggagcataac	aatggccact	58020
gtttctttgt	ctgcacctct	gggatcagaa	gcagtgatca	gtgatcagag	cacgggtctc	58080
tggtatctgg	caggcagggg	tggttggtgc	ccaccctagt	ttctgcaagc	tggtgtgtag	58140
ctgctccagg	caccgctgcc	tgccacagag	tgagaggtg	gggaatgaat	agggtgtatt	58200
gtgctaata	ctaaaattga	ccacaattaa	ccacaactga	cagtctaagc	catctcctgg	58260
gagtttgaag	tgcaagtctt	tccttggaac	ttaatttcaa	tagtttccag	aattccaaaa	58320
tagtaacatc	agacagattc	tgtcagggca	ttattttttt	ctatgtaggg	atacatattt	58380
ctagtgtctac	ctactccacc	atctttctag	aatattctcc	tcaccaataa	tttatatcat	58440
catttctggg	gtttgaagtc	aacaatctgt	attttaacaa	tttctctagg	tgtctctttg	58500
cctgtcttaa	gttttcaatc	cagtttagcc	tctctatcct	caatataaaa	caaaagcacc	58560
atgaaaacat	ttggctctaa	gtgtggttgc	catttaattt	atgttccaaa	ccagaaaaaa	58620
aaaaattgag	agtaaaaagaa	cgtgctatta	ataattcatc	tgtaataata	tatatgaacc	58680
tggactgtct	gaaacagttt	tttgagagac	acttagaaaa	aattatgctt	tggaaatttt	58740
ttatgggggtg	tcatttaattt	gtttttgtcc	aatttttgca	acaaaatttt	gacttctata	58800
gtgaggtgac	attcataaat	ctgagtattc	atatctaaaa	acccaaaagc	atttttttct	58860
aaggatgtca	tgtagatcat	ataaaataac	tatagaaata	ttgaatccat	aatatgtcat	58920
atgagttgca	gccattttta	tattttgtcc	atttttatat	attctatgca	tataatatat	58980
ggtagttttc	tgatagtaat	ttccaattcc	tctcccaaaa	tggactggac	agatttctta	59040
gtgaggggaag	actgttttta	tatcattcaa	atttttatcag	tccttttctg	tgggtccctt	59100
gctgttctta	ttccatagca	tcttatgtag	gattgatctc	ttccttggtg	tagagtccat	59160
attattattt	tcagaagtct	tggtttttcc	attggcaaat	gttcaaataa	aactttataa	59220
ccaaatcttt	ataatgctgt	tgccaacttt	gtgtctttta	ataaagtcca	attgccatag	59280
ggcaattgtg	cagtgggatg	gatatgtgaa	tctgtgtgaa	aaatgatatt	ttaaatgctt	59340
tgtgggggaag	agtaaccagt	ctggattgaa	ttgaatgcta	aattggcttt	acatttggaa	59400
aaaattttaga	tggttatagta	gttcttata	aagaacatta	aacatctcac	tctaaatgaa	59460
gtacctcagg	tgatactgtg	atagctataa	ttgtttatga	cggaaatatt	cactcttaga	59520
agacttgggt	attgacaaga	acttggaaaa	ggatcaagca	gcaacatata	tgaactgtg	59580
cttcagcagg	ggaaatacag	ttatgttcc	gggtcactgg	actcttggtta	tggactgaac	59640
aatccaagct	atataaagag	acataataac	tatgatcaga	actttgtgaa	atatgaccgt	59700
tctatttgaa	ttcaggttct	aagcagtatt	ccccaagag	atctgatatt	gaatcaatgt	59760
tgtagctacc	agccttgaag	ttacctgaac	tttggtattc	tattattccc	ttagcttcta	59820
gaaactgact	atggtgaatt	cttaccctaa	atgtattttt	ccctagtaga	tgaactataa	59880
tctttcttat	tcatagtcta	tgattgggtc	atcttctcta	gctccctttt	ttagatgtgc	59940
tgaggaagtc	cgctgtggtc	ctaaagctgc	acctgtgtgg	ctgttgtcta	atgtcccgtt	60000
ttggtgtctca	atgtcoatgag	tactaagatg	attctgagta	agagtccctaa	ttaatgccac	60060
caaaaatttg	cgaacccttg	tcttttgggg	aagaggggca	gaattcttca	cgatagtcc	60120
caaacctggc	ttcttcaact	ctgtgtacga	gataatttca	aactgctttt	ctcactttta	60180
aattttattc	atagatgtaa	aattttggca	ttttggctaa	tttaatttca	aatttgtatt	60240
tgcttgttcc	tgctttgatg	cgctacttat	gttgtgtttg	aaacatagta	gaaaagaggg	60300
tgctgcggac	aagtatgaga	agacatgctt	acagtcacat	aaaaggagaa	taaaatatg	60360
tgtgtgactg	tagacogtac	ctccatgaac	attacaaatt	tctgactgcc	atctagaaca	60420

cgtgctttat	caacatgata	tcaatgatgt	ggatatttta	cttactttct	attttgttat	60480
acatgttttg	tttagatgtg	acctttgacc	atttctgtat	aattttaata	aaatagattt	60540
aactacacaa	aaatcaccct	aaaagtaatt	ttccatgatg	catttttaaag	gtcatgtttt	60600
ccctgatgac	agcatgtttt	tgtagttaga	ccttgggaaa	gacaacaagg	agatctgaga	60660
gctaattgcaa	aattatcttt	actagctgga	tctccttgga	ctgggtcattt	atcctctgaa	60720
tcctaatttg	ccccttagca	ctcacaaatg	tcatctcccc	aaagccatag	ctgagcagaa	60780
agtggagctt	agcatttttt	attctgatag	aagagactgt	gtccatgcaa	ttatgacagt	60840
aaaaataaat	gagcatagct	tcaaaccattt	ctttaataga	aacttagcct	ttgggtttaa	60900
ggttatataa	agtgaagga	atltgggtaa	ttaatatgaa	gtcaaaccatt	aaaagattcc	60960
tcaagtaatc	caaaggtatc	aatgtttcaa	tgacataaaa	tacctctcta	gtccttatga	61020
tgagaagaga	aggtcctgat	gagtggtctaa	gtagtgtatg	aagtotaagg	ctaaatttct	61080
atgaagaaat	attgtaataa	aatttttgaa	agatactcag	agatatttct	tgagatcatt	61140
atcatgtatt	ctgtacacaa	atgtattctt	tccattttat	tttcagtgtat	tttccagtga	61200
cagctataaac	tttagaaaagg	ctgattgtta	ttctttggct	ttctccctc	aattaaatca	61260
tgtttttttg	gtggaaagag	agatttaaaa	taaaatggaa	gcaagtggta	ttaatcaga	61320
gttactaaaa	ctgaaaatta	gggaaatgta	gaaaatataa	actaatatca	agctaattct	61380
tttctgtatc	agtgttagac	cttttatggg	tgaatgaggt	taaatgtgtg	ttagtataaa	61440
ggagttaaaag	gagtaagcaa	agacactaag	accagagcat	gactttatat	ctatatcagc	61500
ttgagtctat	ttatagttaga	atcactagaa	agtggtgacc	acacagagtt	gcattttttt	61560
cttttgatat	gcatacattt	tccctgaaag	aaaaaaggaa	ggaaggaagg	aaggaaggaa	61620
ggaaggaagg	aaggaaggaa	ggaaggaagg	aaagatggaa	ggaaggaagg	aaggaatgaa	61680
ggaaggaagg	aaggaaggaa	agaaggaagg	aaagattgag	gtaaggaaga	aaggaaggaa	61740
gggagggaga	aaggaagaa	ggaagaaaga	aggaaggaag	gaaggaaga	aggaaggaaa	61800
gatggaagga	aggaaggaag	gaatgaagga	aggaaggaag	gaaggaaga	aggaaggaat	61860
gaaggaagga	aggaaggaag	gaaagatgga	aggaaggaag	gagggagcaa	ggaaggaggg	61920
agggaggaag	ggagggaggg	aagaaggagg	gagggaggaa	ggagggaggg	aggaagggaag	61980
aatatttttt	aaaaagaaac	tctttgatga	ttcaacatca	tggagaagtt	attattatat	62040
tgagcttgac	ctggatctgt	aactcttgac	atttagctct	tgaataataca	tctgttttct	62100
tggctgatag	tctttaaaga	cagaatccaa	cataataagc	ctgcacatgt	atccccatat	62160
ctaaaatgaa	tcttgaaatt	ataaaaataa	atacaatata	tgttcacaaa	tattaaaaaa	62220
atgtgcagag	atatgggaat	acatatgtgt	cttatgtgtg	cttatttcta	tgaagtcggt	62280
agatgtcaaa	gctctttctg	catgcctcct	tgcttagacg	ttttgtctga	aattctgttc	62340
acattgacat	acgtgcatta	aactaatatg	agaatgtatg	cattaaacta	gcttgaatga	62400
tgtccacatt	ctcagttttt	tcatcataac	tttttctttc	cagagtgcac	gatgccgcag	62460
aaaagaaaag	ctaactgtga	aactcaaaga	aggtctttgt	tagggcctga	gtattttttt	62520
tttaattctc	atgactttca	cattcttagc	ttcagtaatc	cttgaagaga	acagagtcaa	62580
acctgtatt	ttaattagga	tctttcagtg	tttgtggcct	tgaggagcga	gagcaagaaa	62640
gacattctat	gggtgtgcgt	gaaagagagg	accaagggtg	ttttctttgt	gactagagat	62700
tatatgtgt	aagagcagat	gacaaccttg	agattcgatt	tgtgatatga	aaccaaatgc	62760
actaaaagga	aagcgtacca	gtttggatta	gatacattaa	atcagtatgt	catgtaaatc	62820
agtgactatt	aaaagagaat	atataggaga	aaaaggattt	agaagttgca	tttttttaacc	62880
aattgcaacg	tttgcaaatg	ggcttgtcac	ataccatcat	gtaagtacta	gtgaagtcta	62940
aggtataaag	aagtattttt	catttttaag	gatcattgca	aagatagaga	atttgacaat	63000
aatgaactg	actggccttc	tacaagtatt	tacttacaac	cacaattgta	atttttccat	63060
ggccaagcta	tgaattatta	aaagaatatt	gacattttgc	tatatatttt	aattatcttt	63120
aaatcatttc	aaatagtga	atagtattat	actaatataa	ctttattaaag	tacattttca	63180
agctcagcta	agttttttta	tcaatgttta	tttcagttag	gggatagttt	tgtttttttt	63240
cttctttgaa	ataatatctt	tgaaccaaat	gtccacattt	ctttacagat	aaaagagttc	63300
tgtttatgaa	ataagaataa	acagcctgta	attttaatat	caccaaaact	attttaattct	63360
ctttttggat	atgtacttca	acttaaaacta	cataatagag	tatagatata	tagatatgtc	63420
tatatctaga	tgtagacaca	tccccaaaaa	cctatagaaa	tgtatttctc	aaatgtgtaa	63480
agtatagtga	aactgccaga	ccacaagcga	tgttttgtat	ttatagatct	acttgcaatt	63540
tggggtgtgc	caaatcccca	caccttggtg	tcaatattag	tttaacaaaa	ctaaaaggaa	63600
atttaaaata	ttaagatcat	cctctttagg	atctacttgg	agcgctgaaa	aaggtgtgaa	63660
aatactgac	tcggacttct	tgtgagtttg	atgtgtttta	catttgaat	gctattctct	63720
tcactgcatt	catgcgtgtg	cttgaagctt	gctgccttgc	aggagacaat	gcaacaactc	63780
ttaccaatgc	cacttttata	agattttgcc	tgcatgtgtg	caatgtgact	cttcagtagc	63840
ctacttaagg	gagtgacagg	aagatgacct	acctgagtc	atccaaagaa	tatttctcta	63900
gttctgttg	gtcctgtgaa	ttcctaattg	ctttataata	aatggccacc	taaaaattaa	63960
tgttaactgg	ttgattgtgt	tgcatgacat	taagttaacc	taactgccgc	aacagggtgc	64020
agctcgcac	atagcaaata	cgttacggga	gagaggggca	cgtcctccct	cagcgcacc	64080

aacagggatc	attaaccaag	gctgacacaa	ttctccagt	agaacagatg	taaccttgga	64140
atctttctcc	acacagtgtc	ccaggaagcg	attcgacatg	agtctgtact	ggcatagga	64200
aataaaactg	gcatggctgc	cacatagatc	ctattttctt	ttgcctctta	ccaagagtta	64260
ttttaaaaat	gaaactattg	tgggccaggc	gtggtgactc	acgcctgtaa	tcccagcact	64320
ttgagaggcc	aaggcaggca	gatcacgagg	tcaggagatc	gagaccatcc	tggttaacac	64380
agtgaacccc	cgtctctagt	aaaaatacaa	aaaaattagc	tgggcgtggt	ggcgggcacc	64440
tgtagtccca	gctacttggg	aggctgaggc	aggagaatgg	cgtgaacctg	ggaggtggag	64500
gttgcaatga	gcagatatca	tgccactcta	ttccagcttg	ggcgaaaaag	tgagactgtg	64560
tctcaaaaaa	aaaaaaaaaa	agaaactatt	gtcaaccaat	gagtgtaaag	gtgttatttt	64620
tgcttttttt	taagtttatg	ttttgaaatc	ctctctcaat	tgcaggaaaa	aaaaataagat	64680
acagaatata	aagagacagc	ataaatgata	gaaaacaaaa	taagcatgtt	catgagccag	64740
aaatcaagaa	gaaaaggcaa	tgataaaaaa	ggctgaagcc	ggaggcatcc	caggccctgg	64800
gtctggaagc	aggctactac	agtggcattc	ttgggcactc	tggggcaccg	aggctctgta	64860
gtaccactca	taacgtgact	ggccagcaaa	atttactgct	taacataaac	aatgtctttg	64920
ccccacctt	gcaaaataat	gctgaaataa	aaggtgttac	tgatcattgt	ctgggactaa	64980
ggtttagtga	ggtttactta	cagaaaaata	aaaagcaaac	agtcatacac	ccaagatttg	65040
gccaaagctg	ctgttggatt	tgacatatcc	tgcaatcaca	gggaaaaggt	tggtactata	65100
ctgagatgtg	gctcaggatg	ggagaccaca	gggcaggcag	gaaggaggca	aaagcaatct	65160
agaagacctg	tgtgactagt	gagaaaaagc	agagtaagag	aaaggaagaa	agagagaaga	65220
tggttgtcct	cttgttaaaa	taaatgtact	aaaacaaata	gaacaatatg	aaaagacctt	65280
acataggtta	agtatcttcc	aaaaaagaca	cagcattcat	gtgagcttca	tattgctact	65340
atagcaaat	gccacaaact	tagtagctta	acacaacatg	catttcattac	tttacagcag	65400
cttagacatc	caacatgggg	cccactgggc	tcaaatccag	gtgttggcag	agctgctttt	65460
ctttctgaga	ctctagagaa	aaatygtttg	ctttggtttt	tcagctctgg	aggctgctgc	65520
gttccttggc	tcttggctgc	ctctccatct	tcaaatgcca	tcactgcagc	ctgcgcttca	65580
tccatcacgt	tggctctgtc	gctcacattt	ctactctct	cttgcaagga	cccttgggat	65640
tctattggac	tcacctggat	aatccaagat	aatcttcatc	ttaaaatcct	taatttagtc	65700
acacacagaa	aatcacctct	gttatgtaaa	gtaacatatt	tccatatcct	ggaggaaggg	65760
ggcattgatg	tgtctaccac	agcatccaca	aagggaacaa	aaaatattgt	ccaataaatg	65820
catatagaaa	taaatttgtg	gattcaggaa	aaagtggagt	catggaacaa	aaatatttaa	65880
tagatagaag	agtttccaga	ctagacatcc	aggaagaagt	tcacccagga	tgcagcttag	65940
agaaaaatgc	aaggaatatg	cgaagggaat	gcatgcatgt	acatgcgcgc	gcgcgcacac	66000
acacacacac	acacacacac	acacacacca	catagaaaag	aacaattcac	agataggagg	66060
ggtagattta	gagactccga	catataacca	tgaggtttac	aataaaaaag	ataaaggaga	66120
aaacaatactg	aaaaaagtaa	ggaattttcc	acaattgaag	aaaaacatga	gccttcagat	66180
aggatgtgcg	tgtctcgtag	tgagaaaaat	aaatgaaaat	aaatccgcac	agaggcacaa	66240
agtaatgaaa	ttgtagcagc	tcaaaatcca	tattctcttt	gggtttgaca	ggaggaataa	66300
attcaagaga	tgtattttac	aatagggtaa	ctacagttaa	taatatattt	tatactcttg	66360
aaagtgtgctg	agtagatttt	aaatgctctt	actataaaaa	tgataagtat	attaaataat	66420
gcataatatta	attagcttga	tgtagccatt	ctacagtata	taagtatttc	aaaacaacct	66480
tttgcatactg	ataaatacat	agtcaaaaata	atttaagaat	ttttaaatga	taaaaaatac	66540
attttaaaaa	ttggaaggcc	atattcttaa	aaactaaaca	tgagaaaagt	attaccaaca	66600
aaaaataaca	attaggcctc	tctagaaacc	taactcttaa	aaacagacat	tacagaatac	66660
tttcaaatg	ctttggcaaa	aacaaaaaac	caaataacag	ggaaagagct	ctatgaatta	66720
aaaattttgc	actcagataa	agcattaatc	aagatgaaat	acaaaatgaa	gtacatggtt	66780
tcttacagct	cagttttcct	atctggatta	actttagttt	tgcaatagta	tttcttgcag	66840
taacgttcta	ttatttgtgt	gtccaaacat	gcatatttat	ccagcaacta	attcaaggta	66900
tgagaggaat	gaagatactg	atgacagaaa	ttagagcagg	gaatcagaag	agagaaggtc	66960
atgttccctt	gcatggcact	cttcagttga	caaaaggaca	tgtgatccca	agatttctct	67020
tgactgagac	tacatttaca	caaatttaag	agtttgttaa	cattaaataa	ccaaagtcac	67080
agccttagga	acttccattg	caaaaaagga	gtttaacatg	gagctgttgt	taaaaggagg	67140
gtcagatggt	cgaaaaatta	attggcaaac	aagttgattg	cataagctgg	aagtactgtt	67200
gaaaactttg	tggttcttta	ttaaacgaaa	acacttcgga	tattgggaag	acagcaacag	67260
tgaaattttc	ttggaatcag	gaataagggc	ctttatatat	tctactcact	gtctacatgg	67320
tcatgatctc	aagttattgt	ttctcataca	tatcagagat	gtgctaaaat	ttgaaatagg	67380
ttttcaatca	ggagccaatt	ctaatacacac	atcagtggca	acttggagcc	ttgagtttgg	67440
aaagattttt	tttagtgtgt	taggttggtc	tgtgtgtgct	ataaagcaat	atctgagact	67500
gggttaattg	taaaaagaga	gggttaattg	gtccacagtt	cttcaggccg	tacaggttagc	67560
atagcaccga	catctgctcc	tggggagtct	tgaaaaagaa	ggcaaagggt	cagcaggtgt	67620
ctcacatggc	aggagcagga	gcaagagtag	ggagaagtgc	cacactttta	aacaatcaga	67680
tcccttaaga	actcactcac	tattgcaagg	acagcaccaa	ggggatgatg	ttacaacact	67740



catgagaaat	ctatcaccat	ggtctaata	cctcccacca	agtctcacct	ccaacattgg	67800
ggattacatg	tcagtgtag	actcaaagaa	gacacatatc	tgaactatat	catgtacaat	67860
tccaagacaa	agtctactaa	agtcctgagat	caattaaattg	tagatatctg	tcattaggta	67920
actgaaatag	aaggaatggc	cacagagggtc	ttgtagggtt	gtggcttggtg	cagggtgtctg	67980
ctgataaatg	tttaacaata	ggttttcata	gggtggtcagg	gaaggcctta	tttgtagcat	68040
ttgccaatct	ccctgatata	aatattccaa	ccatggatga	tttactcaca	agatggaact	68100
gaattctgac	cacagctgtc	tcttgctagc	tgggtgtgagt	cagctccaga	acctcaggag	68160
tctggtggtc	taatgctgaa	acttagtatt	taaagttggt	atcttttgtt	cacctgtacg	68220
gaagttaaagt	atgggtgtga	gaaaagtttc	agttagttta	gttagtattt	ataagaaaga	68280
gtttaaaaga	aaagaatgga	aatggctcgt	gggtcgcata	attgagacta	tgaagagtgg	68340
ttgaataaat	tgggtgtgtt	tatcctggag	aggaggggagc	tggagagtga	tttaataatc	68400
ttcatattta	tggaggtttt	ttttttttga	cagaagatgg	ttcccagtta	ctttccatcc	68460
ctaagtttca	aatcaagata	aatctagcct	taagtattcc	ccttttctat	ccaataatta	68520
tgccttttaa	aatatttttag	aaaaaaatgt	actgtataaa	gaatgctttc	ttagattggt	68580
tatcagttga	tccagtttct	acactttaaa	tctgtctggc	cttttacact	atatgtaaga	68640
ttaggcaata	aagataggga	aggttcaagg	gaaaacttct	gaggccaagt	aatccaatag	68700
gaatccaata	gcaatatggg	aaggcaggaa	ctattttacc	caataactct	agctagaaat	68760
ttcaacaatc	accaaccatt	cctgctcccc	cacatgtcat	tcacacact	gcttcatgaa	68820
ttctaactcc	agaagtcctc	ttgaattttt	cccagcctgt	cctgtcaaat	cgtgtgtcta	68880
gtgcaagcta	ctctttataa	tattgcaatc	gttttctatt	ccactttaaa	taaacagagt	68940
agagaattgt	tgaccagatg	aataaaaagt	tggccaccaa	tttgacatta	tccccctaac	69000
taacattatc	ttaaagtatg	cttctcagga	gggcatttta	agtcatttga	agttctaaat	69060
gcaagactga	atatcttctg	cacctgtttt	cattgggttca	atatgaaaga	ttatactatt	69120
tccaccatgt	taccaaatat	gattggcatt	gtgttaaagt	ttcttaggtt	taatcactct	69180
gaatcctttg	cctaaaatgt	agattttttt	ttttgctata	aaaaagacat	tagagtctat	69240
gccaaaattt	gcaattcttc	tataaaaatta	ttttttgtct	aaatcttaaa	aataacttaa	69300
aatcactaaa	tgttcaggga	aatctctagt	gagaaaaata	aaatttatag	ctcacagact	69360
agattgaaca	gacaaccatc	tgttcaactt	aaaacatttg	tctcaaataa	cataataact	69420
cacaaatgat	gatggattag	gtaacttcat	ttcatattta	ttaaattatt	aacccaactc	69480
tttttaaagc	catcaatttg	catgaagctt	atgagtga	gatatacaaa	aaaaacttaa	69540
tatttgatga	tctcctaata	tgtgctaggt	tttttatatg	tatgacattt	taacaaatat	69600
ttaaagtcaga	tactatctct	tttttcagat	aaagaaattg	agacttaagg	taaataattt	69660
acttacagtc	acaaaaatga	agtacgctta	tacaatctga	atctactgat	ggcttcaaaa	69720
tccttttcta	cgatgaaatg	tagcttcatg	taggggagta	taacatggaa	ataaggcagg	69780
tagtttttcc	tttccaaatt	tttagtatag	atgaagaaaa	agacattctc	aattatcatc	69840
actgtttaaa	aacaatgtct	ttgatttaat	atatggtaaa	tattaaatat	gtggctgtga	69900
aaataagtat	attttttagag	ttcaaagggg	aggaaaatat	cctttgtaag	ctggggcatt	69960
ttcaatatcc	aattttattt	attttttata	atgaaatagt	cagcactcca	accatccatc	70020
tatccacca	ttcatccatt	tatctacctg	tccatctatt	catccatcca	aacatctatg	70080
tatccatcca	ttcacacatc	cattatttca	tcctgcattc	atacatccat	aactactctc	70140
taagaaagaa	gaaaaattta	ttcaggcttc	tctgtagatg	gaagtgtttt	gatactaaaa	70200
tgtggatgtt	tgtaatttta	ttattgccat	ttcctttcca	aatgtatgcc	aatcatacat	70260
ttttctaaga	cttatacatt	acctctgaaa	tgttctctct	tggaaatgat	gcacgtcact	70320
tctactgaca	ttttatttgt	caaagcacat	cacatagtca	tgcctgagcc	tatcctcagg	70380
aagacaaggc	catttgacca	ggaaacacag	gagatccaga	aatattgggtg	aacactggta	70440
acgtccatca	ggctgaaaaa	atgtggtata	aatattaata	tttaagacac	aaagaggat	70500
ttaccatgat	aaaacatatt	taagacaaag	gtttttacta	agagcaaaaa	cataaaacttt	70560
gtgttagtca	gttctgtcta	ctctaacaga	ataccataga	ctgggtggct	ttaacagcag	70620
acattttattt	ctcagccagt	tctgatggct	ggaagtctga	gatcagggtg	acagcttctc	70680
ttgaggacca	tccttctggc	tgcacactgc	tgacttctcc	ttgtatgctt	aagtggcaga	70740
tagcagcgac	ttcctggagt	gacaagggtc	tcaatcccat	tcgcgagggc	tccgcctcat	70800
gagctaataca	ccaaaagtct	ccacctccta	ataccaacac	cttgaggatt	agaatttcaa	70860
aatatgaact	ttggggcaca	caaatattta	gtocataaca	gccttggagg	taaaattcta	70920
agtagcagaa	atctttcatc	tcttctaaaa	ctaacactag	tggaaaacat	aatctttcat	70980
tcaacgctta	gagtctgtct	tggagagcag	gaacagatgt	attatattac	atgtgcacac	71040
atacacatat	acacacaaac	atttgtttgt	atgtgtgtgc	ttatgtggat	atctatatgt	71100
catatataca	ctgcatctag	cacaataggt	aattgctatg	tcagggcaca	tttattatag	71160
ttttctctct	aactcataag	ggagagtttt	ttaatcagct	ggtaatatca	tatatttcag	71220
ttttttcttg	caaataagag	tgggaatagaa	agattttcgc	tgttgagaat	tgtgccctta	71280
agtgttaaca	atattcacaa	gtgttttaag	aaataattag	gttcatttca	ttctatcatg	71340
cttgactat	atttataaca	tgacctttgt	tctatttata	tatacaagta	atatattcta	71400

ataggaattt	ttttgtgaag	aagaaacact	tgataaatatc	ccaattccct	aacagaatta	71460
tacaatagtt	cctcaatgac	cttaccttgg	gaaaaaatta	aatgaaagac	acctgcatta	71520
gagatcaatt	tcctgatgct	cagtttatat	tcatcatgct	aagctatcca	aggacacctt	71580
tcttgccta	tcatttgatg	gaaacgattt	ccatgtgttt	tatgattcaa	ctccattctg	71640
cottagacaa	tacagtcact	tcaaacagtt	caactctaca	gttggtctggc	tgactttgcc	71700
ttgtaaaaa	tgcttttttt	ttttttgggt	cagagtattc	tatatatttac	ctaagaagtg	71760
gaaaacaaat	tttgggcaag	aatagtggca	tacacattac	agagtgattt	cacatttcaa	71820
tattatttac	aaatatgaca	tcaaacatta	gtggttttat	ttcattttta	tatcagaggc	71880
attctaaata	tgatgtgaca	aagttaactc	cgaatttcct	ggtttttgtc	agtttaaccc	71940
agatctttgc	tatgcagttc	tgaacactgc	catgctttca	acttttcaac	aagaaacagg	72000
tggttaatac	acacatgtaa	ctctacaact	tgatcttagc	atttcatgta	atactttggg	72060
aatgcctaaa	tattatgttt	gtagttgtcc	ggagcatctt	attttcactt	tttcaattct	72120
atcaaagagt	acatttaatt	aaaatttaacc	aaaactgaat	aagaataaaa	cctcacttcc	72180
ctaattttatc	ctcttataga	aaaatatttt	cagtggttat	atttatgtga	taccagccgc	72240
atctgggttc	agtaagcacg	tgtttcgagc	atactttgag	atgcattgtt	ccttggcgca	72300
cctcagtttg	tactggaatc	attaatgcat	aatctgaagt	tgtgattatt	gagatttttc	72360
actcaataat	gggattcaaa	tgctgccctg	tttgatctgc	attaactgtt	tggaattcca	72420
gaattattgac	tggcacttca	gaagtcacca	aggtattctg	tagccttcag	agggtaaatt	72480
tcagtcacgt	ggggatgatt	tttttggcaa	agagcatttt	gcactctgag	tcctcacaca	72540
cattctcaca	agtttttaag	cccaggacag	tctccattcc	accacttgta	ggtaaactgg	72600
tgatgatttt	aaaggtaatg	tcagcctgag	aaacagtgaa	atatgctgaa	gatatggaca	72660
caggcacgga	gtctgctca	tcttagtccc	taactctcac	cttagtgaat	tgttccaaca	72720
atgacataat	gaattatatt	taacttttcc	tgctgctcat	gttttgatat	ttgtcatcaa	72780
tcggagctgg	tgagagtttt	aataaagtgc	ttagcatcac	ctgagggtaa	atttctatat	72840
cctttggatt	ccttgatcct	cctctgcaact	ttatgtaatg	agtgaacctt	ctatctagtt	72900
caaatagaga	atgtagagaa	gtaaagtgc	tcagtcaaga	gggcatcact	gatgtcaaaa	72960
tgccagggcca	acatgaaaga	agggcagaaa	ggttccggac	acaaaaggga	gggcactgcc	73020
tggaactggc	agtgtcgggg	tttcagccag	aaccttccct	tagaatttgg	aaactatgga	73080
gaaaacacag	tgatgcagat	caatatatac	cagttttgtt	acagatgttg	aagaagggtg	73140
ctcactactg	tgatcataca	tttgggcttc	ccaacttttt	ctcttgaatt	aaacatatta	73200
ctaaattggc	aggctttttt	cctaacaact	gtgaaatgct	agtctttaga	aattttcagc	73260
atccagcagc	aaataacatg	catgtccaac	ggcgaggatg	gctccaaaaa	agagagaacc	73320
ccaaatgaaa	atgagtcagg	cattcttttt	tctttaagca	gagcaagatc	attcttatca	73380
gaggaaattg	tgagcagggt	acaagaagct	gcacatgcct	aggagggtgag	agttctgtct	73440
actccaggga	aaaatgagaa	gtgttgaaca	agcagcactc	ccagaaaata	acacattgta	73500
gtagacgccc	gttacgggtt	ctccatgtat	taaattgggt	tataacattg	tctttttgtt	73560
tgtctctttt	gagtttataa	gttcccatca	atattttatt	tcctttactt	attttgggtt	73620
taatttgtgc	ttttttctat	ctttaagata	aaagcataga	tgataaactga	tttttagactt	73680
tgcttatttt	ctaatatagg	catttaaaga	tgaaagtttc	ctcttacaac	tgatttagct	73740
gtattcttca	aattttacct	ttcaaaattt	tatagggttt	atttttatta	ttgttcaatt	73800
tgaaatattt	cctaattttc	cctgtcagtt	ccacttttac	atacagatta	tttaaaatta	73860
tggtgcttcc	caaataattg	ggaattttta	cagatatatt	atactattgt	ttgtgatttc	73920
taatagaata	ccattatagt	cagagaaaaa	tgatcatgtat	tatttcaatc	cttttaaat	73980
tatcacaact	tgctttgtgg	ttgagatggt	gatctacctg	agggaatgtt	ttatatgcat	74040
agaacagata	aagtgtattc	ttcaattggt	gaatatattg	ttctatatgt	gtcatttaga	74100
ctaattattga	tattgttgaa	gtcttctagg	tccttattaa	ttttttatct	attagttata	74160
tttaattgctg	aaaaagcatg	tttaattgtct	gtgattggag	tctttttctgt	aattctcctt	74220
cagttttttt	aattgtttaca	tttatgtagt	ttaaagcttt	gtgatttatat	ttatccacat	74280
atttaattgg	aaatttttgt	tgttttaaaa	atgtttaccc	tttctggggc	ttttctctcc	74340
ttccaacctg	gtattttttc	tottcagcct	gaagaagtta	cctcagcatt	ttttatagaa	74400
caggctctgt	ccagacgatt	cagatttttc	tgttgaacat	ataaaaaatat	acagaaatgc	74460
ttttaaggca	ttgtctcagg	atatttgcta	tcattgtttac	agtcttttat	cttctactat	74520
ctttcaactt	tttttttttt	tttttttttt	gagacggagt	ctcactctgt	cgcccaggct	74580
ggagtgcagt	ggcgcgatct	cggctcactg	caagctccgc	ctcccgggtt	catgccattc	74640
tcctgcctca	gcctcccgag	tagctgggac	tacagggcgc	cgccaccgct	cccggtcaat	74700
tttttttttt	tttttttttt	tatgttttag	ggagacgggg	tttcacagtg	ttagccagga	74760
tagtctcaat	ctcctgacct	tgtgatctgc	cgcctttggc	ctcccaaagt	gctgggatta	74820
caggcgtgag	ccactgcacc	cggccatctt	tcaacaattt	aaaaacattt	tatggtcttc	74880
tagtttcatt	catcttatga	gcacaatgcg	tgttttttat	ctctccagc	ctctttcaag	74940
attttctatt	catgttttgt	tttcatcacc	gatttgatga	tcgtttgcct	agttcttggt	75000
atatttgaat	gtattttactg	tttcttatat	atgtgagttg	atatatttca	tctaatttag	75060



aaaattgtca	cccatgttct	cttcaaaaat	gtcttctacc	tcattatctg	tcctcttttt	75120
acaagaccct	taacgtaaat	atatttgatg	gcataatatt	ttctacacat	ctcagatggc	75180
tctccttttc	gttttttatt	tatttttatt	tatttttatt	ttgagaggag	tctcactctg	75240
tcacccaggc	tggagtgcag	tgggtgcaatc	tcgggtcact	gaaacctcta	cctcctgggt	75300
tcaagtgatt	ctgctgcctc	agcctcccg	gtagctggga	ctacaggtgc	ctgccaccat	75360
gcccagctaa	ttttgtattt	taatagagat	gggggttcac	catgttgggc	aggctggctc	75420
cgaactcctg	acctcagatg	atacacccac	cttggcctgc	caaagtactg	ggattacagg	75480
catggctctc	ctttccttct	tctcttctgt	atttttctcc	ttcttctctc	ccatctctcc	75540
ctccctcctt	tttttttct	tatatattcaa	tgtgggtgat	ttctattgat	ctatcttctt	75600
gtttactgat	tcttttcttt	ggtatgccag	tttactaata	gacctgtcca	attaattccc	75660
catctcaata	ttttattttt	tttccctatt	cttgacattt	ggcttttttag	ttgtgtttat	75720
ttctctgcta	aaattcttca	ttttttttct	gaaaaattgt	ctaaaaatag	tgttagatta	75780
tctgacatat	ctattatatt	taataataaaa	ctcctctctg	ataatttcaa	catctatatt	75840
tggagatgoc	tctatttctc	tttcttccct	tgcccatatg	gcatagttat	gtttatacat	75900
cctataatgt	atatatatat	agcttcttca	tgtcttgtaa	ttttttacga	tcccttccat	75960
ttaacagggc	atgagatcta	agcaagggag	agcctcggat	ttctctttgg	gctttataac	76020
ccagctgctg	actccctgag	tcggggcttc	cagtgaattc	tctttgctgt	ctgggtgctc	76080
accagcctt	ttcacaaact	agattttctac	gctttgctgc	tcagctctga	gcctttgagg	76140
cttgagtggg	ctcagtgaag	tccccgggag	ccttgagggt	gtttcccaact	gctgtcctac	76200
tctacccagc	tttccgcaac	agctttttgg	gtgagagggt	tttctcatgg	ctctcctgag	76260
ctgctcccg	cctcaagtca	gctatataag	cctccatttt	tcagatcccc	tactgtgccc	76320
ccaaacttgg	gtgcattatg	tccatgtact	aaagtaaagg	ccccctggga	cagagagggtg	76380
gggtgggtgca	gagctgcctc	tgatggagct	tcctcaggga	cctgagtcac	cacacttcat	76440
aagcttttta	aaatgtgttg	aaaattggac	ttgtttctca	catccctttg	ctggcaaatc	76500
cctcctcctc	ttcccatcac	tccacctagc	atcagggag	cacttcaattc	ctctctcata	76560
ggaagagatc	atgactttct	agatttttct	tcagtttaggc	tttttttgca	tctccagctc	76620
ttcattggct	cttataaaact	gtgttttgtt	attgttgttt	tcaagttatc	catcttgttc	76680
tcattttag	ttctcttatg	gctttctaat	tcctaaccag	aagtggaaac	tgctagctat	76740
tgtttataac	atgggtccatt	tgcagtttat	aggggtggta	tatgaatcaa	gtgtggaaag	76800
gaccagaaaa	aaattgtaat	ggcagatggt	atgttgtctt	aagccttget	ttgcttttgc	76860
cactgaggct	gtgttgtttt	taattcttact	gtgcatggca	ccttctcatc	acactagtgt	76920
tttgcccttc	aggggtatca	tccatataaa	taaactgctg	gaaggccagg	cgtgggtggct	76980
aacacctgta	atctcagcat	tttgggagat	gaggcagggtg	gatcacttga	ggtcaggact	77040
tcgagatcag	cctggccaac	atgggtgaaac	tcgtctctac	taaaaataca	aaaatgagcc	77100
aggtctgggt	gcacacgcct	gtagtccag	ctactcagaa	ggctgaggct	ggagaatcac	77160
ttgaacctgg	gaggtggagg	ttgcggtcag	ccaacgttgc	tccactgcac	ttcagcctgg	77220
gcagcagagc	aaaactccat	ctcaaaaaat	aaaagtgaat	aaaaaataaa	aataaaactgc	77280
tggaagaagt	ttatgaggta	tcctaagaca	tgtacaaata	ctagtgtaa	acccaactgg	77340
gaatctttat	gtcttatttc	gtccacagct	ccccacccac	accatggatt	taagaaagt	77400
ttttaaaaaca	ttttagatgc	aaagctatctg	gttctaaaaac	attttagat	caagctatct	77460
ggtttttcaag	gaatttatat	taagattgat	tttcaaatcc	tgtgtgctct	agtctaggag	77520
gataattatt	tgttaatgta	gataatttcat	agagacttca	ggcaaacaca	tgaatgagga	77580
gcaaggaaag	acccaaagaa	agcatgtaag	tagatatcct	aaatcaaatt	gttatttgac	77640
caaagaattt	ggtgatatga	taaaatccaa	tttctaaata	atgagttttt	ctgttaaagc	77700
tctcaatatg	aattaggaaa	gccttcagct	acacgtaaaa	gaaaaatctaa	ctcatagagt	77760
tttaaacaaa	tgatgagtct	tttctttttc	cttaaatctc	ctggaatcct	gttgacattg	77820
gattagcaac	aatggtgtca	aggactgaaa	gctagtgatt	gcttttgcct	tagacttcat	77880
gcctacattc	aaaacaagaa	gagggtagga	tacagcgtca	ttcattctgc	atcatcagga	77940
aagcaaaaag	ccttcttaga	agcctcttgg	cagtcataata	cttaacacct	ttttggcaga	78000
aactgggtca	tgtgtccgtg	tctaggtgtg	agagagggat	ggaaggtggg	aacatggagt	78060
tgttaggcca	attgtatttc	atctcttggg	aatgggggga	ttgatattgg	gtagacaaaa	78120
atcagttggt	atcactctac	ctaagtgttc	ctctgaaata	tattacttga	ttctggaact	78180
ttatttgaaa	agttatttga	tattcaatag	ttataatggt	aatccaatac	aaaatatata	78240
tgttgctttt	aaaatgataa	atagcaattt	aatatctaga	gtaatctcat	ctacatttga	78300
cagtaatat	aactattcta	ttctcataaa	tcttgtatca	tttttttgtt	aaattgtcat	78360
taattttaagt	aaggaaaagt	agagtttatt	tcccagtcac	aaatagaagt	aaccggttgt	78420
tgtaaaatta	tcaatgtttc	tttcttgaac	cactgcacct	tgaattttga	ttaaagagtc	78480
gaagtattgt	taacatccgt	ggaactttag	aaaaatacca	gtgctaacca	catcacatct	78540
aaaatataag	cacatttcaa	atttatgtga	atttttaata	atctgttttc	tttggttgt	78600
agaaaaatta	ccaaatagca	tattgtatta	agaatgaaat	gttctgtaat	caagatcaaa	78660
ttacaatctt	ataataataa	cagataattg	tatacatgca	atattaaagt	atatgagcat	78720

attcttttaga	caaaatatcc	aaagacatca	atgttttcat	tattaaagag	ttactttcca	78780
gttccactgaa	taaatgaaaa	tattaaagaat	ttgggttatat	taagaataaaa	ctctaagatg	78840
tttctttttac	ttcagtatga	aaagcatgca	aaaatgataa	ctacattttg	ttatgatggt	78900
ttgaaaaatc	tggcataatt	taaaagcaac	tttccatctg	gctgggtgcag	taagcaagtg	78960
gaattagaag	agttgggtctc	tgtttcttga	tgtgaatgat	tgtgattagt	ctgatttctt	79020
tggtttgctt	ttattactgt	tttccacttct	tttcttggta	tatgtgtgtg	gatatgcata	79080
caggatgaca	tttctatcac	attatggctt	aacaaataaa	acagaaaata	tgtttacttt	79140
ggatgtgtgt	gtatttttgg	agacggtatt	tgttgcctac	tcaacagtg	tctttttact	79200
tcttggcagc	ctccttggta	taaccacgca	tttacggaag	atgacgttac	cagcagccct	79260
ggggttaagtc	tcagtcaccc	gaagccagtc	ttggtaatcc	cagcagacta	gcaaggggaa	79320
acaacctagt	tctgtcaagt	ggaaagtga	gagagctgtg	ctgggagggt	tctcagaaaa	79380
gggtttctttt	ggcaaaaagaa	agagaggggg	gaacagttct	ttttcttctg	ccggacaagg	79440
tcatgtgtgt	acgttaagaa	tggaagttct	catgcccact	gagcatgggg	agagtctctg	79500
ctaggtgtgac	ctgggtgagaa	cagacaaccc	ttgagccacc	ttaccctagg	aactcctggt	79560
gataagacag	aatacatttt	ttctcactgt	taaactcttt	tttattattt	gtagctgggt	79620
gcctccaaac	caatataatt	agcogtatgt	aaatattctg	aaatctctgt	caattcaaat	79680
aacattttagg	gtttttttcc	cagtgtatcaa	aaatacagca	tctcaagcaa	tattgtgtgt	79740
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtga	tattattaca	taataattgg	aagacttttg	79800
atgtagatcc	tagtgggtgat	cttaaatgtt	gagtatttga	cttttttttag	catttaataa	79860
ttgtcacaa	aaattttatat	ggagagatat	tttaattata	gaaactcatt	agtttgtcca	79920
taatgtaaaa	gagttaaata	atatagttct	gttgataatg	atattttgta	atagatattt	79980
ttaagctgtt	aggcatgaag	gaaaataatg	ttgtaagtaa	tcagttttat	ataggggtta	80040
tagatatattt	tattatttgg	tattgtcatg	ttgtttcatg	cctcataata	gctgattaca	80100
aatagattttt	aatcaatcac	tctotttatt	ccaaagggtt	aagcagataa	agaatacaga	80160
gaatgcttgt	aaagcatttt	ctaccaatat	attaggacca	tttctggata	aggtccttga	80220
cttcttcttt	taatcgtttc	taaaataaca	tttccaaaaa	cctcaagcaa	aaccacttta	80280
aaaaatctga	attcatataa	ttttacctaa	tgtggaagat	tgggagagca	gtgactttta	80340
tataatattt	taatgtcaat	gtgtgtacat	ctgtaattaa	taaaattagt	acaattcaca	80400
acacatggtc	gttcttaagc	gacagagaca	tagaaatgta	acagcacatt	aaaatctctt	80460
tctagtggcc	ccagagctgca	ccccataaac	tctttgatag	ctcttaacaa	atgcaaat	80520
atgagcatta	acccaggcat	tcgaaggctc	agataaatca	ccatgctctt	caggaattca	80580
tatgaacaat	tcacagtgct	ataatttttc	ctaagttaag	actagactaa	tggtgagaga	80640
gacagaaaga	gaaacaaaaat	ataggtgcac	tctcctctgc	tcattatagg	gttctcttcg	80700
acottgagga	gactgtact	tggggacatg	tactgattca	ttttctgact	ccttttgcct	80760
ttgattttga	catagccttg	gtgttgggaa	attcttccct	caaagcctca	atcgtctcat	80820
ctcaaattta	aacacatttc	cttttctgta	atcagtgagg	gaagagcagc	tggtcaccat	80880
cttctacaca	ctaaaccttt	gagccttttc	ttcagaataa	atgatcctac	ttcttagaat	80940
cataaaatta	gaaggggttt	tgatgtcaga	ccatcctttt	tctgccttta	gacaagacta	81000
cccttccctc	ttaccatccc	atacagatga	gcaaaaccat	cctattttta	aaagagatca	81060
agagaaacta	atcaaaagcc	tccaacagtc	acacattcct	ctgatgagca	acccttactt	81120
tcaggaaatc	atcatcatta	tcatcaaaata	gcattttcct	aacacccaca	tggtcaaaaat	81180
atgtttgtgt	attcagatcc	taaaaggggc	cctagaggcc	cagaaaaggt	tggaaaaaga	81240
aaaaaaaaaa	acgtgcaaaag	gtacacaagc	atcactaggc	tctttgcaag	agagtctagt	81300
tcattgcaat	aataaattat	ttttaaaaga	cattccagaa	actccagggg	attttcattt	81360
tctatttagg	aaagcgatct	tataattaaa	gaatatatcc	attcattttt	ttttgtttta	81420
ctattaggac	ttagtaatga	ctatcaaaact	caagtcta	gaccaaaag	tgagaacata	81480
aatatgcagt	gtattaaatc	tgaacaaaat	ccatactaag	gttttaaaat	ttgcaaacag	81540
tataaactctg	aaccagttgt	ctctgttaca	aagtgtgtat	gtattgaggg	gaattgtctg	81600
gaaaaatgtt	taaagctctc	ttctctccca	ttctggctcc	tcctttatgc	tcctggagaa	81660
cagagctcaa	aggctgctct	caaagtgtca	aaactcccca	cccatggctg	gaatggctot	81720
atgtccttca	gtttcacctt	ccagtcagg	aattcccaat	ttctgagtat	tactgatttt	81780
tgctagggtt	taactaaata	aagcaattta	attgaaggta	agccttccct	taatttataa	81840
atatttgata	aagggaat	ttgccagtcg	aacatgctgc	ttgatgcgg	gggggggatt	81900
ttgacctggg	tggcactcca	gtctggactt	caacttacct	ttaatgtctc	tgccagggga	81960
tgcaacacag	agtaaggctc	cacgtcatcc	attcaactct	tcctcttttt	gggtttctca	82020
gctcctctcc	attgtctcacc	ttcacgagaa	gttccctgta	accgtgaagg	ttatcacaga	82080
gctcagaggg	taggagctga	cccagcacct	gcagatcctg	aaggggccct	aatctaaata	82140
caccattcac	cccaacaggt	gggaacaat	ttgatacaca	ggctcaaaag	tttgttttga	82200
ttactgttgc	tgtgaagttt	tgatttggcc	tcctaaagta	gaggagccaa	tttgatattt	82260
cattgcataa	ttcctgtact	atagtagtag	gtactatcta	gcaagacttt	actgcaaaaa	82320
taaaatatat	taatagaaca	tacaatggta	ttggcataca	gctcttttta	ttttttatct	82380

tttctaataag	atatgtttat	tctatttcct	aaacgtatc	aagacttaaa	attttcaacta	82440
ccaatgaata	acatgcttaa	atatttttagg	gaaatggtaa	aatggtaaac	agctctatta	82500
gtattattga	atatctcata	tttgaaagga	aagaaaagtga	cacttgctgc	tttctcatac	82560
gctatcacat	ttaaacctaa	ttacatttca	agacaagaat	atztatcatc	tttttttctg	82620
ttaaagaagt	tgagcctcct	ttacgataaa	ctgaactcaa	atgtaagcat	ctctaattct	82680
ggagtgcata	tgtgcacaat	tacataaata	atttggttta	agaatcaaca	aaactaaata	82740
aatgttaggt	ttctagaatt	tatccaaaca	tcatgatgat	tgactattta	ttgccgattt	82800
tcctatttga	atatgcagaa	gtttcaattt	taagataata	togttatggt	ctccttattt	82860
gatctcgtat	ttccacagag	ctactctgtc	attaaagtga	cctaaattct	tctccatagc	82920
cttttaagat	tttccgatgt	ttatctgttc	tctgtatcag	tctcgatcac	tgtcttcact	82980
ctaaaagctg	cacttaatat	cttacttacc	gaattagtaa	tttggaatt	accgtatagt	83040
tacatggaaa	tattacttcc	ctctgtgcca	cagactgggc	tttgattact	tcgatttcaa	83100
tgtcccagca	gcattccagat	tttatgaata	ccatttccga	tgctttgctt	aaagttaggg	83160
gocaggcctg	agctcaagtc	tcaaggctga	tgttgtaata	atcaggacag	gcgggttcaa	83220
aagcacaggc	gccagctgcc	ccacctccat	ggcacagccg	tcatggagcc	agccacaggt	83280
ctgtttcaga	ttgcaaaagga	gggtctctga	cttctgtttg	cttttgtgct	ctaggaagac	83340
attgtaggcc	tccataaaca	aaaataaaat	gaaatcgaat	tacaacttct	ttttaaccta	83400
tttaggatgt	aaaggttaaa	tatatatgta	tctatgaaga	aatgcatggt	aaaaagtggt	83460
ttgaaaataag	acatgcggaa	gcaaaattca	tttttctttg	tatgggtaag	tagtatggtt	83520
ttctttgtat	gggtaaagtag	tatggctaag	tattgtattt	tctttgtatg	ggtaagtagt	83580
atgacaatac	gccataatca	ttgtccttat	ctattaacta	aacctcaatg	agaaagataa	83640
attattacat	tgacagagata	tgagacttaa	gacttactca	aaaaatttta	aaggctattc	83700
cttaatgtaa	tacacttcta	tcaggaaatag	tacagaattt	tatctgagat	atttgtatta	83760
atcaatattt	ttgattcata	tgaatcatta	tttgatcag	attttgatcc	aaataaatgt	83820
gaagtataatt	gaataattca	gaatttaatta	gtttccattt	aatcagttca	atccttctga	83880
gttcatgatt	aggcaatttg	gaaaagacta	tataaaataa	tattctattt	gaactatgga	83940
agtattcaaa	agaaactggt	aagttcatga	gtataattgt	ccaagtgagc	tctgtaatct	84000
atgaatatat	aggaaagttot	tgtctttgag	aatacatggt	ttaagtgaat	tctattatct	84060
atattgtcat	tttgattgta	tttcaatttc	gttatgtgta	aacggaagca	atggatgtac	84120
tctttgaaaa	cagtttcaca	aattaaagaac	tttaaacaaag	cttttatctt	ctatttaggt	84180
caattttgtot	aggtatttga	ggtaattttc	atcctcatct	ttttatttgt	tatcttgtcc	84240
aatcctatta	atgagcataa	atggctcccc	aagtgtaaat	atttgaaggg	aaagattggg	84300
tcattgtaaa	ttcaggtagc	atccatagtt	gatgacagaa	tga'cggaag	aaactttcct	84360
cactaaatgt	caatcaaatt	catcagcatg	atacttttac	atgtctgcac	agctggaaaa	84420
aacagtcaat	tctgtttcat	tgttatgtaa	atttatgctg	atactcaatg	taatcaacaa	84480
ccgagtctag	aaccaatcctt	gaaacagatt	agatgattgg	attccttttta	ataataattc	84540
gaaactggaa	ccctaggttt	ttcttaggca	cttcttaaat	atttatggtt	atccagttca	84600
agtaacacag	aaattctgtg	gtcagctagt	ataatctttt	tcaagcagtg	tatgctattc	84660
ttataccac	accaacaaaa	ttgtatctaa	aacattggta	tctaacctag	gaaaaatctc	84720
aggtaagggt	ttacgattca	gtgccttagt	ccccttaagt	catttcggcc	acagccttaa	84780
aacctctctt	taagggtatt	taccatcacc	ctttgtaaaa	actggatttg	agcaagatgc	84840
attttattaa	tcaaatccat	aaggcagtca	atacattact	tcttttgga	tgaaaaagga	84900
aaagagttat	ttcacaagca	gatgaagact	acatatgtaa	ctctacttcc	ctcggtaggc	84960
tccaatacag	gtttaatcct	gaattttccc	attttgaaag	gcttgccaag	tcagttctca	85020
gacctttcgt	gaaacatggt	gctcagaagt	gacatcaaac	gtgatcctaa	tttttgacag	85080
attcttctat	acaatgacac	atacctggcc	ttcaaaatag	agtaaaactaa	aactcaactga	85140
agaagaacaa	aaaggtcact	cttaccattc	ttgaggattt	cgaaaatcaa	tgatcctaca	85200
gaaggagaag	aggccattta	tcattatagc	ctttttgatg	tcaaagaaga	aaaagaaaaa	85260
gaaacagaaa	aacatgcctt	taacatagca	gctgatatta	gtagctttag	aatttacaaa	85320
gcactttact	gttccgttat	ttcaattaac	actcataatg	ttgttgttca	gccagtctta	85380
acatttgtgt	tataattatt	tcctttgaaa	gctgaggaca	ggagggtcaa	ataacttgta	85440
tcattttocaa	aagctcttga	gctgataagt	gaggttctta	ggagtctatc	tccgaaagat	85500
tgagcatgaa	atctgttttt	tttttccatt	ccattgaagt	gtgtatttac	taactgggta	85560
tataattatg	aattgaagac	taacctttat	ttaaattagt	gcaatcagac	tatatccaga	85620
atatttctag	aatgatgttt	taagtgtatt	atgagtaaaa	tgaagggtaa	aatatttttt	85680
gtttgttcc	ttaaatgcaa	acctcttgag	ttaaaatttt	ctcaataatt	atgtagttca	85740
aacaatattt	tccaagatta	tttgaactta	gatacaatta	ctgaatttag	gcatatatac	85800
attagggttt	cttaactcttg	gcattcattg	cttttaagt	gaataattat	ttgttttagg	85860
aagctgtcct	gtgcattgtg	ggatttgggg	catcctgccc	tctacttacc	agatgctaac	85920
agtactccag	gttgtgacat	cctcaaatat	ctttagaaat	tgcacaaatca	tacttaggtg	85980
agaatcaatg	gtctgtatta	atttaactgc	aaagacaagt	gctgtttcta	aatattacac	86040

tggacaattc	taaagggtta	ccataaatta	gcagaggcat	taatctttta	atgatagtat	86100
tgtagtggat	atactggtag	aggacatagc	tatctaagct	aattctatat	atacagtaga	86160
ccaaaactga	cacattccag	gcattcccttc	taattctcct	ttgactcctc	ttatctagag	86220
tgaaaatttt	cttagcttat	tttgcattct	cccagcatat	cttcaactggg	agaaaattcg	86280
tctctcacat	ttttgcacat	cttgcaagtc	aggcactgac	cacctttttg	ttctggattc	86340
tcttttgagg	atgtttatat	agcaaacatc	cttggaatg	aagaatcatt	tctgcctgtg	86400
aaacagtggt	caaacatact	tactccccat	tatagaacat	tcaggttccc	taagttcagg	86460
ttcctcttcc	cctataaatt	cctttgcccc	ttgtaaaatta	ttgtttttaca	tgatcctctt	86520
tgtgttgcca	tgtgggaaca	aaatgttgat	actctggata	ctgctgttac	taaaacttttc	86580
ttgatctctg	tcccaggagt	cttctcattg	cttctacta	gaattcatgt	atccatatta	86640
ggatacattt	tttgttttgc	cagaaaggca	aaatccccag	tccttctcat	tactatgttt	86700
ttgtttgttt	tttgtttgtt	tgttttttatg	cagcctcggc	gctctgtcac	tcaggttgga	86760
gtgcaatctc	agctcactgc	aaacttctgcc	tcctggattc	aagccattcc	tctgcctcag	86820
cctcccaagt	agctgggatt	acaggcgtgc	accaccacgc	caggctaatt	tttgtatttt	86880
tagtagagat	gggttttcac	catgttagac	aggctggtct	cgaactgctg	acctgaaaa	86940
tctgtccttt	gaaatgaatg	acaaattaca	tgctattttat	gccccaaaat	gctaacttcc	87000
acatatatca	tttttagtata	tocttataga	ttatctcaca	tgaaatttct	ttttgcaccc	87060
attgaaagat	tattcctgag	gatgtcatcc	actctatcac	ttattgtttc	ctctttatat	87120
aagcatattg	tctttttaaa	ggaaagctga	tttttacctt	aacaacagtt	tcatttcttt	87180
atagacatca	caaaagttgc	gagttactgc	atttgcattc	tgcttatctc	ttttaggaaa	87240
tgaaggcttc	cttttttaag	ccaacctcta	gcagctgcat	aatatcattg	atagtaattg	87300
tgggtgttaa	ccttaccact	gattttattac	ttttctactt	ttaaataatt	gggtatctga	87360
ggaaatggaa	ataagatata	tattaaatat	agggtgtgtg	atatatatat	atatatatat	87420
tcaagtatgt	atagtttcat	gccaacctcc	atattctata	tataaatata	tattacatat	87480
tatatattat	atatgtatgc	gccaacatct	taaaaagttt	acatagaaag	acatcttgga	87540
ataaattgct	attattagt	gagtgggggg	aagaatcaca	tgagcaatct	aggtagcaat	87600
atatctaccc	tacatgaaga	agatcacatg	atctttgggtg	tttctcattg	agtatccggg	87660
ttagtagata	acttattgac	acagggatcc	cagagatcct	caggggaggaa	agtgtattgtg	87720
accccaacac	aaagcttggtg	aaagtgtatg	aatggactag	agtggcactt	gacaaactat	87780
tctgagagta	gcactccagg	agcattttgga	gaattcacaa	ggatggtaac	attaataaca	87840
agggtggcct	gatactagtt	ttcaacacaa	gctctggccg	tcctaagaaa	aggctttttc	87900
tggccaaaag	tggtgcttac	tctggaaatc	cctaagcact	ggccattctt	gcatgaagtc	87960
tttcttcggg	aaaacatgctg	taaattgattg	aatataaatt	caaagaattt	taattgttga	88020
gcccaggtat	agagtgaactt	cactcttctc	tggggactga	agtggaaaaga	ccaagtgtcc	88080
ttcaggatgc	gtggactcca	tattccacaa	cattgtgtgg	cagcatcaga	agccactgcc	88140
ccagtcgggtg	aaaaccaccc	tctccacctt	ctccactcta	tctttctata	aacaggatga	88200
ctgattccca	tacactgaat	tgaccttgga	attcatggac	attgtggttt	ttgtttgttt	88260
ttgttcgggt	ggttgttttag	ttgattgaga	gaagtgaggg	gaaatgataa	tatcagatgg	88320
ggagaataaaa	ttgattaaaa	tttcttaaaa	ggggcgggtg	atggtggctc	acacctgtaa	88380
tcccagcact	ttgggaggcc	gaggtgggtg	gatcacctga	gatcagaagt	tcaagaccag	88440
cctggctaac	atagtgaac	ccagtctcta	aaaaaataac	cagggcactg	cagggcactg	88500
tggcggtgct	ctgtaatccc	agctgctcgg	gaggctgagg	caagagaatt	gcttgaacct	88560
gggaagcaga	ggttgcagtg	agctgaggtc	acgccattgc	actccagcct	gggcaacaag	88620
agtgaactc	catcacacac	acacacacac	acacacacac	acaaaattaa	ttaaaaggta	88680
ataaaagaag	cacgatcatg	cagagcggtta	tgctggctac	ttttacattt	ttacttttac	88740
attactcatc	tatgtttcat	tatttttatgt	gagttttttg	atctacttag	gcattttag	88800
gtcagggtttg	tttaaatagtt	aaattcatct	acaatcaatc	ttactttatg	catatatgta	88860
tttatagata	cttagaatga	cattaaagat	tttggtagct	aaatctggcc	agtacaaaaa	88920
atatatatata	tctctagcct	aaaatggaat	gttgtcattt	atgagttcat	tgttacctga	88980
ctgtggtatc	tgactaaaaa	aaattatcat	agtatagatt	gctatttttt	agaatgaatt	89040
atttttaagg	agcacttcca	tggaaccata	tctcagagtt	ggacaagagt	tctaaaacac	89100
aatgtagaaa	aattgtcaat	attgtcagtt	atataatgatt	tccagtata	taacacaact	89160
aaataaagta	aaataaaaaa	atgatcccat	ttactggta	cttctaggaa	attcaggtag	89220
gtgtctgagg	tactgaaga	aactgggtcg	gttaccat	ggtgtaatt	aatctctttc	89280
aattctgtaa	gtctgaaata	tatgggtatt	tcaatgcttt	ttttttttga	gtattacatt	89340
aagtcaggaa	acagtctctt	ggcttgacgt	ttgagaggca	gtgcaaaaag	ccttctactt	89400
tcagtgtcat	ggcattgctg	atcacaaat	ttctgatata	ttctgatata	agatctgaga	89460
ataaaacaga	aaaagggtca	gtcatttcag	agaggtgatt	ccattataaa	gggtgggtatg	89520
tgtagcattt	tcttgagaaa	cttttaagtt	tttctttgat	ttttctctaa	gttttaagag	89580
ccctaagctg	ataaaacttt	aatgaatttt	cagtaaatag	agacaacttc	catttagtatt	89640
aaataacctt	tgtgaatcaa	cttgtataaa	tcacaacaca	aatagtga	acaaaacaaa	89700

gcaacaaaaa	acgctaaaact	aaactacaaa	gaagtcttga	gtgtttggat	ctgacccaaa	89760
gtgaccatta	aagttgtaaa	ttttctcatt	aaattgataa	caatgtaagc	cattctctac	89820
atcaattgaa	atgccaacgt	acttctgagt	aataacatcc	cttccatgtg	gtctctgata	89880
ttttgattct	agctttttac	gagcatgagt	atattcttta	ttttgaaggc	tgtgttgata	89940
gatggctctg	aattggaggg	ctacacaaa	ctaaagggat	tctttgctgc	ttgtcatggt	90000
tacagtcctt	tttctcttca	gtagcttttg	cttatctaaa	atgatgaact	ttctcagtag	90060
atgtgcaatt	caatcgagtc	atcttttccc	agatacagga	atgggtatta	atattctgcc	90120
ctctcagttc	tctatgatac	cctttatgac	cattcagaca	caggcattca	tacctactg	90180
aggacagcag	ggacaggata	tgctgctgtg	ataacaactg	aaccaatgac	ttggcttcat	90240
gctctctaag	agctgccaac	tccagtgcgc	ccaataactt	ccaccccttc	actacttggt	90300
ccagtgggtca	gatgggtggg	ggatggggca	ctgcaaggca	ctgctttctg	ctgttctgct	90360
ctaactcctg	accagatttc	acaaacagcg	tgtgctagct	ttaccatcca	caaatagcaga	90420
gaacttttgg	gggaataact	tgcacagccc	tcaaccagtt	ctttcctaaa	atgtatgtga	90480
agtcacccaa	cacattgaag	gttctcagta	gattttcttc	cttctgtctt	tcagtttggt	90540
tacctogcct	ctttgttttc	attgctttca	gattctttat	ttatagaagg	gaaaggggaa	90600
aagctgtata	ccacagccaa	aatttcaatt	ttgaaaaaat	tccaatctac	agaaaagttt	90660
caaatttata	gaaacaaaag	tataataaat	actagtaaat	acctttcaat	taaattcacc	90720
agttacaaat	tttgcacacat	ttgctttttt	ctccctcatt	atctctatat	ctatccatct	90780
atctacctgg	ctacatctct	gtgtctgtct	ttgtgtctgt	atattacaca	tacacacaca	90840
gatgtgtttac	ctttctctatc	ctttctctag	ttactcttag	aaatcatgac	aatatagatc	90900
atgtataaga	aaatcagtaa	taagttaata	ttatccaata	catagattta	cttatactgt	90960
aatttgtggg	ttcacogtag	tttgccttgc	tttgttttgt	ttctgatctc	tatattctct	91020
ttcatggaaa	gagaatgttt	atctgtgtgg	tgacttggtt	tatttttggt	tcogtaactg	91080
aatttctgaa	gaatccagag	gagttatcat	tagaatgttc	tgcatctctg	atttgtctca	91140
ttgtttcctt	ctgttttagca	gcaagtaaaa	catttcttct	gttaagcagc	aagtaaaaaca	91200
tagcaagaat	actatgtagg	tgatattgtg	cacttaaagc	atttgaacag	gaggcacata	91260
attttatgtt	gctccattac	tgatgatgct	ggtttaatga	cttggttatg	atgggtgactg	91320
ccagggtgact	ccattatgaa	gggtgggtatg	tgtgtgtata	tatatatgat	gtaagagtgt	91380
gtatacatat	atatatgtgt	gtgtgtatat	atgtgtgtat	atatatgtgt	gtgacacacg	91440
tatatttata	cagtaaatat	atacatatgt	atatgtatca	cacaacatta	tatttatacg	91500
gtaaatatat	atatgtatat	gatacatgat	aagtgaagaa	ttgtggcctt	gtggcaatgt	91560
gagcatcctt	cttctctaaa	attttcatcc	agtagttttt	atcatctaat	aattggctct	91620
tggtaaaaac	agttattatt	atgtattgaa	aaaaagatga	tatttcta	tttgtcatat	91680
tcttcttatt	ttttaactgg	cattctttga	aaattacctt	tctctttata	tatatatata	91740
tttttttttt	catgattcta	agttatgtat	ttaaaggtatt	ttaaatattt	taagcatctt	91800
gaaaaattta	aagtaggaca	tgttttataa	ttactgtgat	ttottatata	aacatcacat	91860
tttgataaaa	ataaaagagta	tattacataa	actcatataa	gtcttaaat	tatacacatt	91920
tctgtttcct	ttcaaagcaa	tttttgttaa	aggttaggaag	gagtaaaatc	cactgtgcct	91980
tggtttttca	ttttctattc	caactaagaa	gtgctgtcca	cagaaatgta	tcattcagcc	92040
actcagtcac	actttcctga	gaacctgcct	ccatcaaggg	acttcgttag	ctgtaaagtg	92100
ctgactaaac	ttgtgtttat	acctccactc	atgaaatagg	aaatatacac	acacatacac	92160
acatatatat	tcgtgtttat	acctccactc	atgaaatagg	aaatatacac	acacatacac	92220
acataggcat	tcgtgtttat	acctccactc	atgaaatagg	aaatatacac	acacatacac	92280
acacacatac	gcattcgtat	ttatacctcc	actcatgaaa	taggaaatat	ccacacacat	92340
acacacatat	gcattcgtgt	ttatacctcc	actcatgaaa	taggaaatat	acacacacac	92400
acacacatac	acacatatgc	atttgtgttt	atacctccac	tgatgaaata	ggaaatatag	92460
acacacacac	acacacatac	gcattcgtgt	ttatacatcc	acttatgaag	taggaaatac	92520
atacacacac	acacatacac	acatacgcac	tcgtgtttat	atctccactc	atgaaatagg	92580
aaatatacac	acacacatac	acacatacat	ttgtgttttt	acctccactc	atgaaatagg	92640
aaatatacac	acacacccat	ttgtgtttat	acctccactc	atgaaatagg	aaatatacac	92700
acacacatac	atatgcaacc	atgtttatac	ctccactcat	gaaataggaa	atacacacac	92760
acacacatac	atttgtgttt	ttacctccac	tcatgaaata	gaatatgtgc	atataatata	92820
tattatgtaa	ataaaattat	atatatttat	ataatatata	attttcta	atgggtgtga	92880
ggccaatata	catagatttc	tcctggctgc	aggtgaccat	gtcacttgca	ttgattataa	92940
tatattttta	ttcatgggat	ttaaataaag	ttttaacatc	agagactttc	acagagattc	93000
agataacttg	agatagtaca	taatatgttt	aaaaagctaa	ttttttctg	tgaatattgc	93060
ttgtttccat	agacgtttca	ttctacaaa	gttcaaaaata	taattttaac	taacaaacta	93120
tgaaggtaat	tgtaccatt	ctgcagctg	ttagcagctt	ttgattagat	tctcatagca	93180
gaattttccc	atatacagtt	gctaataatag	aagaaaaata	tcatctcctt	attggattat	93240
attgttaact	tgcttttgc	taatatattg	gcattctttg	gtaaatttct	ggaatgaata	93300
acaataaatt	acgcagaata	atctaataaa	ggatatttat	agcctatgtg	aaaataaaga	93360

tacgcatttt	agggactttt	gcagagatac	aaacacttgt	tctgtaaaat	atttgttaaa	93420
cgtagcacat	agggaaagca	cagatcctgg	agtgaanaac	ctacagcttg	aattccactc	93480
cagcatttat	tagaccagt	acttggtcaa	gttgcttagt	ttctctgaac	atcaattttac	93540
ttgtccataa	agagagagt	gtggtacata	atagatattt	tgacaggctg	ttaaaagcta	93600
gagatgaagc	gtgtcgggag	tctgatgcat	agtacttcta	ttaggcaagg	tttttcagag	93660
gaaaaagaac	caataggatg	tgtatgtata	catatgtaca	cacacacaca	cacacacaca	93720
cacacatatg	aatgagagac	atttaattta	aggaactggg	tcatgtgatc	atggggctgg	93780
caaactctgaa	atattcagga	caggcaggca	ggtctgaaga	caagggagggt	tttaacactg	93840
cgettccagt	ccaaaggcag	tctggaggca	gaattccttc	ttcctcaggg	aacctcagtc	93900
tttttctctt	aaggctttca	actgattaga	taagtacgc	acattataaa	ggacaacctg	93960
ctttaatgag	tctactgatt	tcgatgtgga	tctcatctga	aaaatacctt	cgcagaaaca	94020
cttagtctga	ggtttaacca	catttctggg	tgctacagat	aaaattagct	atcacagaac	94080
gtctacacag	aaaggtagct	acatttggtt	aaacataga	attctattta	catgaccaac	94140
cagaatgtgt	ctagagggt	ccagtgcctc	tgcagatttt	ctatttggtg	tggcagtttc	94200
ttggatagcg	tctcctattg	gctgctctta	ctttctgtct	ttccattggt	tctttgaggt	94260
ttcataggaa	cagtctgtgt	ttagttaaaa	gtgcogctgg	ctcccagggt	cccaaagcca	94320
atgagtagat	aatgaatggc	aagcaatacc	tgatcccata	cagaagaggg	aaaacctctc	94380
tctcccacac	ctgtgcctta	aggtagcact	gtttatttta	cagacttgca	aaaaatctac	94440
atgaaaacag	tgacttcaac	ttctaattta	gctttttctc	caattcatgc	tcaaaccaat	94500
ttctcaaatt	gagagcaag	gacgagaaat	gcttcatcag	ttaccttcac	tacagtctga	94560
tctctcgagg	tgcaactaaat	tcctttgtct	tcaactgatt	ctctcctctc	ccaacaggag	94620
atcaatgtac	agaggaatag	ttccttttaa	tccaggagtg	catgcaacta	agcaacttta	94680
gagatgaatg	gttgcatatt	ccccggagcc	aattctagtt	gagctcaaat	gatataattc	94740
taaaaatagt	aattctattt	atttttacaag	tgctatgtaa	acagagagggt	aagtaccagc	94800
attataattc	actaaaaaga	cctgattttg	ctgcacaaac	ataactaaat	ggctacaccc	94860
tttaattgca	gaatccagat	ttcctccaaa	ctttatctca	ttccagtcag	gaaaacagct	94920
atcgtctttt	tttttttcat	caaatgcttt	tattatcatg	tttgaagctt	ttgattaagt	94980
tggcatcgta	agaaacctct	tcctattttc	tttcatgttt	ttcttgacaa	gcctgagtoc	95040
gtcattctgg	ctggatttac	aggttcatgt	ttttgggtac	attcattttat	catggagtga	95100
gtcactttgc	tgtttttggt	tccactgtat	tctgaaaagc	accacacaga	acatgacaag	95160
aatgcaggct	tgcaatggaag	aaattctcat	gccgggtctg	ctctgtctcc	ccagtcatgc	95220
tatcctgcat	aacgtcgtct	ttaaacaata	gaaagcaatg	gctaaggata	aaagaatggg	95280
ttcagataaa	actgaatttt	ctaccacctc	gaatattcac	tccatattta	atctgaagcc	95340
aaatatttta	acataaatgt	atctttattg	tctttgtcct	ggtcttccaa	tagggragtt	95400
ttgtacgtg	gtacctcttt	gtttttttgt	ttgttggtct	ctactatttt	cttaatttta	95460
aattctaagc	ctccagggtg	cttgcttata	aaaacgattc	tggattttct	acttttaaaa	95520
tatggtttct	taaccatttg	cagttttgtc	aagaggaaaag	gagaatctat	aaagtatggt	95580
tacatgaaag	gaaaatctct	gtataacatt	ctatcaaaac	tgtaataaag	tgaaaattaa	95640
ttattaatat	tgatatgatt	tggctgttcc	ctccaaatct	catgttgaga	tgtgatcccc	95700
agtgttgagg	tggaggtctg	ctgagagggt	ttcgggtcat	tgggatggat	ccctcatggc	95760
ttggtgctgt	ccttccccc	tctctcttgc	tctgctctg	gctgtatgac	gtgcctctgc	95820
ccctttcgcc	ttctgccatg	agcaaaaagct	ccctgaagct	tcccagagaag	ctgagcgat	95880
gctgggtgcca	tgcttgtaaa	gtctgcagaa	ctgtgagcca	attaaacctc	tttcttttat	95940
aaactactca	gtcttaggta	ctgcttggtg	gcaatgcaac	aacagcctaa	tacaagtata	96000
cataatggaa	agtgaagcat	gccattttgt	cctttgaata	tatttggaca	attaaaccaa	96060
caataaaaaa	aagaaattat	atgcagtttc	tgactcgggt	tccttgaact	taagtggtag	96120
cagaagattc	ccctatcttg	aagagagaaa	gtcttccctag	gaaaaatgcag	gagctgtttc	96180
aagtgtgtaa	tggagcagca	ttcttctgaa	acacattttt	gcttgggaagc	ctaacaatata	96240
aataaaaaata	tgaagaggga	gcttttctat	tttaaggtgtg	agaagagggt	gtcgggtgcc	96300
cggttctacc	tcgttaagct	cctttcaaat	gctgagatgc	catcgacccc	tgattctgtc	96360
tcccagggaac	tcagactcaa	aactcttgca	ccagaaaaca	ctagatggag	aaaactacct	96420
gacaaaagtc	ctggacgatg	gccttgaat	caattccttc	atgtctttag	agggtctctg	96480
tagtttttcc	ataggtgctt	accagccaca	ttcttggagg	cgagctggct	aaagtaaaat	96540
tctgaactga	actgagcttg	atagagttct	gtgctcatat	tcccagcaca	gtctccatgt	96600
tgggagggaa	aattgctttt	tctcccattg	cagtaaaaaa	aaaaaaaaaa	agtcaatgat	96660
caagtctaga	ttccttaca	cttctgttag	tttctgtcac	tccatggata	atcaaatccc	96720
tcgcaacaaa	acagatgagc	tgtccctcaa	aattgttgac	ttgtgcctta	ttaggttggt	96780
agaagtgaga	atgtggtatt	ttaaattctc	aagactgact	tcgtgtatcc	atagagaata	96840
atgtatttta	tcctattttc	tttaactctgt	atgtatttga	ataagggcga	tttaaaagt	96900
ctctcacatc	agtagaaaata	actgagctag	agtttgcttg	ttgacaatgt	ataggcacia	96960
tatatcatta	gaagagtgat	aatgactttt	attttggtga	aataataaaa	aaggaatcat	97020



aaaaatagag	ctgtctaata	atgaacccatg	tgttttaaaaa	agaaaagtta	actttctcat	97080
cactggaaat	aaggaatgag	ccagtggcca	tggatcacag	atataattgt	aaagattcct	97140
atattgagtg	ggaacacaga	caaaaatacc	cccaaagtct	ttgctaaatc	tatggtcata	97200
taaaagaaat	acagctggat	tgcctatcaa	aaagatccag	ggcagtggtg	actaactttc	97260
tttacttgca	gccaaagtgt	tgaatcttta	gtagagcggt	ttgctttaaa	tttaatttat	97320
taacctgat	tactgcagtc	agcaaattaa	actcaagcct	gtattatgaa	atattatgaa	97380
ataaacactt	tagaactgtc	atctgtatta	agcagctgta	aaaaagcagt	gtcaagcctt	97440
gatgatttca	tataaaattg	aaataatttt	gaatattcct	catggtgatt	tgtatgtttt	97500
gttatgcaga	cacagaataa	aaacaagtga	acaaaaaaa	aatgttattt	aaaaataact	97560
aagaaaaaaa	acaatttgga	aaaaaatctc	gatatcggca	ctaatttaac	tttgtaaatt	97620
ttccaatgta	gttcatgttc	agtatattag	cataatattg	attgtattag	aggggctcag	97680
tatttctttac	ggacttaagt	atgtttaagt	aagagcatat	ccattttgat	taatgagggtc	97740
tatatacctt	ctctcttgat	tactctccag	ttttggggaa	atcactttgg	tagctgcatt	97800
agctctttta	ggtcacctga	aaactcttta	ataaactaag	tggtaacta	gtaaacaaaa	97860
agaactcacg	cggcttcocct	tgaacgaat	acatcactgg	gaattctgag	aaaccaatta	97920
aaacagaatt	attgttttga	atgaatcatc	agagaattct	agtctaaact	cttctaaaaa	97980
cctacatttc	tttctaattt	tattacatta	aattttaaga	tttttttcaa	actttttgaa	98040
tgagaatagt	catcagatta	ttttaaaaga	ttaggctaaa	atatgcaaaa	ttcccttcag	98100
taatacatatt	ttttaactgg	aattataatt	agtcataaag	ggaaagtcat	tttagtggtg	98160
aataaaattc	aaaaaagcta	aacattaaact	gctgaagttg	ctttttgccc	tttgcaaat	98220
ctttcttcat	tatcatcattc	tctctatatt	tttgaatgca	tatatctcca	aagaaattac	98280
tttttgctta	atataaaaatt	ttaggcaatt	agatgcaaaa	gtgtagtaaa	gcaacactaa	98340
agttgccaat	ttaaacatag	ggaagcaaaa	cagcccagga	gttaaagttc	tgacagctat	98400
cttaactagc	acacatggcc	agtgccactc	agtaacacaga	cacacaccca	ttttcacagt	98460
cactgaggag	ctctaagagt	tgattttgaa	acgtagtggg	aattaccttt	tttgggaaaa	98520
taacataaat	ctgagataaa	ttcttgactg	tccgtactca	aaatattttt	ttccaaaatg	98580
aaaaaaatgc	aaatgtcctc	agcataataa	tctaggataa	gtagttaatg	atgctacatt	98640
aaggcattac	ttggggcttg	caaattcatg	actgacattt	gatgatatcc	cagggttagaa	98700
gagttatttc	ctttctttct	ttcctttctt	ccctccttcc	ttccttccct	tctttctctt	98760
tctttctttt	tctttctttc	tttcttctt	tttttatttc	taaaggaatg	tgtaaattaa	98820
taacaaaaac	ctttaacata	taaacagatt	gataaattac	tgagcaaac	aaactgtcca	98880
cccatgtttt	tccttggtgt	agtctgtctc	aaccatacca	gcaaggccta	gaaagagcaa	98940
aaaaaaaaaa	aaatgtatat	atgttgccgt	gtgatatttt	cttaaacaaa	gattttttat	99000
gtaatgccta	actatttctc	tcatttgaat	ctgagttgca	atttagacac	aaatcctgag	99060
gtcagatcct	ggcttatagc	tggatactat	agagcatgtg	ctgtgttcc	gactcctcat	99120
ctatgatgta	gaaatgataa	atcccacagc	agaattgttca	agtgaataag	aaataggaaa	99180
atataacgta	tcctgcataa	ggcctcttat	aaaaaacaca	gattccaaaa	tgacatggtg	99240
attatcatca	ttttattata	gccaataaat	tgccagggat	tttaaaaact	atcattctct	99300
aagaattcta	tttaagaaca	tacatataga	taaaatatgc	attcaagatt	ttgtaacagg	99360
atctggaaat	aaagtcaaca	caaaaacttt	ctatcctgct	gctgggtattc	aattttctat	99420
tcttgaacag	atattaattg	tccacattcc	ctactttctc	tctcaagttt	acttaaaaaa	99480
atatctactg	ggattatcta	catgggtgca	gacacccgtg	aaggataggg	tagtggagaa	99540
aataaaacatg	ctcccgtttc	tatggtgttt	atcatataat	ggaggacatt	cttgggttgt	99600
gcattttatt	ggttcagcta	tgtaagggat	ggtaagggga	atatgttcat	tacagaaaca	99660
tattcttact	ttctctccta	attacagtaa	atgttcagag	gtatgggaat	ggtcaaacag	99720
aaaatggaaa	attataataa	aaaataagaa	agttatccaa	gtccacagta	aaactataca	99780
atlttataac	acagaccaag	aaaatatctg	catagaattt	ggtatgcttt	ccttgcccca	99840
tcaaatccac	catttttagtg	ctctatattc	tctttctgtt	tttaacatat	gtaacggcgg	99900
ggctttctga	gctggcttcc	ttggagtgca	gacattagta	atacagacaa	cttctattcc	99960
tcttccccct	acacattgct	tgtaaatcag	ttattattta	tttatatgtt	tttaattttt	100020
tgaattatga	cagagaagga	gtagatgaat	ttaggtagaa	agatagggaag	gaattgctga	100080
gccaaaaactg	aacaaagaaa	ctgggtcttg	catgggggtta	gtctccaact	cagaataaaa	100140
tgaattttta	tataagtgta	ctgttcagat	caggaggata	gaaattaaaag	ctagaagccc	100200
tcaaaagtgtg	gagaatataa	tagaagatta	taccaaaatt	aagcagaaat	tcaggatctc	100260
ctttcaggta	tgtttgaatc	aaaagcaaac	cagggtattg	caacacaaga	tacacattgc	100320
cttgggacgt	tcagctaccc	tcaaaccatg	aattttgctt	aagggtctca	ggttggtaat	100380
atcactaacc	tgagtgtgac	agagacaagt	caatcaatct	ctggaataag	gcaatttcat	100440
cataggcttc	agcttattca	aatcagtttt	caaacatgat	gggcagcata	tactacaggt	100500
tcaccaagca	taggcagtga	tttatctgtg	aatgggaata	aacagaaata	acccattaa	100560
tttacagata	ttgaaatttg	tagacacagt	ctacaaaaat	actatgtttt	tagggaaaaa	100620
ggtaagtata	taaactcaaa	caagggaacta	tgtattaggt	tatctaaaaa	atttaaaaaa	100680

gatcaaagga	aacttctata	aataaaatct	aaaaacctga	aaccataaag	cctatgggtg	100740
aaattaacag	tacattagaa	ggagatgaag	atagaattgag	cgagttagaa	gaaactcaaa	100800
gaaattatatac	agaataaaac	agaggaaatta	agagacaagg	aggacagaat	gaatgggttag	100860
gctttatatt	gaatcagagt	ccttgaaaaa	aaagaaaaaa	ggatgggttg	aaataatgtt	100920
tgaagaaata	gtgcctgaga	atattccaga	gctgaggaaa	gacacctgca	ctcagattca	100980
atgattggaa	caatttttca	gtagtataaa	tacaaagaaa	tggtgggtgat	tgtaaaactg	101040
caaaacacca	aaatcaactg	aaaattttta	atgtaacctt	gaaaagaaaag	agaacataag	101100
aaattagcat	gataggagaa	atatttaaat	cagtaattga	tttctcatca	acagcaacgt	101160
aagatgaaag	agaatgaaat	aacttcacaa	gctgaaacat	aataactgaa	tctaattgctt	101220
gaatttcttt	cacaattata	ttgtctaata	atccaacaat	cacattagaa	attaaatagg	101280
agcaagaata	cttactgcag	ccttatttgt	attgctaata	gcatagaaat	agcatccagg	101340
tcaataagta	ggcatttcga	taataattat	gagatagcag	ttcattgaaa	tggtgggcat	101400
ccattagaaa	ggaaaaggca	attcttaaaa	atccacgtgg	agttgtattc	cagatgtaat	101460
ttttgcaagt	gcatagccat	ttgcatacag	aaaatgtatg	tgatatgtgc	gacacattga	101520
tagattttgt	ggtaattctt	ggagagatac	tcaagaaaat	aattgtcgtt	gtggagagaa	101580
atgaggtgct	gaagaaaagc	agccaagggt	ggggggattc	atactttttc	tacccttgt	101640
accttttaaa	tctgttttgc	catgtactat	tattcatgaa	ttacatatat	tttttaaggt	101700
tggtttgatt	ttagttttta	attaaaaaca	actaaaatc	aaatatctcc	acagttatca	101760
acagcacaga	ttaaggaaata	gtgtgttgaa	gtgtcttcat	tttaggggtg	attgtgttaa	101820
agttctgggg	acttaaatga	cctttttcat	agcatccaaa	taccgattga	gaatgtaaat	101880
ccaaatctct	ctacaaaatc	catcctttta	tttttactgt	ttaatacctc	cacatatttt	101940
ttaaacaggt	ctatacattt	ggtactatat	aagttgtatt	gccatcaaat	gaatattcat	102000
gttcaactcca	acattcatac	gtgtttttca	acctatgggg	tcctgggtag	atgattaggt	102060
catgagggca	gagtcctcat	gaatgaggtg	agtgcctca	tataggagac	cccagaacac	102120
tcctttgctg	cgctcctcca	ccatgtgaag	gccagcgaag	aggaaggcca	tctatgaacc	102180
aggaagtgat	ccctctctct	tccagacacc	aagtgacctt	gcaccttgat	cttgggcctc	102240
gtaacttcca	gaatcttgaa	tgtatatctg	tttataagcc	aaccagtctc	tggtattcca	102300
ttatagcggc	ccatacatac	caaaagctgt	ggcactaaca	aaatccagca	aagaagaggt	102360
ggatctaatt	gtttcattaa	aatttgatta	tgaatctttg	ctacggccta	aacagcagag	102420
accagagttc	tctcctcca	ctgtgcgagc	ttacaaattg	gccgctaaga	gacaacaaat	102480
ctaccagcac	cttgatcttg	gaattcccag	cctccagagc	tgtaagcaat	aaatttctgt	102540
tgtttatcag	ccaccaatt	tatgcttttt	cattagaatg	gccccaaaaca	agtaagaaaa	102600
tccccaaaaa	caaatacaag	gactggtaca	tgccatatag	ctcagtaata	tttttttgaa	102660
tgaataagtg	aataaaggta	gagtgaatgt	gtattgcctt	tgaatgtaaa	cctttaatac	102720
caattgcagt	atgatactga	attcaactaa	gaattatttt	tacatagttg	tgtagaagca	102780
atttataaata	tggaaatatt	tctcaaattt	acagaaattt	gataaatatt	atattttatt	102840
tatgtaaatt	cccaaactaa	aaagacatgt	cctttctctc	actgtccatg	taagttagtg	102900
gaagacatcg	atctcaaat	acaatattta	actgtattaa	attgtatata	tagatgcaga	102960
ctctaggata	aaagattaaa	tgtttgatat	ttttaagcca	gatccattata	ttaaaatcat	103020
caatgatttt	tactgtgaag	gtgtagccac	atgcacattac	cttcagaaaa	cttcaaagca	103080
gcaaaaagcat	gtcgcagagc	caaatgcagt	tccagtgccc	aagaaaatag	ctaataatac	103140
tgggcatggg	tccaaaaaaa	cccatatggc	aattgtagtt	gaacatcttt	tacagcagca	103200
attccattct	aacccaagtt	ccttccctta	aatagcacct	cttttatttc	ctgtagtcaa	103260
actggctgta	cagtcctcac	tcttgccaaa	gtccttgctt	gggatgtgca	tctccaggaa	103320
ccgaagtgt	aaacctttct	ttttactagc	ctgctctgcc	aaaatccatc	ttgacacacc	103380
ttaaattata	ttagatcaaa	ggctgaaaat	tatatgccat	caaaagcaga	aagataaaat	103440
gtttatctac	cgcattaggg	atgtgcaatg	tttttaagac	acttgatggt	tgagtggagc	103500
attattcgac	gtctctgcag	tgacgcatgg	cttacttctt	tgagtaggtt	gatagatata	103560
ttgtaacagg	ctggtggcaa	atatgaagtg	gcataattcag	tatgtgttta	ggatgtttat	103620
gtgttctctg	attcttgttg	tgtctgtctt	aattggaaat	aagggtttacg	tggtgagagc	103680
agtgaagcaa	cgacagggca	atactataaa	agcgaactct	gccaccagca	ctccatttct	103740
tttaattggt	ttctacatat	ttggaaaactt	ttctaatttc	tccttaaaaa	ataaaacccat	103800
aaatgtcaag	aagaatgttt	ttcttcttaa	tgaggtttgc	ttgccaaagct	ggctttgttg	103860
caatgtctgt	aggtgggcta	cggtaaagac	cagtgggaatt	gaagtaattt	ttaaaggaat	103920
attgtctcaa	atgaaatata	aacaaggaac	tgtgtaccca	ggcttcaaag	tgataaacag	103980
atgatgctat	aatcaagtaa	tttttaataa	atatttgatg	gaatttactg	aagtccatat	104040
ttcagtaatc	catcatccac	tccagatat	acattgagat	tacaaaatta	acaatttggtg	104100
ctgttgccag	aattaaaatt	tcctagtaaa	gttgaactat	tatataacct	tagtattttt	104160
gcaccttaaa	ttttttccag	attattttgc	aggtataaaa	catgttaacc	tttaggacta	104220
ttttatgtcc	aggtactact	taaaaatgta	ttttagatac	aacaatcata	caatattttc	104280
taccgttatg	gtttcacagt	agataactaa	aattatatat	atatatatat	tttttgagac	104340



aaattctcat	gctgtcacc	aggctggagt	gcagtgggtat	gatctcggct	caactgcaacc	104400
tccacctccc	tggttcaagc	gatttctcctt	gattctcctg	cctcagcctc	cagactagtt	104460
aggattacag	gcacctgcc	ccatgcctgg	ctaactttog	tattttta	aaagacaggg	104520
tttgcgcatg	ttggccaggc	tttaacataa	ttgattatgt	ttcaaaaaat	aagaagcaat	104580
ttctgcatac	aaatttcaga	aaaattcaact	tggaataag	ttttattagc	ttacactgtg	104640
ggtagagaaa	agtaaaacat	tgaaaaggta	actgtttgct	ttaacattta	cctgtaaaaa	104700
cattcatgaa	tttaacctaca	atttcttggg	agtagaaata	tattctcaat	gttgttttag	104760
aagcacatat	ttaatggaga	aatttgtttt	ttatagtgtt	atttttaaac	ataattttta	104820
atttagaaaa	ttatgacaaa	aactcgttca	ttcccttttt	tggaaaaaacg	atacttaacc	104880
actagtaaat	gttaagtcct	gcattatgca	caggggttaa	taaaatttag	gatgacatgg	104940
ctcaggcttg	tttaagacaa	atagcactga	taggctgttc	cataaaactt	gttatattgc	105000
ttggaagaaa	tgaggcccat	atataattga	atatatcaaa	gttagtaaaa	agacaaccac	105060
cacgtgttta	tccagccctt	gcaatatagt	gcattctgtg	ctacactgtg	aagatcgcta	105120
accattatga	agattctttac	agtcattggga	tgacaagact	tctgtaatgc	aatgattaca	105180
gcactgtgtg	atgaatgctc	tgccctgtgt	ggataaaaatg	ctttagaaac	atgagagata	105240
cctgcaaaaag	gtagctagta	aaagcttcag	agaagatagg	acttctgaat	ttgggtctta	105300
acattctaaa	aaaagaaata	gtttgaccaa	agacatggaa	atttatttga	atttgacata	105360
ttttgtttgc	ttgtttgttt	gtttgacaga	gatagggttt	ctccatgttg	ctcagggttag	105420
tcttgaactc	ctgagcaatc	tgccctgtctt	ggccctccaa	agtgtctggga	ttataggtgt	105480
gagccaccat	gcattgtctt	gaatttgaca	tattttgata	tttgggtaag	gggagaagat	105540
tagtccaatg	gtttgcacat	tgaccgctc	caaacctcat	gctaaaaattt	gatccccagt	105600
gttggaggtg	gggcctagtg	ggaggtgttt	gggtcatgag	gggtgattct	tcatgaatga	105660
cttgggtccca	ccctggcctt	aatgagtga	ttctcacaat	gtcagttctt	ggaagtgtg	105720
gttgttaaaa	agagcctggc	acctcacccc	tctctcttgc	attctctctg	cacacatcag	105780
cttcccttgc	ccttccacca	tcattgtagg	ttctctgaga	tcctcaccag	aggcagatgc	105840
tggtatgctt	cttgtacagc	ctgcagaact	gtgagccaaa	taaacctctt	tcctttgtta	105900
attaccacag	ctcatgtatt	tctttattga	aacataaatg	gactaaaaca	tttgatgtgg	105960
ttgaagtgtg	agttttatgg	aagagattgc	caaggatgtg	tccaaatggg	gtgggtgggtg	106020
aaagactttg	aacgttttcc	aaatgtatgc	caatacatct	agactttact	tttgagctag	106080
aggaagaaca	ggtgcagcca	aaattaattg	gaaaagtgtg	agattgcatt	ttgtttgaga	106140
aggataaattc	tgctattaaa	agagttagat	gagtcaagaa	gacaccagt	gacaccagt	106200
tcagtggtca	ttgtgaaaga	ggactttggt	tcattggagct	gggggaaaga	ggtcagagac	106260
catgggcagg	attttgtggt	caacttgaca	tcgggatgat	gtacaaagaa	aaggcaagaa	106320
ggaacaatct	gggcagtgat	gtcagtcgaa	atttgggcag	atcgttttga	tagaatggat	106380
caaattggaat	ccaaataaag	taaaattctc	aattatgaga	attcaattaa	ataattttgc	106440
tttaaaaggaa	actaagattt	ttaaatgcca	aagataaaag	ctgaaagtca	ttataacttt	106500
agtcttccct	aaaagtgaat	taagcaagaa	aaaaaaacag	tataattttt	aaactagttt	106560
acagggtatt	tggtttaatt	taaatgatct	ctccagcaga	tattcctttt	gtgggtccata	106620
aattttcagt	tggtttattta	tttttgacc	atacagtaaa	gggttgga	gagataaaaa	106680
tcagggaana	ggaaagtcca	gacacagaaa	ccgctgagtg	ggcagaagca	ctgtccgaga	106740
tcaggggggc	acaatgatgg	aagtgcagtt	aaggttggtt	ccacgctgtc	ctagatgtac	106800
agagccaaga	gggtgagct	ctcaaagcca	cagttagaaa	ggaggtcact	tgagtagcag	106860
gagagaaatg	ctggcaagag	aactgggcca	caaacacagt	ccaaaggag	atcacggaag	106920
cccatgagga	aagtcaggaa	ggagtactg	caactcaata	gctgctatca	taaaaacaac	106980
cctgctgcta	cgtgggagct	ggtgtcttcc	tgtaaaatat	actccaccta	attatcctac	107040
agcaagatac	tgcatcagtg	cattcccatt	gccttgtaag	tcgccttgc	cttgtcttgc	107100
cttgccaagg	gtgtgatcca	aaactgagtg	ggctgatatg	aattgggtgg	tgctttcaat	107160
tcctacata	gtttgcctcc	tgaaaacctc	ctttggtatt	tgggccacgg	taatgcaaag	107220
gagccattca	tccaggtaaa	ttggagctgg	aggtaggggc	tgagcctctt	ctggggcctc	107280
rgggggcttc	atcatgggtc	ctggcctgag	tgcaaagata	gcattctagta	tcacagataa	107340
cttctttttg	atgcctagcc	atatttctga	ttttcttgtt	tattaagagt	gagaactaca	107400
tttctacta	ggctaggtct	tacttcgcag	ttcttaaaat	gtgttaaacc	tatttgtggt	107460
tctcctttga	attcttccca	agttctctcc	acgcctggga	agtttgagg	ctggctctct	107520
agagatgcta	tgtctatgat	gccaaaccca	ttacaaaaa	caagcaaaaa	caaacagcta	107580
cgctagactt	tccaaactct	aaaacatcga	atctcctctt	tgaccctatc	atgaaagtga	107640
gttaacttaaa	ttaaagagta	attgtatttg	tgtaaaatac	attattttgc	aaataatttg	107700
actgtataat	cccagtgtag	ttataattct	gtgtggctaa	ccctgtgttg	ctctggaatt	107760
ctgtcctctg	attttatgaa	ttctaagatg	ctgatitaa	ttatattttt	aaaatatctt	107820
ccagtttact	tgagtccaag	taggctgac	cacagatca	tattcaaaaga	attccaatga	107880
gctgttgagg	aggattttta	gcctccact	agcttctctg	catcagttgg	ctttgagaac	107940
caacctaaagt	atttcagagc	tgctagtga	atgaatcttt	cttacagata	ttacagaggg	108000

ttacagaaag	ttcagtttct	gactcaccct	gattttgaga	aactgtttct	tagggtcatt	108060
ccctaaggtt	ggaatcgctc	tctctctctc	tgttggttag	tgccctgtaa	acactgacaa	108120
ttttctttct	cttcagttct	tcattcttgg	tctagtgtt	cagtttccaa	gtctacatga	108180
ctatgctaca	gtgtaagggt	atttagacgt	acaatttcat	gatttctttc	ttctgggatt	108240
atttgcttga	cttgtgatta	gcttgccctga	tcacagacaa	tagtaacttt	ttaaccattc	108300
ttacatgatt	tcctttttcc	ttaaatttgt	tgtttctgta	ttagaagcag	gaaaaaagg	108360
ccaaagttta	gaatttgaaa	agcagtgttt	gaatgcactt	gttacctggt	aaaccagtca	108420
tttactgcta	tcttacaat	gaccacagca	catggtagac	ttaaagaaca	attatttgca	108480
cattttctca	ttttgtggat	cagaaactgg	cagactcag	ctgagagact	cttctgtttt	108540
acggggattc	acagcgttca	ctcagagaca	gatagctggt	gggcaggccg	gtgtcaggga	108600
ccaaggatgg	catcactcgt	gtgtctggcc	cttgacagg	atgctggagg	tctgggctca	108660
cctgggaatg	gagatggcaa	cacctacatg	tgacctttcc	agcatggcag	tctcagagt	108720
gatatggcaa	cagctgcaca	tgacctctcc	agcatggcag	tctcagagt	gatatggcaa	108780
cagctgcaca	tgacctctcc	ggcatggcag	tctcagantg	gagatggcaa	cacctacatg	108840
tgacctctcc	agcatggcag	tctcagagt	gatatggcaa	cacctacaca	cgacctctcc	108900
ggcatggcag	tctcagagt	gatatggcaa	cagctgcaca	tgacctctcc	ggcatggcag	108960
tctcagagt	gatatggcaa	cagctacaca	tgacctcacc	agcatggcag	tctcaggtta	109020
ctggtacttc	ttaggtctca	gctgaggact	ccagtgcagg	tggtgcaaga	cagcagacgt	109080
agcactgctt	atgtgtatcc	tgaagtccca	tgtgtatcct	gaagtccag	aaagtgcctt	109140
caagtgaatt	ccagtggaga	agggagtcac	caaggctgga	cagtcattta	tccatggcag	109200
gactagcaaa	aaaaatctga	ccatctctca	tcgcacacac	gtgggtaagg	tttgactgg	109260
tatgatcttt	ttccataatc	tcattttcgt	gatttcttaa	ctgagaatat	aatagtaaat	109320
accaatctca	cagaattggt	atgaggaatg	cagaaactta	atcaaattac	ttaattgtta	109380
ttttcatttc	ttattaattt	gttcccattg	aaattaatgt	tatgtctggt	ctcattttaa	109440
attattttatc	tttctgaatt	tgatcccat	cctcaagttt	tcaatgcttg	actttttatg	109500
aattcttgta	ttatacctca	aatttaataa	aatcctttta	atcttgtctt	cacctagca	109560
ctgtctatac	tgtcccctgg	gtggaagttt	cccattcttc	taattacttt	tatacacaaa	109620
tttgacttct	ctctccagcc	cctgtgagaa	acatgtcctt	tctgttacac	aggagtagg	109680
tgaaggcctt	tggaacttct	atttttctca	tatgaaactc	tcttctttca	gatatacaga	109740
ttttctctct	tcttttcat	tcagaactct	gctagacaat	catcttacca	ggaagatttt	109800
tattcatcac	cctgtgctaa	ataacattgg	tactatgtgt	ggctgagcta	ctatttttcc	109860
ttgaatcctg	ctgtaggctt	ttcttcagac	acttaccatc	accaggcgta	atgtgaatgt	109920
gtttgttcat	tgcatgtott	ctocacgtga	atggaactt	catgacaaga	atgtgttcca	109980
gggctgggag	ccgcggctca	cgtctggaat	cccagcacat	tgaggaggccg	aggcgggagg	110040
atcacagggt	caggagctca	agaccagcct	gaccaatgta	gtgaaacccc	gtctctacta	110100
aaaatacaaa	aattagcctg	gcttctgtaa	tcccagctac	tccgaggctg	aggcaggaga	110160
attgcttgaa	ccctagaggt	ggaggttgca	gtgagccgag	atcactcaag	aaaaaaaaaa	110220
agaaaaaat	gttttccttc	acctctgaat	ccctagtgtg	taggggagag	cctggaacag	110280
agttaggggt	ccataagcca	atcaataaaa	tgactgaaaa	agagttaagg	gacaaggcca	110340
aacaaaaaga	gctaatttaa	ctgctaaacg	attattctat	ttaggccaat	tggttaacca	110400
tgactgcttg	taaaattcaa	tttcattgaa	tgggacatat	ttcaaacata	aacataggtt	110460
tttttaatga	atataactga	actgcagatt	gcaatcaaga	tgttccctcc	ctttctcatt	110520
tagatttctc	atcttattag	ccatcactga	ccctctctca	gtgggttaaat	gcttagtttg	110580
ggacattatc	tcagccatac	cctcagaatg	gttgattcag	tggttcgttg	cccatgtgtg	110640
ctgtgatgtc	aacaggctgt	tgaatgctga	gggcaatctc	atatttggct	aatgatggtt	110700
cttcagaaa	caacaccctt	cagattagtt	cagcagggtt	caactttgtg	gtgaccacag	110760
ttgggctgag	caggctgcat	gtcaggcaga	gctgtcagtc	tgctccagcc	aagagtggag	110820
tgggcacttc	ttgggatttg	gataaggaaa	catttgtctg	agcagtttta	ccaccttaat	110880
atgggttga	ttcttctatt	tgtatacaga	gtaagccaaa	ttaaaaaatg	aaaagaaaaa	110940
agaaccagtt	catttaataca	agacatgcta	gtgggttagtc	atcttttata	acaaccacat	111000
cgataattca	cctttttcat	tttcaaatga	gttttgggtt	gttttgtaga	cagagagcct	111060
tagccataaa	ttaaaagtaa	tgataattag	cccatgttcc	ttcattatgt	tgagggtttt	111120
gaacatttct	tcacatagct	attagacatg	tcagccacat	gtaggaaaag	gaactataga	111180
atttcgtaat	tttttttttt	tttggaaaaa	tgagcaacag	aatttttaagg	cagaaacgtg	111240
aaatgcaggt	gatggcaagt	cccagtgaag	tggagaatag	catgctttat	gtgaatgtct	111300
gatatttgtt	ttctcagtgc	ttttgatctc	agaacaccta	acaggactgg	ggcagaagct	111360
ttttgtgac	ttgtgcac	agtgctaaag	atgaaaggaa	acagtcttca	tattcgccgt	111420
ggtgttgatt	gccctataaa	taggaaacta	cccagttaac	cttgccctgtt	gtcatacgga	111480
gagttttatt	aaaaaataaa	cagtgcgtgg	cgggtagcag	aatgtgggat	ttctgcttag	111540
atgcccga	ttctttcata	tacttcatta	aaatgtgcag	gagaacttca	gagccatgaa	111600
taaaaatatt	gttatggaaa	ctgaggcctg	ttatcatagc	ttcagtgtat	tgcaatgatt	111660

atttaaatgaa tgagttttatg tttgaaaata tcccctgtga taatatgaat ttatcgctcc 111720  
 cccctacccc tccgattttct tttatttttga cacatatgga agatgctgtt ttgttttgac 111780  
 actcagagga gatgctcttt ttatcaaaaa tccactgaaca gtaatgagat tttagtgaac 111840  
 aatctttacca gacttccoga acataaagaa atctgatact gaggagtcca cagtgttcta 111900  
 taataagtaa tcttaggtgt gtgcatgctt ttcagtggca gtattcattt ttcacgagtt 111960  
 ttgtatttga tcttaccagg atttgatgta agaagacttg ggtagctctt gtgtagacac 112020  
 aaagaacaga gaggacatcc ataaaagccat agagacagga tcccaaccac agtgtaggaa 112080  
 gaaactgatg actatgccag gcatacagca ccatctcttc agcctaagag caggggggtt 112140  
 accaagctca ccaaaacaac ttaccattcc tctttccgcy tgattggaac tcatcttcc 112200  
 cctcagaggg tgcagagatg aatttagaag gaagtgtgaa gagcccatgg tgtccagaac 112260  
 tcaggcctgc ttgcaaatga gtggctctgg gactgtcttt ccacatctcc aggagcctat 112320  
 tttccgggag gaaaatgaga gcactgttca gaagtactgg aaggaacctg ccaacattga 112380  
 gtttcttgag agtctctgaa gtttagttctt ctaattttta gtaccctgac aatttcattg 112440  
 aagttagtaa cttttgcata cttcagtttt ctcactgtga aaattggggt aatgataata 112500  
 tctaccaacc tcacagacac cccaggtatt aatactttgc atccttcaat ccaatcaagt 112560  
 tgatactcag tattaactat cacatggtcc ctgaaaaattt tattttattc tgatttgga 112620  
 ataaaaaagc tttctctttg accccgaaag tttttctctt tttgttaaaa tatattaata 112680  
 tatttatatg gatttctaaa atattgtgag cccaggaac tctggttaat gtgcctgatg 112740  
 atctctgttg ccgtcaggtt tggtttctca ttagggcact tctgggcttg tagagggcca 112800  
 ctttctcacc ggtgtccaga atggacctc caagactctt ggtctcctt cctcttaaaa 112860  
 ggacacaggt cctatcagat tagagtcctt ctcttatgac ttcatttagc cttaattatc 112920  
 gccttaaagg ccctatctcc aattgccttt ggggctagga aatcaacata tgaatcttag 112980  
 agggacacaa ttaactcaat aacagtgaac ttttaaaaac tacaaaataa gggaaatatc 113040  
 atagtttttt tctttacttt cacatagata ttacatcata ttaaaagata gatcatttct 113100  
 tcattttaat tgaaccaga atttatattg aataagggtt gaccaatatg ggtttttcaa 113160  
 catttactct tatattaatg tattagcaga agacaagagt tcgatatttc ttaataattt 113220  
 tcctagaaat tgactaatat ttttattttt actttctcag atatatctgt ttttaataaac 113280  
 tatttttgtt gttatcta atgtattcaat ttagacaatt tggagaacat ggatgcctat 113340  
 aaacatacat aagaatacaa atgtatcctg ctttcagcat cagagataat ttaggggtat 113400  
 tgcaattgtt tctgttttgg caaattggaa ggattatggt tgatgaactg aggtaagtat 113460  
 tctaggaaga atatttgcgt ttgggtcagg catgctttca gtttttatgt atgtagagt 113520  
 tgatagacca ctgagacatt taaaagatgt tcagaaggta ttgaactttt ggaaaggcag 113580  
 atcaaaatcc cacaaggga gctgacctg tgtacagaca tttgtgaatt gtctgcatat 113640  
 aggtggtatt gaagccatgg atgaaattgc taactaaagc atactcttgt gagaaaagaa 113700  
 gaggacaact taccatcgg gcacattaac cacagtctct ggggctcaca atattttaga 113760  
 aatccatata aatattttaa tatattttta caaaaagaaa aagaaaaact ttcagggtca 113820  
 aagaaaagc ttttttattc tcaaatcaaa ataaatttaa attttcagaa accatgtgat 113880  
 agttaatact gagtgtcaac ttgattggat tgaaggatgc aaagtattga tcctgactgt 113940  
 gtctgtgagg gtgtagcaa aggagattga cattgagtca gtggactcag aaaggcagac 114000  
 ccacccttaa tctggctggg caccatctaa tcagctgtca gcattggccag gatattaagc 114060  
 aggcagaaca ccgtgaaaag cctagactgg cctagcctcc cagcctacat ctctctcatg 114120  
 ctgaaggctt cctgacctca aacatcggac tccaagttca tcatcttttg gacttggagt 114180  
 ggctctctt tctctcaac ttgcagatgc cctattgtgg gaccttggga tcgtgtgagt 114240  
 tcatacttaa atacttaata aactcctata tacatatata tatatatata tatatacata 114300  
 tatatatata tatatatcta ccatattcgt tctgtcactc tagagaactc taatacatat 114360  
 aataaaaaatc tattaatttt ttgtctgaaa cagaaaaaat aaaatattta acctttaaaa 114420  
 atgttcaatg ttgatatcaa tatgatgcca gagcccaatg aaaacaaaag tacttagttc 114480  
 ccacaaaagt tataatgaga cctgattttg acctagtttg gaaatagcaa cctttaaaaag 114540  
 gtttgagaaa aataaatacc tacacaagt tttgaaaata tcccaggtgt ctaacaactc 114600  
 actttctcta tgtctttccc ataccccaaa tatcaaccat gacatttttc cgctgatctt 114660  
 tcagatctca gaaggcgaca tgaaggagat ccctctgctg tgagattgct attttcctat 114720  
 tgtacctcaa ttacattttat aaacttcttt ctttcatgcc agcctaagt gtttttgaat 114780  
 ttattaactt taatgtttta taaaccagtt tctatagcaa caatcctatg acagatgttt 114840  
 tgttaaagtc tctttaaagc acacacctct gtcaatatgt tattttgaac atttcaaagg 114900  
 ataaactctt gaaaaaggct gcacatatct caactttcaa gctcacaatt tgcattaata 114960  
 attataccct ctotaaataa aagaattatt taatagaagg ctgatgagct aattttaaga 115020  
 ataatacagt aaaaggtcaa aataaaactt acctctcg agaagaaagt gtaagggtcaa 115080  
 gaaaataaaa aaaattacaa catggactat actactttcc tcaatgttaa ttactttaat 115140  
 aaatgtgtga cgaatgatta ccaacatttt aaaatctatg tgcatttttc tccaatgagt 115200  
 ggcactgggt tctttgcac ttttagagtg ctcaagctctg gcatatgtag gtcactgacc 115260  
 gggaaattac catctcaatt cactttcttt cttctttgct atttcttato tgatctcgaa 115320

```

gttaaggcat tgaaactatt gcaaaaccct cattatTTTT tcccaaatta aaatggtaat 115380
atttaatatgc tgcataTTTT gatgcatgct tttggctctg gtttcctttt tttatgtgtt 115440
tttttttatt gtgtgtggtt tgaagggttt ttttttattg cttttttgtt aaagaacgta 115500
gcaaaaaaaa tgaagtatac taaaagctat ttcaccaga gaaacataat ttgttgggtt 115560
tttaaaaaata tcatttttcat ctgcttcttt gggaaacatc agaaataggc actgagggat 115620
ggcaagggttt atgctgaact ctaagttaag catgttgctc cttgcagcca gtcactgaac 115680
tttctctgcc gttagcttccf catttttaat gtggactaag actccacttt tatatcacca 115740
cgtccaagtt tagacacgtg accctaagtt gctctatcag ggatctctag gccttcctta 115800
tgtgagacac aagtggtgta tggactgcag tcaaaaggcaa gtgaggtttt tttttgtttt 115860
tttgtttgtt ttttcatttt ttgagatgga gtctcgtctt ttcaccaagg ctggagtaca 115920
gtggcgtgat ctgagctcac tgcaaaactt gcctctgggt tcaagtgaat cccctgcctc 115980
ggcttcctga gttagctggga ttataggtgc atgacatcat gcaactgctaa tttttgtatt 116040
tttagtagag acgggggttt accatgttgg tcaggctggt cttgaactcc tgaccttgcg 116100
atccaccgcg cttggcctcc caaagtgtg ggattacagg tgtgagtcac cgcgccgcgc 116160
tgcaagtgaag caagagtga atgcatggac ttgaggacag aagaggagcc cgaggtttct 116220
agtgggggct atgcacagtt ctgtgggtta aaggttgttc ttcctcttct cctgagctgg 116280
ggagctaggg caagctatgt cttatgtctc ccaagagtca aaacctttgg ctcttcttaa 116340
ataccagcct agctcatact aacactggat gaatacattt ccacaacaga aactcaaaat 116400
ccatctgttt aaggtatgat gacaaatttc atttagaaca acagtatgag agtcatatc 116460
aaatgtgaag caagagtga cacaaggctc ttatttgttc cttaaagaaa aaaaatttat 116520
ttcttagtga gtttaaatca tcaaccatgc ttcaggaaga aaaatgtagc ctggcctcct 116580
ttocatctct ttgtgattgt ggaaaagtgg accttaaga ttctactgaa agattacaga 116640
cctgctcatt aattttacat tccaaacctt tgactggtga taaaatgaac aaaagaattt 116700
aaaaataaagg tggaaaaaaa tggatccctt ttcactcgtg agggccctca ggctatatac 116760
aaacacaata cacaaccct gcatacttta cctgggacaa tgttatgggc tactaagtcg 116820
atccttttag aagagcagtg agttaatgga ttgttttctt gacaatattt gtagtacagt 116880
aaaaataaaa atgggggaaa tattttttatc tggcttttaa atgttatgtt ttatggttgg 116940
gttaatgttg tggctgatca gctgttacat ggtgcatgaa tattgactgg attctccatt 117000
agggctgatg gggcatcacc gaccagctat gtgatctatg ttctccact ggctcttgc 117060
tggcatgaga gatacatttg caggatgagg agcaggaatg agagctatcg attgtagaaa 117120
cagaatatag tagactgtat tgacctgtt caaaattaa aaatctgtt ccatatcttg 117180
cattacactc ttttatttta tattcttact ctgaattcct tcatgaaatg cacaactcc 117240
acctgtata tacatatata tatatgttg catttcttag cttttaaaaa tagtttaag 117300
tataccttct ccaaagggga aatactttga aatattttt gaagagaaat tgtattagtt 117360
tagatccata ataaataatt atattgtttt aaaagctgg gcaaagtaac attttcttat 117420
attgtagaac tctaagcctt ttggcttaga aatggagagc aatattcttc tgcttttcat 117480
cacttacagg gatattcttg gtattattat ataaatttta ttttcattaa atataccata 117540
aaattccaaa tgtgtgttgc gaattactgg cagaaaaatg ttggtaat tttccagtgt 117600
gacttaactg tcattataat taagtaattg tctccaccaa aatgtttgtt taggcaatac 117660
atctctgcatt atttgaaaac ctaataaaaa gttttattaa agctgttcac tcaaaaatag 117720
acaactgtgc cccgtgagc agtagtttaa aaccaaatca atgaatttgc tattatgtag 117780
acaagaaagt gtccatcat tgacattagt aatgtttcca ccaagttgaa cgtgatgagg 117840
gagctgttag ttgttaccct ggaaactatt caaaaggtct agagctgctg aaaaacagaa 117900
gactctgggc tcacccctgg gattccgctg cctttcagac catctaggat ccaaattttg 117960
ggaatgtatt ctgtatgtct gaacatgctt tactgccatt ttagactgat tgtatcta 118020
tttaagttta tgatgccacc tctcttttct cctatatctt taaactttct ggaagacgtt 118080
ctgaaatcat tcaagtttat tctcattttt tatatctcag gactagtcac tcaatcttta 118140
aataaccact tttgatcaag agattactgt acccttctga tacaacttaa gatcataaaa 118200
acaagttgat ccaattcaat agctttttct tatattataa ttcatgcctt ggccgaataa 118260
ttccaacttt tctttttttt gaaatatatg ttaggttttc ctggtttctc atcaatctac 118320
gtgagcactc attctttctg tattctgggt cctactacat cttttatcag tgtctctttt 118380
tgcattcatt gatcagtatc tcttttttta aatgcagaaa aaatagagtg tgcttataaa 118440
tgtttaacta ttagccagct atttaacttc ctaacactat ctgatatgct tgttattaaa 118500
tccaactcat tttctatgcc tttgatgcgc cttatacact actaaggaca gaagagcaat 118560
ggagtcgatc taaaaccaga gaaccagaat ccttactcc cacagagaga ttgcctgtgg 118620
gctttaggca tcgggttact tgtctctaga gctcaagttc acaagcacca gtagcccat 118680
gggtagaatg tgaacctctg ttctatacag catgttgatg aatgcattac ttctgcctta 118740
gtcatgtcgg agcacagtaa atgtcaacta gcagtgacgc accggaacac gacatgcaat 118800
ctgctcactc gagtcatgct gctttcagaa gagaaggcac tgggttaaat ctgcatggca 118860
agcctgcccg agctagaatt cgtatgagaac cctcaggtta atagctttgc tctttgagag 118920
agctetaagc tcttttcatt ccagaccaat ttcacattta catactacct gtcactaaag 118980

```

```

ccccaaaggtc cttcgccaac aagaagcaga tatttactca ctaaagttaa tgtcccagcg 119040
ctttctagcc tttggacaca gtttttaggc aacaaggaaa ataatacata tgtataaatg 119100
gccattttgtg ttcctaaaaat agcaaggggc tataacccaa agcctagaat tctttttcgt 119160
tttttttttt gttgtgtgtg ttgtttgttt gttttgtttt gttttgaaac agtcttactt 119220
tgtgttccag actggagtgc aatgggtgcaa cctagggtca ctgaaaactc agcctccctg 119280
gttcaagtga ttctcctgcc tcaccctcct gggaacctgc aattacaggg gccagtcacc 119340
atgcccggcc agtttttgtat ttttttagtag ggatgggggt tcaccctgtc gttcaagttg 119400
gtctcgaact cctgacctca ggtgatccat cgtcttgccc tcccaaagtg ctaggattac 119460
agggtgtgagc caccacggccc ggocctagaa ttctttttct taaagacaat tataatggta 119520
attccgttta aaatgtcact ataaatctat ttcattttatt actgcatgat tttaatctat 119580
tattccactt aaaagaaaaa caaatcagag aaatcagcaa gggggcaata acaaagtgtg 119640
gttaggggtac acagccactt ttgggacccat attcaatgaa gaataagatg agagaaagat 119700
aatgtgattt cttttattat tattattatt attatacttt aattttctggg atactgtgtc 119760
agaatatgca ggtttgttac ataggtatata acgtgccgtg gtggtttgct gcaccatca 119820
tcctgtcatc tacattaaagt atttctccta atgtatcct tgccctagtc cccaccccc 119880
cgacaggccc cagtgtgtga tgttccctc cctgtgtcct tgtgttctca ttgttcaact 119940
cccacctgtg agtgagaaca tgtggtgttt ggttttctgt tcctgtgtta gttgtctgag 120000
aatgatgggt tccaacctgg atgaagcttg atttattaag accaatagta attacagagt 120060
gtgcgttcca tgagtgaagt aggatgtttt ctgtgacatg tgagagaaag cccaattcaa 120120
tcttccttaa gcataaaaag ataactttatt ggcattgtatg agtaacagtt caggagtaga 120180
tcctcaagag tggcttatct aaggcctcaa agatcataat cagagtctaa ttttaactcat 120240
attatatgta ttgattaaag ttcattctatg taagctctat acttaagctc cagtccctac 120300
tcagaaaagag ggtgacactt cctgatggac ataactgaaa cccagaaatg ggtcacaaa 120360
agccccgagt tagactaact tgtgaaagag cccaccttag aaccaatcat gatgccccaa 120420
gacttggaag gtgtgtgttt tgaagcccca tcactgaagc agtgaaaagg aggcccgcca 120480
tgactggccc cattttgtct ctaagcccac ctttaggtta acggcttttg cttatctctg 120540
catgtaggcc aagctggcta cgggtggaat ttggtttata gtttcaactt aaagcaaggt 120600
ttgtaataat tccttcccaa aactaaccac ggaggaaaca agaagggcgt acacataatt 120660
aagaacatta ggttaaaagt tataagagca ttgtgacctg accaaggatg aagaacttca 120720
cagttcaact cattggaccc tcattgctgc ccagatatat gtggtcattg gttgcctcgt 120780
gatttcaact ccttccctct ttcctcttcc ccaacttaa atgttctaa aattctatta 120840
ggatggttct ttaggacact aatcttccat cttctcagtt tgcttgtcct ccaaaaataa 120900
gtcagcttcc ttgctgaac atcttgtctc ttgacttatt tgctgttggt tggcaagcag 120960
tatgggcttt gaactcagct acatgtctcc aagtctgtga aaatgatgtc ctcttagagt 121020
ccttctgttc acacctgtct ccactccccg gggctggaga tgtagtcagc ttgacctatg 121080
cagaggagat gtgtgttcc ctcaagccat atgtgaattt cctgttgcca taagaagatt 121140
gatcctgggg ctaacaaaac atcaaagcct attatagata atatttaatt aaatctatgg 121200
atacttctag ttccggttag ttccagccaa ttgtcaatgc cacttcataa aaattaagac 121260
aggagacat ttttgagca cttagtatag actagatctt atgttaaatt atttagacta 121320
ggcagacatt tatcatagca gttgtgtaag taattataat tgtgtcttct tagagctgag 121380
gaaacatata ccaaaaaaatt ttaagtaata ctgacaaacc cacatagcca gtgagaggag 121440
aagcaggagc ttagaaacaa gottgtctga ctccagagac tgcagctttg cttataaaga 121500
cagaatagag aatgttgctt gaaaacatag gttcaaatat atgtttcacc acttagtagc 121560
cattcttctt tgaattctcc acctagattt gggatatttt ctctatagc taatgcctaa 121620
acacttaaaa gtattgttct ttttaaggaca ggcaccttca gagcctgtca gaagttgcga 121680
tcaaatttct tccttagtcc tacaatttct attagcctct ttttctatgt cagtactct 121740
ggagtttact taagtcaatc aaccttcaact tcaaaacttc ttccctggaa tctttttcct 121800
tttctttoa tttagcttag ctcaaagtct atgcagtctt ttttttcttt tttttgagac 121860
ggagtctcgc tctgtcacc aggctggagt gcagtggcgc gatctoggct cactgcaagc 121920
tccgcctcgc gggttcacgc cgttctccta ttctcctgcc tcaacctccc gagaagctgg 121980
gactacaggc gaccaccacc acgctggct aattttttgt atttttagta gagacgggg 122040
ttcaccttgt tagccaggat ggctcgatc ttctgacctt ctgatccgcc cgctcagcc 122100
tcctaaagca ggggtgtctt tattttatta tttatttggt cattttattt tattgttttt 122160
tgagaaagag tcttgctctg tcgccaggc tggagtgcag tggcgtgatc tcagctcact 122220
gcaacctcca cctcccaggt tcaagcgatt ctcccacttc agcctccoga gtagctggga 122280
ttacaggtgc ccgccaccat gtctggctaa tttttgtatt ttttagtagag atgaccttc 122340
atcactgtgg acatgtggc ctcacgacct cctgacctca ggtgatctgc ccacctggc 122400
ctcccaaagt gctgggatta caggcgtgag ccgctgcgtc cggccaaagc agggatgtct 122460
ttaatgccgc atcttcagt cctaccatag agcccgcat gcaatagaag tgtgcgctaa 122520
ctcttccact tatccctggg ttaggcccaa ctctccagc tatagtagta gagtcaagga 122580
gatcccagaa aaatctgttt tctctgcacc caggctttta agtcatcatg agcaagactc 122640

```

tgccttttct	tagtttttcc	aggtggtgaa	gatgtggaac	aggaaaaacc	acataaaaaat	122700
gcaatcacat	gaataaatat	tgcctacaat	ggctgggattc	aactgaagaa	cttacactct	122760
aaatcaggag	cacagactca	tgtttatgcc	tttgtcccag	gcaccaactt	ctcttgaaact	122820
tctttgctga	ccctgcctga	aagtggagtt	aactaaatct	tgtgtagatc	tgtctcatat	122880
cactatttag	cccatttgca	gataggtatg	atattgttaa	aatgatgaaa	atgccccacg	122940
ttggactcag	ttggatatcc	tgctccggca	gatcaggttc	taactggaat	cttggttcac	123000
ttcacttttg	taggctaaga	tattctattc	gtacttgact	gagcattgta	ttgatgatcc	123060
ctgataatgc	agctcttcaa	atgtaataaa	tttcttttgt	aattgactgg	ccatgcccac	123120
tcaagagata	tatgtttggt	gcctgattga	gtgtcctaagt	aaagaattaa	atgaataaat	123180
gaaagagtaa	cataagaaat	aaacaacact	gggacaatga	actgagactt	cattttattaa	123240
gaagcaatta	ttgataatgt	tgtatatgat	tttagactat	aactaatata	ctccaaatgc	123300
aatagtagac	aagatagaaa	tggctccctc	cttcatactc	gtgggttgaaa	tacattgtat	123360
tgtctgatgt	ccatagcttt	tttacacatg	ttgttttcat	ttgtttcaac	taacggtaag	123420
gagttgggat	atttgaatcg	gccagtgcga	aatgcagtgta	cttggaaga	gggaatcact	123480
gttagtgaat	cataaacaat	atttgaagggt	ccttcagtggt	tttattaact	tcaaataata	123540
taactagatg	agtctcggtt	ttacaagtaa	ccaggaagta	atgcaagaat	cctagcgagg	123600
gtggatcaaa	aaacataaag	tttatgtata	aaaagcattt	gaactcaaga	atttgacata	123660
gaccttagtg	aaaatgcagc	tatttcttgt	cagtttaaaa	gaaataaata	atttggttaa	123720
ttcaaagcaa	gggactcccta	atcaacttag	ctcacaggtta	atttcaaata	aacataatgc	123780
ttattaacag	ttccaatatt	tgactttttg	ctcaacctaa	attcagcaat	gcaatgtgct	123840
gagatatatc	ccagtaaaaga	gcagctgctt	ttgttttgtt	ttatttttgt	ttattttatt	123900
tcacaaacaa	gtttctgcat	gagcctgaat	ctttacaatg	tgaagctgt	ttggattcag	123960
gtaggaaata	cgtttgaact	gatgcatacc	aaatttccaa	aagttcacct	ttttatctta	124020
ctgcttagct	gttgaataac	acaacttttg	cttagtcaag	ccttctttca	ttttcttgaa	124080
gatgaaaatg	taattcttga	gttacttctg	aagaacaggt	tggggaaatg	caaataagag	124140
cattactctt	ctagagtatg	aaaagattac	caaatttagg	ttttctggtc	agtaaaatta	124200
tattttccta	acttggttac	taattacaga	gtcattttaat	tagattatca	tttcttcttt	124260
ttccattgcc	atctttttaa	atgatgatat	ttccagaact	gctctattta	actgttcagt	124320
gaaattacat	tcatgaagct	gacaattatt	cagaagtaag	tttcttatgt	aactctccca	124380
ttcttcatat	tctttgttct	taattttatat	ttgggtctga	aaattgataa	agttactagt	124440
ttagaaataa	ttactgtga	cttcttattt	tcagaaacat	aaatgagggt	gcacttctcc	124500
gcagaacctt	tttcacattc	ttttaacaac	caaatcattc	ccaattttct	ggtgtgtaaa	124560
ttccatgtga	tcagtacaaa	taaacaaact	gacaagattt	gggcagttgg	aacccattgt	124620
tttacaacgt	ctttgtttaa	aatctttcat	aattcatctt	cagcaatggc	cttcctagca	124680
attagttacc	tttagtgtct	tcattttcgt	ttaaattgtt	aatgatcagg	ataaattgaa	124740
ttattttctc	attgtcattt	tatggtaatg	aagcttctgc	cacttatcac	aagcatcctg	124800
caggcacagt	gttaccacac	aaatatgtga	ctcctcactc	ttcacacact	ggtttatggt	124860
ccctgggttaa	agtggtaaca	gtaggacctg	gcctgattcc	agtttaaatg	tatgccatat	124920
tagatgaaag	attgtgggta	gtcatgctgg	tattcttgcc	ccttggtggat	ggcattctat	124980
gtgcaactca	gttctcctta	agcaacacaa	gagaattttc	gtctocatta	gtctgggtgt	125040
tttacagact	gggattagtt	ctacagttag	aacaaaagga	aatatctttg	tgaatgaaga	125100
tgggaaggcaa	tgtcaattca	aaactttata	aaaacttcag	atagaattca	ggaaagcaaa	125160
gggttgaaaaa	cttagtacca	gaaaatctat	gaagaagaaa	gtgagtcagt	gaattctcaa	125220
gctggaagag	ccttcttgca	ttatctggtc	taggattctc	cagccacaaa	aaaaaaaaaa	125280
aagtaattgt	gtattatcat	ccccattcat	tccctgtcat	atctctgcct	aagcaattgc	125340
agtagaattc	atcctatcat	ttgtatcctc	ttccttactc	ctgggaaaca	tttagatagg	125400
gtaaaggatt	tggttgagca	gaaacctggg	gtgggaaata	gggagcatat	ctagggttgt	125460
caaagaagggt	atttaaggct	gccctgtgaa	atcataccag	tttcaaaatt	agaaacttga	125520
tctttttttac	agctgacttt	tcttcaccac	attttaaact	tgttctttat	tctgcatttt	125580
ctcaagaagg	gatatgatat	taccaagaga	aatacttgct	ctcaataacc	ccaacctcat	125640
tttcttatga	gtttgggttaa	gttagaaaaga	aggtcaaact	tagtagctta	aagaaaaaaa	125700
cacattttct	tttgcttata	attgttgagg	aaggaaattg	gaaagggcta	ggcagggcag	125760
aattggaagt	tttctgtgt	gtctggcaga	tgttggttag	tgtgcaatt	atgtggagtc	125820
tatttaaaact	ggccatccta	tggcttcttc	atgtggctgg	tggatgaatg	tggctgttgg	125880
ctgggaactc	agccggggat	gacaagtgga	tacctccat	gtgtctttgt	agcacagcag	125940
tttcaggctt	ttagaatttc	ttccagtggc	tgcatatac	ctgaaagaat	gtcccaagag	126000
agtctaaggc	agaaatgtgt	ggcttattta	tgaactgttt	tggaaagttac	aatgagacat	126060
ttctgctgca	gtttactgat	cacaagagag	ttactaagat	tgatcgagtc	tctacccatg	126120
tgaggggaggt	gaatcaaaga	acttggttga	cagggttttag	acctgtcata	gagtgtaaaa	126180
aagctaagag	gcttcatatt	caagggaaga	aatactttta	agttctccag	ggatgaggct	126240
agtagtgatg	attcagggca	agaccagtga	agtaagagag	gctgggacat	gcattgaaga	126300



agctcactga	gaaagtcttc	tggtaatggg	ctgcaatgtg	ctggagttag	tccacaatgg	126360
cttgcaagat	ccagttactc	acttggtttc	tcaattccag	ctctgagttc	agtgatgtca	126420
ttgatagttt	gaaaatgact	acagtggaa	atttacacca	cattaattgg	cagactctac	126480
aaataaggg	gttttttccc	caggagaccc	agttgctgaa	tagttaccaa	ttggtaattg	126540
ggcaacttag	aaactacttt	taggagaact	ggactgtctc	atagcaattc	tatgtttgtga	126600
actttgggg	taaaaccact	ctgcttttgt	aaccttttca	gtaaaatttg	cgagggtccc	126660
tattgctttt	gggtgaatga	cattttgggg	gataatctaa	tgtgattctg	aatttgagtc	126720
aacactggct	gtttcagaac	agcacatgtt	gaagcaggag	cctgatgcag	aatacgtcat	126780
tagagggaaa	gtgctggtaa	ttagcagaaa	ttacaggaag	ctctgtactt	caaagacttt	126840
aaaattgagt	gtgtgaacca	agcacatttg	agtttccaga	gaaggaatga	agctccagtt	126900
gacactttgg	ttatacaact	gcattgataat	ttatcattta	cagtataact	ttatgtacct	126960
cataatgttt	aaatgggtta	tagatcaaat	gcaaataatt	aaatattttg	catgacattg	127020
gacaagtcc	ttaaattttc	tgatactcag	attcttctatc	tctaggaatt	agctgaaagt	127080
atcttttatg	agagttgttt	cagtgaagtc	tgtaagatta	aaaagaaaaa	taagagacca	127140
tcattagcca	tgagtttagt	aaatatttcc	cagtgggtga	acaccaattc	caagtttatg	127200
taagttgggt	ttgatgggaa	ataagcaatg	attaaacaaa	ggaaaatcag	gagaaagatt	127260
gttaacaaag	ggcaatgctg	tataagtgc	aaaaaaaagg	ggaaaaccac	agttttttga	127320
tttcacaagg	aagcagagg	ctggctttca	ttcatgcccc	actocagcct	cagttccatt	127380
gcttcttgcc	ggcaaagctt	tctcgtctctg	acagaaggca	agcaaaccct	aagaggcccc	127440
aaggtggcct	gtcagagggg	gtaaaatata	tagttttgca	attgtataat	attaatgttc	127500
ttatcagagt	gagaaatgga	gtagaaagca	gagattttta	taatatgacc	caaggagacc	127560
aattttgaac	attttacagt	attaacaaaa	atgttttagaa	ctttagaata	tatttaactc	127620
aataaaaaat	aaatatattt	tatgttatgt	atgaataaca	taaacaaatg	tttgatttag	127680
ttcagagttg	atattttaaa	ataataaatg	ttttgttcta	gtccatttaa	ttatgggtct	127740
tgattggcaa	ttctggaaag	gactcagaaa	gtaaaaaagg	agagtaggga	aagcctcaag	127800
cttagatacc	acctaagtca	tcattaatag	ctattggtag	aaatatgggt	ggtgaagacc	127860
attctgatgt	gttcccagat	cctactgggg	agaatgggat	tggaaaatgg	agaaaagtct	127920
atctttgtta	tgaagtgtca	cataacttgg	ctgagttgtg	ttcctgtcct	gatatttttg	127980
ggaaggtaga	acttgtgagt	gatgaaattg	tatatattgg	tgcagcactt	tctaaacaac	128040
actttgaaag	agtagcctcc	ttcctctttg	ctgctcctag	taaaatggga	gaagagaaaa	128100
atttagtag	gatggaattg	ttaatcaaaa	ggaaagcaaa	acttaaatat	ctggaaaatt	128160
cttagtctat	ccatattgta	aaaaatgagg	aagtatcttt	gcaagagaag	accaagggtg	128220
tgaccaaagg	acaatctaac	agaattactc	agtcatttaa	cagaatctag	aacctgttgt	128280
cnagaccat	ggaaggataa	tcctaaaagc	aattcaaaaa	ctatcagaac	tgccaccctc	128340
atcgagagcc	caaatgcaa	aagtcggggc	agcagggtgg	tttccaattt	aaagaaggga	128400
ccaccagac	cccgtgctgc	ttcacattgt	ggactctacct	cccttactct	gttaccatgc	128460
accttggtag	ccccagattc	agttctgggt	aactctggca	gggaattgtt	aggggggcag	128520
agccaccaca	gtgaacttct	aataggccaa	tgcccagcag	agccacaaga	gtagggtctg	128580
ccctgagacc	tcagacctgg	agagccacgg	gcataaaatt	cttggtctga	agatccacag	128640
gcacacatct	ccaatccatg	agagctgc	tgtaagtgtc	atctggcaaa	gtcatgtagc	128700
caggggttcc	cagagccttg	gaggtccaaa	ctctgggggg	caaagctaag	ggagtaccac	128760
ccagggtgct	cagaaggac	ttttcccaa	atgggtttgg	aagggcagag	catcaaaccg	128820
aagaagattg	ttattgagac	ttatgtctata	gtgttttctc	tgttgggctg	tggacttagg	128880
gcctctttcc	cctttcctct	ttcctgtttc	tatgttttag	aatggggatg	catgttctgt	128940
gcctgtccca	tcattgtatt	ttggaagcac	ataactgtt	tgatttcata	ggttcacagc	129000
tagggaacaa	tttgctcaa	aatgaatctt	acottgagtc	tcattcatac	ctaacttaga	129060
tgatatttag	atgagatttt	ggactttgaa	ctattgagtt	gatgttgac	caagttaaga	129120
cttttggggc	tactgggatg	gaacgaatgt	ccttgcctgt	gagaaagaca	tgaattttga	129180
gggctaggg	cagaatgctg	tgggtctgaat	gttcatgtcc	cctcaaaaata	tgtataaaaa	129240
tttgattttc	caaagtgata	gtattaagtg	gtggggcttt	tagaagggtga	ttatgggtga	129300
gcctcatga	atgggattac	tgcaattaca	aaagaagccc	aaggaaaacc	cctttctcct	129360
tccaacatgg	gaagatgtag	gtgaaatatg	acatgctttt	ctgtgaacct	aggttaaggat	129420
ccacaccaga	ctccaaattt	cctgggtcct	tgatcgcaaa	ccttttagcc	tccagaacta	129480
taagaaataa	attttctgtt	ttaatgaagc	tgtgcaattt	atgatacttg	gttatagcag	129540
ccagaagagt	ccaagacgtg	gtcctacaat	gaagtttagag	aattttttta	agtgtctgtt	129600
tattgttaca	aatggcaaac	aaaaggtcat	tatgcttaca	cacacaataa	atgtgtacaa	129660
tgtgtatgag	taagttttaa	acaacaattt	tttttaatat	gaaagtccca	gttagtttta	129720
aaagaaaatg	aaacaactgag	agtaataaaa	cottttgtct	tgttttgaca	gtgatgggga	129780
agggttttca	aaaataatga	gttggcttca	gtttgggaatt	aggggaattac	ctaccataaa	129840
actgtctttt	agatatccta	aaatatcatc	tgttttgaga	tacacaacat	ctaaaggcca	129900
atgactttat	tttctctcac	agagaaagga	gacctaaaga	ggattatttt	aggtttggat	129960

tcagaaatgg	ccattgtgta	aagtatgtga	gagcagattt	gaatatttgc	catagtgcag	130020
aaataattgc	ttatagtacc	tgattttttt	aagttattat	ttcatccata	atatactttt	130080
ttcttatatc	tttaaaattt	ttacaagata	aaatgaaaat	tgaactaact	tagacaaagg	130140
ttattttcaa	attataaaag	tatatagatt	tcaaaatggt	tattgaatac	ttatgcacaa	130200
tggtcaaaac	acttatattt	ttatataata	cactatgatt	tttagcattc	tgagcaaaata	130260
tgtgaaacct	tttagatatt	tgcattattg	ttacaaaga	agttagttaa	acatgtcaca	130320
tatatacagt	ttttttatat	tagcttgaat	ttcttaaaat	cagcctttac	caggatatatt	130380
agtcattctc	cactctgcta	ataaagactt	acctgagact	gggtaattta	taaagaaaag	130440
aggtttaatt	gactcacagt	tcagcgtggc	ttgggaggcc	tcaggaaact	tacatcatgg	130500
tggaaggga	aacaaacacg	tcgttcttca	catggcaaca	ggaaggagaa	gtgctgagca	130560
aagaggggaa	agcccttgt	aataccatca	gatcttatga	gaactcattt	gctatcatga	130620
aaacagcagc	atgagggtaa	ccagcccat	gattcaatta	cttcccaccg	ggtccctccc	130680
acaacacatg	gggataatag	gaattacact	caagatgaga	tgtgggtgtg	gacacgcca	130740
actatatcat	ttcatccctg	ccctctttca	agtcctcatg	cctcacattt	caaaacgcaa	130800
tcatgccctc	ccatcagtc	ctcaaagtct	taactcattc	cagcattaac	tacaaagtcc	130860
aagtccaaag	tctcatctga	gacaaggcaa	taccctttca	gctatgggcc	tgtaaaatca	130920
aaagcgagtt	agttacttac	tagatacaat	gagggtacag	gcaatgggta	aatacatcca	130980
tatcaattgg	gagaaattgg	caaaaacaga	gaggccacag	gccccatgcc	agtccaaaaa	131040
ccaatagggc	agtcattaaa	ccttaaaagt	ccaaaatgat	ctttgactcc	acgttttcacg	131100
tccaggtcat	attggtgcaa	gaggtgggct	cccacagcct	tgggcagctc	cacccctgtg	131160
gctttgcagg	gtacagtccc	cctccccgct	gctttcatag	gctggcattg	agttcctgca	131220
gcctttccag	atgcacggtg	caagctgttt	ggtggatcta	ccattctggg	atctgaagga	131280
gggtggccct	cttctcaaa	cttcaatagg	cagtgcacca	gtggggactc	tgtgtggggg	131340
ctctgacccc	acatttcctt	tccacactgc	cctagcagag	ttcttcatga	gggtcccatg	131400
cctgtagcaa	acttctccct	ggatatccca	gcatttccat	acatcctctg	aaacctagge	131460
agaggttccg	aaacctccaa	tcttgtcttc	tgtgcatcca	ctggcccaac	accacgtgga	131520
agctgccaag	gcttggggct	tgcactgtct	gaagcaacag	actgagctgt	accttggccc	131580
cgttttagtca	cagctggcat	tgagccagtt	gggactcagg	gcaccatgtc	ttgaagctgc	131640
acagagcaag	ggggccctgg	ttttggttca	ataaggcatt	ttttcatttt	aggccttcag	131700
gcttgtgatg	ggagcggctg	ccatgaaggt	ctctgacatg	tcctggagac	attttcccca	131760
ttttcttggg	gattcacatt	tggcttcttg	ttacttatgc	aaattcctgc	agtgtgcttg	131820
aattttctctc	cagaaaaatg	gtttttcttt	tttattgctg	cttcaggctg	caatttttta	131880
aacttttatg	ctctgattac	tcttgaatgc	cttgttgctt	agaaatttat	tctgccagat	131940
accctaaate	atctctctca	ggttcaaagt	tccacagatc	tctaggtcag	gggcaaaaag	132000
ctgcagttct	ccttctgtaa	gcatagcaag	agtcaccttt	gctccagttc	ccaacaagtt	132060
cctcatcttc	atctgagatg	accacttcac	tgtccatata	actatcagca	ttttgggtcaa	132120
agccattcaa	caagtttcta	ggaagttcca	aattttccca	catcttccca	tcttctgagc	132180
cctccaagtc	tctagaaagt	tccaaacttt	tccaagtttt	cttgtcttct	tctgagccct	132240
ccgaattggt	ccaacctggt	cttgttacct	agttccaaag	tggtttccat	atttttgggt	132300
atcctttatg	ccccactccc	ttggtactaa	tttaactgcat	cagtttgttc	tcacactgct	132360
aataaagacg	caccccaaac	tgggtaattt	ataaaggaaa	gaggtttaat	tgaatcacag	132420
tcctgaggct	gggaatgtct	caggaagctt	acattcatgg	cagatgggga	agcaaacacg	132480
tccttgttca	catggcagca	agaaggagaa	atactgaata	aagagagaaa	agcccttac	132540
aaaaccatca	gatctcacga	ggactcactc	actatcataa	gaacagcctg	aggaaaccac	132600
cccatgattt	aattacctgc	taccgggttt	ctcccttgac	acgtggggat	tattggaact	132660
acaattcaag	atgagatttg	ggtggggaca	tggccaaacc	atatcaccaa	gatataaaat	132720
taagttgcct	cactttaata	acaagggttg	gttacatttt	aaaattatta	ttaaagtata	132780
tatgtgtgtg	tgtgtgtgtg	tgtgtgtata	tatatataca	tatatgtctt	taaagttatg	132840
ttaagtgttc	catgtactac	tgtattgagc	acatagaggt	gctcagtaaa	tgtcaatgtt	132900
aggtgaataa	atgagcggat	aaaatatgga	ccaacttagc	tggtcagtga	gtttatgggt	132960
acttatcttt	gagaagcatc	ttttgccttt	ctccatattg	agattgttta	attgagctgt	133020
gtaacttttg	tatatgttat	tatatgtgtt	taaaattttg	atataatttg	tctaccttag	133080
tagcaaattt	tattgagaat	atttttttct	caaaatagca	tcccttttaa	ctagaaaaaa	133140
aaacagtttt	tatagctctc	ttttgaacta	aataactaaag	aataaattgg	tcaagttctt	133200
tctctgatca	tgaagtacct	gcaaactgct	tcccataaat	ggcagaaaaag	gttaagagac	133260
attaccagga	tggtgcctcc	aaattgttgc	tggtatcatt	aaaaatgtca	acaaaaatgt	133320
ggagcctaca	gccttgtaaa	aataggaaca	tttaaatacca	tacttttagtc	atttctctc	133380
cctgatttat	gttttcttgg	ttgtttgcag	gcgcagtcac	cagcagtgga	agagctggct	133440
catgtgtggc	tcaggctgac	tccacaatca	gagtgttat	gtggaaatca	atcagaattt	133500
tcttcttaga	agatgtttgt	tctgacataa	tgaactgacat	tccagctaat	ttttattcat	133560
aggtctctcc	ttgcacaatg	atctctattt	ctctcaatgt	tattctgtgt	ctttcttgc	133620



tgctgcaca	ttctgaaaaa	aaaaggaaa	caattcccta	cattttat	tgatacttaa	133680
tgttgtttgc	taacatat	agaacacaat	gcaactttat	atattagagc	acttataata	133740
tattattagga	aaacatcaat	taggtaccac	cagttatttt	agacaggtat	ctcttaggta	133800
aaatgtggtg	aaaatagagg	ggcaatgata	gaattcatat	gtgaaagagt	caattggcca	133860
tcattatgcc	aaaattat	tgtggttcag	gggacatttt	aaactttaat	ttttaagaat	133920
taaactttta	ttaaatttat	tgtagttaa	atgcaatcac	aaggaaagac	tctgaactgg	133980
aaacaccaag	ccaagctctt	tcctagtctt	ggtcccttat	aaaccctgaa	agttaatgca	134040
attattgtaa	tttttaaacc	accgagttct	cagggtgatt	agttatgcag	caatagatag	134100
cctgaaaagg	accattcttt	ctggcactga	aaattaaaga	gagtgattaa	caacataaga	134160
atgtagtgtg	tgctgtctgc	cacagattta	tgtttagct	tcagtgtattg	cttcaaagca	134220
cccttactaa	ttgccagcct	attgctgata	cctagctaaa	ttagcatgtg	ttagttttga	134280
taccactata	ggcattttaa	ggatagctga	tacattctat	ataaaatata	attattttcc	134340
tatctttagt	ttatcctaaa	gtagcagcta	ttatattcgc	ttcttgatta	gctttatata	134400
taaccagaga	aagtaaaata	tcacagagta	tatttgaga	cataaaagtc	tttggacaaa	134460
gctcaagtaa	tgaatcagga	tgctattaca	tcctccacat	gacagtaaat	atattttata	134520
ttcctaaatt	ttaagctttt	aacaaaagca	aattttat	tggactat	caattttctag	134580
ggaaaaggaaa	ttatcattta	ctgtctttga	ggctataatc	tatttagcca	ttatttttat	134640
attgatcaat	ttataataaa	ggtaagagaa	aatactacca	catatatgtt	gtttatataa	134700
ttttaacttt	cataattaaa	atactgggt	tactgcaaga	tgtaaatatt	tataatagct	134760
tatttttggg	aacaattata	ctttatatac	tcctaatacca	ttgccttgtg	tgctcattgaa	134820
gaaattgaag	ttcacaataa	tgactgaaca	aatgctcaaa	gctgggtctgt	ggcagaacca	134880
aaaatttcca	tgccaccttt	ctctttccat	attgggggtga	tctgccta	ttgactttct	134940
gcttatatgt	ctagactcta	cccctcatc	cttctgctag	tgtgttgtt	aaccctttct	135000
attaacccac	tctcgatttt	tctgtgcac	aatcaatctg	tagcctgaat	gttgagtccc	135060
aaatgcatga	gctacctggc	cgagtaatct	aactagatta	gctgagtat	atcactttaa	135120
ggccaatgta	aagttatgtt	gtaactacct	catagttttg	cagaggcaag	aaatagaagt	135180
taagggaagag	aagaagccaa	tcttgaatca	gttagaattt	ccttggacat	agaaaatctc	135240
tacaagcaaa	aacccatttg	attgaacaag	caagcttatg	cagttaaata	tatcaaagat	135300
cttgtcaca	aaagtgtaaa	gggaaagtaa	aataaggagg	gagcatgaag	aagccagctt	135360
atattaaaga	ttcaaagcag	ggatataagg	aaattcaagc	caaaaataag	gaagaattct	135420
tataaatgcc	ccaagaatga	attcgatgtt	tggtcgatat	tccaacagat	ttagtaattgc	135480
tattttttaa	gtcaacaggc	tgcccatttt	tgccctcacac	tctgactgca	tgtaatctgt	135540
caagtaactct	gatgagttct	ggagatgcta	atgcaaaaaa	gatataaaat	ccttaccttg	135600
aaaatgtagt	tcacaattta	gccatggagt	tatggcaagc	atcttgtctt	caatttttagc	135660
ccctcctcca	tcctctctcc	agacacccat	tgtcctcttt	ctcaaccacat	ccacccctt	135720
ttttgtctctg	tctttgtg	actattttata	atctttctca	tgtctaccac	aactattttg	135780
ggtagtaaga	acatcagtat	ggagacccct	taatcctaac	taatatcaac	tctatctgtt	135840
tggtattaat	tcttgtttat	tgaacttgag	gcattgagta	ctacaaaaat	tataatacac	135900
tactggtgaa	cattacttta	ttaatgatta	ggttccactt	ggatgtttgt	cattcgtag	135960
tagctgttct	ctccttgtag	cctgtaaact	ttctatggat	gtcacaaaaa	gagttttaag	136020
gatttggctt	aaattaaaat	taatacatca	agaaaatact	atgctc	caaaaaataa	136080
tcagtttaatt	tagtttttag	aaatctttta	caaaaaacgt	gatattta	aatctttatg	136140
caaggatttt	tgggatatta	aaattgtcac	agatttaata	atacgtttta	ttgtataaaa	136200
tttttctttt	ctcttcaaag	tggtgggaga	gtgaattctc	taagtaaaaa	ctgaagagta	136260
agatgttate	attaaacatt	tcagaaaatg	cacactatcg	tagactg	actgtgaaaa	136320
tgatcagcta	gtagaggttt	tggtgaacat	atagtaactt	ttatcaacaa	gtaatgtgaa	136380
tatgtgaaat	ctattgtctt	tccaaaagaa	agaaaacttt	acacttcttg	gtaaagataa	136440
actttcatgt	aagaaaaaat	aaaaacataa	tttttagcaat	ccaaaccata	ctaaaatcat	136500
aaacacttga	ccacatgttt	gagtacccca	aaaattgttc	ctgtgtggat	tcttcttcta	136560
ggatgatcag	tcctcatggc	cttactactc	tccatttctg	tcccactgag	gttagccaaa	136620
gttcacttgc	cttgtcagtt	aagtttctaa	atcagatgag	ttatgttttc	tataattgag	136680
ttaaaccacag	ttaattgctt	aatagactct	gtctacacta	actgaaaaaa	aagaattaat	136740
tgcttgagga	aaatgcatta	tatattttat	tcacatctac	agtcacocag	gccaaagtga	136800
caaaggcact	ttcaacagtg	gccagggcca	atggcgacag	cggggccagt	gcttagctca	136860
gccatgtgtt	caatctagta	ctttgggatg	tggaataaaa	gaaaatgagt	tataaatgaa	136920
cttctcctta	gagcttaatt	cattattatt	attattatta	ttattatttc	tttacataag	136980
aaaaataatt	taggagtgtt	ttggcaaaag	tttaggtaca	atttaagaaa	atgccatttg	137040
taaaaaaaa	aaaaagacta	gnnttttttt	tttaattagt	ttttactttt	aatgattttg	137100
atttaggttt	taaaaatgta	tttctagacc	aaggtctaac	accaggtatc	tgagattttt	137160
ctaaattttc	tctgaaaaca	tgagacgcac	gtacagttat	ttaaaatttg	ctgcagccat	137220
ttttaataga	ttttttatgt	ttgaagagat	gccaatcgct	tattatagta	agctatgata	137280

gcaatgccaa tgaatcctca attccattgc ttaaataataa gtgaaataat aaaggaaaag 137340  
accagtattg aatatattgc ctcttcctgc tacactctaa catattcact acaataaatg 137400  
gaaagtgtgca catacaataa aaacttaggc aattttattt tttacttatt ttttatttat 137460  
ttttttgata tggagtctcg ctctgtcgcc caggctggag tgcagtgggt cgatctcgcc 137520  
tcaactgcaag ctccgcctcc cgggttcacg ccattctcct gcctcagcct ccctagaagc 137580  
tgggactaca ggcgcgccgc accacgcccc gctaattttt tgtatttcta gtagagacgg 137640  
ggtttcaccc tgttaaccag gatggctctg atctcctgac ctccgatcc acccacctcg 137700  
gcctcccaaa gtgctgggat tacaggcgtg agccactgca cccggccggg aattttatta 137760  
agtataattg ataatacagg caatatcaga aaatcttgaa taatttgtac tctaaaatga 137820  
atztatgctt ttcagtgtcg gaagcattat agagggtgtt tcaactatga aatcattttg 137880  
tcaaacgttc tttgaagtct atgaccttaa gttaaagcatt taaaacccaa tgggttagaa 137940  
acgtccagag aaacaagtat attggcaatt gtaaataatt tttgaagtat ttagcaaaac 138000  
agcgaagtac aataagcatc ctattcacaa ttccaatgta aaaagagatc tggtcataag 138060  
cagaattata ctaagaaaaa ccctatgaag ccaataaagc ttgtttgtta cctccaagat 138120  
ttcaccatct ttttcccggt tccctgcac tatgccctac tgtttctgct tctcatttaa 138180  
tcttaaatcg acttaagtgg atactgggtt tttaaatatt tcttatctgt atcacaagtt 138240  
caacaaggaa aatatcttga taataaaaaa agccaaagga agctttttaa aatttaccac 138300  
tggattgtaa ttacccatga tccccatcct attcctttag aactgttaga taagagtttt 138360  
ctacacttga aactttgagt gtttctaaaa atatttcttg ctttgagctt accaagtga 138420  
tagataccgt ccagacaggg tgaactgaag caagagtccc tggctcgaaa gtgtgcctgg 138480  
catgttctaa taaaacaaaa aggcgcacg ggtgctccta aaagggaata aagtcagcaa 138540  
gtggggagag gggcatgtat gacttcttgt tgattattag aagaacattg agaaatgcaa 138600  
aaccactttg tggttttgtg aatccactgc tgttttcagg atacactgag aggggtaatg 138660  
gcacaaaagg gaaatctcct ggttgatagt ttgtaaatct agacagaagg tgggtgttgc 138720  
tagaatcaag gtaatagcaa gtogagttat cagaaatgtg gaaattgggt ttatattgag 138780  
aaacaagccg atggtgtctg tgagaattgc acgtgtagtg agggagaaca aagggactca 138840  
agagtatatt tttttaacca aagcagctag aaagatgaca ttgcctttgt acccttcatt 138900  
ctctaattgt attcccatc tctgccttca ttctctgatt acctttccca acaggtagct 138960  
ttagcttgtc cacacctaac tatgcttctg tctagggcct tgacacttgc cgattccttc 139020  
cacctggaat cagcttgccc aagatatcct catcaattat ctctcatatt tttcaagttt 139080  
ttatttgaat gtcacctttt caatacaact tgccttgccc cccatcttag attgtatccc 139140  
cctaaataca cttcctgtct accttctccg attcgttttt ctccatagcg cttatcccaa 139200  
tctaacaaac atattttact tattttattt attgcctatt tccccagtaa aaaggcagct 139260  
caataacaag gatgtctgct tgttttgttc actactctct ctccaaagcc tggaaatagta 139320  
tttggcatat aatagcacia taaatatggg tttagatgcat gaattaatgc agggaattag 139380  
ccaagctatt tactgtactc tgggtctctga gaaaatttgc aagcaggaga aagattgtct 139440  
tatggaaaaa cgtatgaatc aaagcaaaaa actccatcat ggtgtatcca gatgaaagt 139500  
gtttattgtg atttagtttg tgataaagtc ttcatcataa ggaggatgaa aacaaaagcc 139560  
ctagtagtat cagatcctca gagaagagct aataagctga gctccttaac atgactcatg 139620  
ctttctctaa cttgggggaa tggttggccc caactctcga tgagtctgca cactgaggaa 139680  
aactcctcaa aatctagcag cctggaagga tgaatgcaaa agaacagtaa caccaattat 139740  
ccctctaccc agctgacatt tctctcccat ccttcatttc cttaccataa cctctgtgct 139800  
tagccatttg ttcattggata atgtccaaga atgtacaatg atatacaaga tcatgataat 139860  
tgaattccaa cttctgtcat tttcttctgt gcccccccat atccagtgat tctgaactgc 139920  
tacagttctg taaacaaaa atcccttttc cccaatttta taactaaaag cttttacttt 139980  
tttattcttc ctagaatagc ctttcttato tcatatcttt gtaaatttta attcatcctt 140040  
taataatcat ttatagcagt tcttcattag tgaaattcct gatacatttc ccacctctc 140100  
tgaaaaatta attgctccct tattgatttc ccattgattc taatagtatt gaaatatttt 140160  
attacaatta ctgggttcaca catctgaatt ctgcttggag ctgtgaagaa tctgaaggca 140220  
agaaacatat tctactttct ttgtataaaa tggacttatc acataataat ggctcattag 140280  
ggtgaatgaa tgattaatat taacaaagaa aattgtcaaa attaggtaag cttcttttaa 140340  
aaagttgaag ttaaacatta gccatagtgt ttctggaaaa ctgagcactt tctgatgtgt 140400  
ttgaaatcac attgagaaag tctgtctttt tgctactttt gtttactgga atgaagggtg 140460  
actggaaaga tttcccagag aaaacaagac cacaatgttt ttgaagttag gaaaaatatt 140520  
ttaattgaaa tagaggtggg acaaagacaa gaaatatgac atgtgatata gtagatataa 140580  
gcgtatatga aatatatggg atgaacatcc atacaggttt cacaggactg aaagggtgcaa 140640  
ctggtcacaga gagtctggtt ttggaagtat ttaaaactca caatcaaagc tctgatagta 140700  
ggatgcaatg tcaatgatta ctaatcgaga caaatttgct caagatcatt gtataattac 140760  
acccaaattc caatttgtga atagatttac tcatcgtgac cttagctgata acatggaaag 140820  
ataaacaagg cagatacaca gaacattttg cagactatgg tggctgcaag aatagctttt 140880  
cgcttgattc aggccttaag tgttagcctg aacactcaga acgcgattta ttgttggaaa 140940

```

gggattaacg aagacattta tttcagaggg tactttgttg ttgttgacat ttttgttggt 141000
gttgactttt ttgttggtgt tcttccctct catctgggat atttcccttg ccttcttgac 141060
ggcttgtcaa tggggagggt ttcgttccctg ctttatctat tgcatactct tctgcttaat 141120
atgaatctat tacacagaat aaggaaatac atttagggct gactaatgta aaaatactct 141180
ttgatgagca gtacactgca acatagctca gagttttcaa atttattata ttggctcttc 141240
caaatatgtt attcatattt gctgagaggt gcttttataa atttctgctt tggagcatac 141300
agctcagtggt aaagatatgt gtttatctga attagctggc tctaattcca aatgaatatt 141360
tgtacaaatc tgtttttaac attgatatta atttattaga caattagaat atggcaaattg 141420
atgcaaagtt tggaaactgt ttcacatttt tttaatgggt tgtactcact cccctcccc 141480
atatacgaga ttttaaaagt ctatagggat atcttagtac atatttatgc agattacttt 141540
tttatttatg gaaggggatt gcttgatcct ccaggtgggt ataaaactgc tatttcattt 141600
tgacatgata taaattgggt tagagaaaac aaattatctt aaagtcttta gaaacaaaa 141660
tgatgctggt ggagcatagt aataacgtaa ataaatctag aagatggaga tttttatatt 141720
tctagaacta gatggggttg tectggatca tgcctctgaa tttagtctct gatttttate 141780
caggggtgat ttttgacttg tataaaaacca tggaaaacca gagccatcat aaagcaagaa 141840
tcgggtttaca atcttttgaa atgtgtatatt acgtagacca tgaaataaaa aatattttgt 141900
tcaagaaaag ttgtttttaa tgctgctctg aacagcagac caaaaataac atttttaaga 141960
gcaagcaagt cgtttttgtg ttttacttgc ctgacctata aatatggaat gttggacca 142020
gaagaatacc tgagtttagg accatacatt cttttaggta aaattttatt gaaaattaaa 142080
gtatatatag aaaagtgcac aaatcagaag cctacggctc aatggatttc aagtgaatat 142140
agccatgtaa ctagcatgcc aataaaaata cacattgata gagcattacc cgaccgggc 142200
cttctcatgc ctcatcccaa aggtaatgct tattctgctt ttaattatt acatattagt 142260
ttggcctatt ctctgaaca caactcttca atgcttgtaa gttccatttt agaagatctt 142320
gcaagtggaa tttgccttct cccactagtc agtctttaac caggagatat caagatggaa 142380
tcagagggaa tctaagcact ttaagtgggt ttgcctgac agcatccttt gtgattactg 142440
aaagaaagct ggaagttgat aaagtgatcc atgttgaaag tacagattgt gctttgatag 142500
tggccatggt gtctctgcca caatgtttcc ctgcactatt tttgccaat attggattta 142560
acagtaaaag ttttaagtaat gccatattcc actaacatat aacaaaaaaa tgggaattaga 142620
aataggtagc aaatttttaa gatcagagaa aaaggaaatt tgacatttaa gaattacatg 142680
tggttagaga tctttatata tcaacatatt gaaagaaatt aattcagtc gttcaggcat 142740
gacgtttatt ttaacaatt agtattctat tctctataat catgttccac agtttaaatg 142800
gcttaatgag ttcttactgg aaggggacta tttcgggaga gtataatggc ctttaatcac 142860
ttcactcaag ctatttagcag gaaagattgt caggaaatat tgttactttt gttataaaat 142920
caattgaact ttactttgga tgaacaaga agtttgtcaa tatggtatat aacctccaag 142980
gtctttctcc ctttctctta tgctatttcc cctcgtctt cgccatgtgt tattgattca 143040
tttgaataat ctatgattat ttctctctt aatagcctga gaagaaaaat agcttctaac 143100
taagcagcta ccaagtctt aagctagatg ctatgtttat attatctcaa ttaatccac 143160
tcagtgtagt cgatggtagt acctgttac aattgtgcaa aatggagttt caggaagata 143220
cacaatttgc tcattatcaa actctcataa catccacaga aaataattga aacacaaagc 143280
catatgactc ttaacctcta ctgaaagatg cttttatata gaatctaaaa tgttatgtta 143340
gatataatat attggctgggt gaagttttat cttttccaaa acagaacaat atttttagtgt 143400
ttctcagtg aaaatagtga acactattca gtttcagggt atgatattct tgattatcct 143460
catgagagag tcagtgtagg tagttcagtg ggtctcaaa catagtaacct ggacaagcag 143520
caacagtgac atctgtgagt ttgttacaca cacacattca tgagccctac cttaaatctc 143580
tgaatatcca agcatgcat ccaggaaatt ctattttaat aggttctcga gatgattctt 143640
atatgcatta aggtttggga accactgaca tatttcttaa aagcacgaat tgcggaaaca 143700
gactgtgtaa gtttatattc atgttctgtg aaatactagc tatgtgacat tgaacaatta 143760
atttatcttt ctggtctcca gtcttcttca tttatgaaac ttatacaata atcatatctg 143820
catcacgttg ttttcagaat tgttgaaac acatagaaaa gtgtcatgct agggccaggc 143880
acggtggtct acgctgttaa ttccagcact ttgggaggcc aaggcggtg catcacctga 143940
ggtcaggagc tctagagcag cctggccaac acggtgaaac tccatctcta gtaaaaaaac 144000
aaaaaattag cctggcattt tggcagcagc ctgtaatccc agctactcgg gaggtgagg 144060
cgggagaatc cgttgaaact aggaagcaga ggttgcagtg agctgagatc gtgccattgc 144120
actccagcca ggaacaaga gtgaaactcc atctcaaaaa aaaaaaagaa 144180
aaaagaaaaa gaaaagtggc atgctcatag caagtactat gttagtata gtaaataatg 144240
ggatcttggt ttcataatac aaattaatta atgatataaa gcattcatta aatatctcaa 144300
tatttggaa ctttctttt aataataaag tctagtaaat gttgttattg aatagaaata 144360
cacttttaaa aacgttgctg attattttta aaatatatga atcagaaaag gaaaggtgat 144420
ggaaaactca tacaaatata gtaaatgca ctgttttgtt gaagatgatt ttatgcagaa 144480
ttcaaagtag atgcaattag tgcttcaaat tagaaactgc aaatgatgaa ttcacaagca 144540
catgatttaa caaacaatc agagaagaga aaaagtttct gatgaatttg agtttctaca 144600

```

tgtggatttc	atcttgtgat	aagccattct	caggagaaag	catgagatgt	tattcgtcat	144660
tccagaaagt	gggagaacat	aaaagttgag	aacagttatt	gcataagcaa	gaattatcaa	144720
tgaacacaat	taatttaata	catacacagg	catttgactg	tatgagaaaa	agcatttcac	144780
gttattttgct	ttgtagatac	aatatcagtt	tcgatgagat	tcattgctgca	cggatgggta	144840
cacctgtcac	ctgtgggtgg	gtaattctta	tacctgtgat	gacaagtaga	ccacggggga	144900
ggactcgcaa	aggattttgag	tgaggagcca	ctgatgctgt	gtaaatgcca	gagccgtgac	144960
cgtgcacttt	tgggggggatg	tgcttaata	tcttcagatt	tcacagaagt	tagggcatca	145020
acggaaaata	cttttgtttt	ttctagctca	tctgcacaag	ttgaacacac	attgttagat	145080
agtgtgtatg	tcagagcata	tgtgaacaaa	tgaaggcgaa	aagtcaatag	ccatacattt	145140
gtatttgtat	tgctctttat	caatctaaaa	aggtacatta	aacaataaaa	tgacaattca	145200
atttttaaca	gcattctaga	ctctagaagg	tgttttctaa	tccactctct	taagccattc	145260
tcacaacagt	acaagggaga	atttcaatga	gaccagggtca	cccagcaata	tggtgacaca	145320
gatgagacac	ctcctcagat	ttttgtttca	aaatttttgt	tctgcctact	atgccataca	145380
tgctgtaatc	atttaattag	aatttatatt	tttaataaatg	aaaactaaag	agtttttgca	145440
attgtgttaa	cactcacgtg	ttaaatttgt	aattatgtcg	gtaaataaaa	agagttttaa	145500
tccacacccc	attagccagg	cgtggtgggtg	cacatctgtc	tgtaatcgaa	gttttagaaa	145560
actgaagtgg	gaggatcact	gagcccagaa	gaggtggaaa	ctgaagttag	ctatgattgc	145620
atcactgcac	tctagccctg	gagacagagc	acgacccttt	gtccaaaaaa	agaggaaaaa	145680
aaaaaaaaag	aaaacaaaaa	ggogcaacac	agagagaagt	gatcttatcc	ttatccctat	145740
gttagatata	tatttttttt	ctggtcagag	aattacaagt	ctgtctaagg	aggctcacat	145800
ttgagaagag	aaaatcctgt	tctattgact	tagagagtta	aagaccctgc	cataagcaga	145860
gagggcacac	gtgggactct	gcgccaggac	aggcacaact	gtgggggacg	cttcatagca	145920
gcttttgacg	atctcctctg	cacctgaagc	gccgcctgta	gaagctagat	gaaacctcac	145980
aatgccaaag	ggttgctggg	cttaggaagc	acgggtcgca	tagggataac	tagatcttta	146040
tggtacctga	agccactgcc	ctttgtctgg	atatctgtct	ctttgtgtgg	ccttataggc	146100
tgcatttttc	ttgcctgtat	gcctgaggtc	ttgatttagt	cacactggca	gggtacaaac	146160
tgccctgact	ctgccagtga	cttcacagtg	cagttgcaat	gtcatttagt	taccttcctc	146220
tgagggaact	gctactgttg	atgaagagtg	ctttggacca	aatattttat	gggcccacag	146280
ttcatgtatt	aaagccctaa	ttcctaattg	gatgatgtga	ggaagtggga	cctctggggg	146340
gtaaaataag	tcattgaggt	agagccctta	tgaattgagc	tagtgtccat	gtaagaagag	146400
atggaagata	tgattcttct	ctccaccatt	tgaggacaca	gcaagaaggc	agccttctgc	146460
aagtacaggaa	gagagccttc	accaagaacc	ctctctgtca	gcactttgaa	ctcagactcc	146520
ccagtctcca	gagttatgaa	aaataaatte	ctgcatttta	ggccaccacg	totaagacag	146580
agaggtaaaa	tatatagtgc	ttgggccact	cgtttgttat	taaattcact	atgtattcag	146640
cttcacttat	atccttagaa	aagtttgtga	atgcagtga	atgggtggag	aacggtagtt	146700
gcagataatc	agagaagaag	agtagagaca	gggtgcaggg	gaaagttagt	cctttaaatt	146760
gaaaaatgat	aacatgatcc	attcatataa	atgcactttt	gttcaattct	gctccagctg	146820
tattatccag	cttctctaaa	gaatgggtgc	tgtacaggac	aggggtgatc	ttaccctgat	146880
gaaagatggc	tctccaggca	gatagcagga	gagacattcc	taattgattc	caggagggaa	146940
tgccaccacc	atcaccacta	tcatttatgt	tgatatacaa	actgaaatgt	caatgatcat	147000
ttctgttctc	taacatttcc	aatcagataa	tttaaacatt	ttactctaag	agtttttcaa	147060
ctcaaatggt	atgcttctcg	ttttgtgcat	ttgtattatt	aactctagtt	tcatgggagt	147120
cccagttttt	atacatcact	gtatagcttt	gatgttaaca	tgatttttag	ttaacataat	147180
ttttgccaaa	gtgagtatta	acctagtgtg	atcacacaat	ttggttattc	tttattctga	147240
tgctaaggga	atccaatgat	ttttgttgat	agtaaccctt	caattctatt	gactgtaaag	147300
agtaattctag	aagaaattta	aagaaaattt	aatcagattt	tacgttttct	gtcgctaatt	147360
tggcatctta	atagctgttt	attttattcg	aggtgcatcc	tgagtcttgt	aatgttcaca	147420
ttgcaatatt	aaagcataac	agatgagcct	aaaatgttca	gtgggttaatt	tgtacagatc	147480
aagatgttgt	aattgcaata	accttaattg	ggctaaccct	tgaataacat	aggtggaaac	147540
tatgtggata	aatccactta	tctgcagatt	tgtgcccacc	tcggttaccc	cagacacaga	147600
aaaaccaaac	cctcctcttc	ttcccccttc	tcagcctact	cagtatgaag	acgatgagga	147660
tgaaaacctt	tatgatgac	cacttccact	tcagtaatag	taaatatatt	ttctcttccc	147720
tatggatttc	ttaatagcat	tttcttttct	gcagctttat	tgtaagaata	cagaatataa	147780
atcatacaac	atacaaaata	tgtgttaact	tactgcttgt	tatctgtgag	gttttcattc	147840
aacagtaggt	tgctcagtagt	caagcttttg	aggagtctaa	gttacataaa	aattgctgac	147900
tgcgtggctg	gggtgggggg	agttggcagc	cataacctcc	acattgttca	atgggtcaact	147960
gtataattttt	ttagcggaag	tgtaggaatg	tttagtatga	tacaacctag	gagaaatatt	148020
ttgtataaat	atgtgtaaaa	tttaagactgt	agaactaaaa	ataatacact	tagttcatta	148080
gttattaata	gctaattattg	atttagctct	gtgataataa	attgacatgc	attacctcat	148140
ttgtcacatt	gtcatgagat	caggattttt	atttgtcttt	catttacaaa	tgaggaaact	148200
aagtctaaga	ggagtttaagt	gatttaccce	gtattacatg	gcaaaaaaaa	agtcagagtt	148260

taaacttaaa	gccgagtcct	tgcaattcta	aagtcacatgt	tcttagctac	tgcctttctg	148320
aacttattag	tcaacctgaa	ttctgaggat	ctcacaaaaa	gttacgtgct	aattattttg	148380
gaagcattta	cattattaggt	ttctaaaatt	acaaaattctt	ttatgtatga	tagggaggta	148440
aaatcatggc	attttagaggc	aaacatatct	tatttagttc	ccattttgtg	tacttaacag	148500
ttgtgaacct	gacgagtacc	atttagtaac	ctcaactgtt	aaggtgtgta	aacaagttca	148560
tttcatagag	gtactgggga	aagttaagcg	agagaatata	tgactaacia	aaaatatgat	148620
tttcattttt	tccttgtgtg	tatacttaag	gggaaattta	ggactgccta	cttggtatct	148680
tccactgaaa	acaaaacaaa	acagaagatt	aaaaatacaa	acatgttgcc	cttggtttat	148740
ttgtctaact	caagttgttc	tgatatcatc	catttctgtg	taaccacaag	cacagttggg	148800
aaagattgag	ttagcaatgt	tcctcaatt	ccagattgcc	ttctctacca	tctaatttct	148860
ttcagtggta	ccacaattct	tccatgctgt	aatagaaact	ttgaaattat	attttgctat	148920
ttttctcttt	tgcatcatta	ttttacattt	tggtgtcaaa	tattttattt	ctgcagaata	148980
tcttataatc	ccatgcttct	aatttctagt	cagtgaactt	cttgattctt	attcctctaa	149040
tgtacaatcc	aaataacact	ttcttctctt	ctttcattta	acaagtaata	atttaacgtc	149100
aacactgtgt	catatctgtg	gtgtcaccta	tcagtatgca	gaacaccaag	ggattccac	149160
tgtagtgtga	ttcttcttct	tgtgtattaa	caccaatgct	ttcttggcct	cttaacgctt	149220
cctccttgat	atttttcagt	tccaggcact	ctgccacaca	ctctcatggc	cacacacagg	149280
accttggttaa	cacctggaaa	ttctccatct	ttgaactatg	aaagattagt	atctgcaatc	149340
agtaaatggc	atcatctctc	atagctttta	ttccccaatg	ccttctatct	agccttgaac	149400
tttggtttttt	ttctgctgtc	tgcttcttcc	ctcattaagc	cagccacatc	attcgatccc	149460
ttcactcaca	gcattttcaa	gaacatcccc	tcttctctct	tttatcttca	gtcactctgg	149520
tgtgaatata	ttacaatta	tacaatacac	tttcagtgtt	cctagactcc	tgttgttaga	149580
gacagctgtg	taacagaatg	ccctgggtgca	gactgggggt	ccctggatag	cgagggtctc	149640
cagtttcagc	tggcctcctc	ccttaggtaa	gagatagaaa	caagaatctt	agtattattc	149700
taatgttcaa	gtatctgggc	ttttctgcta	tagttttccc	ccataaatct	tgatttttag	149760
ccatattaag	tgtttttttc	ctttaccaga	taaacaattt	tgtctccaga	ctttctgcca	149820
ttttcacttt	ttttacotgc	caaaactttt	gtgtctttac	gtactcaatt	taaaaatctc	149880
ctttatgaga	tttcagcttt	ttctcttgga	ctgagattga	gaacctctct	ctgggctcca	149940
ataatttcaa	atgtctgctt	aaattttgaa	gcataatttc	attttatgag	aatacataga	150000
tttcagacta	ctaagcaata	gaaatatgga	tacaagacat	acacggggacc	acttggggca	150060
tagtaagtat	tcaagaatac	tgaatacttg	gtgatatatt	ggtagtgta	ttaggccgtt	150120
ttcacaccgc	tataaagaac	ttcccgagac	tgcgtaattt	ataaagaaaa	gagggttagt	150180
tgaactcacg	ttctgcatgg	ctggggaggc	ctcaggaaac	ttagaataat	ggtgaaaggg	150240
gaagcaggca	tgtcttacat	ggcagcaggt	gagacagaga	gagagagaaa	gaaaaaaaac	150300
agccacttat	aaagctatca	gatctcgtga	taactcactc	actgtcacaa	gagaagcaag	150360
gtggaaacca	ctcccagat	ccaaacacct	cccactgtgc	cccttcacca	acaggtgaag	150420
attacaattt	gtattacaat	ttgagatgag	atttgggtgg	ggacacaacc	aaaccacatc	150480
agggagtatt	ataattggta	aagaatgact	gtccctagt	cattgaaatg	taagtctcat	150540
ggaactaacc	tatatgtgtt	taatgcaaat	ttgaattcaa	gatggcagac	taaacatatg	150600
cattttttac	ttatctttcc	aagtctttgt	taagttttta	acggattata	taaaagagca	150660
agaagacaag	aattaaaaaa	gaagtagtaa	gccacatggg	aagtatgcat	gagagttaga	150720
agctgaggaa	tgaagtagta	atctaaaatc	tcagagaggt	tttgggttca	taggtgtgca	150780
aaaagagaat	gagcattggg	tccaaaaaac	aaggcgaata	atggaagggt	aatagttgaa	150840
cagttgcgct	gatcagtcct	gctttgcagc	tcattgtcaa	agaagagatc	aagttggaat	150900
ttttggccaa	atactatagg	gttgtctgtg	atatttaata	gtaactgagt	gagcagcctg	150960
agagtcaaga	ctgttagcta	tgttttgaga	cccaaaagta	aacctcttgc	attttatcag	151020
ttgacagaag	agaagtgtc	tacatgtgcc	ctgacttaag	cttatttttc	attcgtaagt	151080
gttaggtaat	ttttagtaat	atcattagcc	ttctatatgt	agagttatgt	gagaattaaa	151140
ggtctctttc	cctgcaatct	cagacagaat	tctactgtac	atgcaaacat	gtattatcaa	151200
gtatggacaa	aatcaattgt	actgagtata	atgaagtcca	ggttctctgc	cttttatgtc	151260
ctctaattgt	acacagcata	aatgttgac	tcaagccaga	gcacaaaata	ctcaaaggac	151320
agaatttcagc	ttatcttatg	gtcagatatt	tgcactaaaa	taattgaatc	agtgattgga	151380
tacaaagact	tggatgacat	cacaaaagtgt	tcaggctctt	gaacttccta	ggtccttata	151440
accttctttt	gaaacaatag	aggccgggca	tgggtggtca	tgctgtaat	cccagcactt	151500
tgggaggcca	aggcgggtgg	atcacgaggt	ctagagatag	agactatcct	ggccaacatg	151560
gtgaaatctt	gtctcttcta	aaaatacaaa	aattagctgg	gcattggtgg	gtgtgcctgt	151620
agtccagct	actcggaggg	gtgaggtagg	agagtgcgtt	gaacctggga	ggcggggggt	151680
gcagtgagtg	gagattgtgc	cactgcactc	caacctgggtg	acagagcgag	actccaaaaa	151740
aaaaaaagaa	aaaaggaaaa	atagggtac	atatggaatt	ctaggcatct	cacaaatctt	151800
taacgttagt	atttcttcaa	ttaaaatact	ttttaaaaat	tctaaccgct	agaccactag	151860
agaaaaatac	ttttggtttt	attaaatac	ttatttaacc	aacctctggt	ctcatcagag	151920

agaaaaatag atggcatggt tttacotttc cttgtttcag gcttctgatt agaattccta 151980  
 ctagtcaacc atttccaggg tgcacattct taatatttct caaaatttat attaggtcta 152040  
 aacctacaaa atttattttt ttaagatcaa agaattgtcaa atattagcaa gtcacatggt 152100  
 ttatactggt aaagcaaaact aaatatggcc tgagaaagac tttgtacttc tgtatttgag 152160  
 accttgtgga tgaaccgcaa cctaaattaa taggcagaga aaatttttaa ctttaacttag 152220  
 gaggtagcac ttataacaat agctgggtct tggtaaatcc cagcagccat acttcagcca 152280  
 ctcatacacc gctgagttat caaactgtgt tcaaataagg caaatgccaa tctgtaacca 152340  
 gtccagctgt ttctgtacct cacttctgat tccgtatgt cacgtcactt tattgtctta 152400  
 taaatttggt ctgaccacaa ggcattccctg gaggctctct gaattctgtg tgattctggg 152460  
 ggctgcccaa ttcatgaatc gttcattgct ccattaaact cttttaaatt agtttggctg 152520  
 aaattttcct ttaacaata ccatctctcc tgggagagtc aaactcatat ggcaggtgag 152580  
 gattcagaga gattgttttc caaaagatag aaagttaaagt tgccattttc ttaaggtcta 152640  
 ggcagagaaa ctggtatagc tgtacttcta ccatattcta tcagttacac actgtcatgg 152700  
 agcaggctct tatgcaatgg aagaggacaa aggtggcctc atcttccctc catgctctgt 152760  
 tacaatatat aatctgtctc cctttgcatg ccctgtcttt ccttggattt taggctattt 152820  
 catttccctg caatatcagc tctctgttgg attcaagaat agagatgatt ttgtagtatg 152880  
 ttccactatt ttcccccaa attattaagg tattaagtaat gctctttcat gttccatatt 152940  
 ttaagtggaa gtggaacttt cttgctataa cttttgaatt agcaattcta gactctagac 153000  
 tccaaaggag tctgtatctg caaaagtctc gagggaataa aattgtgaag ttaaaattct 153060  
 aaaaaagaaa aaactcctgt ttaactaaat tatcttcta aaataacaaa aaatgatatt 153120  
 ttataattat aagaactaag gaaattgtct ttatataaat gtctggagaa atagatttct 153180  
 gagaatatat ttcagcaaaa caaggaaaaa ataaccaggg gatatactgg gactgaagta 153240  
 acagtgcctc ttaccccaga gataagtgc atgaggtccc agaatactt taagcaggct 153300  
 tagaagccga atgtataaaa tatatcatgt aaaaataaac gtgacacaga gggcacttag 153360  
 ggtcattctg attcttgacc ttgatctgag ttccaatgac gaaaatagat tggccaaaag 153420  
 atgacatact agccacgcct ttattttcat tacatacact ttttactcca tactgcacag 153480  
 atatatacaa ttattttatc ttccatacca ggcaataagt tacttgccca tcttcttatt 153540  
 aacaataatg tagataaagt atcttatgaa agtagagaaa tgtagtcatg tatttgataa 153600  
 gtgtgtgagt ttgttcatat ggtcttatag gaaataacaa acataattta aattggtaca 153660  
 ggtgtgtcac agaacttta aaaaagtctc acctaatctt aaaaccatgg atttttactt 153720  
 aatgtttctg cattttataa tcattaaaaa caatggaaat tttgttgagc ttaatatgaa 153780  
 ttaaaatttt tatattagga tatcgtaggg tttgccaata gaattctaaa acttaaatat 153840  
 atctaatttg attactatgt aggttatgca ctgtgactca ttagaatata tgatgtgttg 153900  
 ttaaaagtca taatgatcat cagatgaaat atggccatct ttaaagttat ctcatagatc 153960  
 taagtagtga ataaacgaga caagagtaat gtaaaaatgg ttgacattat caatgaaggg 154020  
 tcaatggata actgcgtggc tccggttctg atactcagaa ggaaaccaca tcacttaagt 154080  
 agtaatatga ggaaaatgaa ccacattttt aggaacatc acacaaaactg taaaccaaga 154140  
 acactttact attaaacttt ttttcaaata tgccaatgcc atgaaaaaaa acaaagagct 154200  
 gaggacccat tccagtttaa aggagactca agagacatta cgaccgaatc ctctatgtga 154260  
 tgtaacataa gcatcaaaag acattaaact ggtcaattca taaaactgaa atctggaagg 154320  
 tagatcaaat aaaggttttc tatcaacatt ctgtttcctg aaacggtagc ttgtgtttaa 154380  
 caaagaggat gcccttgtag ttagtactaa ggggtgtagg gtccgtgtgt cagtgcactg 154440  
 cacttggcag tgagtgcgtg ggcgtacgag catgcacacc acacagtgca cacaggggtg 154500  
 atgcaacagt cagtacatcc aggaaaagga tttatggcag ctccgagtga gtgcgtgggt 154560  
 gtacaagcat gcacaccaca cagtgcacac gagggtgacg taacagtcag tacaccagg 154620  
 aaaaggattt aggggagctc tgagtgtgtg gatgtacag cttgcacaca cacagcacac 154680  
 acggagatga tgcaacagtc agtacatccg ggaaaagcac ttatgggagc tctgtgtact 154740  
 attgttgcaa tttttctgta agcttgaaat tgtcctcaa taaaagtga aaaatgttac 154800  
 cccaggaagg atttggcaca cattatttta gatgaatact togaaaactt cctttatttt 154860  
 ttgaaagtta ctggaacagc ctgattacac atttgggatt taaccctct gccttaagta 154920  
 taaacttaga cgtaagtga agaaccagc ttaagttatc ttgagaagca caaaatttga 154980  
 gttactcacac agtttccctt taaatggaaa tgaaatacat ttcaagtcac actaatatat 155040  
 gttgggtttg aactacttgt agcccttctc tagaaaacta aaacaaaaac tctcttttaa 155100  
 tttcatgact ccttcaaata cggaaactat gaagatttat gtcttatgaa gtttatttta 155160  
 cacataagtt attagattct tttaaaatta ttattattat tatttatttt tagagacaaa 155220  
 gtctcactct gtaaccaaga ctggagtgcg gtggcaaaat catatctcac tgcagcttca 155280  
 aattcctggt ctcaagccac cttcttgctc cagctcctg agttgctggg attacaggca 155340  
 tgagctacca tgctgagcat acaaatattt tgggtctgat aaataattat tgataaaatc 155400  
 aacagaagt atcattataa gttaaatatt tacagtgtga tttagagaac atacctgtag 155460  
 aaaggattga aacaataaaa tattatttgc ttggaatttg tatagaattt tgcccttcaa 155520  
 tatagactgt catctaaaca ctcaaataga agacattcaa atttacaana tgggtgctta 155580



ttggccagcc	tagataaattt	ttctttgcttc	ctcagccccc	tttttactta	ctcctgaggg	155640
cttaatatca	cagacaactg	aaattcatct	gcactctact	tactatgtgt	aaccagctgt	155700
gatttttattt	tctgatgcta	ccacatgaaa	aaaaaatttt	tttcctgagc	tatagatgtt	155760
aattgggtgc	tttgtatctt	gctaattaag	ttctagcaac	accttctccc	tcttcctcgt	155820
ttgcacttaa	tgagctcact	tgttgtatta	atttataaga	taattagata	aaacaaaaaa	155880
agttgaattt	cttcaggagt	ggctttggaa	agtgcacctt	aaatattcaa	acatggataa	155940
aaatgtgtac	attacaagac	aaaaaaatca	ctttaagaag	aaatatactt	aatgttagcc	156000
tgtagactca	tactgacatt	ttaaataatg	tgatgatcag	ggcttataca	aaaaggaaga	156060
gattgattca	aaagctcagg	caatcacaa	tattttgggtg	taagcaaaac	aggatcacat	156120
atggtacaac	atgatgctca	taccagaaac	ctttgcaata	tttaagcaca	acaaacaaat	156180
tagttaagca	atgtgcccc	tggaactctaa	ttaccatttt	tatttgcatg	ttcatttttt	156240
tctaaaaattt	ttttaagcca	gtggccaggc	agtattaaat	tctttgctgt	ttatcatgat	156300
accagaattt	atttgacaaa	aagtggaaaa	atcattgacg	tacagtgaaa	ctgatcattg	156360
tttaatatga	gaattctgtc	gttcacagc	agtgaggaa	ttgtggaaat	tgtttttagt	156420
gagaacatcc	agatgttatt	gattccaatt	ttctgggtcca	actcaaaactc	atgtgggcca	156480
ttagctttcc	aaactgtcca	atatcatcag	aaaaggcaat	ggcatctctt	actgctctat	156540
ttttgtcttt	ggttgagtaa	tggaattccac	ttgactggca	tatatattct	ggctgcccct	156600
taggaaatct	aagcatttga	tgtcaaaaaat	acacatcttt	taaaataactt	cttaatatgt	156660
aggtaaaagca	aacattcaaa	attcaaaaata	tcaagctgta	aatgttaata	ctaaacagga	156720
acatatccaa	togacattga	aattgtatat	aatgaacaag	aaacaataaa	ttaaagtga	156780
aagtcataat	aatatgcaat	atttcaggta	ttctttgata	gatgtaatga	cagaagctac	156840
taccttgctt	gccccagtg	tagtaacatt	gagctttcca	gctaggatta	gagcattttt	156900
atatgaatcc	ttaaaaaatg	caataactac	tcctccagga	gaggatgctg	tcctgcttct	156960
ctgagggata	gcactaatat	ttccagggtg	tctgctttac	atcaagactt	tgcttttaga	157020
tggaacacagg	attgtaggga	gactgtgagc	tcaacagtaa	gattagtttg	tctccatttg	157080
atcttttgat	gaaatgcatt	ggggtaaaaac	ctcttcccag	tgctattagt	agctcatgaa	157140
ttagaaaaga	taatttttct	cctacatatt	caagaagaat	cagaaccagg	taattgacat	157200
agccaactaa	acctctatag	ttattgggtt	tgttctgact	caaatgctaa	cttgaatccc	157260
ttatgactgt	taagagcata	aagggggaaga	gaatgcccag	ggaggcaact	ggagagacag	157320
agacagcaga	gctgtgagaa	gactgtttgc	agaaaatatt	cttcccatgt	gtggacttgg	157380
cctttgaagc	agagaattac	aacaggaaat	taggaatagg	ctgggtgtagc	ctcataaaca	157440
agtaaaaaat	tgtgtcagca	caccaaaaata	tttactaga	ctgcccttcc	cctaggaggt	157500
tcacaggtgg	tataataaat	gaaatcagca	atccttctac	atgtctcgct	tatatgggta	157560
ttttggctca	gcccagcatt	agttatttgt	aagctggggc	ataaaatcac	acactagttg	157620
aatattttatg	tacagctcca	gaatccacct	tcactaattt	gtctacttat	ggggaatata	157680
gctgtggggg	gcatggaaaa	tatttactct	gggagccctt	aaatgtaatg	catgaatatg	157740
aatgtgctct	tggaacggga	ggtcctggaa	ctcttggtag	gtgttggtc	cctactgacg	157800
ctttatcatt	ttcttttttc	cttcaactga	atataaaact	gaaaagccgc	ttttaacagt	157860
tagtaagtgg	tgatactgcc	agactcatcc	tataagaagt	tagctaaatt	ttatccagac	157920
ataatatttt	ttattagctt	acttgttagag	tcctcctca	gagcccaact	aaacgtgggtg	157980
ctaaacattc	ttttgocctt	gtagaggaat	aaactctga	gactcctttg	ttttttcacc	158040
aaacagtaaa	attaaccagg	tattgaattc	atactctcat	taaagtcatt	gttaccattc	158100
ttttacaaaa	aaaaataactc	aaggagtaaa	gaaacataaa	aattgacaact	aaaacaatat	158160
cacctacgtt	catctttctc	tggaatgttag	atttggaatg	tatgcataga	aaatgggtctt	158220
agtgtcaaaag	atttaaatgct	gcaagagaaa	tcactctcaa	aagaatatct	cctttaattc	158280
tgtcttctta	tttatcaaat	aatatctagc	gaccgcactt	ttcttttgtt	ccttttgtat	158340
aagaaggaat	tatagcgggt	tgccacatta	gagtaactta	aaagtgcctc	ctaaaatttg	158400
gtagagaatc	ttcttaaaat	tttactccac	cctgcactct	tctggatata	tatcactcct	158460
gagatgggtt	ttccaggctt	agattagttt	tctaaatctc	tcagctttct	tttatctcaa	158520
gtgacacagc	agttaaatta	catcatgagt	ttagcctgga	ctctcttgag	tcocccaaga	158580
aggaaaactg	aaattctgca	aaatgaocct	tatttaaggg	tgaaggaatt	aagagacatc	158640
tcaagcgcgc	ccttatttag	aaggtaaat	aggaatcata	aaataatata	tttgaccgag	158700
tgctcagaaa	tgattaaatc	caacaggcct	gccaacagag	ttgtaccgta	gaattgccaa	158760
gggagttatc	ataaagcaca	gatactgggc	tctgcctttg	accttctggg	tagataaatg	158820
ccagtgattt	tgaaagtaat	tcctgtgat	tctactgaat	ctccacaaat	cttggtgaac	158880
ctctcaattt	taaaaagaag	ttttttttt	ttttcagttt	aagccattta	ttcaaagtca	158940
aacatgcttt	agtgatggag	aagaatctgc	ttttaaatgt	attaaaacaa	attgatagga	159000
atcatgtttc	tattgtttt	cctgtataaa	gttagacaaa	taggatattt	ttgaagttat	159060
aaatcattta	aataccctta	aactgtttac	aatatcggtt	gttatattt	tatcttctgg	159120
ggtaatgtta	tttaaatata	acgaggtact	gagtgcctgc	tgaaactaac	tagaaatctt	159180
aggccttaaa	aatagctatc	tcatattttt	aaaagaaaca	tcaataattt	ttatatattt	159240

ttaaatttat	gagatggaaa	gttagctttt	actaatctta	tcaggctaaa	ctgagtaata	159300
atgaagaaaa	tgaagagttt	agaaatattt	tttggaatat	cagtgaatc	tctaaaaaga	159360
aaaaaaaaac	cctcatctat	atgtgtgagc	gacataaagt	cacactttgt	tgaaatgcaa	159420
aatggccttg	gaaaatttca	tggaatgaaa	ctaaatggca	gcacatcact	tttccagatg	159480
gggtcttctg	gttgtggctc	agatcatggg	ggtgatggca	aactcttcca	aaggaaaaat	159540
agtagcaatc	cagtcacaag	atagtaccaa	acatagactc	acagatgagt	aatatgtcag	159600
tttcttaaaa	gaaagagttg	ttaggaatga	gagtaaggat	gtgcctcgat	tacaataccc	159660
cagatacgat	actattctga	aaatgggtgt	gggtttttgt	gagggatgcc	aaccacacat	159720
tgtgctagaa	atctgcatcg	ggaagaaata	ttttttgcta	catgttacia	atatgcctat	159780
agactgtgat	tcaaataaat	aatgtgttta	ggccaggcgt	ggtggctcac	gcctgtaatc	159840
ccaacatttt	gggaggctaa	gccagggtga	taacctgagg	tcaggagttc	gagaccagct	159900
tggccaacat	gatgaaatgc	catctctact	aaaaatacaa	aattagctgg	gtgtggcgac	159960
gggcacctgc	aatctcagat	actggggaag	cttgaagcag	gagaatcgct	ggaacctggc	160020
aagtggagat	tgcatgtatc	tgagatagca	ccactacact	ccagcctggg	tgacaggatg	160080
agactccatc	tcaaaaaata	ataaataaat	aaaaataatg	tttttataat	tttttcatag	160140
aaaaataaac	ctgaagttag	gcagtgcaga	cttgaatttc	tcatttctca	ttcccattca	160200
ttttcctgtg	tttttgaggg	tttctcctgg	aaagtaaaac	aattcaatgc	tttatcttct	160260
gcccttcaga	agtcgggaca	tcacacacac	attttacctt	taagatattg	gactggattc	160320
atagaggaat	gagccatata	caacatacat	aggagtatga	agaaaggag	acagccttca	160380
aagctaattt	gttaactaat	attgtagttt	aatgtaatga	gaaataaaac	tagaagatga	160440
ttgatagaat	gcagagggca	ctttaaatca	gagagaogat	ttgaaagaaa	gaaatatttt	160500
tatataccct	gatttattag	agatagatta	aaaagttcgt	ttaaaaaacg	tgatcaagaa	160560
cttgcatgta	taagttattc	tttttcaaat	atcatgacga	taatgctgca	taatcaccca	160620
ttcaaaaatt	tcacggcttm	gaacaacaaa	tattactctg	gagctctctg	ttctgtggtt	160680
ggctgagttt	tgactactct	tgacttggct	gagctgggag	gatggatctg	cttcaggctg	160740
caagctggct	gagcttggct	catcacggtt	cattacgagg	cacagactga	agtgtttgga	160800
gaagcccagg	cagtggcatg	ttctttaaag	gcactgagag	gagcttatga	atgaatgaag	160860
cttaactaca	taagcwact	tgatgaagtc	aaaatgcaag	gactgggaag	tacatgccac	160920
caaccatcaa	gccatggtaa	agctgtcgat	gtactacggg	ggagtggagt	gctggtagca	160980
atcattcagt	ctttcacaaa	acactggcaa	aatgcagggt	attcagacag	aatcgtttaa	161040
tacaaaaaac	tacttaaaac	ttaagggtgt	attagctatc	tgtctccaaa	tgtacttttt	161100
gaatttaagt	tataaggact	ttcactgcag	aaagtatgca	ataatgaaga	agataattgc	161160
tttggtcatt	gggaaagtgt	ttttcaggta	gaagtgaatg	cagaaacaac	cattccaagc	161220
aaaaccaatg	acttccaggg	taggctggaa	agagaattct	cttaatagaa	aagaaaagag	161280
acttgggaatt	gagatagaga	cgctaaactg	agctactcct	gttggggctt	tgctgatoct	161340
tcattggaata	cactcattaa	ttatcacaga	agccacctat	gtactctgca	ttcattggga	161400
tttgatgtat	aattggttct	taacttctct	atgttttagca	ttttgcttag	aagttagcac	161460
ttatcttcag	gtattataag	gcttttaaaa	tgacattttc	ccctctagag	gaagtatgcc	161520
tttgtttggt	tatttgtttg	ttttgtcttg	tttcttagag	acagggtctt	gctctgttgc	161580
ccaggctgga	tggaagtggc	ttcatcatag	ctcactgtag	ccttgaaact	ctggactcaa	161640
gccatccttc	tgccctcagtc	ttccaagtag	ctggggctac	atgcttggct	aattttttat	161700
tttattttat	tttttttagac	atggggctctg	gctatgttgc	caaggctgat	ctcaaactcc	161760
tggttcaaaa	ctcctggact	caagtaatcc	ttccacctga	aggtgggagg	ccagcacctt	161820
gacctttcaa	agtgtcgaga	ttacaagcat	gagccgctgg	ttacaagaca	tggccagaag	161880
tatgggggttt	tctatgcttt	cacatataat	acatacttag	gttttctcga	tgatgaaatt	161940
atgtttgggt	tacttttagt	aaacogtatg	tgctttgaat	taataaaaaa	gttgtgattc	162000
atttattttc	aactgctact	ttccttctct	tttggagggtg	ctccgttaaa	agattccctt	162060
tatgttgtgt	cacagagtct	gaattgacac	aaaagcattt	ccaggcatta	ttcttgttcc	162120
cggttggctg	acatagagcc	ccactcactg	atggcactgg	ggaaggacag	agcctgttgg	162180
acaaaccaac	cctaggcatt	agtatcaaat	ggacaaaagg	atcctaagac	gtttagacaa	162240
ctgttgactt	ttatgaaact	gagacaaaaa	tggttaagaaa	tttagataaa	tatttccctt	162300
tgtaaaaatg	acatgaattg	taagtttcct	acactgtaaa	ttagaaaaatt	taaaattatat	162360
aaaactatat	aaaattataa	tttttttctt	aatattggca	tttttatgtg	tactaaggta	162420
tttacctcac	ttttagaatc	tcgaattcta	ttgggagtgt	attattttca	actcataaat	162480
caccttttaa	acatttgatt	cttataactt	ttccttctca	ggaaaaactga	acctatattt	162540
atagaatatg	gatgctccag	cagctgggtc	aaaaaatgat	tccgtagtaa	taatcacatc	162600
aattatatgg	ttaaaaatgtg	aagcctgagt	caccgaaaag	ttaggtcatt	taatttgttc	162660
aatgcagttt	ctaaagtgtt	caagaagtgt	attagattta	aaagagactt	gaaagggaa	162720
ctgatacaat	gtcattacaa	ctgagaattt	tctcaccaga	attcttgaaa	gtactgaagg	162780
atgcaaccct	agtgcatttc	tcattacaca	tgtagatcag	aaaccaagaa	gtctatgagt	162840
aacgtttgga	aagaacaatg	tttaaatatg	aaaaatgatg	tgactcatga	ttgaaaaaga	162900



```

aagtcacgtgta aattggaagt gcaaaaactt tacaggagaa atctatgaga ccaaaaatag 162960
gtagtaaaat aaaaatgaaa gtaaatatgg ttgcctaaaa cacattaaca aatgaaacaa 163020
atagataaaa ccaatgagaa tgggcagcac taagagtaac agagaagttt gaccaggca 163080
atcttgatga attacttggg aaatctggta ataatcaggt aatatgggag cagcatgatt 163140
agttaataat tccactttaa aaaattcaca cagaaaagga cagagtatat atggaagaca 163200
tgacacagctt ctatattaat gtgacactgc tctgagtaat taaacaccgt ttccaggaaa 163260
gatttggtca gttgttccta gaggggtgtg atacatccag gacattcagc ttcatgactt 163320
ctcatttggt ttagttttta tcttttaaat tgggggaaaa tgatgtgtta ttcactgac 163380
ttttcttctg agatgccaat ctaaatctgt tatcttatta aacaataagc agattttgtt 163440
ctgatttagg caattaccat ggtagtaaaa caagaaaatt accctaaca tgggaattagg 163500
ttttgtggac atgatcaggt catctttttg aggtatctgc cttttcctgc attcataata 163560
accactatta ctctgattac ttttatactg tccccataag tagtggagtt ctcaactacg 163620
caatgaaaaa cagaattcag aggaaatgta acctcttgaa ttcttattgt gcaaatttcc 163680
tcttcattca gtgccatgct caccctggaag aataattttg tcaaatattc ttgccaacca 163740
aacagcagtc atattccttc agagaatttt cacactaaaa acaactatta gttttacgct 163800
gacagcacia gtcaatccta atgtctttgg atcatgaatt tatctacaga ttccagaaga 163860
aacaagacaa acatttttgc caatgtcatc catcaatcaa gtggcaaagc agatgtgtgg 163920
atctcaatgc agatagtctc tgtccagctg tctgctctcc atcttgatg ttggttttgt 163980
tgtaggctg gctctctca taaacttgag atggtctgta gcaccttgta aggtatgca 164040
gttcttctct ggcatccact gaaaaaagag tggatatctt ttctttagga aattcatagt 164100
tgggtattca gtgcagctg cattcttaaa caatcactgt tgccaataga aaacaatata 164160
ttaactggct caccataggat cctatacttg tagacagttt cagccaaata caaagatctt 164220
aagaaagggg ggattggtc ctctacctca agaaaaatta aatcaatgtt gatgcaagag 164280
tgggaatgca tgttgagagg caaacagtaa acacaacaaa atgataaatc agatctgctg 164340
gccctcaata ttttcttttc tttgccaatc cagaaaaatct tctatgattc agagctcact 164400
cattaaatgc attgcccttg gataaaaagcc attggtaaaa taaccaacaa gtcactctcc 164460
tttgaacctt tagccatatt catgtctacc tacattatgt atatttcttt gcttccaca 164520
ttccatcaga gtaaaatact tgcgaagagc cagccatggt ctaggacata tggacatgaa 164580
cagatttata ggatgtggtt ttctcatccc aactcttgaa ggatgaatgg ggatcatcca 164640
tgcatgatgag ggagaaagtc ttcaaaagag agtgaagatc aattctaaca agacgataac 164700
taaaacagca tagatgttca gagaactgca agaagcctca ttgcttaacc caaaagnatg 164760
agagagaaga ggcaatgatt ggtagaaatt agatcttcaa ggatcttgta ttagcacaga 164820
aaaagctgaa gatgtatttt atcacgaata gagtaccaac aaaataattt tcatagatga 164880
gcagcatttt taccttattt atatgagaat tcttctggc cagagtgtgg catatcactt 164940
gggaacagga agaataattt attgccttta gtgaggcaat gctgaggcta ttatattatt 165000
gcctttagtg aggaatgct gaggtatta ccaaagttca ggctagaaat gaaacccaaa 165060
tgaagaaggc agaagtaggt ttcttgaggt gaaaacagag tcaggctctc cttaatacat 165120
aggctcttac gactgggaga taattaaatt tagtggatgg ggaaatgaga agtgggggag 165180
catgacctgg ttttctgact tagtgtcata gtgtgtggaa atgcattaag agaaacagaa 165240
atcgtaacct aagaaaaatg cttgtagagg aaaagagtc ttttaaatat gataaatttg 165300
atgtgtacga gacatttcg tgggcaggtc taacaggtaa cttacaatac atgtgtgagc 165360
agcctgttag aagaatctag gcattcagtg tctgctccag ggtcatcagt atgcacgtgg 165420
cagtcaaaac aataagagtg gctgagatca tccagggaga gtgttttgaa tgagaagtaa 165480
gcaaatagaa gacatttga tgcgtcccaa tatttaatga atgaattaaa gatacagagc 165540
ctgtcaagga gctgaagaat gaaaggtcag agaaatagga gcatatttga ggagaagaga 165600
gtgatcagcg gtaaaattga atgaacagac accaagaaag ccaagccag ccatgtagaa 165660
gagcttcaaa ttagaaattt ttaagaggc attcttaaat gaagactgtc ctttattttg 165720
ttttgaaaga tgatttattg attctttaat cactcaatat tgcaactggg atttcttcag 165780
aggctctcaa gtctctctca ttttcacaga tcaaaattct cagggtgcaga gtatgtcagg 165840
acctattcaa gggtacacat ttggctgaca actgtgtcaa gactaaaatt tcatgatcgt 165900
tatttcagtt catctgaaat aaatatcctc caaacataaa ccataaactt tatgttttaa 165960
gagcacatc accctcttac atgaagtct ccagctttgt aactcctcca ttcttatcag 166020
gtatcacttc ttcagacatc cctctcttca gtcattcttc tctttttctc tcagcctgta 166080
tatcataaat acctatcatt tctctcttgt tgtataattg actccatcat cttttgttct 166140
tcattttctac ctggccctaa aaactacaca tcagatcaat cctatgttct ctctttttag 166200
gctccatctc tgtattgaac acaatgctgt aattattgtga attggtctaa tttgaattct 166260
tgccatctaa atccttctcg agccacagt gctgtagaga aaatatgttt ctattctggg 166320
tcagcatttg acgtgtttt tctgtagggt tatacattcc ctgattatta aaagtttatt 166380
tccaagctct cctttctgt gtattcagaa tatacctcac atgtgtcttc acagagacag 166440
tcaatactat cagctagtag ggcatacaac tgtggccctg tcatgcctaa atcatatcaa 166500
tttacatcct cccttctct tccactttat tccccctttc tttgtacaat gtcaatctgt 166560

```

ttcaaccttg	gctactgctt	cagacatctt	gcattgtcag	tcattatcct	tctcttgtgg	166620
atctccaaca	tcttacctct	gccaaatctt	ttcccttcat	cagtaacct	aatcagactg	166680
tattttttaga	tgatgtaaat	ttctataaatt	ttatgttagc	tctggcttat	ccctctttct	166740
tcctactcct	cctcttatag	tcgtgtatct	aggtcacaag	tacactctta	aacaataact	166800
gttgccagca	gaaaacaata	tattaacagg	caattatcaa	gtatgaactc	cgaatttcca	166860
acagaatatc	cttgatactc	tgtgtatgtg	tgcttgtgtg	tgctgtgcgtc	tctctctgtg	166920
tgtgtgtgtg	tgtgtgtgtg	tgtgtgaaga	caagtttatg	acaagaagga	gagactcaca	166980
gaaggtcatc	aaaagttaga	aatttaaattg	agaatacgcg	tgaaagtaat	tttctagcct	167040
gcacctgcc	aagtgttttc	tcatagttca	tgtgaagaaa	taccaatagg	ttgttgtcgt	167100
tagtccacta	cacagtgttc	acctttaatg	taggtggcat	gggcctaac	aaggatggaa	167160
actgatatta	acagagtgtt	atacagcagg	tgctgtacta	agggctttat	gaggaggggt	167220
taagttagtc	atataataat	atacttaaag	ctttaatttc	atgggtggat	agttcactct	167280
catgccatca	taattgttgt	acaatcctga	attaaagaac	ttttcaagat	gttattaatg	167340
aaaaatcttt	aaagatagat	ttctatctga	ccctcccagt	caaaaggctt	ctactcaaat	167400
ttggctaaac	cctattagtg	atgtgggttt	ctgactgctg	ccgtaacatt	tatttggaga	167460
taagatgtgc	tatatattac	agatggactt	tgggaagtga	ctgagggtga	cagaaattaa	167520
ttaaccacaa	gcctccaaat	gaaattttta	tgctgggtgag	taagaaatac	aaatttctga	167580
aacacagcgg	tatgaaataa	tgcagtatca	atggtttaagg	aagcttccta	ggttttgaag	167640
ttctatatta	aaagatagat	atgtaacaaa	cctgcaagtt	gtgcacatgt	accctaaaac	167700
ttaaagtata	acaataataa	aactaaaaaa	aaaaacaaaa	aaactttgat	aagagagtac	167760
atcttattaa	tgatttcaca	atgatgccta	atataattta	gtgtcttggg	aatttaggta	167820
atgaataaat	atgggatttc	ttttcaaaaa	atataagtaa	tttttaatga	aaataatatg	167880
cagaaataaa	tacggggtaa	agtttaataa	ttaacaaata	ttccagaagg	ccagtagtct	167940
gogttgggtca	gaatgaaact	ttcacagagg	ggagagttaa	agtgaagcag	ataaagtta	168000
gaaataaattg	atatcagtg	ctctaaagta	agaccgagga	atttgaattt	tgtaggcagt	168060
gaggagcctc	tgaaatcctg	agaatggatt	caacataagc	aaaatcgat	tttggagca	168120
gccagctggc	atgcatgggt	ggttggcgag	aagtctccag	tgagcaggtc	attgcagggtg	168180
tttgtctcat	gtactagttt	aatgtgcggg	caggggggtt	gctgtgaggg	aatttaagaa	168240
gctgaatca	cgagttctta	gcaactacat	gaggggatta	agacatgtaa	aagaaagtca	168300
actgtgactc	acgatttcc	ctgaataagt	tatatcttat	tccaacgcta	ttttgaatat	168360
ttccagggtg	tatatctga	atatattctt	gatataattca	agattcaacc	tgagtaagtt	168420
acatagacct	gatgacattc	agtattcgag	gtcagataac	aatgtaactg	aattctcctg	168480
taaagagcaa	aaatatgttt	taattatttt	acaagtactc	aacatattaa	ggaacttctc	168540
tagagtttcc	tggaaactca	agtcacgggt	gttgttgatt	ttattaatta	ggaagtttca	168600
atgaaccaat	atagaactac	actgctttat	atgtataata	ggtcctattt	ttgaaatggc	168660
tgatacagct	ttttaagtgg	tttttaaat	gagacaactt	gacatctagc	ttttaatat	168720
taaaggaatg	aactaggata	gctattcagg	tcatttgaat	attttgtgca	aattctcaca	168780
ctcattatgt	catgtctaca	ttcttgcgtg	ttcatataac	tcaaccctcc	ttttgaatat	168840
catgatttta	gcactcataa	aatattacta	agaagcctt	gaggctctaa	gtaacgcaat	168900
aattagccct	cctctaatag	cccaatagaa	tacataaata	attttctccc	actatttctc	168960
ccccagatat	tgaracctca	atccgagttt	taaaaactga	cctatactag	gtactagaga	169020
tctctattgg	agatgcta	agattgtaaa	ctgcatctag	aaaacattaa	accagtattc	169080
taaatgggtt	gagagtotta	cttttattct	gggtcagcca	acttttagatt	cttttgtgaa	169140
tgcatctttc	gtctgcactt	ctgctctcca	aataatcccc	tgtaacagtt	atttttttta	169200
atctttcaca	cttttattct	acatctaaaa	ccttgacagg	atttgtta	ttatcttaaa	169260
aattctcatt	tgtaatattt	atcaaaataa	attagtctcg	agtaactata	tcttgatgtt	169320
ttttaataca	ggtttcta	atgagactga	aatctaaaat	attatcatca	tccaaaataa	169380
tctgaaaaac	tgaaatacaa	tataacgca	catataatat	agttacagt	aataaaatct	169440
agtatttgat	tgcgtaacag	gtgacaacag	tcgacagtaa	tatatgtac	attttaatag	169500
aactgaaaga	gtataattgg	attgtttgta	atacaaagca	aaaataaatg	tttgtgatgt	169560
ttgtgatgat	ggatatatgc	ccccatacaa	agtgcgtg	ctcatgcgtg	ttatcccagc	169620
attttcacag	gcagaggacg	gtggatcact	tgaggtcagg	agctcgagac	cagtttggcc	169680
aacatggtga	aaccggtctg	tactaaaaat	acaaaaatta	gcagggcatg	gtggcaggca	169740
cctgtaatcc	cagctgttctg	ggaggctgag	gcaggagaat	cacttgaaac	caggaggtgg	169800
agattgcagt	aggtggatat	tgagccactg	cactccagcc	tgggogacag	agcgggactc	169860
caccttaaaa	atatatgtat	acaaatatat	atacatatat	attatacaca	catataaatg	169920
tatgtatgta	tttatacata	taaatacata	tatttacaca	cacagagggt	cattatgtaa	169980
caacatgtct	tcaaaactga	taatttttagc	catcttgtca	tataaagcct	ctaaccac	170040
agatttaaaa	tttcttctg	ggaagtaaat	attaattaa	gaaatcccaa	cttcttttac	170100
aaatcaaaac	ccatgttctc	cataaattaa	catcataaaa	cattttttgt	tcatgtcaag	170160
cggtcagggtg	tctttgggga	gtttagaatt	acctgatacc	tctgttcttt	tatatcaact	170220

ccataaggaa atcccactgc attacttgggt atgtgtttct gtaggcctct ttagtgtaaa 170280  
 atttaaaaga aggggggaagt ttaagtaata tcaggattaa tgaaataatt ttcaagtaaa 170340  
 atatatttcc atgggtttac acaaagtatc ttcactgtgc agtgactctt aacagcagat 170400  
 gcgtatttct cactcccatg aaaagtttct cactgggtcca ctgactgtga tctttgtgtc 170460  
 tttaccctt ttggatccag gtggaaggag tcccctcttt gtgacactga agtttcccta 170520  
 gaaaaagta ggagtcatat gatggttctt aaagtaatag acatcctttc tgctcacatt 170580  
 tccttggtcca atgcagggtca catggtcaag cctgatgtca tcagggtggg aggtgtgatc 170640  
 ttctataggt acaggggagc aaatactttc aatctgtcat aaaacctgaa tgaaatagta 170700  
 agatatctgt taaacttatg tttcttaaac acacatgact gtctacacag gggtcccttg 170760  
 tgcattattt gtaatgttaa tacataaaac atgaaggaga gtgtgtctcr ttctcatgat 170820  
 caaattttac ctgttatctt ttctctatta tcaaaatgct ggtagtcttc taatgatctt 170880  
 tatttgttta tttatttttt agttattgaa taatgataat ggtgtctatt tcagatctac 170940  
 aactttctga gttttaaagt catggaggaa aaactataat gaaataaaat ataattttat 171000  
 ctaaaaaata ataaatttgg tgttaaatcc aagcatattg ttattaacag gtaatacttt 171060  
 tattgatttg ggtgttttag gatttttagg agcatagaaa tatatcatac ctgtgtttac 171120  
 tttattaaag aatcttttgt tagaacttcc cagacagcat ttttgagat ggtaacctga 171180  
 gatcatggtg tcatggtgtc cttactaatc acttttaata ggatatttaa accccctttc 171240  
 cagaaagaaa acaaggagct tccaacttcc catgtacccc atcacaaatc atccttcttc 171300  
 tggactgtag taacacatct acccgtcca acacatctac cccatcctct gaggtcattg 171360  
 tgttaataat gtaaccactt ctctcatttt tctgcagttt ttctccattc ctgtaagtgt 171420  
 ggtgtattag tcccttctca tactgttata aattaatacc tgaaactggg taattcataa 171480  
 agaaaggag ttaattggc ttacgtttct gcaggctgta caggaagcat ggttggggcg 171540  
 gcctcaggaa acttatgatc atggcagaag gtgaagggaa agcagacatg tcttacatag 171600  
 tgggagcacg aagggtgogt gaggtgccac acacatttaa acaaccaggt ctctgagaa 171660  
 ctctatcaca agacaacact aaggagatgg tgcataccat tagaaaccac ccccatgatc 171720  
 caatcacttc ccaccaggcc tcatctccaa cactggggat tacaattcaa cgtgagatct 171780  
 gtccctacac acagccaaac catatcatat gtcaatgttg ttctctccct gaaaacaaga 171840  
 acaaggctgg gcatggtggc tcacgcctgt aatcccagca ctttgggagg ccaaggcagg 171900  
 tggatcagga ggtcaggagt tcaagatcag cctgatcaac atggtgaaac cccgtctcta 171960  
 ctaaaaaata aaaattagcc aggcattggt gcacgtacct gtaatccag ctactcagga 172020  
 ggctgaggga agagaatcac ttgaacctgg gaggcggaga ttgcagtga ctgagatcac 172080  
 actactgcat tccagcctag gtggcagagt gagactctgt ctttaaaaaa aaaaaaaa 172140  
 aaaaaaannn gagcaaaacc ttcccctgat gctctatate catacatgtt tttggctctg 172200  
 tggaccatat ggactctatc acaattactc aactatgtga ttgcaatgaa aacagctatg 172260  
 acaatataaa aatgagtggg cataactttt ttcaataaaa ctttattcac agaaacaggt 172320  
 ggcccaatgg tggcggtag attgctgact cctctgctat agtctttctg ttaacctacc 172380  
 ccttactggt tcttcaaaac atctgcttaa aaaaagtttc tatttctcat ggtttccaga 172440  
 ttcttacctc tgtttcatgc ttgaaaactc tgcaatttga cctttatacc caaagttttc 172500  
 tgacagcttg gggcaagagt ggctttctga ctgagtctga agcattatct gtgaattatc 172560  
 ttgggagtac atttccgttt ggctctcttc acttttagact tcttaccoca tggatactct 172620  
 cctctgttcg gtgaaactat ccacccttg gtctcttcca gtatgtgagg tttcttctca 172680  
 gcatcttcac ggttaagaat gcatttaact ttaggagatt caaaaaacgca acaataacca 172740  
 aaataaacia gaattttttt cagatttcaa acctaacatc tggagttaag gagttcaagg 172800  
 ttggtgcagc cctttggcaa tgtggccaga ggtotaagca ttttctatt tctgctcgt 172860  
 cttccatata attttggctt ttgttctcat gtttgttgc ttatgggaac ctgaggtttg 172920  
 aaatgccatg gacaatgctt gtgtgtctaa gacaaaaaaa aaaggacaaa attagtttgt 172980  
 tttttaaatt ctttattcaa tgaatcagaa aggaaaagtg tccctaagac cctggcagcc 173040  
 atgtctcctt aggtatcctt ggctgaatt agccagacc tgaactttgt cagttcagtg 173100  
 catgagagaa gctgggaagg ttcatatttc tagccagggg cactgcctgc ttctccaaat 173160  
 tcggttttca ttaggaagaa agatgagtta aatggatatt ggctaaacaa ttgacatgtc 173220  
 tcccagagtg acctgtgcag gatatttctc ctcccataac tcggtgttag tgttctagga 173280  
 atttatcttt cgactctttt ttctgtttaa ctgcatagca ttctgtgca gtctcattca 173340  
 ctatcttagc atgacacrt aaggctgat gctcaaat tttctaactca gattttagta 173400  
 tccatatacc atctcctaag gggtttcacc ttctggtttc cccacgtgta tttcaataa 173460  
 aagatagctt gaaagtaatg ctgtttcttt aacggctat ttctcataca tctctacctt 173520  
 gattgtaact ataaaaatga taatcaagaa actgaaactc aacttctcct ctcaactcctt 173580  
 caactgctat actcaatcaa ctgccaagtg ccatttacia agtttcttaa catctcttga 173640  
 ggctattaac ctattttcat accactgtc attctcatga ctagtttctt gggtaaaacc 173700  
 tgtattattt ctcaactctgt ctattgaaga ttacattctc acctgggtat tctgcttccc 173760  
 attaatactg ctatcagaac actctctctg aaatagaaac catttttcta ggttaaagcc 173820  
 cttcaacggc ttgtcataat taacagcagg taactcatac agtccctaaa caatcttatt 173880

tatcccaggg	tattgctgag	gactttcttaa	tctttcactc	agttcagact	cactottaca	173940
gctttatttg	gtttacaaag	gatattttacc	tgatatcttac	caggtatctc	aagctgcaag	174000
actgaaatca	ttaccttcaa	ataacctcca	tatctatact	ttgtcccttg	tgttcccttg	174060
tttagaagat	gttttgtaa	caactccatt	cctcctagaa	gttttgtagt	aatcatccct	174120
gattttcttt	ctcctctgct	tcactactaa	ccagcctcct	tttttctgat	cagccacaac	174180
atcctattgc	ttcaattctc	ttaatgcctc	tcaaataatac	tcactccgct	ctagtgtggt	174240
gattacagcc	ttactttcagg	ctactgtaat	tacttgcccta	aaatatgacc	agattctttt	174300
aatcttttcc	atctgttcgt	taaaagaatt	tattctagag	gttttatttt	ctacaatgga	174360
gctacgatta	tattattcac	ttcttcaa	aattcaatat	cttaccatta	ccctctaaat	174420
gaagtccaaa	cttcttacc	tagtttagaa	agcttttcca	gagctggaca	catctatcat	174480
agataatgct	gcaggcaggt	tgtatctgtg	aacctgtcat	cacctccctc	tttgtactta	174540
ccacactgag	gatgctgggc	actgcatggc	ttcccttatt	accatcatca	tggtccctac	174600
tgtaatgtga	attggaagat	tacatgtcct	aatcctccac	cctttcatca	catcatgggc	174660
cttctgatct	caacctgat	gttcttcccta	tgctgtggctc	tgtgtttggc	aaatggtaag	174720
ggccagtctg	tgcccttcca	tgcatggatg	actgattggg	atgtcacctt	tgctccctac	174780
tctcatccca	tcactcccca	tcgctgcaact	tgactcacta	gcgttttctc	ttccctaaac	174840
agcagattca	gtttgggtct	tgaggccttt	gcactttgtc	ttctctctgt	gtgcaagcct	174900
ctgcttttgt	tacactgctt	gaaggattgt	cacctttcaa	aacaggagac	ttccgcatgt	174960
ctgagaaaaga	gcttttaagg	ccgttgcatg	ttttggctgt	ctcccttttc	ccttttgccct	175020
gagaacgacg	tttcaaatag	aagctgtctct	ttcaatctgg	tgaaacggca	tgaggagaaa	175080
aacctatatt	aacctagagg	tgaaatgcaa	tgctcagtga	aaaaaagcta	ccgtgagcca	175140
ctgagatttg	gggactattc	cacagcacac	tccaacctag	ggaaatctga	caaaaacaga	175200
ccatcatatt	tgaagatttg	aattcaactt	ctctctggct	tcttagcctt	ctatcaatgt	175260
atgtcatcag	agaatgctac	cttcttccca	cagtaagaaa	agaagaagaa	atatccctacc	175320
ttctcctcag	atgtaaatta	tgagcttggg	tttcccttct	gtataagttc	tatcagcttc	175380
aatgcatgca	taggtctctt	caaaaaataa	aataaataaa	atagctaaag	atccttcccta	175440
aatgctactt	atcactccat	ttaccatgtc	cctagtgtga	aacaactgtt	tataatcagt	175500
ttaaaaaat	agttttgttc	tctccattcc	cattttgtga	gctccctcca	gcttctcaac	175560
ctttttcatt	ttgtatttca	tccctggcaat	gcactgtaaac	accctttaat	gttattagtc	175620
gtatgtgtgt	ccctaaaggc	aacagatacc	ctttccgttc	ccaattttatc	agaagactca	175680
tggaatttca	actttctgga	ccattccaga	ttttataaaa	tgtagccatc	atttgacttc	175740
agtaactaca	attgcatcat	tttgcctctg	ttgctttgcc	tctgcttcag	attgatctct	175800
accctaaaat	gttgctcctt	cacaaattaa	catataactg	aatatgcaac	attttcactt	175860
ggtgatctca	agatacatct	caaaacttaac	atccccaaaa	caaaatatca	taatttttgc	175920
ctttacaaat	aaaaatctgt	cactacaagt	tacgttttcag	ttttagaaaa	tcataagaaa	175980
ttgaatttta	gaatatgcat	tctcttgtgt	cgggctttga	aagacacaat	gttttgtgtt	176040
ttagtgtaat	atttttaaga	tttgtccaca	ttgcatcaga	tttgcccttt	tttattgctg	176100
agtcataaatt	tgtatacaga	tataccaact	gaatccagtt	atataaaatt	catctacaat	176160
tattttgtgg	acttatgtat	ttatttttct	tagggaaatg	tttaacagtg	gggttttctg	176220
gtcatgtggt	atgcataaat	tgaaatacga	aatgcagaac	tttctctaag	cgactattgt	176280
taggtgtctga	gatttttaacc	tacttataag	ctaactgttt	agttttattaa	tgcccttatgg	176340
atgcaagcag	aagacacaaa	acttctgggt	cagagaaaca	ggactttatt	atccacagta	176400
gagcaatcag	catgagcatc	atgtttgact	tggttttttg	tatcgtccac	gtcccacagg	176460
gatgacacag	agggcccaga	tggttggtctg	aagattacag	gagagggaaga	gtgatcttgg	176520
ggaactcttc	attttaagat	aactggtgag	caaacctaaa	ctttgtcttg	gataaaaaa	176580
tttctctgct	cctcaaagtg	gctcattgca	atcataaccc	tgagaaatgg	cccaggttaa	176640
aaaataataa	aaagtaggag	agtttgatac	tagatacttt	tctagatatt	ttgaagtatc	176700
cagaaaacgt	gtggtattag	gagagaccca	tgaggagcga	tttcacaaca	gctgagtaat	176760
tttacattcc	cattagcaac	ataggaaaat	tatttaattt	cagtaattct	agtaggtgta	176820
tattaacttg	aatttccttg	aagaataatg	gtactgaaca	tcttttcttt	tcttgcttat	176880
tgagcattca	tatgtccttt	tttgcaatgt	gtatgttcag	aattgtttct	ttttaaattg	176940
ggttacatct	tcttattttt	cagtttttaag	ggttctttac	atattattaa	tacactttct	177000
ttgtcagata	tgtgcaactgc	aaatattttt	ctctcagttc	gtggcttaca	ttttcatggt	177060
cttagagaaa	ccttttggaag	aacaaaattt	tatcttggtg	aaatgtaatc	ttttattttt	177120
tagcacttag	tgcttttgta	ttctaagaaa	tgtttcccca	ccccacaagt	ctgaaatttt	177180
tatcttatcc	ttctttttac	aagtttataa	tgtgattttt	gcttttttgt	ctatatattag	177240
ttttgagttc	tttttggtga	tggtgtgagg	tggtgtgatt	taccttttcc	aggtgggaac	177300
aacttggtct	accaacattt	attttaaaga	ttgtcctatt	cctgtttctt	tctgattgaa	177360
ttatgtttgt	cctttctccc	actgaattct	gatattttct	aaaaatcaaa	taataatatt	177420
tgtgcatttc	cagttttggg	ctctcaataa	tgttctttct	ttatgccaat	atcacactgt	177480
cttgagtgtc	gaatatttaa	attaagtact	ctagccagag	gtatttgatg	ggttccaatc	177540

cattacattt	attattatta	ttataactat	aataataatt	attaatgggt	gtttacagaa	177600
ggtaggctag	tcctgtagca	accattttgc	cataactaat	agtgtgatat	tctgtttact	177660
tacaatttga	tatttttctt	ccttttagtaa	attggagatt	gccagaaatt	ccttactatt	177720
tctcccatg	aaatagggaa	gcaaattcac	ctcaccttga	atgtgggctc	attttattga	177780
cttcttgtcc	aacagaaggt	gggacaaaaa	aaaaaacatt	atgttattgg	acttccaaga	177840
ctaggtcata	tgaatccttg	aagcttcttt	ccagctctct	tggaaacactt	tctcagttag	177900
acccgagatg	ctatgtaagt	ctaacaacca	cctcactgct	gtactgggga	agacacatgg	177960
aggtgttctg	atggacagtt	cctgcctagt	ccagaattcc	agatttcctg	ccaagatgct	178020
aagaaagtga	gaatagccct	cttggatctt	ccagaccagt	tcactctgcc	ttagtgttag	178080
tgtgaattct	agaaatacca	tgttgaaagg	aaagctccat	gggtaaatac	gcttctgcta	178140
ataagtggga	taccagaacg	gctgttagca	gctgtcaggt	ggaagtgggt	ctcgtgtcag	178200
attccagtgg	aagttttcag	tgtctctttt	ccttataggc	ttaggatgtt	tctctactgc	178260
tcccagcaga	ggtgctcagc	atactccaaa	gaactctgac	tttgatatcg	tgccaatcag	178320
ggttcgaatt	cacaaatttc	catttataat	ctgtataaca	ttaaatcctg	ttccaatgtt	178380
tctgtcattc	agctttgtca	tctctccata	cagaaaaata	cccacccaat	gtcatcccac	178440
ctctgctgcc	taaacactgt	attaatgtta	agtggcttcc	ccatgctatg	cactgtctat	178500
aaaatagggg	tagtatcacc	ttcctctgga	tgcattgtga	aaagtcaatg	tgaccatcca	178560
cgtaaaaaat	ttgatgttag	gcacagagga	tttgcttaat	aaatgttagg	tattattcac	178620
atgaggactt	gatgaaaaaa	aggtaaaagc	atgtatttat	cacataaaa	ggtcaataaa	178680
atgccagttt	ccttcattct	ttccttttta	gggcactttg	aaaatatgga	aaactagcta	178740
caacacagcc	tcaagaagct	catgattcac	tggttactta	tacaagtgat	cctaattatg	178800
gcttgagttg	tagttgtttt	acaaaatgta	aaaattattg	agataataat	tagttattta	178860
caaaacaatt	ttgctcgtag	agattttaaa	ttctgtcatt	aaaaagacc	acaagcctct	178920
caattgcaaa	gaagttagca	tcaccttttt	ttttttacca	aattcgaaaa	aagcaataat	178980
ctaactacag	aataaaccat	gggcggtaca	gtacaaaaaa	tgttcttatg	tttttaaaag	179040
ttgtgcagtc	cattgatcag	gcaggcagtg	gtggggagaa	caaagccaaa	cactgaatac	179100
acgttttgc	acaaagaacc	tagtctaate	agttccattt	agaaatgcac	tttcatttga	179160
ctatatattg	aaatcatcat	ttttttttct	ctaaaaataa	tatggagtg	ggaaatgctt	179220
tcctatgcag	aaaggttttt	ttattttatt	tgctgagttt	caggaaatga	agcttagttg	179280
ctaccttgca	tagaaaacac	aaactataga	atgcacaaat	ttagcacaga	gtctgccacg	179340
tatggcaatt	ttgataccgc	tacctacaat	tcacatttac	tgcatccatc	caattacacc	179400
catggtatca	atgcacagca	cttagagcag	gctggcagtt	cacaagagtg	caacggatgt	179460
cacgcagtc	gcatacagt	caatctgctt	cctgatatgc	tttaagaaa	cctgttccct	179520
agactcacct	gaaatgcaaa	gagagaggtg	gaggacgatg	gcccattgtt	cctcttgtgt	179580
acctacactg	cagttcttgt	tgatgaccat	ctaattgcaa	ctgtcccaca	aatctttcaa	179640
agagagttaa	ggtgaagcca	gtccctatgt	taacaaacct	caaccttatt	tcagcagatg	179700
gtaaaacttg	attttgttta	agaaccaaag	cttcaacagc	ttcaggaaaa	catgtgtttg	179760
taattcatct	ccattttaat	gccacccttg	catggacgag	ctacatctcc	tgctccaggt	179820
gaatgggttc	ttacgttctg	gacactgtgt	cttcaatttca	gttattgata	cctagagttg	179880
gtgagtttca	agccaatctc	taagtcaaga	gtttatttgg	gagttgggtt	tccttttgaa	179940
atatactccc	tggagcctca	ggctgttgcc	tgttcacctg	tttcttttcc	agaccaaate	180000
atggaaagga	ccagggttat	tctgatccat	tgtgggtgtg	taaatatcaa	gaaggataag	180060
gtacctttcc	tggacttgag	aacttatagc	ctaataagag	aagacaggaa	taaaaaaaga	180120
aaagttttag	ttgctatgag	actggcatat	aaaagtacag	ggacaggaca	aagaaaaaaa	180180
tggaaaatta	tcagaaatgg	gtataaagat	ggcttcatag	aggaggtaaa	ctctgtctga	180240
gaaattagaa	aatgccccaga	aagacatcaa	agagaaggat	aggctgaaag	gtggaaggca	180300
taaatgctgt	taaaaaaagg	aaagagtcac	gaaatagaca	atgaatttct	agaaactaga	180360
aaactggaca	caatgggaca	gggcattgga	tacaattaag	tgacctctga	tttaatgttc	180420
aagctagtat	caaaggagat	gctgtgaatt	ctaactttga	aatagcacac	ataaaccaga	180480
gctgccccag	gcaaatttgt	acatatggtc	tccttaggca	taaagttaat	ggtatagtca	180540
gaaggttaat	aacgtaggaa	atgaattgaa	atggctgctc	tgacacacgc	tacaaagttg	180600
gaacctgatg	caatgtggta	ggcagaattt	tgttccactat	gactttccac	cccgggtgcca	180660
gctttgtgat	tatgttatat	gcatggcaga	agggaactgc	agttgttaatt	aatgttgcta	180720
ttcacctgac	tttaacagag	ggaggtgatc	ctgggtggtc	caggtggggc	cagtgtaatc	180780
acacgagtc	gtactagcag	aagcagaagg	cagacagatn	agggaaagag	gcaggacaga	180840
gatatttgaa	gcctgacaag	gacttgacat	ggtatttaata	gttttgaa	tggcggggaa	180900
cataaggaag	gggttacagg	tggcctctaa	aagctgatga	tgacctctgg	ccaacagctg	180960
ttgacctgga	gaagaatgtg	tgttaaacaa	gtgtggatgg	tgatgataat	aatgaagatg	181020
attttgtcta	tatgctgaga	agacatcatg	ttaggagtga	ttacagataa	tgacgcaaaa	181080
aaggagcaaa	gtgttgaggt	agaggtgaga	gaaggggtga	gctcaagagg	caggcaggaa	181140
tccttagtca	ggcacagtgg	ctatacatc	cttttcattt	ctccttgga	ttgcagatgc	181200

gaaacagatt	cctttttctca	gatgcccatt	cattaggggt	ggccatgtga	ctgaattcca	181260
gccataaaga	tcacatgtgg	cattttaagg	cagaagcttt	tcccttctcc	cagcagaatg	181320
gaaaagctga	agcaatagga	ggagatgcac	catacaatcg	aaggaagcag	agaccctcaa	181380
tatggaacaa	cgagaaacat	ccctgcagta	atagttgaac	aaaaacacac	tccattgtg	181440
ttgtgccctt	tcttgacatt	ttagactgtt	cattttcaca	gctggaccac	tgcaaccatc	181500
acacatgtga	gaagaagggtg	ggtctagaag	gaagaaagt	agggaaagcta	caaatattca	181560
tgtttgttag	tggggaccat	gaaggcgaga	tagatttcaa	tttcctcggc	cgggcatggt	181620
ggctcatgcc	tgtaattcca	gcactttggg	aggccaaggc	gggcaaatca	cctgaggcca	181680
ggagttcaag	accagcctgg	tctaacatgg	tgaaccccca	tctcaactaa	aaatacaaaa	181740
attagccaag	tgtggtgatg	ggcgctgtga	accccagcta	cttgggaggc	tgaagcagga	181800
gaatctcttg	aacctgggaa	gcggaggttg	cattgagcca	agatcatgtc	actacactcc	181860
aggctgggtg	acagagagag	actccatctc	aagaaaaaaa	aaaaaaagat	ttctattttc	181920
tccataaggt	agtggaaatg	ggatctgctg	acctcctgag	tgtgtaggag	tggagggtga	181980
gaatgggata	cccaaaagca	gaggagctca	tggaggacaa	gaactgtgag	gactggaaga	182040
gaaagcatgc	taggggtagg	attgcagaat	agagctcaaa	cttccaggtc	aatgatgagg	182100
gttcagcagg	acttgacac	tgggcatttg	cagtgactcc	atgtctcaat	attgtctgta	182160
tagtgaacag	atgctttgaa	tgtgggagac	tagaataaat	gcatttttat	aaagattttt	182220
gattaaggca	ttagtaaata	gcttcagtag	aactgtttac	ttctttctac	tgcaaagata	182280
tcccaagggt	tttagcctt	catcctcagt	tgctttctta	atagttacca	tgaatatacg	182340
taaggccatc	cataatttca	cacctatact	tatcatctca	aggcaagcct	tgtagacag	182400
gcataagctc	ataataaatt	acctgatcca	gataaggctt	ttttttttgt	ttccccaatt	182460
acactcatca	accacaaatt	aagattaatt	acatagatta	cttgggtctgt	aaacatttaa	182520
ctaccatcaa	tggtatgaat	gaccatgtta	aaggaatttc	ctaagtgcaa	tagcagagta	182580
ctaccattcc	ttgagtatgg	atagtcaata	ttttgtaaag	ctataaatac	gggaatctgt	182640
aaagaatata	ttctgtatgt	ggagtcata	ccaaatctgt	tcaaaatgcc	tatgttaaat	182700
gtaattagta	tattctgatt	tataatctac	catataaact	cattaaaaga	aaccacacaag	182760
cagctcgcca	ttaaaaaaa	aaaactgtta	aattgatgga	aatctggtac	ttatttttta	182820
ggcattatgc	agtgtgcttc	attattatac	acagattctt	ctcactatag	tatcgtttct	182880
gttaaaagct	gtgtgtgtca	ctcatacagg	atacttacag	agcgttttta	aagcagtaca	182940
taaatcacatg	aaattatttc	aaatgtgagt	taaattgcaa	gtcacaaatt	agttaagttag	183000
attagtgaat	agaaataagt	gatttatttt	aatagccaaa	aaacaagctt	aaagcagggtg	183060
aaaggcatag	agcagacaaa	ggctaaattt	tatggagcat	ttgcacattt	gcaagatttc	183120
attaaatttt	ctcaacacaa	ttttcctctt	ctagtaatat	gggagactag	atattctaac	183180
tggtctttct	actaattaaa	aacacctaaa	aagtcttggg	aaatttgttt	tataaatgaa	183240
tcaatgcacc	agaaagaaag	taagaattct	catttgaaaa	ctaaatagag	aaataaacct	183300
tgagaagaaa	gaagaattct	gaaacagggt	tgaatttgag	gatatacccc	aaaaatcttg	183360
acttgcaaat	ttgtttgcac	agcctctcag	agtgccaggaa	acaggaggac	atccagggtcc	183420
ctaaaaagat	gtgagttgat	cataagtact	cttgatgagc	tggaatgatg	agaaggctac	183480
actcttagca	tagctgtgag	ccgaaactaa	agacaactcc	tttctccagc	tgatacaagg	183540
taaattgtcg	ataaacttga	ccctgaatgg	aaggtaaaaa	cgtaaataca	cagagataca	183600
aacatacaca	caaacctccc	atcaaccctt	taataagaaa	gaaaggaaaa	agctagacct	183660
ccctccaatt	tacacttaac	gcatggtaga	tacagatata	gacatggata	tatatcacia	183720
aaaaccacga	gtttatttta	taggcaattt	acatacggca	aaaagaatac	aaatcttttt	183780
ggagaatttc	agcttcatta	ctaaactcat	ctctagagaa	tgttactaga	aaaatgagca	183840
ctcaccagca	gatttcaacta	aagaatcaag	aaagaaagaa	ccatgaggaa	gaacttgcaa	183900
acacaagagg	catcagaaag	aaggctgttt	agtaagaacc	cgtaggaatg	taatacacaca	183960
tggaatataa	aatctatatt	taatatcttt	aaaggaatga	aagactagtt	ttaaaatatg	184020
atcatggaaa	aagaaaacat	aagaataaac	atgatgattt	ttaaaagaag	aaccaagtag	184080
aactttcaga	tataaaagaa	ccagtgggtcc	tgggtatgac	cacagcaagg	acagagctga	184140
gtgccttagt	gaactgaggg	acctgaataa	attaccggga	aggcagtgca	gacaagcaag	184200
gaataaagt	caatgaagga	caacctagca	caggttgaag	aaagaatgtg	aaggatgaac	184260
atatctctca	ctggagttct	gaaaacagaa	gtggcaggaa	aatataaaga	ttgtaactga	184320
ggattattga	tgactgatga	atgatgacaa	ttaatacatt	catgaaaaca	tataaatact	184380
aaccaggata	gttaaatttaa	aataaaacac	tcacacttta	acacacctta	tgataaaacg	184440
ggagaacacc	aaagtaaaaa	gagcattgtga	aaaattagtca	gcaagaaaag	acagattaaa	184500
tcccagagag	tgacagttat	atcaactgct	aactttccaa	gagcaaaaag	gacattagca	184560
gaaagtagag	tgatgtttgt	tctgtattgt	tctgaaagaa	aataactgcc	aacctacaac	184620
actattgcct	gtaaaaactta	caagaggccg	ggcgggcg	ctcacgcctg	taatcccagc	184680
actttgggag	gccgaggcgg	gcggatcacg	aggtcaggag	atcgagacca	tcttggttaa	184740
cacagtgaag	ccccgtctct	actaaaaaac	acaaaaaat	tagccggg	tggtggcagg	184800
cgctgtagt	cccagctacg	cgggaggctg	aggcaggaga	atggcgtgaa	ccggggaggc	184860



ggagcttgca gtgagccgag atcgcgccac tgcactccag cctggggcgac agagcgagac 184920  
 tccgtctcna aaaaaaaaaa aaaaaaaaaa aaaaaactta caagacagga gaaaccaga 184980  
 gattttgtcc aagtcaatcc tgattaaatt aaaccacaaa taggagtaga gaaataagaa 185040  
 cttagagagg actaaaatgg aagtggggag ttgagagcaa aaatctgttt acatgggtaa 185100  
 ataaaaatca aaataatata aaaataatca tttatcttgg gataaaacaa aactaaacaa 185160  
 gatagactaa attatgccat atcgatacaa tatagcctgg gaaaaatgtg aagataaatt 185220  
 tctaaatttc cctgtattgt ttaggggaga ttaccagttt ttaaattatt tttaaactta 185280  
 ggtaagttaa ctgtaataaa aaaattcctt gggtaaccca gtagttttta aggaactgaa 185340  
 tataatgaaa atacaacata taattcccaa aaaagtaatc acaaattaat gagaaaaata 185400  
 atcaaccatc tgaatctata agtaagaaca tcatataaag gtgggataaa tagaaataaa 185460  
 aactaatatt ctaaaaataa gttagtatg tgaataatta gaatatgtat aaattaaata 185520  
 aatactccag gtaagaaatc atcgatatac agcctccagg gtcttagaag gaaacaaaca 185580  
 gcacacttaa ctaggacaac ctggtgacag tacaatagag aaaatatttt taaaagtata 185640  
 gatataccct gttttataac aataagaaga ttctcagggg aggggtatata aaatatacca 185700  
 catgcaactgc caatgaaagt gtaaaactgt taaactttct gaaaacaata caccacaaaa 185760  
 acctgaaaaa cgtaatatcc ttaggctcta agaaaagtga cactaagaaa atatgtatct 185820  
 atagacatgc ttattattcc atgattttata attagcataa atgtagcaac tacttaatt 185880  
 tccaacaaca tgaaaatagt atttaaaaaa ttcattaata gcatggggca atactcattt 185940  
 cataaggcat atgaatcaag aataaaatc aaagaactcc aactgattaa atagactccc 186000  
 cttggccaag agtatctcaa ggaaacccaa aaaactagtt cagaccacaa taggaagcgg 186060  
 ggtaaacaat gcctccttat accttccct ttggagttca ggcatacaac tgactgacat 186120  
 taattattaa atagagatca gaagactgac aacacagact ttttgtaaca agaagatacc 186180  
 aaattctaac ctgagtctgg tatagcatca catgacagat agcagcaggc tttgaaggaa 186240  
 atcaaggat atagtata tcaaatgtat ttctttgaca tattttgaaa tgaccctgaa 186300  
 aagctgtttt ttgtagagga aatttgcagc ccgtaaataa tctccttccc ttactagata 186360  
 tttctagag tctgacatcc ttttaaggat gataggaaat acatatgatc tattgtctct 186420  
 gaagcctgct acctggagac ttcattccca taacaagaac cttgggttcc ataatcccc 186480  
 ttatcttaac tcaattgttt ctttcttttc ttttctttt tgaatttcag gctaagttta 186540  
 ttttttatt ttttttatt ccaataggtt ttgggggaa agctgggtga tggttacatg 186600  
 aataagttct tttagaggtga tttctgagat ttgtgtacac ctatcacctg agcagtgtac 186660  
 actgtaccca gtgtgtagtc ttttatccct caccaccccc tattctttcc ccaagttccc 186720  
 caaagtccaa tgtatcattc ttatgctttt gcactcctcat agcttagctc tgacacatga 186780  
 gtgagaacat atgatatttg tttggttttc tatgactgaa ttacttccact tagaataata 186840  
 gtctcaaat ccattccaagt tgtgtggaat gccattattt cattctttt tatggctgag 186900  
 tagtatatat gccacaaata tatatatata cttaatatat atactatata tatatataa 186960  
 tatagtatat aaatatatct aaatatagta tataaatata taaatataat atataaatat 187020  
 atactatata ttatatatac aaacatatat acacatatag tataatatat atactatata 187080  
 tattatatat atacacacat atatatatac acaccacatt ttctttatcc acttgttcat 187140  
 tgatgggcat tcgggctggt tccatatatt tgcaattgtg aattgtgctg ctagaaacat 187200  
 gcatgtgcaa gtaattttt tgtataatga cttattttct tctgggtata tacatagtag 187260  
 tgggattgct gtagtcaatg gtagttctac ttttagttgt gtaaggaaatc tccataatgg 187320  
 ttgtactagt ttacattccc accaactctg ttcccttttc actgcattcca cgccaacatc 187380  
 tattatgttt caattttttg gttatggcca ttcttgagg agtgaggtgg tatcgcatg 187440  
 tgggtttgat ttgcagttcc ctgataatta gatgttgagc atttttccgt atgctgtgtg 187500  
 gccattttta tttttcttt agagaattgt ctatcctcc ccttaggctc cacttccaat 187560  
 attgggggtc acatttcaac atgaaatttg gagtttgaa acatgaagtt tggaaatata 187620  
 caaactatat aagcaggatt atatatagac aataaagttc aatgtatttt tcaaggcact 187680  
 cattatttat atatttatat atttatatta tttatatata aaaataatat attatttata 187740  
 tatataatat atatatata tatataataa tatatatata atataatat taatatataa 187800  
 tataataata aataatatta tttatatata taaatttata tatataaatt taatatgcta 187860  
 tataaatata atatatataa taaagtatac tccacaattg cctaatacag atttctttta 187920  
 caaatccata ggacacctat aaaattgaca gatataaaat gtgtttccat ggtattttaa 187980  
 agatttatgt tatgcagata actgcctctg aaagcagaaa cattaatgtg caaataaata 188040  
 acaaaaggac aactagttta cagatcaatg aatgccctct taaaaaagtc ttgggtcaaa 188100  
 gaagaaccca aaatagatat tagaaaaat ttttaaaaaa tagataatga aaatatatat 188160  
 taagcctagt aacttacagt cagacagaaa tggagttta gcagatatta gaaaagaaaa 188220  
 tactaaaaatg aataagcttg gcatgtattg aagaagttat aacaagacaa ggaagaaaaa 188280  
 ccaaagacag aagtaaactc catggtgaac tgtagttccc ataatcccca caactagtgg 188340  
 gagggacctg gtgggaattg aatcatgggg gcaattacct ccttgctgtt ctcatgatag 188400  
 tgagttagtt cttgtgggat ctgatggtt tataaccttt gctctgcact tctctttgct 188460  
 gctgccatgt gaagaaggac atttttgttt cctcctcctc catgatcgta agtttccctga 188520

```

ggcctcctca gtcattgctga actgtgagtc agttaaacct cagcctcagg aatgccttta 188580
ctagcagcgt gcgaatgcac taatacatcc catatctcct taaaatgtac aaaaccaagc 188640
tttgcgctga ctaccttggg cacatgtcat caggacctcc tgaggctgtg tcatgggtac 188700
atccttaacc tttgcaaat aaactttcta aattgattga gacttgtctc agatactttc 188760
tgttttacaa attacctttt gttctagacc actcacaaga gtgacctatgc aaaatggaag 188820
tgtgccactt actcagctag-aaacgctcct tagcttttcc tctcactggg aatgaaagtc 188880
aatattctta ccttgacctg tcaggccctg tacttaagaa aagaacagca tgctttgacc 188940
taaaattacc tctgaatggg ctttgtctgt aaaatggaag agacatggag aggcgcggc 189000
accgaggtg ctttctaaaa taaggggtgc cttaaaagtc gtgttgaagt ttgtcttcct 189060
ggaataggaa gtgggtggaa tattttaatt agggaggtga tgtgattgaa tttgtttata 189120
aaattatttt tggttaaatg taatagagaa ggaatttgat acagtgggta ataatgaaga 189180
ggaacaattt tttagaatat taaaatatcc caggcttgaa tgaacgtaga gatggagaaa 189240
tgtgtaagaa ctgaagaggc tgttgagagt tagatggaaa agacaagtgg acggattagt 189300
gttgggataa gaaaggaaga aaggagtcac tgatggggcc atgtttcaga aggtttaggg 189360
gtgaaggctg ctgcaattca ttgagaccag agcctttgaa agatagataa gcatgcttg 189420
gtgcagtggg tcacatgtga aatgtcctac gaaacataaa agtgaaagga ggagacaaat 189480
ataataaaaa atatatattc ttgatgtcaa aactaaaata taaatatttt ggagactttt 189540
gtgtgtattt ggatgctatt ctcatgctct ttttctgga aaaaataata caaaaacaaa 189600
attatttcac gagttctcaa ttttgtcct tctgttttta tcagataaat gctaataact 189660
ttcatatctt tcttctcctg cagtttccca tgtcttccaa atttatttca catcattatc 189720
ttacttttcc tcaaggccgt ttttctcct gactacagca atgcagattt caattctgcc 189780
attgaattcc cagacatatt cgtcatccc attttcatcc cccaccacc tgccattttc 189840
ttcgtgttaa cttgttttcc tgactcacag aaatcacctt tctcgtata catttttagg 189900
atgtcagact ttattctaatt gatttctcct agttgcccc caaaattgta ttctacrgtg 189960
tgattttaaa gctgaatttt caagatgata ttcatatct atattttcac aagcttttct 190020
tctatgaatg ttattgtcag ctgtcagggt gtgagatggg acttgatact acattctttc 190080
caagctgttg cctgaatcgg ttttaagacaa agtcattact aggtctgtaa ctgttgctct 190140
gcaaaattga gcagcacgta ttttaacct cactacttct agctctccaa cacttttagt 190200
caatagagta tacaacacc tgtaatttcc agtgagcaca gctcccaggc tctctctctg 190260
tctctctctc tctcttttct ttttttttct tgccctcagc ctctcgggct ttatttgttg 190320
gatttgcacc ttcaccttct gcatgcagtg tgccatggct agttccctt acatttttgt 190380
catgattttg gtagaggcaa tgatttctct gttgtagaaa aaagggcagc aacataggat 190440
tacaaaagta ttgctaagaa attgcaacaa gctacttgca gtttatgtat gattactcac 190500
agtttttga tgggtgaacc cttaatttct gaaccagcag gtgaaagatg agagaagaat 190560
aagagacctt tctatagatc ttcaggcaga caggcttggt ggcttcctaa tatttcggtg 190620
ggatactggg atgggttga ggcaacatac tgtttaataa agtagacagt tttttaaaaa 190680
taatgaattg tgtctctaag atatattttt accagaatga tactatatag gaatatgcgt 190740
aaacccttg actttgatct caagcaaaac cttttcccta ttatccctcc ctcttaagt 190800
catgagtttg gtaagtaact acagaaatct gttctctcac agttctggaa actagaagtc 190860
tgcaagtcaat gtgttggtgg ggttggttcc ctctggagaa tctgttctgt gtcctgcct 190920
taactttagg gcattgccgg caacccttga cttgtagatg catcacttca atctctgcct 190980
gtccacaag gtgttggtcca ctgtgtctgt gtccagtgtc tttgtccagt gtctgctttt 191040
tcttctaata aggacattag ctatatgcac tcaccctaatt taagtatgat ctctattata 191100
cttgattgta tctgcaaaaca cccatttcc aaataaagtc acttttcccta gggttaggat 191160
ttgttttttt tttttttttg gtggaggagg aaaggaagga agtgggcaca gttcaattca 191220
taaggaacca actaaatata aatgccactg tggtaagatc agcttgacca tgtagatttt 191280
taaatgggtg ttttctttgt ttctattgog ttttttgctc atcttatcag aaaatttgat 191340
aacttttagt aataaatatg aaggagtaaa tcattaaaaa tttaaagtga aggccaggcg 191400
tggcggtcca cactgtatt cacagcactt tgggaggccg aggcggcg atcacctgag 191460
atcaggagtt tgagaccagc ctggccaaca cgtgaaact ctatctctac taaaaataca 191520
aaaattagcc ggtgtgtgtg acaggcacct gtaataccag ctactcggga ggctgaggca 191580
ggagaatcac ttgaacctgg gagatggagg ttgcagtga cccagatcat gccactgtac 191640
ttcagcctgg acaacaaagc aagactctgt gtcaaaaaaa taaaaataaa aataaaaaaa 191700
aaaaataaaa gtgaatccca cagatttgct tatattcttt ataactagat taagtgtcta 191760
caacagggct ctttttgact aactttatgg ggaatacaaa caggtgccaa ccaactccaca 191820
ttccaaaaga aggcaaagac ttgctttgca ggaactgcaa agaggtgtcc aaaatgtttt 191880
cctggcctta ggctcagcat ccccccgaag gttatgaagg aagagctgtg gtctccctt 191940
ggagagattg gatggatgct gagtgtcat cttcttcccc ttccctgaca gacaacttga 192000
tgtgcatccc tggacttaca gggacaaaga agtgccgat ttattccaga aaatatttaa 192060
aggatgagag gcttgcaaaag aggccagag caaaatcaaa gaaggctata gcctgaaaa 192120
aattttattc cccgatagc aggccagatt gcatctttct tatcactctc tgggtggacat 192180

```



tgtgagacag	agcttagcca	gggattatct	tagatcttgt	caaagaaggc	cctggccaat	192240
gaggcgatct	ctgcagaaag	cagctggaag	tgcatcatoc	cagatcccag	gttgagagac	192300
cagcctcagg	agaacagctg	agggtgaggg	attcattcta	cctgggaaaa	ctgcatgtga	192360
tggataacca	tctgtgggca	gggatctcaa	agaaccccca	agtatgccct	gaagaattca	192420
gcaccaaac	tcttattact	ttcaaaggaa	tcaaacacag	gtttccaagg	gggcatgcca	192480
ataactttac	tagtgccgtg	ctctcccttt	ctctgtaaca	cctctcactt	cagtcctccg	192540
tgagccatag	tgtttcaagg	gtgtgtgatg	aagcgatgga	agcctcagg	ctggaaatag	192600
gaagaaagtt	tactacaagc	ggcctgtgta	ttaaagtggg	cccaaacttg	tgaagaaaac	192660
ttggatcaaa	gttggcatct	tgattcttat	ggagtacaca	gaattgcaac	caataaaaga	192720
gacaattctt	gagaggaagg	gtgattagag	gacattttgt	tacctgggag	tgaacagata	192780
ctttatgaga	aatgctctat	atttgattaa	gtaacagggg	tttgctcttc	aaagtggggg	192840
tggttttaag	taggcagtct	gtggggcgcg	ggtaagaaaa	tggatttctg	attttatctt	192900
tgctcatttt	ccaggttacg	taaatattaa	gaacattggt	aatttaactt	aataaagaag	192960
ttcataaata	gtccaatatt	aaaagtgtat	taaataatac	ttttggaat	acatgaattt	193020
tactgaatgc	cctctagcct	tactacaaaa	agaatgcttt	gcaataata	aaagctaaat	193080
aaaaataagc	cagctccagc	cactttaagt	gacggaacac	actctgtaac	ttggggatgg	193140
ggacagggca	ggaatgaag	aaattaaagg	caaggcgcc	tcactgaggt	atatcaaatc	193200
ctattagacc	aggtcatttc	cttggtcggc	aactggacag	ggctcctatt	gtcttctcta	193260
ctttggctga	aatcttttat	ttatcctcca	catttggttc	atttgaggt	aattctattc	193320
ctgtttctac	atttaccatg	ctggatcagt	ttttccctg	attttatttt	taagttaacta	193380
tgatattcgt	actaaatatg	taaatgttta	ttattgggtt	ttagctgttt	ctataataaa	193440
gagttgtagt	tattgttaagt	tgcatcgcac	taagctttta	aaatgtattt	ctccactgta	193500
gagaagtatg	ttccattgaa	atttgattgc	acacaaagct	tgacatgagg	tttattctct	193560
ttgtgaaata	aaccattcaa	tctggactgc	atccacattc	atctgaaact	tgaaggaaat	193620
aagtcattct	tcacttatgt	tttaatatgc	catatttcta	ttaaattaat	ggaagggttag	193680
acctaagct	caatgattgg	acacttatta	ttaatgattc	tttgacata	gagtgcagtg	193740
atagctcaca	agaaaatttc	accaaagtca	tcttatatat	ttctcataat	aatcctaaga	193800
ggtagggttg	atagacatta	gcattctgac	atcagaattg	gagacagatt	cttctgtctc	193860
atttaaggga	tttgcccca	aattaatcag	tccatgataa	agccagctct	ataatattac	193920
tctaaagaat	attcaaaagg	tcccgggcac	agtggctcac	gcctgggagg	ccgaggcagg	193980
tggatcatct	gaggtcagga	gttcaagacc	agcctagcca	aaatggtgaa	acctcgtctc	194040
tactaaaaat	acaaaaaaa	aaaaaaaaa	tagctaggag	ttgtggtggg	tgcctgtaat	194100
tccagctact	agggaggctg	aggcaggaga	atcgcttgaa	cccgggaggc	ggaggttgca	194160
gcgagccaag	attgcaccac	tgcaactccag	cctggcgagc	agagcgagac	tctgtatcaa	194220
aacaaaaaca	aacaaaaaga	atattcaaaa	aggtgcatgg	ggcaaggaga	ggtcatttca	194280
catcctcttg	aggaacacag	gtgactccag	accacaattc	tcctagatgg	ccgggggccc	194340
ctgctccct	ccttttggtt	ctagggaactt	gattcctgaa	gaggggtcat	gcgccaacat	194400
ctagtttaga	gtttttctat	tacaccacct	ggctctttat	attaatttgt	ttccctgatn	194460
ttttttttta	atctcctgga	tcacaatata	atcgtttgaa	tttttgtgt	tgtgtatata	194520
agggctccca	agaaatgtgt	aataaaaagt	gttggtggga	aaatcttgct	aacagaatcc	194580
agtagattaa	taactaagaa	aataaggcac	acacaacaaa	aggttgtgca	tggctgcaag	194640
ttcaagagtg	ggaactgatt	agagtggtag	aataaataca	tgtgcatgtg	ttctgaatcg	194700
attagacata	taaaaagata	tctagattct	ttgaaaaatt	aataagaac	tttttttcta	194760
agcataaata	tgaagtcca	gtataaaact	accaaacaac	agagaagtga	taaagtgcta	194820
gcataaaaaa	ttagcatcat	gattattctg	tattgtttac	atagatctat	caagtcaaat	194880
gttgggtcag	agccattctt	tattcagtta	tcaaaatggt	agagccattt	ggatgagttc	194940
agagacttct	tctttatgat	aaaaaagata	attgtaaatc	aaaaaagagt	ttaaaggcta	195000
tactaattaa	acagctaatt	ggaaattgga	agatttggtt	ctccaaactt	ctactatttt	195060
ttattttctt	ttctgtttgt	ggaagtgttg	gaaagcaaca	ttttattctg	tgattagcat	195120
caaagagttt	caggcatggg	ttataggact	ggaccatgca	tacttgaagt	gtacttcaaa	195180
ccataacatt	ctatgagatt	togtgagcaa	ctacctctta	ttgataaaaa	gaattgctgt	195240
ttaaacctta	ttttaaagta	cttacttttt	gctttctcaa	atataaggat	gatgtactat	195300
ggattagtaa	tatcattacc	tatggaaaca	aaagatatata	aaatttactg	ttcactcact	195360
tctccttaat	ttccaagaac	attaatcttg	aatttaagct	taaacttact	ttaaacatta	195420
tctttattat	cttattttct	atgaagaaaa	tattccaacc	tatctactag	tatgccactt	195480
taaaaacatt	aaaagccagt	ggataactgc	aaaagaaggg	cttttaattt	tatataaaat	195540
aataaaataa	tttattctat	tgataattcc	aaactctcaa	ataatatctt	gctgcagtgc	195600
taaggaaatg	gacaaaggaa	gaaaaaacag	cttttcatgc	ctttcctgaa	acaattgcag	195660
gaaatttttg	tcacgctaca	attattcttt	gatcatgaaa	aattctttta	aagacacgat	195720
agccacaacc	attttatctt	ctgacttact	aagcagtctg	aggggtgaata	gagagtttcg	195780
attccagggt	atgggtataa	ttactaactg	caaaaatcct	attgcctttc	attaagtagt	195840

taaaaatattt	aattgagact	acagtggtgc	tgacacacagc	gttggtacat	gcataattat	195900
ccctacacat	acaggaacac	tgagggtact	tttaacaata	aaacagatca	tcaaaaaatt	195960
acatttttaa	tttaagtttt	gactttaatc	ttctccgtga	ttaaatacct	atctctgcat	196020
tttttctgca	aatgaggaca	ttaagctaaa	acaaatgaac	cataaagtga	cgggaaaaaa	196080
aactttgcac	tgtaataata	aatggataaa	tctttaatat	gtattaacca	ttgcactatg	196140
tctttatttt	ctaacagctt	gtatgagaaa	gaagaactgg	tgatgcagaa	agtcaaatac	196200
cgccagctta	gcggtgcagc	atcctctcct	cccacataag	cagagatcgg	agcatgagat	196260
aaaatacctg	gatgcccttt	gctccagcct	cggtgctcca	caactttgct	tctgacagag	196320
tacttatctc	tctgaccact	gggaaactgc	taaaagagag	aaacttgaaa	aggattggac	196380
ttttctgtgc	aaatctcttt	gaaaattgcc	acctccaggt	tagcttttaa	gagaagccca	196440
atatattagg	aacctgaaaa	taaaggaaag	tttgacacatt	gaaacatcac	ttgctaatag	196500
ttctattatt	ggaaacggaa	atatggaatt	ctagaaaaag	aaatgtcatt	atggggttag	196560
gaattaacca	cttgctactt	atgttaatgt	gacgtgggtt	aaaaaagctg	caggaagttc	196620
ctgaaattat	tgaacaaaa	ataaagtatt	ttcccctgga	atctaagtaa	tgtaagtga	196680
attctttaaa	cattctcttc	aactttatat	ttcaaaattg	cttcacagta	atttcttatg	196740
ttatccatca	cttgctaac	tggaaggcaa	gcatttttat	tggttttagt	actatttagc	196800
tttatgaaca	gcattctctg	tttggtgcaa	ttacaaacat	ttatttccat	agggatggaa	196860
agattatgct	ttgctctctc	tgccaggtac	caattgtcaa	tagaaaatag	agccaactag	196920
agtaacttta	gctcttcaat	caacacatcc	agtattaaga	aaaaaaatag	attgatattt	196980
gagacgtaaa	ttcaaatctt	tattcaatac	gcaagaagtg	taattgtggg	agattaggtt	197040
gggaaataat	aaaaagctgt	ataattagag	tgctcaggatt	tacaccctcc	actggaagct	197100
actatatcag	gtataactcc	gcaaaaattgt	agatgggttg	caactaatcc	ttgctcacat	197160
tttratgatct	attactatgt	gccaggtgtt	ctgtctgaaa	cagcatggga	agaggaatca	197220
gagacagaat	tgccacctat	gtggggcctt	gctgggggtg	agaaattttg	tttctcacat	197280
ttttgaaatg	taatactttg	atctgaattt	tactcctgct	taaggacacc	aagatgaaag	197340
cggatggcac	cctgcccccc	accctgggtg	agtttggtta	gaaatgactt	tagttctatg	197400
aaagtggatt	cttagttata	aacataaaga	actatcaccc	gctagtaaga	aaggatttta	197460
ttgaaaagat	gttgggagtt	cattttatct	cagggattct	gcagatgggc	agagagacta	197520
gaaaaccaag	agcaogaacc	aggcataaatt	caaacttcac	aacagtgagg	gtaccagaac	197580
agcttctagg	gaacaacgcc	aggcacgact	gcctggaaat	tgctgggtac	gggtgcttga	197640
ttgtcactat	ttcctggcat	tgccagctgc	agaggcagct	aactaacaga	gccaggggtg	197700
catccggggc	tctctttatg	ggggcatcca	cagtgaggag	tagtggggtt	tgatgcagga	197760
aattactgtg	ttgtatcttg	ggttttctca	atttatacaa	caaagtata	catacgttca	197820
gatggaagta	agaagtacca	catctgagag	cggaagaggc	actgtaatca	cccatcccaa	197880
agaagatgat	ttcttaggaa	aagaagttag	tttgggaaat	atattagatg	tattctcctg	197940
tctcttccat	attcttggga	atttgagcca	toacttatct	ctgatgtgcc	ttgcttgaga	198000
agtggtttct	atactatatt	tgatgatgtg	gatctgataa	cacaatatcc	aaatattttc	198060
cagctgtgtt	aactgagctc	ctagaggcag	atctcctgag	aattgtcagt	tgtgtttatt	198120
ttccagttaa	gtctactttc	agagagccat	tattgaaaga	gaaaagtttc	aacagaaaga	198180
tgattattgt	taataattatc	gtggtaagac	cacttaattg	gagatctatc	ctgttagcac	198240
atttttacac	accactgttt	gtgttggtta	ctataggtgc	aattgtgcac	agcagacttc	198300
aagagcttat	tcatcttcca	taataaaact	ctgtaccatt	actgttgaa	agcaacttgc	198360
catttctccc	tcttttcacc	tctgcaacag	aatgataaac	ctggagagca	ttatgctaaa	198420
taaaataaag	cagttacaga	aggacacata	ttgcatgatt	ccacttatat	gaagtatcta	198480
aaataataac	gcttattcaa	atacacggtg	ggattttttac	tgggaaaaac	gctcgctctt	198540
tttaaaaaaa	aattgagaga	gatttgcttt	agttgatcaa	aattataaag	taccggaaac	198600
tccccaagat	ggcatattgt	tgaagccata	gtgtgtgcac	aggtgttgaa	taggcccttc	198660
agagataaga	agagtaaaag	gtggtataaa	aaagagaaaa	agtgcataga	tcagtcattt	198720
gcaacattaa	aagaaatgct	ttatcttggg	ggagatcctt	tggccaaact	atttcaactt	198780
ggaaagatgt	agtaataata	aaagatttca	atacaaggaa	ataaagaaat	tgcatccgtg	198840
ctacttctca	aaagagtaag	aatttaactg	ataaggttaa	ttattataaa	attaactttt	198900
accatctaca	ttaaaattag	gaattttctg	agaatttgta	ttctttttgt	cctttcaata	198960
aagaactcaa	tatgtttaac	tctattttta	acaggaatgg	ctgcctatgt	cttgagtttt	199020
gaatgcaaga	ccctcaaatg	ctcaggaatt	atcaagtaaa	gtttatgtta	agaaactagc	199080
attctgttga	atcactcaat	aatggttatt	atttaggata	tgcaaaagt	aatcacaaaa	199140
acttagactg	aaagatactg	cttacaatta	taggtgggaa	ataccataaa	atacaacctt	199200
tattttattt	ggaactcgtt	ttaatgcaga	ataatcctag	cgctctat	agtaacaaga	199260
agaaaccaat	ttaaatata	tgctgattta	aatagtataa	ataataaaaa	tgacaatttt	199320
ttgttaattt	tcagactcta	catagctatt	tttgctctct	ctattcttat	gaaatattca	199380
gggaagatat	tattactttc	actttacaaa	tgggataact	gagaactcaa	taaattgtat	199440
aatttatctc	aagacacaga	gctgggtcat	ggtagagcta	tcatcagaaa	tctcagcatt	199500

attagttatc cctttccaat tctgaagtc tctgggaagt gtcagaattt acactcctca 199560  
 ctaggaaacta ctattgcagt tggaaactctg aggcctttatt tgggagtttt tccgtgattac 199620  
 agaaaatctc ttcttaagag aggttttaaat aaacaaaata agtcggggat attaccagat 199680  
 agccctata tccctcagagc tcccagcatc acacctttta taagaacagt atagaaaaac 199740  
 aaagtctcctt cctcctcctt gccctgtgtt atttttccaa aaaacaaaca aacaaaaacc 199800  
 taactacaca ctaagtgtga aagtgtgttg agtgggggaa ggcaagctgg ggctgtacca 199860  
 ggtcaagggg tgaaaagaat taggggatta ttacagttct agttcgaaga caaacacttt 199920  
 tcaatgtatg tcaatgaact ttattgaaca gccgccatat actagtaacc ctcttaggtg 199980  
 tgtgttacac ttacacatcg aaaccagggt ttcccagatt tcttatgatg aaacagatag 200040  
 aaggtgataa tctgtgcaca gcacacatgg acagtgtgac ggaaggagac caattaagga 200100  
 cganccgggt cgtatttct acacacctgc caccagctgg acggctgtgc tggaggtcta 200160  
 agccctggat gcttagctgt gtgatctgtg aaccggcagc atcagcgttc ccagggtgct 200220  
 ggttagaaat acacctctca ggcccaccca gaccttctga atcagaatct gctgtttcca 200280  
 aaattcccaa gtgattctca tgcaccttaa agcttttagaa acactgttct aattagttt 200340  
 cttaaaatat tgctatggga tacaggcttt agtaaatct caggatattc taccatgtac 200400  
 tcaagtttga gaaacaggag atttaataaa tactgatgtt tggatcccat ccatagagat 200460  
 tctgttttga ttggttagg gtgtaactcg gcattaacat ttttaaatg cccctgggtg 200520  
 gtttcatgaa tggcaatgtt tgggaacacc tgctttaagt taagccatga gctaattgtt 200580  
 cttcatcata ttgcagatgt gggaaactgag acgttataag gaaatccaat ttgcgagtg 200640  
 tagagccaga cttaaagctta gacccttaac tcacttatte tcaaaactgg tctgtgctgt 200700  
 ttattatttt acaggagagt tctatattgc tactgtttat acattagtat catttaaat 200760  
 tattttaata tatgccortg atggataata ctgagtgctc acttgattgg attgaagat 200820  
 gcaaagtatt gatgctgttg tgtctttgaa ggtgttgcca aaggagattt gagtcaagt 200880  
 gctggaatgg cagacacacc ctttatctgg gtgggcagca actaaatcag ctaccagctc 200940  
 ggccgggata taaagaaggc agaaaatcat gatggttaag caaactaat atggcctgag 201000  
 aaggactctg tacttctata ggtgagctct tgtggatgaa ctgtaacctt gcttaatagt 201060  
 cagacaaaat ttaaaacctt atttaatagt atgcactgta acaatggctg aatgttgccc 201120  
 agtcccagtg ggattcaacc actcatagac tgcttttgtt caaactgct tcaataaagg 201180  
 caaacgcga gctggaacca atctcactgt ttctgtacct cgttctaat tccgtgacct 201240  
 cactttacct tttttgtcta taaatttatt ctgaccacaa ggcacccctg gagcctctgt 201300  
 gagtctgctg tggttctggg gactgccgga ttccggaatc gttcatttct cagttaaact 201360  
 cctttaaatt aattcagctg aagtttttct tttatcaatg aaaagactag actggcttag 201420  
 ccttccagcc tgcaccttcc tcccagctg gatgcttctc gcccttgaat atcagactcc 201480  
 aagttcttca gttttgggac tcagactggc ttcttctgct ctcagcttgc agatgcccta 201540  
 ttgtggggtc ttgtgttctg gtgagttaat acttaatacc ctctccttta tatatacatc 201600  
 ctattagttc tgtccctcta gagaacctg actaatacaa tgtctccatt gaaaagaaaa 201660  
 gaaaatctat taataaactg atatagtcag agccctcaa gaaaaatacc aaagaaactc 201720  
 caatgttgta gaataattt ttattgtctc aaagacatca aaataattac atgccttgtt 201780  
 tacgatgctt ttaagttgat cacattcaaa gatgtgtcct atccattcat gtacatacat 201840  
 tcaatttcat attgactctt gcctttttca gcagtgatca gtaaaaatta tctaaaaatc 201900  
 aatcctgaag gttatacttt atttttccat tttgaacctt gcccttgaaa gatcatttat 201960  
 atattttaaa cacattttta aaaatgaatc tccagaagtc taatttctca tgctaaccac 202020  
 attagagagg ttaattcgat gacgaactct tagaacaat catcattaga acttgggtat 202080  
 tatttcaaac gcactctctc tccaaatctt agcagttgaa acaatttcac aggttaaacc 202140  
 agccagcttg acagccctg aatggctact cactaaagg tccaagcaga ggcaaatga 202200  
 tggctctatc tottaaagac agagcaacag aatatttga attaaataga actggactta 202260  
 aatctcatcc cagtggacaa ctgggaaaac ttggaaacat taatcctgct gaattttgt 202320  
 gcatcattta ataactaata catactgaat taagtgttta gcaggattta caacactgtg 202380  
 tataaggagc ctggcatgtg tttcctgatc tttggtgtt tttaggttaa tattatgaca 202440  
 gtgtgtaaac ttggtgtcga gaattaaaat ttgcttaaca gttctagtgt tctgtacact 202500  
 gttacctatg ttcactgcct ccaactcatt gaggtcatg atgctaaggt gaattctgga 202560  
 ttgaaatcta ggtctgtctg cttatagggc ctttttccaa cttcagggtt tccgtctttt 202620  
 gctcaattga tcccttcaag gctccatcac rtttgagcta cagcaaatca tgggtgtccr 202680  
 tgttcaactga tgggctatgt tccagaagtt ccagagaaaag taaaggggga taaaagaga 202740  
 gagagagaga agaccataa atattctgaa gtatatgact aatctagtat aatggaagct 202800  
 cagaaaaata attgtatttc caaatatata tttctgaatt ttttgggtatt tgttattgg 202860  
 attctctgaa ggccacttt cttttctttc taatgctcta tgtccttaca aaggaatgac 202920  
 tattaattca ctggaataag aatcacacta attggcacac agtcccaatc tgcttggcat 202980  
 gtcattttaat gtgcagccat ttacctggtc aagtgaatac ttgaaaatta aacagtttcc 203040  
 ttgtgctatg attgatggca atgcagtcta ggggttaagtc ttaaacgtaa tcccttatag 203100  
 gatttccctag gttctccctc agagtttcta actccataga tttgggggtg ggtcccagaa 203160

```

tttccatttc taacacgttc ccaggcgatg ctgaagcttc tgggccaggt accacacttt 203220
gaaaactgct gttttaatgc ttacatgggg tagcatgagt tagttttgccc tgggggctttt 203280
aattccaagt tctgctactt aacagctgtg ttataatgat taagttatgt gatgtctctg 203340
tagcttgatt tctttgtata atgaggaaaa taatcatwcc cttttacata agattattgt 203400
gagaatttaa taaacaagaa atttcttata atgcctggta catagtaatc actcaataag 203460
ttatgtcaat tgtcaaagca catgtctgaa ttatagatga gagagaaata ttgtgaattc 203520
tatggcactt taatggcctg ttctctctac ccatctctag ccgtacctta cactggctta 203580
tcctgtgctc ttcttttctt gagggaaacc aaccacatat actgcctaaa gcactctttt 203640
ggcacttcta acatagggtg aaggaggaaa tttcaagaaa ttatgacaaa ctacaagact 203700
caaatctcct tttaaatttt aaaaatcaaa acatgtattc atatcccatg gcacatatgg 203760
atgaagatat tgtttttctc agttaatatt ttagttttgc ttttgtgcca gagccttctt 203820
ttttttttgt aaatgtccct tatcaggcta ctgcagaatt gcacaaatac tgaattgccc 203880
caaaatattt gcctttaatt tgtttcttta aagcaaatgt aaaactacaa tgggttatat 203940
ttacctagag gttttatcac catacgctta atttaaacat atataaaaaat agaattagtt 204000
atattttagt ttattttctc cattcactta atttaataata attcttagtc cataacttag 204060
atataacaaa aatttgtatt ttttctatcc tccatttgcc ctaaaatctcc ttaaacaaaa 204120
caaaacccaa ggaaacawtt ttgcctggaa aacgtgaagt ttgattagtt ccacctacct 204180
taatgcactt taatttgggc cccttctcct cggtagtcta gaataataac tttttttttt 204240
ttttttttta agagatctgt ttggaaaacc taccaaaaca agacaaactc aatgattttc 204300
ttacagagag aagcctgggg aaagaattag caggaatttc tcaacgggtg ccgctgtctac 204360
tagtttttta tgcattgctg cttgtcattt ggcagaaatc aattgttctc tttacaccac 204420
aagagtgggt gaaatggggg taaaactgca agttaagact gctctgaatg tggattcaac 204480
acttcaactg tgtcctccaa catgcgcctt caaagtacca cttggctggg aattaaaaag 204540
ggttgccctt agcaaagctt taatttaaaa tagtcacagg tgacagctct attatttttg 204600
cacgytcaga tgcagccaca gctgttttta ttgatctcag ctgcatacac acccatttgt 204660
tgtaattatt agttttctgt gtagctgaag atacatatct cgaatgccta tcaaggctaa 204720
attaaattaa ggaaatcgta cttttcacct tcacctctt tggctctgct ttgctgcagg 204780
aaattgccc aatgtaaaac tttgagcctc atttcatctc cccccactag gagtgatttc 204840
caaagtgtgc ctaggttccct gatctattcc aatttaatag ttactgacat tttttccctg 204900
tatatttaac acactacaag caattaccat gtgrcaatta tgaatttaaa aattaaaaaa 204960
aacacaatta ttgctactac tgattaaaca ttgttaggac tttgaagaat aaaaagtgta 205020
attcaacctg ccctcggctt tctaaaaatt gcctttttgc tcttaaaaat gcatgtacag 205080
cttttttcat ataaaaataa tttcgagttt cttctatacg cataaaatat tttcagctat 205140
ttttgatttc aggaagtatg aaaaattaa gttatgtaga cctcactttg ttttgcgat 205260
tcgaamtctg tctcagtgac agacagtttt cactgtattt gatgtgttg cagtaaatgg 205320
cataacgyg ttcccaccag taatgtaaga agaaacatgg aggaagcaag taagggtcta 205380
ggaaatttgg gagagaggaa aagagacata attaatgagg agagggatca agaagattgg 205440
caggattttt agaagggaat ttgatttgca aggtaccac aacatggcac acaaaattgt 205500
aagaaaaaca aatttttctt gaacatttat ataaagattc ctttgggaaa atagaacaaa 205560
tttggttgta gagtggctg ggggttgatt taaattggaa aaacacagtt ttgtttttt 205620
ttaatttgaa ataagagctg atatgcaata ttgtagggga gttggttgac ttttttagtca 205680
gaatagtggc ttttacaacc atggtgacaa cattaactgt ggatcctctt gacgtcttca 205740
taagttcatt aatgctggg gaaaatatgc atagcaacta atctaccaat atttgagaga 205800
attaggcaac ctctcaagaa ttagtgaaag aaatgtaagt caacaagctt atacaatgta 205860
aaaaccatga ataggcaggt aataaataat agaaattgat tttttctgtc cagtaaagac 205920
catgaaaaga gaaatattat aatttttaact tgagtgtctc agaatactgg gttgttttt 205980
ttaattgatt aatatgattt taaaaaatta tcatgaattt aaaaatattt tctccattac 206040
tttgagttat cactttaaac atargtaata tcaagatatg tttctgaatt atatatttaa 206100
ttatgaccac taaagagcac ccatgaaatg gaagtgttaa cagcaatgtt ctgttgtagg 206160
aagataatca tattggttat gtctgcttta tagtaattgt attgttgatt gatttgccct 206220
ttcctaactt aagtcctttt ggtcctttct tctattttgt ctaagagacc ctgttcaaag 206280
ggacatttta ttttcctttg tacaacagta tttgcctgac atttaactct ctctaataaa 206340
taatatataa ctctagctct aatacattta cttacctaag gaaatcgccc ttgtgatgga 206400
ccccoggagg tgagatacat ttctggatga ggaatctgtg agaagttgag catttggtca 206460
gctactaagt cactgccacc acctcgttag ctaaacatac tctgtgctca ttccttcatc 206520
agtaaaattt ggttgggaca catgrcaggt gataataag gttattagct gcaatgctta 206580
ttaaaatttt tgaagatata ctttagcaca ttttaataat tattgagact gtcccttagt 206640
aacagtagct cttctaaatg aaagctttta aaattgcatg taagtcaaaa caaagcatta 206700
tttgttattc aactttatat aaaagctgtc cagtgtattc aaatatgtac taacatttaa 206760
tttcaattca aaataagtat ttttatgttt ttataaagtg attaaatcac tttattgaat 206820

```

tctatccctt	tataaatgaa	taaaggaatg	aactcaagtt	gtttctattc	tattagcctt	206880
tacttttccc	ttcccccaat	taaccccaag	caaaaatgta	ttgactttga	cctgagaaga	206940
gatacgtcaa	ttttgttatt	tatttttgct	ctactcctat	ttcccataca	tatatgggac	207000
atataatatca	gcacaaatta	gcaggcccac	caatttctta	ctcttgatc	cagtctgatc	207060
nnttctaact	cgtgaaataa	actaccatgc	agcacggatg	atcattcaaa	ttacagctta	207120
gggttgatca	taatgtcttc	attttagtat	cccccttagg	ttgacattat	ttattaaaaa	207180
ggtagttttc	aatcggattt	atggggcatt	atcgatagta	agtctacttg	atacattgca	207240
catacctttc	ttctgccaaa	aagaagtgtt	tacaaaaatg	tatttgacca	aatactttac	207300
ggtaaacatc	acrgtctgaa	agggaaactat	cttctttgaa	aggattaaag	cctccagata	207360
gatacaataa	agattttttt	aaagtagaca	catgttaaata	catggaacag	caaaggggat	207420
actttatgga	aattgaattca	caagataata	atttgaattt	gacaagggtga	taattaaagt	207480
ccccagatag	atttcttcca	catctgtatg	cctttcagta	aagttgggtta	gcatattaac	207540
tactgctgga	gaatacagaa	aatattcatg	ggatgtaaaa	ctgcaaatta	ttattcattt	207600
caatttgtat	aataagtgtg	acaaaatgca	gtgcatacag	tgttacacaa	gaggtagcaa	207660
actccattat	agacattttt	agagcaaacg	tgggatccct	atatgacaat	ttttgtcttc	207720
aaatattcaa	gacatttaag	tatgaattac	cactttttgc	aattttaaag	aaatttttgt	207780
tatcttcaat	gctttctagg	gctaacaaat	tcttacttca	aatgactaga	atcattttta	207840
aatattatgt	actaggatat	gtggatatga	acatatatat	ttatacacia	atatatgtac	207900
acagccaaat	aaacaaataa	ttagtgtaat	ctatatgtat	taatattgnt	atattttcct	207960
ccagagaaaa	attgaggttt	gctgaccaga	gaagaagaaa	gcatcaatgt	gtgattaaaa	208020
aaaaaatgta	tatatatata	tatccactac	atttctaatt	tgaatatgtg	atcctgcata	208080
ctaattctct	tgtcataat	tgagtttcat	agctacttca	ttttaattta	gacattttata	208140
tgagaaagca	tgtttaatat	gatgataaga	aactgtatga	aattttggga	aagaactgtt	208200
aagtgtgccc	acacactgta	ggcactgaat	gtcacacttg	agaatgtccc	tggtcctagc	208260
ttatctataa	caggaatatt	ttccrtcata	tgggaatttaa	agataagaaa	tgaatcacca	208320
cgcagagaga	tgtgctatca	catcccactc	atggaaaaaa	caaatgaaaa	aaaaaaaaac	208380
atgaagaaag	actttttgaa	gtgcagcatc	acctgcattt	atgatatttt	cagacatata	208440
aaacaaatat	tattctcatg	gttttgataa	aaattgtcac	ttttaaaatt	tgacatggga	208500
tatcacaatg	gacaatgcag	ggacccttca	gcccatagtc	aacagggtgat	caatttgtga	208560
aactgatatt	ctctattagg	aagggttagct	agagttaggag	ataaaaaaca	acatgattac	208620
aaaaaggagg	atcattttgag	accaacttta	atgtgaaatt	gtgtagaaat	gggggaaaaag	208680
atacagaaaa	catcttcaca	agtccacttg	agaaactaag	ttggtgcaaa	agttattgca	208740
ctaatttact	ttgcaccaac	ctaattgtaa	gttatgcttg	aagaaactta	aaaggagaga	208800
cggagagagt	acacaactat	aaaagcaagt	ggaaacaagaa	gtgaaaatga	ccaaagaaca	208860
tattttgtga	acatggccat	tttgacaatc	aagggagaat	agtaatttaa	agtacaatgc	208920
cacaatctgg	agaagactgc	tcttgcacac	aagtgaagay	tctcatcggt	cctgtctgat	208980
gcaaattaca	ggtacattgc	tgacacaggtg	tcagatcgca	catagctggg	ctggcactgc	209040
ctctcctctg	gagaggaatg	cagcacattc	tccacaggcg	actggaaagt	ctggattctg	209100
tcactctagaa	atacacctta	gtwatccctt	tgccaaatta	atgggaaaaac	aacctcttca	209160
cttctgtgtt	ttagaatttc	tgttttatgc	cttttcattg	tttcatgcaa	ttttattttt	209220
tcacgaggtc	aggcacagct	aactgttgat	tttcacccaa	ttaccttggt	attggcttgg	209280
ctccatggag	cagccccctt	caagaaagt	tcccaagaaa	ctatgtactt	cttctacttg	209340
gactcagctg	tgtacctatt	tctctcgtca	gccattagag	tgttccacta	atatagtcaa	209400
agcagaacat	ctggcctatt	atataaatga	atattagtgt	tgaagaagat	atctttggag	209460
acagtagaac	aaaatggatt	ttttttccta	cacaggaact	cttgggtttt	cctcactgcc	209520
cattgtcatt	ttttctacct	tactcagaac	atgattttcc	ctcaactgca	cctttctgta	209580
actttgacct	gtgccatcct	tgtgaaataa	gtgatatgtg	atttatttta	rtttctoctt	209640
ctaagtgaac	atgcagagtc	cttcagagac	catctgtgcc	tcctgctgag	tctctgtgtt	209700
ttctaccogg	gctagcttcc	tccagagccc	agtctcaggt	agatctgaac	cacacatgga	209760
ggagatttta	agaacaagtc	ttgtgacact	tcctatgctt	tgggtccaaa	aactattgat	209820
ttctctattt	cctgcaagt	gtgtcagatt	ctggcaaaac	tagcttggag	tttactgagt	209880
ttaatgatac	tgaatgacat	caggactcac	tcttctcttt	tcattttttt	gctatgagtg	209940
ggaaaaaata	taactgtata	agcaatgtac	tttttttctt	aacgcaattt	aatctttact	210000
aaaattaatt	ttgataatca	tatatgtaca	aagtgtttta	ttttgttact	ttttaattct	210060
tagacattga	cttttaaaaa	ttttaatcgt	tgctattttt	acccctgact	ttatgccag	210120
tgtctatatg	cataaacaca	aatctttcta	ctcctatctg	tttagcaaaa	tgtaaataaa	210180
atgtctttta	tttattttcaa	ttttgtgtat	tttttttaaa	tttacttgcc	tgggttgagc	210240
atcttttagt	atatattttca	ttgtgtttta	ctgaaaattt	gacttaagac	tcagtgtatt	210300
actgtcaaac	tctcccgta	tgactatctc	aggtagctga	ggtatcactg	acagcataag	210360
sagcgcaaaa	ccctcggtga	atgcaaatg	gcatatccga	caaccccaag	ctaacaagat	210420
cataaccagg	gacttgcaaa	catgttttta	ggacataaac	tcrtcttaag	gttttactta	210480

aagtascatc	catctcatct	ttaaccagcc	tctcctaate	tttgacgaat	tgteccattct	210540
aatgcagctc	ttcttcattc	tttcacccgt	ggctccatta	aaygtttttc	tgacggtagc	210600
ctctccattg	gagtaactgg	actgaggatg	gactcccttc	ttaagaaatc	cagaaaagca	210660
acaaaaatct	ttccagttac	tactggaaaa	tttctgcagt	catcatacat	gtatcattag	210720
gttctcacct	accattccta	gagtctatct	atctattttac	ctctgagggt	tcttagatta	210780
gccaaacact	tttgagctc	tcgtattttgc	attgtagggc	cttggtgag	actagatctc	210840
ccaatatttg	gatataattga	ggactggaag	ttaaagaaasa	ctgccacttc	acacctatgg	210900
aaatactacc	tttttccata	gaggcagctt	gaatacatga	ttaggaattc	actgtgactt	210960
tggktttagg	gaaaaaaamc	aaaatgggtt	atttgggttat	atagagaagg	aaggaaggaa	211020
ggaaggaagg	aaggaaggaa	ggaaggaaga	aaggaaggaa	ggaaggaaga	gaaagatcct	211080
ttctttttcc	ccccaggaac	atggcagttt	gagaaaaatcg	ggaataaaac	awgtctttata	211140
atttgttaaa	tattgtaaaa	tactttcctt	attgttagta	gaattccatc	ttggcagact	211200
atttcttcta	ggaaaccatt	tacccttctc	ccttctctctg	ggcactrcat	ttctctttct	211260
ggtaagaaat	ctgtcaaagg	cacttcacca	ggaatctggc	tcttataaaa	tgcartaaaa	211320
ctgcaggcaa	tggggaaatg	accattactg	aaactccttt	ggagasggct	tagcttatga	211380
agtttttgag	cagttctacc	tgatgaccag	cttactatgc	tcactctttac	ttcctcctgt	211440
aacaggatga	ctgacacgtc	tcctctttgt	catgtgacct	tgacagacct	tcaggaattt	211500
atgtcgactg	cacattttcc	ttggccagtg	gctctggctc	tgccattga	cttgcatcag	211560
tcaacagaaa	tggtgcagac	ctaacatgag	cagaggctct	aagtaaactg	gtgtgatttg	211620
gattggcctc	ctgtgcttct	gccatttgct	ggagcaacat	tattcatgcc	gccacaggtc	211680
cccaaatgag	aacatgcag	cagctgatct	agaacttaagc	tatagcctag	aatcacatcc	211740
agcccatccc	aagacacca	gagtgcagcg	gaactctccc	agcagtttca	agagcagga	211800
atggctgttg	ttgcaagcct	ttgggtttcc	tggttatgta	taaagcagca	ttactcacta	211860
aaaacttcat	aaatacaaa	ctttctgcat	gagtttctat	tctgtgccct	gcaagctttt	211920
attaaaggca	tgtagagtga	aagtctgatt	ttacctgaat	tttaggaggt	cagggccaag	211980
gctggatgca	gcctagcagt	tgtgctgtgc	catgggaagg	gacagcatgt	gccccaaaa	212040
aaagtccagaa	caaaaaaac	cacaaagtgt	gagtgtggaa	aagtgctaca	ggcttctgga	212100
atcagttggc	tcactgaagt	tcaagcagca	actatgaaaa	agttgtggga	catattagca	212160
ttttataggg	attcttagaa	atacctaggg	agagaaaccc	cataaaaggc	tagattttct	212220
gccataatac	acaaagggac	acaggctatt	ggtatttagg	cattaaaggg	aagtttgacc	212280
cacccctgaa	ggctgaataa	gtgtgagaca	cctggtttat	atttatataa	atttttgacc	212340
aggacaaaatt	caaccttcta	agcacaatgc	aaagtgcagt	atccaatcta	ttaagcacca	212400
tgccctctaa	ctcataataa	atagcatata	gcaatcctgc	cacaggcgct	aacattttatt	212460
gagtttttct	actgactagg	ctgcgcctaaa	atatttttca	ggtttttaact	catttactgm	212520
ttcatgagat	aaattatttt	actatcttga	ttaaacaact	aagtaaagtt	ttgttttagaa	212580
gagtttagta	gttacaccaa	aatccagcag	aagaaaatga	ctgtaatttc	ctatataaca	212640
atcctttgat	agtttttctt	tatoccttct	cottacatct	gtgactaaca	cattatactt	212700
ccttaaaaata	aggtgggagc	cagcattttat	aaaatatatg	catatagaga	aaactaacac	212760
atacattaag	gagaggtgga	gaaaaaaaga	aagatcatat	ataatcattt	atttttatgt	212820
ycattttatgt	aattttatcta	tgtatataaa	tgacttacaa	taaaaatgag	tgtattccta	212880
gaaataatag	acaacaggga	attgtattct	tgggggtgaag	tctacaatgg	atagatggaa	212940
tagttgtatg	aataacattt	ttgagtatat	tagcttatct	tcaaaatgtg	cttggctctg	213000
tcattttagat	tatatattat	ccatgtatat	aaagaataat	gatatttaata	tactcttact	213060
gctaaattta	tacattacta	aaaataaaaa	gtgtcatata	tttgagcctg	aggacttatt	213120
tgaaagtctt	acatgaagaa	tattagaaac	atagggatta	cgtatcttga	ggatgaaatc	213180
tgtataattt	ctacttcagc	aaatcttgaa	aagcactctg	atatgtcatc	tattgcctaa	213240
taatgctgat	catatggaaa	ctggatcaac	ttgcaaaactg	gatcaacttg	caaactaata	213300
ttacatttag	taattattagt	ttacttcaat	tatctttcct	aactctoacc	ttgaaagtac	213360
tccactcatt	aaactatgca	tatacatata	tatatatata	tatatatata	tatatataga	213420
gagagagaga	gagagagaga	gagagagaga	gacaggatct	agctttgtca	cccaggctga	213480
agtacagtg	cacaaccttg	gctcaactgaa	acatccgct	cctgggttca	agcaattctt	213540
ctgcctcatc	ctccccagta	gctcagatta	caggcatgtg	acaccacacc	aggctaattt	213600
tttgtatttt	ctgtagagac	gggttttcac	catgttggcc	acgcttgtct	tgaactatgg	213660
aaactcaagt	aaccggcctc	ctcggcctcc	caaagtgtctg	agattacagg	catgagccat	213720
ggtgcccggg	ctattcttgt	actttgggtg	tctttttttt	tttttttgag	tagtcataca	213780
gaattataaa	gtgattcaca	ccctcttatt	ctaaatgtgt	tcagtctaaa	tgyaaaagtt	213840
ttagtataaa	ttaattctgt	atatttttat	ttaattttaa	gagtggagag	atatttagcta	213900
ataaaaattag	ctttggaaat	aaaaagaaca	gatacggtta	tagttccttt	ccccaaatgt	213960
tttaaaacta	caaaagcaat	taagaagcag	tatcacaaga	tttaaaagttt	ttaaggatat	214020
tattttgttc	cctaatagac	tacacaccgt	caatagttaa	agttcactaa	aaatccagaa	214080
gttgccacat	taggctgaac	tcacatttat	tattttctgtt	attagcttaa	cttatattta	214140



ttataggagg	gatgacttct	ttttacaatc	atttaatatg	acaaataata	tattacattt	214200
tgatttaatg	acaactttgt	gctttatcta	aaaggtagca	ttatttttgt	gtgtgaatta	214260
atctatgttc	caataaaact	tccaacataa	gtaaggctct	gtatgtatgt	tatgttcttt	214320
ctatatctct	ggatttatatg	gatttacata	cttgatgcc	agtacatatg	tacatatgtt	214380
taagtataat	atacatgtct	gagtataata	tatacatctt	tactgtacaa	actatgcata	214440
tgcataatcca	tattgcatgc	agctatgtag	atagactctg	acagcataga	aaaattttta	214500
acttaagcaa	agttgaatag	ctctcaagta	ctgatatatg	tatgtgtcca	atattatgat	214560
tccaccattg	ctaattgcaca	caaaaaaac	taccaattta	tttttcttat	ataattatat	214620
ctctgataaa	attattgttt	attcagaaac	ctaatatoga	ccattaatgt	tccagtttca	214680
gaaaaacaaa	actcctaaga	gaatgaatag	aaattttctt	aaggaattat	aaagaaccat	214740
ctcagaattt	tactctgtta	ctgcaaaatc	tcatgcaaa	ataaccaagt	acggtatgtg	214800
aacgtctctt	cttctaaagc	tcatgaaact	gctctctgat	tcctctagcg	ttgacaraga	214860
atctggagtt	cagtactcca	tttcattcct	ggacattttag	cccattattc	ttgtatccat	214920
atttcataat	ttcctttcat	gggggataat	tgtaagttaa	aggtgaattt	gttgactcaa	214980
accttataag	gaatcataga	tcaacctaaa	gatttctctaa	aaatatacct	acatatgtga	215040
tacttgcttt	gtctaagctg	cttaacaaca	acagaaaaaa	acaagcaaac	aaaaactcaa	215100
aaacaaaacc	aaaccaaagt	aaaactgat	ggcccaaact	tgtaaagtgt	attttcttgg	215160
ttaattattt	aaataacaaa	tatgaggaag	aaaggcattc	tagtgaatct	gctttaaatt	215220
acataggaga	gagtccttatg	taaaactaatg	ataatgaata	tggtcggagg	gtttgtatgt	215280
ggagggtctt	gtgttaagca	ctgtgaatac	tttgttccat	ttaaaccgca	ccttagactc	215340
tacaaarctg	agagagatta	tgacagttga	ccaagattac	acaatgagaa	agtaagagat	215400
agaagtggaa	cttgatcaca	ggaagtcact	tctaaagact	caacatttga	ccctgggtctc	215460
taacgcattg	attttgagcc	cagcagcatg	tgaatttatt	cctatcagga	taaatagaat	215520
gcaagttaact	tatttaactt	gagtcctcaga	tacatccaaa	taaaaataaa	tgccctcatt	215580
tatagcatca	cattctcagt	actaagtaag	ctatctataa	tgatacaatt	ccattgaggc	215640
agaagacttc	acttcatatc	tacacgacat	ttcattcttt	ctttctattt	gttttttcta	215700
gaagaattaa	ctgaaattca	tcccaagatg	aggcatcttg	gctgagggtga	gatatgcaaa	215760
tcattctgtg	tgtttgacag	tcacgggtag	ataaatcata	tcactaacia	aagtcagttg	215820
ttaaaacttg	aagcacattt	aataaaaaaga	gagatttctcc	cagtcacaca	ggccagggtg	215880
gtgcatagaa	atggcatttt	atcacttact	gaccagagag	ttgcaaatac	aatcccatca	215940
cctaaaaaca	aggaaacaaa	acaataataa	gaaaactttt	ttttttaatt	tttaatagaa	216000
agtcagtttt	gcttctgagt	aggatttga	aaataaaact	atgggttctt	ttaacttttt	216060
ttgctttacc	ttactagaca	ctgagttatt	attttttgaa	ggaaagtga	ttataaatca	216120
gaaattattt	tctctttttg	ttataaacct	taggacataa	gaaatacata	ttccagagag	216180
aatttataga	aaaaataaaa	gtaatgcttc	cattattagt	attctcccta	aaactatagt	216240
tagaaattat	aaaagttagg	aagggtccat	caatagtatt	gattgaaaat	gtaatgttac	216300
atgtatcaga	tacataaatc	cataaatcca	taacaatggc	aaaggagagac	atcattacta	216360
tttgataaaa	ttaatatact	tgaatatatt	cccacataaa	ttcactaact	attcaaaaaa	216420
cttcacagga	cttttgaatt	tccgttgttt	gttttactga	ttatgacagc	tcacaaagca	216480
gtatgtgtaa	ctttcaataa	taatttagtg	atgaaatatt	accaaacaag	aggagaggat	216540
tttgattacc	tatgggtatta	gtttatatca	ttgtgtaaca	aatcttcata	aaaatataat	216600
tcataaaaaat	tatatttcat	aaaaatattc	ataaaaaat	aatttttata	aacatattac	216660
cacgtgttat	cagctgggtc	ccagacacag	agtcctgcag	agtcagtgga	agatgtttgg	216720
cagactacat	tgtcatcaga	aggattggct	gggaagaatc	tgcttccaaa	ctcattcagc	216780
tttggtagaa	gttatttcc	tgtggttgca	tgactggtct	ttttgctgg	tgtagttgca	216840
ggtccacatt	cgttctagag	gctgctgcg	gtccttagag	gcctcatagg	caagggaactc	216900
atagtttctt	gocatgaaga	cttttccaac	atggctgctt	acttcttcaa	gctgtgaagg	216960
agatccrgtc	tcagttggcc	aggctctgtg	aaaggtaacc	tcatcaccgg	agtcaagtg	217020
catcaccttt	cccattgttc	attggttaga	agtcaccagct	cctgcccaca	ttcaagggtga	217080
aggggttata	caaatgtgtg	accaccaaga	agtcagatt	atgtgggtca	cttaggtgt	217140
aactgccaca	actacatatt	tggatataat	ttcaaagaaa	gactgtgaaa	aagcataaag	217200
aattgttaga	attgctgag	aattgaggac	gttcatctgc	aatgctgtc	aggcttacat	217260
taaaacagtc	tagcttactg	agaaagtgtt	aaaaaatggg	tttgatagac	tttacttatt	217320
gggagaagcc	atttgacttg	tctttgaggg	gaaaaataat	ttaaaaatac	agatatactc	217380
tctctgcaaa	acaattcctg	gaatatgatc	taacagaaaa	gccagcaga	cctgattcaa	217440
acctgatgtg	aacacagaat	gctttgaaat	gagtaaaatt	aattattaaa	cctaattttt	217500
cagggtgagga	aactgaaaca	ctgggtttaa	gtatcttttg	cagggtcaca	cagctaaaga	217560
attttggagc	aggaattcaa	attcaggcag	ctggcttcag	acctcatgct	attaaacctg	217620
atattaaact	tgacatccat	cttcatatgca	aatgttactc	tctctatcag	gaaaataacg	217680
catttataaa	agccagctca	gatgttactt	ccaaccaaca	aatttctctg	acacactaag	217740
taatagagtt	aatcacaccg	tctgtgaagt	actaccacaca	gtatccgggc	tctaccacat	217800

tgtaatgcaa	taggtgtggt	cacactgttt	gtctctcctg	gtgaatcggt	aattcatcag	217860
agcatgactg	tggtgtgtgt	ccattatcc	ttagtaaata	atgtagtgcc	ttgtgcatag	217920
gaagaaatta	atcttgatgg	ctttcaagtt	ccaccccaaa	cagtcaagcc	atgttgattg	217980
aaaagtatct	tctcagtttg	agagattacc	atcagagtat	ttgaaacaag	attgtatcct	218040
tggggactcc	atattgagga	cattttcttc	ataggattct	aaggctaat	gacttggcct	218100
gatcctaacc	taatccttta	gaaggctaga	gaataaaatt	aaatatgttt	ttcacttttc	218160
cagtggagta	agcagggttt	tattgtgctt	cttgaatcat	tgtcacacta	gtaatctctt	218220
caaaagcgaa	tttgttctgg	aaaataatgg	gttagaggcc	tctgtggagg	aatacagtag	218280
tggaatattt	tgaaataatt	gtaaagcaaa	acagataaatt	gcgtttttaa	gctctttgaa	218340
atatatacgt	aagatgttat	gtgcctgagg	ttgaacaaaa	agataaaatag	ttacagtcac	218400
taccocaata	tgtaccaatt	acaaatagca	ttgtgtgtac	atgtcctcta	ttataaaaatc	218460
agaacgggat	gaaaaagatt	ataatcacgt	taataatttg	atttgcttca	ttcatctttt	218520
gagttatctt	ttcataaaaat	tagatactgt	gttatttctt	tctggaaagt	acaatggtgc	218580
atgtgaggag	aatgttttca	tgtaaatcaa	tgctgacaag	aatattacac	ttaaaaaaca	218640
cagaaggcag	gcagggttggg	ggttggagga	cagacaaatg	aagaagacca	gattgaaatt	218700
attagttgcc	agaaatatat	ctattgactt	tttacatttt	tagaagtacc	tctgttagct	218760
tcccaaaaata	cagctgttta	cagtgtattga	taagttcccg	tgcttttaag	cttattcaca	218820
tccattagtt	ctgccttttt	cccctgttaa	aaatctgaag	ctgtcacatt	gaagtagcat	218880
gatcagctaa	tgttcctgcc	agattcaaaag	catgtcccca	ggggtggcaa	aagtattcaa	218940
aatctcaaaag	aaatggcttt	ttaaatgttg	cctgttgaca	ttggtcactc	catttgctgt	219000
atcagaaatg	ttgaaataaa	tatcaggcaa	ttatagaaac	aggactttga	tgatcaattt	219060
tctataaata	ttttatgttt	agcccaaaaa	aaagaaggca	tttggaattc	actattttgt	219120
ataaaacttt	tattttaaaa	tagtatgtag	tatatatttca	aaattgggta	attaattttc	219180
tagttttcac	ttcaataaat	gattattttac	tctattccct	ctagcattag	attattttct	219240
tgcaaacctg	tttttttttt	tctttttttc	tttttctgt	aatagtttta	gagtttctgc	219300
cttaacacat	ttaggtatat	ttttaggaa	caaagggaaa	aggtatcagg	gagaggaaa	219360
gatttctaaa	atgtaaattc	caaagacagg	gaatgtttaa	agtgtttgcc	agtcctgttt	219420
cttacagagc	acagaactca	gatgctctta	taaaagataca	ggataaatca	catcatttcc	219480
tgctccatca	tcagaatatt	attatatgat	ttagatcact	tttttaaaaa	agaacatggm	219540
cttagtacag	aaacaacagca	aaagcctggg	gaaggagagg	agtgcaccat	gaggagtcac	219600
tggggagcag	aagccagctc	atttgactga	tttgggtcgt	gtgcaaaaata	attgctaaat	219660
aatgtcatat	ctgtgagact	ccgggtattt	tcaaaaaccag	ctggcaaaat	tgtgtttatc	219720
tctacccctc	gctgggtttc	acgggttctc	tgttctctct	ccttttctct	cattctctct	219780
ttaccctaatt	tcctgaccac	tgtaatccaa	taatctaagg	ttttaggatt	tggatgacta	219840
aggttaccca	tggaaattgtt	tggaaatgta	gacctgtaat	ggagagggga	gaaaatgaag	219900
aaatagaagc	tgtacgaaaa	tagtcaatac	tgaggccagg	taccgtggct	catgcctgta	219960
atctcagcac	tatgggatgc	cgaagtgggc	agatcactgg	aggtcaggag	tttgagacca	220020
gctggggcaa	catgggtgaaa	cctcatcttt	agtataaaat	acaaaaaatta	tccaggcttg	220080
gttgtggatg	cctgtaatcc	cagctactcg	ggaggctggg	gcaggagaat	cgcttgaacc	220140
tgggagggcag	aggttgcagt	gagccgagat	tgccgcatgt	cactccagcc	tgggcaacaa	220200
gagtgaact	ctgtctcaaa	agaaaaaaaa	aaaaagaaaag	aaagaaaata	gtcgatactg	220260
agacctggaa	actgagagcg	ttcatgaatg	ctgcatccaa	agaatatattt	gtactacgtc	220320
ttattcatga	tacaaatcaa	gcaaataaag	acactctgtt	gttcacatat	gacactatat	220380
aggtcaacgg	ggtgagagag	ccaccagaa	acagacacac	aattttgtta	tcagatattc	220440
tggagagggt	tctctgaggg	agtggcatct	gaagaatata	cagatgttaa	ccaaatgaag	220500
caggtgggtt	tggggaaaaa	agtattccaa	ggagaggggc	aggtgttagg	acaactaaag	220560
agcaagggtg	attagaatac	tttgatgaag	tgaaaaaaac	actccaatga	gtgagcgctg	220620
atgaagaaaa	gggtggagag	cagattattg	aggtccattt	agatcatgtt	ttagatcctg	220680
gacagcatcc	ttaaaataat	aaggagccac	taaaagtttg	aagaagggca	atgacatgtt	220740
ccaatttgct	tttttacaag	atcactctga	cttctgcctg	gagtagcata	taaagggact	220800
aagcacgata	ccaggtggca	cataggagct	gaagtrgctc	ttgtcaaaat	aaggtgatgg	220860
gagtgaggag	ggatttgttt	cctaggctgc	tacaacagag	aactgtgaat	ggagtagctt	220920
aaaataacag	aaatctattc	tgtcccagtt	tgggatggag	gtttcagcag	gacatgctct	220980
ctctaaagac	tttaggggaa	aatctgttca	atgtccttct	cttagcttcc	agtgttgctg	221040
gcaatccatg	gagctccttg	cttgttgga	tatcactcca	tcatacgggt	gttcttctctg	221100
tatgtcttca	ccttctcttc	tccgtgtatg	tctgcctctg	tacctcttct	cctcttccaa	221160
caaggacccc	agtcataatg	gaatagagcc	actctaata	cctcatttta	actgattaca	221220
tctgcaataa	tctattttct	aaataaggct	atattcatag	gtattgcaga	ttaagactgc	221280
aatatatctt	tcttggggat	atagtttaac	cccaaacagg	ggattattga	aagggaagtga	221340
gataagggtt	agtggaaaga	aaccatgtaa	aggttttaaa	atatattttt	ggtggtagac	221400
tcaacaggac	ttcatgatta	agtctgagtt	tagggatgga	agcagagtcg	tggttgactt	221460



ccagggtttct	tccagatgat	gatgccattt	gttgagacac	aaaatccaac	ggatcaagta	221520
agtgggtgggt	tgagcatggg	ttcatttttt	tgacatgcc	agtttgatct	gtctgtgaaa	221580
tttttatgtg	gagctgtaga	tttgggtggt	aaaaatgcct	ttggaattca	aatgagagat	221640
ttgagttgga	gagataagtg	tgggagtcac	ttctattcaa	attatcatca	aagctatgca	221700
agtagataac	tttctccaac	cagataatgt	ttagtcagaa	gagaagaaac	cttgacatca	221760
acattaaaca	ttttaagaa	caatgtggac	tatttcagac	taatatgaac	aaaaaggacc	221820
agactaacc	tgccataaga	aaaaacaaac	cgtcaagaaa	cagacaggac	atttgaaacg	221880
atgggttttag	agacaaaaaa	catcaggcgag	ccaaggacag	aaaaataaag	aaatacattg	221940
atcccaacaa	ttgcctgaga	ttacctaagt	tcaggtaaaa	gacaatatg	tctgctttca	222000
atattttctat	ttaatgtgat	attgaaattt	gcattcatag	tagtaagaca	gcaataaata	222060
aaaggcatcc	aaattgtata	ggaggaaata	aactggtttt	atctgtagac	aatatcataa	222120
actatataaa	taactatgaa	acatacaaaa	aggtataaga	gctaattgat	gatttttagt	222180
aggtttcaaaa	attcaaat	aatatataac	attaaaatca	cttgatacaa	gagcaaaaga	222240
caatatgtaa	ttgaatttta	aaaaattgta	cttataatag	caaaaaatat	aaaaatattc	222300
cagataaatc	tgacaaaatt	tgtgaaagtt	tcacacagtt	aaaaatagaa	aacactaagg	222360
aaaaattaat	gattacctaa	ataaatgcag	aaagatacat	ttttaatggg	ttggaagata	222420
atattcttaa	gatgtcagtt	gtccccaat	tcacttatag	cttccctggt	atcccagcaa	222480
gctacattgt	ggaaattgac	aagctgaatt	taaaattcct	atgtaaagcg	aaaagaattg	222540
ttacagctgt	aacacttttc	taaaagaaca	aaactgggaa	taagtatat	tttaagacag	222600
ttattagcat	taagatagac	aatcaatag	gataaaatag	aaagtaaaaa	aaaaatagac	222660
ctatacatat	atggacaact	gattttggcc	aaggggcaaa	ggaaacttgt	tgggagaata	222720
gcaatatcat	attttcaaca	aatgatgttg	gaacatctgg	gtattcatta	caaaacgggt	222780
aatctttgat	ccatatttta	aatttaactc	aagttgaatt	atagatgttg	gtgtaaaatc	222840
tttaactata	aaattcatgg	aagaaaacat	atgagactaa	cagtgtaaat	tagcgttaag	222900
taaagatgta	ttagatgcaa	cagaacaaaa	catgatccat	gcaagaataa	atgtgataaa	222960
ctggacttca	taaaaattaa	acaatcgcaa	caacaaaaaa	taacaaagaa	atgaaaaaga	223020
gcttctgctc	tttaaaaaatc	attattaaga	aaattaaaag	acaattctcc	atggtacaca	223080
agaaaaagatt	tacaaaagggt	atatctaata	taagatttgt	atccagaaag	tataaagaaa	223140
cctcaatggt	caataagaga	aaaaaaataa	aaatgagcaa	aagctttagc	agaccactga	223200
aaaaaaatgg	gtagagaata	tgcatatgar	aagatgctca	atatcattag	tcattaggaa	223260
aatgcaaatg	aaagcataac	aagatagcac	tgccctcttt	tttaaaagtc	taaaactaaa	223320
aatgctgacc	atatcaagtg	ttggtgagaa	tatggagaaa	ctagaacact	catatcctgt	223380
ctgtagggaat	gcaaaaatgg	taaaattact	tgaaaaacaa	taatgaagca	gattccttaa	223440
ataaagggtg	atctatccaa	ctactattag	atctattcaa	ttgatctagg	tatttaccce	223500
tggaagttaa	agcatatctt	cattataaga	cttctacaca	aattatcaca	tctttactta	223560
cagcagctga	aacctggaaa	caactcta	gcccgtcaac	agaggaatgg	atggataaag	223620
aaactgtgat	gcagtggaa	acgactcaac	gaagatgaga	ctaaaaataa	ttatactgag	223680
taaaagaatc	caacaaaaat	agagcaaaac	ctgtgccaac	ctgtttatac	cttactccag	223740
taaatgcaaa	ctaatacaca	atgaaaaaaa	ttactttatt	gagaactggg	gagaggaagg	223800
agaggggaa	gggtagataa	agaaaagagg	agagattaaa	aggagcataa	gaaaacctca	223860
gagaataata	ggtttgtggt	aaacattacc	gtggtaatgt	ttttagggtg	tattcacatg	223920
taaaaactta	tccaattata	catttttaaat	atgtacagtt	tagtgtgtca	gttatgcctc	223980
tgtaaagtgg	atttttaaaa	aagttcctat	ttccaagttc	acaatttcat	ttgaactctt	224040
aaaaactggc	caggagcagt	ggctcatgcc	tgtaatccca	gcactttgag	gagcagaagc	224100
aggcagatca	cgagggttag	agtttgacac	cagcctgaac	aacatggtga	aacctgtct	224160
ctactaaaaa	tacaaaaagt	agccagacgt	gggtgtgggc	acctgtaatt	ccwgttccag	224220
gaggctgagg	caggagaatt	gcttgtacct	gggaggcgga	ggttgcaagt	agccgtgatc	224280
gcaccactgc	actccagctt	gggtgacaga	gtgagactcc	atctcaaaga	aaaaaaaaaa	224340
aaaaaactta	caaccaaggtc	aaagcagagg	agctggcaca	agagactgag	aaaaagagca	224400
gagtgataga	gaataagaaa	tgagagctcc	cacggaaagt	aagggcagga	accacacagt	224460
ccttccctcat	gctacttaga	agtttaaaaa	aaaaatgaga	gttaaaaaag	gccattcggt	224520
tcagaagtaa	cattatggac	taatgaaaag	gaatttagtt	aaataaggca	tgagacaaaa	224580
gaaagttagt	tgactgagaa	atgatgaaat	agagtgagca	agtaatatgg	tttggctgtg	224640
tcctcatcca	tatctcatct	tgaattgtag	tttccacaat	cccacgtatc	atgggaggga	224700
ccctgggagg	taactgaatc	atggggggcag	gtctttctct	tgctgttctt	gtgatagtga	224760
ataagtctca	tgagatctaa	tggttttata	arggggaatt	tttctacaca	ggctctctct	224820
cttgactgct	gccatataag	tccttttgct	cttctctcat	cttctgccat	aattgttaagg	224880
ccttctcagc	catgtggaaa	tgtgagtcaa	ttaaacctct	ttcctttgtc	tcaggatagt	224940
ctttattagc	agtgtgagaa	cagactaata	caagcaagtat	aaaaaacatt	aaatgtttgt	225000
cttctaaggg	aagagaggag	agtagagaga	gagagattgt	tagctgaagg	gtaaaagtatt	225060
cttggttatta	agatatcaga	gcctagaaca	tatttaataa	ctgatgagaa	ggatacaagg	225120

gagagagaaa	atttgaatca	atagtttgtt	tccactacca	cagaaaagga	tgagatccag	225180
aggtttgata	gaggaatgag	ttttcctcat	tggagagata	agagcagatg	ggtttgaaatg	225240
ctggatccta	agggtgggat	attaagggag	tctgtttttt	atggccttta	ttttctcttt	225300
gatcttggca	gcaaggatgt	ctgccaagat	ttaagggttt	ggacaggagg	atcatagtgtt	225360
taatgaataa	aaacatata	gaaatagcca	cttcagagag	tggggcagac	agtatgtgtt	225420
ttagttttaga	ccagagtccc	tggagttata	gggttttgaa	ttcaaatacct	agctcctcca	225480
ttcacctgtg	gtactgtgaa	caatgacaga	accaagttaa	gaccccaaat	cttctttaaa	225540
gtgggatgat	aatggcatgt	tcacccataga	cttcttggga	gtaataaatg	aaatacttta	225600
gttcaactat	tttcacaggt	cctgacactg	ggttttgaat	aaattgtgcc	caggactatt	225660
gctattataa	agcaaaatga	aaaaacacaa	tggcccaatt	aatatgtttc	caaggagtcc	225720
aatactaaga	agaaaagtat	tgttggaaat	ggaaatccac	attactagat	taacatgtgg	225780
agaacttgct	caaagaggag	gctggtttag	atgctgtgat	aatttttagat	gtcaaattgga	225840
ctggattatg	gaaataccca	gagaactggt	aaagcatcat	ttttgggtgtt	tctgcgagga	225900
tgtttccaga	agactttggc	atctgctca	gtggactgag	tgaggaagat	ccctccttac	225960
cgtgggcagg	tgccgtctca	tcagctgatg	gccagatgg	aataagatag	aggaaggaat	226020
atgtgtttct	ctccttctta	gggctggaac	ttactcttca	ttccctgctc	ttggacaaca	226080
gaactccact	ttttggactc	taggtattac	actagcacc	cacttcccat	agccgagtcc	226140
ttactcctta	gatcttggtc	tgagagttac	accattggct	tccagggcca	cactactcca	226200
tgccaggatc	tccagcttgc	agatggcttg	tctggaggct	tttcagtctc	tataatcacg	226260
agccaattct	cttaacaaat	gctatctatc	tatctatcta	tctatctatc	tatctatcta	226320
tctatctatg	tctatctcca	tccatccatc	catctatgta	tctattatct	atatctatcc	226380
tattgggttct	atctgtctgg	agaaccctaa	tacagatgcc	agcaaaccaa	aaccaagtgg	226440
caaagtgtcta	ccattgacat	tcctctcctt	ccttaatgac	tcttagtaac	caaaaacaca	226500
tgtaaaattc	catgtaatac	acaagccaga	aaaggtaaaa	tattgtatct	gctagttcac	226560
acagctcatt	tcactaccac	aatctaccat	tattcaaata	ctgattttaga	aatgacagc	226620
ctccaaaaga	ctaaaatcat	cagttttttac	ttagaagaaa	aagaaatgaa	attttaatga	226680
cagggaattt	taatcttact	atttcaattt	ataagatgtg	actggctgaa	tattgttatg	226740
tactaaaatg	ataaatacta	tgtgttatta	aatattttgt	cattgaaaaa	tgacctatta	226800
ttctgacctc	ttttattttc	aggggtactt	ttagataaag	gagtttataa	aggcttctgc	226860
taaagaagac	atcagagaaa	atgtcttcca	attgatttat	cttgctttgt	ttctgagcat	226920
cttgactcca	actgtattgc	aatgaaaaat	aattttttta	aatggcagag	actctgattt	226980
gtcctaggcc	ccttcttcta	aattccaaga	gtctatgtga	actcttctta	tgagtttctt	227040
aaaattccag	aaagtagtct	ctactgggtt	aaatgggtgc	ccctcaaaat	ttatgtcatt	227100
tccagaaccc	cagaatgtgc	ccttatttgg	aaatagggtc	attgtggatg	tacttagtta	227160
agatgaggta	atactagagt	agagtgggct	ctacatccaa	tattgctggg	gtctttctag	227220
gaagaggagc	agagccacag	ggaatgggtg	ccatgtgaag	acagaggtag	agattgactg	227280
atgtgcctgt	cagccaagga	aggtggcgca	ttgcccggca	ccatcaggaa	gtcggagata	227340
agcctggcac	agattctctg	tccagtggga	accagcctgt	gtgttaattt	cagacttcta	227400
ccctccagaa	ctatgagaca	ataaattgcc	taaaactggt	ttaagccact	cagtttgcaa	227460
tagtgtatta	tgtcagccct	aaaaagctaa	tacaaagccc	tagagaattt	caataaagg	227520
gtcaggaaaat	atagatcaca	gacaataatg	ataggacctt	ctagcattct	tacacttctg	227580
taatgtttgt	tgtctttctg	gtctctctta	tatgtcttta	ttgtgattgg	caaaaaatcc	227640
ttgaaaaaac	caagaaacaa	tacgaacaga	aacaaagcta	tgtactttgt	ttgggaagca	227700
acctcaaatg	gaaagatggg	ggctgtgttc	taaaagggtg	ggagaaattt	atagcgaaga	227760
taaagagata	aagataaatg	gtcctgtgca	ccactgaatt	ctgagaactc	tgaacaaaa	227820
ctaagtatat	gttagtgccc	agtgaatagt	tgttgaaatg	atggatgaat	caacaaataa	227880
atgaattgat	gagataatca	atctgtgaga	caaaaagcaa	cacaaatgag	tagacaagag	227940
tgggttagtt	tggctaaaaa	ttgaagatca	ccattttttt	cagccaagta	ggcaggcatc	228000
tgctacttgc	caggcatggg	tattggtgtt	tggcataatg	aatagcaaaa	acaaagtcct	228060
actgtcaagg	aacatagact	cttgggaattt	agaagaaggg	gcatgggaca	aatcagagtc	228120
tccgcoatta	aaaaaaaaat	atttttaatt	gcaatacagt	tggagtcaag	atgctcagaa	228180
ataaagcaag	ataaatcaat	tggtttaaaa	tatctttcac	actaccottc	catggaaggt	228240
gcagagaagg	ttccagtcta	aatgtaggca	actggagact	cccttttctt	atattccttt	228300
aaaccttatg	ccccaaaatg	tgtaatcaag	tctattcttg	aacagaaaag	aacacagtgc	228360
cctttctctt	tggaaatttta	tataagcccc	taagaaaagc	tgctattgtc	ctagtttgta	228420
aaagtacaaa	tgggtgagta	tgcattctgct	ctgttcagtt	ggaaaattag	tacagggttc	228480
agcactcctc	gataccaatt	gactattgaa	tgcgtactaa	gggaagcttc	tgtacagacc	228540
agtaaacacc	acaattgcag	aaatcctcta	attaaagaaa	cacaocataa	tcttctgggt	228600
gaatctgaag	aaaaggtttt	ttagaaaagt	acatctgtat	aaggtaacatt	tgtgtaaaaa	228660
acaatcattt	ttcattgaag	tgagctgtga	ttgttagatg	ttgttctaag	aaaactcagc	228720
ttaaaatttc	ttataggctg	ctttggctta	aaataattgc	ctaactggat	ggtcacaaat	228780

```

gaccaagaaa ccaaataatat ttcatagtat taactatcat tacagagtgt taaataatac 228840
tgcacagtag agatcttttg aaaaatattt taaatgatag attctatttt gggttgaggc 228900
aaagtcttaa acataacaag ttaaataaat ttttaatgaa atttttacaag tgaataaatt 228960
aatgttcaag acatagaatc atgccttttg gaaatgactc tcatgatatt ctattatttt 229020
aaaaactatg tgcctatttt taggaattaa attgctctgg tagatacccg ataaatatct 229080
atctcacaaa tcatgttttt ctgtcatatg taaatttttt aaatgtttta gtttataggt 229140
tggttggtct tgtcaccag gctggacagc agtgctgtga tctcggctca ctgaatactc 229200
tcctttctgg gttcaaggga tcctccctcc tcagcttccc aagaagctgg gactacaggc 229260
atgcaccaac atatctggct aatttttaaa ttctttgtag agatggcatc taggtttccc 229320
tggttggtct tgaactcttg ggctcaagca gttccctac tttggccttc caaagtatgg 229380
gattacaagc atgagccact atgcctgggt agtttctaatt ttttacattc agttttatttt 229440
tatgtgactg gcattttgtgt aggattattt ttataaccaa tatgttttag gtatgtaacc 229500
cagaagtaaa tcaactaatta atctgcaccg gaggaagtat aatttaggga gtagtagaac 229560
tctatctgat agactgcact gcaggtaagg tgtcacagcc ttgaagcgcc tcagtgactt 229620
tgggaaaaac aagcaccaag actgaccttc cagatccaag gtctggtagc aggatggttt 229680
tcattttccat ctgtttggag tctcagcttc tgacataaag gcctgcttta tacaaaatga 229740
gcctgattga aagatgtaag ccaccagggt agaggagag ctacaggagg cagacaggag 229800
aaagtaagag aagagtgcac ttgttcttcc actagcttgt ggctactaac aaatttcctc 229860
agaaagtgtc tgaggattcc tcagaacaat ttacagagat aactgtaagc tgcagagggc 229920
tatgaaaacg ctcatgggtg ctgacaggag cccctgggtg gtggtgggtt gggaatacag 229980
gggctctgta ggggttgaa gaactgtgct tgacaccaat caatgggagc ctggagaaac 230040
tgaggcaggg atctgaaatcg tgctgagact caaacgtttt gagttagagt actcaccagg 230100
tactctaact caatcatatg ccttgggtat aaggaaatta ggaataattg gaactgtggc 230160
tggcccaaaa tttcatgccc ttttatagc cattcatcaa atttagaatg aggtaaagga 230220
aggattcttt ttattatttt ttaaaatacc cacctcattt tttacacca catcataaatt 230280
caccgagagg gagaattagg cctgtggacc tccttttttg tagtacctca tatgtaattt 230340
tttttttttt ttttacagat tcatgttttt tggtacaagt gaacgtttta taacraaaag 230400
gottttttgt tgttgttttt atttctata aaaatacctc tgggtgaaaa ttgttaagaa 230460
agctaattat tgtatcttta catgactcta aatttggtct atttaaaaag tcaaaacata 230520
gacatttgga aatgactttc tcctttcagt actgaagtgt agaggagagaa ggaaaaaaag 230580
tgagaaattc cagtgcctgg atgttcccag gctaatttct agacaagtga gttttgataa 230640
gttcaagttt cagatgagaa tttctttttt cttctctcat tggttttccc acatcgtgag 230700
ttaaatgtc tctgaaagag tctgaaaaaa tatatatatt aatgtggaga attatttaca 230760
taaaatttta ataaactaat atgagaatga gacctccaa taaatattgt ttagagttat 230820
tttaatagtc ctctccccta tcataaccca tttaaaaatg tgggtatata tatatgtgtg 230880
tgcattcata aaaatttagt gtgcagttct tagtttttct ttatgcaaaa cacacaaaat 230940
aaatgtaat aattgaagcc attacacaga catttttctt gctaagttct gtaaattagat 231000
attccaataa agacactacc aacatcttac tttgtcttaa atataattga gagtatttcc 231060
atattaaacg ttttaataaa aaatgattgg atttcaaatt gccttaaaga ttcataatgt 231120
aatattcttc accctaaatc acccagatta tttctaattg tttctttatt ttgocctcat 231180
aaatacagcc tttgattaat tttagcggaat ttatcaatct gagatatttt taccttccca 231240
cattacagca tggcattgaa tgaaaactta ctttgttgc taaatgtatc aaacacagtt 231300
tctgtgtgca agttcctctc cttttctaaa tttgtctaga ggatctcata aaacgtaact 231360
cctctgacaa gggaaccatt tttagcaccaa cactgcaaaa gottctgtgt tcctaaggga 231420
aagatccttt cctgaattaa atttaacctc ttttagtact ccatttagcc acctgataaa 231480
tccacttgag ctatcttttg ggaagagaga ggtatctggg aacaataaca ctctctttt 231540
gaacagttta ataaagcttt gtgagatttc aagatgaaag ataatgtgta atgctgatag 231600
tgccctccaa ggctctgcat tcatggatcc aattacgttt tttgtcatgg taaaagccac 231660
agtggatata ttaaatraga gtgtggttta agaatgaagg cccaggagtc tggagatctg 231720
gtttctaagg ctgacttcac ttctgctttc ttatctcact aggggtatgc agcttaacat 231780
ctttacctca gtgtctcctt ccataaagtg cccagcaaat atctgagaaa ttcttttaaa 231840
atgacagtgc aaattgccat ttagaatcac cttggaatgt ctagaaaaaa atgaggtgaa 231900
tgttcgttca gaacgggaaa tacaatcttc tgccttaattt cagattttatc atcaagtttg 231960
tcttttactt tttaaaagtc atgagatttc cagaagagga atgacatttt caaagcctta 232020
aggacacttg tgaaaacact ccttcaacta ttctttattt ctacccaaaa ttttgactct 232080
ggcttttctc caacttcctc tcttccccaa ttcccaattc caacttgaaa agagtaattg 232140
caatcttaac tttttccatt ctggagtatt ttcttgcagc cgatttggtt catataattg 232200
taaaatttat catgtcagat tttgttttag ttgcacgttt gctggcttta gtcagtcaat 232260
cccaaaaccc ttaaaactgat taatttcacc gtgaaataat tgattacgaa tttgtagcat 232320
tatctgactt tattttaaaa tgcaagttga tagaacattg tcatttattg attaatctat 232380
tgccctttgc cttgagataa ttttgaagaa gcagaatagt gccattagta agacaatatc 232440

```

tatgtattac	aaatgatcat	gttcttaaaa	tacacacgca	cacacacacg	cgcattgcaca	232500
cactcacact	ttctagtaat	aagcagtggt	ttgagtaaaa	tcttttgaaa	gatgttttagc	232560
aaatcgaaac	aatttctgtc	ttcctatgtg	atgctcgcaa	ttatatgggt	tagatatatta	232620
ttgaaggact	tgggaaacct	catagtccca	ttggcattat	tctcaacata	tcaaagatttc	232680
attcagttata	aataaataat	ttcattactt	ataataataa	aagttatcat	ggaaaattttt	232740
ataacctagt	aaataggatg	tcatagaaat	attcaacacg	gataaataaa	atatatacat	232800
agtttaaaatt	agaacacctg	ttatagaatg	gtacagtcta	actctctggc	caggtaagct	232860
tctagcatga	aacttcacac	aatcatacct	acaatatggt	cttgccctaat	tccttggtcc	232920
aaaggaaagt	ttgataagga	agttgaataa	tttagcttcc	ttttagagat	ggtagagcct	232980
atttaagtag	ctttcctgta	gtacaaaaag	attaggcagc	tctgattgga	actctagatt	233040
gaaaatgagt	agaaataacc	tcttatagaa	cacgtctaaa	tttaactttg	cttcacaccg	233100
ataaactata	gcctctacta	ctttatagac	agattatagc	tcatcagtag	gactaaaaat	233160
cactgtggaa	ttactctgca	atagtcctgt	tgctatgtct	ataaatataa	tttcagttag	233220
tgaactttcc	attttctagc	tgcttggtct	tacttttttt	gcgtggcaca	ctaaagggtc	233280
ttaggaatat	ggtaaatgac	aaatttaaat	agcctcagat	aaaacatgaa	agtcaacatt	233340
aaattatttg	gttaaacatt	attttcagaa	caatttttaa	aaataatatt	ttgcaactga	233400
ttttaactta	atgtttatca	tattctaaaa	aggtaaaaaa	aatgcaatgt	tggtttattct	233460
cgttaagcct	aacatgaaaa	taaaagcatt	atttagggga	aaaagtccca	tttaattatg	233520
tgaacacata	attaaataat	tatcataaga	ggcaaaaaaa	gatagatagc	atcagatatt	233580
gtagcttggt	agagcttcag	tactaggggg	tcaaacagtt	gaaaaataatc	tgggaaacag	233640
ttttaagtggt	tttatattta	aaacacctac	acacacaaac	acacacacac	acacacacac	233700
actctcacgt	aggcagtggt	aaatttacat	tgcttccttc	ccatgttatt	gttgtgtatg	233760
ggcaggctta	tttttcacat	atttccctct	caatagcctt	ggggttctaa	agagagacac	233820
aacattatca	cccaagatgc	ttgacaaaga	tgggtatttt	gaggggtgatc	cagattttact	233880
gatgatatga	ggcctggaaa	tctgaaaatt	taacaaactt	tcctagtaat	ttttataaaa	233940
aacaaaaattc	aagaaaaaact	actgcatgaa	aaaaatgtgaa	gaagccagtg	gatactttta	234000
aaaaagtgtt	aaaatgggtc	ctatgtaata	gacaaataat	ctctgagcta	gataaaaagt	234060
caacatgaag	tataatctaa	tattaaaaag	cccagagaag	ttgctttcgt	aagttccaac	234120
attagcattt	agctttctcc	tgggttaaaag	tttaaaatga	agaagataca	tactctgcac	234180
agggtctagg	aaggtaagag	acccaaggac	ataatgatct	ctgtaaatgc	ctctgtgcca	234240
tttccaaata	gccgtcctca	tgcttctctc	tccatccttc	tttcttgggt	accgtctctc	234300
ttccttcttc	tgtctccttt	gctgcaacag	tattttaagt	gatataataat	acatattaac	234360
tctatcacat	cttttaacat	acatgttggt	ttaatgactg	tggagcgatt	gtaggaattg	234420
tccattttac	ttaatttttc	agaggttttt	gggttaagaca	aaattccctc	agagactcaa	234480
atgtcatctg	ttgattgaaa	tatacatctg	tggttttgaga	ttaagcccaa	acgaagggtg	234540
gcttctctct	ctggtatcga	ctatactttg	agtcattttg	ttacagttaa	acaaaaatat	234600
caaaaatggca	cgaaaaaatt	aactgtgggt	ccctaattctt	tgcttctcat	gaaatggatt	234660
gcctatacca	tacttaataa	acatgtgcat	agcctttcca	aagctccaaa	cctcacgatg	234720
aaatagtcct	ctcgtccctt	cctgtgtgga	gtgttgggaa	gattcccttt	ccctgtcaag	234780
gggcctttcc	tcoggtgttg	accacaaggt	agttttttga	ggggatctta	agttgtatta	234840
gtattttatg	agttctttaga	taggggttaa	taattctctc	tactttggcg	tggaaagaga	234900
atggagtgtg	atagtgaatg	tgggaaaaag	ttgtgaaaga	ctgtgaaatg	agctgtaaaag	234960
attactaaat	cacctgacta	gcagagtctt	ccaagatttc	tctgcctttc	atcatctttg	235020
agctattttg	caactttgta	aaatttttaa	aatatgatat	aaatgcaatt	gactttcttc	235080
cagaaaaatg	caaagagagt	gtccagtga	aatgtctaag	attattgtct	tgtgaatcga	235140
ccagttttac	ctgtagatga	ttttaaat	gcctttgaat	tggttgtaac	atcttattgt	235200
ttctcttatt	aatcaagtaa	aatctttgat	tcatgttcat	gatacatctg	tatgagctta	235260
ccatgtcttt	aaatgcctta	tcatgttaac	ataacctact	ttctagacaa	atagsactcc	235320
ctttcttatt	ttcaagtaag	tagcaaacac	ttatttgaaa	ttctgagccc	atcaatttat	235380
tttttatatg	aaaggatgaa	catttcctag	aagccctctt	ggatcatctt	aggtaaacct	235440
catatcaaat	ctgtgcta	atgttatttg	tcctggaact	ggttcttagt	ccaaatttta	235500
taccattttat	tcgactctta	tatccttcac	cttgatcaat	ataaagtga	tttgccacac	235560
attcggtttg	accaatatta	ttctctgtat	agtggtttta	actcaattat	caaactgtat	235620
tttaaaaaatt	gaatggccag	gtgtggtggc	tcacatcttc	tataatccca	gcactttggg	235680
aggccaagg	gggaggatca	cctgaggtca	ggagttggag	accagcctgg	ccaacatgg	235740
gaaaccctgt	ctctactaag	aatacaaaaa	aattggccgg	gcacggtggc	tcatgcctgt	235800
aatcccagca	ttttgggagg	cagagggcgg	cggatcacaa	ggtcaggaga	tcaagaccat	235860
catggctaac	acgatgaaac	cccatctgta	ctaaaaacaa	aaaattagcc	aggcttggtg	235920
gtgggcgcct	gtagtcccag	ctactcggga	ggttgaggca	ggagaatggc	atgaacccgg	235980
gaggcggagc	ttgcagttag	ctgagatcgt	gtcactgcac	tcgagcctgg	gccacagagc	236040
gtgccatcaa	aaaagaaaaa	agaaaaaaga	aaagaaaaca	aattagctag	ttgtggtggt	236100

gtgtgcctgt	agtctcagct	gcttgggagg	ctgaggcagg	agaattgctt	gaacccagga	236160
cgagaggtt	gcagtgcagc	cagatggcac	cactgcactc	cagcctgggc	aacggagcaa	236220
gactctgtct	caaaataatt	taaaataaac	aaataaataa	aaatagaata	ttttggttg	236280
gtgtacatgg	gtgagctgct	ttattttatg	tatgtagaat	ttctaaaata	attgtgcttt	236340
taccgtctag	cttctataat	ttataaatat	gtaataaata	gtagataatg	ttaatgagtg	236400
tggtgttttg	cattttgtta	gttggcttaa	aaatgagaat	gataaaaaag	gcatgggtatc	236460
agggcatttt	aaaattatta	gccatggggg	taaaaaagaa	aaaggaaagt	gagacaagtt	236520
gccagcatgg	ctacacagag	aaattccagt	ttccccaaaa	ctggaaaaga	atagcatttt	236580
atatgaggac	agtgtgctta	atacataaca	aagatagctg	ctatatatta	gaaattatgt	236640
ttgttattcc	ttaagcagtt	attttttaac	ttgatagttt	attctggtta	gatataatac	236700
aagaatataa	ctctagtctc	ttcttgcaaa	aaaaaaaaaa	aattccaatg	agcaagatga	236760
ttaatccagt	aaagaaacat	gtccagcctg	gggacaaaaa	aaaagtagat	caaatttttg	236820
ttaggaagat	taaccaagta	aaaatccatt	agctgggaatt	tattgtaaaa	gccaataaga	236880
aatcatccaa	gaaataaaaa	actaaaaata	gccctcaata	tggataaaaa	aaagacatag	236940
agtgattctc	tttgcatcca	atagagactg	agaaaacaca	actgtcagaa	tattaaatat	237000
tgctttggaa	agttttggaa	tatgatgaaa	gtaaattaga	caattgctag	aaaaatatcc	237060
ttcagtttgt	tccccacaca	tcacaaaatt	cagcttgata	ccattttctt	tttcttgaca	237120
aatttagggc	ttttattagt	gctatgacag	aaagaaggaa	tgctaccaa	aagaccattt	237180
gaatttactt	taattatttc	agagtaggga	aacgataatt	ggaaagtagt	ttataacctt	237240
gagtttgtaa	aatctgtaaa	ctctcacac	gatgtgaagg	cagagaaagt	atcaaactca	237300
gtccctata	ataagctcat	tacttcataa	aatatatata	cccttcactc	atgtgtcaga	237360
aatgtttaaa	attttcacca	ctgggtacatt	atttttgggc	cttacatttt	tgtggatttg	237420
gtgaatacct	gaaagaaata	aaataggatt	ggataatgtg	aatttctttt	acactcattt	237480
tcattattag	aaaataaagc	ccaaataaaa	tatgacagag	cagaattagt	tttaatacag	237540
gaaaaatttg	caagttgaag	aggagaaaat	gcagccagga	actaacggta	cacacctagg	237600
tggttaaagc	agtgtggatg	gtgataagag	aacataagga	aaattctgcc	ctccagctac	237660
tttgaattta	gtgttctgcc	tagtatgaat	attattgaac	cctatggtat	ggtacttaac	237720
tatctaatag	gatgataact	ctctcctacc	tgtagaaaat	gtagatgcct	tgtctacttc	237780
tgcttatata	catgctgaaa	catactgatg	tctgctgtct	tcttaatttt	acactaattt	237840
ttaaagtaaa	gattgatttg	ataaaaaata	tgcacttgga	aaaattattc	tgctattccc	237900
acatttcatg	ttcatgtcta	tttacagcta	acaagactag	cacgcaaata	gatataatgt	237960
ccaagatctc	gcttcttttc	atgtctggct	tctccctgtt	taccacaaat	tattttcata	238020
atattttact	gtgattccac	aaaccagaga	caaatctctg	aagggaatag	tgttccaagg	238080
catggccatc	attagaagac	aataagcttg	ttttccttcc	aacattctta	gctttgttga	238140
aggctaagtg	gaagaaatta	acatactgca	tgcctttcaa	tgaataattgt	ttctaattat	238200
tttgcttctc	aaattattcc	accaggcatt	gattagactt	tttaaatcca	tttcataatc	238260
gtcactctca	gctaacattt	gtaatttttt	aattgttgtt	aaagagaatc	tattaattga	238320
aatataatta	tctcttttaa	taaaagttaa	tgggtagcca	acataattcaa	238380	
gtaatcatca	atcttggtca	gaaattaaaa	gtaagatgag	catctaaact	tggcactcaa	238440
agactgacca	tctgcacctt	tgaggcaaaa	taaaattcag	tttaggaaaa	ccttatgaaa	238500
atcaatgttt	taattatgct	atcaagggtc	gtggtaggca	gaaacttctt	tgtctcacc	238560
cccaaaaatg	tccagttctt	aatcctgaaa	acctgtggaa	tcttgtgtaa	caaagggact	238620
tcatagatgt	aattaatggt	aacgaccggg	aggtggagag	tgacctcgtg	tatcctgggtg	238680
ggtccaaggt	agtcacaggc	atctttataa	tcagtgaagg	tctccctgct	gtgcttagag	238740
agggggatgc	tggagaaga	gtggtcagag	aagcaacatt	gctgactcya	aagacagagg	238800
gcaggccaag	agccaaggca	tgcaggaggc	ctccagaagc	tggggcaggc	aagagaatgg	238860
actcagccct	ggagccctca	gaaggcatgc	agccctgccc	attccttgct	tttagccagg	238920
taagatgtct	gtcagcctga	tgagaactat	gaaataatga	atgtgcttgt	ttttttcacc	238980
actaaatttg	tgcttatttg	ttatagcagt	gatagaaaac	taagacaagg	ctatatcttg	239040
gcatgtcaga	ttttaagtta	tctgctatag	tttagaaaa	ccanagaag	gagctgcaat	239100
ttgtctcttt	gaaaaaaaaa	aaaaaaaaaa	ggatcacctt	ctaggggatt	aaacattaat	239160
gggtctgggtg	ttgtggctga	cacctgtaat	cctagcactt	ggggaggccg	aggcgtgct	239220
gcactccagc	ctgggcaaca	tagtgagacc	ctgtctccag	aaaaaaaaaa	aaaaaagaaa	239280
aagaattaaa	cgttgacaga	ttattaaagt	aggcactgtg	tgagacctag	cttgggtttg	239340
cgctataga	tatttaaaag	ttgatccagg	ttttcacttg	aaagcagaac	tactgcctta	239400
aattcccaact	tcacaaaaat	aatcatgga	ttgagggaaa	aatttacttg	tttgctttat	239460
aaaaagagat	atcgatctct	tcataagtta	tatatgtttt	acaaggttgc	actgtttgaa	239520
ctgttaagtgt	gaatggttgc	taacactcca	gaaaccaaga	ggtacatttt	aactggaaaa	239580
attttcttcc	tgtatcttac	aaattaattg	aagtttctct	acgcttgaaa	atatgtcaaa	239640
agtattatgt	agctttacca	cagttttatc	taacttctag	aagaatttaa	attcatataa	239700
agataaagag	taacatacca	atagagttaa	gagagttttc	agatttgctc	agaagaatgc	239760

```

tcytttgaaa acctatgaag tagattttac ccaatgtata tctggatcta aaaattaaag 239820
aaaatatcag tcgtgttcag attcctttat accctgcaga agagagaaag aataagcaac 239880
atcaatggag catataacat gtatggttta gcactttcat atttttaatc ttaactatto 239940
agccaaatac gtcttatttt tttattttta tagatgaaga tattgaggtt tgcatttttt 240000
ttttataaat tgctcagtoa tacagtgggt aaatagctga caggagagtt cactccaggt 240060
cttactggct ctcaaacctt tgctttttta aaatctccaa actagcgccct ctccctttta 240120
actgcaaaat aagcacaaag ttatcccagt tctacacagt gctaaacaaa ttcctgtgag 240180
caaacaatta gcacaggcag atggagtgag ggggaggttg tttataacaa tggaaagctg 240240
tctgctgtct gtggattaaa gattcaaaact ctttgatcct cctcccaggg ataggtgagg 240300
gcctatgtct cctcctcatt aacatgagtg atccttggtt aggttctcct ttgactgaca 240360
gaatatggga gaaagtaagg ctgaaccata tactgggctc aggttccaa cctgacatg 240420
ttccacttcc tgtctccagg aacattccac ctgggagctc tgtgctgcca tgcaaatgtc 240480
acattgcaact gaggccgcca tgctgtaaaa aaccccaagc tacctacctg aaaagctgga 240540
gagaatcagc acccatcagc ttttccagca ttttgggtcc tcccagctaa atcatcgga 240600
ttgtgaagca gagatgagac ctctgccat gccctttcca aatcctggac caacagaatc 240660
atcatataca ctagttaagct tttactttta gccactaatt tggggtgtag ctcttttgca 240720
gcaaaagatc atcagaacac tgccatgcag gagctgataa acttgctcac tgttatgtat 240780
gtatccaatg actactcaca cacacattac ttgcttcaact ctactttctg gctttccatt 240840
cagcaaat ttaagaaatga aaatgttatt cgtgggaaat taactcaaga tcaatattgt 240900
tgtagttaat ctctttgtaa atggtaaaaat attaaattat tgtgagtcac ttttatttaa 240960
agaagtgttg ttctttaaat gaaagaagtt ttgggtcttt gtggatactc tgcatataga 241020
cattctagac atgaaagaat gttgaagaca aagaatgttg aagaaatata gacatgaaag 241080
actgttgaa tttgggtttt tgtggatact ctgcatatag acattctaga ctggagtgat 241140
acatctgtt caggtttcta tgtttttaaa atgataactt gacacgcta ccaatgccaa 241200
tttttaggat atatatctgt atatctgtgt gaactaagga aaattcagga atgattaaac 241260
ctacatat tttggcaggaga gactggataa tgtaagtctt tatatttttc acaacttcaa 241320
gtttatagca tccaaatgag caattgctga catacctagg ggatttctct gcaggttcaa 241380
gtctgatctg gcctgagggc aacactctta ctgagtgtgt tccctaggcac tccctggcag 241440
ttggctccag gccacaataa agagccctga tgattctctg agcaggccca acttccattc 241500
acattcatgg gaatatgagg atgacttgtg atcttcagga cttagataga ctctttcagt 241560
tgggttaggg ttaagctcagc tcatctctag agacttcca cagtggagct catgcatgac 241620
tctgtgagg ttgacagga cagccagaga caggcaccta aggagtgcac taccagcagg 241680
tggaactctc actgagggag gtagacaagg gagaaaagcca ggtgtccaca tggagcaggc 241740
cttactcagg gagactgaga ttttgctcta cacatcataa aacgtggagg tcattaatgg 241800
aatttttcac aggacatgac tgccatagcc atgatagggt ccctggctaa tctttcaatt 241860
rtgatagcat cataagataa ttttgaatat gaggagagaa gaataactct agaactgcaa 241920
tatccaatat ggtaaccct agcaacctaa ggctacttaa actaatataa attaaaactt 241980
tagttctca gtgccactag ccatatttca agtactcaat aaccacacac acttggctac 242040
catgttgga agcactgaca tagaccattt ccattactgc agaaagtctt cctatttgac 242100
agtccacctc tggaaaccaat ccggagtctt tagggacctc aaagactgag gtgctaaatc 242160
tcagagcagt actctgctta atgcttagtt aaaagacttg ctaacttata tagttgatct 242220
agagaacttt aaaggcagct agttcgtagc aactatgttg ctggaccttg aaactgtatg 242280
tcaggaactt ggtgttctag tggtagcttc tcttttatct accatgttca cacttttct 242340
accaactcatt tatccattca gaaagtattt cagaagtccc tatgatttac caggtgctat 242400
ttcagacact gaggcaactgt ggggaacaaa acaaacaaag tctcctttct caggtatctc 242460
acattccatg tggtagtga gactgtaaaa attcacacac agaagatact ttcatacag 242520
aggaagtgtt atgaagaata tttcaaaagg ggtgtgggtt gggagaggtt gatgttcagg 242580
tgtttgcttg agaatgaact gttcatacaa agaatacaata attcatttgt tccacaata 242640
tttattgagt aactgttatt agcaggctac tttattaggt tgccagagca ggggtttctt 242700
agcacaatta aaacacaata acatttgtta gaaattcaaa gacctatgtc cactcttgca 242760
taatgaatca gagtctcgag gttatggtcc agagactggt gtatttataa atcactgaag 242820
taatttttaag gtatagccag aatagagagg acaccggcat tcttcttgaa actcaacaca 242880
ctagacaatg agaaatcatt aaaatgaagt aaatattttg attgagattg ttttggcttc 242940
aaaattaata atagcttgga gaggaaagaa ggtaaattat aaaagacaat taagaatctc 243000
ttaaatgtat ttagataata gttacagagg gacaaaaatg agtaggatct gtgataacag 243060
aaagaataaa aataaacaag aggacttaaa aaagtaagaa taagaaagaa gtcaacagta 243120
accagaaat tttcaacctc atgtctaaga gaatgatgat gctatttagc aatatacca 243180
aaccaaaaat actacgagaa gtagggtgtg ttacttgtg atgttgtaaa tttataatta 243240
ctttttcttt attttggatg catgcttttc ctttttctga agttctgaga catacaaaaa 243300
caataaagaa aaacatgatt ttatgccaga aaataagata ggaacaattc ctcatgctca 243360
atataat ttt agcctccac ataattccaa atatatgtgc agcaaattgt gggagtctcg 243420

```



aaattagatc	caacttctta	ttacagttaa	agataaaaag	aaaacaaggc	tttgtctttt	243480
ttaggatcct	ttttggaact	tgaggtataa	aaataactct	tcaaaaaaca	taactcaaca	243540
tcaaaagtcca	ataaaacagt	aaactggact	aaatatattc	gtatattagc	ttgacctag	243600
tctgggaatt	gagccagact	tttcaaatta	tactatcatt	atttacagaa	aaaggaaatg	243660
ttactaaca	ttattaaata	aaagcacata	tacacatgcr	taacaggaaa	caaaatgaat	243720
gttaatgtta	acaaatgttg	aagatgtgtg	tgtgtgtgtg	tgtgtatgtg	tgtgtatata	243780
aagcagataa	gatattctct	tgagcatgat	tggattggaa	atagtagcta	tgccagggga	243840
aattttatgc	aatcccttg	gctgtgggct	acacatttat	tgtgttatac	aaatatgcca	243900
aaaaaaatgc	catttacaca	gttgccataa	acaaaattga	aattatacat	tagtgtttaa	243960
agtttttttt	tttctttcgc	ctccttttct	taatgaatgg	cagataatga	aatttaggag	244020
tttgcaaaaa	caaacgtagt	ttaaattgta	ccttagttgt	ctatgaaata	caaatacatt	244080
ttatatattt	atggaaacat	ttgtgtgtgt	tcagaaagtc	catattttgc	attcaagatt	244140
gacctgtttt	taagtcatat	ttcattttgt	acactcaaat	tgactaaagg	cagatacttt	244200
ggcattcact	ttttgattca	ttattaaggc	attattttga	ttgattctgc	ttaaggtagt	244260
tttcttgatc	agagtagacg	tttaggccac	ctatctagac	aaatatccca	ctttcctatc	244320
tgaatatatt	gatctctcct	tacccattct	agggttttgt	gcactctctaa	gatgatcatc	244380
ttgtgtgtgg	gtcctgatct	tccagtgac	ttagcagcac	agtaatttgg	ctgaaatgtt	244440
ggtgagttca	gacaagaaga	aggtgatgat	gacaagagag	cgtcacgggg	aaattctgcc	244500
ctgaggaagg	aatagtttga	ggctggagag	atgtgctacc	cccgccactc	tttctcaaat	244560
ggtatttatt	cttgaaagac	agtgtaaagt	gtctgaaatt	gcagaaagca	agtgtgtgct	244620
gtagaaatac	ataccatgac	gtccttcaac	togtttcctt	aaaggttaaa	gaaagaaaaa	244680
tgtgcactct	gaagaaaatt	ccaaaccctc	attgtgagga	gtaatccaat	atttcaattt	244740
agaaattcag	agggttttaa	ataagaagca	attattctag	gcaaaaagca	aatataaatg	244800
ccagcagtca	aaaaaccagt	gaaaagatat	gattaaaact	gagatgtaaa	aaatagatat	244860
ttatctgaag	ttcttgactt	ttaaagtcca	caggcatttt	cccttaagaa	aagaataaaa	244920
acattaaatg	ttaaagaaaa	acataagaaa	tattataaaa	aagataatta	ttcagaaaaa	244980
attagtattt	tgttaccac	accaaagaca	aacagagtat	ttttcaatga	ctggaagcca	245040
gtttaagtga	ggaaaaaaaa	aaacacgtta	ttattactgc	tattatccat	tatttttatt	245100
tttacttttg	gcagtgttat	ttgctaatac	gctaaccgat	ggtagtgga	ttgatctttt	245160
atgtattata	aaggttgtat	cttctcattt	taagggaata	ttttaactac	attgtccaat	245220
tgtacactat	aaatgcagca	agaccaggto	aagtgaact	tcagtgggag	agtctctttc	245280
tttcttgttg	tgtagggtct	tcctctccac	ctgctacctt	gactttttag	attccctgtt	245340
ccctgggtct	gtgcttgtat	aatatacaag	ctgtccttga	catagcacgt	tcctcttttt	245400
tccttcatta	tttttaaatg	gttataatat	actcttaaaa	acaaatttga	atattactaa	245460
tagattctaa	tattatctta	ctctctgaaa	ttaagtagtg	atgtatattg	tgttaaacgc	245520
ttgtctatgc	tgatgcaaca	tatgggcagg	tctctctctg	ggcctatatg	tatttgtttc	245580
atatcggttg	acacagatto	attcattttt	ttaaatgggt	atataatatt	tcagtgtata	245640
aattaatcac	ctgtaagtgg	ctmgtaat	aatttgttgc	tacttctctc	caagatgaac	245700
agtgttttag	tgagcatcta	gccatttctg	tattctgtcta	cttattgatt	tatgcatata	245760
ttcaccacct	tcttcttcca	caaataagac	acacatcctc	ttcatgagag	tctacacaaa	245820
aatgttacaa	ataacatttt	taacgcaata	gttcctttaa	gtcacactt	gtaatgtttc	245880
tgcccagact	taagccagcc	aaatgtgtgg	aaataaatte	catttgtgta	ttaaatatca	245940
aagataggga	acattcataa	caaatrtaaa	satagccaag	gattcattga	aacattttcca	246000
cataccatct	ctccaaatct	ggttttaaag	agattgtaac	ataatttcag	gaataaagac	246060
cttctggaat	tgagatttat	ggaaaagaga	ttatagctcc	acaagattct	agggatgcaa	246120
aaggtctgga	ggagcctcca	ggcacaggca	ctttgtttcc	atgctgaaga	ttcaatgtgg	246180
gttctgaaaa	tgctgcttta	gcaagcacac	atttgttcca	ctggtgttgg	attttctatt	246240
gattaatagt	taccattttt	ttcttctctt	aggaaagaca	acctgtaggc	acagaaatca	246300
ttgtctgct	tacactgaaa	tctcctgctg	actttgagag	ctgagcattg	gattttgatg	246360
ggagagtga	acttagtgaa	gaaatgattt	gaacctttgt	tgatctaata	cttctgtgat	246420
acagttaatct	aaacagaatg	agtctaaagt	cagtataaag	acctgtgtct	ctccatgttt	246480
tgctgcttat	aattgcagag	gaacattttg	agatagaaaa	ttttatccct	ctttcaagtg	246540
actttttata	aaacataacc	ttttaagaga	ggtcattctt	ttgaaaaatt	gtctgaatac	246600
aaaaaagtta	ctgaacagca	agggattgta	gccataatgt	tcttgaccac	tttagattga	246660
caaatagtat	ctcaaaattg	atcaggttct	ggagaatcta	ttgaggttgt	atggagtaac	246720
caagtgatgg	aagaggttgg	aagtgaataa	ttttatgtgg	tattatgtga	ttttttttgg	246780
tgggggtagt	gtctggagct	gagcatgatg	gagcctagat	ggggcagcct	tctaattgctc	246840
ccagtatttc	gcaaatcata	tgtcacgtca	aaattgtaat	gacaaagctc	acagcagctg	246900
cctacggcag	gtttgggtgc	agctctaatt	agagcattga	tcatttctct	ccccttcagt	246960
aatgcacatg	agtgacacatt	ttcatatata	agggcaaaag	acattttcaa	gtttggatgg	247020
aatctttcct	acttagaagt	aataaaaaac	aatactttga	aatctttacca	aatgttaaac	247080

aaatagcaac	aatttttcca	tttgaagatg	tgtgtcttaa	ggctctgttg	atctttcaaa	247140
tttctatttt	ggacatggaa	actacagatg	aaatttaact	tactcaaagt	tacacagaac	247200
tcctggctga	tctcttttac	ttaattcttc	taaaatctaa	agtaagaata	attttgaaat	247260
tttattggta	atgcttaaat	aacaaaagtt	actttaatat	gttacatgtt	tgaagtttca	247320
tttatactta	atatctaatt	taacgcttgt	gaaaatatta	ttcagttatt	ttttttcttt	247380
tctaaaatga	cttggttcagg	gctccttttg	ggattttaag	tgagaaaaac	tctatttcat	247440
aattattgta	ccatgctcat	ccaataacac	ttcatagatg	gttagccatc	tctaaaatta	247500
aattttgtag	ttgaggagca	ttgaaaatat	cacctatatt	tggatttctg	tttaacactt	247560
caaaatgcat	tttatcataa	tttaaaatft	gattttaata	caaacctctt	tatagaaaac	247620
ctgataaatg	tagttttatt	tgtttgcttg	cttttttttg	cagggaggga	tattcccttg	247680
ataccactct	gtcctttatga	ctcatcgggt	atttataaat	gttatcatcg	tttttctgat	247740
ttttaaataa	gttttcagaat	taatacattt	aactgaataa	atcaaccaat	aatgtcaaac	247800
ttaaaatgtg	tttgtaacaa	gagtcagcac	ttataatgaa	aaatataatt	aattaagagg	247860
ttayaaaact	tataagcaga	gtttactctg	cttacagaag	ggcaaacatt	tgttatttga	247920
tacaacatat	taagtattta	tcccatgcaa	tcactgtcct	aggctttgag	tttatagtga	247980
tgatcaaaac	gattttacagg	tttcaagaac	cctgctcaca	tacagcttac	aatcctatgt	248040
gggaaaatga	taatagtgaa	ataattacat	taattaatat	atacttgatt	caaatgtaaa	248100
taattattct	gaaggaaaga	cacctacatc	aagagagctg	gcttaaattc	ggggatcaag	248160
gaagcctttc	caaataattg	ttgatgggat	tgaaagacaa	ttgtgggatg	agatgaccac	248220
ctgggcttgg	tatgggggag	atacaactgt	cagtgggaaa	gccctggaga	tggggaagaa	248280
gaacttcttc	aattggagaga	agttcctgag	tgagkagaag	gcaggtgacc	acagtgtaga	248340
gtgatgctat	agaagccaac	cagtggtgta	tgcaagcaga	aggaatttat	ccaaaaagaa	248400
agggggaggc	attagaggga	tttagtgtgg	agagtgtgtg	tgacaagatc	agatttgcaa	248460
cttgcaactc	tctctcaggt	tgagcatggg	gggatgatgg	gatgagccca	gagtgactg	248520
acgcatttcc	agtagtccag	gagagtggca	tgtggcatga	actgtgtgag	gaagggggag	248580
ctggggggaa	gaagtggggt	aacaacaccc	tatttgttgt	tttgcttctt	acactttgaa	248640
aaatatttca	aagcaggaat	gctattccag	acatttaaca	cctggaacag	gaataagtac	248700
caaccaataa	tcgtgggaga	ctgacgaatc	agaatgaaca	tcagctctgc	atggcagtat	248760
ggttttaaaa	cactttcatg	tctatgtaaa	caaagtaaaa	atgttaaaag	attattttac	248820
gcctttgggt	atcagatagt	cagactttta	gtagtttata	ttttattgca	gtotgatgag	248880
gtctgtcttt	aatagtagtt	ttctcttctt	cccccaaccc	cattacatta	aatgggcaa	248940
tgatactttt	ccttggttagt	aagcaaggcc	aagttaggat	tatcagaaag	tcaataccta	249000
aacacaaaaga	atagtgcagc	caaacccgga	aaatattgtc	tgttttgcca	agaggaagca	249060
tctcactgag	tatctggaaa	gctcattggt	tctcaattat	ggttatttta	ttagttgcca	249120
taactcagct	atagtcataa	tgtaactgac	cagcaccgat	gatgaaatca	ataaccacta	249180
caacagagta	aatgctgttt	gggtgcaag	aaacatcatt	tttatctaag	tgaaagtaca	249240
tctcatttaa	atgtatttca	agttgacatt	ttgtatatat	tgtaataaaa	cttcaatttt	249300
actaaaatct	ctgcaatatc	taatcaatat	actgaatgat	atgctctccc	cttttgtgct	249360
caaataggat	ctgtttatat	tttagttaag	aaatgctatg	ccattttatt	atattagaaa	249420
aatatttact	ggtaggaatt	tggtttaaac	tctccctggt	attcagctgg	gaagtattat	249480
acaagtaagt	ctttaaagac	tacaattgga	gaccgggcac	ggtggctcat	gcctgtaatc	249540
ccagcacttt	gggaggccaa	agtgggtgga	tcaggagttc	gataccagcc	tgccaacat	249600
ggtgaaaacc	cgctctctac	tgaaaataca	aaaattagcc	aggtgagggt	gcaggcgcct	249660
gtaatcccag	ctactcagga	ggctgaggca	ggagaatccc	ttgaacctgg	gaggcagagt	249720
ttgcagtggg	ctgagattgc	accattgcac	tccagcctgg	agaacaagag	cgagatttcc	249780
tctcaanaat	aaaaaaaaaa	aaaaangaaa	aaaaaagact	aaaattggag	agtttaacgt	249840
atcaaattta	ggagataaat	ggtaataaat	atgtttgtat	atgaaaatat	tttaatacaa	249900
tatttgaaat	gaagaaaactg	agatcacaca	actttttgag	cgttgagttt	atacatttat	249960
tttctttctt	tctttctctt	tctttctttc	tttttttttt	tttttgagat	ggagtctcac	250020
tctgtcaccc	aggctggagt	gcagtggcac	agtctcagct	cactgcaacc	tctgtctcct	250080
aggttcaagt	gattctcctg	cctcagcctc	ccgagttagt	gggactacag	gtgtgtgcca	250140
ccagccttgg	ctagcctttt	tgtatttttt	tagtagagat	agggtttcna	ctgtgttagc	250200
caggatgggt	ttgatctcct	gacctcgtga	tctgcccata	tcggcctccc	aaagtgtctg	250260
gacgtgagcc	actgcgcccc	gcctattttc	tttctttttc	ctatatcatt	tcattttttt	250320
attgatacgg	aatatttttac	atatttatgg	agtacatgtg	atattttgtt	acatgcatag	250380
aagggtgaat	tatcatcacg	gttttgggga	tatatatccc	cttcagttat	tagcattttt	250440
atgttttaag	aacattttcac	attctctctt	ctcgctactt	tgaaatatac	aatacattgt	250500
tgtttaactat	agtcactcta	ttctgcattt	gaacattaga	acttaaaata	ctttccagcc	250560
aggtgtgggtg	gctcacacct	gtaatcccag	cactttggga	ggccgagggtg	ggcgggtcac	250620
ctgaggtcag	gcgttcaaaa	ccagcctggc	caacatgggtg	aaatgtttgt	atttgtaaaa	250680
ctacaaaaat	cagctggggc	tggtgtgggtg	cacctgtaat	cctaactact	caggaggctg	250740



```

aggcaggaga attgcttgaa cctgggagggt ggatgttgta gtgagcccag attgggtcat 250800
tgactccag cctgggtgac aagagcaaaa gtctgtctca nagaaaaaaa aaaaaaaa 250860
gaacttatag cttccaacta actctatggt tgacccatt gatcatctt tcttcattcc 250920
ccactctcag ccatacacac ttcccagcct ctggcatcta tcattctact gtctacctac 250980
atgagatcaa catTTTTaat tcccatgtat gagtgataac atgtggtgtt tgtctttctg 251040
tgtctggott atttcaacta acatagtac ctccagttcc atttatgttg ctgcaaatga 251100
cataatttca atgntTTTTg tgcacaatta gtattccatt ttgcttatct atttgTTaat 251160
tgatggagat ataggttgat gctatatctt tgcaatgggt aatagtgtga cagtaaatat 251220
gccagtgtgt gtctcccttt ggaacaccga tttattttcc tttggataaa tacctggtag 251280
tcgaatttct ggatcatatg gtacttctat ttttaatttt gctcagaaat ctccatagta 251340
tttctgtcata atggctgtac taatttacat ttccaccaac agtgataaaa agctcctttt 251400
tccctgtacc ctccaccagta tctgtcattt ttttgttttt tttagtaata gccattctac 251460
tggttgtaagg tgatcacaca tagtggtttt gattcacaat tccctgatag ttagtgatgt 251520
tgagcatctt ttttatatac ttggtggtta tgocatttgt atgccttttt ttgagaaatg 251580
tctactcatg tctctcatg tcttttgctt actttttaat aggattattt gtgagatttg 251640
tgaggtgtgt tttgtttgtt ttgtttgttt gttgtttttc ttacagttga gctatttgag 251700
tccctgttat tttctggata ttagtcacct gtacagtgaa tagcttgcaa atattttctc 251760
ccattcaaca ggtgttttg agattctctt taaaatagct gcaacaaaca aacaaacaaa 251820
caaacccggc caagcacggg ggctcatgcc tgtaatccca gtacttaggg aggtgaggc 251880
gggcgatca cgacgtcggg agatagagac catcctagct aacacagtga aaccccgat 251940
ctactaaaaa tgcaaaaata ttagcctggc gtggtggcgg gtgctgttag tcccagctac 252000
tcgggaagct ggcagagg aatggcgtga accgggagg cggagcttgc agtgagccga 252060
gattgtgcca ctgactgca gcctgggtga cagagcgaga ctccatccaa aaaaaaaa 252120
aaaaaaaaac cctaggaata aatgtaacta aggaggtaaa atatacctac aagttgcact 252180
aaaacacact gacaaaagaa attgaagagg gtgcaacaaa atggaagat atcctatgct 252240
catggatgaa gagacttaat atgattaaaa tgatcgtatc atccgaagca atccacacat 252300
tcaatgtaat ccctatcgaa ataacattat tttttcacag aaaaaaattt aaaaatcctg 252360
aagtttgtat agaaccaaaa aagagcgcaa atagccaaaa ctatactgag caaaaaggac 252420
aaagcttag gcatacact acctaacttc aaaatacaag gctatagtaa caaaaatagc 252480
atggtgttgg tataaaaaga cacatagaga ccaatggaac aaaacagaga atctagaaat 252540
aaaaccccat atttacagct agctgatttt tgacaaaaat gccagaaca tacattgggg 252600
aaaggatatc ccttttaaaa aatgtttgca ggaaaattgg atttccatat gcagaaaaat 252660
gaaactggac ccctacctct caccatacac acaattcaac tcaacatgga ctaaaagactt 252720
aaacgtaaga cctgaagcta taaaaccact agaaaaaaac agggaagaca cttcaggact 252780
ttgttctagg caaacatttt atgggggaga cctcaaaagc acagaggaca aaaacaaaaa 252840
taaataaatg gggctgtatt aaactacaaa gctgcagagc aaaggaaagt attttcttaa 252900
tccttactgg tctttaaaaa gttttggatg ttgaccaaca catctattat gataattaa 252960
tgatttggac atgtcaagct tgtcaggata tgcgcaggtt gccgcttta ggaagagcac 253020
agtgaactct tctaattcta tttttctatt tcttaaacat agctgactat aaaattgcaa 253080
agaaatttgt gtatgagcta gggaagatgt tgggttgggt tgagattcaa ggaaggagt 253140
ggactttaaa atggtggaat caccagtaga ggacaacacc gtgtaccaa aacgttcaca 253200
ggacaagcca ggtgtacac catgatatat gagttgtgat gctgatgaag gacatagtaa 253260
gcttccaata atgggtcaaa aaaaaaaaaa agaaaaaaag aaaagcatta atattaggca 253320
atgtattttg gtgcctataa ttttatattct tatcaatacg gatagctcca tattgatctg 253380
tttatatata tctatttgtt tatatcattt gattaaaaata tggcattgac cattggaaag 253440
gtacatctca aattatcctg gttaaatgtg aaagtatgaa gaggtgtgta ttataagcat 253500
ttaagtttca atcaagtagc aagtgtgtgc aagatggtat atccaatcag atattgtgag 253560
ggacatgtga ttgctataga ttattctgct gtcttaagag ataggctgtg gatattcaga 253620
ttgtgatttt ggagttaaag agggcaaaat aaattgcctg ctgaactcac agtcattgtt 253680
gagagagact gacaggaaaa ggtaaaaatg aatcatcatc tacaactggc tggattggac 253740
ctgacggaat aagatccagc aggaagagtg tgtgactacc attcctggaa ctgggttttg 253800
ctgaatcatt ggacagtttt gctgaatcat tgagcataca agttttgagg gatacatgtg 253860
catttagaaa gtaacgaata agaattatctg taatttctg ctacttttca tagcccatgt 253920
attaacacca aagcaatttt agatgagcta tcaataaaaa tattaaaaaa gaaatcacag 253980
tctattttatt taacacacat tggttatagt caacaaggta atgtgttgtg ctgcaataat 254040
acaagtaaac atccgtctaa gaatccattg tttagtaggt attactgtac gaatttttaa 254100
caaagctgct ttaaacacta taccaacagt tttaaataca aaagccaggt ggtcaagctc 254160
taatataaat gaataaatgt ggccttctgg aagaccctag agagacaaca ggacacagag 254220
tgagcacag gaagaaaaga agtccacttc ctgcataaat ggcggcggca actctgttcc 254280
acctgacaga cgctcctcog aaatgcagtc ccatttaaaa cattttttga ttgttttaga 254340
taaaacttat aacattgttg aagaagcaac taattctaga tatttttata attttaagct 254400

```

gccagaaaaa	gtaagtccac	aattggaaat	ggcccaagge	ccccaggatg	taccttacct	254460
atgccaatat	tgagaagatt	attccagtg	aaaaggtcca	tgtaactttc	attaacacta	254520
tggtttgttg	gaaacacact	aaaccactgt	tccataattc	cttttttttt	ccagttactc	254580
aaagcaaaaa	taccagaatt	ttatgtttac	aaatgtgagt	ttttaataga	aacatgcaca	254640
gtgtatactt	tatatattgc	cggaattgac	ttatcgaatg	ataatttaac	aagattgttc	254700
atttgaagtt	tatgccact	tttataaata	aaagaatcat	tttgggtgtc	ttcctctctt	254760
tctcttttatt	tttcttttct	tatttcagtc	tacaactact	cccccttctt	ctggcccatg	254820
tggagatatac	ccatttccca	acctgctccc	tggtcagtta	caaggaggga	gggaagacat	254880
ctggcagagg	aagattccca	gggaactatg	aaaggagata	gtgactactg	cagagcttgt	254940
tacaataaca	gactattaag	gctgggtgcag	tggtcacgc	ctataatccc	agcacttcag	255000
gaggccgagg	agtgtggatc	acctgaggtc	aggagttoga	gaccagcctg	gtcaacatgg	255060
tgaaaccccg	tctctactaa	aaatacaaaa	attagccggg	tggtgggtgtg	agcatctgtg	255120
atcccagcta	cttggaggac	tgaggcagga	gaatcacttg	aattcaggag	gcacaggttg	255180
cagtgcagcca	agattgtgoc	actgcactcc	agcctgggog	acaagaggga	aactccgtct	255240
caaaaaaaaa	aaaaaaaaaa	accacaaaaa	acaaacaaca	acaacaacaa	aacagactat	255300
tagcactttc	tcatatccct	tgtttgctta	agaatagtat	ttgaataata	taacggccta	255360
tattttatct	acctactctc	tgacttcctc	tggtttggag	gggggtgaat	catcagaggt	255420
gttgttgac	agtatgtgtg	tggttaaata	gggtcccttt	tctctactca	tcttttctat	255480
gcaaaataaaa	gccattggtt	ataatgaaga	ggaaatcaga	ggggaagagg	tctattttga	255540
atttttghtaa	ccgaaaaagc	tcattgatttt	atgtgaatat	tccattggct	gcttagcttg	255600
octacttact	tgaatttggg	gtttattccc	aacactgcag	cttactatga	ccaaggtttg	255660
ggaacattct	tgaaaatttc	cttgaggaca	aatatccgct	ttgttgatt	ctttgttatt	255720
tatccatttt	gccaaattat	ctgcaagtag	aaatatcgaa	ataagaagct	ctttagcaat	255780
ttacttttga	tattgggttt	cttttgaagg	acagttatta	aaatagcttg	taggattact	255840
cattttcrtt	tttcttcttt	ttaaataata	agcaatgtca	tcaacttttt	ccctgtatta	255900
tatttctcct	caataattga	tatgctacat	taaaggaaca	caaaatggct	ttaattatgc	255960
aataatgatc	aaaggcaaga	gtgttccctg	ggaactaatg	gttgccctgag	aggaggtgat	256020
ggcttgaggt	ccagctgggt	attaagccgc	aggaaatgct	gcaggccaag	atttgtatta	256080
tttctctgag	atgaaaatga	acccaaaaaa	aggcaaaatg	ggtttttctc	cactaatggg	256140
taaaatgaac	tcatttttga	tgcaagaagc	ctttatgtag	aaggaaatgta	ttccataaaa	256200
gcaaaatcaa	aatgttcagt	ggtctctgct	ttttgtttta	aatatagtat	agcacaaata	256260
atagtccatt	attgattttta	aatcttgatg	caactaaaaa	tatcatgcaa	cacttgagtt	256320
tttgtctagt	tctagaactt	ccatagaata	ttatgtccaa	caattgtttt	gatagctttt	256380
gtaagctaag	aatatatttt	gtatgcattt	aacattgaaa	atggttactt	ctgaaaatat	256440
tcagaaaaca	gctatctcat	aacaaaagaa	tacaggcatt	attttctttt	ttttctggag	256500
ttcattcaaa	aaatatggg	gaaaggtgtc	tcattaaaag	atgcgttgag	atttgtgtgtc	256560
tctctgcagt	attagagatg	aatcacttaa	ccttcttaaa	gaaactgcct	aatcaatttg	256620
taaagtagtt	agtatagctg	cccccatctc	tgattttag	taggattatg	caaagcagag	256680
tattttgtag	atattaatat	tactaatata	aaaatgtagt	tattactata	tttactttac	256740
catcttaacc	aagtgaacaa	atatattttta	tcattattttg	ccatttttgc	cacctctgtg	256800
acatggggta	tgtcacaggg	catagtagac	aactgaaaga	gtcctaata	gtcaaaactg	256860
gaaaagtttc	agaacaaaat	taaccagtag	tattagatta	taaccacaaa	tacaaaataa	256920
atgtttctga	attcattttg	atttaaatga	atgacagaat	acataagtca	atgggggaga	256980
gtttattctt	gcatgcagaa	gaatccagat	aatttatgtg	gatgccctgc	cttcaaagag	257040
gcagagcccta	actctcattc	ctggacagca	cagagtgaact	tccttccaaa	gagtagagga	257100
ccgaaagggg	tgaccaaaaag	attgaagaaa	gatcaagcag	ttatcatgag	taaagcaaac	257160
cttgacaagt	ttatcgcaat	gtttagaatt	ttgttatatt	caatogagga	ctttacaaaa	257220
ttgtgttaaa	ctttatgatg	gatattgggtg	tccttcttaa	tagagaaaagt	tcaaaagccg	257280
gggtgctttgg	aggaaacatt	atcttttgtc	tgccactata	aatgtgacta	aaatagtacg	257340
taataagcat	atggccacaa	acttaaatgc	attatgtttg	caagaaaata	tggtggcagg	257400
tgtgtagcag	gccttgcaga	agattttag	gaaaaatcat	aaaacaaagt	acatagtgtg	257460
agatgtttgc	tatacatgag	gattttttta	aaagcagatc	tagtagaata	tgatttactt	257520
agagaagatt	tgtatctctt	gtgttcagct	gaattatagc	atctaacaca	gcctgtgccca	257580
cacagtagga	actcactcaa	tttttgttga	aattattcaa	cgaatatttt	attttaggct	257640
tttgcaagat	atgacttttg	taataaatgt	agcacactta	attcattgaa	cactaaagga	257700
aacaaatgct	aaagaaacta	gtttccaggc	acaaatgact	tgcttaatat	cacaaggcac	257760
atggtgggga	ggggaggtaa	ctacaagatg	ccacctgaa	ggagtactg	tttcatctgg	257820
agcactagag	atagtgggtg	ctattgatgt	tatctagcaa	gactgagggg	ccaactttct	257880
gagttcaaac	cgtgggtttt	ccacctgtaa	atgaggaaca	acgataggac	tggcctcaga	257940
gataacccat	gaggactaag	ttgggttaatg	tagagtactt	agatagctgc	ctaaaactat	258000
gtaatcatta	tgtaaaagata	agctattatt	aattttaatg	gtcataattt	aaatgaacat	258060

tctaggat	at	attgcaatac	accaaagtca	tttatgttat	aatttatatg	258120
ctatccagga	gagaaattgc	aacacagatg	tgcaggcacc	ccactatcac	cccaaattaa	258180
tattatggtt	attaattcaa	gacctataaa	atagcatgtg	tcattttataa	aactctcaaa	258240
tgtccatatt	taaaaacttg	cttaaaattc	ttaaaaatca	aaaagttaat	gggttttgaa	258300
gtctcttggt	aaaaaaataa	caaatcagtg	taaatgaatg	acagtttaat	atcaaaaaga	258360
tgaaaagtgt	atagccaagt	aacaaatgaa	attgttaagc	agggttgaaa	aattaccaag	258420
tgcaatggaa	aaattaacac	agggatttta	tatttgtaat	tattgattaa	cttcttctat	258480
taattcttat	tttgacaata	tttaaagcca	aatattggca	tatattaaac	tgagaaccga	258540
atccttaaat	tgctgtatct	cagggtacta	aaccaaattt	ttctaaaacg	ttgaaacaaa	258600
tttctactca	ttgggcttta	ttgaagatat	tattgcttta	tccttttagtt	agaatgatgt	258660
tattataatg	ttgtttctga	agaacatacc	ataattaat	aatgttaatt	ccccatttct	258720
tttatcat	agatttctac	ttttagtgt	tttcatgaag	gacatgaaac	attactattg	258780
aatgacatat	acaaaaagtt	gaagatgtgt	taatgttctt	ttattaggct	gatggaagta	258840
atcaaacata	tttattattt	atccttagtg	aagtttaaat	aataaagtct	tgtatactat	258900
taaactatat	attactttta	cttgtcacca	tcttttctct	aagcctgggt	tagaggtaaa	258960
aatcttttca	aattgtgtgg	cttcaacttc	caacttgctc	accttctctg	ggtaagagtt	259020
gaccataatc	tatcaaggac	acaaatactg	tattccttct	tcccagggca	tttatatagt	259080
cacagggaag	gccttagcct	gccttttgga	cttccctatg	ctttaagatt	tttttcttta	259140
tgtacgataa	gtagaagagg	aagaaataca	tcaaaagaag	tttgcgtgca	attcaactac	259200
cttattgacc	ttaacttctc	caatcaacta	aaagtatctt	tctacatcat	tcatttcagc	259260
atttttccct	ttttcttatt	tatttgtttt	tcttttttct	tttctatcat	ccatttgact	259320
tttgtcacag	attagattta	acagcttgca	ttgtatgttc	atfttctctaa	aatatttagag	259380
cttctattaa	aagattggtg	taaagaaatt	aggggtccag	gcgggtcatg	cctataatcc	259440
cagaactttg	ggaggccgag	gtgggaggat	cacgaggcca	gaagattgag	accatccttg	259500
ctaaccagggt	gaaaccgcgt	ctctactaaa	tatagaaaaa	tttagccggg	cgtgggtggca	259560
cgcgccgtga	gtcccagcta	ttccggaggc	tgaggcagga	gaatcgcttg	aaccaggagt	259620
tgcagtgagc	tgagattggg	ccactgcact	ccagcctggg	caacagagca	agactccatc	259680
tcaaaaaagt	aaataggata	attatattct	tatatctatt	aacatatttt	gatggatccc	259740
ctgacatgaa	taagggcaga	gacggtagca	agttaagatg	ggccagttgg	atttcatgcc	259800
ttcaaggacc	tttcattcga	gcataaggaa	aaaaataaga	gtatacatat	ttataatata	259860
aggccaaatg	tttgaaatcg	tgaaagcttc	cttctgtatc	tcaaagagca	atcaactctg	259920
gcacaagtga	tttcaagtga	ctttgtggga	gcagttggca	tctgaaaaac	atcttaaaaa	259980
acagctctata	acttgatttt	gtttcttttc	acttacatgt	tatgaaaaga	gagaaataga	260040
gcctatgtct	gctatctcct	ggaccctccc	ctagtacatt	tttccattgc	taactttart	260100
ctacagcctt	tcactgtaat	aaaccattac	taagagtgtg	ttagtgtttc	taaattcttt	260160
gagtcctttt	agctttcact	gaatctaata	tttgtgttag	gaccccccca	cacaccccta	260220
aaaaagaggc	tctagagttc	gtcagctggg	acattcaagt	ggccaggccc	aatatattca	260280
gaaatgctga	cttcccttaca	aaaactaaaa	gctttataat	tttcaaaaaa	aaccccaaac	260340
ctagtttgaa	taacacataa	caagttttga	gtgaacgctt	agcactgtct	caccatgagc	260400
tcattgattg	gaggacagtg	gcagggccac	acacgtgccc	tcctgttagc	caaattgtagg	260460
ccagtttaca	gacatcagga	agttgccact	gcgatgcagt	cattcttgac	ctctgtgaag	260520
aaattcttcc	agttaaaaat	ttatttatgt	ctacaagcat	cctctttcaa	atgcaaccac	260580
cccgtggaat	atttttaagtc	tcacagaaaa	gtcaccttta	ttttagcatg	aaatggctta	260640
aaaatcagat	tatttttctt	caaacatcag	atataatttc	cattaaggaa	atagaagtct	260700
ttatagtgat	tgatggagag	aagttatttt	ggcataaaaag	gaaaatgtgc	ttgggtggaa	260760
taccagagca	gacagctatg	agctgtcaga	gagaagaact	tgtggggagc	agaggagagg	260820
ggaccttgaa	agctgggaga	gaaaggcaca	aaaacagcaa	tgcaagaagt	atatttttaac	260880
cactttcagt	ttcactacta	gctgccctta	cagagtgtat	gtgattaaag	aaactcttac	260940
taaccgattt	ttaaccgcg	ctgagtcctt	catgtatctt	agcttgattt	tttttgccct	261000
caatcacgtg	tctacactag	atcaagtgtc	ccatctacca	aatcaaacac	tcgtttttta	261060
gtagggtgta	aactgtcact	aaggaatgtt	tgggtcaatg	tccacctata	gatactgtct	261120
tcaactgtact	tgaggcagta	ttggagaact	tatgttttct	atggaagact	tagagcatta	261180
ctggaaaaga	gacggctttg	tttcttttca	tattaaatgt	caaggagagg	cggtaaagcc	261240
tctctctgtg	ttttctatag	aacccagttc	agggtgtgtg	ctcatcactt	actatccctg	261300
gtattattaa	tgatcaattc	atctactcct	caccagactg	caaagttttt	gaggaaagaa	261360
ctccttcatt	ctccactatc	tacacagact	acgtataaat	taacaatgaa	taaatgaaca	261420
aatgccttct	tcatatatct	tgactagtct	atatgttgtt	agcattatat	ttaaatacca	261480
ctttttcata	agagttgttg	attagaaaaac	tgtgaaggga	ttgtttgttt	gtttgtttgt	261540
ttgtttgttt	tccttaaaaa	attaatactt	gcggcggggc	gcggcggggc	acgctgttaa	261600
tcccagcact	ttgggaggct	gaggcgggcg	gatcacgagg	tcaggagatc	gagaccatcc	261660
tggttaacat	ggtgaaaccc	cgtctctact	aaaaatacaa	aaaaacatta	gccggcggtg	261720

gtggtgggca cctatagtcg cagctactcg ggaggctgag acaggagaat gacgtgaacc 261780  
 cgggaggttg aggttgcagt gagccgagat cagccactg cactccaccg tgggtgacag 261840  
 accgagactc cgtctcacia caacaacaaa aaataataat aatacttggg caggaagacc 261900  
 acagctatca cttctagatc taacattctc tcaagatgag tggagacaga ggtagagtgt 261960  
 gtgctggatg gatataggag tggacttact tggttgtcat catacggttg taccatttct 262020  
 ttttaataat gactgaagat gacattggga ataaataaac atagaccttt gagtttcata 262080  
 gccacttaac tccctagttt tgtttttcaa attagttgag aggtgatact tatagccata 262140  
 actttaataa cattaccatc atcatctcaa ttgtggcagc tacaatgtca agaaactcac 262200  
 aaagttaaaa tgtgaagaaa ctttagaggt gggttgggtg ggagaagatt gatgttgata 262260  
 cgattcatgt atctttcagg attccatggg attgcactct gtcatcaatt tgctctaagg 262320  
 actaagtctg aaaaaactta ttgtgtgtca ttactgaaat actcagcagt ggtttgggtt 262380  
 ctgaataactt ttaaagcatt ctctctcttc tccgcattat accataaaat atatcttagc 262440  
 atattattgt tttcacttgc catttgttta atatatgaga atataattaa gcatatgcct 262500  
 tgaatcaaat gctaaccaga ttaaactata tctaagagag tgtgtctttt caaaacagat 262560  
 tgtgaagttg tgttctggtt cccatattac tggcattgtt caatattttg ggacttctat 262620  
 tttggaaatg cattcagttc caactttagc ccctaagaa atgctcccta catctaaagg 262680  
 ctaagatgcc ctcttttatt atttttctga tcaaatattt aagaaataag cttcaaatat 262740  
 ttgttaaat tttctcaaaa gtaaaatttt tatgtttaaa atatgacaat ctaattgtca 262800  
 tctttaatgt attaaaatct tttatatcca gtttttattt tattttattt acttatttat 262860  
 ttatttgaga tagggctctc ctctgtcacc caggctggaa tgcagtggca caatcttggg 262920  
 tcaactgcaac ctctgcctcc taggcccagg tgatctctcc accttagcct cccgagtaac 262980  
 tgggactaca ggcccacatc actgogcctg gctaattttt atatttttag tagagacggg 263040  
 gtttagccat gttggccagg ctctgtctga actcctgacc tcagttgatc caccctctct 263100  
 agcctcccaa agtgcctggg ttacaggtgt gagccatata ttcagttttt agaagatcat 263160  
 tagaattcaa atgttgccag actttaagtg tgggtcacta tctgatggag ggcttctctt 263220  
 agaagatgtc cccaatggca gggccttgtt ataaagggtg gaagagagat aatcctctga 263280  
 ctaagaggcc agagaagcag aagatttttt ttcatcagat ttacagtcag taggaagaca 263340  
 gaaaggagaa ggaagagaag gcatgaacag catatgtgtg aagtagaatc ttaatagtgt 263400  
 gcatctttta agtcaggatt ccgtctactg ttggccaaaa taaatcatta ttatctgggtg 263460  
 gttggaaaaa ataaggacat tcttgggtt tctccaaaaa cttatttttg tgtttcttaa 263520  
 ttacccttag gagaccttaa tgatcaacac tgtatcaaca gagaagtgag aattttattc 263580  
 tcttatagaa agtgcattgt attatgcaat gtattcacat aattatttac agttcttcag 263640  
 ttctagatga ctgatactac agaaacctga gataatccct gcttccatta gtttgggtgg 263700  
 aacttttggt gagagacttg agtcatactg aatcccttga attactgcca agagctgggtg 263760  
 atcatcaagc ttgagttaat atcaatgtta tgggtctatg gagaggataa ctgcaggaga 263820  
 acaatcatca tgtggtaggt ttaccacgtt ggcctgctga actccatgct caaactccaa 263880  
 ctacttttaa gtaatgacat taaaatcat attttccatt tatctgtgga agctagtggag 263940  
 taaagaataa gatagagtct actgaaccta tagaatgtta ctaagtatta ggtgttgtat 264000  
 ttaatttcca gtttgtctaa tgctggaggc aattttacct tctcctacca gtgaaaaagt 264060  
 ttatgccagt aagacttgtg atttttgttc tcccccaaca catgcttota tataaattta 264120  
 ttatgggaaa agtgcattata ataaaaactt tctggaaaca ttatagatag agtgtggtct 264180  
 ggtgtgacag atattttgtt tcttcacaac attctctctc tgagtattca ccattggcta 264240  
 gatattctgt agtttctgta gtagatacaa aagctttaca aggtgtattt ttccacaaag 264300  
 aggttagcta gattaatagt gagaggatac atcaaaagac atggaaatga tttttagaga 264360  
 aatgagagca aataactaaag tattgaatta agtaaaacaa gaaaaatagc tccctccacc 264420  
 ttcaaaaaa ttggtgagac caggattgtg gagggcacct tggcaatggg cctttagact 264480  
 cagtgaatgg ataaaatgtg tacacagtga gaagagaaga aagtgtctac acagaagtta 264540  
 gtttttgttt aatttgatat tttctcttta cctcgttcta gtcaagatga cctgaagcct 264600  
 tctagtgaag aaccagccag gcaagtcca cttcttaggg ccgttaaate ccttctctta 264660  
 ttaatgatgt taattgcatt tggatctcca tccagatatt tgccctacct taatttcatg 264720  
 ttaatgtgcc atgggctaaa gaggcagtat tttttaaaag catctgtaag tttcatttat 264780  
 gacagaattt ctgtaataaa agtgtagtca agagtgttga tggaaaaatta gggtagacata 264840  
 aatacgtgag aactggaaaa tgtataatct taacagtagc acattatttt tattatctct 264900  
 ctttcccaca ggctgatgag gcctgggata ctaatatnaa aaacccaaat tagaaacttc 264960  
 tctctgtgg tgtttattgc ttgcctgca gtgcattgca tcttaattct aaagctctna 265020  
 actcacaata tctgacatcg ttttacctc tgacacgtca aaatcagggc ctaattgntc 265080  
 ctgtggttgt gaattatgaa caaatatact tcttaagaag atggattttt catttaattt 265140  
 tcttttctag cttcacataa tgtacatata cagaggttgc ctgcgatttt aatatgtcta 265200  
 cacctacaaa aacacacaat acacacaaac tttcaaactg aagcacacag atctgtaaac 265260  
 atacacatga agatttgttg caacacaatt cattctcaaa tctatttctt gttatgctta 265320  
 tgattaagat ctataacttc tcagggttga tttatttgtt ttgtacgaga ctgagtaaag 265380

ctaaagacca	cgaatatgat	gggtgttget	aaaataaact	tctcaagaga	catcaagttt	265440
taattctgcc	tatttcaaat	attccctgtt	gaaatataaa	cataaaggaa	ccattaatta	265500
tataaaaata	gaaatacatt	tgtgactttc	agagctgtca	cgaatagat	attggaaggc	265560
aggttattta	gaggactcat	gtaagacaga	aaagaactac	gcacagatca	cogatgatga	265620
cacagttatg	tggagaaagt	aatctgccac	aggtcaccca	gacagggagt	gggaaagtga	265680
tggctcogtc	ctcgatcaact	tttatatccc	tttcattcca	aagccaagca	tgttctataa	265740
aagcagaaat	ctctgtactc	ttttgacatc	ctaactcctt	ctgctaccct	catttaccct	265800
catacatggt	ttatacagat	gtgggcttgt	cagaaaaatc	acaaaatttt	aatgttagaa	265860
tggacottat	catgctattt	tagttatcag	ctgctgagct	gttttctatg	tttgagttcc	265920
cttctctcta	aaaaatatac	aaaaatcaat	agaactttca	gtgcacttgc	agggtgggtt	265980
tacctttttt	aggccttgat	ctcacagcct	gatccttaac	tcactctactt	tccaatactg	266040
gctgacagag	catccaccat	ccaaaggcag	cgtagacaaa	ggttcaatga	gtaggaaactc	266100
ttaattatga	cataatgaca	ttaataaactt	ttaccttatg	ttttatgttt	ttggagacaa	266160
aataattcca	aacttattat	tataaccata	aacataaata	tttgtatcat	taataacagt	266220
gtaggacott	aatttatagt	ttaaccattc	acatttgagt	ctttaatccc	tgctcaattc	266280
caaagtata	catagtttta	ggggtccatt	tttattttctc	tccacatgta	gtgattttatg	266340
tttctctgta	cttctacta	agtaacctgg	ccttattcca	ttatatattt	agtttccata	266400
tatacataca	tctgtctctg	aggactttta	atttcatttc	attgggtcaat	gtatctgttc	266460
ttgctgttgt	aacagactac	tgctactaat	actactgctg	aattactatt	attattatta	266520
ttacttttca	gtattttotaa	agagcttttt	aaaaatatgt	cattaagtta	ctgttttaag	266580
taaaacattt	tatatagaga	ttcatataca	tattgaactt	atgtttttat	tttcttgcat	266640
gtactttaag	tgatcttgaa	atcaacatta	taacaacctg	ataaaataga	gtgaaggttt	266700
ctgatctttg	cttcatttga	ggagcaccct	atataagatg	taaattaggt	aaacgtttta	266760
catttgaggag	aaattcacta	tacaacaatc	tgattctgag	actccaaaga	tcgtttttta	266820
tgtttaaaat	atctattttct	ctattcaaac	tttcatttta	tttgccgcac	ctaatatctg	266880
acacatttcc	aaataagtaa	aaacaaaatt	caccaaatct	tgtatctttt	aaaatgtatc	266940
tttgtttcc	gtcttctatg	ttttgattat	ttcttttaaa	tttttaaaat	aaatttgtgt	267000
ttagttttga	accataaaaa	taactcattc	aaagtcatca	aagtaaaagt	aatcatctct	267060
taggcatata	gttgtcagta	atctgatttt	aacccaacag	actatatata	tatttaagac	267120
agggtctctc	tctgttgccc	aggctggagt	gcaatggcac	aatcatggct	cactacagcc	267180
ttaaactccc	aggctcaagc	gatcgtccca	agtagctggg	gactacaggt	gcacgtctcc	267240
actcctggca	aatttttgtg	ttttttgtag	atgtgggggt	ttgccataag	acgaattgtt	267300
gagtcaggat	ctagatggca	cattagtcca	cgttatttca	gttaagggtt	cctgagcctc	267360
tactttgtgc	catgatataa	gcaagggtgc	aagctctgtc	tgcaaacagc	agtcacctca	267420
tccaaaccgt	acacttacaa	gtgaggcaac	aaaggatat	aggggttcgg	gaaaaactac	267480
ggaaagcgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtatc	aggcagaaaa	ttatcctcac	267540
attttcctac	gagtatccta	gttgatcctc	tgccaccatg	ctctttccat	gggtgcccct	267600
tgctgtgtoc	tttccacccc	acccttccag	agggatctgg	atgtggatgc	ctatgctgag	267660
tgtaatgaag	cctcgagatg	tgttagaatt	taattgaata	ggccaagtat	gctaacattt	267720
tttcaatcca	caaaaacgaa	attagatctt	gacctacaca	aaatgtggct	agctcctctg	267780
ttgagaaacc	ctgacaccag	atctattaat	acctttccta	tggtcacttt	atgttttgaa	267840
agtttgctac	tatttggtga	tgacaccacc	aactaggatg	aatataaatg	ttcattttca	267900
aagatgttaa	aggcatcatt	ctcttatttc	taataattaa	ataataaatg	tggagatata	267960
cacacacaca	cacacggttt	ccatagtttt	tttttcaggc	aaattcgcta	aaatctcata	268020
aacattataa	ttattattaa	ctcctaggaa	taatatctac	atttaaggaa	agagtaattt	268080
taatttaagt	agacacattt	aatgatgcaa	gtatggatac	ctcatgcaaa	caaatgcctt	268140
tatacttact	cagaataaat	aatgggaatt	ccacatggaa	gcttatgaga	aggctcttta	268200
tgatcttatt	ttgcttttgt	tttagctttc	tgagtaaaaca	agcccctaca	cactgagtat	268260
tagattcacc	tggaggtott	atttcataat	gtatccaggg	ctttagccct	agacatgctg	268320
attaagactg	gggtgggctc	aagaatttgc	atttttcaca	aattccaagg	tgatattgat	268380
tttattotta	gtagatcttc	tcattaaaaa	taagtgtaac	cctctgcaat	taacagaata	268440
aagtcaaaat	ctctatcgca	ggattcaaca	gagggatgac	aatctggccc	aaccaccttg	268500
catagctttg	ggacctaaca	ttactcttgt	tttacagcag	tagttctgcc	attcgttaagt	268560
gaaatgtggg	ctgttctctg	aataataccat	tctcttttgt	atctttgcac	tttgatcttg	268620
ctgtattttc	tggccagaaa	gcccttcac	ctttacagt	tagaaactgg	ccacttacc	268680
ttcaaggcca	agttccaata	aagtttcttc	taagaagagt	gctgcctatt	tccaaattta	268740
agtatataaa	attgaggatt	gaggaaatcc	caaaattcca	gtacatttgt	ttcataatgc	268800
aatctaagat	cattctgtta	atgttccaag	tgcttccaac	ggctccaaga	agtggtatga	268860
gactcaagtt	gaattttgaa	tcacaaagt	tattcattgt	ccacctgaca	tcttttttta	268920
ttttatacca	tgttttttat	gtaataacat	atttgtgtct	ctaagagttt	ttcacgtgga	268980
ttttaataat	gtgccaattc	acaaaagaat	ttgacttaac	acttctgagc	attattcatt	269040

gatacacagt tgaataacag atagtttaga taggaggaaa agtcagtata aaggaatgaa 269100  
 atttttttta aagctcaaca ttctctagag attttacttc tcataatctaa tgggtgtaatt 269160  
 ctctcttatt aaaaaatgtg ttaattttaa ctattataat tttatcagat gctgatttcg 269220  
 tgtgtgtgtt ctgtgtgtgt ttgtgtgtgt gtgagagaga gagatgatct gatgtgtatt 269280  
 cctaagttta caagattcta aaccttttca cttataaata gatagttcag aggggtgacat 269340  
 ttttggtaga gaaatcttaa tgaagcttaa aatgcaagtt tctgtgtaga ggtaccatct 269400  
 ggtaaatctg cttcaaatga tgggtggatgc accatcatta cccaaatggg tgaagcctg 269460  
 gctgcctata gtctccctta aaggttaagg agtgatatat ggggtgctaa gaaaggctta 269520  
 tcaggctact gtacatcaga gcaactgacaa aacttcctca ggaaatcacc aaatgaaaca 269580  
 aggacctatt cagaaatgtt ggtttataga tatgccatta caatggaact catctaaatg 269640  
 acagcatggc ttaagtggag aatttttact cccaggctcag gaaattctaa ggcaggaaat 269700  
 aatgcctatc ttaactcttg agatgtggcc agaattcagg ttgtttttct actgtgtgct 269760  
 ggtttttctca gacatgtgaa tttggggaga taagaacaga atagcatatt agctgcaaca 269820  
 tgtggcactt gtcagattaa caaaggaggt gggaggcttc atacaagtct ccattttccc 269880  
 tgatagagtt tcaagttgag aacagtataa tgttcatatt ttacatctg atgggaaaat 269940  
 gggtaagaat aaaagggtgt tgagccatag aaacagaatc tgtttctttt cactttttat 270000  
 agcaatagga gtaaaaggca ctctaaaagc tcaactgaaag gccacaaagg cttgtctttg 270060  
 tcttttgttt tcatttttaac tttctgtttt tttacaaaaa aatctatatt ttgtccatt 270120  
 atttaatggc aagttgcctt taaaatgtat ctggcctcat cacagaaata ctaaggtag 270180  
 tgattttgca taaataatca cagagaatgg catttcttaa gttaattgtg tctttctcac 270240  
 taattcccat caagagcgtg aaagctacaa ttttaggtgat ctttcagacg attagtgtag 270300  
 tcattccagg agtctctttt gttatctaat ctaagtcact ctagtataa ttcccctgt 270360  
 tttttttttt tttttttttt tttttttttt gagatggagt cttactctgt tgcctaggct 270420  
 ggagtgcagt ggtgtaatct tggctcactg caacctccac ctcccggtt caaacaattc 270480  
 tcttgctcca gctccttgag tagctggatt acatacacgt gccaccatac tcgggtactt 270540  
 tttttgtatt tttagtagag acgggggttc accatgttg tccaggctggt ctcaaaactcc 270600  
 tgacctcata atccaccacc cccctcagcc ccccaaagtg ctgagattac aggcattgag 270660  
 cgtgtgtccc agcccttggt tttgtagggt agaaaaatgag cctgtttcca catggagggc 270720  
 agtgggtgtg aagttgtatt atgttttgaa aaatactgaa agcaaacagg gaggggaagca 270780  
 gattaacatg tttttaatca tttatgcact aatattgtat acaatgtgtg tgtgtgctg 270840  
 tgtaaagaaa gaatacactg catgtaacac agtaaggat tgtatttata tattgtcag 270900  
 gcagaagata tttaaacagc ctggattaat tcaactcatct tgtttgtact aagaaacaa 270960  
 gactgaatga gttacaaata aacaagttcc ccaaattgta ttatttgtgt ctcatgtgag 271020  
 tgtctcataa ttgtatatgt attgcattta tcacaaaagt tatatttgaa cacaagggtg 271080  
 acagttataa cgtgcagtag caaaactata gtgagccata tctagcgatt tagctttcca 271140  
 ggtgaaacag ccaactctagt tatgtaaaat gataggaaat aaatcaatcc catcttagcc 271200  
 taggacgaca ttgacatcag catcagttat tccaataact gcataatcaa tatttatggg 271260  
 cttaatcaag agagacatga cacctggatt cgctgcaggt gagaaggag ggcaatgtca 271320  
 aggtggattt ggtgaagtcc aggtggggaa agcagagtaa atcagcagca aagtcaacaa 271380  
 gcaatctgct cacagatoca caatattcgg ctgctttata gaacacagct ttattctttg 271440  
 tctgtgatgg aatatcaatg cttccatttt gggaaaagtc taacgaattc tttagctttt 271500  
 taaaattaaa aaaatatata tatagccagt ttgtattttg tattttttat aaaaggcata 271560  
 taaaaatgca aagcatagtt tctgtctttg agaagttttg aatcttgttg gtgagtcaag 271620  
 aaatgtagaa gaagcaatta taagcaggat ttgaatccta cctgtatcac taatttgttg 271680  
 tgtgtacaa atcaattctt gtgcctaggc caaaataaag caaaaaaaga ctacactggc 271740  
 tccacattcc aagtaaaatt actaattcaa tggtaactata aaatgtcaat gaatatattc 271800  
 cagaaaataa gagtgaaaaa tttcaagaat gaaggaaaag aagagtcaga tgtggtgaaa 271860  
 gaaggcttgg attagcaagc atttgattga tattaaaagc aaggataaga atttgctgaa 271920  
 tggagagggtg gggaggagtg agggttatta tagaaaaaaa atgaagagaa taggaaaaca 271980  
 aacacaggtg aaaaatgagc atgaggggat cacctgggat tgagaagatg acatcaactg 272040  
 ctggaaatgg aagttttgca tggagagcat caggtcagtt tacagaacgc catggacact 272100  
 gaaataacag ggctgggttt gaagctgttg aaaatttcaa tcagggaatcc tttcctatct 272160  
 gactcagaga aaagggtgt ttggaaaatg ttcactgaa gcaggggggc ggggaggga 272220  
 gcaagattaa actggtgact atcatctcca gatatgacct agtccgtaga atgtttgatt 272280  
 attaaacaaa accaaatgct aacatcagca ggtccacaac aaacagaaga tttacaatct 272340  
 cctgaaattg caaagatctg gtagaataga tttcacatgg caatagttgg cagaagctaa 272400  
 gttgcttctg ctttccatgg ctctccttat ctccacattg ttgtgactga agctggcctg 272460  
 ctccccattg tcagcctgga acagaaaggt gtttgcatca gagatcacta ctgtagggag 272520  
 catagattga caagtgcctt aggaaactac taccgaggtc tcacctctgag atgagaaggc 272580  
 tctcatttag aacaaacatg gaaaggaagg attgtatgtg agttttgttt tgaagcaga 272640  
 atcaatatac taataattga gactgagtga actagtctag gaggcaaagg agaggaacta 272700



gcttacacac	gaggaagctt	aaaaatattg	tttgtgtata	ttaaaaataa	aataaatgcc	272760
taggcatggt	ggctcacacc	tgtaatttca	gcattgtggg	aggccaaggc	gggagaatcg	272820
cttgaggcca	ggagtttgag	accaacgtgg	gtaacatgga	gagactccat	ctctacaaaa	272880
aattttaaag	ttagcccaat	gtgggtgtac	ttacctataa	ttctagccta	ctagagagtc	272940
taagatggga	atcacttttt	tcctggagtc	taagactcca	gtgagctgtg	actctgccac	273000
tgtactccag	cctggatgac	aaagtgaac	cctgtcttac	tccaaggaag	aaaatgaaaa	273060
taataactttt	gaaagtcctc	agatagaaga	ctcttacctg	cttcatttta	ttagtataat	273120
atatgacaaa	ttaaaaatat	taaatttaag	tgtttatttg	ccacttactc	aaaattttag	273180
gtatacacag	gttgaccag	aaaagaaaca	aatgctaaat	ccaaaaatat	tgctgtgctt	273240
catgcctaca	ttacttttga	gtacacatat	ttcttctgta	acccattata	aggagttttc	273300
aaaatataat	atgttcttaa	taactttacat	taaataattc	agtggtaaat	acaagttata	273360
atatattgaa	tggtgactgg	tcaagagttc	ccttttttca	taaaacagat	ttcaattctc	273420
atgttagttt	ggccaactga	aagtaaatat	gcttggtaga	aaacagtcta	agtgagacat	273480
tattaatgaa	ataatatgtc	tgaaggtctg	gtactaatgc	tggatcacga	atataatttt	273540
tgaacatgaa	gagctactaa	atgtaactga	gtttagactg	ggaaactttt	ccagtgatcc	273600
actaggtact	agtttagttg	catggctgaa	tgaccagct	atttgccaga	ggagagggaa	273660
atgatatgta	gctgactgtc	aaatcatatg	ctattttatta	tagttatatt	ttgtttgttt	273720
taactcttaa	gtgaattgtg	agtttctgca	aatcagaaaa	ttgtttatta	atgtttgttt	273780
gtactgctgt	gcttaattca	aaaccaccta	atgagtgatt	tttgaaatca	acccaattca	273840
tacatgatgg	gtagatttaa	aaaatagttt	tacattgttt	cttatttctg	ttagaactgc	273900
aatcccagga	taggaagatt	gcttcaaaaa	ctataacaga	tttctgaaat	tgagtaaat	273960
tgcttcaatt	gtctattaaa	agttttgaag	tataataaac	aaaaaaatat	attaagtaaa	274020
gcaaggttca	aaatcacgtt	tccagtaaac	tttgcatttg	cagtacattt	atgtagacaa	274080
aacaagtcca	caatagttta	aacagacatt	cacagcaggt	gattccaaga	ccatgggaag	274140
gatttggttc	ctgtttattt	tctgagttgt	cttggatgct	ctccttcag	ttatgtcttc	274200
ttctctttct	catgtatcat	gtcttatttc	aactattctg	acagcatgtc	aagcattagc	274260
agcagaataa	tctgtatgca	cagtgggaga	gagaggcaga	ccaaatacac	attgaataag	274320
gaaaaagaag	tttccagcgg	ttgatacatt	attctcccta	gcaaagggct	agatttgcta	274380
agcatatgga	gacatgctta	aggatcaata	gggagaactt	tgaaatatat	gcccatcctg	274440
tgaaaattta	tatcttgact	gaggatatgt	tttgatagta	taagtaatat	tctcataaaa	274500
tttttgaggt	gacacatgag	aaatggagga	aaccataatg	taaaaagcac	atgttaagtc	274560
cttgccaatg	attaagccat	ccttttgctt	tataaagaca	ttgattttca	ttctatcctg	274620
atctttttaga	gtagttgggn	ttctatatat	cttgagaatt	cctatgagaa	taaaacacag	274680
ctaaaatttag	tgtaatgagc	ttaagttaga	ggaaagcaag	ataccctgga	tcttggtaga	274740
atatacttgg	tttaacgaat	ttcttaagat	atatccatga	ggatatcatt	ttccttacca	274800
aaatataatg	catatcttta	tttatttggt	tttttaacct	cagagcttct	agggtagact	274860
caaaaaagac	attctgctag	ccttatgttt	tactatgttt	ccataaatgc	taacatttct	274920
ttcaaatatt	tacccccaa	gcttatttta	gatgtatcag	ctaagggaga	ggagtcagaa	274980
agatacctta	taatgaagtt	tcctcttctt	tttcttatat	tcgtacaat	ccgataaat	275040
gtttctgaa	tatcgagtag	acctctgaga	actcagcagg	tgattcca	tcaaattoac	275100
aaccttccaa	gatgacattt	tccttagaaa	atcccagtat	ctaaccctac	caactggatt	275160
aaaatcaaac	ttctttatga	aaaaatatac	atcattaaat	tgtgaaatca	aatatagctc	275220
tattaattaa	aatgtaatgg	taggaatagg	aaaaagtggt	agtgtgcgtt	gtaatagaaa	275280
gagatgacaa	gtgogcacag	ctgaggaacg	ttccttatat	ttccaaggct	tctgtgtcag	275340
aagttcgata	tcaccataac	cttttgatgg	gtcttagtta	ataaatagtt	cgttattata	275400
ttttattcat	actgtaatat	tgcttttaaa	ttcgtcctct	tcattcatgg	ctgtctttaa	275460
atcaatagaa	tcagttaaaa	tatacagaat	ataaagtaga	aaatacagcg	tattttctgg	275520
ttagaatatt	atgttgattt	aagacttaat	tgcatctctg	gaaatttagg	tttaatcatt	275580
ccacaaaaaa	acacttttag	aagcaaaagt	gatgattaaa	gtattcaaca	aacataattt	275640
aataatattg	gttttagttga	caaaataaaa	tgttgttggt	aaagcctttc	ttacccttgc	275700
tctaaaaacg	gaaaaataag	ctgggcatgg	tggtcactc	ctgtaatccc	agaactttgg	275760
gaggttgagg	tggttgagg	atcccttgag	gtcaggagtt	tgagaccagc	gtggccaata	275820
tggcgaaact	ccatctctac	taaaaataca	aaaaaattag	ccaggtgtag	tggtgtgtgc	275880
ctgtagttcc	agctgctttg	gaggctgagg	catgagaatc	acttgaaccc	aggaggcaga	275940
tgttgacgtg	agcogagatt	gtgccactgc	actccagcct	gggcaacagg	gaaaataaga	276000
acaaatgtaa	ttcttagttg	ccatagtggt	tttattacac	aaagccttgc	aagcatgtgg	276060
tgatttatat	ttaatcataa	tttattgatt	atattaaaaa	atagagacac	aatgggtctca	276120
cagagagggg	atgaacatat	attattttgg	ctaactatat	tttatgagta	actgcattta	276180
catttccttg	gttttgaact	tagccatgct	atgaacaact	gaataatctt	tattgttata	276240
gtttcaaaat	atttgaaatt	atctaattggc	tcttagatta	tacaataaaa	attataaaac	276300
attatattga	aaaaatgtat	taattattaca	aaaccttaca	ataaaaacata	ataatacagt	276360

gttggttttg	catgtgtctc	ttttatataa	aaatcagaag	gagaaaaatcc	agttattttgt	276420
tctttttttg	agatttttact	aaattacaat	gccctcaata	atatgaagac	atacaattta	276480
ccaacaagtg	gccgggcgct	ctgtctcaag	cctgtaatcc	cagaactttg	ggagccgagg	276540
tgcgtggatc	acgaggtaaa	gaagtgaaga	ccatcctggc	caacatggtg	aaaccttgtc	276600
tctactaaaa	atacaaaaaa	ttagccgggc	gtggtggcgg	gcgccgttag	ttccagctac	276660
tccggaggct	gaggcaggag	aatcacttga	acctgggagg	cggaagttgc	agtgaaccga	276720
gatcgaccca	ctcactgcac	tccagcctgg	gagacagagc	gagactccgt	ttcaaaaaaa	276780
aaaaaaaaaa	aaattacca	caagttgata	atttcttaca	gaattaacgt	cacctgaag	276840
tttacccttt	tggtattaca	gctgtttatc	atgtacataa	ctcccttttt	attttgagag	276900
gggttaaaagt	taattcgtat	ctataattta	tagagtaaaa	ttatatttgt	taacaaaaata	276960
aaaacttttt	ataatacttt	aatgaaaggc	ttattcacca	aagaaaaata	taaaaaattac	277020
agtatctcat	caataatttg	gcagatatct	caactcttat	tttttctcgt	attttaagac	277080
tataaattat	ataaaagtaa	cagtattcat	tgctaaacag	taaaacaatt	tttttctgtg	277140
tttacatcta	gcttactgtt	ttagtaataa	aaatgttctc	aattttcatg	cattgcagtc	277200
acatccttaa	aaaatctgag	atttcttgat	tttctgtaaa	tttggcattt	tagtctgaat	277260
tattaaactt	aagtaaccag	gatgtaaaat	tttatcgctt	ttttttcatt	taaaattaag	277320
aatgacatct	ctctgagttt	ttatgtccaa	aattctggat	acttctaaaa	ggatgtgagc	277380
attactgcag	ggtagatggt	aatcctagac	tttggaatac	aaattaaatg	agctgttcta	277440
tctgaccatt	ctctgtaaca	cagtttcagg	gacttgaacg	acctgatttg	aaaaacaagt	277500
atgaacagtt	agacataatg	tgatctaaag	gtagagtatt	tatgtataat	cttaagttac	277560
aaaattattt	gctgaaaaact	ttaaagtcac	atcgatatct	aatatatata	accttattta	277620
tatatatttt	attttagcat	ctgcctttct	ttccaaaaat	gctgaaaaat	aagtcagtta	277680
tcttttctct	catttgggga	ccatgagaat	tttctctttg	agaaatatgt	gttttttttt	277740
ttttgttttg	ttttgttttt	ttttttttgn	ggcagctctg	tgagctcaaa	tttcttaggt	277800
ttaatctaag	aaattccagg	agcgttactc	tcaaccatga	aagctttttg	ataggagtga	277860
actgcagatg	atctggcttt	ggaacattac	cagtaacttt	caaagaattt	tcttcatgaa	277920
agtcagaatg	tcagtgtgtg	tgctaaaatt	tcctggttaa	acatgtttct	ttttcttttt	277980
tttttttccc	cagctgaaaa	tacaaggcaa	acactgcgct	tcaaaaacat	taaaaaatcct	278040
tgctttttatt	ctcatattag	ggttcaatat	cagtggatgg	aagtaaaaaa	gtgtacacat	278100
cactcaaaat	aatcaatata	ctgagagctg	gtagccttac	tttgagttct	cacttctgct	278160
tttatgtaag	ccttggtgcc	tatttggaa	gtttttctac	ctgatacagg	aaatgagaag	278220
gtgatattcc	ttccagttgt	aatcatccac	gtttctatgg	tgtaaaagtc	ctgtattcct	278280
tttaccocca	acttttacta	cgcatacaact	gcattgccagt	tactggctga	gttcttcaca	278340
ttacaatga	cattaaaaatt	tcaaaaatag	catttgagat	agggataaaa	atggcagaga	278400
aatcaagcaa	gttcccaaag	gtcacagagc	ccaataagaa	acacaaacag	aataacatag	278460
gagtcagatc	agtagccaag	atttgatttg	tgtgatcacc	ataatataga	tcttaaacca	278520
aaactgatgg	ctacttaact	taattttgtg	aaaagaatga	acacagagag	aaagatgggc	278580
ctcatacaca	cacacacgca	cacgcacaca	cacagcatat	ttaactgcat	tctactaaac	278640
agatactctt	tcagggtgaca	attggctagc	ctttttaaaa	ttacttaatt	aattattatt	278700
tcttttttaag	cagagtcttt	ctctgaaacc	caggctggag	tgcggtggcg	ggatccggac	278760
tcactgcaac	ctccaccccc	ggggttcaag	cgattctcat	acctcagcct	cccaggtaac	278820
tggaatata	ggcatgtgcc	accatacgtg	gctaattttt	tcagtaaaaga	agagggtttca	278880
ccatcttgcc	caggctgggt	tcaaaactcct	ggcctcaagt	aatccgcttg	ccttggcctc	278940
ccgaagtact	gggattaaag	ccttgagcca	ccactccagg	actggctggc	ctttcttgat	279000
agaacagtta	agtttttaaaa	gcaaatgaga	aatactctct	tttttaaaact	ttcccttttg	279060
gatgaaattg	tgaaattata	gctaactacc	attgactaga	caaaaactcca	actgtgtttt	279120
tggtcttgca	tttggttatat	tttaactctg	actcaagaaa	accttgtaaa	gtgtcttttg	279180
ttattacaga	atctagaagc	cctaagcaaa	tatatcactc	tttttctata	tattaggaga	279240
atccccattt	gccttatctg	tattttcaaa	ctttggggct	tcaaatgttt	gaagtaaaat	279300
aatattttgta	ttttaatatt	tacctagtca	attttctaa	aaattcaact	tactaaatgc	279360
ttaatgtcaa	tgctattcaa	acacaaagta	tataactac	acttaattaa	ggattcatat	279420
acagagagtc	atggaaaaata	taactcataa	tttataattt	acaagtctca	acattttgca	279480
tattttttcaa	aagggaataa	tatatacatg	tatacatata	tacacacaca	tttagatatg	279540
aggtaactaaa	ataaatataa	tgtaacttac	taataaaaatc	aatgtattgc	atgaattgtc	279600
aaaattctat	atttttgcta	tactaattca	actcttttgt	gccacattat	gttagagtca	279660
cttattttctt	tatggagctg	tcagagctag	tttactcagt	aaaatactct	gtatgtttac	279720
agcctttata	tgatattata	cttaaatcat	atgcaatata	attcatatta	tgtgcaatgt	279780
aatccaaayg	tattctttga	aacatttgta	atgtgtattc	agtaaaaaata	tactgaaata	279840
aaaggtaggc	acctggcaca	atccatctct	tagcccttct	cacgttgtat	tgaaatgatt	279900
tctatccaag	tttcatgtac	cttttagtcta	agctcctatg	gggaatttca	taccatgctt	279960
ctacaactaa	aatttaaccc	catactgata	aataatttgt	ggtcaataaa	tatttgtttc	280020



agctggctga	agaagtaagc	ctttccaatt	aataataaaa	attaaaattt	tatgggattt	280080
tccaaataat	tagaatcaga	ggaagagcga	gagagagaga	gagagactga	gatctcaggc	280140
atatcaacct	tgtggataaa	tagagggtta	tagaaatgaa	tgacaaaacg	tgctgtaaat	280200
tgcttagctc	tgcaaatctg	ctaattctca	ggagagtaga	aaagacttga	catttatcaa	280260
gtgtgtgtca	tgtgaaacac	ttcgtgcaag	gtaattttca	ctctttatc	cttttagtac	280320
caataggtat	cagatatcac	tgacacagta	gctgcaccta	attatccagc	taatttttct	280380
acttataact	tgaaatacgt	cactatatga	caatggtaaa	ctgtagcatt	ttcaaatttt	280440
accgtatgac	ggttgtaaaa	atgaagttaa	ctacttttaa	acattccatt	ttaattttata	280500
tatatatatt	tgttttctga	tattttattat	cgcatatgaa	tgattttata	tgtgattaat	280560
ttatataaca	aagtacacca	ttgaacttca	tgaatatgaa	atcataatct	ggtatacata	280620
gacttttagt	aataaacag	catttttagga	ggaattatat	tatgagctga	gtggcaagga	280680
taacaaattc	tgctctgttt	taattattta	agtcacagtt	ttactagtag	tagaaaacaat	280740
tctgaaaaaa	aaaaaagaaa	aagaaaaaga	aaaagaaaaa	caaaagatct	ggtcagatgt	280800
gatggttcat	gcttgcatt	ctaataccct	gggaagctaa	ggttggaggt	tgtagaattg	280860
ctgaagacca	ggagttggac	ctgggcgact	tagtgagacc	ccgtctctac	aaaaaatata	280920
aataaatttt	aatttgaagc	aatggtctga	gaaagtgaga	aattgtcgac	ttgtaccctg	280980
gataatttta	tgcttgattt	tgatttttct	aacatttctt	actttaaaaa	ttatccttga	281040
aaatttcaga	agtggcttca	cacttaattt	tcatgatcat	tttcaatgtt	tcttccaaaa	281100
aatgatctac	atggtaatta	ttttatgtgg	cataattctc	tagttgagga	gacacgatgc	281160
ttttactccc	caaataaaaat	atggatatat	agctctttgt	catatgagca	catgttgcaa	281220
gaatcatttg	atatgtttat	gctgaaatag	aaccttaatg	actcatttat	atttccttac	281280
atccaatttt	attctgcatt	acgaagtgtt	taaataatat	ggtataatat	attgtttgag	281340
tctagcctct	aacctcctgc	aaactggcat	cagaataatt	tacttttctt	aagattttaat	281400
agtcacaaaa	atattcatta	aaattaaaaa	cattacatct	ggaaatacaa	ctttgctgtt	281460
taaactgatc	attgtactct	actttccttt	tttgtaatcc	gaatggtaag	gtataattta	281520
caagttatat	tttataagtt	cataaatgag	gagtaaattt	tgttttataa	aaacaaacaa	281580
taattgttaa	gttagtattt	atcacagggg	gaaaggcctt	gattcaacaa	tccctgccaa	281640
gttgcaagtc	tcaaatccta	cttagatata	tattacttgt	ttgcgtactt	ttaaatgtgc	281700
cttccctcac	tacagagtat	atatgctgat	ggctttattt	tttagcactt	acattcatag	281760
attcctgcca	tatgattgca	ttttacagta	taatacgaac	atgttcataa	agatttcatt	281820
tgaatctatt	cacagttttt	atatatactc	catgaaaatg	ttatactttt	aatatcaatt	281880
atgtgatatt	ctcaaattgt	cattgattat	tctggtccat	tgttgagaga	tgttcctcac	281940
tcttagtaac	agtttctaca	tccctggaatt	cataataata	acaagagaca	tttagatagt	282000
gtgatggtta	atagtgtcaa	cttgattgaa	gtatgcaaag	tattgttctt	gggtgtgtct	282060
gtgaggggtg	tgccaaagga	gattaacatt	tgcatcagtg	ggctgggaaa	ggcagacca	282120
cccttaattc	gggtgggcac	catctaatac	gctgccagca	cagccaggac	attaagcagg	282180
tcgaaaaaaa	tgtgaaaagg	ctagactggc	ctagcctccc	agcttacatc	tttctcccgg	282240
gctggatgct	tccctgcactc	gaacatcgga	ctccaaagttc	ttcagctttg	ggacttggac	282300
tggtctcctt	gctcctcagc	ttgcagacaa	tctaaagcgg	gaccctgtga	tcatgtgagt	282360
taatattctc	taataaaactc	tccattatct	tatctatcta	tctatctatc	tatctatcta	282420
tctatctata	ttctattact	tctgtccctc	tagagaaccc	tgactaaaac	acatagtaac	282480
ccacagtatt	atttaccac	atatagtaac	cattagctta	tttaagccat	accacaaacc	282540
tatgatgcag	ttgttatttt	ccctcatata	aacgagaaat	ctgaggatga	cagaagttaa	282600
gccatttgct	tgagagtttt	tagctaataa	gtgaccagga	cagaaattaa	cttatctcta	282660
taaaatgtta	tttttggttaa	tattgaatct	cagctatagt	aaacaggata	ttttatgtac	282720
agactgggat	atatgtgaaa	tgattttacc	ttattttatat	tccaggaaaag	aagaaaaatg	282780
attacgttct	tctcagggtg	ttacttcata	aacgggtataa	ctttttattt	tgggatatta	282840
tgacaagaat	atttgggctt	tggtggaagt	ggaaggactt	gggactacat	gtcaaatttt	282900
attttgatag	taaatattgt	gtccaagggt	ggccatcctt	taaagtatgt	aaattcaggy	282960
ttacccctct	gtgattatag	aagacttata	tccgtgactt	gataatggga	aatttaactaa	283020
atgattttcc	atataatgac	cattagcttc	tcaaaggaac	taaaaaagtg	ttaatgagaa	283080
aacacacatt	tttattgact	acaaaccata	atttttgatg	gtctcataat	caattttaat	283140
atagagccat	atttataaat	atcatttgca	tttgtgtgtg	gattttttatt	tgatataatta	283200
tttatttttaa	tttttttatt	tcaatagctt	ttgggataca	gggtgttgtt	ggttacatgc	283260
atgaattgta	tagtagtgaa	gtctgagatt	ttaacacacc	agtcactcaa	atactgtaca	283320
ttgtatccaa	tatgtcattt	tttatccctc	accaaaccctc	cctcttctga	gtctccaaag	283380
tccattatat	tactctacat	tttgcatacc	cagagttccc	acttacaagt	gacaacatac	283440
agtatttaat	tttccattcc	tgagttacct	cacttagaat	aatggcctcc	agctccgtcc	283500
aaagttgctgc	aaaagacatt	atgtttatgg	ctgattagta	ttccatgggtg	tatctatacc	283560
acattttctt	ttcttttctt	tttttttttt	tttttgagac	agagtctcac	tctgtcacc	283620
aggtcggagt	gcactggcac	aatctcagct	cactgcaacc	tctgcccccc	gaggtcaaga	283680

gattctcctg	tctcagcctc	ccaagtagct	gggactacag	gcacctgcc	cctcacctgg	283740
ctaatttttg	tatttttagt	agagacagg	tttcaccgtc	ttgcccagg	tggtcttgaa	283800
ctoctaacct	cgtgatccac	ctocctccct	cggcctccca	aagtgttgag	attacaggca	283860
taagccaccg	cgcccagcct	ataccacatt	ttctttatct	actcactgg	ggatggggac	283920
ttagaacgg	tccatatttg	caattgtgaa	ttgtgctgca	ataaacatac	acctgtagat	283980
gtctttttta	tataatgact	tctttttatt	tgggtagaca	cccagtagtg	ggatttgatg	284040
attgaatagt	agatccctt	ttatttcttg	actaaatctc	tacactggtt	cccatcgaga	284100
ttgtactaat	gtacattccc	accagcaatg	tttaagcatt	gccttttcac	catattcaca	284160
gaaacggcta	ttgtttgttg	actttttaat	gattgcattt	ctgcaggagt	gagatgggat	284220
ctcattgttg	ctttaatttg	cattttcctg	ataactcata	tgtttgtag	ccatttgtag	284280
ttcttttttt	gagaaatgct	tgttcatgtc	atttgacacac	ttttgatgg	tttttttct	284340
tgctgatttg	tttgagttat	ttgtagattc	tagatattaa	tattttgtct	gatgcacagt	284400
ttgcaaata	tttctcttat	tctggagatc	gtctatttgt	tctgataact	atttctttgc	284460
tggtgcagcag	tttttttagt	taatgtgggc	caattaattt	attttgttta	cgtttgcatt	284520
tgcttttgag	gtcttattca	ttatttcttt	gcctaggcct	atgtccagaa	gagtttttct	284580
taggttaact	tctagaaatt	tatagtttca	gtcttttagt	ttcagtcctt	gatccatctt	284640
taatggatgt	atgtataagt	tgagagatcc	agtttctttc	ttctacatgt	ggctagccag	284700
ttttcccgag	accattttat	aaacagtggg	tactttcccc	aatttatgat	ttgttacgtt	284760
ttgtcaaaat	taagtacagt	gtaagtattt	ggattttattc	ctgggttctc	tatactgttc	284820
ctttgggtgta	tggtgtctact	gtatactgg	accacgttgt	tttgaaact	atagccttgt	284880
agtatagttt	caagtccagt	aacgtgatgg	ctccagattt	gttcttattg	catagaaatt	284940
ctttttttcg	ggctcttatt	ttggttccat	atgaatttta	cgtttttaaa	aagtattgta	285000
aaaatgatat	tggtattttg	atagcaattg	cattcaattt	gtagattgtt	ttggtcagta	285060
tggtcatttt	catgatattc	attcttccaa	cccatgagca	tggtgatgta	ttccatttgt	285120
ttgtttcatc	tacaattttg	ttcagcaata	ttttgtagtt	ctccttgtat	agatctttca	285180
ctccttgtgt	taactatatt	accaggcatt	ttattttttt	atttttgtat	gtttgcagct	285240
gttgtgaaag	gggttgagtt	cttaatttga	ttctcagctt	ggttgttgtt	ggtgcatagc	285300
aatgctaagt	atttgtgtac	aatgattttg	ttaaattgaga	attcactaaa	tttggttatc	285360
aaatctagga	gtctttcttt	atgatgtaaa	agagaagcaa	aggccaatgg	agtgtcaccc	285420
tctaagccta	cccttacatc	ccagttacgt	tgctaactca	gaaaaatcag	ctgaaggcca	285480
cttggaattt	ccctactctg	acccagatag	tcttttgatt	aaaatcata	ggttattagt	285540
ttttattttt	cagatggaa	aaatgaagac	taaaagaatg	tttatgtgga	aactgtgttt	285600
cccaaaaccc	ttctgcagta	gtcttttcac	tgctgaaatc	gttgatatac	taccattata	285660
aaacaaacaca	ctcttttatt	gttcacctaa	cctgcacgac	tttattcctt	agaagatttt	285720
caatattttt	ttttaaagca	tactggaaag	aacagaagca	ttaaagaaaa	aaaataaata	285780
aagggaactcc	ccccacctcc	accaacacac	acaggtatcc	tcttttctca	ttcatcagtg	285840
aggacgcttg	gtcagtaaa	gaattttctca	tgatccctcc	tcttttctct	acagggcata	285900
gatttgcaca	cgtgaagcca	ggcttcacat	gactgtattc	cataatagca	cacaaaaaac	285960
actgtcaaaa	tcaatgaaaa	cttcacaata	taaagaatat	agctagaatc	atggtaatga	286020
tcagttgatt	gatataatat	tagataagtg	caggatggta	actttttata	actaaacttt	286080
caaattggctc	agtgaattgt	ctaacattcc	atggcaaat	tgtatgaaga	ctacctggaa	286140
ctcagctatc	tacaattttg	ttggcagggg	aactagggtt	gtgagtttgt	ttccccctc	286200
tatgtttctaa	tgctcagcaa	actgtgaaat	tttccatgaa	atataatagt	tacgtaaata	286260
taaaaaagca	aaactttttg	gtatgttaat	tattgcacca	acttgtgttg	tttgactact	286320
attaacaata	aactaaaaca	attctacctg	cttgattgaa	gcaaaaatgt	caatgtgtaa	286380
ggatgatggg	tagatcacaa	aatcaaagaa	acagctacat	agtctgactc	agacaggaca	286440
tgtcaaacag	catccctgta	aggaaacttag	tctacagact	cacataggcc	ctgcctcagg	286500
aataaataag	ctgcacgtgt	gttttgcttc	cttgatttct	ttgatgtcag	ggctagatac	286560
tgggaagag	actcagggca	aaaaaagagt	atattgattg	acagcttcc	caagacagcc	286620
cacaatagaa	aagacatttc	ttttcaaaga	aactgagtat	aattgtcaaa	aaagaaaata	286680
gatactggtc	atcaaagcaa	gaccttatac	tttgtcaaa	tttactttta	atgtcacctc	286740
ctccaaaaag	ccattttctc	attcccctaa	atcatttctc	gtatatctca	gctttcatta	286800
aacaagcatg	ggccatgtat	ttaagaaaa	agaattttac	ggaggacaag	acagaccaga	286860
ccttaatttc	aggaacata	aattttgcca	aagatgatat	tgccatacta	ctatttctgt	286920
gattctctta	ggatcctgat	gccttgtgtc	ttagttatgt	ttttctttaa	tcagaagttt	286980
aaaaagtata	ttatatttta	ttttaagttc	tgtgatacat	gtgcaggaca	tgaaggtttg	287040
ttacataggt	aagcattttg	catggtggtt	tgccacactt	atcaattccat	cacctaggta	287100
ttaaagcccag	catgcattag	ctattttatc	tgatgctctc	cctccccaca	accccgaaat	287160
agaccccag	gtgtgttttc	cctccctgtg	tccatatgtt	tttattgttc	tgctccact	287220
tataaagtac	aacatgtagt	atttggtttt	ctgtttttgt	gttagtttgc	tgaggataat	287280
ggcttccagt	tccatccatg	tccctgcaaa	ggacatgata	tcattccttt	ttatgggtgc	287340

atagtattcc	atgatgtata	tgtaccacat	tttctttatc	cagtctatca	ttgatgggta	287400
tctgagttga	ttccatgtat	ttgctatggg	gaatagtgtc	gcaatgaaca	tatgtgtgca	287460
tatcttaaac	aaatttgtaa	gaaaaaaaca	aacaacccca	tcaaaaagta	ggcaaaggac	287520
atgaacagat	acttctcaga	agaagacatt	catgcagcca	acaaacaaga	aaaaaatctc	287580
aatatcactg	gttatttagag	aaaagcaaat	ctaaaccaca	agataccact	tcacaccagt	287640
cagaatgggtg	attattaaaa	agtcaagaaa	caacagatgc	tggcgagggt	gtggagaaat	287700
aggaacactt	ttacactgtt	gggtggcaata	tcaattagtt	caaccattgt	ggaaggtagt	287760
ggggcaattc	ctcaaagaca	tagaaccaga	aataccattt	tactcagcaa	tcacattact	287820
gggtatatgt	ccaaaggaat	ataaatcatt	ctgttatcag	gaaattttta	agcttctttg	287880
tgatgtgttt	tattagttaa	aacaataatt	tattagttaa	aatgttgtgt	ctttcctaac	287940
acttaccaca	tgggtgtatc	tgcaatgcac	actaatgaac	gcttcaaaat	tagccttaaa	288000
tgacacagct	cctcactgtc	actctttgct	tactctgtgt	ctgatggctc	ttctgcatga	288060
acaggaaaaat	ctgaattctc	acaattatct	ctaaagcttt	tattaccttc	ccttaaccca	288120
agccagtttt	tattacctgt	atgacactta	gacagttttac	attgtaatcc	cacctcttaa	288180
tggattttaaa	ctcattttcc	actttgggtat	ccccatattt	agtcattatt	tgtacttctg	288240
ttattgcaga	cccactccac	cttgtgttgc	agtgtgtgta	tctgtgatcc	cctgtagagt	288300
gtgagttcct	agagtcagag	tatccaggga	tagctctctt	taaacatcta	atgggattct	288360
atgaacataa	tgaataaaca	tttatgttag	ctaaatgtat	aaagagaaaa	tatatacttg	288420
ccccctttatt	aaagttgttg	tttcatatta	ttatatgcca	acaccatact	agtcctattg	288480
acagagagtt	atatgtgtga	tttgtattac	ctttaaagat	attagagcat	aaaataaattg	288540
gaataaactg	ttaggacaaa	ataaagaggt	acaatacaga	cactgaaatg	ggattggcca	288600
attctactta	ctgtggacaga	aaagctttct	agaatagatg	aatctcaaag	gataaacgga	288660
ggcataatcc	tgcagacaaa	gaagaaaagt	gctttccagg	tgaagaagag	agtggtagca	288720
cgaacaaata	tacaaaggat	gaggaagggtg	gagcatccaa	tttaaggatc	aaaataacaa	288780
ataattaaat	taggttattt	agaaggtaag	atcatagata	aacacacaca	tgcatgtgtg	288840
taatggaatt	taaaatcatt	ttttaggtaa	gaaagattcg	ttggaatgtt	ttagagggaa	288900
gaattaagta	attctataca	cattttagaa	agctcattct	gatactctat	aaagaatgtg	288960
tcaagtgtga	aaattagtaa	gatgaagagt	cagtaaatgt	gaatctaaaa	atgtgaatga	289020
gcacaagaga	ttattacata	tatatgtgtg	tgtgtgtgtg	tgtgtgtata	catatatata	289080
tatttttaat	ccaaagcata	tggttaactga	taacaggcgg	gagtattaga	aagggtcatc	289140
caggttgaat	ccaggatttc	atgggagata	gaagggaatga	acagtgtttc	cagacactga	289200
gattaagaat	gtgagaaaag	aagcagttgt	aagtgtgttg	aacttttgac	gtctatacaa	289260
ggagtctact	ggttactaga	aggtttacaa	agagaccatg	gtggatatta	ctagtctttg	289320
tgacattata	gtgtactggg	ataactcttg	gtgctatttg	gggttgctaa	aaatgaaata	289380
aggaagggaa	ggggacagaa	gataaaaatg	gagggaggat	aaaggggaga	acatgagagt	289440
ggcaagttaa	aaagtagggca	ctagagcaga	agacagaagg	aaagcgaggc	atacaaggta	289500
agggaaagggt	aagaaggagg	cgagaagaga	acctgtgtga	tttccaacat	ctaagtgtgg	289560
acaggagaga	ttgtctgtaa	aagggagaag	acatggtcac	gaggaaaggg	gggtgtagca	289620
aattttcatc	atggaagcct	aaggtaaaaat	tttcagagaa	ggatgtttta	tgtaagtgtg	289680
atctaaaatg	gccaaagatca	atcatgatga	taagtgaaca	ttcagataaa	gtttcagaac	289740
agataaaaact	ctgtaatggg	gacagcagcc	atcggagtgg	ttacatggta	tggcctgggg	289800
agggatgtgg	ggaatcctgg	gggtgtgaac	atggcctatg	tctcaaagtg	gtgaccaatc	289860
acattaccgc	acttcattgtg	ctttgctata	agcagggtcat	ccctcgattc	aaaatgtgtt	289920
aaaatgtaat	acgaaattaa	tataaacact	aagagggtta	aaaaatattag	tggcctttctc	289980
ggattacctg	ggtaccatca	gctgaaggat	tcaaaccaaa	ctctgttaga	ctcagatgcc	290040
ttagctgctg	accogtgtac	tactctgctg	tcaaattocaa	tccttgccaa	gcctctccat	290100
tggcatgtta	aatggactta	gtctctgttg	tcctttttag	tcttattttg	aaggcaccta	290160
cctattctac	caactgataa	attgaattgt	tattactgtt	ttacagtaag	atttggtag	290220
aagctttggg	tagaccataa	ttttttgtca	gatctgtgtg	tctgaactct	ccattaagga	290280
actgtttaga	tattacatat	acttttgctg	aaattcagag	gtactcataa	atttgacgac	290340
ttttaaaaaa	atgtactatc	agcagtggta	aatgataact	aaaatgggat	aattttactt	290400
aacagtatct	tgagcttaac	aaagcttcag	ataaaaacaa	gattgcattg	aatatcatgc	290460
aataaaaagga	aatacttaaa	gcaaaggat	ttatatgttc	ttatgtgtat	gttcttacag	290520
ggatggaaaa	gtctattttc	ataaaaatcta	attttttaat	ttacaatata	gagccctttg	290580
cttcttttcc	tgttttaggt	aagatctttt	cttctcttga	aagattatgt	atattttta	290640
atgattaatc	ttattttacc	tttacagaag	tactgtgaat	tagcagggca	gatattatga	290700
catctcctta	acatatgaat	taattgtggg	ctgccaaata	gtacatgatc	ttttactgga	290760
acgtagatcc	agggtggctca	aatagatatt	taagggcaga	gcacctaaac	tgaccagcca	290820
atgtaagcag	ttcatcttcc	gagcagattt	atttttcact	gtaaccaaat	gtattttact	290880
gctcctggaa	aaagtgttct	cccgtgagct	ttgttagtgt	gttttcacca	aggaactgct	290940
atctggggtg	cccacactgt	gtagagtttt	tgtcctgaaa	agctaaagtc	catatatatga	291000

agaaaaccta	ccacataaag	atgtttccta	gaatacccgt	catgatcaaa	ggtttgcagc	291060
tgtagtggaa	ctaactaatg	gatgcttcat	tttagtaagg	gcctcttttc	ttccattgat	291120
catagttgaa	tattgtgggt	tcagtttaag	atgagtcctat	gtgtgacatg	gattttaaata	291180
cccaaatttc	agtggtttga	taaaaattat	aagaaatact	gcaattatct	caaactaaaa	291240
cttgtcaaga	tttgtgtaat	atcatagaat	gtggacaaag	tgattaaaaa	atatattcta	291300
ttgactctgt	gacataatth	tagcagatac	atctttatat	tggccaacct	ttctttgaat	291360
taatcttgac	ttacgagttt	agaatagtg	catgtctgga	gagaaaaaga	cttcatgtga	291420
aatataaaca	ctctatgtac	tatttttagta	ttaatttttag	aaagatattt	ggcacacctt	291480
gaaacgtgat	ctaataatcac	tttcaattct	aagtctattg	catcatcaag	cagaattata	291540
taaactattt	ttaaaagttt	atcaactgga	ttttatgtta	ttagcaatac	atgagatgtc	291600
atggctttta	aaggatggct	atttttattat	gtagtatcct	tcaaatatta	tttttagtagt	291660
tttttgtact	aaccataggg	caattaatga	ttcagaaata	tattttaattt	ctattttata	291720
aatcttatat	tcatggcaat	atactacccc	tcactgattt	ttgcttggct	ttattaaact	291780
gagtttctgt	tttatctctg	caaaaataaa	taaaaaataa	aaatatgctc	aaatattaag	291840
caccccataa	atattaggtg	gataaataaa	tataaccaa	ctgctcttgc	aaaagtgaag	291900
aagtttttaa	tatagagatt	tcattccatt	cccttttaatt	tttcaaaata	ttagatgata	291960
caaaaatcat	gtgcacaatt	cagactcata	gctattttta	gaaactataa	tttttgattc	292020
aaaagaaatc	tgcaatcttg	caaaaatgag	actcagttta	acagtgtatt	tccaaagaaa	292080
ttgtagctgt	tattcttgcc	tttcttctta	gacaagagac	ttgtgatgg	atctcttaat	292140
attccatagc	taacaagaaa	aagagcagaa	aaagccatgg	gaactataaa	tataggcagt	292200
gatatttggt	tattgtggtt	gaaaacatta	cttggaagt	agaccacaa	aggttctcgt	292260
tctagctctc	catctaactt	ccatctctag	agatgtgccc	ttgacaaaat	gattttttcc	292320
tctggacttt	aatttcttta	tctggaccag	gtaagctcaa	agatctcagt	ttagtatttg	292380
atttttccag	attaaaatct	aagatgtggt	atcagataca	cttttctatt	tttcttttat	292440
ttgtcagaca	aacaagggtga	aaatgtgttt	aaaaactagg	tttatccatt	tttttctcgt	292500
acagtgttcc	taattcaaca	ctacattttt	ctatatactt	ttagtagaaa	gtgaatcata	292560
agttacttca	gtaggatata	tctgttgttt	tgctcttgta	ctcttccttt	actattacta	292620
ttatttcata	acataaataa	tgtaagaga	tctgggtcta	aatgtaggat	ttattttttc	292680
aagtttttac	aaattctatg	aattccctac	agtttctttg	gcogtcacta	tttgtctggt	292740
tgtttataga	agccgagaag	cagaacccct	atggctgaag	actggctcctg	atagagattc	292800
ttcttcta	cttctcaaac	caggaagggtg	ttcaggtcac	tctgtaaatg	attcaaagac	292860
agatactatg	taaagttaca	tttttctctt	aaaatccagt	ctgtaagcaa	attttatgcc	292920
ttatttttaa	taacaagata	tgtagctttg	gcaacatgtc	atcttatttg	gataggctat	292980
gccaacagga	ccaacacaga	gcaagccaaa	aaagatcttt	gaatgacaga	cagcttaaga	293040
agaacagaa	ctgtagagaa	aaataagaga	aaaggagaaa	tgtagtgagc	agacaaaaaa	293100
aataaaataa	aatagaataa	aaggagcttc	cacacaaggc	tgtaggggtc	attcaccaca	293160
taccaaggga	taactaccaa	gtaaatatta	taaaataaat	acttgctgga	gaaactgaat	293220
atccacctgt	aaaataatga	atcagaacac	ctacttcact	tcatgccata	tacaaaaact	293280
aaoccaaaat	agatcaaaga	tctaaattta	ataagtataa	atataaaact	cctagaaaga	293340
aacataggtg	aaaatatgca	aaagttttta	ttagggaatg	agttcttata	tatgatgcca	293400
aaagcacaag	caaccaaagg	aaaatcgata	aattagattt	tatcaaaatt	aaaaactttt	293460
atgcatttaa	tgataactatc	aagaaaatga	aaagcaagta	acagaatagg	agaaaaatatt	293520
tgcaaacata	tgctcgacaa	gtattaagta	tctagaatgc	ttcaagaact	cttacaaatc	293580
agcagtaaaa	acacaattca	attaaaagat	gagcaaagtt	caatattaag	ctattcccca	293640
gagaagatac	acaaatggcc	aataagcagt	gaaaagatac	tagcattagt	cattagagaa	293700
tgcaaatcaa	acctacaatg	aaatagcact	ttgcacctac	taggtggcta	taattaaaaa	293760
ataagcaaac	agaaacaaaa	caactattgg	tgtaggatga	gagtaatcgg	aatcctcata	293820
cattgctagt	aggaatgaaa	catggtacag	ccactatgaa	aaaagaaatg	ttttcagttc	293880
ctcaacaagt	taaacataga	attaccatat	gaccagcaa	ttccgcagct	aggtaaatgc	293940
ctgagagaag	tgtgttagtc	cattttccaa	ctgctgataa	acacatcccc	ggggtctggg	294000
aattttatac	ataaaagagg	tttaattggac	tcccagttcc	acgtggctga	ggagggcctc	294060
actocacaatc	acagcagaag	gtgaaagaca	tgctttacat	ggcagccagc	aagagaggat	294120
gagagccaag	tgaaaggggc	tttgccctta	taaaaccatt	gagatctcat	cagacttatt	294180
cactaccatg	agaacagtat	ggagaaaacc	accccatga	ttcaattatc	tcccaccatg	294240
tcctttccac	atgtgggaag	tatggtaacc	acaattcaag	atgaaatttg	ggtaggggaca	294300
caacaaagcc	atatctgaag	taagacaaat	tatctcacia	aactatacac	caatattcct	294360
agcagcatat	tcatttatagg	taaaagaaga	aaaaaggcac	atgtccatta	tattcatata	294420
atagaataat	attccatcat	aaaaaggaat	gggtagtgt	tacatactac	atgatgaacc	294480
ttgaaaatat	tatgctaagt	gaaacaagtc	tgacaogaaa	gaccacataa	tgtagatttc	294540
catacagaag	aaatgttcag	aacaagtaaa	ggcacagagg	cataaaatag	attagtgggt	294600
gccagtggct	ggcgggagat	ttccattaac	agctaacatg	tacagggttt	ctttttgggt	294660

tatcagaaaa	ttctggattt	catattttatt	gttgagagc	atagtgaata	tactaaaaa	294720
aacaaacaaa	acactaacat	atactcttgt	aactgggtgaa	ttttgcttat	gtgaaaaata	294780
tgctcagtaa	aatgctaaag	taaaacaacc	tgaagagttg	actatatata	tttgtagata	294840
tacacaagta	tgcatcttagc	ttttataaac	aatgtcttgt	taaattatta	ctagcaattt	294900
tatagtcagt	taagattgaa	tacatgttta	attcctgcct	ttattgaata	ttcattctgc	294960
aactacttgt	gctgggcact	gtcctaggtt	caaataattt	aacaataatt	aagagagaca	295020
tgcttcttct	agaaaagatc	aatgatttga	aaacattttt	atttcaggac	actttttatac	295080
tcttgaaaat	tattgaggac	cccaaagaac	tattttttat	ataggataca	tccatcaata	295140
ttcactttat	tagatattaa	actgagaaaa	aatttttaagc	atgtgttgaa	ataataaact	295200
attttaatat	aaataatgca	tttattaaaa	tattttctat	tagaaacatt	ttagagaaga	295260
gtaaaattat	ttcatatttt	tgcaaatatt	ttgacatctg	actgaagaga	agattttcag	295320
atttttacat	ctgctccagc	atttagtcta	ttgcaggctc	ttgttttggt	taaaatgtat	295380
gaaggaaatt	ttgccttgca	cggatatgga	aaagagagga	gtatttcaat	taccttttca	295440
gaaaattgtg	aatatatatg	tatatatatg	tgtgtgtata	tatatgtgta	cagatagata	295500
gatagatgat	agatagataa	ctacatcagc	actaaacaag	tggaatttc	ttacatgttt	295560
gttgcaatgt	gtaatccgga	actgtatcag	tgaattcttt	ataacctgtt	acattaaaaa	295620
tgattggtcg	ttctttcact	ttgaagagat	cttttaataca	aaagtgattt	tgcaaatatt	295680
tgcatgtgtc	atttggaaaa	ggtttggtca	tgaagctttg	cagattttcc	aattgtgat	295740
acattttatg	atacaaataa	cactgtttaa	taccaccact	gttctcaaaa	ggagttttaa	295800
gtgtggaagc	cgaagctgac	caagctaatt	gtggcacaca	cacgttttcc	gaaattctgc	295860
ttttcacttg	aaagctagaa	ttttataatg	aataacaagt	actgtcagat	gtttccctta	295920
gggtcacttt	gttcatgttt	gaaaaagaaa	agtctgccaa	atgcctactt	atgaattacc	295980
atggtttgtc	agtcattctc	tcaattagaa	gcgaagagct	acaaaaagt	gggcagcgaa	296040
ctctcactcc	aacgaccgca	tgagcgcccc	ctgcccgtcaa	ctgtcacgct	gccgtgcagc	296100
agaagtgtcg	gatttcatct	gaggatgtga	aaaaggcatg	tactcaggat	ggaaattcca	296160
cataatgaac	acttttcgct	gcttcatcaa	ggacgtgctt	aactaaaagc	agcatcggtt	296220
ttggttggtt	gtttacactg	gggtgtgagc	agtgaagact	tcagtggcac	ctagtgcggt	296280
agctcctcga	ttcttcatct	gcactttcgc	cattgatgag	ccactagttt	tgctccccct	296340
atgcaatgtt	agcacagtga	aaaagacaaa	tacatttctg	tttgttttgt	tttttttgag	296400
atggagtctc	tctctggcgc	caaggctgga	gtgcagtggc	gtgatctcgg	ctcaccacaa	296460
gctccgcctc	ccgggttccc	gccattctcc	tgttccagcc	tcctctccga	gtagtgtagc	296520
tgggactaca	ggcgcccgcc	gccacgcccc	gctaattttt	gtatttttag	tagagacagg	296580
gtttcaccat	gttgacacag	gtgtctgca	tctctttacc	tcgtgatccg	cccaattcgg	296640
cctctcaaa	tggtgggatt	acaggcgtaa	acgtttctta	atattatggc	aataaatata	296700
gttttggtc	cagagtcccc	ctaaaagtgt	attgggacac	ccagagacct	gcctgagcac	296760
cataactgga	taactgctgc	tctagattct	aaaactttct	ctgagttgct	ttatcaattg	296820
tccttttctt	gttttcttac	acatgggaga	ttcttctcta	ttgtctctga	aaatcctcat	296880
gtttcttatg	gttattttat	atggcttcat	gatgcacaca	cacatcctta	tatatatttt	296940
cttccgaatc	ttctctaaca	tgccctcttc	ttgcctatag	atcatgacag	tattctacgt	297000
acatattttg	aggagttttt	attatgttca	ctctgggaga	gctttcgctc	ctcagggtac	297060
aggagacttg	tgaaccccag	agtcagtggc	agtgcctgca	ctccctagct	tgctgctcac	297120
atcggtagct	gaaatgcctt	agtccttgct	cagttatttc	ctttaaatag	atgctaggtc	297180
gaataggtgt	tgtggcctct	tagtaactga	gtgatgggag	aggctatttc	tttgcttata	297240
agaacacact	gcttttctaag	tgagaagagc	ccagcttcc	gacagagcac	cattagaaga	297300
accctccact	gtccttggtta	ggttatagtg	cttatcaatt	tctctccttt	acagggccca	297360
atocaaatgag	tgacctgttt	tgggaagcaa	acatgtttaa	agaaacccta	cttgaaagtt	297420
aaagactaca	attgcatttt	agaatataga	ctagtgtctac	caattgtgat	tgctcctcctg	297480
aacgctatgc	ttttgtgaca	gttaatggaa	tttaaaaagg	aaaagtaaac	gtatctataa	297540
cctaactttt	gtaattgaaa	ggattggatt	ggaatggaat	cctaatacat	tatttctctc	297600
agaattaagt	ccattgttct	taacctgtta	ttcttcagtg	acctcgcagg	actgcaagct	297660
acctaaaact	gaatgtaaga	ttttgtgagt	tttttttttt	tttccctgca	tgatatatag	297720
acatatatac	actggggaaa	gaatatcaaa	aggtacattt	gttttattca	ttcaaatatt	297780
aaatatccaa	atatctctta	tatacacagg	tataggtatt	tagttattgg	atggtaaaat	297840
atatatattt	ttatatgtat	gttttggtca	tttcaattgg	taaaatagag	catcagtggtg	297900
cactatggac	agaagcagta	ccatagtttt	ttcctcttat	atcaactttt	cttctcattc	297960
cctctttttt	cttctgatcc	atctccttcc	cctccctcaa	ttccagtttg	tttttctctt	298020
ttaaagttgg	ctatggacag	caaagacaa	tgaaatgtaa	tttaaaatac	gcacatttaa	298080
catattctat	attataaaatc	atgctgctat	aaagacacct	gcacacttat	gtttattgctg	298140
gcactattca	caatagcaaa	gacttggaac	caatccaaat	gtccaacaat	gatagactgg	298200
attaagaaaa	tgtgtcacat	atacaccatg	gaatactatg	cagccataaa	aaatgatgag	298260
ttcatgtcct	ttgtagggac	atggatgaaa	ttggaagtca	tcattctcag	taaactatcg	298320

caaggagaaa	aaaacaaaCa	cogcatgttc	tcactcatag	gtgggaattg	aacaatgaga	298380
acacatggac	acaggaaggg	gaacatcaca	ctctggggac	tggtgtgggg	tagggggagg	298440
ggggagggat	agcattaggc	gatataccta	atgctaaatg	acgagttaat	gggtgcagca	298500
caccagcatg	gcacatgtat	acatatgtaa	ctaacctgca	cattgtgcac	atgtacccta	298560
aaactttaag	tataataata	aaaaaaaaatt	cttcattgac	ttacatgcaa	tgaataattt	298620
ataattagcc	tatgttacta	ttcattttcc	ttttattttt	ttcttgcaaa	attatgtttag	298680
aactgtgact	gaaatgtatg	agttttctcaa	tagatgctat	tgattgagtt	attttgaagc	298740
acaaaaataa	attgaattgg	ttaatataca	ctttgttaggt	caaaactggc	cctgggaatt	298800
attttttaga	gctattccac	attattcaac	ttcgtaagct	tactgttggg	tatttatata	298860
tttttaattt	ttgaattata	atagaagcag	tttaggactt	aatataaaaa	atatgtaaaa	298920
tgtaaataca	ctcatttttc	atttttaaca	catgctttca	tgtcataacg	gatcccaaaa	298980
taccaaaagat	attaggggaa	aaaataaaact	gttggtgtct	taaaatacat	tcctttgttg	299040
aatcatcctt	gctaaccctt	taggggtattg	acagcctatt	atttttcata	tgtgccatct	299100
ttatctagaa	aactgagaga	acaactaatt	atatcctttt	gcaaagagt	gcaacagaat	299160
ggcttttggt	caacacaatt	tttaagtctg	ttgaacagga	ctggtgaatg	gcttaaaaaat	299220
ttgccatggg	gtgtgtgtgt	gcacatatga	gaatatgtat	gttaatatct	agccacctta	299280
gtgtcatgga	aagcgtggcc	tggggatttg	attatacatt	gtgctttgtc	ataaatttta	299340
tgggttcttt	gcaacattat	tggaggaggt	atgcctctat	gtctttcatt	tagcttgtat	299400
atttttggtt	tgatagacat	ggtaattact	gctcttaaa	tttgtgcaaa	tgccactggg	299460
aaaggggata	ggagtaaaga	attaaagtga	aggctcatga	ataaacctat	taacaaaagc	299520
agagtgattt	cttgaataat	cccttcatct	ctccccatgt	cataatcctt	tctcataaat	299580
aattatacaa	gcaagcctag	acacacacta	gtgttgaa	attgtgctgc	aaaatgcatt	299640
tagctgcatt	aaataccaag	agaagccttg	agttccaaaa	cctccttaaa	gtggaattct	299700
cagttgtttc	cagagaagag	gcaagttata	gtacatataa	tctattatga	acgtatctga	299760
gtagaacacc	atgcaataag	gcgctattga	attgggaggg	aggtatcaga	gctaaagagc	299820
acaaagacgg	gccatcgaga	tattagagga	gatttctctt	catatgtaat	tctgctttac	299880
atgtttctct	aatcttattt	cctttctccc	taccgcctct	ttttttttta	gccacaaatc	299940
attgogtttg	tacagattac	aggaaaacac	tcaaatattg	ctcgaagaag	cataatcttt	300000
cttctgcagt	tggtataaaa	tgagatctac	ttgtaaaaat	tagtgtcatt	gtctacaaca	300060
ctttcagatg	actctcatgc	caccaggtca	atattcctgc	tagggatgag	ttagttctta	300120
cacttggttg	atcaccaaga	atgtgggact	cataagggca	atggatgatg	caggcgcata	300180
gtgtcctttg	atgttactgg	aggtgtaaaa	tgaaggtttt	ttttcattct	aatcaaaagt	300240
ttaatgggat	agtaagtatt	tattatcttt	atcctggaag	ggattttatt	gcttttgaca	300300
tttttaaaaa	tgtaaaattt	taattttaat	ttaatgtgtt	aaaaaattt	ttaaactttt	300360
atatrgtttt	acaattcagt	ggaattctct	cttctttata	ttattgtact	tgcatataa	300420
atattttaga	tgttttcaat	catgagttat	tgtcactatg	ttttattaga	aatatccttc	300480
tcactatgag	ataaagggac	gaaatgagtg	ctaattgtaat	tctacagggg	tcagatagca	300540
tttccatggg	tacattgatt	cactagcagc	atgtcctgaa	taactcctgc	tgtattgcaa	300600
acccttgctg	ggcagggctt	agtatatctt	taatgtttct	gcatatagct	ccaatttagc	300660
tccaattttc	ttcctacatt	gtagtactag	atcaaaaaat	acttattggg	tgaacctata	300720
atgtatgcta	cttaggcagc	tctggcatga	ggcatgacat	tatattttaa	ataaagaaac	300780
acattccagc	attccaaaaat	tctcaaagca	taacctgtg	taaaaccata	gttaaagttt	300840
caaaatttga	aacacgaaaa	ctgacttttt	aaaatgttaa	ccatacaatg	actaatgcag	300900
tgtgctcttt	gcacgtgcat	aaacaataag	aaacattatt	aaaataaaaa	atttatattt	300960
taaagttaac	atacactatt	taaaatactg	agcaaacatt	tataataagta	ggggattttat	301020
ataaaaatctg	aatgatgaaa	gtacttaaaa	agtactaata	gtaactaatt	tattgaaatc	301080
ttgtggcagt	cttcatatga	ataatttaac	caccagaata	gttacggaag	gtaggtacaa	301140
atgaataacc	cattttgtata	ggagttaaact	gatgcctaga	aagagaaagt	cactaattca	301200
agctcataca	acgtacaagt	agaaaagtga	ggatttttagc	acaggtaatc	ttgatacaga	301260
atgatttcca	ttatttttaa	ataagagtaa	tacatgtatg	tatatgaatt	caaataatac	301320
agaatgataa	aaatggcaga	atacggagcc	cccttttcca	cccctcgagt	tccttctccc	301380
caaccaatat	ttatattaat	agcttatttt	atttatctta	aaaatattat	attttacact	301440
cattattttct	atctatatct	ctatatagat	atatatcttc	atcattataa	aataagatat	301500
acagtataaa	acctttctct	taatatgaat	ggatgaaactg	atctaccata	tattattagt	301560
agctatattg	aattccgatg	tatggatggg	cctaattatc	ttttttatta	ataaaaattt	301620
agtttggtta	tatcattaat	attctcatat	tttgctattt	gcaaaaatag	ctggaataaa	301680
caagagttaa	ttttatttct	atttactgta	aatttgttca	ttattactga	agtaaaagga	301740
ttgagatgac	ataatgccta	tcagtgcctt	taaaatattt	caataacaac	aaaaaagaaa	301800
cctctttcaa	gtgtgcaaca	tcctgataat	taacttatct	gggtaatgag	tgtatgaaag	301860
ttcattataa	atgatatttc	tatgtgtgtg	tgtatttaga	atttttacia	tagttttgtc	301920
aaaagttatt	ttttaatgaa	gcactctgatt	tttagggagg	gatctaagct	ttccacacat	301980



gcttctattc	tccatagtag	tgtaagaatt	tcaaatgtgg	acacgttaaa	gtattttctag	302040
aggaggatta	agtgatatga	atgaaactgt	tggggacott	acatttttatg	tgtaatgaga	302100
gctgaaagg	ggttctacaa	agaagtgtga	taatagagga	cagatttttg	gaatgaggtga	302160
atgtcattcc	aataaggact	atatttatct	agggatattt	tgaaagaaac	tggtgatgag	302220
gagaatgaag	agaaatagtc	attagtgcac	acatgtcaag	aaagaaaaca	tattacttct	302280
ttggagatat	tttctctctc	tctctctctc	cccctgcctt	cccctgtccc	tctctccata	302340
aggctctatt	tatctatoca	tcctctctgc	atatgtcttt	atccatactt	atatctccat	302400
actcatatct	ataccgatat	ctatatttat	atctgtaagc	tgatcttagc	ctactcatca	302460
tggtaacata	tggcagattt	gtgtatacct	gttatcagtt	cccaaactctt	tacacacact	302520
tctctgtcat	catgatttaag	gggagtaatg	tgctcttacg	tttttgagaa	ttgggcccaa	302580
tggggacagc	tatttttctc	tggtataaga	ttccatagat	tggtggcaaca	atggcaccat	302640
gatgacttct	aaactcttga	tgggagactt	gcttctgtga	cttaatggat	tattagccct	302700
gcaatgggaa	ctacacaccc	aaaggccaag	aggaaacatgc	aaaggcaaac	agagagacaa	302760
gagagcccat	caatcacgag	aagatggcag	gaagtgtgtc	cgttcccatt	gcagttattc	302820
ggacagctta	agattgaaat	ataatagaaa	gttatatgac	gtactctaca	gacaagtta	302880
tattttatta	ttattattgt	tttgtaatgt	agaaaacatc	taccocctaaa	aatctgtgga	302940
taatagggtta	ctagattttg	taactaaata	agataataga	caaaatataa	tagatataga	303000
aaaagtcaga	aatgatccctc	atccattttta	gaaacccaat	caattttcaat	ttaatccaaa	303060
tctcttccct	cttcaacaag	gcactacgtt	atcctcatcc	ttccagcttt	ccttcccaca	303120
gctttgatca	ttcagggtta	gtcttcattg	cccatacttg	ttcctatttg	ttttaaatga	303180
agtcttaata	aattcttctc	attgggtggg	aataagatat	attcaataag	gtgaaatgtc	303240
taactttaat	tactgaacaa	tgaagcatgg	tagagggtta	tactttaata	atataattta	303300
ttaattatac	atcatgggtcc	aagggtctcta	ctttaattaa	tattttccac	tagcaaaaaa	303360
taactatcgg	tgtacaaagt	cccacagatt	agacaccaga	acottaggca	ggtagtaagc	303420
cccagtgagt	tcagtggcta	aagtgggctt	taagtaccta	agggttatct	ttattcatgt	303480
gaaagttttc	tggctagaga	gttaacagct	gagtgcattt	ttagtaaaat	actgcaggaa	303540
atggctgata	aaagtatcaa	tggtgtatat	ctgcttaaa	gagatgcata	tctgttcttt	303600
ctcaaacac	tggttaagctg	tcacccatag	acttattgtta	gaaacaatta	tctcacagta	303660
gttttatctc	cagacatttt	tctgcccaga	caaaagaatc	tatggaagta	gtcattttctc	303720
tagtttgttt	tagggaggat	tggtgtgggt	ctcctatgag	aaatcacttg	cacattatgt	303780
tcagggtatac	aaacacgtga	atgtatttgc	tatacagagt	ccattttctta	cacacagcaa	303840
ggtatagttt	caaattgctg	aagccaaata	aaccaaattg	gaagaaattg	atggtaaact	303900
ttgtcagaat	gttggttctc	tctcatattt	atgaatctgt	caaaggatag	actttttgtta	303960
aactaatagg	tttttatatg	ttctaattat	gcaaggaaat	ctatcctgtc	ttagcaatca	304020
agtggttaaga	gagaaacata	tggttagaga	tcagggaaga	atatgttaag	tgaataggac	304080
actgaaaaag	tctgctgtga	atacagtggt	gggcagccat	tgtagagatta	agtagtaaat	304140
gcccagtcac	acagaaaaaa	aaatgggaatt	gtaatataaa	gtcacaaaata	taatttggtg	304200
attgacttac	acggattaca	aatttggtat	attgagcttt	ccgggcttag	tgaataacat	304260
cactctttgc	atttttttgc	tacatcatct	ggccacaaaa	ttttaaagac	tatttatgaa	304320
agtcaggtta	atatttaaa	tcacaaagag	tcttagaaaat	tttgaacatc	acactgactt	304380
cgtacctgtt	gtactatggc	atatgtcttt	agtcaactaa	ttatttttct	cgtaaacaaa	304440
aaaaaaggaa	ataaaaaatc	ccaaaaaaca	aataacccaa	taaaaataat	gagtaaaata	304500
tcagggttga	tattctctca	aagaagacat	acaaatgaag	agcaagtata	tgaaaaaatg	304560
ttcaacatca	ctaatacaaa	atcaaaacca	cagtggagata	acagctcacc	ccagttagaa	304620
tggcaattct	ccaaaagaca	aaagataacg	tggttgcgag	gacgtggaga	aaagagaatc	304680
attgaacatt	gttggtggga	atgtgaatta	gtatagcctt	tacgaaaaac	agtatggaga	304740
ttcctcatga	aaacaaaaat	agaagtatca	tttgatccaa	cagtcctact	actgggtaga	304800
tatccaaaga	aaatgaaatc	ggtatgtcaa	agaagtgtct	gcgcttccat	gtttatgaca	304860
gcattattca	caatagccaa	ggtatgaaat	caacctaaat	ggacatcaat	ggaaaaatgg	304920
ataaagaaaa	tgtggtatgt	atacacaatg	caatactatt	caaccataaa	aagaatgaaa	304980
tcattgcgaca	acaccaatga	acctggaaag	cattatgtta	agtaaaagaa	accaaacata	305040
ggaaaacaaa	caccgcatgt	ttcactcatg	tggaaattcaa	atcacattgg	cacatgaagg	305100
tagagtacaa	tggtagctgt	cagaggctgg	gtgtttaggg	gagaaatggg	atggagagat	305160
gtcggctcaga	gcatacatct	acatttgata	gaagaaatga	atttcaagag	atctattata	305220
tagcaagggtg	actctaatta	atgaaaatat	gattcttattc	ttgaaaaatg	tagaatgaa	305280
gtaatatgcc	atcaccacag	aaattgtaac	agtgcagggt	aatgcatttg	tgaattagct	305340
agatttaaca	agtcaacaat	gaatatcacac	tttataacat	catgttggtc	atgataaaaa	305400
acatacaatg	ttatctgtca	attaaaaaaa	tatctaggaa	gaatctgtac	agaagattgt	305460
gggtattttat	aaaatgcata	tttactttgt	aagtcaccaa	atttgtgaat	aacattattg	305520
gattttatttt	gottaataga	atagaataaa	taatagaata	aattataatt	aaatatttaa	305580
agtgatccct	ttagaccttg	atgattttat	aaatataggt	gagatgctag	tttgcttacc	305640

ctaaatatct	attttctgcc	ccagaaacaa	tcctttaata	gaacacttta	cctttcotta	305700
acttccatca	ccaaaattgg	caattaagaa	tattttcaca	cagaaaaaac	cactattgat	305760
atgtgtgtat	ttttagcaag	aaagccagtt	ttttgagctg	tatgatggag	ccttttcaact	305820
cattagtgat	gcaactgact	tctgcacacc	atcctacaga	agaagaaact	catgttcgta	305880
tataagcaaa	atgacatatc	attacacata	ataactcatt	gtggtgggtt	ctaagcaagt	305940
gaagcagtac	tggctaaate	catcagtgtg	gtattggctc	tctattctac	ctgttcttaa	306000
aaccagtaag	gtagagttcc	cgctccttga	tataagaata	aggattccac	cttctcctgc	306060
ccctcccaac	tgaattctc	aaatgtgttt	gtcgtgggtt	catccaatat	tgcccaagga	306120
aagtgtgttt	tattagcttg	ggattccatc	tgtgaagact	ggcatttcta	tcttactaac	306180
agatacagaa	catatgaaga	atccctgagt	tcctacatag	ctgtcaagaa	gtaaatgaac	306240
tgatttgact	gttattccct	tcactcactg	gaaaaatagc	tcttcccaga	atcaagtatt	306300
gttgactctg	ttccaatcct	cagagcaatt	cttgccaaac	ttcttttgag	aggtgctgcc	306360
ttgagaaagc	atgacctatg	aaaatgagtt	gaagctccaa	accagcccat	accacgtgat	306420
ttgcatagta	caagcctcac	tgatgatcac	tatccaccat	atcttagaga	tgggatttag	306480
aagttactca	tctctggaga	ttgtatccca	gggtctagca	caagtctcta	cacaagtggg	306540
actcaaaagt	agcacttgca	ttagtattag	ctgagaattt	tttaaaaaaa	aatcggagaa	306600
cgaagcaatg	aagtaaatgt	agaaaattcc	tcttcatgtg	aaattcctgc	taacatgttg	306660
tacagcatgt	taggatgggg	accacacctc	ctttttactc	acccattata	gcccaacgat	306720
ggaacacagt	gcctgacaat	aagtatgtgt	tgagtaaagt	aaccgctgtg	atcctcccac	306780
tgcatcacog	caagtacctt	tagaccccaa	agagcataat	acagatatgg	tttggtatg	306840
tcctcaccca	aatctcatct	tgaattgtaa	tccccagttt	tcttactggg	ttcagaaaga	306900
gaagtatttt	tccccacatg	tggaagaagg	gacctaatgg	gtaactgaat	aatgagggca	306960
gtttccccc	tgccgttctc	gtgatagtga	gtttctacaa	gatctgatgg	ttttgtttgt	307020
tatttgtag	tttgttttga	gacacagtct	tgctctgtca	cccaggttgg	agggcagttg	307080
tgtgatctcg	gctcactgca	acctctgcct	cccgagtcca	agcgattctc	ctgtctcagc	307140
ctcccagtag	gctgagacta	caggtgtgtg	ccaccacgcc	cagctaattt	tatgtattct	307200
taatagagat	cgggtttcac	cgtgttagcc	aaggcgtgtg	cgatctcctg	tcctcgtgat	307260
cgcgccacct	cagcctctca	aagtgtgtg	atgacaggtg	tgagccacca	tgcccggtcg	307320
atctgatctg	atggttttat	aagcatctgt	catttccctg	gcttgcaatt	ctctctcctg	307380
tcgctgtgtt	aagaaggttc	ttgcttcccc	tttatctttt	gocatgatta	taagtttctt	307440
gtggcctccc	cagccacgtg	gaactgtgag	tcaattaaac	ctcttttctt	tataaaataa	307500
ccagtcttga	gggtatttct	ttatagcagt	gtgaaaacgg	actaatagac	aaagaaagcc	307560
tcaagtaaa	aaaggtacat	tgtagaatat	caaaaatatc	cagtaattct	ttttcatagg	307620
aaacgtggct	tgattcatgtt	tgttcattga	gaaccacatc	tattggcttt	gtatcttgct	307680
tcaagttgtt	ctagaaattc	caactattat	tgaggcattt	gcgtattaaa	ttacttttta	307740
gaaatcttta	cagtgaaggt	gaatctggta	ataatacgta	acaacattat	gctaaccact	307800
ttaatgttct	agatgtattt	gataagaacc	ttattctcag	tattctgagt	aaactcgggg	307860
cctggaaaac	atttagcctg	tacaaaagatg	tatatgtgtt	atatttttct	taattgaaag	307920
acgatataata	ttttgaaaaa	aacatttagt	ctcctaaaaa	tataaaaaaa	tcattgttta	307980
gagaatgcaa	ctaactcaca	aattttaaat	aaataaccag	tgcttatagt	gtagttgtat	308040
tatccattca	taaaattgat	tgcaatatgt	tagtgcgtgc	agcttagtat	aacacatttt	308100
ccccgaacc	acaaaaatgt	gtttatttat	ttattcattt	taaaactact	ttatagtaat	308160
atacagatta	agtaaacatt	ttagtaatga	gcttacagat	tttatacgat	catgcggttt	308220
tggttttctt	actgggttca	gaaagagaag	tatttttcag	tggggattgc	ctagctgcaa	308280
ccttgacatt	ttcactgtct	tgctgcaggg	agttcaggag	catgtataag	actattctat	308340
ttaatttagt	tttacaatct	cattgtatct	ggcaatttaa	gacatagaaa	agtaactttt	308400
ccttaattaa	aataaacttt	tggtatttgg	atagcaggat	aatgaatacc	cagacaggca	308460
gtatgtgggt	atgagttagt	catgaacttt	ggaattcaca	gaccttggtt	tagatttcag	308520
attctccaat	tattagctat	gtcagttagg	gcaaattgcc	ttaattcttt	aaactcaatg	308580
tattgatgtg	gaaaaagggg	caataaatcc	tatcattcaa	agttgtaatg	agcagtaaa	308640
tatatgaata	tgtaaaaatg	actaggctag	tcctgacta	tgggacatag	catttatttc	308700
catgtgcact	ttgtgtgagg	gagtgttaata	tccaatttct	gtattatcat	actgcaacta	308760
tgaatatgga	ccaaatata	gatacatctt	taccatttac	agactacttt	tccatgtaca	308820
cacacatagc	cctttgctaa	aatgtgatca	tggaaattag	atttcataaa	attgaattat	308880
aacattggaa	ggccatgtag	cttaagatta	aaaacataga	atttgacagc	agacacaaatg	308940
agctggaatt	ctattctact	tgtttcctgt	cctatcttga	gcaagccact	caacattttc	309000
agtctctttc	tttttcatgt	aaatgtacat	atccatgtca	tagatttgtg	atgtctatta	309060
aggaagatgt	atgaaagcac	tgtcacaaatg	accaataaaa	ggagaggatt	caataaatgg	309120
tcattgtccc	ttaacagatg	tctttaaaaa	catattaaat	ttgaaacatt	gtttcagagt	309180
gtcttattgg	atgaaatgat	aataactgta	cacatgggtg	aagattagtg	attggaagtc	309240
aagaattttt	gcttcagctc	cttgaccttg	aggttgaaat	ttaagcctcc	tcattctagt	309300



tttttaaaaa	acgttttctaa	cagaaatata	ctttgtggat	cattatacct	catttctaate	309360
cagctccctc	aagcttaate	tgtatgaact	ttggggaaaa	gataagcact	gtgaataagt	309420
tggcatgctt	gaacattctt	tgaataagta	gaaaatattg	ctcttttcatt	ttattgacag	309480
aaagattatc	ttgatagctt	atacttctgt	ttttaatgta	aataataggt	atcaaattct	309540
aaaattgaat	aatggtgacc	aatttaatga	gtgtctgtaa	taaggggaat	ttataaatgt	309600
tttgactaa	ttgcagtttg	taaagttatt	gaacttccct	ttatacttag	atgataattt	309660
attattttatt	tattttattt	tgagatggag	tccactctg	ctgcccagag	tggagtgcag	309720
tggcccgatc	tcagctcact	gcaacctctg	cctcccaggt	tcaagtgatc	cttctgcttc	309780
agtctcctga	gtatccggga	ttacaggcac	gtgccaacac	gcccagctac	ttttttgtat	309840
ttttagtaga	gatgagggtt	cactatgtta	gccaggatgg	tctccatctc	ttgacctcat	309900
gatctgocca	cctggccctc	ccaaagtgtc	gggattacag	gctgtagtca	ctgcccgcgg	309960
accaattttt	tattttttatt	gacaatgtct	ctttggataa	agaaagttag	tgaacgcctt	310020
ggtcaatgca	actgtggtta	agagaacaga	aatgatcatg	cacaatagca	agatttcagt	310080
taaggttcct	ggttgcaagt	gataaaaaatt	taaagcagga	aaataatcta	ttagaaggct	310140
atggaataga	tgctcagagac	aaatgttaag	gttctgaaat	tgggcaataa	gcaagggaag	310200
aaagacotca	aaggcattaa	cctgcagtgc	ttctgaacgt	gggctctgga	gctgaagttc	310260
caaatctctg	ctccaccact	taatagaact	ttgtgaactt	gggcaagtga	cttaaccttt	310320
gtatgtocca	gtattcagat	cttcaaaatt	agactaccct	tacagctaac	tgagttaaca	310380
cgtgaaagac	acataataga	tottcaaaaa	tgccagaaaa	aaaataaatg	tggccagaac	310440
aatggccatc	acattatata	ccatggactc	cactggacgt	ggttatggaa	aactaatctc	310500
gctgtccttt	tgaattttgca	tacctccaca	aagttcctga	cctatatattg	attttgcctt	310560
ggttgagagg	agaacagaag	ggatgaaatt	tctttacttt	ttctctaagt	gaaaggata	310620
attccctgaa	actaagaaga	ggagggattt	ggatgttaaa	cagccacaca	ttttgaaaat	310680
gtccactaca	gttagaataa	ccatataatc	tagctacott	gagaaagtcc	cagtttacaa	310740
ctgatatccc	acatggttaa	acacaccttc	gtggcagaag	tgccacaatt	tggatgataa	310800
attatgggtca	ctgtgattgt	cattcactcc	cttttgcctg	taaaaatgtg	atatattctt	310860
cttcttatac	ttactggttc	agtgaaaaaa	gaccttaata	acaaaattaa	attttcattt	310920
ataaaaaaaa	taatgcattt	attcttttca	gcaaacaaaa	caaaaacaca	acaacaacaa	310980
caacaaaaaa	ccagaaagtc	caaaatacta	ttattctgct	atctctaagt	cttggaatc	311040
tgtggactat	tttttgactc	taattttttc	taatcctatc	tcagtatttc	atcacctaca	311100
gagtaaaatta	gcattgtccc	cacaacaata	ccctacatac	ggtatctata	tctattttata	311160
tacatgtata	caaatatata	cataaatata	tatatgcata	tatacatatc	tatatgtata	311220
tagatagatg	tagatatatg	aaaggatata	ctatatacag	taggcctcca	ttacctcaga	311280
gacacatctc	aagaccttca	gtggatgcct	gaaaacgtgg	atagtgcgga	accttatata	311340
tactatgtat	aatttttttc	tttgtcacca	tttccacagat	aaaagattca	ttttgctgta	311400
tatcttagca	acctcagcat	atgatttttt	tccctttctt	tatttaagtca	agaacttgca	311460
tcattttctc	taatggaagc	actttacagc	ttctgtttgg	catagccaaa	tggccagtat	311520
cactgctttt	gtgctttgag	gccattatta	agtcacaata	ggatgacttg	gacataagca	311580
ctgaaatagt	caatctgata	gctgggggtg	ctagttagtg	actaatgggt	ggggagcaga	311640
gacagccctg	agacctgaa	caaattgaatg	attcatcccg	agtttgatgg	agaaagagca	311700
caaaaacttca	tcaccatact	cagaacagca	cacaatttaa	aacttatgaa	ttgtttattc	311760
ctggaatttt	ccacttaata	tttttgagac	atggtttact	gcaggtcatt	gaaacctaaa	311820
aaagcaaaac	tttgaataag	gagaaactac	tctgtgtgtc	tacatgcaca	tgtataagta	311880
gtctctcttt	cacacacata	tacacatata	ggaaaggaag	agaagacatg	tggattctag	311940
tttctcattt	tcataacttg	attatgagtc	caaattgagt	atttatgact	tgccctcttc	312000
atgaccaggt	acatactccc	tctactttcr	gggaacactt	ctgtaatatg	ctagaatttt	312060
catgcctaaa	gattctaaag	gtttttcttt	ttacatatag	aatgaaaaga	gtctttcatt	312120
aacttccaat	taatgaacat	gctgggtctg	tacaccatct	accaccoaga	acgctgatct	312180
ttcaagatgt	tgtttcccat	ctggcactat	agtgagtttt	ccatgaatca	tccagtatct	312240
cacaagggtc	acacagtaag	aacottgaat	octatgggaa	taagctcaat	gootaacatc	312300
gtttgcatta	tattctttgt	ttagtagcaa	tgatatataa	aagttgtggg	tatagagttt	312360
gttgaaaata	tctgaagaag	gtacagacag	caaaggcaga	cacagaagaa	aaatatatca	312420
attttttaac	agcagctggt	ctactgaagg	caaatcactg	cactctccat	gattcaagaa	312480
atcaactacc	acccccccaa	ccccccctc	accacacaca	cacgcagtag	tatttgctag	312540
catcagctct	gctcctctat	cagggcctct	aggttggtgt	cagtatgaat	gaattagaca	312600
ctcaggggtg	ccattagctt	ggcaacctgt	ccattttacc	atgtcctagg	catgtttcta	312660
tcataaagac	ctttgtcact	tgacttaata	aggagacaca	cagtggccag	gaaaagagat	312720
atttcatcac	agaacctgct	gccatgtttg	ttagaaggag	aaggagctag	atatgtgact	312780
atgtgtccat	tcttgagccc	tggcacttgg	gttgctctga	tggtcaggaa	cttgggaagga	312840
agacaattga	aatattgatg	acaagaaaat	ttggggaaga	gacatgtggc	tataactctc	312900
agaatgaacc	aaaacttgaa	gatatttttg	gatgttttaa	aaaggatgac	ctcagaatag	312960

gaggattttt	acaattaaaa	gaataggatg	acttggtttt	tgggtgccag	tcagcctctt	313020
tactcagtc	tocctgtcac	ttcccattgg	gctcatgact	aaaatagcca	ttgtgtcagg	313080
gatggagggt	acgcatgggc	tcagctacat	ggacttacac	tcaccaaggc	tgcccttccta	313140
ctatcagtct	accagctgta	gagaccaaca	ctgtgcaccc	aatgtgacac	tattccccag	313200
gggatcaggc	atctacctgg	tggcaggcag	atcacagtgg	acagcctcca	tcattggaaa	313260
ggaagtattt	tggtttctact	ggataagatt	ttggatgtgg	atgtgtctgt	cctgaacaca	313320
atgcttctgc	caaacacgga	cttacagact	gccttatgca	ctgtcgcagt	attcctcacg	313380
gcatggcttc	tgatcaagga	actcacttca	cagaaaaaga	agagtgccaa	tggggccatgc	313440
tcattgggatt	caccgggttt	atcatgttcc	ccaccgtcct	gaagcagctg	gcttgataga	313500
atggtaaaat	gaccttttga	agacagctct	agccccagct	aggttaacttc	acagggcggg	313560
ggcgagggtc	tctagatggc	tgtaaatgct	ctaaactaac	tatccgatat	atgggtgtcat	313620
taatttttat	ccaaattcat	cttcttcacc	tgtgtattat	caatagaaaa	tagcttaatt	313680
tgccaatcta	tcttgggtca	aagtttacca	taaaagctttt	catgaatttt	agtttcaaaa	313740
atttacctct	tatgtaatat	tgtgtataca	tttatatagt	aagaaataat	atagtaaaaga	313800
aaatcttaaa	cacatggcta	agtttggcag	aatgtcataa	agatcacatt	gtacaacaaa	313860
tgccagaaaat	tatagtgtct	tccataattt	tgtttctttg	agactgattc	cactgggtttt	313920
caaatattgc	tacagttgaa	acaaaattaa	aagaataaaa	actcagaatg	atcacataga	313980
gtggctaaat	taatgatatt	caagttctgt	ttcttcactc	ttataatcac	ggtgttataa	314040
ttgtttattt	caaatcaacc	gctcaaacac	aggaatccat	agcaccaaaa	atttttgata	314100
cagaaacttc	actgagggca	agcctaaatg	atcccaaatc	tctatgaacc	ttttcttgaa	314160
atgaatgc	gtaactgagt	ccgtgtttgt	caaggccatt	tgtaaaactg	gaagttctct	314220
aatttaacat	ccatgtaaaa	tacaatat	ataaaacaac	ttgtaataaa	tgtatgttaa	314280
tttgatgtta	catatatatg	tatatatnca	attacatata	tatatatata	attaaattca	314340
agagaaacca	agtgtattgt	taggactgag	accaataaaa	tatttaataa	aataattttg	314400
gagggaggac	ttgtaatcac	gaactggggg	gaatatccac	gggcaaacca	tgaaccagat	314460
tcaggacaat	gtcgttgtcc	tctgaatccc	aggttaagtc	actttgactc	ttaaatggca	314520
gaaggactct	gggttttcaa	aaccataaag	cctgttatct	aacgtatttt	cgtttccacca	314580
gtgcacagct	cctcttgttt	atggatgcag	atgcctttcc	agaaggctag	aaattataga	314640
aataacattt	ggtattttca	gagtctgtat	atggaagtac	ctacctacca	tgtttttatt	314700
taaagaattt	tgaatatgtg	atttgactca	aatttgggaa	ttgtgtgagg	aacaaaacta	314760
ttttggtggc	ttcaattagg	tctatatgca	atagaacgtg	aatacttttc	aaaaacagaa	314820
atagaacagt	gcctacgtga	gctagcacca	attatgggtcc	ttggtactcc	atggcctatt	314880
tacagctaca	ttaatccatg	agtcttataa	ttcaaattggc	tccagtggct	ttgatgttca	314940
ttagggacac	aacagccctt	tgccctccct	ggagaagtgc	tgtgttttgg	gttctaacaa	315000
cataaatact	ccccagtc	agtgttttta	tggagcccaa	ttcaatgtac	gatctccccg	315060
tggcatcacc	tacctataat	gattaaggat	ttgggagatt	catttagtga	attttatcaa	315120
gataacaatc	ttaacaaaca	ctgtagcata	tgcacactcc	aaaggcttcc	cctctttcta	315180
cgttaaatcc	aatggattcc	tgggactgtg	tctcttatag	gcttttactg	ggcctaaatt	315240
ttagccaata	agcttgtcaa	acagctagaa	acacatttaa	ctcttcaagc	ttacctactc	315300
tatccatgct	cttcgggtaa	gtgtccactt	tgaatttcac	cccaatgcaa	tcttttatct	315360
tggttggatg	cacaccttca	gaacctattc	ctaagaaatt	cttgcatata	ttgttggcat	315420
aaatgtcttg	caattctgtt	gttatatcat	ttttttctg	agtatatttg	acccctattt	315480
aatgcttagc	tottgtctca	gttctaggac	tgcaggcaat	gaagactggg	taagtagggg	315540
ttaggatgag	aattatcttc	tcagtctgag	gtaacttcc	catatgtaaa	ggctactaag	315600
gcaggtttgg	aaatgggttt	atatatgcat	ttccgaatat	cctaataata	tttggctgct	315660
tacattagta	aaaatcatta	aagttgcttt	cactcaaaga	ctgtaagata	taaagaaaag	315720
ttatttataa	tgtaaagcat	tgaacagaaa	acaatcggaa	actaatcaat	gaaatgggta	315780
tatataggag	gattccaaaa	attcggagac	tctaaccagt	gaatccagcc	ttgctagtac	315840
atccctgcag	ccagatacag	ttgcacttgc	tggaccacta	caacatcggg	tgccaatcta	315900
accactgaat	ccaacctcct	tgtacatcac	tgcgaaccga	tgcaagttgca	cttgctggac	315960
cactacaaca	tgggtgcca	atttaatact	ttcttctttt	cactctctac	cccrgtttca	316020
gtatccttgg	cagtatgcta	tgttcaactg	actttgagat	gtatgattct	attttgacac	316080
caacaggctt	agaaaagagt	aaactgaaca	ctctggcttt	tgtagggaga	agtagaactc	316140
cgtgtagcac	gaagtcttat	gcaaaagtag	gaagcagtg	aggaggattg	gcagacccaa	316200
aaatgaaaag	tgcacaaat	ttatatacag	ccagataa	ttgttataag	tcaatactct	316260
agatttttta	aatctcccat	ctccaaggca	atttaggcaa	cagcaagtat	cttataaaat	316320
tctctttttt	tagaaaatat	agatgaatta	tttaagatgg	attatcatta	tttattgtgt	316380
atttagtata	ggtttattta	tctcacactt	ctttgtcttt	ttccattatt	ttcagctgtt	316440
caaaaattct	gcatttgtaa	caacttcttc	aatatgtaaa	tttaaaaatc	cctcaatatt	316500
tgccatctta	tcttgaagt	tttaccatct	tactctaaag	taacttgaac	accacatgca	316560
ttattgttgg	agttttataa	cattagtatt	tatctgatcc	taattgttta	ttgtaattgt	316620

```

atagattttt tcactaattt tggagggtta aactattggt tcatagatgc aataaatcct 316680
ggaaaacttgt ttgcaataact tttaaaagca gttttcaaaa tttctcctct atcacacagg 316740
agacacactg taatgactac tatttcctct gatttccttt aggtgcgttt cttttgactg 316800
tattttcatc agtctcatca tttttctgtg tcattccattt gogctgggac ttgtgcctac 316860
tgatggtttt caagtgtggc tgcaatttgg ttcccttgaa ggtattttta aatatgctga 316920
tgcactagta ccattcccaa accaactgaa acacattctt caatggcaag gtcattggtgc 316980
tggattttta aacaaaaatc ttcctaagtt attttaatat acaactacaa catattcact 317040
ggtatagata atattgaata caaaaaaac ctatatgatg actcgttcct tctgtgagag 317100
agcaaagtcc acaattttaa aaaatttaata atactgttaa ctacagaggga tcagaccagg 317160
tggaagcac gaatatgcac tctgcataat gaagcttatt tccagtgtac aaatctacag 317220
caagcagaaa aggatacttg gtgcagtttg ctctagatac acagctaaca cagcgagcca 317280
tgcagtgggg cctccaccta gaggaactga ttacaggaag aggaagtttt gatttcaacc 317340
ttgttaggct ttccttccag ttagtaatgg tttcaagctg aatggatgac acaacatgaa 317400
aaattcaact acttaagaat agcatgcgcc aagtatatct tataactttc tgttaagatt 317460
catttcaact aataattttc tatataaatc tctattaatt taagtttctg aataactgta 317520
gggtcaacaa catatttggg actctcctac tttgagcttg gttgaaccac ataatttgaa 317580
agaggatatt ttataaagtt aaaaactga taactttaaa gactgataaa tttctgtttg 317640
cattcagaat atagtggcag aaaaaaatat tcttttctaa attataatga ttaaattggt 317700
ttgatggtat tatgttgcta taaataattt cctagagata ttaagggtata cttacataag 317760
atttattcac atttatgata ttttaggctg accttaaaaa ttatttatga atttaattgc 317820
ttatgcataat gtgataaatg ctaattataa tatttacttg gctttaataa atatttccag 317880
ttgcaatttg ataggctaac tgtatgtaaa aatttcatata tattgtctag aatagttttt 317940
ctttattctg atccttttta gttatagtct tatagatatg gccttagttc aaaagcacta 318000
tacactcgtg aaacattttc aagtcaatgt aaaatattgt aatgtgatgt cagaataaaa 318060
tctttttgaa gatagagatt ttcattggtt ttttccaaat cagagttaa agtagtcaat 318120
ctcatgattt gtacagactg aaaaagtata gaatgaatat tttacataaa aaataactta 318180
aatgaatato cttagaatac aaatcaactg tatattcact cgaggcactt aaaatattct 318240
atatgccaaa aactgcatac ctctttccaa ttttaataac tgccttctct ctctctctct 318300
tagtttacaa atatttctca atattttaa ttttagaact gaatcatggt ggggaaatga 318360
agtctttggg gaaataattt attatgaaaa atttttatgt agttatttaa aaaattctaa 318420
ctcagttaaa caatattata tggaaatgcc atagtttgaa aaattgtcaa ggttaagata 318480
aaacaaaaaa atatttttga cttttttttt cttttctttt attattatac ttaagtttt 318540
agggtacatg tgcacattgt gcaggttatt tacatatgta tacatgggcc atgctggtgt 318600
cctgcacca ttaacttgtc atttagcatt aggtatatct cccaatgta tccctcccc 318660
ctccccccac ccacaacan gtccccagag tgtgatgttc cccttctgt gtccacgtga 318720
tctcattgtt ncaattccca cctatgagtg agaatatgcg gtgtttggtt tttgttctt 318780
gtgatagttt actgagaatg atgatttcca atttcatcca tgtccctaca aaggacatga 318840
actcatcatt ttttatggct gcatagtatt ccatagtgta tatgtgccac attttcttaa 318900
tccagtctat cattgttgga catttggtgt ggttccaagt ctttgcatt gtgaataatg 318960
ccacaataaa catacgtgtg catgtgtctt tacaacaaca tgatttatag tctttgggt 319020
atataccag taatgggatg gctgggtcaa atggtatttc tagttctaga tccctgagga 319080
atcgccacac tgacttccac aatgggtgaa ctagtttaca gtcccaccaa cagtgtaaaa 319140
gtgttccat tctccacat cctctccagc acctgttggt tcttgacttt ttaatgattg 319200
ccattctaac tgggtgtgaga tggatatctca ttgtggtttt gatttgcatt tctctgatgg 319260
ccagtgtatg tgagcatttt ttcattgtgc ttttggctgc ataaatgtct tcttttgaga 319320
agtgtctgtt catatccttt gccactttt tcatggggtt gtctgttttt tctttgtaa 319380
tttgtttgag ttcattgtag attctggata ttagcccttt gtcagatgag taggttgca 319440
aaattttctc ccattttgta ggttccatgt tcaactctgat ggtagtttct tttgctgtgc 319500
agaagctctt taatttagtt agatcccat tgtcaatttt gtcttttgtt gccattgctt 319560
ttggtattta gacgtgaagt ccttgcccat gcctatgtcc tgaatggt 319608

```

&lt;210&gt; 2

&lt;211&gt; 2226

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

<221> CDS  
<222> 96..167

<220>  
<221> 3'UTR  
<222> 168..2226

<220>  
<221> polyA\_signal  
<222> 2200..2205

<220>  
<221> allele  
<222> 132  
<223> 8-130-143 : polymorphic base A or G

<220>  
<221> allele  
<222> 132  
<223> 8-126-286 : polymorphic base A or G

<400> 2  
ttgcaggctcc acattcgctc tagaggctgc ctgcggctcct tagaggcctc ataggcaagg 60  
aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113  
Met Ala Ala Tyr Phe Phe  
1 5  
aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa gga 161  
Lys Pro Val Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly  
10 15 20  
aaa taa cgcatttata aaagccagct cagatgttac ttccaaccaa caaatttctc 217  
Lys \*  
ggacacacta agtaatagag ttaatcacac cgtcctgaac attcaccctg ggagctctgt 277  
gctgccatgc aaatgtcaca ttgactgag gccgccatgc tgtaaaaaac cccaagctac 337  
ctacctgaaa agctggagag aatcagcacc catcagcttt tccagcattt tgggtcctcc 397  
cagctaaatc atcggcattg tgaagcagag atgagacctc ctgccatgcc ctttccaaat 457  
cctggaccaa cagaatcatc atatacacta ggttttgtgc atctctaaga tgatcatctt 517  
ggtgtggggt cctgatcttc ccagtgactt agcagcacag taatttggct gaaatgttga 577  
tgagttcaga caagaagaag gtgatgatga caagagagcg tcacggggaa attctgcctc 637  
gaggaaggaa tagtttgagg ctggagagat gtgctacccc cgcactctt tctcaaattg 697  
aaagacaacc tgtaggcaca gaaatcattg ctctgcttac actgaaatct cctgctgact 757  
ttgagagctg agcattggat tttgatgga gagtgaaact tagtgaagaa atgatttgaa 817  
cctttgttga tctaatactt ctgtgataca gttatctaaa cagaatgagt cttaaagtcag 877  
tataaagacc tgtgtctctc catgttttgc tgcttataat tgcagaggaa cattttgaga 937  
tagaaaattt tatccctctt tcaagtgact ttttataaaa cataaccctt taagagaggt 997  
cattcttttg aaaaattgtc tgaatacaaa aaagtaactg aacagcaagg gattgtagcc 1057  
ataatgttct tgaccacttt agattgacaa atagtatctc aaaattgac aggttctgga 1117  
gaatctattg aggttgatg gagtaaccaa gtgatggaag aggttggaag tgaataattt 1177  
tatgtggtat tatgtgattt tttttggtgg gggtagtgct tggagctgag catgatggag 1237  
cctagatggg gcagccttct aatgctccca gtatttcgca aatcatatgt cagctcaaaa 1297  
ttgtaatgac aaagctcaca gcagctgctt acgccaggtt tgggtgccagc tctaattaga 1357  
gcattgatca tttctctccc cttcatgaat gcacatgagt gcacattttc atatataagg 1417  
gcaaaggaca tttcaaagtt tggatggaat ctttcctact tagaagtaat aaaaaacaat 1477  
actttgaaat cttaccaaat gttaaacaata tagcaacaat ttttccattt gaagatgtgt 1537  
gtcttaagggt ctggttgatc tttcaaattt ctattttgga catggaaact acagatgaaa 1597  
tttaacttac tcaaagttac acagaactcc tggctgatct cttttactta attcttctaa 1657  
aatctaaagt aagaataatt ttgaaatttt atttgtaatg cttaaataac aaaagttact 1717  
ttaatatgtt acatgtttga agtttcattt atacttaata tctaatttaa cgcttgatga 1777  
aatattattc agtatttttt tttcttttct aaaatgactt gttcagggtt ccttttgagg 1837  
ttttaagtga gaaaactctt atttcataat attgttacca tgcctcatcca ataacacttc 1897  
atagatgggt agccatctct aaaatttaaat tttgtagttg aggagcattg aaaatatcac 1957  
ctatatttgg atttctgttt aacacttcaa aatgcatttt atcataattt aaaatttgat 2017

```

ttaaatacaa acctctttat agaaaacctg ataaatgtag ttttatttgt ttgcttgctt 2077
ttttttgcag ggaggatat tcccttgata ccactctgtc tttatgactc atcggttatt 2137
tataaatggt atcatcggtt ttctgatttt taaataagtt tcagaattaa tacatttaac 2197
tgaataaatc aaccaataat gtcaaaactt 2226

```

```

<210> 3
<211> 2431
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> 5'UTR
<222> 1..95

```

```

<220>
<221> CDS
<222> 96..167

```

```

<220>
<221> 3'UTR
<222> 168..2431

```

```

<220>
<221> polyA_signal
<222> 2405..2410

```

```

<220>
<221> allele
<222> 132
<223> 8-130-143 : polymorphic base A or G

```

```

<220>
<221> allele
<222> 132
<223> 8-126-286 : polymorphic base A or G

```

```

<220>
<221> allele
<222> 328
<223> 8-155-258 : polymorphic base C or T

```

```

<400> 3
ttgcaggctc acattcggtc tagaggctgc ctgcggctct tagaggcctc ataggcaagg 60
aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113
                               Met Ala Ala Tyr Phe Phe
                               1         5
aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa gga 161
Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly
          10         15         20
aaa taa cgcatttata aaagccagct cagatgttac ttccaaccaa caaatttcct 217
Lys *
ggacacacta agtaatagag ttaatcacac cgtccttgaa ggtctccctg ctgtgcttag 277
agagggggat gctggaagaa gagtggtcag agaagcaaca ttgctgactc yaaagacaga 337
gggcaggcca cgagccaagg catgcaggag gcctccagaa gctggggcag gcaagagaat 397
ggactcagcc ctggagcctc cagaagcat gcagccctgc ccattccttg cttttagcca 457
ggaacattca ccctgggagc tctgtgctgc catgcaaatg tcacattgca ctgaggccgc 517
catgctgtaa aaaaccccaa gctacctacc tgaaaagctg gagagaatca gcacccatca 577
gcttttccag ctttttgggt cctcccagct aaatcatcgg cattgtgaag cagagatgag 637
acctcctgcc atgccccttc caaatcctgg accaacagaa tcatcatata cactaggttt 697
tgtgcatctc taagatgac atcttggtgt ggggtcctga tcttcccagt gacttagcag 757
cacagtaatt tggctgaaat gttgatgagt tcagacaaga agaaggtgat gatgacaaga 817

```

```

gagcgtcacg gggaaattct gccctgagga aggaatagtt tgaggctgga gagatgtgct 877
acccccgcca ctctttctca aatggaaaga caacctgtag gcacagaaat cattgctctg 937
cttacactga aatctcctgc tgactttgag agctgagcat tggattttga tgggagagt 997
aaacttagtg aagaaatgat ttgaaccttt gttgatctaa tacttctgtg atacagttat 1057
ctaaacagaa tgagtctaaa gtcagtataa agacctgtgt ctctccatgt tttgctgctt 1117
ataattgcag aggaacattt tgagatagaa aattttatcc ctctttcaag tgacttttta 1177
taaaacataa ccttttaaga gaggtcattc ttttgaaaaa ttgtctgaat acaaaaaagt 1237
aactgaacag caagggattg tagccataat gttcttgacc acttttagatt gacaaatagt 1297
atctcaaaat tgatcagggt ctggagaatc tattgagggt gtatggagta accaagtgat 1357
ggaagagggt ggaagtgaat aattttatgt ggtattatgt gatttttttt ggtgggggta 1417
gtgtctggag ctgagcatga tggagcctag atggggcagc cttctaattgc tcccagttat 1477
tcgcaaatca tatgtcacgt caaaattgta atgacaaagc tcacagcagc tgcctacgcc 1537
aggtttggtg ccagctctaa tttagagcatt gatcatttct ctccccttca tgaatgcaca 1597
tgagtgcaca ttttcatata taagggcaaa ggacatttca aagtttggtt ggaatctttc 1657
ctacttagaa gtaataaaaa acaatacttt gaaatcttac caaatgttaa acaaatagca 1717
acaatttttc catttgaaaga tgtgtgtctt aaggtctgtt ggatctttca aatttctatt 1777
ttggacatgg aaactacaga tgaaatttaa ctactcaaa gttacacaga actcctggct 1837
gatctctttt acttaattct tctaaaatct aaagtaagaa taattttgaa attttattgg 1897
taatgcttaa ataacaaaag ttactttaat atgttacatg tttgaagttt catttatact 1957
taatattctaa tttaacgctt gtgaaaatat tattcagtat ttttttttct tttctaaaat 2017
gacttggttca gggctccttt tgggatttta agtgagaaaa actctatttc ataattttgt 2077
taccatgctc atccaataac acttcataga tggttagcca tctctaaaaat taaattttgt 2137
agttgaggag cattgaaaat atcacctata tttggatttc tgtttaacac ttcaaaatgc 2197
attttatcat aattttaaatt ttgatttaaa tacaaacctc tttatagaaa acctgataaa 2257
tgtagtttta tttgtttgct tgcttttttt tgcagggagg gatattccct tgataccact 2317
ctgtctttat gactcatcgg ttatttataa atgttatcat cgtttttctg atttttaaat 2377
aagtttcaga attaatacat ttaactgaat aaatcaacca ataatgtcaa actt 2431

```

&lt;210&gt; 4

&lt;211&gt; 2215

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; 96..311

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 312..2215

&lt;220&gt;

&lt;221&gt; polyA signal

&lt;222&gt; 2189..2194

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-130-143 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-126-286 : polymorphic base A or G

&lt;400&gt; 4

ttgcagggtcc acattcggttc tagagggtgc ctgcgggtcct tagaggcctc ataggcaagg 60

```

aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc      113
                               Met Ala Ala Tyr Phe Phe
                               1           5
aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa ggt      161
Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly
          10           15           20
aac ctc atc acc gga gtc aag tgt cat cac ctt tcc cat gtt cca ttg      209
Asn Leu Ile Thr Gly Val Lys Cys His His Leu Ser His Val Pro Leu
          25           30           35
gtt aga agt ccc agc tcc tgc cca cat tca agg gaa cat tca ccc tgg      257
Val Arg Ser Pro Ser Ser Cys Pro His Ser Arg Glu His Ser Pro Trp
          40           45           50
gag ctc tgt gct gcc atg caa atg tca cat tgc act gag gcc gcc atg      305
Glu Leu Cys Ala Ala Met Gln Met Ser His Cys Thr Glu Ala Ala Met
          55           60           65           70
ctg taa aaaaccccaa gctacctacc tgaaaagctg gagagaatca gcacccatca      361
Leu *
gcttttccag cattttgggt cctcccagct aaatcatogg cattgtgaag cagagatgag      421
acctcctgcc atgcccctttc caaatcctgg accaacagaa tcatcatata cactagggtt      481
tgtgcatactc taagatgata atcttggtgt ggggtcctga tcttcccagt gacttagcag      541
cacagtaatt tggtgaaat gttgatgagt tcagacaaga agaaggatgat gatgacaaga      601
gagcgtcacg gggaaattct gccctgagga aggaatagtt tgaggctgga gagatgtgct      661
acccccgccca ctctttctca aatggaaaga caacctgtag gcacagaaat cattgctctg      721
cttacctga aatctcctgc tgactttgag agctgagcat tggattttga tgggagagt      781
aaacttagtg aagaaatgat ttgaaccttt gttgatctaa tacttctgtg atacagttat      841
ctaaacagaa tgagtctaaa gtcagtataa agacctgtgt ctctccatgt tttgctgctt      901
ataattgcag aggaacattt tgagatagaa aattttatcc ctctttcaag tgacttttta      961
taaaacataa ccttttaaga gaggtcattc ttttgaaaaa ttgtctgaat acaaaaaagt      1021
aactgaacag caagggattg tagccataat gttcttgacc acttttagatt gacaaatagt      1081
atctcaaaat tgatcagggt ctggagaatc tattgaggtt gtatggagta accaagtgat      1141
ggaagagggt ggaagtgaat aattttatgt ggtattatgt gatttttttt ggtgggggta      1201
gtgtctggag ctgagcatga tggagcctag atggggcagc ctctaatgc tcccagtatt      1261
tcgcaaatca tatgtcacgt caaaattgta atgacaaagc tcacagcagc tgccctacgc      1321
aggtttgggt ccagctctaa ttagagcatt gatcatttct ctccccttca tgaatgcaca      1381
tgagtgcaca ttttcatata taagggcaaa ggacatttca aagtttggat ggaatctttc      1441
ctacttagaa gtaataaaaa acaatacttt gaaatcttac caaatgttaa acaaatagca      1501
acaatttttc catttgaaga tgtgtgtctt aaggtctgtt ggatctttca aatttctatt      1561
ttggacatgg aaactacaga tgaaatttaa cttactcaaa gttacacaga actcctggct      1621
gatctctttt acttaattct tctaaaatct aaagtaagaa taattttgaa attttattgg      1681
taatgcttaa ataacaaaag ttactttaat atgttacatg tttgaagttt catttatact      1741
taatatctaa ttttaacgctt gtgaaaatat tattcagtat ttttttttct tttctaaaat      1801
gacttgttca gggctccttt tgggatttta agtgagaaaa actctatttc ataattattg      1861
taccatgctc atccaataac acttcataga tggtagcca tctctaaaat taaattttgt      1921
agttgaggag cattgaaaat atcacctata tttggatttc tgtttaacac ttcaaaatgc      1981
attttatcat aatttaaaat ttgatttaaa tacaacctc tttatagaaa acctgataaa      2041
tgtagtttta tttgtttgct tgcttttttt tgcaggagg gatattccct tgataccact      2101
ctgtctttat gactcatcgg ttatttataa atgttatcat cgtttttctg attttttaaa      2161
aagtttcaga attaatacat ttaactgaat aaatcaacca ataattgtcaa actt      2215

```

<210> 5  
 <211> 2132  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> 5'UTR  
 <222> 1..95

<220>  
 <221> CDS  
 <222> 96..212

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 213..2132

&lt;220&gt;

&lt;221&gt; polyA\_signal

&lt;222&gt; 2106..2111

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-130-143 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-126-286 : polymorphic base A or G

&lt;400&gt; 5

ttgcaggtcc acattcggtc tagaggctgc ctgcggtcct tagaggcctc ataggcaagg 60

aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113

Met Ala Ala Tyr Phe Phe

1 5

aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa gga 161

Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly

10 15 20

aca ttc acc ctg gga gct ctg tgc tgc cat gca aat gtc aca ttg cac 209

Thr Phe Thr Leu Gly Ala Leu Cys Cys His Ala Asn Val Thr Leu His

25 30 35

tga ggccgccatg ctgtaaaaaa ccccaagcta cctacctgaa aagctggaga 262

\*

gaatcagcac ccatcagctt ttccagcatt ttgggtcctc ccagctaaat catcggcatt 322

gtgaagcaga gatgagacct cctgccatgc cctttccaaa tcctggacca acagaatcat 382

catatacact aggttttgtg catctctaag atgatcatct tgggtggtggg toctgatctt 442

cccagtgact tagcagcaca gtaatttggc tgaaatgttg atgagttcag acaagaagaa 502

ggtgatgatg acaagagagc gtcacgggga aattctgccc tgaggaagga atagtttgag 562

gctggagaga tgtgctaccc ccgccactct ttctcaaatg gaaagacaac ctgtaggcac 622

agaaatcatt gctctgctta cactgaaatc tcctgctgac tttgagagct gagcattgga 682

ttttgatggg agagtgaaac ttagtgaaga aatgatttga acctttgttg atctaatact 742

tctgtgatac agttatctaa acagaatgag tctaaagtca gtataaagac ctgtgtctct 802

ccatgttttg ctgcttataa ttgcagagga acattttgag atagaaaatt ttatccctct 862

ttcaagtgac tttttataaa acataacctt ttaagagagg tcattctttt gaaaaattgt 922

ctgaatacaa aaaagtaact gaacagcaag ggattgtagc cataatgttc ttgaccactt 982

tagattgaca aatagtatct caaaattgat caggttctgg agaattctatt gaggttgat 1042

ggagtaacca agtgatggaa gaggttggaa gtgaataatt ttatgtggta ttatgtgatt 1102

tttttgggtg ggggtagtgt ctggagctga gcatgatgga gcctagatgg ggcagccttc 1162

taatgctccc agtatttcgc aaatcatatg tcacgtcaaa attgtaatga caaagctcac 1222

agcagctgcc tacgccaggt ttggtgccag ctctaattag agcattgatc atttctctcc 1282

ccttcatagaa tgcacatgag tgcacatttt catatataag ggcaaaggac atttcaaagt 1342

ttggatggaa tctttcctac ttagaagtaa taaaaaacia tactttgaaa tcttaccaaa 1402

tgtaaaciaa atagcaacia tttttccatt tgaagatgtg tgtcttaagg tctgttggat 1462

ctttcaaatt tctatttttg acatggaaac tacagatgaa atttaactta ctcaaagtta 1522

cacagaactc ctggctgatc tcttttactt aattcttcta aaatctaaag taagaataat 1582

tttgaatttt tattggtaat gcttaaataa caaaagttac ttaatatgt tacatgtttg 1642

aagtttcatt tatacttaatt atctaattta acgcttgtga aaatatatt cagtattttt 1702

ttttcttttc taaaatgact tgttcagggc tccttttggg attttaagtg agaaaaactc 1762

tatttcataa tattgttacc atgctcatcc aataacactt catagatggg tagccatctc 1822

taaaattaaa tttgtagttt gaggagcatt gaaaatatca cctatatattg gatttctgtt 1882

taacacttca aaatgcattt tatcataatt taaaatttga tttaaataca aaactcttta 1942

tagaaaacct gataaatgta gttttatttg ttgtcttgct tttttttgca gggagggata 2002



ttcccttgat accactctgt ctttatgact catcggttat ttataaatgt tatcatcgtt 2062  
 ttcttgattt ttaaataagt ttcagaatta atacatttaa ctgaataaat caaccaataa 2122  
 tgtaaaactt 2132

<210> 6  
 <211> 1981  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> 5'UTR  
 <222> 1..95

<220>  
 <221> CDS  
 <222> 96..260

<220>  
 <221> 3'UTR  
 <222> 261..1981

<220>  
 <221> polyA\_signal  
 <222> 1955..1960

<220>  
 <221> allele  
 <222> 132  
 <223> 8-130-143 : polymorphic base A or G

<220>  
 <221> allele  
 <222> 132  
 <223> 8-126-286 : polymorphic base A or G

<400> 6  
 ttgcaggctc acattcgctc tagaggctgc ctgcggctcct tagaggcctc ataggcaagg 60  
 aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113  
 Met Ala Ala Tyr Phe Phe  
 1 5  
 aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa ggt 161  
 Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly  
 10 15 20  
 aac ctc atc acc gga gtc aag tgt cat cac ctt tcc cat gtt cca ttg 209  
 Asn Leu Ile Thr Gly Val Lys Cys His His Leu Ser His Val Pro Leu  
 25 30 35  
 gtt aga agt ccc agc tcc tgc cca cat tca agg ggt ttt gtg cat ctc 257  
 Val Arg Ser Pro Ser Ser Cys Pro His Ser Arg Gly Phe Val His Leu  
 40 45 50  
 taa gatgatcctc ttggtgtggg gtctctgatct tccagtgac ttagcagcac 310

\*  
 55  
 agtaatttgg ctgaaatggt gatgagttca gacaagaaga aggtgatgat gacaagagag 370  
 cgtcacgggg aaattctgcc ctgaggaagg aatagtttga ggctggagag atgtgctacc 430  
 cccgccactc ttctcaaat ggaaagacaa cctgtaggca cagaaatcat tgctctgctt 490  
 acactgaaat ctcctgctga ctttgagagc tgagcattgg attttgatgg gagagtgaaa 550  
 cttagtgaag aaatgatttg aacctttgtt gatctaatac ttctgtgata cagttatcta 610  
 aacagaatga gtctaaagtc agtataaaga cctgtgtctc tccatgtttt gctgcttata 670  
 attgcagagg aacatttttga gatagaaaat tttatccctc tttcaagtga ctttttataa 730  
 aacataacct ttttaagagag gtcattcttt tgaaaaattg tctgaataca aaaaagtaac 790  
 tgaacagcaa gggattgtag ccataatggt cttgaccact ttagattgac aaatagtatc 850

```

tcaaaattga tcaggttctg gagaatctat tgagggttgta tggagtaacc aagtgatgga 910
agagggttgga agtgaataat tttatgtggt attatgtgat tttttttggt gggggtagt 970
tctggagctg agcatgatgg agcctagatg gggcagcctt ctaatgctcc cagtatttcg 1030
caaatcatat gtcacgtcaa aattgtaatg acaaagctca cagcagctgc ctacgccagg 1090
tttggtgcca gctctaatta gagcattgat catttctctc ccttctcatga atgcacatga 1150
gtgcacattt tcatatataa gggcaaagga catttcaaag tttggatgga atctttccta 1210
cttagaagta ataaaaaaca atactttgaa atcttaccaa atgttaaaca aatagcaaca 1270
atttttccat ttgaagatgt gtgtcttaag gtctgttgga tctttcaaat ttctattttg 1330
gacatggaaa ctacagatga aatttaactt actcaaagtt acacagaact cctggctgat 1390
ctcttttact taattcttct aaaatctaaa gtaagaataa ttttgaaatt ttattggtaa 1450
tgcttaataa acaaaagtta ctttaatatg ttacatgttt gaagtttcat ttatacttaa 1510
tatctaattt aacgcttggtg aaaatattat tcagtatttt tttttctttt ctaaaatgac 1570
ttgttcaggg ctctttttgg gattttaagt gagaaaaact ctatttcata atattgttac 1630
catgctcacc caataacact tcatagatgg ttagccatct ctaaaattaa attttgtagt 1690
tgaggagcat tgaaaatata acctatattt ggattttctgt ttaacacttc aaaatgcatt 1750
ttatcataat ttaaaatttg atttaaatac aaacctcttt atagaaaacc tgataaatgt 1810
agttttattt gtttgcttgc ttttttttgc agggagggat attcccttga taccactctg 1870
tctttatgac tcatcggtta tttataaatg ttatcatcgt ttttctgatt tttaaataag 1930
tttcagaatt aatacattta actgaataaa tcaaccaata atgtcaaact t 1981

```

&lt;210&gt; 7

&lt;211&gt; 1992

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; 96..167

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 168..1992

&lt;220&gt;

&lt;221&gt; polyA\_signal

&lt;222&gt; 1966..1971

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-130-143 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-126-286 : polymorphic base A or G

&lt;400&gt; 7

```

ttgcaggctc acattcgttc tagaggctgc ctgcggctct tagaggcctc ataggcaagg 60
aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113
                               Met Ala Ala Tyr Phe Phe
                               1               5
aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa gga 161
Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly
                10                15                20
aaa taa cgcatttata aaagccagct cagatgtttac ttccaaccaa caaatttcct 217
Lys *

```

```

ggacacacta agtaatagag ttaatcacac cgtcctgggt ttgtgcatct ctaagatgat 277
catcttgggtg tggggtcctg atcttccag tgacttagca gcacagtaat ttggctgaaa 337
tgttgatgag ttcagacaag aagaagggtga tgatgacaag agagcgtcac ggggaaattc 397
tgccctgagg aaggaatagt ttgaggctgg agagatgtgc taccocccgcc actctttctc 457
aaatggaaag acaacctgta ggcacagaaa tcatgtctct gcttacactg aaatctcctg 517
ctgactttga gagctgagca ttggattttg atgggagagt gaaacttagt gaagaaatga 577
tttgaacctt tgttgatcta atacttctgt gatcacagta tctaaacaga atgagtctaa 637
agtcagtata aagacctgtg tctctccatg ttttgctgct tataattgca gaggaacatt 697
ttgagataga aaattttatc cctctttcaa gtgacttttt ataaaacata accttttaag 757
agaggtcatt cttttgaaaa attgtctgaa tacaaaaaag taactgaaca gcaagggtatt 817
gtagccataa tgttcttgac cacttagat tgacaaatag tatctcaaaa ttgatcaggt 877
tctggagaat ctattgaggt tgtatggagt aaccaagtga tggaagaggt tggaagtga 937
taattttatg tgggtattatg tgattttttt tgggtgggggt agtgtctgga gctgagcatg 997
atggagccta gatggggcag ccttctaattg ctcccagtat ttgcgaaatc atatgtcacg 1057
tcaaaattgt aatgacaaaag ctcacagcag ctgcctacgc caggtttgggt gccagctcta 1117
attagagcat tgatcatttc tctccccttc atgaatgcac atgagtgcac attttcatat 1177
ataagggcaa aggacatttc aaagtgttga tggaaatctt cctacttaga agtaataaaa 1237
aacaatactt tgaaatctta ccaaatgtta aacaaatagc aacaattttt ccatttgaag 1297
atgtgtgtct taagggtctgt tggatctttc aaatttctat tttggacatg gaaactacag 1357
atgaaattta acttactcaa agttacacag aactcctggc tgatctcttt tacttaattc 1417
ttctaaaatc taaagtaaga ataattttga aattttattg gtaatgctta aataacaaaa 1477
gttactttta tatgttacat gtttgaagtt tcatttatac ttaatatcta atttaacgct 1537
tgtgaaata ttattcagta tttttttttc ttttctaaaa tgacttggtc agggctcctt 1597
ttgggatttt aagtgagaaa aactctatct cataatattg ttaccatgct catccaataa 1657
cacttcatag atggttagcc atctctaaaa ttaaattttg tagttgagga gcattgaaaa 1717
tatcacctat atttggattt ctgtttaaca cttcaaaatg cattttatca taatttaaaa 1777
tttgatttaa atacaaacct ctttatagaa aacotgataa atgtagtttt atttgtttgc 1837
ttgctttttt ttgcagggag ggatattccc ttgataccac tctgtcttta tgactcatcg 1897
gttatttata aatgttatca tcgtttttct gatttttaaa taagtttcag aattaataca 1957
tttaactgaa taaatcaacc aataatgtca aactt 1992

```

<210> 8

<211> 1898

<212> DNA

<213> Homo sapiens

<220>

<221> 5'UTR

<222> 1..95

<220>

<221> CDS

<222> 96..182

<220>

<221> 3'UTR

<222> 183..1898

<220>

<221> polyA\_signal

<222> 1872..1877

<220>

<221> allele

<222> 132

<223> 8-130-143 : polymorphic base A or G

<220>

<221> allele

<222> 132

<223> 8-126-286 : polymorphic base A or G

&lt;400&gt; 8

ttgcaggctcc acattcggttc tagaggetgc ctgcggctcct tagaggcctc ataggcaagg 60  
 aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113

Met Ala Ala Tyr Phe Phe

1

5

aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa ggg 161

Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly

10

15

20

ttt tgt gca tct cta aga tga tcatcttggt gtggggctcct gatcttccca 212

Phe Cys Ala Ser Leu Arg \*

25

gtgacttagc agcacagtaa tttggctgaa atgttgatga gttcagacaa gaagaaggtg 272

atgatgacaa gagagcgtca cggggaaatt ctgccctgag gaaggaatag tttgaggctg 332

gagagatgtg ctacccccgc cactctttct caaatggaaa gacaacctgt aggcacagaa 392

atcattgctc tgcttacact gaaatctcct gctgactttg agagctgagc attggatttt 452

gatgggagag tgaacttag tgaagaaatg atttgaacct ttgttgatct aatacttctg 512

tgatacagtt atctaacaag aatgagtcta aagtcagtat aaagacctgt gtctctccat 572

gttttgctgc ttataattgc agaggaacat tttgagatag aaaattttat cctcttttca 632

agtgactttt tataaaacat aaccttttaa gagaggtcat tcttttgaaa aattgtctga 692

atacaaaaaa gtaactgaac agcaagggat tgtagccata atgttcttga ccactttaga 752

ttgacaaata gtatctcaaa attgatcagg ttctggagaa tctattgagg ttgtatggag 812

taaccaagtg atggaagagg ttggaagtga ataattttat gtggtattat gtgatttttt 872

ttggtggggg tagtgtctgg agctgagcat gatggagcct agatggggca gccttctaatt 932

gctcccagta tttcgcaaat catatgtcac gtcaaaattg taatgacaaa gctcacagca 992

gctgcctacg ccaggtttgg tgccagctct aattagagca ttgatcattt ctctcccctt 1052

catgaatgca catgagtcca ctttttcata tataagggca aaggacattt caaagtttgg 1112

atggaatctt tctacttag aagtaataaa aaacaatact ttgaaatctt accaaatggt 1172

aaacaaatag caacaatttt tccatttgaa gatgtgtgtc ttaaggctctg ttggatcttt 1232

caaattttcta ttttgacat ggaaactaca gatgaaattt aacttactca aagttacaca 1292

gaactcctgg ctgatctctt ttacttaatt cttctaaaat cttaaagtaag aataattttg 1352

aaattttatt ggtaatgctt aaataacaaa agttacttta atatgttaca tgtttgaagt 1412

ttcatttata cttaatatct aatttaacgc ttgtgaaaat attattcagt attttttttt 1472

cttttctaaa atgacttggt cagggctcct tttgggattt taagtgaaga aaactctatt 1532

tcataatatt gttaccatgc tcatccaata acacttcata gatggttagc catctctaaa 1592

attaaatttt gtagttgagg agcattgaaa atatcaccta tttttggatt tctgtttaac 1652

acttcaaaat gcattttatc ataattttaa atttgattta aatacaaac tctttataga 1712

aaacctgata aatgtagttt tatttgtttg cttgcttttt tttgcaggga gggatattcc 1772

cttgatacca ctctgtcttt atgactcatc ggttatttat aaatgttatc atogtttttc 1832

tgatttttaa ataagtttca gaattaatac atttaactga ataaatcaac caataatgtc 1892

aaactt 1898

&lt;210&gt; 9

&lt;211&gt; 1783

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; 96..167

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 168..1783

&lt;220&gt;

&lt;221&gt; polyA\_signal

&lt;222&gt; 1757..1762

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-130-143 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-126-286 : polymorphic base A or G

&lt;400&gt; 9

ttgcagggtcc	acattcggtc	tagagggtgc	ctgcgggtcct	tagaggcctc	ataggcaagg	60
aactcatagt	ttcttgccat	gaagactttt	ccaac atg gct gct tac ttc ttc			113

	Met	Ala	Ala	Tyr	Phe	Phe
1				5		

aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa gga	161
Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly	

10

15

20

aaa taa cgcatttata aaagccagct cagatgtttac ttccaaccaa caaatttctc	217
Lys *	

ggacacacta	agtaatagag	ttaatcacac	cgtcctgaaa	gacaacctgt	aggcacagaa	277
atcattgctc	tgcttacact	gaaatctcct	gctgactttg	agagctgagc	attggatttt	337
gatgggagag	tgaaacttag	tgaagaaatg	atttgaacct	ttgttgatct	aatacttctg	397
tgatacagtt	atctaaacag	aatgagtcta	aagtcagtat	aaagacctgt	gtctctccat	457
gttttgctgc	ttataattgc	agaggaacat	tttgagatag	aaaattttat	ccctctttca	517
agtgactttt	tataaaacat	aaccttttaa	gagaggtcat	tcttttgaaa	aattgtctga	577
atacaaaaaa	gtaactgaac	agcaagggat	tgtagccata	atgttcttga	ccactttaga	637
ttgacaaata	gtatctcaaa	attgatcagg	ttctggagaa	tctattgagg	ttgtatggag	697
taaccaagtg	atggaagagg	ttggaagtga	ataattttat	gtggtattat	gtgatttttt	757
ttggtggggg	tagtgtctgg	agctgagcat	gatggagcct	agatggggca	gccttctaata	817
gctcccagta	tttcgcaaat	catatgtcac	gtcaaaattg	taatgacaaa	gctcacagca	877
gctgcctacg	ccagggttgg	tgccagctct	aattagagca	ttgatcattt	ctctcccctt	937
catgaatgca	catgagtgc	cattttcata	tataagggca	aaggacattt	caaagtttgg	997
atggaatcct	tcctacttag	aagtaataaa	aaacaatact	ttgaaatcct	accaaatggt	1057
aaacaaatag	caacaatttt	tocatttgaa	gatgtgtgtc	ttaagggtctg	ttggatcctt	1117
caaatttcta	ttttggacat	ggaaactaca	gatgaaattt	aacttactca	aagttacaca	1177
gaactcctgg	ctgatctctt	ttacttaatt	cttctaaaat	ctaaagtaag	aataattttg	1237
aaattttatt	ggtaatgctt	aaataacaaa	agttacttta	atatgttaca	tgtttgaagt	1297
ttcatttata	cttaatatct	aatttaacgc	ttgtgaaaat	attattcagt	attttttttt	1357
cttttctaaa	atgacttggt	cagggtcct	tttgggattt	taagtggaga	aaactctatt	1417
tcataatatt	gttaccatgc	tcatacaata	acacttcata	gatgggttagc	catctctaaa	1477
attaaatttt	gtagttgagg	agcattgaaa	atatcaccta	tatttggatt	tctgtttaac	1537
acttcaaaat	gcattttatc	ataatttaaa	atttgattta	aatacaaaacc	tctttataga	1597
aaacctgata	aatgtagttt	tatttgtttg	cttgcttttt	tttgcaggga	gggatattcc	1657
cttgatacca	ctctgtcttt	atgactcctc	ggttattttat	aaatgttatc	atcgtttttc	1717
tgatttttaa	ataagtttca	gaattaatac	atttaactga	ataaatcaac	caataatgtc	1777
aaactt						1783

&lt;210&gt; 10

&lt;211&gt; 2309

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; 96..311

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 312..2309

&lt;220&gt;

&lt;221&gt; polyA\_signal

&lt;222&gt; 2283..2288

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-130-143 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-126-286 : polymorphic base A or G

&lt;400&gt; 10

```

ttgcagggtcc acattcggtc tagaggctgc ctgcgggtcct tagaggcctc ataggcaagg      60
aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc      113
                               Met Ala Ala Tyr Phe Phe
                               1           5

aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa ggt      161
Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly
                               10           15           20

aac ctc atc acc gga gtc aag tgt cat cac ctt tcc cat gtt cca ttg      209
Asn Leu Ile Thr Gly Val Lys Cys His His Leu Ser His Val Pro Leu
                               25           30           35

ggt aga agt ccc agc tcc tgc cca cat tca agg gaa aat aac gca ttt      257
Val Arg Ser Pro Ser Ser Cys Pro His Ser Arg Glu Asn Asn Ala Phe
                               40           45           50

ata aaa gcc agc tca gat gtt act tcc aac caa caa att tcc tgg aca      305
Ile Lys Ala Ser Ser Asp Val Thr Ser Asn Gln Gln Ile Ser Trp Thr
                               55           60           65           70

cac taa gtaatagagt taatcacacc gtcttgaaca ttcacctgg gagctctgtg      361
His *

ctgccatgca aatgtcacat tgcactgagg cgcctatgct gtaaaaaacc ccaagctacc      421
tacctgaaaa gctggagaga atcagcaccc atcagctttt ccagcatttt gggctcctccc      481
agctaaatca tcggcattgt gaagcagaga tgagacctcc tgccatgccc tttccaaatc      541
ctggaccaac agaatcatca tatacactag gttttgtgca tctctaagat gatcatcttg      601
gtgtggggtc ctgatcttcc cagtgaacta gcagcacagt aatttggctg aaatgttgat      661
gagttcagac aagaagaagg tgatgatgac aagagagcgt cacggggaaa ttctgccctg      721
aggaaggaat agtttgaggc tggagagatg tgctaccccc gccactcttt ctcaaatgga      781
aagacaacct gtaggcacag aaatcattgc tctgtttaca ctgaaatctc ctgctgactt      841
tgagagctga gcattggatt ttgatgggag agtgaaactt agtgaagaaa tgatttgaac      901
ctttgttgat ctaatacttc tgtgatacag ttatctaaac agaattgagtc taaagtcagt      961
ataaagacct gtgtctctcc atgttttgct gcttataatt gcagaggaac attttgagat      1021
agaaaatttt atccctcttt caagtgaact tttataaaac ataacctttt aagagagggtc      1081
attcttttga aaaattgtct gaatacaaaa aagtaactga acagcaaggg attgtagcca      1141
taatgttctt gaccacttta gattgacaaa tagtatctca aaattgatca ggttctggag      1201
aatctattga ggttgatagg agtaaccaag tgatggaaga ggttggaagt gaataatttt      1261
atgtggtatt atgtgatttt ttttgggtgg ggtagtgtct ggagctgagc atgatggagc      1321
ctagatgggg cagccttcta atgctccag tatttcgcaa atcatatgtc acgtcaaaat      1381
tgtaatgaca aagctcacag cagctgccta cgccagggtt ggtgccagct ctaattagag      1441
cattgatcat ttctctcccc ttcatgaatg cacatgagtg cacattttca tatataaggg      1501
caaaggacat ttcaaagttt ggatggaatc tttcctaact agaagtaata aaaaacaata      1561
ctttgaaatc ttaccaaagt ttaaacaaat agcaacaatt tttccatttg aagatgtgtg      1621
tcttaaggtc tgttggatct ttcaaatctc tattttggac atggaaacta cagatgaaat      1681

```

```

ttaacttact caaagttaca cagaactcct ggctgatctc ttttacttaa ttcttctaaa 1741
atctaaagta agaataattt tgaaatttta ttggtaatgc ttaaataaca aaagttactt 1801
taatatgtta catgtttgaa gtttcattta tacttaatat ctaatttaac gcttggtgaa 1861
atattattca gtattttttt ttcttttcta aaatgacttg ttcagggctc cttttgggat 1921
tttaagttag aaaaactcta tttcataata ttgttaccat gtcacatcaa taacacttca 1981
tagatgggta gccatctcta aaattaaatt ttgtagttga ggagcattga aaatatcacc 2041
tatatttgga tttctgttta acacttcaaa atgcatttta tcataattta aaatttgatt 2101
taaatacaaa cctctttata gaaaacctga taaatgtagt tttatttggt tgcttgcttt 2161
tttttgcagg gagggatatt cccttgatac cactctgtct ttatgactca tcggttattt 2221
ataaatgtta tcacgtttt tctgattttt aaataagttt cagaattaat acatttaact 2281
gaataaatca accaataatg tcaaactt 2309

```

&lt;210&gt; 11

&lt;211&gt; 2075

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; 96..311

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 312..2075

&lt;220&gt;

&lt;221&gt; polyA\_signal

&lt;222&gt; 2049..2054

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-130-143 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-126-286 : polymorphic base A or G

&lt;400&gt; 11

```

ttgcagggtc acattcgttc tagagggtgc ctgcgggtcct tagaggcctc ataggcaagg 60
aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113
                               Met Ala Ala Tyr Phe Phe
                               1       5
aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa ggt 161
Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly
                               10      15      20
aac ctc atc acc gga gtc aag tgt cat cac ctt tcc cat gtt cca ttg 209
Asn Leu Ile Thr Gly Val Lys Cys His His Leu Ser His Val Pro Leu
                               25      30      35
gtt aga agt ccc agc tcc tgc cca cat tca agg gaa aat aac gca ttt 257
Val Arg Ser Pro Ser Ser Cys Pro His Ser Arg Glu Asn Asn Ala Phe
                               40      45      50
ata aaa gcc agc tca gat gtt act tcc aac caa caa att tcc tgg aca 305
Ile Lys Ala Ser Ser Asp Val Thr Ser Asn Gln Gln Ile Ser Trp Thr
                               55      60      65      70
cac taa gtaatagagt taatcacacc gtctgggtt tgtgcatctc taagatgatc 361

```

His \*

```

atcttggtgt ggggtcctga tcttcccagt gacttagcag cacagtaatt tggctgaaat 421
gttgatgagt tcagacaaga agaagggtgat gatgacaaga gagcgtcacg gggaaattct 481
gccctgagga aggaatagtt tgaggctgga gagatgtggt acccccgcca ctctttctca 541
aatggaaaga caacctgtag gcacagaaat cattgtcttg cttacactga aatctcctgc 601
tgactttgag agctgagcat tggattttga tgggagagt aaacttagtg aagaaatgat 661
ttgaaccttt gttgatctaa tacttctgtg atacagttat ctaaacagaa tgagtctaaa 721
gtcagtataa agacctgtgt ctctccatgt tttgctgctt ataattgcag aggaacattt 781
tgagatagaa aattttatcc ctctttcaag tgacttttta taaaacataa ctttttaaga 841
gagggtcattc ttttgaaaaa ttgtctgaat acaaaaaagt aactgaacag caagggattg 901
tagccataat gttcttgacc acttttagatt gacaaatagt atctcaaaat tgatcaggtt 961
ctggagaatc tattgaggtt gtatggagta accaagtgat ggaagaggtt ggaagtgaat 1021
aattttatgt ggtattatgt gatttttttt ggtgggggta gtgtctggag ctgagcatga 1081
tggagcctag atggggcagc cttctaagtc tcccagtatt tcgcaaatca tatgtcacgt 1141
caaaattgta atgacaaagc tcacagcagc tgcctacgcc aggtttggtg ccagctctaa 1201
ttagagcatt gatcatttct ctccccttca tgaatgcaca tgagtgcaca ttttcatata 1261
taagggcaaa ggacatttca aagtttggat ggaatcttct ctacttagaa gtaataaaaa 1321
acaatacttt gaaatcttac caaatgttaa acaaatagca acaatttttc catttgaaga 1381
tgtgtgtctt aaggctctgtt ggatctttca aatttctatt ttggacatgg aaactacaga 1441
tgaaatttaa cttactcaaa gttacacaga actcctggct gatctctttt acttaattct 1501
tctaaaatct aaagtaagaa taattttgaa attttattgg taatgcttaa ataacaaaag 1561
ttactttaat atgttacatg tttgaagttt catttatact taatatctaa tttaacgctt 1621
gtgaaaatat tattcagtat ttttttttct tttctaaaat gacttggtca gggctccttt 1681
tgggatttta agtgagaaaa actctatttc ataataattgt taccatgctc atccaataac 1741
acttcataga tggtttagcca tctctaaaat taaattttgt agttgaggag cattgaaaat 1801
atcacctata tttggatttc tgtttaacac ttcaaaatgc attttatcat aatttaaaat 1861
ttgattttaa tacaaacctc tttatagaaa acctgataaa tgtagtttta tttgtttgct 1921
tgcttttttt tgcaggaggat gatattccct tgataccact ctgtctttat gactcatcgg 1981
ttatttataa atgttatcat cgtttttctg attttttaaa aagtttcaga attaatacat 2041
ttaactgaat aaatcaacca ataatgtcaa actt 2075

```

&lt;210&gt; 12

&lt;211&gt; 1923

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; 96..212

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 213..1923

&lt;220&gt;

&lt;221&gt; polyA\_signal

&lt;222&gt; 1897..1902

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-130-143 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-126-286 : polymorphic base A or G



&lt;400&gt; 12

ttgcagggtcc acattcggtc tagagggtgc ctgcgggtcct tagaggcctc ataggcaagg 60  
 aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113

Met Ala Ala Tyr Phe Phe

1

5

aag cct gta agg aga tcc rgt ctg agt tgg cca ggt ctt gtg aaa gga 161  
 Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly

10

15

20

aca ttc acc ctg gga gct ctg tgc tgc cat gca aat gtc aca ttg cac 209  
 Thr Phe Thr Leu Gly Ala Leu Cys His Ala Asn Val Thr Leu His

25

30

35

tga ggccgcatg ctgtaaaaa ccccaagcta cctacctgaa aagctggaga 262  
 \*

gaatcagcac ccacagcatt ttccagcatt ttgggtcctc ccagctaaat catcggcatt 322  
 gtgaagcaga gatgagacct cctgccatgc cctttccaaa tcttgacca acagaatcat 382  
 catatacact agaaagacaa cctgtaggca cagaaatcat tgctctgctt acactgaaat 442  
 ctctctgctga ctttgagagc tgagcattgg attttgatgg gagagtgaat cttagtgaag 502  
 aatgatattg aacctttggt gatctaatac ttctgtgata cagttatcta aacagaatga 562  
 gtctaaagtc agtataaaga cctgtgtctc tccatgtttt gctgcttata attgcagagg 622  
 aacattttga gatagaaaat ttatccctc ttccaagtga ctttttataa aacataacct 682  
 ttaagagag gtcatctttt tgaaaaattg tctgaataca aaaaagtaac tgaacagcaa 742  
 gggattgtag ccataatggt cttgaccact ttagattgac aaatagtatc tcaaaattga 802  
 tcagggttctg gagaatctat tgagggttgta tggagtaacc aagtgtgga agagggtgga 862  
 agtgaataat ttatgtggt attatgtgat tttttttggt gggggtagt tctggagctg 922  
 agcatgatgg agcctagatg gggcagcctt ctaatgctcc cagtatttgc caaatcatat 982  
 gtcacgtcaa aattgtaatg acaaaagctca cagcagctgc ctacgccagg tttggtgcca 1042  
 gctctaatta gagcattgat cttttctctc cccttcatga atgcacatga gtgcacattt 1102  
 tcatatataa gggcaaaagg catttcaaag ttgggatgga atctttccta cttagaagta 1162  
 ataaaaaaca atactttgaa atcttaccac atgttaaaaca aatagcaaca atttttccat 1222  
 ttgaagatgt gtgtcttaag gtctgttgga tctttcaaat ttctattttg gacatggaaa 1282  
 ctacagatga aatttaactt actcaaagtt acacagaact cctggctgat ctcttttact 1342  
 taattcttct aaaatctaaa gtaagaataa ttttgaaatt ttatttgtaa tgcttaataa 1402  
 acaaaagtta ctttaatatg ttacatgttt gaagtttcat ttatacttaa tatctaattt 1462  
 aacgcttggtg aaaatattat tcagtatttt tttttctttt ctaaaatgac ttgttcaggg 1522  
 ctcccttttg gatttttaag gagaaaaact ctatttcata atattgttac catgctcatc 1582  
 caataacact tcatagatgg ttagccatct ctaaaattaa attttgtagt tgaggagcat 1642  
 tgaaatatc acctatattt ggatttctgt ttaacacttc aaaatgcatt ttatcataat 1702  
 ttaaaatttg atttaaatat aaacctcttt atagaaaacc tgataaatgt agttttatatt 1762  
 gtttgcttgc ttttttttgc agggagggat attcccttga taccactctg tctttatgac 1822  
 tcatcggtta ttataaatg ttatcatcgt tttctgatt tttaataag tttcagaatt 1882  
 aatacattta actgaataaa tcaaccaata atgtcaaact t 1923

&lt;210&gt; 13

&lt;211&gt; 2308

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; 96..167

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 168..2308

&lt;220&gt;

<221> polyA\_signal  
<222> 2282..2287

<220>  
<221> allele  
<222> 132  
<223> 8-130-143 : polymorphic base A or G

<220>  
<221> allele  
<222> 132  
<223> 8-126-286 : polymorphic base A or G

<400> 13  
ttgcagggtcc acatttcgttc tagagggtgc ctgcgggtcct tagaggcctc ataggcaagg 60  
aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113  
Met Ala Ala Tyr Phe Phe  
1 5  
aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa gga 161  
Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly  
10 15 20  
aaa taa cgcatttata aaagccagct cagatgtttac ttccaaccaa caaatttcct 217  
Lys \*  
ggacacacta agtaatatagag ttaatcacac cgtcctaaac aatacgaaca gaaacaaagc 277  
tatgtacttg ttttgggaag caacctcaaa tggaaagatg ggggctgtgt tctaaaagga 337  
acattcaccc tgggagctct gtgctgccat gcaaagtca cattgcactg aggccgccat 397  
gctgtaaaaa accccaagct acctacctga aaagctggag agaatcagca cccatcagct 457  
tttccagcat tttgggtcct cccagctaaa tcatcgccat tgtgaagcag agatgagacc 517  
tcttgccatg ccctttccaa atcctggacc aacagaatca tcatatacac taggttttgt 577  
gcatctctaa gatgatcatc ttggtgtggg gtcctgatct tcccagtgc ttagcagcac 637  
agtaatttgg ctgaaatgtt gatgagttca gacaagaaga aggtgatgat gacaagagag 697  
cgtcacgggg aaattctgcc ctgaggaagg aatagtttga ggctggagag atgtgctacc 757  
cccgccactc tttctcaaat ggaaagacaa cctgtaggca cagaaatcat tgctctgctt 817  
acactgaaat ctctgctga ctttgagagc tgagcattgg attttgatgg gagagtgaag 877  
cttagtgaag aaatgatttg aacctttgtt gatctaatac ttctgtgata cagttatcta 937  
aacagaatga gtctaaagtc agtataaaga cctgtgtctc tccatgtttt gctgcttata 997  
attgcagagg aacattttga gatagaaaat tttatccctc tttcaagtga ctttttataa 1057  
aacataacct ttaagagag gtcattcttt tgaaaaattg tctgaatata aaaaagtaac 1117  
tgaacagcaa gggattgtag ccataatgtt cttgaccact ttagattgac aaatagtatc 1177  
tcaaaaattga tcaggttctg gagaatctat tgaggttgta tggagtaacc aagtgatgga 1237  
agaggttga agtgaataat tttatgtggt attatgtgat ttttttggg gggggtagt 1297  
tctggagctg agcatgatgg agcctagatg gggcagcctt ctaatgctcc cagtatttcg 1357  
caaatcatat gtcacgtcaa aattgtaatg acaaagctca cagcagctgc ctacgccagg 1417  
tttggtgcca gctctaatta gagcattgat ctttctctc cccttcatga atgcacatga 1477  
gtgcacattt tcatatataa gggcaaaagg catttcaaag tttggatgga atctttccta 1537  
cttagaagta ataaaaaaca atactttgaa atcttaacca atgttaaaca aatagcaaca 1597  
atttttccat ttgaagatgt gtgtcttaag gtctgttggg tctttcaaat ttctattttg 1657  
gacatggaaa ctacagatga aatttaactt actcaaagtt acacagaact cctggctgat 1717  
ctcttttaot taattcttct aaaatctaaa gtaagaataa ttttgaaatt ttattggtaa 1777  
tgcttaataa acaaaagtta cttaatatg ttacatgttt gaagtttcat ttatacttaa 1837  
tatctaattt aacgcttggtg aaaaattatt tcagtatttt tttttctttt ctaaaatgac 1897  
ttgttcaggg ctcttttggg gatttttaagt gagaaaaact ctatttcata atattgttac 1957  
catgctcatc caataacact tcatagatgg ttagccatct ctaaaattaa attttgtagt 2017  
tgaggagcat tgaaaatatc acctatattt ggattttctgt ttaacacttc aaaatgcatt 2077  
ttatcataat ttaaaatttg atttaaatat aaacctcttt atagaaaacc tgataaatgt 2137  
agtttttatt gtttgcttgc ttttttttgc agggagggat attccottga taccactctg 2197  
tctttatgac tcatcggtta tttataaatg ttatcatcgt ttttctgatt tttaaataag 2257  
tttcagaatt aatacattta actgaataaa tcaaccaata atgtcaaact t 2308

<210> 14  
<211> 2706



```

ataatgttct tgaccacttt agattgacaa atagtatctc aaaattgac aggttctgga 1597
gaatctattg aggttgatg gagtaaccaa gtgatggaag aggttggaag tgaataattt 1657
tatgtggtat tatgtgattt tttttggtgg gggtagtgtc tggagctgag catgatggag 1717
cctagatggg gcagccttct aatgctccca gtatttcgca aatcataatgt cacgtcaaaa 1777
ttgtaaatgac aaagctcaca gcagctgcct acgccagggt tggtgccagc tctaattaga 1837
gcattgatca tttctctccc cttcatgaat gcacatgagt gcacattttc atatataagg 1897
gcaaaggaca tttcaaagt tggatggaat ctttcctact tagaagtaat aaaaaacaat 1957
actttgaaat cttaccaaat gttaacaaa tagcaacaat tttccattt gaagatgtgt 2017
gtcttaagggt ctgttggtatc tttcaaattt ctattttgga catggaaact acagatgaaa 2077
tttaacttac tcaaagttac acagaactcc tggctgatct cttttactta attcttctaa 2137
aatctaaagt aagaataatt ttgaaatttt atttgtaatg cttaaataac aaaagttact 2197
ttaatatggt acatgtttga agtttctatt atacttaata tctaatttaa cgcttgtaa 2257
aatattattc agtatttttt tttcttttct aaaatgactt gttcagggtc ccttttgga 2317
ttttaagtga gaaaaactct atttcataat attgttacca tgctcatcca ataacacttc 2377
atagatgggt agccatctct aaaattaaat tttgtagttg aggagcattg aaaatatcac 2437
ctatatttgg atttctgttt aacacttcaa aatgcatttt atcataattt aaaatttgat 2497
ttaaatacaa acctctttat agaaaacctg ataaatgtag ttttatttgt ttgcttgctt 2557
ttttttgcag ggagggatat tcccttgata ccactctgtc tttatgactc atcggttatt 2617
tataaatggt atcatcggtt ttctgatttt taaataagtt tcagaattaa tacatttaac 2677
tgaataaatc aaccaataat gtcaaactt 2706

```

&lt;210&gt; 15

&lt;211&gt; 2612

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; 5'UTR

&lt;222&gt; 1..95

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; 96..212

&lt;220&gt;

&lt;221&gt; 3'UTR

&lt;222&gt; 213..2612

&lt;220&gt;

&lt;221&gt; polyA\_signal

&lt;222&gt; 2586..2591

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-130-143 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 132

&lt;223&gt; 8-126-286 : polymorphic base A or G

&lt;400&gt; 15

```

ttgcaggctc acattcggtc tagaggctgc ctgcggctcct tagaggcctc ataggcaagg 60
aactcatagt ttcttgccat gaagactttt ccaac atg gct gct tac ttc ttc 113
                               Met Ala Ala Tyr Phe Phe
                               1         5
aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa gga 161
Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys Gly
                               10        15        20
aca ttc acc ctg gga gct ctg tgc tgc cat gca aat gtc aca ttg cac 209

```

Thr Phe Thr Leu Gly Ala Leu Cys Cys His Ala Asn Val Thr Leu His  
 25 30 35

tga ggccgccatg ctgtaaaaaa ccccaagcta cctacctgaa aagctggaga 262

\*  
 gaatcagcac ccatacagctt ttccagcatt ttgggtcctc ccagctaaat catcggcatt 322  
 gtgaagcaga gatgagacct cctgccatgc cctttccaaa tccctggacca acagaatcat 382  
 catatacact agtaagcttt tactttaagc cactaatttg ggggtgtagt cttttgcagc 442  
 aaaagatcat cagaacactg ccatagcagga gctgataaac ttgctcactg ttatgtatgt 502  
 atccaatgac tactcacaca cacattactt gcttcactct actttctggc tttccattca 562  
 gcaaatttta agaaatgaaa atgttattcg tgggaaatta actcaagatc aatattgttg 622  
 tagttaatct ctttgtaaat ggtaaaatat taaattattg tgagtcattt ttatttaaa 682  
 aagtttggtt ctttaaatga aagaagtttg ggtcttttgt ggatactctg catatagaca 742  
 ttctagacat gaaagaatgt tgaagacaaa gaattgtgaa gaaatataga catgaaagac 802  
 tgttgaagtt tgggttttttg tggatactct gcatatagac attctagact ggagtgatag 862  
 atcttgttca ggggttttgt catctctaag atgatcatct tgggtgtggg tccctgatctt 922  
 cccagtgact tagcagcaca gtaatttggc tgaaatgttg atgagttcag acaagaagaa 982  
 ggtgatgatg acaagagagc gtcacgggga aattctgccc tgaggaagga atagtttgag 1042  
 gctggagaga tgtgctaccc ccgccactct ttctcaaag gaaagacaa ctgtaggcac 1102  
 agaaatcatt gctctgctta cactgaaatc tccctgctgac ttgagagct gagcattgga 1162  
 ttttgatggg agagtgaac ttagtgaaga aatgatttga acccttgttg atctaatact 1222  
 tctgtgatac agttatctaa acagaatgag tctaaagtca gtataaagac ctgtgtctct 1282  
 ccattgtttg ctgcttataa ttgcagagga acattttgag atagaaaatt ttatccctct 1342  
 ttcaagtga tttttataaa acataacctt ttaagagagg tcattctttt gaaaaattgt 1402  
 ctgaatacaa aaaagtaact gaacagcaag ggattgtagc cataatgttc ttgaccactt 1462  
 tagattgaca aatagtatct caaaattgat caggttctgg agaattctatt gaggttgat 1522  
 ggaagtaacca agtgatggaa gaggttgga gtgaataatt ttatgtggtt ttatgtgatt 1582  
 ttttttggtg ggggtagtgt ctggagctga gcatgatgga gcctagatgg ggcagccttc 1642  
 taatgctccc agtatttctgc aaatcatatg tcacgtcaaa attgtaatga caaagctcac 1702  
 agcagctgcc tacgccaggt ttggtgccag ctctaattag agcattgatc atttctctcc 1762  
 ccttcagaa tgcacatgag tgcacatttt catatataag ggcaaaggac atttcaaagt 1822  
 ttggatggaa tctttcctac ttagaagtaa taaaaaaca tactttgaaa tcttaccaa 1882  
 tgtaaaaca atagcaaca tttttccatt tgaagatgtg tgtcttaagg tctgttggat 1942  
 ctttcaaatt tctatttttg acatggaaac tacagatgaa atttaactta ctcaaagtta 2002  
 cacagaactc ctggctgatc tcttttactt aattcttcta aaatctaaag taagaataat 2062  
 ttgaaattt tatttgtaat gottaaataa caaaagttac ttaatatgt tacatgtttg 2122  
 aagtttcatt tatactta atctaattta acgcttgtga aaatattatt cagtattttt 2182  
 ttttctttc taaaatgact tgttcagggc tccctttggg attttaagt agaaaaactc 2242  
 tatttcataa tattgttacc atgctcatcc aataacact catagatggt tagccatctc 2302  
 taaaattaa ttttgtagtt gaggagcatt gaaaatatca cctatatattg gatttctgtt 2362  
 taacacttca aatgcattt tatcataatt taaaatttga tttaaatata aacctcttta 2422  
 tagaaaacct gataaatgta gttttatttg tttgcttgct tttttttgca gggagggata 2482  
 ttcccttgat accactctgt ctttatgact catcggttat ttataaatgt tatcatcgtt 2542  
 tttctgattt ttaaataagt ttcagaatta atacatttaa ctgaataaat caaccaataa 2602  
 tgtcaaactt 2612

<210> 16  
 <211> 434  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> 5'UTR  
 <222> 1..370

<220>  
 <221> CDS  
 <222> 371..436

<220>  
 <221> 3'UTR  
 <222> 437..434

<220>  
 <221> allele  
 <222> 407  
 <223> 8-130-143 : polymorphic base A or G

<220>  
 <221> allele  
 <222> 407  
 <223> 8-126-286 : polymorphic base A or G

<400> 16  
 tcccagtggg attcaaccac tcatagactg cttttgttca aactgcgttc aaataaggca 60  
 aacgcccagc tggaaccaat ctcactgttt ctgtacctcg cttctaattc cttttcagaa 120  
 aacaaaaact cctaagagaa tgaatagaaa ttttcttaag gaattataaa gaaccatctc 180  
 agaattttac tctgttactg caaaatctca tgcaaagata accaagtacg aagaattaac 240  
 tgaaattcat cccaagatga ggcactcttg ctgagttgca ggtccacatt cgttctagag 300  
 gctgcctgcg gtccttagag gcctcatagg caaggaactc atagtttctt gccatgaaga 360  
 cttttccaac atg gct gct tac ttc ttc aag cct gta agg aga tcc rgt 409  
 Met Ala Ala Tyr Phe Phe Lys Pro Val Arg Arg Ser Xaa  
 1 5 10  
 ctc agt tgg cca ggt ctt gtg aaa g 434  
 Leu Ser Trp Pro Gly Leu Val Lys  
 15 20

<210> 17  
 <211> 760  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> 5'UTR  
 <222> 1..696

<220>  
 <221> CDS  
 <222> 697..762

<220>  
 <221> 3'UTR  
 <222> 763..760

<220>  
 <221> allele  
 <222> 733  
 <223> 8-130-143 : polymorphic base A or G

<220>  
 <221> allele  
 <222> 733  
 <223> 8-126-286 : polymorphic base A or G

<400> 17  
 tcccagtggg attcaaccac tcatagactg cttttgttca aactgcgttc aaataaggca 60  
 aacgcccagc tggaaccaat ctcactgttt ctgtacctcg cttctaattc ctgtacgtca 120  
 ctttaccttt tttgtctata aatttattct gaccacaagg cacccttgga gcctctgtga 180  
 gtctgctgtg gttctgggga ctgcccgtatt cgcgaatcgt tcattttctca gttaaactcc 240  
 tttaaattaa ttcagctgaa gtttttcttt tatcaatgaa aagactagac tggcttagcc 300  
 ttccagcctg cacctttctc ccattgctga tgcttctgc ccttgaatat cagactccaa 360  
 gttcttcagt tttgggactc agactggctt ccttgcctct cagcttgagc atgccctatt 420  
 gtgggggtctt gtgttcgttt tcagaaaaca aaaactccta agagaatgaa tagaaatttt 480

ctttaaggaat tataaagaac catctcagaa ttttactctg ttactgcaaa atctcatgca 540  
 aagataacca agtacgaaga attaactgaa attcatccca agatgaggca tcttggtga 600  
 gttgcaggtc cacattcggt ctgagggctg cctgcgggtcc ttagaggcct cataggcaag 660  
 gaactcatag tttcttgcca tgaagacttt tccaac atg gct gct tac ttc ttc 714

Met Ala Ala Tyr Phe Phe

1

5

aag cct gta agg aga tcc rgt ctc agt tgg cca ggt ctt gtg aaa g 760  
 Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp Pro Gly Leu Val Lys  
 10 15 20

<210> 18

<211> 23

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 13

<223> Xaa=Gly or Ser

<400> 18

Met Ala Ala Tyr Phe Phe Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp  
 1 5 10 15  
 Pro Gly Leu Val Lys Gly Lys  
 20

<210> 19

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 13

<223> Xaa=Gly or Ser

<400> 19

Met Ala Ala Tyr Phe Phe Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp  
 1 5 10 15  
 Pro Gly Leu Val Lys Gly Asn Leu Ile Thr Gly Val Lys Cys His His  
 20 25 30  
 Leu Ser His Val Pro Leu Val Arg Ser Pro Ser Ser Cys Pro His Ser  
 35 40 45  
 Arg Glu His Ser Pro Trp Glu Leu Cys Ala Ala Met Gln Met Ser His  
 50 55 60  
 Cys Thr Glu Ala Ala Met Leu  
 65 70

<210> 20

<211> 38

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 13

<223> Xaa=Gly or Ser

<400> 20

Met Ala Ala Tyr Phe Phe Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp  
 1 5 10 15

WO 01/40493

PCT/IB00/01507

Pro Gly Leu Val Lys Gly Thr Phe Thr Leu Gly Ala Leu Cys Cys His  
 20 25 30  
 Ala Asn Val Thr Leu His  
 35

<210> 21  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> VARIANT  
 <222> 13  
 <223> Xaa=Gly or Ser

<400> 21  
 Met Ala Ala Tyr Phe Phe Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp  
 1 5 10 15  
 Pro Gly Leu Val Lys Gly Asn Leu Ile Thr Gly Val Lys Cys His His  
 20 25 30  
 Leu Ser His Val Pro Leu Val Arg Ser Pro Ser Ser Cys Pro His Ser  
 35 40 45  
 Arg Gly Phe Val His Leu  
 50

<210> 22  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> VARIANT  
 <222> 13  
 <223> Xaa=Gly or Ser

<400> 22  
 Met Ala Ala Tyr Phe Phe Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp  
 1 5 10 15  
 Pro Gly Leu Val Lys Gly Phe Cys Ala Ser Leu Arg  
 20 25

<210> 23  
 <211> 71  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> VARIANT  
 <222> 13  
 <223> Xaa=Gly or Ser

<400> 23  
 Met Ala Ala Tyr Phe Phe Lys Pro Val Arg Arg Ser Xaa Leu Ser Trp  
 1 5 10 15  
 Pro Gly Leu Val Lys Gly Asn Leu Ile Thr Gly Val Lys Cys His His  
 20 25 30  
 Leu Ser His Val Pro Leu Val Arg Ser Pro Ser Ser Cys Pro His Ser  
 35 40 45  
 Arg Glu Asn Asn Ala Phe Ile Lys Ala Ser Ser Asp Val Thr Ser Asn  
 50 55 60  
 Gln Gln Ile Ser Trp Thr His



65

70

<210> 24  
 <211> 427  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> allele  
 <222> 231  
 <223> 8-102-231 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 219..243  
 <223> 8-102-231.probe

<220>  
 <221> primer\_bind  
 <222> 212..230  
 <223> 8-102-231.mis

<220>  
 <221> primer\_bind  
 <222> 232..250  
 <223> 8-102-231.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..20  
 <223> 8-102.pu

<220>  
 <221> primer\_bind  
 <222> 408..427  
 <223> 8-102.rp complement,

<400> 24	cccacagaaa tatctaattg aaatattaaa ttgatttggg ttatctactc tcttgagaga	60
	gatgggtataa aaattcatta attataatth tatgtgcatg taacaaacag tcttttttgt	120
	tttcatgggt taggtacatg tcaactgtggc aggtgtaagt gtgataattc agatggaagt	180
	ggacttgtgt atggtaaatt ttgtgagtgt gacgatagag aatgcataga ygatgaaaca	240
	gaagaaatat gtggaggat gtatattggc tctgtagaaa ttaataaaag tacctgtttt	300
	tttcacctat ttcattgttc ttttatctct acataagttt ctgctctagg tgtgctaata	360
	tagtttaaac ctatgtttat ctggaaaaca tttcacataa ggagagtggg actatggcat	420
	taagagt	427

<210> 25  
 <211> 310  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 105  
 <223> 8-104-105 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 93..117  
 <223> 8-104-105.probe

<220>  
 <221> primer\_bind  
 <222> 86..104  
 <223> 8-104-105.mis

<220>  
 <221> primer\_bind  
 <222> 106..124  
 <223> 8-104-105.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..21  
 <223> 8-104.pu

<220>  
 <221> primer\_bind  
 <222> 295..310  
 <223> 8-104.rp complement

<400> 25	
gatgggtgttt ttccttttta gaatatTTTT gtctgaatat atgtgttttt ttcaaacaca	60
aagtaaacag aaaataataa gcgatatgtg aaatgctttc tttcrtgggt tttcttgact	120
ggattctttat aaaattcttc ttccaccta gggacttgtg tatgtgggtga atgtacctgt	180
cacgatgttg atccgactgg ggactgggga gatattcatg gggacacctg tgaatgtgat	240
gagagggact gtagagctgt ctatgaccga tattctgatg acttctgttc aggwaagggc	300
tcttccaatt	310

<210> 26  
 <211> 418  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 251  
 <223> 8-94-252 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 239..263  
 <223> 8-94-252.probe

<220>  
 <221> primer\_bind  
 <222> 232..250  
 <223> 8-94-252.mis

<220>  
 <221> primer\_bind  
 <222> 252..270  
 <223> 8-94-252.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 8-94.pu

<220>  
 <221> primer\_bind

&lt;222&gt; 400..418

&lt;223&gt; 8-94.rp complement

&lt;400&gt; 26

gtggtctatg	caggtatgga	tggacattct	cacacctaac	caagcaatgt	ttgcttttcc	60
tcttcctttc	ttcccatcac	tagttgccat	gtaccgagaa	ccatctttgc	atgatgttgg	120
ggaaacggtc	ccgaagcctg	gggtgacgcc	aagtaaaagc	acaagtgcgt	ctgcaataat	180
gaatggaggc	aaaccagtca	acaagagtaa	gacaacatag	ccagatcctc	acaggtgttg	240
tgacttattc	rtcctgagca	cagttgagtg	atttatcctc	accagacatt	cctgctccgt	300
ggctgaagag	cagcaggaag	taagctaata	cttattcttt	gctgtctccg	aacttctctg	360
ttgcaagtgg	ataaatctca	acctttgcac	ccccacaaac	aagaagacac	ctggataa	418

&lt;210&gt; 27

&lt;211&gt; 419

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 43

&lt;223&gt; 8-95-43 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; misc binding

&lt;222&gt; 31..55

&lt;223&gt; 8-95-43.probe

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 24..42

&lt;223&gt; 8-95-43.mis

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 44..62

&lt;223&gt; 8-95-43.mis complement

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 1..18

&lt;223&gt; 8-95.pu

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 400..419

&lt;223&gt; 8-95.rp complement

&lt;400&gt; 27

gactggaact	attctaggag	atttgggttt	aatagtgtgc	tcrcctcctt	gaaagcctta	60
gtgattccgg	gactctcctc	ataagtgtgc	actttcttta	tactttccag	gtaaatgtga	120
atgtggcaaa	tgcacctgct	atcctccagg	agatcgccgg	gtgtatggca	agacttgtga	180
gtgtgatgat	cgccgctgtg	aagacctcga	tgggtgtggtc	tgtggaggta	gtaacctttc	240
tcatagctgt	atgtacctg	catgcaactt	gctttacctg	cctttgttat	tctactgact	300
cttgcttttt	caattgctgt	taaaaataag	ataaacagaa	agcaatatac	cattgaacct	360
aaaagcaata	tacaattagg	tttghtaatga	cttttatctc	cctgactcct	ttatttagc	419

&lt;210&gt; 28

&lt;211&gt; 350

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> allele  
 <222> 181  
 <223> 8-97-181 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 169..193  
 <223> 8-97-181.probe

<220>  
 <221> primer\_bind  
 <222> 162..180  
 <223> 8-97-181.mis

<220>  
 <221> primer\_bind  
 <222> 182..200  
 <223> 8-97-181.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 8-97.pu

<220>  
 <221> primer\_bind  
 <222> 331..350  
 <223> 8-97.rp complement

<220>  
 <221> allele  
 <222> 98  
 <223> 8-97-98 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 86..110  
 <223> 8-97-98.probe

<220>  
 <221> primer\_bind  
 <222> 79..97  
 <223> 8-97-98.mis

<220>  
 <221> primer\_bind  
 <222> 99..117  
 <223> 8-97-98.mis complement

<400> 28  
 ctgagaaacc agccattcaa tacactttta ctttggatg atgggttatt agaagcctgt 60  
 tgtcagtggtg tcaacgatat tctattcgag atggaaayct ttagttataa ggtgatggtg 120  
 agtaatagcc tttgtaattt caggttcttg tcattgtggg aagtgcattt gttctgctga 180  
 rgagtgggtat atttctgggg agttctgtga ctgtgatgac agagactgcy acaaacaatga 240  
 tggctctcatt tgtacagggtg cagtattaac cttttctaatt tgctctatgc cacagtttgt 300  
 tatagagcca agagacactc gtcattgcaat gcttttagtgg gctggaccaa 350

<210> 29  
 <211> 434  
 <212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 68

<223> 8-98-68 : polymorphic base A or G

<220>

<221> misc\_binding

<222> 56..80

<223> 8-98-68.probe

<220>

<221> primer\_bind

<222> 49..67

<223> 8-98-68.mis

<220>

<221> primer\_bind

<222> 69..87

<223> 8-98-68.mis complement

<220>

<221> primer\_bind

<222> 1..19

<223> 8-98.pu

<220>

<221> primer\_bind

<222> 415..434

<223> 8-98.rp complement

<220>

<221> misc\_feature

<222> 414,416

<223> n=a, g, c or t

<400> 29

atttcattgt	ggacacttgt	gatttataat	agcatgttta	aattttggcac	attttgatca	60
taatcatrat	acctatatgt	attttattgc	agggaaatgga	atatgtagct	gtggaaactg	120
tgaatgctgg	gatggatgga	atggaaatgc	atgtgaaatc	tggcttggct	cagaatatcc	180
ttacaatta	catgagagag	gtctggattc	ttattttttc	tgggccatta	gaacatataa	240
atgcgaagga	aacctatgtat	attcaccact	aggacagggt	aaaaagacca	ttgtatgttt	300
ttctatttct	gaattacgaa	tgaaatccga	gtacctatta	gaaatgagtt	atgcaaattt	360
agatgcaaat	aacattagaa	aaaaaagatt	cttcataat	taacataagt	ggtncntaac	420
gagagcaatt	tttc					434

<210> 30

<211> 477

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 108

<223> 99-14021-108 : polymorphic base A or G

<220>

<221> misc\_binding

<222> 96..120

<223> 99-14021-108.probe

<220>  
 <221> primer\_bind  
 <222> 89..107  
 <223> 99-14021-108.mis

<220>  
 <221> primer\_bind  
 <222> 109..127  
 <223> 99-14021-108.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-14021.pu

<220>  
 <221> primer\_bind  
 <222> 465..477  
 <223> 99-14021.rp complement

<400> 30  
 ttgtgtgta atcgcccctt ttctgcaaca cttgtgggtt agggaaaata attctaaagc 60  
 aagagcaaag acagagttgg gagatcacca gtgaggttca atttccrtc acattcactc 120  
 tgctccacac ctcagataat catgtgctta actgcgaaac ttgcttgaca attacagaac 180  
 actttctcac ccattactac cttgatcctc acaattctgt ggggtagtag gagcagatgc 240  
 tgaaattgcc atacgcaa at cagtgaactg aagcttagag acctccagca ggggcagagg 300  
 gtcagcgga actatcccag gggtcagcca acaagaaagt atattggaat cagagtatta 360  
 aaataagaat aataaaacca actaaaattt accgtgcttt ttatttcac tcagtgcaca 420  
 caattcttaa cagtgtcagt gatggatccc tgtgcccag ggrmcagact tcttact 477

<210> 31  
 <211> 473  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 415  
 <223> 99-14364-415 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 403..427  
 <223> 99-14364-415.probe

<220>  
 <221> primer\_bind  
 <222> 396..414  
 <223> 99-14364-415.mis

<220>  
 <221> primer\_bind  
 <222> 416..434  
 <223> 99-14364-415.mis complement

<220>  
 <221> primer\_bind  
 <222> 64..82  
 <223> 99-14364.pu

<220>  
 <221> primer\_bind  
 <222> 434..454  
 <223> 99-14364.rp complement

<400> 31  
 catgcccac ctaaataattt acatgccttg acagataagc ccttagcctg cccaatgggt 60  
 aacttcaaca gcatctctag tacaactggt gctcattctg tgttttaatt caaccagct 120  
 ataagatacg aatgataga attgctctag attctctatt ggtaaataa ggagatattt 180  
 gtgctattgc caataatata tgctgtacct ggataaacc ctttgggcaa gttgtgatgc 240  
 aaatactcaa gaaaataggc cacatagtta caacaggact tacctaattc cccatgggtca 300  
 tttggctgat tcagtcagtt gctttcaagc ctagggtctt ggctcaatat tattacataa 360  
 actagaattt tctattact attaatatta cttgtattt ttctttataa acttygtact 420  
 tattgcttgt caaatttcag cagaagtaca actcctgaga gaataatgct ggc 473

<210> 32  
 <211> 502  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 99  
 <223> 99-15056-99 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 87..111  
 <223> 99-15056-99.probe

<220>  
 <221> primer\_bind  
 <222> 80..98  
 <223> 99-15056-99.mis

<220>  
 <221> primer\_bind  
 <222> 100..118  
 <223> 99-15056-99.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-15056.pu

<220>  
 <221> primer\_bind  
 <222> 482..502  
 <223> 99-15056.rp complement

<400> 32  
 caggaaactc acaagaagsc agatttcctt cgagcacctc ctgaataaag aggcaaaggc 60  
 cttcttaact cttacaattt acaagtggct atgagtgcyt ttatagttcc cataataatt 120  
 tctccacgta gacttcttaa ataataattt ctctgtttt atattctctg tgcttatggt 180  
 tatatcaaac aagttaccac ttaatcaaat gccgatttgc attgctcact atgtaacttt 240  
 aattttcttt gctcttatt tttggatctt aattctaaaa ctatgatgatc ataaattcat 300  
 ttaggaataa gcttgatgat tagccttctt ttgaaccctt ttgtgctcct cacaatattt 360  
 gtttcgatga aacagtggc aacatttgat ctatgattgt taatagaaaa acaccaatgt 420  
 ctcaagttat tgtaaacata ggcataattg accttgggtt ctataaatat gtttgggtgt 480  
 ccccaaaaata cgtctcctt tt 502

<210> 33  
 <211> 494  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 412  
 <223> 99-15229-412 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 400..424  
 <223> 99-15229-412.probe

<220>  
 <221> primer\_bind  
 <222> 393..411  
 <223> 99-15229-412.mis

<220>  
 <221> primer\_bind  
 <222> 413..431  
 <223> 99-15229-412.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..20  
 <223> 99-15229.pu

<220>  
 <221> primer\_bind  
 <222> 476..494  
 <223> 99-15229.rp complement

<400> 33  
 ctgtcattga gaaatgctac caataatact tagagaattt gatacaactc agtctgaaaa 60  
 agctaagatt agcagaacag agctgtctcc aaatatattga agaactattt tatttaaggg 120  
 attggaccca tttttgtatg tagttccaga ggagcagatg gtgaccactg tccaggcaga 180  
 tgtgtctcaa tgtaaggaca acatctgtaa tattaataat tagaatgtat cctgtaattt 240  
 tctctctacc cttggaaacc agtcgagatc cagagtcttt cactgggagg cttaaagcct 300  
 agagcagcct tgggtgctaga ggcggacagg gataatgaac taatcttgaa ccaattcatc 360  
 catagcaatc tcaatgcttt cgttagctct tataggattt taatacggcc araggatga 420  
 aggtagtctt gctggtttag aagccctgcc taccacaacc cctacaccac cccatcccct 480  
 gcatagtctg atgt 494

<210> 34  
 <211> 485  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 291  
 <223> 99-15232-291 : polymorphic base G or T

<220>  
 <221> misc\_binding  
 <222> 279..303  
 <223> 99-15232-291.probe



<220> .  
 <221> primer\_bind  
 <222> 272..290  
 <223> 99-15232-291.mis

<220>  
 <221> primer\_bind  
 <222> 292..310  
 <223> 99-15232-291.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-15232.pu

<220>  
 <221> primer\_bind  
 <222> 467..485  
 <223> 99-15232.rp complement

<400> 34  
 caatagaaca ggctgctcct ttataattat taatcatagt gtatattaat tcatcatcac 60  
 atacgtggct agaaaaaaat ttagaacaaa aagatatgtg atatgtaaag gcctacgata 120  
 attcagactt ctttgaggag agcttttatt ttattgttat tcttatttta tctcttgta 180  
 atataaattg agagaataaa cagacaaaaca ttacaaatta gtgattaatt gcatttaaag 240  
 cctagttaaag actatttaaag actattatgc ataatacagg aaaactacct ktattattta 300  
 tagtgggtgc cttctgaagg atctgaagga gaatcagttc tatgcctctc tcctcattcc 360  
 caggaggtgc ctggcattcc ttggcttgta gacgcacac cctaattctc acctctgcct 420  
 tcacatgggtg tccctgtgtg gtgtgttttt gcccatgtg tctcctcttt ttatatggat 480  
 gccag 485

<210> 35  
 <211> 477  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 382  
 <223> 99-15253-382 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 370..394  
 <223> 99-15253-382.probe

<220>  
 <221> primer\_bind  
 <222> 363..381  
 <223> 99-15253-382.mis

<220>  
 <221> primer\_bind  
 <222> 383..401  
 <223> 99-15253-382.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-15253.pu

<220>  
 <221> primer\_bind  
 <222> 459..477  
 <223> 99-15253.rp complement

<400> 35  
 aaaatcaatt ccccaacact cattttgtac gctaattttg taagatcctg aaaagtttca 60  
 ctatttttat gtttcatgtg ttacagatga aaaaaaaact agaattcaaa ttttctgagt 120  
 ttttttttac aatattttat gattacaaag ttagaagact aagaataaaa tggcctaatt 180  
 tccataatgt gagtggtaaa tgcagagcac tggcctaag aaaatatttc aaaaatttag 240  
 tcactttttc cttaattttt ttccaacctt tgatctgttg aatgagcatt ttgcatatat 300  
 aaataaataa attacttttg aaataatctt gactggtttc tgttgaccac agtaaccacac 360  
 tgcacagcac agcctgtaat tyctatgaac ctagggaaat gtatttaagt ttattttttg 420  
 attacacagg tcctcattgt gtaactaac attgcataga atatgccagt gatgatg 477

<210> 36  
 <211> 456  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 392  
 <223> 99-15256-392 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 380..404  
 <223> 99-15256-392.probe

<220>  
 <221> primer\_bind  
 <222> 373..391  
 <223> 99-15256-392.mis

<220>  
 <221> primer\_bind  
 <222> 393..411  
 <223> 99-15256-392.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-15256.pu

<220>  
 <221> primer\_bind  
 <222> 439..456  
 <223> 99-15256.rp complement

<400> 36  
 cctctctatg atgcttctta ttaagcaatt ggggaaatgt aataaacaag ggttggtgag 60  
 catcttcctt agtgagatgt ttttgaaga attggataat tgagtgaata atagtgagaa 120  
 actcctgtgt ctgatgttgc tccatgttgg aatgctttta tgttctcaga gaatgagta 180  
 ctgagagcca attgtgatga tacacaatgg ttttaccacag gttggatatg gtcctctgta 240  
 ctggtagcct ttaagtcagt ggcactaatc agtcagtcac tgcatgctt tgtgttggtc 300  
 catcatatgg tatgccctct tagagaacat cctgattagt ccttagacat cttttcaatt 360  
 tgaacactgg ggctcctcat tcgggtaaaa aytatggaca gtcagtgaag ctgttgcaat 420  
 ggccctcat agcagattgg atctcaatgc actttg 456

<210> 37

<211> 541  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 337  
 <223> 99-15258-337 : polymorphic base G or T

<220>  
 <221> misc\_binding  
 <222> 325..349  
 <223> 99-15258-337.probe

<220>  
 <221> primer\_bind  
 <222> 318..336  
 <223> 99-15258-337.mis

<220>  
 <221> primer\_bind  
 <222> 338..356  
 <223> 99-15258-337.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-15258.pu

<220>  
 <221> primer\_bind  
 <222> 521..541  
 <223> 99-15258.rp complement

<400> 37  
 cagtaaagaa ggacttagga aatatttttt gaatcatgag ctgctaatag atcagtaaatt 60  
 aggattttatt aaacacagct gtattcagga ctctgacctg tgtgggcctt agggaaatac 120  
 aaaattttaca aactgatgtg attttcttac cagtaagaaa tcttatgaaa gattaaatta 180  
 aaaaaatata aatgggggca actcaatcac ataaaagtaa tatattccat gtgactgaaa 240  
 tactagggaa aatttagaag tagaatttaa gtgagaattt caagcagggt tctgaaagat 300  
 tctacaggat gaaggaagaa ttgcccatat gccaatkgcc tatgtgaaat cacaaaaaca 360  
 gaaatcaata aggcattgtat ggaagtacag agtgattgcc tagttagaaa aagagcgtga 420  
 agggatcagt taacacaaac aagaagagtt taatgcttat ctgcaataag ttggtagagc 480  
 aaaattaagc acttcccagt atactgatag acgttaatty coactctacc atgtgaaatt 540  
 t 541

<210> 38  
 <211> 500  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 200  
 <223> 99-15261-202 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 188..212  
 <223> 99-15261-202.probe

<220>  
 <221> primer\_bind  
 <222> 181..199  
 <223> 99-15261-202.mis

<220>  
 <221> primer\_bind  
 <222> 201..219  
 <223> 99-15261-202.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-15261.pu

<220>  
 <221> primer\_bind  
 <222> 481..501  
 <223> 99-15261.rp complement

<400> 38  
 cttctaattcc ttgtttcca cttattttat ttcattcctc attttatccc ttttttctaa 60  
 attccatttt attatactta aggtgctttt aatatggta tcatactcct gatagtgtta 120  
 tttctttctt agtcttctta tataagcgct atacgttcac attccatctc ctttggttat 180  
 ctttccattt cttcaccgar cctctttgct ctcttttttt atagctgggt cactcaaaat 240  
 gtcttacttt gccatttttg aaatttat ttattctttt atgtactgaa taaaatttaa 300  
 aaatacttta tcatgggtgg aggtaccggt gatgtccaaa taagtgttta tattaattgt 360  
 tgggggtttt ttgtttgtgt gttttttgaa aggttaagaa aatctcattc agaaagtaag 420  
 ttgttttaaaa attctggacc aaatttacca cacatcaagc agatacttac caagttgttt 480  
 gtagacatta gcagtattta 500

<210> 39  
 <211> 541  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 432  
 <223> 99-15280-432 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 420..444  
 <223> 99-15280-432.probe

<220>  
 <221> primer\_bind  
 <222> 413..431  
 <223> 99-15280-432.mis

<220>  
 <221> primer\_bind  
 <222> 433..451  
 <223> 99-15280-432.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-15280.pu

<220>  
 <221> primer\_bind  
 <222> 521..541  
 <223> 99-15280.rp complement

<400> 39  
 atgtccatcc atcttgccca gagagagttt ctacaacact tctctgcaa gccctttccc 60  
 tacttgctc acctattgct ttcctctgtt acgttgattt cccctcactg tttcttccaa 120  
 catcttccca cctcagagca tggacacttg ctgctctttc tgtgtcatga tgctgtcac 180  
 ttgtcccttt cttaatgtct cctccctgag ccaatcttct ccaccccccac aacttacgca 240  
 cacttacatg tcataatttc ctccatagcc tttaacacca ttgaaatga tatatatattg 300  
 attgctttta aaatttctct gtcccccac taaatataaa ctccaggatg gcaagaatgt 360  
 agtccattat ctattttctc cagcctccat acttttaaga aaataaattt tggttgtata 420  
 agccatccag tyagtgtac ttggttatag caccctagc aaaagaatac aaaaaaagg 480  
 agaatgtttg caatcatctg ttgaggcta ggaattccca gagagggraam caaggagtaa 540  
 t 541

<210> 40  
 <211> 489  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 150  
 <223> 99-15355-150 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 138..162  
 <223> 99-15355-150.probe

<220>  
 <221> primer\_bind  
 <222> 131..149  
 <223> 99-15355-150.mis

<220>  
 <221> primer\_bind  
 <222> 151..169  
 <223> 99-15355-150.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-15355.pu

<220>  
 <221> primer\_bind  
 <222> 471..489  
 <223> 99-15355.rp complement

<400> 40  
 taacttctcc gtctctcctt cttagcccat atgtcaataa tgactgaaag tattcatttc 60  
 catctttaaa ctgcctatc cagccacctc ccacctccat ctctttcctt ctaagttttc 120  
 ttcaccttct actttgggca aaaggaaaty gatgtgtcag acaggcctag ttttgaattc 180  
 tggatctgct agcacttctc tgtgtgtcct tggttatatg atatagtctt aaaccttaat 240  
 gttcttgctt gtaaaatggg gataataaaa acctctaac agtggttggt tcatgcagct 300  
 ttcattacaa acttcctcat tcaaaatctt caatgatctc catttttcac aaaatgaaat 360  
 tcaaaatttc ttagattat tgagacaagt cccctactct tcacctaaat ttatctttta 420  
 tttattctct catcattatc aacaactact aggccttggt gccttgactc cagaggcaaa 480

aatctttatc

489

&lt;210&gt; 41

&lt;211&gt; 450

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 298

&lt;223&gt; 99-15663-298 : polymorphic base C or T

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; 286..310

&lt;223&gt; 99-15663-298.probe

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 279..297

&lt;223&gt; 99-15663-298.mis

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 299..317

&lt;223&gt; 99-15663-298.mis complement

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 1..18

&lt;223&gt; 99-15663.pu

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 430..450

&lt;223&gt; 99-15663.rp complement

&lt;400&gt; 41

ttccaccttc	ttctaaacgt	gttgcttcaa	tacgttgata	ggtgaggaca	cttaaaaatt	60
agactttata	gaaatagggt	tttttttgtt	tacatatata	gttcttttgg	tatcatatat	120
ttagcctctt	tctaaaattt	attttttgat	actgaaggga	gaaataggga	gttattaatc	180
aacaggcatt	aatttttagtc	aagcaaaaata	aataagctgt	agcgatctgc	tctgtaacat	240
tgtacctaca	gccaaacaatt	atatgttgtc	cacttaaaaa	tgtgtagat	ctcatagyaa	300
ctcttcttac	cacaataaag	taaaaattct	gaaacaataa	gtgaatacct	aaataatata	360
aacaaatata	atattgtagt	tttgggcact	taataaatga	cagcctcatt	tctcaattag	420
agatcatcac	aagttagaca	gatgacgatg				450

&lt;210&gt; 42

&lt;211&gt; 502

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 185

&lt;223&gt; 99-15664-185 : polymorphic base G or T

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; 173..197

&lt;223&gt; 99-15664-185.probe

<220>  
 <221> primer\_bind  
 <222> 166..184  
 <223> 99-15664-185.mis

<220>  
 <221> primer\_bind  
 <222> 186..204  
 <223> 99-15664-185.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-15664.pu

<220>  
 <221> primer\_bind  
 <222> 483..502  
 <223> 99-15664.rp complement

<220>  
 <221> misc\_feature  
 <222> 54  
 <223> n=a, g, c or t

<400> 42  
 gtttaccatt agcactgtca tatttgtgtg acttgtcatt ctctacagcg ggnacgggc 60  
 tggcacgggg cctgatgctg acttgcacaa gggaagcctc ctgtctctga cttccccagg 120  
 ataattctcg gggaaagtgt gctccctagt gttaagagcg gtttaatggc tggagggttt 180  
 cagckggctg accaggcaga gaaggagggt gaatcacctc tcagcactct ccacttagac 240  
 tttgtgtggt cgtcgggttg tcaaaccctc taactagtgt tattgcagat ttggcattcc 300  
 agtgcaaaaca aaagacagaa acacaatgtt cacatgctt ccagagatca cctggatata 360  
 agatcatttg attttcaagt aagtcgaaac cttgggtggaa atcattaact atcctgttta 420  
 tgaccaaaaa ataaaatccc aaatttcttc tcttcatttc ttacctgctt taaaattgta 480  
 tccaaagcgt gaaagtaaaa ga 502

<210> 43  
 <211> 476  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 398  
 <223> 99-15665-398 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 386..410  
 <223> 99-15665-398.probe

<220>  
 <221> primer\_bind  
 <222> 379..397  
 <223> 99-15665-398.mis

<220>  
 <221> primer\_bind  
 <222> 399..417  
 <223> 99-15665-398.mis complement

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 1..20

&lt;223&gt; 99-15665.pu

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 458..476

&lt;223&gt; 99-15665.rp complement

&lt;400&gt; 43

cgtaaagtgtg	aaaagcatag	cctcttcttg	gaatgttaag	tataaatatc	tgaaatactg	60
ggcttgatat	gtcaacagga	gattgatgga	taaaaataga	attttatata	aaaaacaact	120
ggacatatta	gattgttaac	ttggaagaaa	gaccatattc	aaagaagaaa	acatagtgac	180
taatttcaaa	catttaaagt	cttcctctg	gaaacaaagg	aatatctttg	ttctaact	240
tcaaagaaca	gggttaaaaa	atagactcac	cacagagtaa	atgcacaatt	gacaatcgtg	300
aatgaattaa	aaaccaaaaca	aaatatcttg	tcagctttct	atctatgaaa	ctaagaaaca	360
ggcttcctac	taaggtaatg	aatgtaattc	acagagarca	ttcacgtata	agtttcattc	420
atgtttcaaa	tttcattgat	ttgatcaatg	ggttattcta	ataccctccc	ttattt	476

&lt;210&gt; 44

&lt;211&gt; 459

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 139

&lt;223&gt; 99-15668-139 : polymorphic base C or T

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; 127..151

&lt;223&gt; 99-15668-139.probe

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 120..138

&lt;223&gt; 99-15668-139.mis

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 140..158

&lt;223&gt; 99-15668-139.mis complement

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 1..18

&lt;223&gt; 99-15668.pu

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 439..459

&lt;223&gt; 99-15668.rp complement

&lt;400&gt; 44

agaggtgaga	gaaaggtgaa	ttgtgcaa	atggacatcg	aagttattca	gacacatatg	60
gtttccatgt	cgtgagacct	taaagcactc	tcagaaactc	caagaaagct	gttgattggt	120
cagatttctc	acttttctgc	cctcaaaaca	agattgtcct	gaacttatag	gaaatatact	180
caaaagtagt	atgattttaag	gaagtcttcc	aaatacctgc	ctcgtttaca	gataatcaat	240



```

ggaattccaa aagattttat gtgttttaag ccctaaaaat gcaaataatcc aggaaagggc 300
tagactaaaa cagagctggc atgtatgcct cagtgcaggt gtatatctca gtgtctcctg 360
aagccagggc cttagaggat tgtggaaata ggtacactga cagcagggac tggaagccac 420
agtctggaga gcaaagagca gaatccatac ttacacctc 459

```

<210> 45  
 <211> 547  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 166  
 <223> 99-15672-166 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 154..178  
 <223> 99-15672-166.probe

<220>  
 <221> primer\_bind  
 <222> 147..165  
 <223> 99-15672-166.mis

<220>  
 <221> primer\_bind  
 <222> 167..185  
 <223> 99-15672-166.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-15672.pu

<220>  
 <221> primer\_bind  
 <222> 533..547  
 <223> 99-15672.rp complement

```

<400> 45
ccaataccat aactcctcta taggacatgg aagagtatta tatatgacaa atgattgcta 60
tgattattat tatcagtgtt attattatcc taatcctaag taatccaata aaagaaaaat 120
acatctgtgc ctgtgcgtat gtgcacgtgt gtgcagtcac atacaygttg agtaaaggta 180
aagtctagct gtattttaatc aacctacctg aatcctcagg aaaaaattct aaacctagtt 240
taaaacatgt aaactctaag ctctctcctt atagtcagtt agtagcagca catcttaaaa 300
tctgggtgtga atattctctt agttctacat gagtctaact aaacagagga ttattcttag 360
gtgtttgaaa gagacatatg tgacactgct gttttgagaa caatttaagt gttgtcttgt 420
catgtacaga agttctcata ttactttaca taaatggttg cataattggt ttatagtaaa 480
taatagactg tcaatatttc taggataact caaaaacaaa atttctctaga mmacattttg 540
aaaaggg 547

```

<210> 46  
 <211> 500  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 318  
 <223> 99-15682-318 : polymorphic base A or T

<220>  
 <221> misc\_binding  
 <222> 306..330  
 <223> 99-15682-318.probe

<220>  
 <221> primer\_bind  
 <222> 299..317  
 <223> 99-15682-318.mis

<220>  
 <221> primer\_bind  
 <222> 319..337  
 <223> 99-15682-318.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-15682.pu

<220>  
 <221> primer\_bind  
 <222> 482..500  
 <223> 99-15682.rp complement

<400> 46  
 gtttgatgag caacaagtgg ccacacaagt attggagaaa aaaaaaatta gaatgtgggg 60  
 agagaggcag tagacacaat aaaaaattct atataacaaa tgctatatct ttaagaaatc 120  
 gaatctttcc attaaatatt tgtttaaagt tacagactac ttatagtgta aagtatcact 180  
 tatcacaag atcagtaact tatttcctct gtatagtaga tgctcttct gtagaattaa 240  
 ctttccacta taatctctaa gatacagttc aagggcacaa ttttataatt caaagatatt 300  
 tacggcatga aattgagwtc taaaactott gtatctttta caaccatttt gtaattaaat 360  
 aactgttgac atttacaatc attgaagaac tatttgaact ctgtagagta tagatattga 420  
 agtacaaaat taattatgag ataatatatg gagcctgkcg gctttatttt ttaataagtw 480  
 tgtatgtatg ccaataaagg 500

<210> 47  
 <211> 461  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 217  
 <223> 99-16081-217 : polymorphic base C or T

<220>  
 <221> misc\_binding  
 <222> 205..229  
 <223> 99-16081-217.probe

<220>  
 <221> primer\_bind  
 <222> 198..216  
 <223> 99-16081-217.mis

<220>  
 <221> primer\_bind  
 <222> 218..236  
 <223> 99-16081-217.mis complement

```

<220>
<221> primer_bind
<222> 1..18
<223> 99-16081.pu

<220>
<221> primer_bind
<222> 443..462
<223> 99-16081.rp complement

<400> 47
caaaggacag agaaccagca ggcaggccct gggtaagcc ccgtgatgtc ccaggaggag      60
gggaggaggc cggagtcgga agggagcgag ggagccaggg aggcaggggc ctctgagggc      120
agggagttct ccatgaagtt ccagaagcca atgaccagat cggcgcatgc aaacagctta      180
aaagaaaaca ttaggcactg gtggcttcgc tctaaaygaa cagttcttaa aactgctttc      240
agttctagcc ataataaagg catTTgaatt atgttgcttt tgatgaaact ataaagatat      300
tggtctttat acagtatcat gccagaaaca aatttataac attgttatgg tataacagca      360
ggaatacttg gaatacacat ttttcagctg agctctaaga attacttttc ccttgcccca      420
ggttggaat taagaactat aacttactcc accccactcc a                               461

<210> 48
<211> 532
<212> DNA
<213> Homo sapiens

<220>
<221> allele
<222> 218
<223> 99-16082-218 : polymorphic base A or G

<220>
<221> misc_binding
<222> 206..230
<223> 99-16082-218.probe

<220>
<221> primer_bind
<222> 199..217
<223> 99-16082-218.mis

<220>
<221> primer_bind
<222> 219..237
<223> 99-16082-218.mis complement

<220>
<221> primer_bind
<222> 1..18
<223> 99-16082.pu

<220>
<221> primer_bind
<222> 512..532
<223> 99-16082.rp complement

<400> 48
caattcagca agagccactt tggttaacaa accttotggg aatgaagggtg ctttacaaag      60
aagcaggctg tgataaaaac aaacaagaca acattcataa actgtgggaa gcattgttgt      120
cattgggtca cactcctgc accaggcagg tggttgtctg ctgcgttcct ttacagaaca      180
gatgctgagc ctgcctggag gtggcaattt accaatorat ggtcttaagc aattccaaag      240

```

gctggggttaa	ggggttagaaa	agagaagctc	aaaaatgtta	gggatggaga	aggggggagt	300
gattcaggaa	gaggagaaac	ctgttcattt	cctcccaa	tacaaccact	gtcacatcca	360
tggttagtcc	tgtgcaaaact	tccagtcccc	agctgatatc	cctgcagaca	agtagagaga	420
ggctagaaca	aaagctaaag	tgtagatgtc	ccatacacta	atcagtgttg	ttttttaatc	480
agaggttgaa	attcatactc	tgatgcaaac	tgtatttagt	agwtgttgct	gc	532

<210> 49  
 <211> 451  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 81  
 <223> 99-20933-81 : polymorphic base A or C

<220>  
 <221> misc\_binding  
 <222> 69..93  
 <223> 99-20933-81.probe

<220>  
 <221> primer\_bind  
 <222> 62..80  
 <223> 99-20933-81.mis

<220>  
 <221> primer\_bind  
 <222> 82..100  
 <223> 99-20933-81.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-20933.pu

<220>  
 <221> primer\_bind  
 <222> 432..451  
 <223> 99-20933.rp complement

<400> 49	
ttccattcac	atgagaaact atgtgtttac tatttctgtt atgttttgta tgattttgtg 60
tgcttgata	ttttcagtaa mtgctggggt agcaagtgtc agaatcactc caaaaaaact 120
gagatatatt	tgccaagtca acagtctcca gaotattgtt tcagcaagac aaggggcaag 180
gctctttctg	ggcctgagta atcagtaaat atataaaaag aataagaata atagtgaagt 240
tactgctaga	cgtatttcct tacatctgaa cattttcttt catttgcaac acttaacctg 300
gaatcggtg	cttcagaaa atcctgtaaa aatcatgtag cttccaagat ttaaagctgg 360
cctagawaac	atgaacatga tcccatgtct tatctttact catacatcag gaattctcta 420
aatttctggg	agaacatttt gtagaagaca c 451

<210> 50  
 <211> 511  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 71  
 <223> 99-20977-72 : polymorphic base A or C

<220>  
 <221> misc\_binding  
 <222> 59..83  
 <223> 99-20977-72.probe

<220>  
 <221> primer\_bind  
 <222> 52..70  
 <223> 99-20977-72.mis

<220>  
 <221> primer\_bind  
 <222> 72..90  
 <223> 99-20977-72.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-20977.pu

<220>  
 <221> primer\_bind  
 <222> 491..511  
 <223> 99-20977.rp complement

<400> 50  
 gtacatggta ggtggtagat ggtgaaataa tttttatatt taaggagttt caaagatgat 60  
 ctaaaacatg maggcctaaa acaatagatg aaacactatt tcaaaatgta ttctctcttt 120  
 gttttcactc tccatgttac aaaaatggca acaattacg taaatgccaa ggaagccaat 180  
 atatcatatg gtaaatgaca aatcaactgt aacattgaaa caacaattaa tagctattat 240  
 agctattaaa atttgaagca aaattgtgca tctttaaaaa ttatacacac atgtgagagg 300  
 actcatgact gaaatctcaa tataccatct atccaagttg agttattttc cttttttttt 360  
 ttttttaaga taattattct tcttctact tctgggaggg acagtgtatg ggaggtacct 420  
 gtcaggcact gtgagaaccc tgggctctga acagatatgg ggtattttct tcagtatcct 480  
 caatgcagct ccaataacta atcccatttc t 511

<210> 51  
 <211> 466  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 89  
 <223> 99-20978-89 : polymorphic base G or C

<220>  
 <221> misc\_binding  
 <222> 77..101  
 <223> 99-20978-89.probe

<220>  
 <221> primer\_bind  
 <222> 70..88  
 <223> 99-20978-89.mis

<220>  
 <221> primer\_bind  
 <222> 90..108  
 <223> 99-20978-89.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-20978.pu

<220>  
 <221> primer\_bind  
 <222> 446..466  
 <223> 99-20978.rp complement

<400> 51  
 acttaactgc tacctaattgc agcctgtaca agcggataa ttgaactaaa atgtcttcaa 60  
 cactaaaaat aaaatgcaaa tcaaatctst ttaaaaaacc aaaaccaact tgtattttga 120  
 agattaactg ccactgtgtc taaacccaaa tctgtctagc cagagctgaa tttgtgatta 180  
 caaagcagta acgcaaagggt tagaaaggat caaagatctt gaaaaacctc ttctcagatc 240  
 catctcactt ttccattggc cacatttcca atacatctct gcccattaa aaccttacca 300  
 aaattgctag ttccagtacta taagtttaaa acaaatgggt tgotcaattc cttttgatgc 360  
 atcttcgcga tctctcgctc tttttctttt tttctatttt cactgccagc ccttcattac 420  
 ctctcttagg tggctctccc acctgcagtt ttccttttca aatcct 466

<210> 52  
 <211> 449  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 300  
 <223> 99-20981-300 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 288..312  
 <223> 99-20981-300.probe

<220>  
 <221> primer\_bind  
 <222> 281..299  
 <223> 99-20981-300.mis

<220>  
 <221> primer\_bind  
 <222> 301..319  
 <223> 99-20981-300.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-20981.pu

<220>  
 <221> primer\_bind  
 <222> 429..449  
 <223> 99-20981.rp complement

<400> 52  
 tttgccatcc ctttgctgat gggttgattt ggaatgtgtc atttogtttg tgaaatgaga 60  
 catagtcaag gtacccatgt gctcaagtgc ttagattaca acaatgtttt gatgcaaag 120  
 tgcaaagtac tcagagatca aactatgggt ctaataacag gccatagcaa aatagagcaa 180  
 atgaatcctg tgaaatcaga gagaatgcat caaataaaga tgtactacct aaagtgcaaa 240  
 atctactagg agcactttga catttcagtt caagttctac agtgtttcac attttttcar 300

tctctattgt agtctcactt ggaggtgatt gcttgatcac tagaggaata tgatattatt 360  
 cgtttcagaa atgaagcagc tatggtgttc tcttgtgaat agcactagat atgaattagg 420  
 attatgatct tgtttgtgta gaatgttcc 449

<210> 53  
 <211> 449  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 48  
 <223> 99-20983-48 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 36..60  
 <223> 99-20983-48.probe

<220>  
 <221> primer\_bind  
 <222> 29..47  
 <223> 99-20983-48.mis

<220>  
 <221> primer\_bind  
 <222> 49..67  
 <223> 99-20983-48.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-20983.pu

<220>  
 <221> primer\_bind  
 <222> 431..449  
 <223> 99-20983.rp complement

<400> 53  
 catgacacat caataagaga agcctgctgg cacagaggag ggcaggtraa accacctttg 60  
 tagaagaggc tcatttgaaa atgctcctga aagatatgat atcagaacac tatcttatgt 120  
 agagtggata agactttgat gatcttgaaa atgcttactg aggaatacat agcattttatc 180  
 tttctttcct tgattaaaga actttcatat atacatattt atcctgtatg gatagggtagg 240  
 agaggtgatg ccagccocaca gagatgacca gtccctattc cagaagttct gagttgttgc 300  
 ttaagtgaag aagtatgctg gtctgctttc aaacttctgt aaacttcagc ttagtggttag 360  
 aacagttaga aaatccaaat atttagtttc aatgcctgag tagtccattt actgattttc 420  
 accaactctg taccatcacc ttggtctaa 449

<210> 54  
 <211> 466  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 148  
 <223> 99-22310-148 : polymorphic base C or T

<220>  
 <221> misc\_binding

<222> 136..160  
 <223> 99-22310-148.probe

<220>  
 <221> primer\_bind  
 <222> 129..147  
 <223> 99-22310-148.mis

<220>  
 <221> primer\_bind  
 <222> 149..167  
 <223> 99-22310-148.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..19  
 <223> 99-22310.pu

<220>  
 <221> primer\_bind  
 <222> 446..466  
 <223> 99-22310.rp complement

<400> 54  
 gtgtgatacg agatcattct ttttttaaaa gctccctagg gtttcagaag tgcagcacag 60  
 gttgaaagct accgatatag agcaaagctt tactaaaagc tgatatgtgg aagcaaagaa 120  
 tgtgaaatga ctctctgaagg caccaaaytg acaatgcaaa tcaaatccaa gaacaagctc 180  
 taaatgtgtg cttgtatttt actgaatccc ttttgtaaac ccatgcaata ttttaccca 240  
 atattattgc aatacaaaact gggaaagata agatactgga atgtaacctg catcagacag 300  
 atagcaatat ctcatgtatt tagagcagag cagaccaagt tttggagtag agggagtagt 360  
 togatgactg gcagagaagc gggtaagaat ttaaagacaa tagtagaatc attatctctc 420  
 tgctacctcg ttgggacaaa gctctctaaa ataagcaact acacag 466

<210> 55  
 <211> 471  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 147  
 <223> 99-25922-147 : polymorphic base G or T

<220>  
 <221> misc\_binding  
 <222> 135..159  
 <223> 99-25922-147.probe

<220>  
 <221> primer\_bind  
 <222> 128..146  
 <223> 99-25922-147.mis

<220>  
 <221> primer\_bind  
 <222> 148..166  
 <223> 99-25922-147.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..21



<223> 99-25922.pu

<220>

<221> primer\_bind

<222> 451..471

<223> 99-25922.rp complement

<400> 55

ctctaataatc	aataaagcct	caaacatggt	tgctgattct	aggacatatt	gtcaatcacg	60
cactcacagg	agaattttcc	atctacctga	aataatttaa	atttatctta	tatttctctt	120
tgaatgagaat	catacaaaat	ggaattkac	tgaattcttg	tgtttgaga	gcacaacata	180
tagcagaact	attaaaaaaa	atcaagtaca	tttgtaatat	ttgaaataga	aaagaagttg	240
gccaagatat	cccaaaatat	gctaaaaagt	cctctaattg	tgatgctgaa	agaaactttt	300
ctaaactatc	aaaaatgaaa	tgcaaatgt	agttagtagg	gctaaaaaaa	ttactaaatt	360
acctttttct	tatctctaca	aaaaacatta	caaataatat	ttgtcgat	gaagtgtgat	420
caaagtatat	gtaactaaaa	actaaggaa	catttatagt	ttatcaggca	g	471

<210> 56

<211> 499

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 121

<223> 99-25950-121 : polymorphic base G or C

<220>

<221> misc\_binding

<222> 109..133

<223> 99-25950-121.probe

<220>

<221> primer\_bind

<222> 102..120

<223> 99-25950-121.mis

<220>

<221> primer\_bind

<222> 122..140

<223> 99-25950-121.mis complement

<220>

<221> primer\_bind

<222> 1..19

<223> 99-25950.pu

<220>

<221> primer\_bind

<222> 479..499

<223> 99-25950.rp complement

<400> 56

ctaccaaatc	atcaactacc	aaatacctca	gtgcattttc	tagcattaac	tttatttagt	60
accagaatta	tcacagagtc	taaagttatt	tcacacttaa	ttttgtagaa	ataaatagat	120
stgtagaat	cttccttatg	gattcaatat	tttgggaaag	aagcctcagt	gatggatatt	180
ttgttggtt	agaagtggct	atctattgtt	actttgtaat	aaattatctt	aaagggtgtt	240
tattgtaagt	atcacatata	atccaggata	ttttcctttg	gaagaggcaa	acccagttaa	300
attgggaaaa	agaatatagt	ctgcaaatac	aaacattgaa	aatgtgacc	tctgcccctt	360
ttcaactctt	ataggacaaa	ttcagaactc	aactaaatga	aattctttat	attgttaaaa	420
aatttcccct	agatctcaga	cagatgctga	gatctgtttt	gtagcattca	cccacgtacc	480

taaattctcac tctcagcaa

499

<210> 57  
 <211> 484  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 373  
 <223> 99-25961-376 : polymorphic base A or C

<220>  
 <221> misc\_binding  
 <222> 361..385  
 <223> 99-25961-376.probe

<220>  
 <221> primer\_bind  
 <222> 354..372  
 <223> 99-25961-376.mis

<220>  
 <221> primer\_bind  
 <222> 374..392  
 <223> 99-25961-376.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..20  
 <223> 99-25961.pu

<220>  
 <221> primer\_bind  
 <222> 464..484  
 <223> 99-25961.rp complement

<220>  
 <221> misc\_feature  
 <222> 395  
 <223> n=a, g, c or t

<400> 57  
 tctccctgt gaatgggaac atgtatgaat ttgaaattat gttctacatt ctctccaca 60  
 gttggaaaag gagggaaaga cagacacacc cctggactca gagggttctg cctgcctcac 120  
 caagggtctg aagggtcact ttctgecttc ttcccttcc attctttctt caaataattg 180  
 tccatgaaac tatatgcagt tggagcctga tggcttccc cttaccacct cccaagtga 240  
 aaatggkttc cttgttgaat ttgtgagaag cctttcccca agtctcttgc tttgcttgaa 300  
 tcccagagct tagatttccg agaaaataaa ctatgcagta ggaataggat tgggtgtggc 360  
 cctgggacg ggmtacacag acaacttata tctcnaaact ctggaagacg atcattgtaa 420  
 acccttgaat gtggcaggg catggcaggt cactgtgaga ttagcttctg ttaaactgag 480  
 ggct 484

<210> 58  
 <211> 470  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 399

<223> 99-25965-399 : polymorphic base A or G

<220>

<221> misc\_binding

<222> 387..411

<223> 99-25965-399.probe

<220>

<221> primer\_bind

<222> 380..398

<223> 99-25965-399.mis

<220>

<221> primer\_bind

<222> 400..418

<223> 99-25965-399.mis complement

<220>

<221> primer\_bind

<222> 1..21

<223> 99-25965.pu

<220>

<221> primer\_bind

<222> 451..470

<223> 99-25965.rp complement

<400> 58

ctcaaaatac	atatacacca	gctttaaatg	ggaggccaag	ataacggaaa	gaaagaatga	60
ggtttcgatt	gaggatgctt	agataagaaa	agcgagagc	cccctttcct	gggtcaagtt	120
gcttttcagt	gccagctcac	ctttgtcaac	ttcctaggtc	aaatgtcatg	ggaaaggaaa	180
ataatgatcc	aatcagtaaa	ctttaaatga	tagaataaat	agagaaaaca	attggctgag	240
agaaagctga	ctcgattgta	acgttttagct	actagagaag	atgaaagttc	aaagaactta	300
acatgaagtg	taaggagata	ataagttttg	ctcattgtta	atttgtctca	tgattctgtc	360
aatgcgtact	ggtcacgtga	ctttcacaaag	gaaaatgcrt	tattcaccac	agcagatcat	420
cttcctcatt	aaaaaccaa	ggtacaatgt	gggtactgtg	acttttagaa		470

<210> 59

<211> 523

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 241

<223> 99-25966-241 : polymorphic base A or G

<220>

<221> misc\_binding

<222> 229..253

<223> 99-25966-241.probe

<220>

<221> primer\_bind

<222> 222..240

<223> 99-25966-241.mis

<220>

<221> primer\_bind

<222> 242..260

<223> 99-25966-241.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..21  
 <223> 99-25966.pu

<220>  
 <221> primer\_bind  
 <222> 503..523  
 <223> 99-25966.rp complement

<400> 59  
 caatagtgtgta aacagccaac cattaaaaac acataaaata agtttcataa agatgaaggt 60  
 gacacaggag tccagactaa aawgtatgag tatgagttca ggaaagggtt tctaagaagg 120  
 tattattttaa cttctgggca ttcataattta agtataggaa aagtcattgct agtattcagg 180  
 aaaaatctga gtcattgcttg atggtatgaa agtgtgaggc atgtattgag aatgttcaag 240  
 rgctgggttga ctgccactec ttcttccaag ctcatagcaa atcccacttc agcacggaac 300  
 tgttctttaa gtccacactt accgctcttg ctccctcatt ccccatgtgc cttgtttatt 360  
 tagaggtaga tatattggtc aggtcaggca agctaagctt cagtaacaca tcaaccctta 420  
 catttcagtg gcttcaccca gtgaagattt gtttctcact taggctccaa gggatatcta 480  
 ggctggcagg agatcagctg cacatcatct tcactgactc tca 523

<210> 60  
 <211> 493  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 56  
 <223> 99-25967-57 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 44..68  
 <223> 99-25967-57.probe

<220>  
 <221> primer\_bind  
 <222> 37..55  
 <223> 99-25967-57.mis

<220>  
 <221> primer\_bind  
 <222> 57..75  
 <223> 99-25967-57.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..20  
 <223> 99-25967.pu

<220>  
 <221> primer\_bind  
 <222> 473..493  
 <223> 99-25967.rp complement

<400> 60  
 aacaagtgc atgacaaatg tacattttct ctatttggac tgttacacag agcctrgatt 60  
 gaaaaggagc aagagaagaa gcaggcaciaa gagaacagct gggctattac tataattgga 120  
 ggtgtgagaa agagaaggtc aagaactcct ccagttttc tggcaaaaac aagttaaaaa 180

cataaaaaaa	taaaaaaata	aattaaaagc	aaataaatgt	gccaaacgaca	aagtcagaga	240
gtcctagaag	gacaagctcg	tgagggatag	gaagggtcaag	ggttttatatt	cattgtatta	300
agaatggaga	ttttgctgag	ccataccgca	cagatatcta	gtcagttgga	aacataaatc	360
taagtgaaga	acaaagtctt	gtgctagaga	taattattca	agaaccattc	ttaaacaaaa	420
tgattatact	agaaaagata	tatcaattac	ttttcatata	aaacaaaaaa	tgcgatattt	480
ggcattctga	ttg					493

<210> 61  
 <211> 530  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 200  
 <223> 99-25969-200 : polymorphic base G or T

<220>  
 <221> misc\_binding  
 <222> 188..212  
 <223> 99-25969-200.probe

<220>  
 <221> primer\_bind  
 <222> 181..199  
 <223> 99-25969-200.mis

<220>  
 <221> primer\_bind  
 <222> 201..219  
 <223> 99-25969-200.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..21  
 <223> 99-25969.pu

<220>  
 <221> primer\_bind  
 <222> 510..530  
 <223> 99-25969.rp complement

<400> 61	
gttagtgact	ccttctttta cacatttctg gtttcaaagc agattatcaa gtaaaatttt 60
aaactgccac	caggagattt agctaaggag taccagctga ttttgttcta atgcagtctt 120
taaaataatg	tacactgtga catattcaag tcaagtacag catttatatg ctacacagtc 180
aagtaaaactg	tgtagcatak aaatcctacc acattctcca aaccagacag agggagaatc 240
acagatgccc	catgaatcac ctagaaatcc tgtcaacata taacaaatta tatgtggtag 300
accataaaag	tcaatatcaa gttaaaagca ttttttttgt cctcatgtaa aataaaactct 360
ggaaggagag	aatgatcttc acatgtcaat gaaaatctga gaaaaggagg gggtacagaa 420
cagagcaaaa	tcagagttca attcagaagc cataagggaag caggggaggg agccatgctt 480
accaacagca	aagagtgaag tcaggagtgc agaaaagcaa acaccgtagc 530

<210> 62  
 <211> 448  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 315

<223> 99-25972-317 : polymorphic base C or T

<220>

<221> misc\_binding

<222> 303..327

<223> 99-25972-317.probe

<220>

<221> primer\_bind

<222> 296..314

<223> 99-25972-317.mis

<220>

<221> primer\_bind

<222> 316..334

<223> 99-25972-317.mis complement

<220>

<221> primer\_bind

<222> 1..21

<223> 99-25972.pu

<220>

<221> primer\_bind

<222> 428..448

<223> 99-25972.rp complement

<400> 62

gacctatgag	ttcattggtt	cattccactt	aatctagaga	attcatttta	cctagacaga	60
cactaaaaaa	gacacacagg	tgacacaca	cttaggcata	aattgtcagt	ttttagccca	120
ggtctgtcct	attccocatta	ttacatataa	ttggattaga	aatgtcattt	taaaattatt	180
aagctatagg	taaggccctt	ctttgctaca	tatatatata	atcttgactt	ctttaaaatc	240
tagcctagaa	aacatttttg	tttcttttct	tcttttctct	ggtcccttct	ttagctocca	300
agaatttcag	aaaaytggtg	catttttagat	tatttttgcca	gctgcatact	tttctgtcta	360
atttgcagat	gtcacttact	tgataacact	tcacacagct	gtctaaccoc	agcttaaatg	420
attttctgat	ttctgaagaa	gtggctac				448

<210> 63

<211> 544

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 143

<223> 99-25974-143 : polymorphic base A or G

<220>

<221> misc\_binding

<222> 131..155

<223> 99-25974-143.probe

<220>

<221> primer\_bind

<222> 124..142

<223> 99-25974-143.mis

<220>

<221> primer\_bind

<222> 144..162

<223> 99-25974-143.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..21  
 <223> 99-25974.pu

<220>  
 <221> primer\_bind  
 <222> 524..544  
 <223> 99-25974.rp complement

<400> 63  
 gctataatct ctccttcctt ggtagccttg ggggtgttta ttttcttagg gttttaagtt 60  
 atttttcttg gcctgaaaac tcattggtgcc tactgtcaga gctgcacaga acccagtgtc 120  
 cagccactgc gtgcctccaa gcrctgacat cctaacaaca gtctgggtct ctgaggtctt 180  
 ggagcagagg gaggtgagac aaagataaca ggggtctaac tgtgcctact ggaagtctct 240  
 gctctcaa atataaaaaa cttaaaatga acaacatttt actaaatata gcctgatcac 300  
 tgcatttgca tgggggctgg attgatctgg aatgatcaga gctaacatga agctcttttc 360  
 tggagatgtg ggacatcaaa gtcacatact aagaagggat gaagacattg cagtgtatcg 420  
 gtctccctca cctgtctctt ctctagcgtt accccctctc tgaatctttt cttactggcc 480  
 acaaagaaca aaactctcag tgcaatgcc a tgacaaattt ctccaggaag sytaaccaa 540  
 tcgt 544

<210> 64  
 <211> 540  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 311  
 <223> 99-25977-311 : polymorphic base A or G

<220>  
 <221> misc\_binding  
 <222> 299..323  
 <223> 99-25977-311.probe

<220>  
 <221> primer\_bind  
 <222> 292..310  
 <223> 99-25977-311.mis

<220>  
 <221> primer\_bind  
 <222> 312..330  
 <223> 99-25977-311.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..21  
 <223> 99-25977.pu

<220>  
 <221> primer\_bind  
 <222> 520..540  
 <223> 99-25977.rp complement

<400> 64  
 caattctctc aaaattgtct caaataaaca agtattgagc catcgtgatg aattatgttt 60  
 gttcacagggt tattccattt aattttctct tcccacctca ttaagatgta aatagtaact 120

```

cagcttcata gagaagactg aggctaagag aaaaggattg tccaggctga aaggttagaa 180
aaaggcagaa gctgctcttc tactcagatt tctgacttca attccacaaa ggtcttaaaa 240
ttaggaaagc aacacttaag cactttaaat agctatgaaa aatgcaaaat ggaatctatt 300
caagcccatg rttctgtgtt aattgtgctc tgatgattgt tctctttctt tgcagcccca 360
cggtaacgga ggtggaagtc agttctactt ctctgtgtgt ttgcaaggaa tgttcctagg 420
aatattctgt tgcaccctgg gaacattatc ttcacccgta ttttaagctt tttatagaca 480
agcaaaaagaa ccatttaaaa tatatatacc acagcttctg atacagtgtt gaaatactac 540

```

```

<210> 65
<211> 538
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> allele
<222> 93
<223> 99-25979-93 : polymorphic base A or G

```

```

<220>
<221> misc_binding
<222> 81..105
<223> 99-25979-93.probe

```

```

<220>
<221> primer_bind
<222> 74..92
<223> 99-25979-93.mis

```

```

<220>
<221> primer_bind
<222> 94..112
<223> 99-25979-93.mis complement

```

```

<220>
<221> primer_bind
<222> 1..19
<223> 99-25979.pu

```

```

<220>
<221> primer_bind
<222> 518..538
<223> 99-25979.rp complement

```

```

<220>
<221> misc_feature
<222> 412,462
<223> n=a, g, c or t

```

```

<400> 65
cactacagta atcgagagaca atgcagtgac aggattgact acccgtggat cagcctgaag 60
cttcaccttt tttttcaaag tgcattttga gartatttgt gctatccatt agtaaaaaatt 120
accaaagagg agcataatgg aagcatagag aaatagtaaa aatagaaaca tccagatatt 180
ctatgaaccc taggaaattt acacaacagt attattattc aatatattgt tgtcgtgtgg 240
caccaacgcc agagaagaat taattgctga gcaacggccc agacaggagt toccaagaag 300
taggttcagg tccatgagtt gggaacttgc tgagttgctg tggatctttg cttctttaaa 360
gtgttgcca tggattgcgg gcatcatcag tattacctgg gatcttcgta gnaatcacag 420
aatcttggtc cctaaccag atctgcagaa tcagttactg cnggcttcac atgataccca 480
ctggatgtgc atgtacattc aagtttgaaa tgatggtgtg aatcaggcag cagaaatg 538

```

```

<210> 66
<211> 469

```



<212> DNA  
<213> Homo sapiens

<220>  
<221> allele  
<222> 194  
<223> 99-25985-194 : polymorphic base C or T

<220>  
<221> misc\_binding  
<222> 182..206  
<223> 99-25985-194.probe

<220>  
<221> primer\_bind  
<222> 175..193  
<223> 99-25985-194.mis

<220>  
<221> primer\_bind  
<222> 195..213  
<223> 99-25985-194.mis complement

<220>  
<221> primer\_bind  
<222> 1..21  
<223> 99-25985.pu

<220>  
<221> primer\_bind  
<222> 449..469  
<223> 99-25985.rp complement

<400> 66  
ctttgcttac aatcaaata gatacaaggt atttaaaca ctaactataa tgtttgga 60  
tctgtgcttt taaaaataga tagactagtt caaaaaaaca caaataaca aattcataat 120  
aagtaaacac tttgtcactt tgtaagtgt tcagtatcta taacctactt aggtattatt 180  
tcagcataat atayattatt acattaacga caaaaaaata aataccttag atctgtacaa 240  
aagtatagac tgaactagat aagacaagag aacattttta tagatttgaa ctgagagagc 300  
tctgcacgtc actttaagac atggctgaac tgtccaagaa gcatctgtga ttattggggg 360  
gtctccctg tgaacttaa aacatattaa tctctgacaa tcacttgcaa tcaggtaaga 420  
tttcatcct gagctaagt atgctgtgct gaaaacttta ctccccatt 469

<210> 67  
<211> 553  
<212> DNA  
<213> Homo sapiens

<220>  
<221> allele  
<222> 398  
<223> 99-25989-398 : polymorphic base A or G

<220>  
<221> misc\_binding  
<222> 386..410  
<223> 99-25989-398.probe

<220>  
<221> primer\_bind  
<222> 379..397

<223> 99-25989-398.mis

<220>

<221> primer\_bind

<222> 399..417

<223> 99-25989-398.mis complement

<220>

<221> primer\_bind

<222> 1..19

<223> 99-25989.pu

<220>

<221> primer\_bind

<222> 533..553

<223> 99-25989.rp complement

<400> 67

cccatcttat	cttcaaatecc	ccatgttaca	ctataggtgc	agtaagtata	aaacaaacct	60
aattagtatt	cttagataat	gcagacattt	aaaaagcaca	agtcattttt	ggaaaacgaa	120
gaagtgcatt	gccactgagt	ttaccctgaa	atcatgaaaa	tggtctgatg	gagtgctaata	180
gtacatatgc	ttaacaataa	aaggtaaaaa	ctctcaccat	cacttttggt	agtcattttct	240
ctccgacccc	cacatgtaaa	ctaattccag	ggtaattgca	gggtgatagt	tttgattttc	300
tgtattccaa	gacagtaatt	cttgagagct	atttgcata	caactactat	cagtggctac	360
taactcaa	aacagcgata	attataataa	tcattacrtta	tttactgagt	attcactatg	420
gactttgcta	accataactca	agcataactgt	ctttccaaga	tacaaatggt	ttagaaaatg	480
aaattttctag	aggtaaggcc	ctggcctcat	tcagattatt	tcagttcata	ttgggattkr	540
aaaacaactg	tga					553

<210> 68

<211> 451

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 264

<223> 99-26146-264 : polymorphic base G or T

<220>

<221> misc\_binding

<222> 252..276

<223> 99-26146-264.probe

<220>

<221> primer\_bind

<222> 245..263

<223> 99-26146-264.mis

<220>

<221> primer\_bind

<222> 265..283

<223> 99-26146-264.mis complement

<220>

<221> primer\_bind

<222> 1..19

<223> 99-26146.pu

<220>

<221> primer\_bind

&lt;222&gt; 436..456

&lt;223&gt; 99-26146.rp complement

&lt;400&gt; 68

ttttacacc	atcaaaacct	aaaaatcctt	catacatctt	aatatctacc	caggaaatga	60
gtttaagtga	atcaattaag	aggaaatgaa	tactcgactt	attcagaccg	aagttgttat	120
ttgggatttg	ttactagtat	gtgtattttt	attatgacac	aactaatgca	gtgatgtgtt	180
atgaaacaaa	tctgagccaa	aaagcagggt	ttgaaatcaa	cttcacttat	aaaggcatta	240
tcttggttac	attatttaaat	atckttttaca	tctacagatg	cttatcacct	taagatggga	300
ttacttcctt	ataattacac	atcataaatt	caaactattg	taagttgaaa	tgcatcttagt	360
accttagtaa	acctatttta	atatcaaaaa	aatcccaaat	tgaactatct	taagttgggg	420
accatctgta	gttyyttgca	tgaaaaatag	g			451

&lt;210&gt; 69

&lt;211&gt; 454

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 276

&lt;223&gt; 99-26150-276 : polymorphic base A or G

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; 264..288

&lt;223&gt; 99-26150-276.probe

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 257..275

&lt;223&gt; 99-26150-276.mis

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 277..295

&lt;223&gt; 99-26150-276.mis complement

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 1..19

&lt;223&gt; 99-26150.pu

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 437..454

&lt;223&gt; 99-26150.rp complement

&lt;400&gt; 69

gaaagattag	ttgcatgaga	taatctgac	tctaaaattc	tgccctttta	atattttatc	60
aagggatcca	agaacagtta	ctgcaatatt	cgtaccacaa	tcaactttgc	aatttgaaaa	120
gacaccagct	tggttgagga	gaatgaattg	cgagcggaga	gagtcagaga	ggagataaga	180
ctcagtttga	ggaaggccta	ttgagacatt	tggttcatgt	gacaatctgg	tgttttgtac	240
tggtggtcatt	tccacggaga	tgagataaaa	tgagcrtatt	ttggacagtt	tatttaacag	300
catactaact	tttcatattt	tgaggtttct	aaagttgaac	gcattcttcta	attgatgaca	360
tgtcagtttg	atacattggt	tttctctggt	aaaacatat	gctatgatac	atggcatctg	420
agatgcaaag	aaatatggta	cttttggtgg	caca			454

&lt;210&gt; 70

&lt;211&gt; 449

&lt;212&gt; DNA

<213> Homo sapiens

<220>

<221> allele

<222> 44

<223> 99-26153-44 : polymorphic base A or C

<220>

<221> misc\_binding

<222> 32..56

<223> 99-26153-44.probe

<220>

<221> primer\_bind

<222> 25..43

<223> 99-26153-44.mis

<220>

<221> primer\_bind

<222> 45..63

<223> 99-26153-44.mis complement

<220>

<221> primer\_bind

<222> 1..19

<223> 99-26153.pu

<220>

<221> primer\_bind

<222> 429..449

<223> 99-26153.rp complement

<400> 70

atgcttaatg	cacatctacr	taatctatat	aaatcaatca	atcmacttat	gtctacctgt	60
tcagggtata	aaatctttgc	atactacggt	aacatagtat	acaagttcct	tgtgcaacag	120
atagtgtaga	gcaattaact	gctgtcaagt	tttatctttc	ctgtaaaact	cccagcacct	180
gcactgaact	tcgctggtea	ataagtgcac	tatatacaca	cccatatgca	catacatwat	240
ataatatttt	tatatgtcaa	ttgctcctct	agattgagtc	caatgctcag	aattataacg	300
gtaatttctc	aaaaacaaag	aaacggaagg	aaagaaggaa	gggggatgga	gagaagtcag	360
aaacagagaa	tgagggaaga	agaaaggaag	tgctgaaaat	gtatttgggg	tgaataaaca	420
catgagatgg	tataaagagg	caggtaatg				449

<210> 71

<211> 511

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 290

<223> 99-26156-290 : polymorphic base A or C

<220>

<221> misc\_binding

<222> 278..302

<223> 99-26156-290.probe

<220>

<221> primer\_bind

<222> 271..289

<223> 99-26156-290.mis

<220>  
 <221> primer\_bind  
 <222> 291..309  
 <223> 99-26156-290.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-26156.pu

<220>  
 <221> primer\_bind  
 <222> 491..511  
 <223> 99-26156.rp complement

<400> 71  
 gatgagtgtg aggtagtgtc tcattttggt tttgagtttt cctaattgatt actgacattg 60  
 aaaatctttt tataatgtct atatttataa aattatattt atatagacaa agaccccaaa 120  
 aaacatattt gtctagggcc ttgtagaccc aaggggaagc cctgatggat tcgaatccta 180  
 attocaccac ctattagctg tgtagtgttg aatatatctg taaacctact tgagtatcag 240  
 aattttttata ttggctgcat tttaactgta gatagctgtt ctggagcaam aatactgtaa 300  
 aattagtctt ttcttgaaaa acaggcagaa cctagtattg acagatataa ctattttttg 360  
 caocctctt ctatatctta tgctattgtc cactagctta ttatattgta acttgatatt 420  
 aattttaaga aagatttgaa attagccata ttttagtatg tcagttttcc ataacaagga 480  
 aaaaaaaca cagaataaag atttaagcca c 511

<210> 72  
 <211> 551  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> allele  
 <222> 189  
 <223> 99-27345-189 : polymorphic base G or C

<220>  
 <221> misc\_binding  
 <222> 177..201  
 <223> 99-27345-189.probe

<220>  
 <221> primer\_bind  
 <222> 170..188  
 <223> 99-27345-189.mis

<220>  
 <221> primer\_bind  
 <222> 190..208  
 <223> 99-27345-189.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-27345.pu

<220>  
 <221> primer\_bind  
 <222> 531..551  
 <223> 99-27345.rp complement

&lt;400&gt; 72

taacccacac	ggatttagct	agagttctag	ttagctcatg	agtagggaca	gaactgggtt	60
tggagttaat	tttactctgt	acttatgact	taaaaccgga	ttggaattac	cttctgagta	120
agtgttccca	tattaccata	tctaaattag	gtgtttcatt	ttttataact	acggtagcat	180
cttctcagsa	tcaactatat	aatttttagg	gccagtgaa	aactgaaact	atgatgtcct	240
tcactagaaa	atgattcaga	attttcagga	ggtgccagca	gagtgttagt	ccaaaagcag	300
gtccttctac	aggaccacga	atgatggcac	agcctgggaa	acaataaagc	tggccctgcc	360
cccttctcga	gtatttatca	gaactttagt	ttgtaatttt	tataaaatac	gtacggtaat	420
ttttctgttg	catttgcttg	ttttctggaa	aactgcaagc	ttcacaacgt	gagtgcacatg	480
catactgtat	ttcttgggtc	agctcagcat	ctagcacagt	gcctgatgca	gcagmcaccg	540
ataaattctg	t					551

&lt;210&gt; 73

&lt;211&gt; 514

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 380

&lt;223&gt; 99-30329-380 : polymorphic base C or T

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; 368..392

&lt;223&gt; 99-30329-380.probe

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 361..379

&lt;223&gt; 99-30329-380.mis

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 381..399

&lt;223&gt; 99-30329-380.mis complement

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 1..18

&lt;223&gt; 99-30329.pu

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 496..514

&lt;223&gt; 99-30329.rp complement

&lt;400&gt; 73

gacatacccc	aaacacagca	gcacaaagca	actgcctgtg	attgtcaatt	atctgcacta	60
actttgaata	gacaactgag	agtaaaattg	accattagct	gttattaatc	ttttaaatag	120
cttattttatc	aggacaatat	tttctttgag	gaatggtttc	acatcgttga	taaacagttt	180
cctattacta	acattaaact	aaataatata	tgtcatattt	cttttttacc	cttagaaagt	240
taatctaata	atattattct	gattagtggg	acttttttta	atttttgtaa	tggtgtttat	300
ggtgtttgat	ttgtactttt	ttgtcttttt	catacctttt	aataacatcc	gatttactac	360
tggagcattt	tatttttcaty	gtctctttaa	atacttaata	acttttagat	ttgttgttca	420
caaaactaaa	taattgottg	atgtttcatt	ttatccttct	tattaaatag	gcagctcgtg	480
tacatatgaa	agtgtctttt	tataaccgca	aacc			514

&lt;210&gt; 74

&lt;211&gt; 511

```

<212> DNA
<213> Homo sapiens

<220>
<221> allele
<222> 342
<223> 99-31798-344 : variable motifCAT or ACTGTCTCTACCTCA

<220>
<221> primer_bind
<222> 1..20
<223> 99-31798.pu

<220>
<221> primer_bind
<222> 491..511
<223> 99-31798.rp complement

<400> 74
caaccataa caaatggaag gcagagccca atggcaaagg tagtgccaag gcagatgtgt      60
tcccacacag ctagaagttg gggagagagg aggcctaaaa tgcttcaga ctgggtctac      120
catagaggaa ggtaagaagg taagatacct taagattcgg gcatggggaa ggggcagaga      180
aggaaaattg catgatctca tactaggtga cctcagtacc agtgaagttt tgattggatt      240
tgcgagctga tctaagccaa ctccaacatt caacaatggt aagggaaccc ttagraattc      300
actgtaggt aagggtaca tatattcttc attacaacct gactgtctct acctcattat      360
gcatttatat ccttattata gcagaggtag ttatgattaa agtaactatc agactgaaat      420
cctcccaaag ggtaaacatt attagcaagc aggaaggaaa caagatatgt ctaggagaga      480
ttttaagtg cagaaatatc tccactccgt c                                     511

<210> 75
<211> 474
<212> DNA
<213> Homo sapiens

<220>
<221> allele
<222> 159
<223> 99-5873-159 : polymorphic base C or T

<220>
<221> misc_binding
<222> 147..171
<223> 99-5873-159.probe

<220>
<221> primer_bind
<222> 140..158
<223> 99-5873-159.mis

<220>
<221> primer_bind
<222> 160..178
<223> 99-5873-159.mis complement

<220>
<221> primer_bind
<222> 11..28
<223> 99-5873.pu

<220>
<221> primer_bind

```

&lt;222&gt; 466..474

&lt;223&gt; 99-5873.rp complement

&lt;400&gt; 75

aaaggagcag gcgtaacaat aagcaggggt agtcgccaca aaacttgaga taagaggaaa	60
actaaaaaag tctaataaaa tcagtagtct taaaaagatg acatgatagg aagagaagtg	120
ttaaaaaaga aaaaaaatag gtatgaaaga gagtaacaya taccggaaaa gggataaaat	180
acatcctttg aaagaacaaa gagttattca aattgaattc ttaatgaatt acttaaacag	240
cagattagat attgttaaaa agaggaatag ggaattaaat gatatatgtg atgatattac	300
ctagtgtaac catcaaagat gtattgcaaa tgataaagaa aaaaatgctg ccatggcaat	360
attaatatca taaaaatata ctttaagaag taaataaatg caactaggaa tagagaaagc	420
taatgaataa taatatitaa aaaaaagtat aacaagtata cataagatgt aata	474

&lt;210&gt; 76

&lt;211&gt; 490

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; allele

&lt;222&gt; 220

&lt;223&gt; 99-6012-220 : polymorphic base G or T

&lt;220&gt;

&lt;221&gt; misc\_binding

&lt;222&gt; 208..232

&lt;223&gt; 99-6012-220.probe

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 201..219

&lt;223&gt; 99-6012-220.mis

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 221..239

&lt;223&gt; 99-6012-220.mis complement

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 11..29

&lt;223&gt; 99-6012.pu

&lt;220&gt;

&lt;221&gt; primer\_bind

&lt;222&gt; 477..490

&lt;223&gt; 99-6012.rp complement

&lt;400&gt; 76

attgtattta gtcttgactt gttttcctga ggggccaggt tgatttgcac gctcttgagg	60
aaatatacac gtcttctcag ttttaataat tgactgacag ccctgtgggt tctcaggacc	120
cagtgaagctg ctgctcccag gtcagctctgc aaaggatgct gggtcccttg tggctctcatc	180
aagggtgagga atttctctgat ttttagagatt tctttatcck aattttgaag actttctttc	240
acatttctag gcataaaaaa atgtacagca ctctactgct tgtttaacaa atggatagtg	300
atatactctgc caacaaagac cacatggagt atttcattga ctatcagaga agtttctctg	360
aaaggcacca tacttagtgt tttatttcca tgagtgaagg aaaattagtt atttgaagta	420
tttggtctgc ttttagttgt tctaaagtag tgctgatttt atatgcccat aatattcata	480
tatacaccca	490

&lt;210&gt; 77

&lt;211&gt; 529



<212> DNA  
<213> Homo sapiens

<220>  
<221> allele  
<222> 99  
<223> 99-6080-99 : polymorphic base C or T

<220>  
<221> misc\_binding  
<222> 87..111  
<223> 99-6080-99.probe

<220>  
<221> primer\_bind  
<222> 80..98  
<223> 99-6080-99.mis

<220>  
<221> primer\_bind  
<222> 100..118  
<223> 99-6080-99.mis complement

<220>  
<221> primer\_bind  
<222> 11..28  
<223> 99-6080.pu

<220>  
<221> primer\_bind  
<222> 519..529  
<223> 99-6080.rp complement

<400> 77  
acaacaacaa aaatgtgtcc ctgaaaccca tgctatatcc aactgaatat tctaattgtct 60  
ttgattacaa agccatctct agcaatttaa tacaattayg aaatggaaaa gttggcaaat 120  
gcaaaacaat agctcgtgtt caaggtatgt ctttattagg ggaagtttat cgaaacagat 180  
gtttatgcta tttcctataa actagattct aaaatatatt attctataaa gatgtattga 240  
ctttatatga aaaaattatt gaaaaatcta caagatgggtg aaactcttta gaactatatt 300  
tctattacaa gtttattttt aatttcaaaa atgtactgca taaatgcagc aaaaccttta 360  
ttgtcacata ttaaaacatg tacattattg tgtgcaaatt aaaatttcat taccttaaac 420  
caaaaagtga gttggccaga tagtaataa tttaggtctt aaggctgaaa agcgcttgta 480  
ttaattactc aactccacca ctattttgcc aaagcagtca cagacaata 529

<210> 78  
<211> 489  
<212> DNA  
<213> Homo sapiens

<220>  
<221> allele  
<222> 156  
<223> 99-7308-157 : polymorphic base C or T

<220>  
<221> misc\_binding  
<222> 144..168  
<223> 99-7308-157.probe

<220>  
<221> primer\_bind

<222> 137..155  
 <223> 99-7308-157.mis

<220>  
 <221> primer\_bind  
 <222> 157..175  
 <223> 99-7308-157.mis complement

<220>  
 <221> primer\_bind  
 <222> 1..18  
 <223> 99-7308.pu

<220>  
 <221> primer\_bind  
 <222> 469..489  
 <223> 99-7308.rp complement

<400> 78  
 tgttgtctgg atatggtgra ctgtccttca cacacagatg tgggaagcca tgatcatcag 60  
 ttgcattatt cctgaggggc aatgcattcc agttacatag aaccagtttc tacgtttcag 120  
 ggatatatgta ttcatggtga caaatttatt cacatyttta gtaattttta gtaattcaca 180  
 ttttaagtaa ttttcctgaa tgtgcctcat tggcttctgt gcctcttcag aaaagatgaa 240  
 ctaaacactg gcataatgtgt tcagatttca acattccgtt gttttcattg tggataattt 300  
 ctgtcccata tttttgtgta aagtttagaca ataaagtgtt aatattctgg cgtcggcaca 360  
 ttttctttcc tgataaataa caattcacat atctttttta aatatcagag aatatagtaa 420  
 ccaatttoca attctttttt caccatgtat ctattggagt tttaaaatga ctaataactaa 480  
 ggcaactat 489

<210> 79  
 <211> 112  
 <212> DNA  
 <213> Pan troglodytes

<400> 79  
 tcccagtggg attcaaccac tcatagactg cttttgttca aactgcgttc aaataaggca 60  
 aacgccgagc tggaaccaat ctactgttt ctgtacctcg cttctaattc ct 112

<210> 80  
 <211> 118  
 <212> DNA  
 <213> Pan troglodytes

<400> 80  
 tttcagaaaa caaaaactcc taagagaatg aatagaaatt atcttaagga attataaaga 60  
 accatctcag aattttactc tgttactgca aaatctcatg caaagataac caagtatg 118

<210> 81  
 <211> 146  
 <212> DNA  
 <213> Pan troglodytes

<400> 81  
 ttgcaggtcc acattcggtc tagaggctgc ctgcggctct tagaggccac tcatagttcc 60  
 ttgccatgaa gacttttcca acatggctgc ttacttctta aagcctgtaa ggagatccag 120  
 tctcagttgg ccaagtcttg taaaag 146

<210> 82  
 <211> 94  
 <212> DNA  
 <213> Pan troglodytes

<400> 82  
 gaaaataacg catttataaa acccagctca gatgttactt ccaaccaaca aatttcctgg 60  
 acacactaag taatagagtt aatcacactg tcct 94

<210> 83  
 <211> 229  
 <212> DNA  
 <213> Pan troglodytes

<400> 83  
 ttgcaggctc acattcgttc tagaggctgc ctgcggctct tagaggccac tcatagttcc 60  
 ttgccatgaa gacttttcca acatggctgc ttacttctta aagcctgtaa ggagatccag 120  
 tctcagttgg ccaagtcttg taaaaggtaa cctcatcacc ggagtacagt ctcacacct 180  
 ttcccatggt ccattggtta gaagtcacag ctctgcccc cattcaagg 229

<210> 84  
 <211> 205  
 <212> DNA  
 <213> Pan troglodytes

<400> 84  
 tgaaggtctc cctgctgtgc ttagagaggg ggatgctgga agaagagtgg tcagagaagc 60  
 aacattgctg gctctaaaga cagaggacag gccacgagcc aaggcatgca ggaggcctcc 120  
 agaagctggg gcaggcaaga gaatggactc agccctggag cctccagaag gcacgcagcc 180  
 ctgccattc cttgctttta gccag 205

<210> 85  
 <211> 82  
 <212> DNA  
 <213> Pan troglodytes

<400> 85  
 aaacaatacg aacagaaaca aagctatgta cttgttttgg gaagcaacct caaatggaaa 60  
 gatgggggct gtgttctaaa ag 82

<210> 86  
 <211> 234  
 <212> DNA  
 <213> Pan troglodytes

<400> 86  
 gaacattcac tctgggagct ctgtgctgcc atgcaaatgt cacattgcac tgaggccgcc 60  
 atgctgtaaa aaacccaag ctacctacct gaaaagctgg agagaatcag caccatcag 120  
 cttttccagc attttgggtc ctcccagcta aatcatcggc attgtgaagc agagatgaga 180  
 catcctgcca tgccctttcc aaatcctgga ccaacagaat catcatatac acta 234

<210> 87  
 <211> 714  
 <212> DNA  
 <213> Pan troglodytes

<400> 87  
 gaacattcac tctgggagct ctgtgctgcc atgcaaatgt cacattgcac tgaggccgcc 60  
 atgctgtaaa aaacccaag ctacctacct gaaaagctgg agagaatcag caccatcag 120  
 cttttccagc attttgggtc ctcccagcta aatcatcggc attgtgaagc agagatgaga 180  
 catcctgcca tgccctttcc aaatcctgga ccaacagaat catcatatac actagttagc 240  
 ttttacttta agccactaat ttgggggtgta gctcttttgc agcaaaagat aatcagaaca 300  
 ctgcatgca ggagctgaga aacttgetca ctgttatgcg tgtatccaat gactactcac 360  
 acacacatta cttgcttcac tctgctttct ggctttccat tcagcaaatt ttaagaaatg 420  
 aaaaagttat tcatgggaaa ttaactcaag atgaatattg ttgtagttaa tctctttgta 480

aatggtaaaa	tattaaatta	ttgtgagtca	tttttattta	aagaagtttg	gttcttttaa	540
tgaaaaaagt	ttgggtcttt	tgtggatact	ttgcatatag	acattctaga	catgaaagaa	600
tggtgaagac	aaagaatgtt	gaaggaatat	agacatgaa	gaatgttgaa	gtttggtttt	660
ttgtggatac	tctgcatata	gacattctag	actggagtga	tacatcttgt	tcag	714

&lt;210&gt; 88

&lt;211&gt; 220

&lt;212&gt; DNA

&lt;213&gt; Pan troglodytes

&lt;400&gt; 88

acatgaaaga	atgttgaagt	ttgggttttt	gtggatactc	tgcatataga	cattctagac	60
tggagtata	catcttggtc	aggtttctat	gttttcaaaa	tgataacttg	acacacctac	120
caatgccaat	ttttaggata	tatatctgta	tatctgtgtg	aactaaggaa	aattcaggta	180
tgattaaacc	tacatatatt	gccaggagag	actggataat			220

&lt;210&gt; 89

&lt;211&gt; 173

&lt;212&gt; DNA

&lt;213&gt; Pan troglodytes

&lt;220&gt;

&lt;221&gt; misc feature

&lt;222&gt; 91..92,131

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 89

ggtcctgata	ttcccagtga	cttagcagca	cagtaatttg	gctgaaatgt	tgatgagttc	60
agacaagaag	aaggtgatga	tgacaagaga	nncgtcacgg	ggaaattctg	ccttgaggaa	120
ggaataagttt	naggctggag	agatgtgcta	cccccgocac	tctttctcaa	atg	173

&lt;210&gt; 90

&lt;211&gt; 1105

&lt;212&gt; DNA

&lt;213&gt; Pan troglodytes

&lt;220&gt;

&lt;221&gt; misc feature

&lt;222&gt; 201,744,803,808..809

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 90

gaaagacaac	ctgtaggcac	agaaatcatt	gctctgctta	caactgaaatc	tcctgctgac	60
tttgagagct	gagcaactgga	ttttgatggg	agagtgaagg	ttagtgaagg	aatgatttga	120
acotttggtg	atctaatact	tctgtgatac	agttatctaa	acagaatgag	tctaaagtca	180
gtataaagac	ctgtgtctct	ncatgttttg	ctacttataa	ttgcagagga	acattttgag	240
atagaaaatt	ttatccccct	ttcaagtgac	tttttataaa	acataacctt	ttaagagagg	300
tcattctttt	gaaaaattgt	ctgaatacaa	gagaagtaac	tgaacagcaa	gggattgtag	360
ccataatgtt	cttgaccact	ttagattgac	aaatagtgtc	tcaaaattga	tcagggttctg	420
gagaatctat	tgaggttgta	tggagtaacc	aagtgatgga	agaggttgga	agtgaataat	480
tttatgtggt	attatgtgat	tttttttggt	gggggtagtg	tctggagctg	agcatgatgg	540
ggcctagatg	gggcagcctt	ctaagtctcc	cagtatttctg	caaatcatat	gtcacgtcaa	600
aattgtaatg	acaaagctca	cagcagctgc	ctacgccagg	tttgggtgcca	gctctaatta	660
gagcatcgat	catttctctc	cccttcatga	atgcacgtgc	gtgcacattt	tcatatacaa	720
gggcaaaagg	catttcaaa	tttnggatgg	aatctttcct	acttagaagt	aataaaaagc	780
aatactttga	aatcttacc	aanattannc	aaatagcaac	aatttttcca	tttaaagatg	840
tgtgtcttca	ggtctgttgg	atctttcaaa	tttctatttt	ggacatggaa	actacagatg	900
aaatttaact	tactcaaaag	tacacagaac	tcctggctga	tctcttttac	ttattcttctc	960
taaaatttta	agtaagaata	attttgaat	gttattgtga	atgcttaaat	aacaaaagtt	1020
acttttaatat	gttacatgtt	ggaagtttca	tttatactta	atatctaatt	taactcttgt	1080
gaatatatta	ttcagttttt	ttttt				1105

<210> 91  
 <211> 114  
 <212> DNA  
 <213> Hylobates sp.

<220>  
 <221> misc\_feature  
 <222> 45,75  
 <223> n=a, g, c or t

<400> 91  
 tccagtgag attcaaccac tcatagactg cttttgtcca aactngcgtt caaataaggc 60  
 aaacgccgag ctggnaaccc atctcactgt ttctgtacct cacttctgat tcct 114

<210> 92  
 <211> 117  
 <212> DNA  
 <213> Hylobates sp.

<400> 92  
 ttttagaaaa caaatctcct aagagaatga atagaaatta tcttaaggaa ttataaagaa 60  
 ccattctcaga attttactct gttactgcaa aatctcatgc aaagatagcc aagtatg 117

<210> 93  
 <211> 146  
 <212> DNA  
 <213> Hylobates sp.

<400> 93  
 ttgcaggctc acattcgttc tagaggctgc ctgcagtcct tagaggccac tgatacttcc 60  
 ttgccatgag gacttttcca acatggctgc ttacttcttc aagcctgtaa ggagatctgg 120  
 tctcagttgg ccaagtcttg tgtaagtaa cctcatcacc ggagtcacgt ctcatcacct 146

<210> 94  
 <211> 229  
 <212> DNA  
 <213> Hylobates sp.

<400> 94  
 ttgcaggctc acattcgttc tagaggctgc ctgcagtcct tagaggccac tgatacttcc 60  
 ttgccatgag gacttttcca acatggctgc ttacttcttc aagcctgtaa ggagatctgg 120  
 tctcagttgg ccaagtcttg tgtaagtaa cctcatcacc ggagtcacgt ctcatcacct 180  
 ttccaagt ccaattggtta gaagtcacc ctctgccca cattcaagg 229

<210> 95  
 <211> 205  
 <212> DNA  
 <213> Hylobates sp.

<220>  
 <221> misc\_feature  
 <222> 187  
 <223> n=a, g, c or t

<400> 95  
 tgaagttctc cctgctgtgc tcagagaggg ggggtgctga agaagagtgg tcagagaagc 60  
 aacattgctg gctctaaaga gagaggacag gccacgagcc aaggcatgca ggaggcctcc 120  
 agaagctggg gcaggcaaga gaatggactc ggccctgcag cctccagaag gcatgcagcc 180  
 ctgcccnttc cttgctttta gccag 205

<210> 96  
 <211> 234  
 <212> DNA  
 <213> Hylobates sp.

<400> 96  
 gaacattcac tctgggagct ctgtgctgcc atgcaaagt cagattgcac tgaggccacc 60  
 atgctgtaag aaacctcaag ctaccaacct gaaaagctgg agagaatcag caccatcag 120  
 cttttccagc cttttgggtc ctcccggcta aatcataggc attgtgaagc agagatgaga 180  
 cctcctgcca tgccctttcc aaatcctgga ccaacagaat catcatatac aata 234

<210> 97  
 <211> 715  
 <212> DNA  
 <213> Hylobates sp.

<400> 97  
 gaacattcac tctgggagct ctgtgctgcc atgcaaagt cagattgcac tgaggccacc 60  
 atgctgtaag aaacctcaag ctaccaacct gaaaagctgg agagaatcag caccatcag 120  
 cttttccagc cttttgggtc ctcccggcta aatcataggc attgtgaagc agagatgaga 180  
 cctcctgcca tgccctttcc aaatcctgga ccaacagaat catcatatac aataggaagc 240  
 ttttacttta agccactaat ttgggggtgta gttcttatgc agcaaaagat aatcagaaca 300  
 ctgccatgca ggagctgata aacttgctta ctattatgtg tatatccaat gactactcac 360  
 acacacattt cttgcttcac tctactttct ggctttccat tcagcaaatt ttaagaaatg 420  
 aaaatgttat tcatgggaaa ttaactcaag atgtatatgt ttgtagttaa actctttgta 480  
 aatggtaaaa tattaataa ttgctaata tctttattta aagaagtttg gttctttaaa 540  
 tgaaagaagt ttgggtcttt tgtggatact ctgcatatag acattctaga catgaaagaa 600  
 tgttgaagac aaagaatgtg gaaggcatat agacatgaaa gaatgttgaa gtttgggttct 660  
 tttgtggata ctctgcatat agacattcta gactggagt atatatcttg ttcag 715

<210> 98  
 <211> 213  
 <212> DNA  
 <213> Hylobates sp.

<400> 98  
 acatgaaaga atgttgaagt ttggttcttt tgtggatact ctgcatatag acattctaga 60  
 ctggagtgat atatcttgtt caggtttcta tgtttttaaa atgataactt gacacaccta 120  
 ccaatgcaaa tttttaggat atatatctgt gtgaactaag gaaaattcag gaatgattaa 180  
 acctacatat tttctcagga gagactggat aat 213

<210> 99  
 <211> 209  
 <212> DNA  
 <213> Hylobates sp.

<220>  
 <221> misc feature  
 <222> 26..27  
 <223> n=a, g, c or t

<400> 99  
 ggttttgtgc atttctaaga tgatcnnett ggtgtggggt cctgatcttc ccagtgactt 60  
 agcagcacag taatttggct gaaatgttga tgagttaaga caagaagaag gtgacgctga 120  
 caagagagcg tcaaggggaa attctgccct gaggaaggaa tagtttgagg ctggagagat 180  
 gtgctacccc cgccactctt tctcaaatg 209

<210> 100  
 <211> 1415  
 <212> DNA  
 <213> Hylobates sp.

&lt;220&gt;

&lt;221&gt; misc feature

&lt;222&gt; 343,383,387,570,1118

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 100

```

gaaagaaaac ctgtaggcac agaaatcatt gctctgctta cactgaaatc tctgtgtgac 60
tttgagaggt gagtggttga ttttgatgga aggggtgaaac ttagtgaaga aatgatttga 120
acctttgttg atogaatact tctgtgatac agttatctaa acagaatgag tctaagggtca 180
gtataaagac ctgtgtctct tcgtgttttg ctactataaa ttgcagagga acgttttgag 240
atagaaaatt ttatccact ttcaagtgtac tttttataaa acataacctt ttaagagagt 300
tcattctttt gaaaaattgt ctgaatacaa gaaaagtaac tgnacagca aggattgtag 360
ccataatgtt cttgaccact ttnagantga caaatagtgt ctcaaaattg atcagggtgcc 420
acagaatcta tagaggttgt atggagtaac caactgatgg aagaggttgg acacatctga 480
ataattttat gtggtattat gtgatgttat tttggtgggg tagtgtctgg agctgagcat 540
gatggggcct agatggggca gccttctaan gctcccaaca tttcccaaat catatgtcat 600
ctcaaaattg taatgacaaa gctcacagca gctgcctaca ccagggttgg tgccagctct 660
aattagagca tcgagcattt ctctccctt catgaatgca catgcgtgca cattttcata 720
tatgagggca aaggacattt caaagtgttg ttggaatctt tcctacttag aagtaataaa 780
aacaatactt tgaaatctta ccaaataa aacaaatagc aacaattttt ccatttaaag 840
gtgtgtgtct tcaggtctgt tggatctgtc aaatttctat tttggacatg gaaaccacag 900
atgaaattta acttacacaa agttacacag aactcctggc tgatctctt tacttaattc 960
ttctaaaacc taaagtaaga ataattttga aattttattg gtaatgctta aataacagtt 1020
actttaatat attacatgtt tgaagatttt catttatact taatatcgaa ttttaacttgt 1080
gaaaatatta ttcagtattt tgttttggtt tgttttcnaa aatgacttgt tcagggtccc 1140
ttttgggatt ttaagtgtga aaaactctat ttcataatat tgttaccatg ctcatccaat 1200
aacacttcat agatgggttag ccactctctaa aattaaattt tgtagttgag ggccattgaa 1260
aataccacct atattgggat ttctgtttta cacttcaaaa tgtatcatta tcataattta 1320
aaattagatt taaatacaag cctctttata gaaaacctga taaatatggc tttatttgtt 1380
tgcttggttt ttttgcaggg agggatattc ccttg 1415

```

&lt;210&gt; 101

&lt;211&gt; 112

&lt;212&gt; DNA

&lt;213&gt; Gorilla gorilla

&lt;220&gt;

&lt;221&gt; misc feature

&lt;222&gt; 99

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 101

```

tcccagtagg attcaaccac tcatagactg cttttgttca aactgcgttc aaataaggca 60
aacgccgagc tggaaccaat ctcaactgtt ctgtacctng cttctaattc ct 112

```

&lt;210&gt; 102

&lt;211&gt; 118

&lt;212&gt; DNA

&lt;213&gt; Gorilla gorilla

&lt;400&gt; 102

```

tttcagaaaa caaaaactcc taagagaatg aatagaaatt atcttaagga gttataaaga 60
accatctcag aattttactc tcttactgca aaatctcatg caagataac caagtacg 118

```

&lt;210&gt; 103

&lt;211&gt; 146

&lt;212&gt; DNA

&lt;213&gt; Gorilla gorilla

&lt;400&gt; 103

ttgcagggtcc acattcggttc tagagggtgc ctgcggtcct tagaggccac tcatagttcc 60  
 ttgccatgaa gacttttcca acatgactgc ttactttctc aagcctgtaa ggagatccag 120  
 tctcagtcgg ccaagtcttg taaaag 146

<210> 104  
 <211> 94  
 <212> DNA  
 <213> Gorilla gorilla

<400> 104  
 gaaaataacg catttataaa acccagctca gatgttactt ccaaccaaca aatttctgg 60  
 acacactaag taatagagtt aatcacaccg tcct 94

<210> 105  
 <211> 229  
 <212> DNA  
 <213> Gorilla gorilla

<400> 105  
 ttgcagggtcc acattcggttc tagagggtgc ctgcggtcct tagaggccac tcatagttcc 60  
 ttgccatgaa gacttttcca acatgactgc ttactttctc aagcctgtaa ggagatccag 120  
 tctcagtcgg ccaagtcttg taaaaggtaa cctcatcacc ggagtcacgt ctcatcacct 180  
 ttcccatgtt ccattgggta gaagtccag ctcccgcca cattcaagg 229

<210> 106  
 <211> 205  
 <212> DNA  
 <213> Gorilla gorilla

<400> 106  
 tgaagggtctc cctgctgtgc ttagagaggg ggacgctgga ataagagtgg tcagagaagc 60  
 aacattgctg gctctaaaga cagaggacag gccacgagcc aaggcatgca ggaggcctcc 120  
 agaagctggg gcaggcaaga gaatggactc agccctggag cctccagaag gcacacagcc 180  
 ctgcccgttc cttgctttta gccag 205

<210> 107  
 <211> 82  
 <212> DNA  
 <213> Gorilla gorilla

<400> 107  
 aaacaatacc aacagaaaca aagctatgta cttgttttgg gaagcaacat caaatggaaa 60  
 gacgggggct gtgttctaaa ag 82

<210> 108  
 <211> 234  
 <212> DNA  
 <213> Gorilla gorilla

<220>  
 <221> misc\_feature  
 <222> 192  
 <223> n=a, g, c or t

<400> 108  
 gaacattcac tctgggagct ctgtgctgcc atgcaaatgt cacattgcac tgaggccgcc 60  
 atgtgtgaaa aaaccccaag ctacctacct gaaaagctgg agagaatcag caccatcag 120  
 cttttccagc attttgggtt ctcccagcta aatcattggc attgtgaagc agagatgaga 180  
 cctcctgcc tncctttcc aaatcctgga ccaacagaat catcatatac aata 234

<210> 109



<211> 714  
 <212> DNA  
 <213> Gorilla gorilla

<220>  
 <221> misc\_feature  
 <222> 192  
 <223> n=a, g, c or t

<400> 109  
 gaacattcac tctgggagct ctgtgctgcc atgcaaagt caccattgcac tgaggccgcc 60  
 atgctgtaaa aaaccccaag ctacctacct gaaaagctgg agagaatcag caccatcag 120  
 cttttccagc attttgggtt ctcccagcta aatcattggc attgtgaagc agagatgaga 180  
 cctcctgcca tncctttcc aaatcctgga ccaacagaat catcatatac aatagtaagc 240  
 ttttacttta agccactaat ttgggggtgta gctcttttgc agcaaaagat aatcagaaca 300  
 ctgccatgca ggagctgata aacttgctca ctgttatgta tgtgtccaat gactactcac 360  
 acacacatta cttgcttcac tctgctttct ggctttccat tcagcaaatt tgaagaaatg 420  
 aaaaagtatt tcatgggaaa ttaactcaag atgaatattg ttgtagttaa tctctttgta 480  
 aatggtaaaa tattaataa ttgtgagtag tttttattta aagaagtttg gttctttaaa 540  
 tgaaagaagt ttgggtcctt tgtggatacg ttgcatatag acattctaga catgaaagaa 600  
 tgttgaagac aaagaatgtt gaaggaatat agacatgaaa gaatgttgaa gtttgtttt 660  
 ttgtggatac tctgcatata gacattctag actggagtgta tacatcttgt tcag 714

<210> 110  
 <211> 220  
 <212> DNA  
 <213> Gorilla gorilla

<220>  
 <221> misc\_feature  
 <222> 122  
 <223> n=a, g, c or t

<400> 110  
 acatgaaaga atgttgaagt ttgttttttt gtggatactc tgcatataga cattctagac 60  
 tggagtgata catcttggtc aggtttctat gtttttaaaa tgataacttg acacacctac 120  
 cnatgccaat ttttagggta tatatctgta tatctatgtg aactaaggaa aattcaggaa 180  
 tgattaaacc tacatatatt gccaggagag accggataat 220

<210> 111  
 <211> 209  
 <212> DNA  
 <213> Gorilla gorilla

<220>  
 <221> misc\_feature  
 <222> 97,115,117,130,134,160,193  
 <223> n=a, g, c or t

<400> 111  
 ggttttgtgc atttctaaga tgatcatctt ggtgtggggt cctgatcttc ccagtgactt 60  
 agcagcacag taatttggct gaaatgttga tgagttnaga caagaagaag gtgangntga 120  
 caagagagcn tcanggggaa attctgccct gaggaaggan tagtttgagg ctggagagat 180  
 gtgctacccc cgncaactctt tctcaaatg 209

<210> 112  
 <211> 1105  
 <212> DNA  
 <213> Gorilla gorilla

<220>

<221> misc\_feature  
 <222> 959  
 <223> n=a, g, c or t

<400> 112  
 gaaagaaaac ctgtaggcac agaaatcatt gctctgctta tactgaaatc tctgtctgac 60  
 tttgagagct gagcattgga ttttgatggg agagtgaac ttagtgaaga aatgatttga 120  
 acctttgttg atctaatact tctgtgatac agttatctaa acagaatgag tctaaagtca 180  
 gtataaagac ctgtgtctct ccatgttttg ctacttataa ttgcagagga acattttgag 240  
 atagaaaatt ttatccccct ttcaagtgc tttttataaa gcgtaacctt ttaagagagg 300  
 tcattctttt gaaaaattgt ctgaatacaa gagaagtaac tgaacagcaa gggattgtag 360  
 ccataatgtt cttgaccact ttagattgac aaatagtgtc tcaaaattga tcaggttccg 420  
 gagaatctat tgaggttgta tggataaacc aagtgtgga agaggttga agtgaataat 480  
 tttatgtggt attatgtgat gtttttttg tgggggtagt gtctggagct gagcgtgatg 540  
 ggccctagat ggggcagcct tctaagtctc ccagcatttc gcaaatacata tgtcacgtca 600  
 aaattgtaat gacaaagctc acagcagctg cctacgccag gtttgggtgc agctctaatt 660  
 agagcatcga tcatctctca cgccttcctg aatgcacatg tgtgcacatt ttcatatata 720  
 agggcaaagg acatttcaaa gtttgatgg aatctttcct acttagaagt aataaaaaac 780  
 aatactttga aatcttacca aatattaaat aaatagcaac aatttttcca tttaaagatg 840  
 tgtgtcttaa ggtctgttg atctttcaaa tttctatttt ggacatggaa actacagatg 900  
 aaattttaact gacacaaagt tacacagaac tcttggtgta tctgttttac ttaattctnc 960  
 taaaatctaa agtaagaata atttgaaat tttattggtg atgcttaaat aacaaaagtt 1020  
 actttaatat gttacatgtt tgaagtttca tttatactta atatctaatt taactcttgt 1080  
 gaaaatatta ttcagtattt ttttt 1105

<210> 113  
 <211> 112  
 <212> DNA  
 <213> Pongo pygmaeus

<220>  
 <221> misc\_feature  
 <222> 69..71,99,106  
 <223> n=a, g, c or t

<400> 113  
 tcccagtgagg attcaaccac tcatagactg cttttgttcg aactgcgttc aaataaggca 60  
 aacgccgann nggaaccaat ctcaactgtt ctgtacctna cttatnattc ct 112

<210> 114  
 <211> 118  
 <212> DNA  
 <213> Pongo pygmaeus

<400> 114  
 tttcagaaaa caaaaactcc taagagaatg aatagaaatt atcttaagga attataaaga 60  
 accgtctcag aattttcttc tgttactgca aaatctcatg caaagatgac caagtatg 118

<210> 115  
 <211> 146  
 <212> DNA  
 <213> Pongo pygmaeus

<400> 115  
 ttgcaggctc acattcgttc tagaggctgc ctgcagtcct tagaggtcac tcatagttca 60  
 ttgccatgag gacttttcca acatggctgc ttacttcttc aagcctgtaa ggagatctgg 120  
 tctcagttgg ccaaatcttg tataag 146

<210> 116  
 <211> 94  
 <212> DNA

&lt;213&gt; Pongo pygmaeus

&lt;400&gt; 116

ggaaataacg catttataaa acccagctca gatattactt ccaaccaaca aattgcctgg 60  
 acacactaag taatagagtt aatcacacca tctt 94

&lt;210&gt; 117

&lt;211&gt; 229

&lt;212&gt; DNA

&lt;213&gt; Pongo pygmaeus

&lt;400&gt; 117

ttgcaggtcc acattcggtc tagaggctgc ctgcagtcct tagaggtcac tcatagttca 60  
 ttgccatgag gacttttcca acatggctgc ttacttcttc aagcctgtaa ggagatctgg 120  
 tctcagttgg ccaaatcttg tataaggtaa cctcatcacc ggagtcattgt ctcacacct 180  
 ttcccggtt ccattgggta gaagtcaccag ctccctgccca cattcaagg 229

&lt;210&gt; 118

&lt;211&gt; 234

&lt;212&gt; DNA

&lt;213&gt; Pongo pygmaeus

&lt;400&gt; 118

gaacattcac tctgagagct ctgtgctgcc atgcaaagt cagattgcac taaggccgtc 60  
 atgctgtaag aaacccaag ctacctacct gaaaagctgg agagaatcag caccatcag 120  
 cttttccagc cctttgggtc ctcccagcta aatcataggt attgtgaagc agagatgaga 180  
 cctcctgcc tgcctttcc aaatcctgga ccaacagaat catcatatac aata 234

&lt;210&gt; 119

&lt;211&gt; 599

&lt;212&gt; DNA

&lt;213&gt; Pongo pygmaeus

&lt;400&gt; 119

gaacattcac tctgagagct ctgtgctgcc atgcaaagt cagattgcac taaggccgtc 60  
 atgctgtaag aaacccaag ctacctacct gaaaagctgg agagaatcag caccatcag 120  
 cttttccagc cctttgggtc ctcccagcta aatcataggt attgtgaagc agagatgaga 180  
 cctcctgcc tgcctttcc aaatcctgga ccaacagaat catcatatac aatagtaagc 240  
 ttttacttta agccactaat ttgggtgta gttcttttgc agcaaaagat aatcagaaca 300  
 ctgccatgca ggagctgata aacttggtca ctgttatgta tgtatccaat gactactcac 360  
 acacacatta ctgtctcac tctactttct ggctttccat tcagcaaatt ttaagaaatg 420  
 aaaatgttat tcatgggaaa ttaactcaag atgaatattg ttgtagttaa tctctttgtc 480  
 aatggtaaaa tattaataa ttgtgagtc cttttattta aagaagtttg gttctttaaa 540  
 tgaaagaagt ttgggtcttt tgtggatact ctgcatatag accttctaga ctggagtga 599

&lt;210&gt; 120

&lt;211&gt; 198

&lt;212&gt; DNA

&lt;213&gt; Pongo pygmaeus

&lt;400&gt; 120

gaagtttggg tcttttggg atactctgca tatagacctt ctgactgga gtgatatac 60  
 ttgttcagg tcttatgtt ttaaaatgat aactgacac acctaccatt gccaatttt 120  
 aggatata tctgtgtgaa ctaaggaaag ttcaggaaatg attaaacct catattttgc 180  
 caggagagac tggataat 198

&lt;210&gt; 121

&lt;211&gt; 152

&lt;212&gt; DNA

&lt;213&gt; Pongo pygmaeus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 73

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 121

tgacttagca gcacagtaat ttggctgaaa tgttgatgag ttcagacaag aagtgatga	60
tgacaagaca gcntcacggg gaaattctgc cctgaggaag gaatagtttg aggtggaga	120
gatgtgtac ccccgccact ctttgtcaaa tg	152

&lt;210&gt; 122

&lt;211&gt; 119

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 70,81,83,85,88,93

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 122

tgtcagaaaa caaaaactcc taagagaatt aatagaaatt atcttaagga attataaaga	60
acccatctcn cagaaattta ntntnttnac ggnaaaatct catgcaaaga taaccaagt	119

&lt;210&gt; 123

&lt;211&gt; 146

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta

&lt;400&gt; 123

tagtacgtcc acattcattc tagatgtgc ctgaagtcct tagatgcctc tcatagttcc	60
ttgccatgag cactttttcca acatggctga tgactgcttc aagcctgtaa ggagatctgg	120
tctcagttgg ccaagtcttg gataat	146

&lt;210&gt; 124

&lt;211&gt; 74

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 6,37,48,56

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 124

ctcagnatat tacctccaac ctacaaattt cctgggnaca cactaagnta ataagnagtt	60
aatcacaccg tcct	74

&lt;210&gt; 125

&lt;211&gt; 229

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta

&lt;400&gt; 125

tagtacgtcc acattcattc tagatgtgc ctgaagtcct tagatgcctc tcatagttcc	60
ttgccatgag cactttttcca acatggctga tgactgcttc aagcctgtaa ggagatctgg	120
tctcagttgg ccaagtcttg gataatgtaa cctcatcacc ggagtcacgt ctcacacct	180
ttcccatgtt ccattgggta gaagtccag cttctgcca cattcaaga	229

&lt;210&gt; 126

&lt;211&gt; 202

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 127..128,130..131

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 126

tgaaggtctc cctgctgtgc tgagagaggg gcatgctgga agaagagtgg tcagagaagc	60
aacattgctg gctctaaaga cagaggacag gccatgaacc aaggcatgca ggcggcctcc	120
gaaagcnnngn ncaggcaaga gaatggactc tgccctggag cctccagaac gcgtgcagcc	180
ctgcccattc cttgctttta gc	202

&lt;210&gt; 127

&lt;211&gt; 82

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 6,8,30,52,72

&lt;223&gt; n=a, g, c or t

&lt;400&gt; 127

aaacantncc aacagaaaca aagctttgtn cttgttttgg gaagcaacct cnaatggtaa	60
gatgggggct gngttctaaa ag	82

&lt;210&gt; 128

&lt;211&gt; 243

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta

&lt;400&gt; 128

gaacattcac cgtggctgct ctgcgctgcc atacaatgtc agattgcact gaggccgcca	60
tgctgtaaga aaccccaagc tgccctgctg aaaagactgg agagacacag caccatcag	120
cttttccagc cttttgggtc ctcccagcta aattacaggc attgtgaagc agagatgaga	180
agagatgaga cctcctgcgt gccctttcca aatcccggtc cagcagaatc atcctacaca	240
ata	243

&lt;210&gt; 129

&lt;211&gt; 727

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta

&lt;400&gt; 129

gaacattcac cgtggctgct ctgcgctgcc atacaatgtc agattgcact gaggccgcca	60
tgctgtaaga aaccccaagc tgccctgctg aaaagactgg agagacacag caccatcag	120
cttttccagc cttttgggtc ctcccagcta aattacaggc attgtgaagc agagatgaga	180
agagatgaga cctcctgcgt gccctttcca aatcccggtc cagcagaatc atcctacaca	240
atagtaagtt tttacttgaa gccactaatt tggggagtag ttcttatgca gcaaaagata	300
atcagaacac tgcgccatgg caggagctga taaacctgct cactgttacg cgtgtatcca	360
atgactactc acacacacat gacttgcttc actctacttt ctggctttcc actcagcaaa	420
ttttaagaaa tgagaatgtt attcatgaga aattaactca agatgaatat tgttatcgtt	480
aaactcttcg taaatggtaa aatactacat tattgctagt catttttatt taaagaagtt	540
tggttcttta aatgaaagaa gtttgggtct ttttggtgata ctctgcatat agatattcta	600
gacatgaaag aacgttgaag acaaaagaatg ttgaaggcat atagacatga aggaattttg	660
aagttgggtt cttttgtgga tactctgcat atagacattc tagactggag tgatatgtct	720
tggtcaa	727

&lt;210&gt; 130

<211> 214  
 <212> DNA  
 <213> Macaca mulatta

<400> 130  
 acatgaagga attttgaagt tgggttcttt tgtggatact ctgcatatag acattctaga 60  
 ctggagtgat atgtcttgtt caagcttcta tgtttttaaa atgataactt gacacaccta 120  
 cccaatgcca atttttagga cataaatctg tgtgaactaa ggaaaattca ggaatgatta 180  
 aacctacata ttttccaag agagactgga taac 214

<210> 131  
 <211> 77  
 <212> DNA  
 <213> Macaca mulatta

<400> 131  
 agagcgtgac ggggaaattc tgccctgagg aaggaatagt ttgaggctgg agagatgtgc 60  
 taccgccgcc actcttt 77

<210> 132  
 <211> 306  
 <212> DNA  
 <213> Macaca mulatta

<400> 132  
 taaaatgact tgttcagggc tccttttggg attttaagt agaaaaactc tatttcataa 60  
 taatgttacc acgctaacc aataacactt catagatggt tagccatctc taaaattaaa 120  
 tttttagtgg gaggagcatg gaaaatacca cctatatattg gatttctggt taacacttca 180  
 aaatccatta ttatcataat ttaaaattag atttaaatac aaacctcttt atagaaaagc 240  
 tgataaatgt gattttatatt gtttgcttgt ttttttgacg ggagggatat tccottgata 300  
 ccactc 306

<210> 133  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> sequencing oligonucleotide PrimerPU

<400> 133  
 tgtaaaacga cggccagt 18

<210> 134  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> sequencing oligonucleotide PrimerRP

<400> 134  
 caggaaacag ctatgacc 18